Torsade B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
de I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pointes I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ventricular B B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tachycardia I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
low O O
dose O O
intermittent O O
dobutamine O O
treatment O O
in O O
a O O
patient O O
with O O
dilated B B_DISEASE
cardiomyopathy I I_DISEASE
and O O
congestive B B_DISEASE/B_LOCATION
heart I I_DISEASE/I_LOCATION
failure I I_DISEASE/I_LOCATION
. O O

The O O
authors O O
describe O O
the O O
case O O
of O O
a O O
56 O O
- O O
year O O
- O O
old O O
woman O O
with O O
chronic O O
, O O
severe O O
heart B B_DISEASE
failure I I_DISEASE
secondary O O
to O O
dilated B B_DISEASE
cardiomyopathy I I_DISEASE
and O O
absence O O
of O O
significant O O
ventricular B B_DISEASE
arrhythmias I I_DISEASE
who O O
developed O O
QT B B_DISEASE
prolongation I I_DISEASE
and O O
torsade B B_DISEASE
de I I_DISEASE
pointes I I_DISEASE
ventricular B I_DISEASE
tachycardia I I_DISEASE
during O O
one O O
cycle O O
of O O
intermittent O O
low O O
dose O O
( O O
2 O O
. O O
5 O O
mcg O O
/ O O
kg O O
per O O
min O O
) O O
dobutamine O O
. O O

This O O
report O O
of O O
torsade B B_DISEASE
de I I_DISEASE
pointes I I_DISEASE
ventricular B I_DISEASE
tachycardia I I_DISEASE
during O O
intermittent O O
dobutamine O O
supports O O
the O O
hypothesis O O
that O O
unpredictable O O
fatal O O
arrhythmias B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
occur O O
even O O
with O O
low O O
doses O O
and O O
in O O
patients O O
with O O
no O O
history O O
of O O
significant O O
rhythm O O
disturbances O O
. O O

The O O
mechanisms O O
of O O
proarrhythmic O O
effects O O
of O O
Dubutamine O O
are O O
discussed O O
. O O

Positive O O
skin O O
tests O O
in O O
late O O
reactions O O
to O O
radiographic O O
contrast O O
media O O
. O O

In O O
the O O
last O O
few O O
years O O
delayed O O
reactions O O
several O O
hours O O
after O O
the O O
injection O O
of O O
radiographic O O
and O O
contrast O O
materials O O
( O O
PRC O O
) O O
have O O
been O O
described O O
with O O
increasing O O
frequency O O
. O O

After O O
angiography O O
by O O
the O O
venous O O
route O O
in O O
patient O O
n O O
degree O O
1 O O
a O O
biphasic O O
reaction O O
with O O
an O O
immediate O O
reaction O O
( O O
dyspnea B B_DISEASE
, O O
loss B B_DISEASE
of I I_DISEASE
consciousness I I_DISEASE
) O O
and O O
delayed O O
macro B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
papular I B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rash I B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appeared O O
, O O
whilst O O
patient O O
n O O
degree O O
2 O O
developed O O
a O O
generalised O O
sensation O O
of O O
heat O O
, O O
persistent O O
pain B B_DISEASE
at O O
the O O
site O O
of O O
injection O O
immediately O O
and O O
a O O
generalised O O
macro O O
- O O
papular O O
reaction O O
after O O
24 O O
hours O O
. O O

The O O
positive O O
skin O O
tests O O
are O O
in O O
favour O O
of O O
immunological O O
reactions O O
and O O
may O O
help O O
in O O
diagnosis O O
of O O
allergy B B_DISEASE
in O O
the O O
patients O O
. O O

Risk O O
of O O
transient O O
hyperammonemic B B_DISEASE
encephalopathy I I_DISEASE
in O O
cancer B B_DISEASE/B_PERSON
patients O O
who O O
received O O
continuous O O
infusion O O
of O O
5 O O
- O O
fluorouracil O O
with O O
the O O
complication O O
of O O
dehydration B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
infection B B_DISEASE
. O O

From O O
1986 O O
to O O
1998 O O
, O O
29 O O
cancer B B_DISEASE/B_PERSON
patients O O
who O O
had O O
32 O O
episodes O O
of O O
transient O O
hyperammonemic B B_DISEASE
encephalopathy I I_DISEASE
related O O
to O O
continuous O O
infusion O O
of O O
5 O O
- O O
fluorouracil O O
( O O
5 O O
- O O
FU O O
) O O
were O O
identified O O
. O O

None O O
of O O
the O O
patients O O
had O O
decompensated O O
liver B B_DISEASE/B_GENE
disease I I_DISEASE/I_GENE
. O O

Onset O O
of O O
hyperammonemic B B_DISEASE
encephalopathy I I_DISEASE
varied O O
from O O
0 O O
. O O
5 O O
to O O
5 O O
days O O
( O O
mean O O
: O O
2 O O
. O O
6 O O
+ O O
/ O O
- O O
1 O O
. O O
3 O O
days O O
) O O
after O O
the O O
initiation O O
of O O
chemotherapy O O
. O O

Plasma O O
ammonium O O
level O O
ranged O O
from O O
248 O O
to O O
2387 O O
microg O O
% O O
( O O
mean O O
: O O
626 O O
+ O O
/ O O
- O O
431 O O
microg O O
% O O
) O O
. O O

Among O O
the O O
32 O O
episodes O O
, O O
26 O O
( O O
81 O O
% O O
) O O
had O O
various O O
degrees O O
of O O
azotemia B B_DISEASE
, O O
18 O O
( O O
56 O O
% O O
) O O
occurred O O
during O O
bacterial B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infections I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
14 O O
( O O
44 O O
% O O
) O O
without O O
infection B B_DISEASE/B_PERSON
occurred O O
during O O
periods O O
of O O
dehydration B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Higher O O
plasma O O
ammonium O O
levels O O
and O O
more O O
rapid O O
onset O O
of O O
hyperammonemia B B_DISEASE
were O O
seen O O
in O O
18 O O
patients O O
with O O
bacterial B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infections I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
p O O
= O O
0 O O
. O O
003 O O
and O O
0 O O
. O O
0006 O O
, O O
respectively O O
) O O
and O O
in O O
nine O O
patients O O
receiving O O
high O O
daily O O
doses O O
( O O
2600 O O
or O O
1800 O O
mg O O
/ O O
m2 O O
) O O
of O O
5 O O
- O O
FU O O
( O O
p O O
= O O
0 O O
. O O
0001 O O
and O O
< O O
0 O O
. O O
0001 O O
, O O
respectively O O
) O O
. O O

In O O
conclusion O O
, O O
hyperammonemic B B_DISEASE
encephalopathy I I_DISEASE
can O O
occur O O
in O O
patients O O
receiving O O
continuous O O
infusion O O
of O O
5 O O
- O O
FU O O
. O O

Azotemia B B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
, O O
body O O
fluid O O
insufficiency O O
and O O
bacterial B B_DISEASE
infections I I_DISEASE
were O O
frequently O O
found O O
in O O
these O O
patients O O
. O O

It O O
is O O
therefore O O
important O O
to O O
recognize O O
this O O
condition O O
in O O
patients O O
receiving O O
continuous O O
infusion O O
of O O
5 O O
- O O
FU O O
. O O

1 O O
. O O

The O O
effects O O
of O O
two O O
unselective O O
potassium O O
( O O
K O O
( O O
+ O O
) O O
- O O
) O O
channel O O
blockers O O
, O O
quinine O O
( O O
12 O O
. O O
5 O O
, O O
25 O O
and O O
50 O O
mg O O
/ O O
kg O O
) O O
and O O
4 O O
- O O
aminopyridine O O
( O O
1 O O
and O O
2 O O
mg O O
/ O O
kg O O
) O O
, O O
on O O
conditioned O O
place O O
preference O O
and O O
biphasic O O
changes O O
in O O
motor O O
activity O O
induced O O
by O O
morphine O O
( O O
10 O O
mg O O
/ O O
kg O O
) O O
were O O
tested O O
in O O
Wistar O O
rats O O
. O O

Quinine O O
is O O
known O O
to O O
block O O
voltage O O
- O O
, O O
calcium O O
- O O
and O O
ATP O O
- O O
sensitive O O
K O O
( O O
+ O O
) O O
- O O
channels O O
while O O
4 O O
- O O
aminopyridine O O
is O O
known O O
to O O
block O O
voltage O O
- O O
sensitive O O
K O O
( O O
+ O O
) O O
- O O
channels O O
. O O

2 O O
. O O

In O O
the O O
motor O O
activity O O
test O O
measured O O
with O O
an O O
Animex O O
- O O
activity O O
meter O O
neither O O
of O O
the O O
K O O
( O O
+ O O
) O O
- O O
channel O O
blockers O O
affected O O
morphine O O
- O O
induced O O
hypoactivity B B_DISEASE
, O O
but O O
both O O
K O O
( O O
+ O O
) O O
- O O
channel O O
blockers O O
prevented O O
morphine O O
- O O
induced O O
secondary O O
hyperactivity B B_DISEASE
. O O

3 O O
. O O

It O O
is O O
also O O
suggested O O
that O O
the O O
blockade O O
of O O
K O O
( O O
+ O O
) O O
- O O
channels O O
sensitive O O
to O O
these O O
blockers O O
is O O
not O O
sufficient O O
to O O
prevent O O
morphine O O
- O O
induced O O
hypoactivity B B_DISEASE
whereas O O
morphine O O
- O O
induced O O
hyperactivity B B_DISEASE
seems O O
to O O
be O O
connected O O
to O O
both O O
quinine O O
- O O
and O O
4 O O
- O O
aminopyridine O O
- O O
sensitive O O
K O O
( O O
+ O O
) O O
- O O
channels O O
. O O

Nociceptin O O
/ O O
orphanin O O
FQ O O
and O O
nocistatin O O
on O O
learning B B_DISEASE
and I I_DISEASE
memory I I_DISEASE
impairment I I_DISEASE
induced O O
by O O
scopolamine O O
in O O
mice O O
. O O

1 O O
. O O

On O O
the O O
other O O
hand O O
, O O
nocistatin O O
is O O
recently O O
isolated O O
from O O
the O O
same O O
precursor O O
as O O
nociceptin O O
and O O
blocks O O
nociceptin O O
- O O
induced O O
allodynia B B_DISEASE
and O O
hyperalgesia B B_DISEASE
. O O

2 O O
. O O

3 O O
. O O

The O O
present O O
study O O
was O O
designed O O
to O O
investigate O O
whether O O
nociceptin O O
/ O O
orphanin O O
FQ O O
and O O
nocistatin O O
could O O
modulate O O
impairment B B_DISEASE
of I I_DISEASE
learning I I_DISEASE
and I I_DISEASE
memory I I_DISEASE
induced O O
by O O
scopolamine O O
, O O
a O O
muscarinic O O
cholinergic O O
receptor O O
antagonist O O
, O O
using O O
spontaneous O O
alternation O O
of O O
Y O O
- O O
maze O O
and O O
step O O
- O O
down O O
type O O
passive O O
avoidance O O
tasks O O
in O O
mice O O
. O O

4 O O
. O O

While O O
nocistatin O O
( O O
0 O O
. O O
5 O O
- O O
5 O O
. O O
0 O O
nmol O O
mouse O O
- O O
1 O O
, O O
i O O
. O O
c O O
. O O
v O O
. O O
) O O
administered O O
30 O O
min O O
before O O
spontaneous O O
alternation O O
performance O O
or O O
the O O
training O O
session O O
of O O
the O O
passive O O
avoidance O O
task O O
, O O
had O O
no O O
effect O O
on O O
spontaneous O O
alternation O O
or O O
passive O O
avoidance O O
behaviours O O
, O O
a O O
lower O O
per O O
cent O O
alternation O O
and O O
shorter O O
median O O
step O O
- O O
down O O
latency O O
in O O
the O O
retention O O
test O O
were O O
obtained O O
in O O
nociceptin O O
( O O
1 O O
. O O
5 O O
and O O
/ O O
or O O
5 O O
. O O
0 O O
nmol O O
mouse O O
- O O
1 O O
, O O
i O O
. O O
c O O
. O O
v O O
. O O
) O O
- O O
treated O O
normal O O
mice O O
. O O

5 O O
. O O

6 O O
. O O

Meloxicam O O
- O O
induced O O
liver B B_DISEASE
toxicity I I_DISEASE
. O O

We O O
report O O
the O O
case O O
of O O
a O O
female O O
patient O O
with O O
rheumatoid B B_DISEASE
arthritis I I_DISEASE
who O O
developed O O
acute O O
cytolytic O O
hepatitis B B_DISEASE
due O O
to O O
meloxicam O O
. O O

Recently O O
introduced O O
in O O
Belgium O O
, O O
meloxicam O O
is O O
the O O
first O O
nonsteroidal O O
antiinflammatory O O
drug O O
with O O
selective O O
action O O
on O O
the O O
inducible O O
form O O
of O O
cyclooxygenase O O
2 O O
. O O

The O O
acute O O
cytolytic O O
hepatitis B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
occurred O O
rapidly O O
after O O
meloxicam O O
administration O O
and O O
was O O
associated O O
with O O
the O O
development O O
of O O
antinuclear O O
antibodies O O
suggesting O O
a O O
hypersensitivity B B_DISEASE
mechanism O O
. O O

This O O
first O O
case O O
of O O
meloxicam O O
related O O
liver B B_DISEASE
toxicity I I_DISEASE
demonstrates O O
the O O
potential O O
of O O
this O O
drug O O
to O O
induce O O
hepatic B B_DISEASE
damage I I_DISEASE
. O O

Induction O O
of O O
apoptosis O O
by O O
remoxipride O O
metabolites O O
in O O
HL60 O O
and O O
CD34 O O
+ O O
/ O O
CD19 O O
- O O
human O O
bone O O
marrow O O
progenitor O O
cells O O
: O O
potential O O
relevance O O
to O O
remoxipride O O
- O O
induced O O
aplastic B B_DISEASE
anemia I I_DISEASE
. O O

The O O
antipsychotic O O
agent O O
, O O
remoxipride O O
[ O O
( O O
S O O
) O O
- O O
( O O
- O O
) O O
- O O
3 O O
- O O
bromo O O
- O O
N O O
- O O
[ O O
( O O
1 O O
- O O
ethyl O O
- O O
2 O O
- O O
pyrrolidinyl O O
) O O
methyl O O
] O O
- O O
2 O O
, O O
6 O O
- O O
dimethoxybenz O O
amide O O
] O O
has O O
been O O
associated O O
with O O
acquired O O
aplastic B B_DISEASE
anemia I I_DISEASE
. O O

Cells O O
were O O
treated O O
for O O
0 O O
- O O
24 O O
h O O
with O O
each O O
compound O O
( O O
0 O O
- O O
200 O O
microM O O
) O O
. O O

Results O O
were O O
confirmed O O
by O O
determination O O
of O O
internucleosomal O O
DNA O O
fragmentation O O
using O O
gel O O
electrophoresis O O
for O O
HL60 O O
cell O O
samples O O
and O O
terminal O O
deoxynucleotidyl O O
transferase O O
assay O O
in O O
HBMP O O
cells O O
. O O

The O O
catechol O O
and O O
hydroquinone O O
metabolites O O
, O O
NCQ436 O O
and O O
NCQ344 O O
, O O
induced O O
apoptosis O O
in O O
HL60 O O
and O O
HBMP O O
cells O O
in O O
a O O
time O O
- O O
and O O
concentration O O
dependent O O
manner O O
, O O
while O O
the O O
phenols O O
, O O
NCR181 O O
, O O
FLA873 O O
, O O
and O O
FLA797 O O
, O O
and O O
the O O
derivatives O O
formed O O
by O O
oxidation O O
of O O
the O O
pyrrolidine O O
ring O O
, O O
FLA838 O O
, O O
NCM001 O O
, O O
and O O
NCL118 O O
, O O
had O O
no O O
effect O O
. O O

No O O
necrosis B B_DISEASE
was O O
observed O O
in O O
cells O O
treated O O
with O O
NCQ436 O O
but O O
NCQ344 O O
had O O
a O O
biphasic O O
effect O O
in O O
both O O
cell O O
types O O
, O O
inducing O O
apoptosis O O
at O O
lower O O
concentrations O O
and O O
necrosis B B_DISEASE/B_GENE
at O O
higher O O
concentrations O O
. O O

We O O
propose O O
that O O
remoxipride O O
and O O
benzene O O
may O O
induce O O
aplastic B B_DISEASE/B_GENE
anemia I I_DISEASE/I_GENE
via O O
production O O
of O O
similar O O
reactive O O
metabolites O O
and O O
that O O
the O O
ability O O
of O O
NCQ436 O O
and O O
NCQ344 O O
to O O
induce O O
apoptosis O O
in O O
HBMP O O
cells O O
may O O
contribute O O
to O O
the O O
mechanism O O
underlying O O
acquired O O
aplastic B B_DISEASE
anemia I I_DISEASE
that O O
has O O
been O O
associated O O
with O O
remoxipride O O
. O O

Synthesis O O
and O O
preliminary O O
pharmacological O O
investigations O O
of O O
1 O O
- O O
( O O
1 O O
, O O
2 O O
- O O
dihydro O O
- O O
2 O O
- O O
acenaphthylenyl O O
) O O
piperazine O O
derivatives O O
as O O
potential O O
atypical O O
antipsychotic O O
agents O O
in O O
mice O O
. O O

The O O
synthesis O O
and O O
preliminary O O
pharmacological O O
evaluation O O
of O O
a O O
series O O
of O O
potential O O
atypical O O
antipsychotic O O
agents O O
based O O
on O O
the O O
structure O O
of O O
1 O O
- O O
( O O
1 O O
, O O
2 O O
- O O
dihydro O O
- O O
2 O O
- O O
acenaphthylenyl O O
) O O
piperazine O O
( O O
7 O O
) O O
is O O
described O O
. O O

Compound O O
7e O O
, O O
5 O O
- O O
{ O O
2 O O
- O O
[ O O
4 O O
- O O
( O O
1 O O
, O O
2 O O
- O O
dihydro O O
- O O
2 O O
- O O
acenaphthylenyl O O
) O O
piperazinyl O O
] O O
ethyl O O
} O O
- O O
2 O O
, O O
3 O O
- O O
dihy O O
dro O O
- O O
1H O O
- O O
indol O O
- O O
2 O O
- O O
one O O
, O O
from O O
this O O
series O O
showed O O
significant O O
affinities O O
at O O
the O O
5 O O
- O O
HT1A O O
and O O
5 O O
- O O
HT2A O O
receptors O O
and O O
moderate O O
affinity O O
at O O
the O O
D2 O O
receptor O O
. O O

7e O O
exhibits O O
a O O
high O O
reversal O O
of O O
catalepsy B B_DISEASE
induced O O
by O O
haloperidol O O
indicating O O
its O O
atypical O O
antipsychotic O O
nature O O
. O O

Sub O O
- O O
chronic O O
inhibition O O
of O O
nitric O O
- O O
oxide O O
synthesis O O
modifies O O
haloperidol O O
- O O
induced O O
catalepsy B B_DISEASE
and O O
the O O
number O O
of O O
NADPH O O
- O O
diaphorase O O
neurons O O
in O O
mice O O
. O O

RATIONALE O O
: O O
NG O O
- O O
nitro O O
- O O
L O O
- O O
arginine O O
( O O
L O O
- O O
NOARG O O
) O O
, O O
an O O
inhibitor O O
of O O
nitric O O
- O O
oxide O O
synthase O O
( O O
NOS O O
) O O
, O O
induces O O
catalepsy B B_DISEASE
in O O
mice O O
. O O

Nitric O O
oxide O O
( O O
NO O O
) O O
has O O
been O O
shown O O
to O O
influence O O
dopaminergic O O
neurotransmission O O
in O O
the O O
striatum O O
. O O

Neuroleptic O O
drugs O O
such O O
as O O
haloperidol O O
, O O
which O O
block O O
dopamine O O
receptors O O
, O O
also O O
cause O O
catalepsy B B_DISEASE
in O O
rodents O O
. O O

OBJECTIVES O O
: O O
To O O
investigate O O
the O O
effects O O
of O O
subchronic O O
L O O
- O O
NOARG O O
treatment O O
in O O
haloperidol O O
- O O
induced O O
catalepsy B B_DISEASE
and O O
the O O
number O O
of O O
NOS O O
neurons O O
in O O
areas O O
related O O
to O O
motor O O
control O O
. O O

METHODS O O
: O O
Male O O
albino O O
Swiss O O
mice O O
were O O
treated O O
sub O O
- O O
chronically O O
( O O
twice O O
a O O
day O O
for O O
4 O O
days O O
) O O
with O O
L O O
- O O
NOARG O O
( O O
40 O O
mg O O
/ O O
kg O O
i O O
. O O
p O O
. O O
) O O
or O O
haloperidol O O
( O O
1 O O
mg O O
/ O O
kg O O
i O O
. O O
p O O
. O O
) O O
. O O

Catalepsy B B_DISEASE_ADJECTIVE[DISEASE]
was O O
evaluated O O
at O O
the O O
beginning O O
and O O
the O O
end O O
of O O
the O O
treatments O O
. O O

RESULTS O O
: O O
L O O
- O O
NOARG O O
sub O O
- O O
chronic O O
administration O O
produced O O
tolerance O O
of O O
L O O
- O O
NOARG O O
and O O
of O O
haloperidol O O
- O O
induced O O
catalepsy B B_DISEASE
. O O

It O O
also O O
induced O O
an O O
increase O O
in O O
the O O
number O O
of O O
NADPH O O
- O O
d O O
- O O
positive O O
cells O O
in O O
the O O
dorsal O O
part O O
of O O
the O O
caudate O O
and O O
accumbens O O
nuclei O O
compared O O
with O O
haloperidol O O
and O O
in O O
the O O
pedunculopontine O O
tegmental O O
nucleus O O
compared O O
with O O
saline O O
. O O

In O O
contrast O O
, O O
there O O
was O O
a O O
decrease O O
in O O
NADPH O O
- O O
d O O
neuron O O
number O O
in O O
the O O
substantia O O
nigra O O
, O O
pars O O
compacta O O
in O O
both O O
haloperidol O O
- O O
treated O O
and O O
L O O
- O O
NOARG O O
- O O
treated O O
animals O O
. O O

Prolonged O O
left B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ventricular I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dysfunction I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occurs O O
in O O
patients O O
with O O
coronary B B_DISEASE/B_LOCATION
artery I I_DISEASE/I_LOCATION
disease I I_DISEASE/I_LOCATION
after O O
both O O
dobutamine O O
and O O
exercise O O
induced O O
myocardial B B_DISEASE_ADJECTIVE[DISEASE]
ischaemia I I_DISEASE_ADJECTIVE[DISEASE]
. O O

OBJECTIVE O O
: O O
To O O
determine O O
whether O O
pharmacological O O
stress O O
leads O O
to O O
prolonged O O
but O O
reversible O O
left B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ventricular I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dysfunction I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
patients O O
with O O
coronary B B_DISEASE
artery I I_DISEASE
disease I I_DISEASE
, O O
similar O O
to O O
that O O
seen O O
after O O
exercise O O
. O O

DESIGN O O
: O O
A O O
randomised O O
crossover O O
study O O
of O O
recovery O O
time O O
of O O
systolic O O
and O O
diastolic O O
left O O
ventricular O O
function O O
after O O
exercise O O
and O O
dobutamine O O
induced O O
ischaemia B B_DISEASE
. O O

SUBJECTS O O
: O O
10 O O
patients O O
with O O
stable B B_DISEASE_ADJECTIVE[DISEASE]
angina I I_DISEASE_ADJECTIVE[DISEASE]
, O O
angiographically O O
proven O O
coronary B B_DISEASE/B_LOCATION
artery I I_DISEASE/I_LOCATION
disease I I_DISEASE/I_LOCATION
, O O
and O O
normal O O
left O O
ventricular O O
function O O
. O O

INTERVENTIONS O O
: O O
Treadmill O O
exercise O O
and O O
dobutamine O O
stress O O
were O O
performed O O
on O O
different O O
days O O
. O O

Quantitative O O
assessment O O
of O O
systolic O O
and O O
diastolic O O
left O O
ventricular O O
function O O
was O O
performed O O
using O O
transthoracic O O
echocardiography O O
at O O
baseline O O
and O O
at O O
regular O O
intervals O O
after O O
each O O
test O O
. O O

There O O
was O O
no O O
difference O O
in O O
the O O
maximum O O
double O O
product O O
( O O
p O O
= O O
0 O O
. O O
53 O O
) O O
or O O
ST O O
depression B B_TIME[MEASURE]/B_DISEASE
( O O
p O O
= O O
0 O O
. O O
63 O O
) O O
with O O
either O O
form O O
of O O
stress O O
. O O

After O O
exercise O O
, O O
ejection O O
fraction O O
was O O
reduced O O
at O O
15 O O
and O O
30 O O
minutes O O
compared O O
with O O
baseline O O
( O O
mean O O
( O O
SEM O O
) O O
, O O
- O O
5 O O
. O O
6 O O
( O O
1 O O
. O O
5 O O
) O O
% O O
, O O
p O O
< O O
0 O O
. O O
05 O O
; O O
and O O
- O O
6 O O
. O O
1 O O
( O O
2 O O
. O O
2 O O
) O O
% O O
, O O
p O O
< O O
0 O O
. O O
01 O O
) O O
, O O
and O O
at O O
30 O O
and O O
45 O O
minutes O O
after O O
dobutamine O O
( O O
- O O
10 O O
. O O
8 O O
( O O
1 O O
. O O
8 O O
) O O
% O O
and O O
- O O
5 O O
. O O
5 O O
( O O
1 O O
. O O
8 O O
) O O
% O O
, O O
both O O
p O O
< O O
0 O O
. O O
01 O O
) O O
. O O

Regional O O
analysis O O
showed O O
a O O
reduction O O
in O O
the O O
worst O O
affected O O
segment O O
15 O O
and O O
30 O O
minutes O O
after O O
exercise O O
( O O
- O O
27 O O
. O O
9 O O
( O O
7 O O
. O O
2 O O
) O O
% O O
and O O
- O O
28 O O
. O O
6 O O
( O O
5 O O
. O O
7 O O
) O O
% O O
, O O
both O O
p O O
< O O
0 O O
. O O
01 O O
) O O
, O O
and O O
at O O
30 O O
minutes O O
after O O
dobutamine O O
( O O
- O O
32 O O
( O O
5 O O
. O O
3 O O
) O O
% O O
, O O
p O O
< O O
0 O O
. O O
01 O O
) O O
. O O

CONCLUSIONS O O
: O O
In O O
patients O O
with O O
coronary B B_DISEASE
artery I I_DISEASE
disease I I_DISEASE
, O O
dobutamine O O
induced O O
ischaemia B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
results O O
in O O
prolonged O O
reversible O O
left B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ventricular I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dysfunction I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
presumed O O
to O O
be O O
myocardial B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
stunning I I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
similar O O
to O O
that O O
seen O O
after O O
exercise O O
. O O

Dobutamine O O
induced O O
ischaemia B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
could O O
therefore O O
be O O
used O O
to O O
study O O
the O O
pathophysiology O O
of O O
this O O
phenomenon O O
further O O
in O O
patients O O
with O O
coronary B B_DISEASE
artery I I_DISEASE
disease I I_DISEASE
. O O

Anorexigens O O
and O O
pulmonary B B_DISEASE/B_PERSON
hypertension I I_DISEASE/I_PERSON
in O O
the O O
United O O
States O O
: O O
results O O
from O O
the O O
surveillance O O
of O O
North O O
American O O
pulmonary B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
hypertension I B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

BACKGROUND O O
: O O
The O O
use O O
of O O
appetite O O
suppressants O O
in O O
Europe O O
has O O
been O O
associated O O
with O O
the O O
development O O
of O O
primary B B_DISEASE
pulmonary I I_DISEASE
hypertension I I_DISEASE
( O O
PPH B B_DISEASE/B_GENE
) O O
. O O

MATERIALS O O
AND O O
METHODS O O
: O O
We O O
conducted O O
a O O
prospective O O
surveillance O O
study O O
on O O
patients O O
diagnosed O O
with O O
pulmonary B B_DISEASE
hypertension I I_DISEASE
at O O
12 O O
large O O
referral O O
centers O O
in O O
North O O
America O O
. O O

Data O O
collected O O
on O O
patients O O
seen O O
from O O
September O O
1 O O
, O O
1996 O O
, O O
to O O
December O O
31 O O
, O O
1997 O O
, O O
included O O
the O O
cause O O
of O O
the O O
pulmonary B B_DISEASE_ADJECTIVE[DISEASE]
hypertension I I_DISEASE_ADJECTIVE[DISEASE]
and O O
its O O
severity O O
. O O

Patients O O
with O O
no O O
identifiable O O
cause O O
of O O
pulmonary B B_DISEASE/B_GENE
hypertension I I_DISEASE/I_GENE
were O O
classed O O
as O O
PPH B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O O

RESULTS O O
: O O
Five O O
hundred O O
seventy O O
- O O
nine O O
patients O O
were O O
studied O O
, O O
205 O O
with O O
PPH B B_DISEASE/B_GENE
and O O
374 O O
with O O
pulmonary B B_DISEASE
hypertension I I_DISEASE
from O O
other O O
causes O O
( O O
secondary O O
pulmonary B B_DISEASE
hypertension I I_DISEASE
[ O O
SPH O O
] O O
) O O
. O O

The O O
use O O
of O O
anorexigens O O
was O O
common O O
in O O
both O O
groups O O
. O O

However O O
, O O
of O O
the O O
medications O O
surveyed O O
, O O
only O O
the O O
fenfluramines O O
had O O
a O O
significant O O
preferential O O
association O O
with O O
PPH B B_DISEASE/B_LOCATION
as O O
compared O O
with O O
SPH O O
( O O
adjusted O O
odds O O
ratio O O
for O O
use O O
> O O
6 O O
months O O
, O O
7 O O
. O O
5 O O
; O O
95 O O
% O O
confidence O O
interval O O
, O O
1 O O
. O O
7 O O
to O O
32 O O
. O O
4 O O
) O O
. O O

The O O
association O O
was O O
stronger O O
with O O
longer O O
duration O O
of O O
use O O
when O O
compared O O
to O O
shorter O O
duration O O
of O O
use O O
and O O
was O O
more O O
pronounced O O
in O O
recent O O
users O O
than O O
in O O
remote O O
users O O
. O O

CONCLUSION O O
: O O
The O O
magnitude O O
of O O
the O O
association O O
with O O
PPH B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
increase O O
of O O
association O O
with O O
increasing O O
duration O O
of O O
use O O
, O O
and O O
the O O
specificity O O
for O O
fenfluramines O O
are O O
consistent O O
with O O
previous O O
studies O O
indicating O O
that O O
fenfluramines O O
are O O
causally O O
related O O
to O O
PPH B B_DISEASE
. O O

The O O
high O O
prevalence O O
of O O
anorexigen O O
use O O
in O O
patients O O
with O O
SPH O O
also O O
raises O O
the O O
possibility O O
that O O
these O O
drugs O O
precipitate O O
pulmonary B B_DISEASE
hypertension I I_DISEASE
in O O
patients O O
with O O
underlying O O
conditions O O
associated O O
with O O
SPH O O
. O O

Clinical O O
aspects O O
of O O
heparin O O
- O O
induced O O
thrombocytopenia B B_DISEASE
and O O
thrombosis B B_DISEASE
and O O
other O O
side O O
effects O O
of O O
heparin O O
therapy O O
. O O

Heparin O O
, O O
first O O
used O O
to O O
prevent O O
the O O
clotting O O
of O O
blood O O
in O O
vitro O O
, O O
has O O
been O O
clinically O O
used O O
to O O
treat O O
thrombosis B B_DISEASE
for O O
more O O
than O O
50 O O
years O O
. O O

Although O O
several O O
new O O
anticoagulant O O
drugs O O
are O O
in O O
development O O
, O O
heparin O O
remains O O
the O O
anticoagulant O O
of O O
choice O O
to O O
treat O O
acute O O
thrombotic B B_DISEASE
episodes O O
. O O

The O O
clinical O O
effects O O
of O O
heparin O O
are O O
meritorious O O
, O O
but O O
side O O
effects O O
do O O
exist O O
. O O

Bleeding B B_DISEASE
is O O
the O O
primary O O
untoward O O
effect O O
of O O
heparin O O
. O O

Major O O
bleeding B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
of O O
primary O O
concern O O
in O O
patients O O
receiving O O
heparin O O
therapy O O
. O O

However O O
, O O
additional O O
important O O
untoward O O
effects O O
of O O
heparin O O
therapy O O
include O O
heparin O O
- O O
induced O O
thrombocytopenia B B_DISEASE
, O O
heparin O O
- O O
associated O O
osteoporosis B B_DISEASE
, O O
eosinophilia B B_DISEASE
, O O
skin B B_DISEASE
reactions I I_DISEASE
, O O
allergic B B_DISEASE_ADJECTIVE[DISEASE]
reactions I I_DISEASE_ADJECTIVE[DISEASE]
other O O
than O O
thrombocytopenia B B_DISEASE
, O O
alopecia B B_DISEASE
, O O
transaminasemia O O
, O O
hyperkalemia B B_DISEASE
, O O
hypoaldosteronism B B_DISEASE
, O O
and O O
priapism B B_DISEASE
. O O

These O O
side O O
effects O O
are O O
relatively O O
rare O O
in O O
a O O
given O O
individual O O
, O O
but O O
given O O
the O O
extremely O O
widespread O O
use O O
of O O
heparin O O
, O O
some O O
are O O
quite O O
common O O
, O O
particularly O O
HITT B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
osteoporosis B B_DISEASE
. O O

However O O
, O O
only O O
longer O O
experience O O
will O O
more O O
clearly O O
define O O
the O O
incidence O O
of O O
each O O
side O O
effect O O
with O O
low O O
molecular O O
weight O O
preparations O O
. O O

A O O
case O O
of O O
bilateral O O
optic B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
neuropathy I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
a O O
patient O O
on O O
tacrolimus O O
( O O
FK506 O O
) O O
therapy O O
after O O
liver O O
transplantation O O
. O O

PURPOSE O O
: O O
To O O
report O O
a O O
case O O
of O O
bilateral O O
optic B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
neuropathy I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
a O O
patient O O
receiving O O
tacrolimus O O
( O O
FK O O
506 O O
, O O
Prograf O O
; O O
Fujisawa O O
USA O O
, O O
Inc O O
, O O
Deerfield O O
, O O
Illinois O O
) O O
for O O
immunosuppression O O
after O O
orthotropic O O
liver O O
transplantation O O
. O O

METHOD O O
: O O
Case O O
report O O
. O O

In O O
a O O
58 O O
- O O
year O O
- O O
old O O
man O O
receiving O O
tacrolimus O O
after O O
orthotropic O O
liver O O
transplantation O O
, O O
serial O O
neuro O O
- O O
ophthalmologic O O
examinations O O
and O O
laboratory O O
studies O O
were O O
performed O O
. O O

RESULTS O O
: O O
The O O
patient O O
had O O
episodic O O
deterioration O O
of O O
vision O O
in O O
both O O
eyes O O
, O O
with O O
clinical O O
features O O
resembling O O
ischemic B B_DISEASE
optic I I_DISEASE
neuropathies I I_DISEASE
. O O

Deterioration B B_DISEASE/B_PERSON
of I I_DISEASE/I_PERSON
vision I I_DISEASE/I_PERSON
occurred O O
despite O O
discontinuation O O
of O O
the O O
tacrolimus O O
. O O

CONCLUSION O O
: O O
Tacrolimus O O
and O O
other O O
immunosuppressive O O
agents O O
may O O
be O O
associated O O
with O O
optic B B_DISEASE/B_GENE
nerve I I_DISEASE/I_GENE
toxicity I I_DISEASE/I_GENE
. O O

Hypercalcemia B B_DISEASE
, O O
arrhythmia B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
mood O O
stabilizers O O
. O O

A O O
printout O O
of O O
all O O
cases O O
of O O
hypercalcemia B B_DISEASE
that O O
presented O O
during O O
a O O
1 O O
- O O
year O O
period O O
was O O
generated O O
. O O

After O O
eliminating O O
spurious O O
hypercalcemias B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
those O O
associated O O
with O O
intravenous O O
fluids O O
, O O
the O O
authors O O
identified O O
18 O O
non O O
- O O
lithium O O
- O O
treated O O
patients O O
with O O
hypercalcemias B B_DISEASE
related O O
to O O
malignancies B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
other O O
medical O O
conditions O O
( O O
group O O
A O O
) O O
and O O
12 O O
patients O O
with O O
lithium O O
- O O
associated O O
hypercalcemia B B_DISEASE
( O O
group O O
B O O
) O O
. O O

Patients O O
in O O
group O O
B O O
were O O
not O O
comparable O O
to O O
those O O
in O O
group O O
A O O
, O O
as O O
the O O
latter O O
were O O
medically O O
compromised O O
and O O
were O O
receiving O O
multiple O O
pharmacotherapies O O
. O O

Thus O O
, O O
two O O
control O O
groups O O
were O O
generated O O
: O O
group O O
C1 O O
, O O
which O O
included O O
age O O
- O O
and O O
sex O O
- O O
comparable O O
lithium O O
- O O
treated O O
bipolar B B_DISEASE/B_PERSON
normocalcemic O O
patients O O
, O O
and O O
group O O
C2 O O
, O O
which O O
included O O
bipolar B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
normocalcemic O O
patients O O
treated O O
with O O
anticonvulsant O O
mood O O
stabilizers O O
. O O

The O O
electrocardiographic O O
( O O
ECG O O
) O O
findings O O
for O O
patients O O
in O O
group O O
B O O
were O O
compared O O
with O O
those O O
of O O
patients O O
in O O
groups O O
C1 O O
and O O
C2 O O
. O O

Patients O O
with O O
hypercalcemia B B_DISEASE
resulting O O
from O O
medical O O
diseases O O
and O O
bipolar B B_DISEASE/B_MEASURE
patients O O
with O O
lithium O O
- O O
associated O O
hypercalcemia B B_DISEASE
had O O
significantly O O
higher O O
frequencies O O
of O O
conduction O O
defects O O
. O O

The O O
clinical O O
implications O O
of O O
these O O
findings O O
are O O
discussed O O
. O O

Attenuation O O
of O O
nephrotoxicity B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
a O O
novel O O
lipid O O
nanosphere O O
( O O
NS O O
- O O
718 O O
) O O
incorporating O O
amphotericin O O
B O O
. O O

NS O O
- O O
718 O O
, O O
a O O
lipid O O
nanosphere O O
incorporating O O
amphotericin O O
B O O
, O O
is O O
effective O O
against O O
pathogenic O O
fungi O O
and O O
has O O
low O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
compared O O
the O O
toxicity B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
NS O O
- O O
718 O O
with O O
that O O
of O O
Fungizone O O
( O O
amphotericin O O
B O O
- O O
sodium O O
deoxycholate O O
; O O
D O O
- O O
AmB O O
) O O
in O O
vitro O O
using O O
renal O O
cell O O
cultures O O
and O O
in O O
vivo O O
by O O
biochemical O O
analysis O O
, O O
histopathological O O
study O O
of O O
the O O
kidney O O
and O O
pharmacokinetic O O
study O O
of O O
amphotericin O O
B O O
following O O
intravenous O O
infusion O O
of O O
the O O
formulation O O
in O O
rats O O
. O O

Incubation O O
with O O
NS O O
- O O
718 O O
resulted O O
in O O
significantly O O
less O O
damage O O
of O O
cultured O O
human O O
renal O O
proximal O O
tubular O O
epithelial O O
cells O O
compared O O
with O O
D O O
- O O
AmB O O
. O O

Histopathological O O
examination O O
of O O
the O O
kidney O O
showed O O
tubular B B_DISEASE
necrosis I I_DISEASE
in O O
D O O
- O O
AmB O O
- O O
treated O O
rats O O
but O O
no O O
change O O
in O O
NS O O
- O O
718 O O
- O O
treated O O
rats O O
. O O

Amphotericin O O
B O O
concentrations O O
in O O
the O O
kidney O O
in O O
NS O O
- O O
718 O O
- O O
treated O O
rats O O
were O O
higher O O
than O O
those O O
in O O
D O O
- O O
AmB O O
- O O
treated O O
rats O O
. O O

Our O O
in O O
vitro O O
and O O
in O O
vivo O O
results O O
suggest O O
that O O
incorporation O O
of O O
amphotericin O O
B O O
into O O
lipid O O
nanospheres O O
of O O
NS O O
- O O
718 O O
attenuates O O
the O O
nephrotoxicity B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
amphotericin O O
B O O
. O O

Patterns O O
of O O
sulfadiazine O O
acute B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
nephrotoxicity I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Sulfadiazine O O
acute B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nephrotoxicity I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
reviving O O
specially O O
because O O
of O O
its O O
use O O
in O O
toxoplasmosis B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
HIV O O
- O O
positive O O
patients O O
. O O

We O O
report O O
4 O O
cases O O
, O O
one O O
of O O
them O O
in O O
a O O
previously O O
healthy O O
person O O
. O O

Under O O
treatment O O
with O O
sulfadiazine O O
they O O
developed O O
oliguria B B_DISEASE
, O O
abdominal B B_DISEASE
pain I I_DISEASE
, O O
renal B B_DISEASE
failure I I_DISEASE
and O O
showed O O
multiple O O
radiolucent O O
renal B B_DISEASE/B_LOCATION
calculi I I_DISEASE/I_LOCATION
in O O
echography O O
. O O

All O O
patients O O
recovered O O
their O O
previous O O
normal O O
renal O O
function O O
after O O
adequate O O
hydration O O
and O O
alcalinization O O
. O O

A O O
nephrostomy O O
tube O O
had O O
to O O
be O O
placed O O
in O O
one O O
of O O
the O O
patients O O
for O O
ureteral B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
lithiasis I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
single O O
functional O O
kidney O O
. O O

We O O
communicate O O
a O O
case O O
in O O
a O O
previously O O
healthy O O
person O O
, O O
a O O
fact O O
not O O
found O O
in O O
the O O
recent O O
literature O O
. O O

Probably O O
many O O
more O O
cases O O
are O O
not O O
detected O O
. O O

We O O
think O O
that O O
a O O
prospective O O
study O O
would O O
be O O
useful O O
. O O

Downbeat B B_DISEASE_ADJECTIVE[DISEASE]
nystagmus I I_DISEASE_ADJECTIVE[DISEASE]
associated O O
with O O
intravenous O O
patient O O
- O O
controlled O O
administration O O
of O O
morphine O O
. O O

IMPLICATIONS O O
: O O
This O O
case O O
documents O O
a O O
patient O O
who O O
developed O O
dizziness B B_DISEASE
with O O
downbeating B B_DISEASE/B_MEASURE
nystagmus I I_DISEASE/I_MEASURE
while O O
receiving O O
a O O
relatively O O
large O O
dose O O
of O O
IV O O
patient O O
- O O
controlled O O
analgesia O O
morphine O O
. O O

Hemodynamic O O
and O O
antiadrenergic O O
effects O O
of O O
dronedarone O O
and O O
amiodarone O O
in O O
animals O O
with O O
a O O
healed O O
myocardial B B_DISEASE
infarction I I_DISEASE
. O O

The O O
hemodynamic O O
and O O
antiadrenergic O O
effects O O
of O O
dronedarone O O
, O O
a O O
noniodinated O O
compound O O
structurally O O
related O O
to O O
amiodarone O O
, O O
were O O
compared O O
with O O
those O O
of O O
amiodarone O O
after O O
prolonged O O
oral O O
administration O O
, O O
both O O
at O O
rest O O
and O O
during O O
sympathetic O O
stimulation O O
in O O
conscious O O
dogs O O
with O O
a O O
healed O O
myocardial B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
infarction I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

All O O
dogs O O
( O O
n O O
= O O
6 O O
) O O
randomly O O
received O O
orally O O
dronedarone O O
( O O
10 O O
and O O
30 O O
mg O O
/ O O
kg O O
) O O
, O O
amiodarone O O
( O O
10 O O
and O O
30 O O
mg O O
/ O O
kg O O
) O O
, O O
and O O
placebo O O
twice O O
daily O O
for O O
7 O O
days O O
, O O
with O O
a O O
3 O O
- O O
week O O
washout O O
between O O
consecutive O O
treatments O O
. O O

Resting O O
values O O
of O O
LVEF O O
, O O
FS O O
, O O
+ O O
LVdP O O
/ O O
dt O O
, O O
and O O
MBP O O
remained O O
unchanged O O
whatever O O
the O O
drug O O
and O O
the O O
dosing O O
regimen O O
, O O
whereas O O
resting O O
HR O O
was O O
significantly O O
and O O
dose O O
- O O
dependently O O
lowered O O
after O O
dronedarone O O
and O O
to O O
a O O
lesser O O
extent O O
after O O
amiodarone O O
. O O

Both O O
dronedarone O O
and O O
amiodarone O O
significantly O O
reduced O O
the O O
exercise O O
- O O
induced O O
tachycardia B B_DISEASE
and O O
, O O
at O O
the O O
highest O O
dose O O
, O O
decreased O O
the O O
isoproterenol O O
- O O
induced O O
tachycardia B B_DISEASE
. O O

Consequently O O
, O O
dronedarone O O
might O O
be O O
particularly O O
suitable O O
for O O
the O O
treatment O O
and O O
prevention O O
of O O
various O O
clinical O O
arrhythmias B B_DISEASE
, O O
without O O
compromising O O
the O O
left O O
ventricular O O
function O O
. O O

Phase O O
2 O O
trial O O
of O O
liposomal O O
doxorubicin O O
( O O
40 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
) O O
in O O
platinum O O
/ O O
paclitaxel O O
- O O
refractory O O
ovarian B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
fallopian I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
tube I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cancers I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
primary O O
carcinoma B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
of I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
the I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
peritoneum I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

BACKGROUND O O
: O O
Several O O
studies O O
have O O
demonstrated O O
liposomal O O
doxorubicin O O
( O O
Doxil O O
) O O
to O O
be O O
an O O
active O O
antineoplastic O O
agent O O
in O O
platinum O O
- O O
resistant O O
ovarian B B_DISEASE
cancer I I_DISEASE
, O O
with O O
dose O O
limiting O O
toxicity B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
the O O
standard O O
dosing O O
regimen O O
( O O
50 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
q O O
4 O O
weeks O O
) O O
being O O
severe O O
erythrodysesthesia B B_DISEASE
( O O
" O O
hand B B_DISEASE
- I I_DISEASE
foot I I_DISEASE
syndrome I I_DISEASE
" O O
) O O
and O O
stomatitis B B_DISEASE
. O O

METHODS O O
AND O O
MATERIALS O O
: O O
Patients O O
with O O
ovarian B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
or I I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
fallopian I I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
tube I I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
cancers I I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
or O O
primary O O
peritoneal B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
carcinoma I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
with O O
platinum O O
/ O O
paclitaxel O O
- O O
refractory O O
disease O O
( O O
stable O O
or O O
progressive O O
disease O O
following O O
treatment O O
with O O
these O O
agents O O
or O O
previous O O
objective O O
response O O
< O O
3 O O
months O O
in O O
duration O O
) O O
were O O
treated O O
with O O
liposomal O O
doxorubicin O O
at O O
a O O
dose O O
of O O
40 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
q O O
4 O O
weeks O O
. O O

RESULTS O O
: O O
A O O
total O O
of O O
49 O O
patients O O
( O O
median O O
age O O
: O O
60 O O
; O O
range O O
41 O O
- O O
81 O O
) O O
entered O O
this O O
phase O O
2 O O
trial O O
. O O

The O O
median O O
number O O
of O O
prior O O
regimens O O
was O O
2 O O
( O O
range O O
: O O
1 O O
- O O
6 O O
) O O
. O O

Six O O
( O O
12 O O
% O O
) O O
and O O
4 O O
( O O
8 O O
% O O
) O O
patients O O
experienced O O
grade O O
2 O O
hand B B_DISEASE
- I I_DISEASE
foot I I_DISEASE
syndrome I I_DISEASE
and O O
stomatitis B B_DISEASE
, O O
respectively O O
( O O
no O O
episodes O O
of O O
grade O O
3 O O
) O O
. O O

One O O
patient O O
developed O O
grade O O
3 O O
diarrhea B B_DISEASE
requiring O O
hospitalization O O
for O O
hydration O O
. O O

Six O O
( O O
12 O O
% O O
) O O
individuals O O
required O O
dose O O
reductions O O
. O O

The O O
median O O
number O O
of O O
courses O O
of O O
liposomal O O
doxorubicin O O
administered O O
on O O
this O O
protocol O O
was O O
2 O O
( O O
range O O
: O O
1 O O
- O O
12 O O
) O O
. O O

Four O O
of O O
44 O O
patients O O
( O O
9 O O
% O O
) O O
evaluable O O
for O O
response O O
exhibited O O
objective O O
and O O
subjective O O
evidence O O
of O O
an O O
antineoplastic O O
effect O O
of O O
therapy O O
. O O

CONCLUSION O O
: O O
This O O
modified O O
liposomal O O
doxorubicin O O
regimen O O
results O O
in O O
less O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
stomatitis B B_DISEASE
, O O
hand B B_DISEASE
- I I_DISEASE
foot I I_DISEASE
syndrome I I_DISEASE
) O O
than O O
the O O
standard O O
FDA O O
- O O
approved O O
dose O O
schedule O O
. O O

Definite O O
, O O
although O O
limited O O
, O O
antineoplastic O O
activity O O
is O O
observed O O
in O O
patients O O
with O O
well O O
- O O
defined O O
platinum O O
- O O
and O O
paclitaxel O O
- O O
refractory O O
ovarian B B_DISEASE
cancer I I_DISEASE
. O O

Efficacy O O
of O O
olanzapine O O
in O O
acute O O
bipolar B B_DISEASE
mania I I_DISEASE
: O O
a O O
double O O
- O O
blind O O
, O O
placebo O O
- O O
controlled O O
study O O
. O O

The O O
Olanzipine O O
HGGW O O
Study O O
Group O O
. O O

BACKGROUND O O
: O O
We O O
compared O O
the O O
efficacy O O
and O O
safety O O
of O O
olanzapine O O
vs O O
placebo O O
for O O
the O O
treatment O O
of O O
acute O O
bipolar B B_DISEASE
mania I I_DISEASE
. O O

METHODS O O
: O O
Four O O
- O O
week O O
, O O
randomized O O
, O O
double O O
- O O
blind O O
, O O
parallel O O
study O O
. O O

A O O
total O O
of O O
115 O O
patients O O
with O O
a O O
DSM O O
- O O
IV O O
diagnosis O O
of O O
bipolar B B_DISEASE/B_LOCATION
disorder I I_DISEASE/I_LOCATION
, O O
manic B B_DISEASE
or O O
mixed O O
, O O
were O O
randomized O O
to O O
olanzapine O O
, O O
5 O O
to O O
20 O O
mg O O
/ O O
d O O
( O O
n O O
= O O
55 O O
) O O
, O O
or O O
placebo O O
( O O
n O O
= O O
60 O O
) O O
. O O

There O O
were O O
no O O
statistically O O
significant O O
differences O O
in O O
EPSs B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
groups O O
. O O

However O O
, O O
olanzapine O O
- O O
treated O O
patients O O
had O O
a O O
statistically O O
significant O O
greater O O
mean O O
( O O
+ O O
/ O O
- O O
SD O O
) O O
weight B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
gain I B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
than O O
placebo O O
- O O
treated O O
patients O O
( O O
2 O O
. O O
1 O O
+ O O
/ O O
- O O
2 O O
. O O
8 O O
vs O O
0 O O
. O O
45 O O
+ O O
/ O O
- O O
2 O O
. O O
3 O O
kg O O
, O O
respectively O O
) O O
and O O
also O O
experienced O O
more O O
treatment O O
- O O
emergent O O
somnolence B B_DISEASE
( O O
21 O O
patients O O
[ O O
38 O O
. O O
2 O O
% O O
] O O
vs O O
5 O O
[ O O
8 O O
. O O
3 O O
% O O
] O O
, O O
respectively O O
) O O
. O O

CONCLUSION O O
: O O
Olanzapine O O
demonstrated O O
greater O O
efficacy O O
than O O
placebo O O
in O O
the O O
treatment O O
of O O
acute O O
bipolar B B_DISEASE
mania I I_DISEASE
and O O
was O O
generally O O
well O O
tolerated O O
. O O

The O O
effect O O
of O O
pupil B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
dilation I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
with O O
tropicamide O O
on O O
vision O O
and O O
driving O O
simulator O O
performance O O
. O O

PURPOSE O O
: O O
To O O
assess O O
the O O
effect O O
of O O
pupil B B_DISEASE
dilation I I_DISEASE
on O O
vision O O
and O O
driving O O
ability O O
. O O

METHODS O O
: O O
A O O
series O O
of O O
tests O O
on O O
various O O
parameters O O
of O O
visual O O
function O O
and O O
driving O O
simulator O O
performance O O
were O O
performed O O
on O O
12 O O
healthy O O
drivers O O
, O O
before O O
and O O
after O O
pupil B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
dilation I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
using O O
guttae O O
tropicamide O O
1 O O
% O O
. O O

A O O
driving O O
simulator O O
( O O
Transport O O
Research O O
Laboratory O O
) O O
was O O
used O O
to O O
measure O O
reaction O O
time O O
( O O
RT O O
) O O
, O O
speed O O
maintenance O O
and O O
steering O O
accuracy O O
. O O

Tests O O
of O O
basic O O
visual O O
function O O
included O O
high O O
- O O
and O O
low O O
- O O
contrast O O
visual O O
acuity O O
( O O
HCVA O O
and O O
LCVA O O
) O O
, O O
Pelli O O
- O O
Robson O O
contrast O O
threshold O O
( O O
CT O O
) O O
and O O
Goldmann O O
perimetry O O
( O O
FIELDS O O
) O O
. O O

The O O
mean O O
differences O O
in O O
the O O
pre O O
- O O
and O O
post O O
- O O
dilatation O O
measurements O O
were O O
tested O O
for O O
statistical O O
significance O O
at O O
the O O
95 O O
% O O
level O O
using O O
one O O
- O O
tail O O
paired O O
t O O
- O O
tests O O
. O O

RESULTS O O
: O O
Pupillary B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
dilation I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
resulted O O
in O O
a O O
statistically O O
significant O O
deterioration O O
in O O
CT O O
and O O
HCVA O O
only O O
. O O

Five O O
of O O
12 O O
drivers O O
also O O
exhibited O O
deterioration O O
in O O
LCVA O O
, O O
CT O O
and O O
RT O O
. O O

CONCLUSIONS O O
: O O
Pupillary B B_DISEASE/B_PERSON
dilation I I_DISEASE/I_PERSON
may O O
lead O O
to O O
a O O
decrease O O
in O O
vision O O
and O O
daylight O O
driving O O
performance O O
in O O
young O O
people O O
. O O

A O O
larger O O
study O O
, O O
including O O
a O O
broader O O
spectrum O O
of O O
subjects O O
, O O
is O O
warranted O O
before O O
guidelines O O
can O O
be O O
recommended O O
. O O

A O O
case O O
of O O
isotretinoin B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
embryopathy I B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
with O O
bilateral O O
anotia B B_DISEASE/B_BACTERIUM[BIO]
and O O
Taussig B B_DISEASE
- I I_DISEASE
Bing I I_DISEASE
malformation I I_DISEASE
. O O

We O O
report O O
a O O
newborn O O
infant O O
with O O
multiple O O
congenital O O
anomalies O O
( O O
anotia B B_PERSON/B_DISEASE
and O O
Taussig B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
Bing I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
malformation I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
) O O
due O O
to O O
exposure O O
to O O
isotretinoin O O
within O O
the O O
first O O
trimester O O
. O O

In O O
this O O
paper O O
we O O
aim O O
to O O
draw O O
to O O
the O O
fact O O
that O O
caution O O
is O O
needed O O
when O O
prescribing O O
vitamin O O
A O O
- O O
containing O O
drugs O O
to O O
women O O
of O O
childbearing O O
years O O
. O O

Effect O O
of O O
methoxamine O O
on O O
maximum O O
urethral O O
pressure O O
in O O
women O O
with O O
genuine O O
stress B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
incontinence I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
: O O
a O O
placebo O O
- O O
controlled O O
, O O
double O O
- O O
blind O O
crossover O O
study O O
. O O

The O O
aim O O
of O O
the O O
study O O
was O O
to O O
evaluate O O
the O O
potential O O
role O O
for O O
a O O
selective O O
alpha1 O O
- O O
adrenoceptor O O
agonist O O
in O O
the O O
treatment O O
of O O
urinary B B_DISEASE/B_LOCATION
stress I I_DISEASE/I_LOCATION
incontinence I I_DISEASE/I_LOCATION
. O O

A O O
randomised O O
, O O
double O O
- O O
blind O O
, O O
placebo O O
- O O
controlled O O
, O O
crossover O O
study O O
design O O
was O O
employed O O
. O O

Half O O
log O O
incremental O O
doses O O
of O O
intravenous O O
methoxamine O O
or O O
placebo O O
( O O
saline O O
) O O
were O O
administered O O
to O O
a O O
group O O
of O O
women O O
with O O
genuine O O
stress B B_DISEASE
incontinence I I_DISEASE
while O O
measuring O O
maximum O O
urethral O O
pressure O O
( O O
MUP O O
) O O
, O O
blood O O
pressure O O
, O O
heart O O
rate O O
, O O
and O O
symptomatic O O
side O O
effects O O
. O O

Methoxamine O O
evoked O O
non O O
- O O
significant O O
increases O O
in O O
MUP O O
and O O
diastolic O O
blood O O
pressure O O
but O O
caused O O
a B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significant I I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rise I I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in I I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
systolic I I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood I I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pressure I I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
significant O O
fall O O
in O O
heart O O
rate O O
at O O
maximum O O
dosage O O
. O O

Systemic O O
side O O
effects O O
including O O
piloerection O O
, O O
headache B B_DISEASE
, O O
and O O
cold O O
extremities O O
were O O
experienced O O
in O O
all O O
subjects O O
. O O

The O O
results O O
indicate O O
that O O
the O O
clinical O O
usefulness O O
of O O
direct O O
, O O
peripherally O O
acting O O
sub O O
- O O
type O O
- O O
selective O O
alpha1 O O
- O O
adrenoceptor O O
agonists O O
in O O
the O O
medical O O
treatment O O
of O O
stress B B_DISEASE/B_LOCATION
incontinence I I_DISEASE/I_LOCATION
may O O
be O O
limited O O
by O O
associated O O
piloerection O O
and O O
cardiovascular O O
side O O
effects O O
. O O

Hyperglycemic B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O O
of O O
amino O O
compounds O O
structurally O O
related O O
to O O
caproate O O
in O O
rats O O
. O O

The O O
chronic O O
feeding O O
of O O
small O O
amounts O O
( O O
0 O O
. O O
3 O O
- O O
3 O O
% O O
of O O
diet O O
weight O O
) O O
of O O
certain O O
amino O O
derivatives O O
of O O
caproate O O
resulted O O
in O O
hyperglycemia B B_DISEASE
, O O
an O O
elevated O O
glucose O O
tolerance O O
curve O O
and O O
, O O
occasionally O O
, O O
glucosuria B B_DISEASE
. O O

Effective O O
compounds O O
included O O
norleucine O O
, O O
norvaline O O
, O O
glutamate O O
, O O
epsilon O O
- O O
aminocaproate O O
, O O
methionine O O
, O O
and O O
leucine O O
. O O

Toleration O O
of O O
high O O
doses O O
of O O
angiotensin O O
- O O
converting O O
enzyme O O
inhibitors O O
in O O
patients O O
with O O
chronic O O
heart B B_DISEASE
failure I I_DISEASE
: O O
results O O
from O O
the O O
ATLAS O O
trial O O
. O O

The O O
present O O
study O O
examines O O
the O O
safety O O
and O O
tolerability O O
of O O
high O O
- O O
compared O O
with O O
low O O
- O O
dose O O
lisinopril O O
in O O
CHF B B_DISEASE/B_PERSON
. O O

Patients O O
with O O
New O O
York O O
Heart O O
Association O O
classes O O
II O O
to O O
IV O O
CHF B B_DISEASE
and O O
left O O
ventricular O O
ejection O O
fractions O O
of O O
no O O
greater O O
than O O
0 O O
. O O
30 O O
( O O
n O O
= O O
3164 O O
) O O
were O O
randomized O O
and O O
followed O O
up O O
for O O
a O O
median O O
of O O
46 O O
months O O
. O O

We O O
examined O O
the O O
occurrence O O
of O O
adverse O O
events O O
and O O
the O O
need O O
for O O
discontinuation O O
and O O
dose O O
reduction O O
during O O
treatment O O
, O O
with O O
a O O
focus O O
on O O
hypotension B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
renal B B_DISEASE
dysfunction I I_DISEASE
. O O

RESULTS O O
: O O
Of O O
405 O O
patients O O
not O O
previously O O
receiving O O
an O O
ACE O O
inhibitor O O
, O O
doses O O
in O O
only O O
4 O O
. O O
2 O O
% O O
could O O
not O O
be O O
titrated O O
to O O
the O O
medium O O
doses O O
required O O
for O O
randomization O O
because O O
of O O
symptoms O O
possibly O O
related O O
to O O
hypotension B B_DISEASE
( O O
2 O O
. O O
0 O O
% O O
) O O
or O O
because O O
of O O
renal B B_DISEASE
dysfunction I I_DISEASE
or O O
hyperkalemia B B_DISEASE
( O O
2 O O
. O O
3 O O
% O O
) O O
. O O

Doses O O
in O O
more O O
than O O
90 O O
% O O
of O O
randomized O O
patients O O
in O O
the O O
high O O
- O O
and O O
low O O
- O O
dose O O
groups O O
were O O
titrated O O
to O O
their O O
assigned O O
target O O
, O O
and O O
the O O
mean O O
doses O O
of O O
blinded O O
medication O O
in O O
both O O
groups O O
remained O O
similar O O
throughout O O
the O O
study O O
. O O

Subgroups O O
presumed O O
to O O
be O O
at O O
higher O O
risk O O
for O O
ACE O O
inhibitor O O
intolerance O O
( O O
blood O O
pressure O O
, O O
< O O
120 O O
mm O O
Hg O O
; O O
creatinine O O
, O O
> O O
or O O
= O O
132 O O
. O O
6 O O
micromol O O
/ O O
L O O
[ O O
> O O
or O O
= O O
1 O O
. O O
5 O O
mg O O
/ O O
dL O O
] O O
; O O
age O O
, O O
> O O
or O O
= O O
70 O O
years O O
; O O
and O O
patients O O
with O O
diabetes B B_DISEASE/B_GENE
) O O
generally O O
tolerated O O
the O O
high O O
- O O
dose O O
strategy O O
. O O

CONCLUSIONS O O
: O O
These O O
findings O O
demonstrate O O
that O O
ACE O O
inhibitor O O
therapy O O
in O O
most O O
patients O O
with O O
CHF B B_DISEASE
can O O
be O O
successfully O O
titrated O O
to O O
and O O
maintained O O
at O O
high O O
doses O O
, O O
and O O
that O O
more O O
aggressive O O
use O O
of O O
these O O
agents O O
is O O
warranted O O
. O O

Cocaine O O
, O O
ethanol O O
, O O
and O O
cocaethylene O O
cardiotoxity B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
an O O
animal O O
model O O
of O O
cocaine B B_DISEASE/B_LOCATION
and I I_DISEASE/I_LOCATION
ethanol I I_DISEASE/I_LOCATION
abuse I I_DISEASE/I_LOCATION
. O O

OBJECTIVES O O
: O O
Simultaneous O O
abuse B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cocaine I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ethanol I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
affects O O
12 O O
million O O
Americans O O
annually O O
. O O

In O O
combination O O
, O O
these O O
substances O O
are O O
substantially O O
more O O
toxic O O
than O O
either O O
drug O O
alone O O
. O O

Their O O
combined O O
cardiac B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
toxicity I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
may O O
be O O
due O O
to O O
independent O O
effects O O
of O O
each O O
drug O O
; O O
however O O
, O O
they O O
may O O
also O O
be O O
due O O
to O O
cocaethylene O O
( O O
CE O O
) O O
, O O
a O O
cocaine O O
metabolite O O
formed O O
only O O
in O O
the O O
presence O O
of O O
ethanol O O
. O O

The O O
purpose O O
of O O
this O O
study O O
was O O
to O O
delineate O O
the O O
role O O
of O O
CE O O
in O O
the O O
combined O O
cardiotoxicity B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
cocaine O O
and O O
ethanol O O
in O O
a O O
model O O
simulating O O
their O O
abuse O O
. O O

METHODS O O
: O O
Twenty O O
- O O
three O O
dogs O O
were O O
randomized O O
to O O
receive O O
either O O
1 O O
) O O
three O O
intravenous O O
( O O
IV O O
) O O
boluses O O
of O O
cocaine O O
7 O O
. O O
5 O O
mg O O
/ O O
kg O O
with O O
ethanol O O
( O O
1 O O
g O O
/ O O
kg O O
) O O
as O O
an O O
IV O O
infusion O O
( O O
C O O
+ O O
E O O
, O O
n O O
= O O
8 O O
) O O
, O O
2 O O
) O O
three O O
cocaine O O
boluses O O
only O O
( O O
C O O
, O O
n O O
= O O
6 O O
) O O
, O O
3 O O
) O O
ethanol O O
infusion O O
only O O
( O O
E O O
, O O
n O O
= O O
5 O O
) O O
, O O
or O O
4 O O
) O O
placebo O O
boluses O O
and O O
infusion O O
( O O
n O O
= O O
4 O O
) O O
. O O

Hemodynamic O O
measurements O O
, O O
electrocardiograms O O
, O O
and O O
serum O O
drug O O
concentrations O O
were O O
obtained O O
at O O
baseline O O
, O O
and O O
then O O
at O O
fixed O O
time O O
intervals O O
after O O
each O O
drug O O
was O O
administered O O
. O O

RESULTS O O
: O O
Two O O
of O O
eight O O
dogs O O
in O O
the O O
C O O
+ O O
E O O
group O O
experienced O O
cardiovascular B B_DISEASE
collapse I I_DISEASE
. O O

The O O
most O O
dramatic O O
hemodynamic O O
changes O O
occurred O O
after O O
each O O
cocaine O O
bolus O O
in O O
the O O
C O O
+ O O
E O O
and O O
C O O
only O O
groups O O
; O O
however O O
, O O
persistent O O
hemodynamic O O
changes O O
occurred O O
in O O
the O O
C O O
+ O O
E O O
group O O
. O O

Peak O O
CE O O
levels O O
were O O
associated O O
with O O
a O O
45 O O
% O O
( O O
SD O O
+ O O
/ O O
- O O
22 O O
% O O
, O O
95 O O
% O O
CI O O
= O O
22 O O
% O O
to O O
69 O O
% O O
) O O
decrease B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in I I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cardiac I I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
output I I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
p O O
< O O
0 O O
. O O
05 O O
) O O
, O O
a O O
56 O O
% O O
( O O
SD O O
+ O O
/ O O
- O O
23 O O
% O O
, O O
95 O O
% O O
CI O O
= O O
32 O O
% O O
to O O
80 O O
% O O
) O O
decrease O O
in O O
dP O O
/ O O
dt O O
( O O
max O O
) O O
( O O
p O O
< O O
. O O
006 O O
) O O
, O O
and O O
a O O
23 O O
% O O
( O O
SD O O
+ O O
/ O O
- O O
15 O O
% O O
, O O
95 O O
% O O
CI O O
= O O
7 O O
% O O
to O O
49 O O
% O O
) O O
decrease O O
in O O
SVO O O
( O O
2 O O
) O O
( O O
p O O
< O O
0 O O
. O O
025 O O
) O O
. O O

Ventricular B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
arrhythmias I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O O
primarily O O
observed O O
in O O
the O O
C O O
+ O O
E O O
group O O
, O O
in O O
which O O
four O O
of O O
eight O O
dogs O O
experienced O O
ventricular B B_DISEASE
tachycardia I I_DISEASE
. O O

CONCLUSIONS O O
: O O
Cocaine O O
and O O
ethanol O O
in O O
combination O O
were O O
more O O
toxic O O
than O O
either O O
substance O O
alone O O
. O O

Co O O
- O O
administration O O
resulted O O
in O O
prolonged O O
cardiac B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
toxicity I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
was O O
dysrhythmogenic O O
. O O

Peak O O
serum O O
cocaethylene O O
concentrations O O
were O O
associated O O
with O O
prolonged O O
myocardial B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
depression I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Worsening O O
of O O
Parkinsonism B B_DISEASE
after O O
the O O
use O O
of O O
veralipride O O
for O O
treatment O O
of O O
menopause O O
: O O
case O O
report O O
. O O

We O O
describe O O
a O O
female O O
patient O O
with O O
stable O O
Parkinson B B_DISEASE
' I I_DISEASE
s I I_DISEASE
disease I I_DISEASE
who O O
has O O
shown O O
a O O
marked O O
worsening O O
of O O
her O O
motor O O
functions O O
following O O
therapy O O
of O O
menopause O O
related O O
symptoms O O
with O O
veralipride O O
, O O
as O O
well O O
as O O
the O O
improvement O O
of O O
her O O
symptoms O O
back O O
to O O
baseline O O
after O O
discontinuation O O
of O O
the O O
drug O O
. O O

Viracept O O
and O O
irregular B B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
heartbeat I I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
warning O O
. O O

A O O
group O O
of O O
doctors O O
in O O
Boston O O
warn O O
that O O
the O O
protease O O
inhibitor O O
Viracept O O
may O O
cause O O
an O O
irregular B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heart I I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beat I I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
known O O
as O O
bradycardia B B_DISEASE
, O O
in O O
people O O
with O O
HIV O O
. O O

Bradycardia B B_DISEASE/B_PERSON
occurred O O
in O O
a O O
45 O O
- O O
year O O
- O O
old O O
male O O
patient O O
who O O
was O O
Viracept O O
in O O
combination O O
with O O
other O O
anti O O
- O O
HIV O O
drugs O O
. O O

Frequency O O
of O O
appearance O O
of O O
myeloperoxidase O O
- O O
antineutrophil O O
cytoplasmic O O
antibody O O
( O O
MPO O O
- O O
ANCA O O
) O O
in O O
Graves B B_DISEASE/B_PERSON
' I I_DISEASE/I_PERSON
disease I I_DISEASE/I_PERSON
patients O O
treated O O
with O O
propylthiouracil O O
and O O
the O O
relationship O O
between O O
MPO O O
- O O
ANCA O O
and O O
clinical O O
manifestations O O
. O O

OBJECTIVE O O
: O O
Myeloperoxidase O O
antineutrophil O O
cytoplasmic O O
antibody O O
( O O
MPO O O
- O O
ANCA O O
) O O
- O O
positive O O
vasculitis B B_DISEASE
has O O
been O O
reported O O
in O O
patients O O
with O O
Graves B B_DISEASE
' I I_DISEASE
disease I I_DISEASE
who O O
were O O
treated O O
with O O
propylthiouracil O O
( O O
PTU O O
) O O
. O O

Nevertheless O O
, O O
there O O
have O O
been O O
no O O
studies O O
on O O
the O O
temporal O O
relationship O O
between O O
the O O
appearance O O
of O O
MPO O O
- O O
ANCA O O
and O O
vasculitis B B_DISEASE
during O O
PTU O O
therapy O O
, O O
or O O
on O O
the O O
incidence O O
of O O
MPO O O
- O O
ANCA O O
in O O
untreated O O
Graves B B_DISEASE/B_LOCATION
' I I_DISEASE/I_LOCATION
disease I I_DISEASE/I_LOCATION
patients O O
. O O

Therefore O O
, O O
we O O
sought O O
to O O
address O O
these O O
parameters O O
in O O
patients O O
with O O
Graves B B_DISEASE/B_LOCATION
' I I_DISEASE/I_LOCATION
disease I I_DISEASE/I_LOCATION
. O O

PATIENTS O O
: O O
We O O
investigated O O
102 O O
untreated O O
patients O O
with O O
hyperthyroidism B B_DISEASE/B_LOCATION
due O O
to O O
Graves B B_DISEASE/B_LOCATION
' I I_DISEASE/I_LOCATION
disease I I_DISEASE/I_LOCATION
for O O
the O O
presence O O
of O O
MPO O O
- O O
ANCA O O
, O O
and O O
for O O
the O O
development O O
vasculitis B B_DISEASE/B_TIME[MEASURE]
after O O
starting O O
PTU O O
therapy O O
. O O

Twenty O O
- O O
nine O O
of O O
them O O
were O O
later O O
excluded O O
because O O
of O O
adverse O O
effects O O
of O O
PTU O O
or O O
because O O
the O O
observation O O
period O O
was O O
less O O
than O O
3 O O
months O O
. O O

The O O
remaining O O
73 O O
patients O O
( O O
55 O O
women O O
and O O
18 O O
men O O
) O O
, O O
all O O
of O O
whom O O
were O O
examined O O
for O O
more O O
than O O
3 O O
months O O
, O O
were O O
adopted O O
as O O
the O O
subjects O O
of O O
the O O
investigation O O
. O O

The O O
median O O
observation O O
period O O
was O O
23 O O
. O O
6 O O
months O O
( O O
range O O
: O O
3 O O
- O O
37 O O
months O O
) O O
. O O

MEASUREMENTS O O
: O O
MPO O O
- O O
ANCA O O
was O O
measured O O
at O O
intervals O O
of O O
2 O O
- O O
6 O O
months O O
. O O

RESULTS O O
: O O
Before O O
treatment O O
, O O
the O O
MPO O O
- O O
ANCA O O
titres O O
of O O
all O O
102 O O
untreated O O
Graves B B_DISEASE/B_LOCATION
' I I_DISEASE/I_LOCATION
disease I I_DISEASE/I_LOCATION
patients O O
were O O
within O O
the O O
reference O O
range O O
( O O
below O O
10 O O
U O O
/ O O
ml O O
) O O
. O O

Three O O
( O O
4 O O
. O O
1 O O
% O O
) O O
of O O
the O O
73 O O
patients O O
were O O
positive O O
for O O
MPO O O
- O O
ANCA O O
at O O
13 O O
, O O
16 O O
and O O
17 O O
months O O
, O O
respectively O O
, O O
after O O
the O O
start O O
of O O
PTU O O
therapy O O
. O O

In O O
two O O
of O O
them O O
, O O
the O O
MPO O O
- O O
ANCA O O
titres O O
transiently O O
increased O O
to O O
12 O O
. O O
8 O O
and O O
15 O O
. O O
0 O O
U O O
/ O O
ml O O
, O O
respectively O O
, O O
despite O O
continued O O
PTU O O
therapy O O
, O O
but O O
no O O
vasculitic B B_DISEASE
disorders I I_DISEASE
developed O O
. O O

In O O
the O O
third O O
patient O O
, O O
the O O
MPO O O
- O O
ANCA O O
titre O O
increased O O
to O O
204 O O
U O O
/ O O
ml O O
and O O
she O O
developed O O
a O O
higher O O
fever B B_DISEASE/B_MEASURE
, O O
oral B B_DISEASE
ulcers I I_DISEASE
and O O
polyarthralgia B B_DISEASE
, O O
but O O
the O O
symptoms O O
resolved O O
2 O O
weeks O O
after O O
stopping O O
PTU O O
therapy O O
, O O
and O O
the O O
MPO O O
- O O
ANCA O O
titre O O
decreased O O
to O O
20 O O
. O O
7 O O
U O O
/ O O
ml O O
by O O
4 O O
months O O
after O O
discontinuing O O
PTU O O
. O O

CONCLUSIONS O O
: O O
PTU O O
therapy O O
may O O
be O O
related O O
to O O
the O O
appearance O O
of O O
MPO O O
- O O
ANCA O O
, O O
but O O
MPO O O
- O O
ANCA O O
does O O
not O O
appear O O
to O O
be O O
closely O O
related O O
to O O
vasculitis B B_DISEASE
. O O

Prevalence O O
of O O
heart B B_DISEASE/B_LOCATION
disease I I_DISEASE/I_LOCATION
in O O
asymptomatic O O
chronic O O
cocaine O O
users O O
. O O

To O O
determine O O
the O O
prevalence O O
of O O
heart B B_DISEASE/B_LOCATION
disease I I_DISEASE/I_LOCATION
in O O
outpatient O O
young O O
asymptomatic O O
chronic O O
cocaine O O
users O O
, O O
35 O O
cocaine O O
users O O
and O O
32 O O
age O O
- O O
matched O O
controls O O
underwent O O
resting O O
and O O
exercise O O
electrocardiography O O
( O O
ECG O O
) O O
and O O
Doppler O O
echocardiography O O
. O O

Findings O O
consistent O O
with O O
coronary B B_DISEASE/B_LOCATION
artery I I_DISEASE/I_LOCATION
disease I I_DISEASE/I_LOCATION
were O O
detected O O
in O O
12 O O
( O O
34 O O
% O O
) O O
patients O O
and O O
3 O O
( O O
9 O O
% O O
) O O
controls O O
( O O
p O O
= O O
0 O O
. O O
01 O O
) O O
. O O

Decreased O O
left O O
ventricular O O
systolic O O
function O O
was O O
demonstrated O O
in O O
5 O O
( O O
14 O O
% O O
) O O
patients O O
, O O
but O O
in O O
none O O
of O O
the O O
controls O O
( O O
p O O
= O O
0 O O
. O O
055 O O
) O O
. O O

Finally O O
, O O
resting O O
and O O
peak O O
exercise O O
abnormal B B_DISEASE
left I I_DISEASE
ventricular I I_DISEASE
filling I I_DISEASE
was O O
detected O O
in O O
38 O O
and O O
35 O O
% O O
of O O
patients O O
as O O
compared O O
to O O
19 O O
and O O
9 O O
% O O
of O O
controls O O
, O O
respectively O O
( O O
p O O
= O O
0 O O
. O O
11 O O
and O O
0 O O
. O O
02 O O
, O O
respectively O O
) O O
. O O

We O O
conclude O O
that O O
coronary B B_DISEASE
artery I I_DISEASE
or I I_DISEASE
myocardial I I_DISEASE
disease I I_DISEASE
is O O
common O O
( O O
38 O O
% O O
) O O
in O O
young O O
asymptomatic O O
chronic O O
cocaine O O
users O O
. O O

Therefore O O
, O O
screening O O
ECG O O
and O O
echocardiography O O
may O O
be O O
warranted O O
in O O
these O O
patients O O
. O O

The O O
cardioprotective O O
effect O O
of O O
the O O
ethanol O O
extract O O
of O O
Picrorrhiza O O
kurroa O O
rhizomes O O
and O O
roots O O
( O O
PK O O
) O O
on O O
isoproterenol O O
- O O
induced O O
myocardial B B_DISEASE
infarction I I_DISEASE
in O O
rats O O
with O O
respect O O
to O O
lipid O O
metabolism O O
in O O
serum O O
and O O
heart O O
tissue O O
has O O
been O O
investigated O O
. O O

Oral O O
pre O O
- O O
treatment O O
with O O
PK O O
( O O
80 O O
mg O O
kg O O
( O O
- O O
1 O O
) O O
day O O
( O O
- O O
1 O O
) O O
for O O
15 O O
days O O
) O O
significantly O O
prevented O O
the O O
isoproterenol O O
- O O
induced O O
myocardial B B_DISEASE
infarction I I_DISEASE
and O O
maintained O O
the O O
rats O O
at O O
near O O
normal O O
status O O
. O O

Phase O O
2 O O
early O O
afterdepolarization O O
as O O
a O O
trigger O O
of O O
polymorphic O O
ventricular B B_DISEASE
tachycardia I I_DISEASE
in O O
acquired O O
long B B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
QT I B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
syndrome I B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
: O O
direct O O
evidence O O
from O O
intracellular O O
recordings O O
in O O
the O O
intact O O
left O O
ventricular O O
wall O O
. O O

The O O
contribution O O
of O O
transmural O O
dispersion O O
of O O
repolarization O O
( O O
TDR O O
) O O
to O O
transmural O O
propagation O O
of O O
EAD O O
and O O
the O O
maintenance O O
of O O
TdP B B_PROTEIN[GENE]/B_DISEASE
was O O
also O O
evaluated O O
. O O

METHODS O O
AND O O
RESULTS O O
: O O
Transmembrane O O
action O O
potentials O O
from O O
epicardium O O
, O O
midmyocardium O O
, O O
and O O
endocardium O O
were O O
recorded O O
simultaneously O O
, O O
together O O
with O O
a O O
transmural O O
ECG O O
, O O
in O O
arterially O O
perfused O O
canine O O
and O O
rabbit O O
left O O
ventricular O O
preparations O O
. O O

dl O O
- O O
Sotalol O O
preferentially O O
prolonged O O
action O O
potential O O
duration O O
( O O
APD O O
) O O
in O O
M O O
cells O O
dose O O
- O O
dependently O O
( O O
1 O O
to O O
100 O O
micromol O O
/ O O
L O O
) O O
, O O
leading O O
to O O
QT B B_DISEASE
prolongation I I_DISEASE
and O O
an O O
increase O O
in O O
TDR O O
. O O

Although O O
both O O
dl O O
- O O
sotalol O O
and O O
azimilide O O
rarely O O
induced O O
EADs O O
in O O
canine O O
left O O
ventricles O O
, O O
they O O
produced O O
frequent O O
EADs O O
in O O
rabbits O O
, O O
in O O
which O O
more O O
pronounced O O
QT B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
prolongation I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
seen O O
. O O

An O O
increase O O
in O O
TDR O O
by O O
dl O O
- O O
sotalol O O
facilitated O O
transmural O O
propagation O O
of O O
EADs O O
that O O
initiated O O
multiple O O
episodes O O
of O O
spontaneous O O
TdP B B_DISEASE/B_GENE
in O O
3 O O
of O O
6 O O
rabbit O O
left O O
ventricles O O
. O O

CONCLUSIONS O O
: O O
This O O
study O O
provides O O
the O O
first O O
direct O O
evidence O O
from O O
intracellular O O
action O O
potential O O
recordings O O
that O O
phase O O
2 O O
EAD O O
can O O
be O O
generated O O
from O O
intact O O
ventricular O O
wall O O
and O O
produce O O
a O O
trigger O O
to O O
initiate O O
the O O
onset O O
of O O
TdP B B_PROTEIN[GENE]/B_DISEASE
under O O
QT B B_DISEASE
prolongation I I_DISEASE
. O O

A O O
pilot O O
study O O
to O O
assess O O
the O O
safety O O
of O O
dobutamine O O
stress O O
echocardiography O O
in O O
the O O
emergency O O
department O O
evaluation O O
of O O
cocaine O O
- O O
associated O O
chest B B_DISEASE/B_LOCATION
pain I I_DISEASE/I_LOCATION
. O O

STUDY O O
OBJECTIVE O O
: O O
Chest B B_DISEASE
pain I I_DISEASE
in O O
the O O
setting O O
of O O
cocaine O O
use O O
poses O O
a O O
diagnostic O O
dilemma O O
. O O

Dobutamine O O
stress O O
echocardiography O O
( O O
DSE O O
) O O
is O O
a O O
widely O O
available O O
and O O
sensitive O O
test O O
for O O
evaluating O O
cardiac O O
ischemia B B_DISEASE/B_LOCATION
. O O

Because O O
of O O
the O O
theoretical O O
concern O O
regarding O O
administration O O
of O O
dobutamine O O
in O O
the O O
setting O O
of O O
cocaine O O
use O O
, O O
we O O
conducted O O
a O O
pilot O O
study O O
to O O
assess O O
the O O
safety O O
of O O
DSE O O
in O O
emergency O O
department O O
patients O O
with O O
cocaine O O
- O O
associated O O
chest B B_DISEASE/B_LOCATION
pain I I_DISEASE/I_LOCATION
. O O

METHODS O O
: O O
A O O
prospective O O
case O O
series O O
was O O
conducted O O
in O O
the O O
intensive O O
diagnostic O O
and O O
treatment O O
unit O O
in O O
the O O
ED O O
of O O
an O O
urban O O
tertiary O O
- O O
care O O
teaching O O
hospital O O
. O O

Patients O O
were O O
eligible O O
for O O
DSE O O
if O O
they O O
had O O
used O O
cocaine O O
within O O
24 O O
hours O O
preceding O O
the O O
onset O O
of O O
chest B B_DISEASE
pain I I_DISEASE
and O O
had O O
a O O
normal O O
ECG O O
and O O
tropinin O O
I O O
level O O
. O O

Patients O O
exhibiting O O
signs O O
of O O
continuing O O
cocaine O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
excluded O O
from O O
the O O
study O O
. O O

All O O
patients O O
were O O
admitted O O
to O O
the O O
hospital O O
for O O
serial O O
testing O O
after O O
the O O
DSE O O
testing O O
in O O
the O O
intensive O O
diagnostic O O
and O O
treatment O O
unit O O
. O O

RESULTS O O
: O O
Twenty O O
- O O
four O O
patients O O
were O O
enrolled O O
. O O

Two O O
patients O O
had O O
inadequate O O
resting O O
images O O
, O O
one O O
DSE O O
was O O
terminated O O
because O O
of O O
inferior O O
hypokinesis B B_DISEASE_ADJECTIVE[DISEASE]
, O O
another O O
DSE O O
was O O
terminated O O
because O O
of O O
a O O
rate O O
- O O
related O O
atrial O O
conduction O O
deficit O O
, O O
and O O
1 O O
patient O O
did O O
not O O
reach O O
the O O
target O O
heart O O
rate O O
. O O

Thus O O
, O O
19 O O
patients O O
completed O O
a O O
DSE O O
and O O
reached O O
their O O
target O O
heart O O
rates O O
. O O

None O O
of O O
the O O
patients O O
experienced O O
signs O O
of O O
exaggerated O O
adrenergic O O
response O O
, O O
which O O
was O O
defined O O
as O O
a O O
systolic O O
blood O O
pressure O O
of O O
greater O O
than O O
200 O O
mm O O
Hg O O
or O O
the O O
occurrence O O
of O O
tachydysrhythmias B B_DISEASE
( O O
excluding O O
sinus B B_DISEASE
tachycardia I I_DISEASE
) O O
. O O

CONCLUSION O O
: O O
No O O
exaggerated O O
adrenergic O O
response O O
was O O
detected O O
when O O
dobutamine O O
was O O
administered O O
to O O
patients O O
with O O
cocaine O O
- O O
related O O
chest B B_DISEASE/B_LOCATION
pain I I_DISEASE/I_LOCATION
. O O

PURPOSE O O
: O O
Prenatal O O
cocaine O O
exposure O O
has O O
been O O
linked O O
with O O
subependymal O O
hemorrhage B B_DISEASE
and O O
the O O
formation O O
of O O
cysts B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
that O O
are O O
detectable O O
on O O
cranial O O
sonography O O
in O O
neonates O O
born O O
at O O
term O O
. O O

Infants O O
were O O
categorized O O
into O O
1 O O
of O O
2 O O
groups O O
: O O
those O O
exposed O O
to O O
cocaine O O
and O O
those O O
not O O
exposed O O
to O O
cocaine O O
. O O

Infants O O
were O O
assigned O O
to O O
the O O
cocaine O O
- O O
exposed O O
group O O
if O O
there O O
was O O
a O O
maternal O O
history O O
of O O
cocaine B B_DISEASE
abuse I I_DISEASE
during O O
pregnancy O O
or O O
if O O
maternal O O
or O O
neonatal O O
urine O O
toxicology O O
results O O
were O O
positive O O
at O O
the O O
time O O
of O O
delivery O O
. O O

RESULTS O O
: O O
Five O O
of O O
the O O
122 O O
infants O O
were O O
excluded O O
from O O
the O O
study O O
because O O
of O O
insufficient O O
medical O O
and O O
drug O O
histories O O
. O O

The O O
incidence O O
of O O
subependymal B B_DISEASE
cysts I I_DISEASE
in O O
the O O
117 O O
remaining O O
infants O O
was O O
14 O O
% O O
( O O
16 O O
of O O
117 O O
) O O
. O O

The O O
incidence O O
of O O
subependymal B B_DISEASE
cysts I I_DISEASE
in O O
infants O O
exposed O O
to O O
cocaine O O
prenatally O O
was O O
44 O O
% O O
( O O
8 O O
of O O
18 O O
) O O
compared O O
with O O
8 O O
% O O
( O O
8 O O
of O O
99 O O
) O O
in O O
the O O
unexposed O O
group O O
( O O
p O O
< O O
0 O O
. O O
01 O O
) O O
. O O

This O O
result O O
is O O
consistent O O
with O O
results O O
of O O
similar O O
studies O O
in O O
term O O
infants O O
. O O

Thalidomide O O
neuropathy B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
patients O O
treated O O
for O O
metastatic O O
prostate B B_DISEASE
cancer I I_DISEASE
. O O

We O O
prospectively O O
evaluated O O
thalidomide O O
- O O
induced O O
neuropathy B B_DISEASE
using O O
electrodiagnostic O O
studies O O
. O O

Sixty O O
- O O
seven O O
men O O
with O O
metastatic O O
androgen O O
- O O
independent O O
prostate B B_DISEASE
cancer I I_DISEASE
in O O
an O O
open O O
- O O
label O O
trial O O
of O O
oral O O
thalidomide O O
underwent O O
neurologic O O
examinations O O
and O O
nerve O O
conduction O O
studies O O
( O O
NCS O O
) O O
prior O O
to O O
and O O
at O O
3 O O
- O O
month O O
intervals O O
during O O
treatment O O
. O O

SNAP O O
amplitudes O O
for O O
each O O
nerve O O
were O O
expressed O O
as O O
the O O
percentage O O
of O O
its O O
baseline O O
, O O
and O O
the O O
mean O O
of O O
the O O
four O O
was O O
termed O O
the O O
SNAP O O
index O O
. O O

Thalidomide O O
was O O
discontinued O O
in O O
55 O O
patients O O
for O O
lack O O
of O O
therapeutic O O
response O O
. O O

Of O O
67 O O
patients O O
initially O O
enrolled O O
, O O
24 O O
remained O O
on O O
thalidomide O O
for O O
3 O O
months O O
, O O
8 O O
remained O O
at O O
6 O O
months O O
, O O
and O O
3 O O
remained O O
at O O
9 O O
months O O
. O O

Six O O
patients O O
developed O O
neuropathy B B_DISEASE
. O O

Older O O
age O O
and O O
cumulative O O
dose O O
were O O
possible O O
contributing O O
factors O O
. O O

Neuropathy B B_DISEASE
may O O
thus O O
be O O
a O O
common O O
complication O O
of O O
thalidomide O O
in O O
older O O
patients O O
. O O

The O O
SNAP O O
index O O
can O O
be O O
used O O
to O O
monitor O O
peripheral B B_DISEASE_ADJECTIVE[DISEASE]
neuropathy I I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
not O O
for O O
early O O
detection O O
. O O

Overexpression O O
of O O
copper O O
/ O O
zinc O O
- O O
superoxide O O
dismutase O O
protects O O
from O O
kanamycin O O
- O O
induced O O
hearing B B_DISEASE/B_GENE
loss I I_DISEASE/I_GENE
. O O

The O O
participation O O
of O O
reactive O O
oxygen O O
species O O
in O O
aminoglycoside O O
- O O
induced O O
ototoxicity B B_DISEASE
has O O
been O O
deduced O O
from O O
observations O O
that O O
aminoglycoside O O
- O O
iron O O
complexes O O
catalyze O O
the O O
formation O O
of O O
superoxide O O
radicals O O
in O O
vitro O O
and O O
that O O
antioxidants O O
attenuate O O
ototoxicity B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
vivo O O
. O O

We O O
therefore O O
hypothesized O O
that O O
overexpression O O
of O O
Cu O O
/ O O
Zn O O
- O O
superoxide O O
dismutase O O
( O O
h O O
- O O
SOD1 O O
) O O
should O O
protect O O
transgenic O O
mice O O
from O O
ototoxicity B B_DISEASE/B_GENE
. O O

Immunocytochemistry O O
confirmed O O
expression O O
of O O
h O O
- O O
SOD1 O O
in O O
inner O O
ear O O
tissues O O
of O O
transgenic O O
C57BL O O
/ O O
6 O O
- O O
TgN O O
[ O O
SOD1 O O
] O O
3Cje O O
mice O O
. O O

Transgenic O O
and O O
nontransgenic O O
littermates O O
received O O
kanamycin O O
( O O
400 O O
mg O O
/ O O
kg O O
body O O
weight O O
/ O O
day O O
) O O
for O O
10 O O
days O O
beginning O O
on O O
day O O
10 O O
after O O
birth O O
. O O

Auditory O O
thresholds O O
were O O
tested O O
by O O
evoked O O
auditory O O
brain O O
stem O O
responses O O
at O O
1 O O
month O O
after O O
birth O O
. O O

In O O
the O O
transgenic O O
group O O
, O O
kanamycin O O
increased O O
the O O
threshold O O
by O O
only O O
15 O O
dB O O
over O O
the O O
respective O O
controls O O
. O O

The O O
effects O O
were O O
similar O O
at O O
12 O O
and O O
24 O O
kHz O O
. O O

The O O
protection O O
by O O
overexpression O O
of O O
superoxide O O
dismutase O O
supports O O
the O O
hypothesis O O
that O O
oxidant O O
stress O O
plays O O
a O O
significant O O
role O O
in O O
aminoglycoside O O
- O O
induced O O
ototoxicity B B_DISEASE
. O O

Fatty B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
liver I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
by O O
tetracycline O O
in O O
the O O
rat O O
. O O

Dose O O
- O O
response O O
relationships O O
and O O
effect O O
of O O
sex O O
. O O

Dose O O
- O O
response O O
relationships O O
, O O
biochemical O O
mechanisms O O
, O O
and O O
sex O O
differences O O
in O O
the O O
experimental O O
fatty B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
liver I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
by O O
tetracycline O O
were O O
studied O O
in O O
the O O
intact O O
rat O O
and O O
with O O
the O O
isolated O O
perfused O O
rat O O
liver O O
in O O
vitro O O
. O O

In O O
the O O
intact O O
male O O
and O O
female O O
rat O O
, O O
no O O
direct O O
relationship O O
was O O
observed O O
between O O
dose O O
of O O
tetracycline O O
and O O
hepatic O O
accumulation O O
of O O
triglyceride O O
. O O

With O O
provision O O
of O O
adequate O O
oleic O O
acid O O
as O O
a O O
substrate O O
for O O
the O O
isolated O O
perfused O O
liver O O
, O O
a O O
direct O O
relationship O O
was O O
observed O O
between O O
dose O O
of O O
tetracycline O O
and O O
both O O
accumulation O O
of O O
triglyceride O O
in O O
the O O
liver O O
and O O
depression B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
output O O
of O O
triglyceride O O
by O O
livers O O
from O O
male O O
and O O
female O O
rats O O
. O O

Marked O O
differences O O
were O O
observed O O
between O O
female O O
and O O
male O O
rats O O
with O O
regard O O
to O O
base O O
line O O
( O O
control O O
) O O
hepatic O O
concentration O O
of O O
triglyceride O O
and O O
output O O
of O O
triglyceride O O
. O O

Accumulation O O
of O O
hepatic O O
triglyceride O O
, O O
as O O
a O O
per O O
cent O O
of O O
control O O
values O O
, O O
in O O
response O O
to O O
graded O O
doses O O
of O O
tetracycline O O
, O O
did O O
not O O
differ O O
significantly O O
between O O
male O O
, O O
female O O
and O O
pregnant O O
rat O O
livers O O
. O O

However O O
, O O
livers O O
from O O
female O O
, O O
and O O
especially O O
pregnant O O
female O O
rats O O
, O O
were O O
strikingly O O
resistant O O
to O O
the O O
effects O O
of O O
tetracycline O O
on O O
depression B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
output O O
of O O
triglyceride O O
under O O
these O O
experimental O O
conditions O O
. O O

These O O
differences O O
between O O
the O O
sexes O O
could O O
not O O
be O O
related O O
to O O
altered O O
disposition O O
of O O
tetracycline O O
or O O
altered O O
uptake O O
of O O
oleic O O
acid O O
. O O

Prednisone O O
induces O O
anxiety B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
glial O O
cerebral O O
changes O O
in O O
rats O O
. O O

OBJECTIVE O O
: O O
To O O
assess O O
whether O O
prednisone O O
( O O
PDN O O
) O O
produces O O
anxiety B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
/ O O
or O O
cerebral O O
glial O O
changes O O
in O O
rats O O
. O O

METHODS O O
: O O
Male O O
Wistar O O
rats O O
were O O
studied O O
and O O
3 O O
groups O O
were O O
formed O O
( O O
8 O O
rats O O
per O O
group O O
) O O
. O O

The O O
moderate O O
- O O
dose O O
group O O
received O O
5 O O
mg O O
/ O O
kg O O
/ O O
day O O
PDN O O
released O O
from O O
a O O
subcutaneous O O
implant O O
. O O

In O O
the O O
high O O
- O O
dose O O
group O O
, O O
implants O O
containing O O
PDN O O
equivalent O O
to O O
60 O O
mg O O
/ O O
kg O O
/ O O
day O O
were O O
applied O O
. O O

In O O
the O O
control O O
group O O
implants O O
contained O O
no O O
PDN O O
. O O

Anxiety B B_DISEASE
was O O
assessed O O
using O O
an O O
open O O
field O O
and O O
elevated O O
plus O O
- O O
maze O O
devices O O
. O O

The O O
number O O
of O O
cells O O
and O O
cytoplasmic O O
transformation O O
of O O
astrocytes O O
and O O
microglia O O
cells O O
were O O
assessed O O
by O O
immunohistochemical O O
analyses O O
. O O

RESULTS O O
: O O
Anxiety B B_DISEASE/B_GENE
was O O
documented O O
in O O
both O O
groups O O
of O O
PDN O O
treated O O
rats O O
compared O O
with O O
controls O O
. O O

The O O
number O O
of O O
stained O O
microglia O O
cells O O
was O O
significantly O O
higher O O
in O O
the O O
PDN O O
treated O O
groups O O
in O O
the O O
prefrontal O O
cortex O O
than O O
in O O
controls O O
( O O
moderate O O
- O O
dose O O
, O O
29 O O
. O O
1 O O
; O O
high O O
- O O
dose O O
, O O
28 O O
. O O
4 O O
; O O
control O O
, O O
17 O O
. O O
7 O O
cells O O
per O O
field O O
; O O
p O O
< O O
0 O O
. O O
01 O O
) O O
. O O

Stained O O
microglia O O
cells O O
were O O
significantly O O
more O O
numerous O O
striatum O O
and O O
hippocampus O O
in O O
the O O
high O O
- O O
dose O O
group O O
compared O O
to O O
controls O O
. O O

CONCLUSION O O
: O O
Subacute O O
exposure O O
to O O
PDN O O
induced O O
anxiety B B_DISEASE
and O O
reactivity O O
of O O
microglia O O
. O O

The O O
relevance O O
of O O
these O O
features O O
for O O
patients O O
using O O
PDN O O
remains O O
to O O
be O O
elucidated O O
. O O

Phase O O
II O O
study O O
of O O
carboplatin O O
and O O
liposomal O O
doxorubicin O O
in O O
patients O O
with O O
recurrent O O
squamous B B_DISEASE
cell I I_DISEASE
carcinoma I I_DISEASE
of I I_DISEASE
the I I_DISEASE
cervix I I_DISEASE
. O O

BACKGROUND O O
: O O
The O O
activity O O
of O O
the O O
combination O O
of O O
carboplatin O O
and O O
liposomal O O
doxorubicin O O
was O O
tested O O
in O O
a O O
Phase O O
II O O
study O O
of O O
patients O O
with O O
recurrent O O
cervical B B_DISEASE
carcinoma I I_DISEASE
. O O

METHODS O O
: O O
The O O
combination O O
of O O
carboplatin O O
( O O
area O O
under O O
the O O
concentration O O
curve O O
[ O O
AUC O O
] O O
, O O
5 O O
) O O
and O O
liposomal O O
doxorubicin O O
( O O
Doxil O O
; O O
starting O O
dose O O
, O O
40 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
) O O
was O O
administered O O
intravenously O O
every O O
28 O O
days O O
to O O
37 O O
patients O O
with O O
recurrent O O
squamous B B_DISEASE
cell I I_DISEASE
cervical I I_DISEASE
carcinoma I I_DISEASE
to O O
determine O O
antitumor O O
activity O O
and O O
toxicity B B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
profile O O
. O O

RESULTS O O
: O O
Twenty O O
- O O
nine O O
patients O O
were O O
assessable O O
for O O
response O O
, O O
and O O
35 O O
patients O O
were O O
assessable O O
for O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
overall O O
response O O
rate O O
was O O
38 O O
% O O
, O O
the O O
median O O
time O O
to O O
response O O
was O O
10 O O
weeks O O
, O O
the O O
median O O
duration O O
of O O
response O O
was O O
26 O O
weeks O O
, O O
and O O
the O O
median O O
survival O O
was O O
37 O O
weeks O O
. O O

The O O
main O O
toxic O O
effect O O
was O O
myelosuppression B B_DISEASE
, O O
with O O
Grade O O
3 O O
and O O
4 O O
neutropenia B B_DISEASE
in O O
16 O O
patients O O
, O O
anemia B B_DISEASE
in O O
12 O O
patients O O
, O O
thrombocytopenia B B_DISEASE
in O O
11 O O
patients O O
, O O
and O O
neutropenic B B_DISEASE
fever I I_DISEASE
in O O
3 O O
patients O O
. O O

Grade O O
> O O
or O O
= O O
2 O O
nonhematologic O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
included O O
nausea B B_DISEASE
in O O
17 O O
patients O O
, O O
emesis B B_DISEASE
in O O
14 O O
patients O O
, O O
fatigue B B_DISEASE
in O O
9 O O
patients O O
, O O
mucositis B B_DISEASE
and O O
/ O O
or O O
stomatitis B B_DISEASE
in O O
8 O O
patients O O
, O O
constipation B B_DISEASE
in O O
6 O O
patients O O
, O O
weight B B_DISEASE
loss I I_DISEASE
in O O
5 O O
patients O O
, O O
hand B B_DISEASE
- I I_DISEASE
foot I I_DISEASE
syndrome I I_DISEASE
in O O
2 O O
patients O O
, O O
and O O
skin B B_DISEASE
reactions I I_DISEASE
in O O
3 O O
patients O O
. O O

CONCLUSIONS O O
: O O
The O O
combination O O
of O O
carboplatin O O
and O O
liposomal O O
doxorubicin O O
has O O
modest O O
activity O O
in O O
patients O O
with O O
recurrent O O
cervical B B_DISEASE
carcinoma I I_DISEASE
. O O

Antimicrobial O O
- O O
induced O O
mania B B_DISEASE
( O O
antibiomania B B_DISEASE/B_MEASURE
) O O
: O O
a O O
review O O
of O O
spontaneous O O
reports O O
. O O

The O O
authors O O
reviewed O O
reported O O
cases O O
of O O
antibiotic O O
- O O
induced O O
manic B B_DISEASE
episodes O O
by O O
means O O
of O O
a O O
MEDLINE O O
and O O
PsychLit O O
search O O
for O O
reports O O
of O O
antibiotic O O
- O O
induced O O
mania B B_DISEASE
. O O

Unpublished O O
reports O O
were O O
requested O O
from O O
the O O
World O O
Health O O
Organization O O
( O O
WHO O O
) O O
and O O
the O O
Food O O
and O O
Drug O O
Administration O O
( O O
FDA O O
) O O
. O O

Twenty O O
- O O
one O O
reports O O
of O O
antimicrobial O O
- O O
induced O O
mania B B_DISEASE
were O O
found O O
in O O
the O O
literature O O
. O O

There O O
were O O
6 O O
cases O O
implicating O O
clarithromycin O O
, O O
13 O O
implicating O O
isoniazid O O
, O O
and O O
1 O O
case O O
each O O
implicating O O
erythromycin O O
and O O
amoxicillin O O
. O O

The O O
WHO O O
reported O O
82 O O
cases O O
. O O

Of O O
these O O
, O O
clarithromycin O O
was O O
implicated O O
in O O
23 O O
( O O
27 O O
. O O
6 O O
% O O
) O O
cases O O
, O O
ciprofloxacin O O
in O O
12 O O
( O O
14 O O
. O O
4 O O
% O O
) O O
cases O O
, O O
and O O
ofloxacin O O
in O O
10 O O
( O O
12 O O
% O O
) O O
cases O O
. O O

Cotrimoxazole O O
, O O
metronidazole O O
, O O
and O O
erythromycin O O
were O O
involved O O
in O O
15 O O
reported O O
manic B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
episodes O O
. O O

Cases O O
reported O O
by O O
the O O
FDA O O
showed O O
clarithromycin O O
and O O
ciprofloxacin O O
to O O
be O O
the O O
most O O
frequently O O
associated O O
with O O
the O O
development O O
of O O
mania B B_DISEASE/B_GENE
. O O

Statistical O O
analysis O O
of O O
the O O
data O O
would O O
not O O
have O O
demonstrated O O
a O O
significant O O
statistical O O
correlative O O
risk O O
and O O
was O O
therefore O O
not O O
undertaken O O
. O O

Patients O O
have O O
an O O
increased O O
risk O O
of O O
developing O O
mania B B_DISEASE
while O O
being O O
treated O O
with O O
antimicrobials O O
. O O

Further O O
research O O
clearly O O
is O O
required O O
to O O
determine O O
the O O
incidence O O
of O O
antimicrobial O O
- O O
induced O O
mania B B_DISEASE
, O O
the O O
relative O O
risk O O
factors O O
of O O
developing O O
an O O
antimicrobial O O
- O O
induced O O
manic B B_DISEASE
episode O O
among O O
various O O
demographic O O
populations O O
, O O
and O O
the O O
incidence O O
of O O
patients O O
who O O
continue O O
to O O
have O O
persistent O O
affective O O
disorders O O
once O O
the O O
initial O O
episode O O
, O O
which O O
occurs O O
while O O
the O O
patient O O
is O O
taking O O
antibiotics O O
, O O
subsides O O
. O O

Levodopa O O
- O O
induced O O
ocular B B_DISEASE
dyskinesias I I_DISEASE
in O O
Parkinson B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
' I B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
s I B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
disease I B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

Levodopa O O
- O O
induced O O
ocular B B_DISEASE_ADJECTIVE[DISEASE]
dyskinesias I I_DISEASE_ADJECTIVE[DISEASE]
are O O
very O O
uncommon O O
. O O

Usually O O
they O O
occur O O
simultaneously O O
with O O
limb O O
peak O O
- O O
dose O O
choreatic B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dyskinesias I I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
report O O
on O O
a O O
patient O O
with O O
leftward O O
and O O
upward O O
deviations O O
of O O
gaze O O
during O O
the O O
peak O O
effect O O
of O O
levodopa O O
, O O
and O O
hypothesize O O
that O O
a O O
severe O O
dopaminergic O O
denervation O O
in O O
the O O
caudate O O
nucleus O O
is O O
needed O O
for O O
the O O
appearance O O
of O O
these O O
levodopa O O
- O O
induce O O
ocular B B_DISEASE_ADJECTIVE[DISEASE]
dyskinesias I I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
comparison O O
of O O
glyceryl O O
trinitrate O O
with O O
diclofenac O O
for O O
the O O
treatment O O
of O O
primary O O
dysmenorrhea B B_DISEASE
: O O
an O O
open O O
, O O
randomized O O
, O O
cross O O
- O O
over O O
trial O O
. O O

Primary O O
dysmenorrhea B B_DISEASE/B_ORGANISM_FUNCTION
is O O
a O O
syndrome O O
characterized O O
by O O
painful O O
uterine O O
contractility O O
caused O O
by O O
a O O
hypersecretion O O
of O O
endometrial O O
prostaglandins O O
; O O
non O O
- O O
steroidal O O
anti O O
- O O
inflammatory O O
drugs O O
are O O
the O O
first O O
choice O O
for O O
its O O
treatment O O
. O O

However O O
, O O
in O O
vivo O O
and O O
in O O
vitro O O
studies O O
have O O
demonstrated O O
that O O
myometrial O O
cells O O
are O O
also O O
targets O O
of O O
the O O
relaxant O O
effects O O
of O O
nitric O O
oxide O O
( O O
NO O O
) O O
. O O

The O O
aim O O
of O O
the O O
present O O
study O O
was O O
to O O
determine O O
the O O
efficacy O O
of O O
glyceryl O O
trinitrate O O
( O O
GTN O O
) O O
, O O
an O O
NO O O
donor O O
, O O
in O O
the O O
resolution O O
of O O
primary O O
dysmenorrhea B B_DISEASE
in O O
comparison O O
with O O
diclofenac O O
( O O
DCF O O
) O O
. O O

A O O
total O O
of O O
24 O O
patients O O
with O O
the O O
diagnosis O O
of O O
severe O O
primary O O
dysmenorrhea B B_DISEASE/B_GENE
were O O
studied O O
during O O
two O O
consecutive O O
menstrual O O
cycles O O
. O O

In O O
an O O
open O O
, O O
cross O O
- O O
over O O
, O O
controlled O O
design O O
, O O
patients O O
were O O
randomized O O
to O O
receive O O
either O O
DCF O O
per O O
os O O
or O O
GTN O O
patches O O
the O O
first O O
days O O
of O O
menses O O
, O O
when O O
menstrual O O
cramps O O
became O O
unendurable O O
. O O

In O O
the O O
subsequent O O
cycle O O
the O O
other O O
treatment O O
was O O
used O O
. O O

Patients O O
received O O
up O O
to O O
3 O O
doses O O
/ O O
day O O
of O O
50 O O
mg O O
DCF O O
or O O
2 O O
. O O
5 O O
mg O O
/ O O
24 O O
h O O
transdermal O O
GTN O O
for O O
the O O
first O O
3 O O
days O O
of O O
the O O
cycle O O
, O O
according O O
to O O
their O O
needs O O
. O O

The O O
difference O O
in O O
pain B B_DISEASE
intensity O O
score O O
( O O
DPI O O
) O O
was O O
the O O
main O O
outcome O O
variable O O
. O O

However O O
, O O
DCF O O
continued O O
to O O
be O O
effective O O
in O O
reducing O O
pelvic B B_DISEASE/B_GENE
pain I I_DISEASE/I_GENE
for O O
two O O
hours O O
, O O
whereas O O
GTN O O
scores O O
remained O O
more O O
or O O
less O O
stable O O
after O O
30 O O
min O O
and O O
significantly O O
higher O O
than O O
those O O
for O O
DFC O O
( O O
after O O
one O O
hour O O
: O O
GTN O O
, O O
- O O
12 O O
. O O
8 O O
+ O O
/ O O
- O O
17 O O
. O O
9 O O
; O O
DFC O O
, O O
- O O
18 O O
. O O
9 O O
+ O O
/ O O
- O O
16 O O
. O O
6 O O
and O O
after O O
two O O
hours O O
: O O
GTN O O
, O O
- O O
23 O O
. O O
7 O O
+ O O
/ O O
- O O
20 O O
. O O
5 O O
; O O
DFC O O
, O O
- O O
59 O O
. O O
7 O O
+ O O
/ O O
- O O
17 O O
. O O
9 O O
, O O
p O O
= O O
0 O O
. O O
0001 O O
) O O
. O O

Low B B_DISEASE/B_PERSON
back I I_DISEASE/I_PERSON
pain I I_DISEASE/I_PERSON
was O O
also O O
relieved O O
by O O
both O O
drugs O O
. O O

Headache B B_DISEASE
was O O
significantly O O
increased O O
by O O
GTN O O
but O O
not O O
by O O
DCF O O
. O O

Eight O O
patients O O
stopped O O
using O O
GTN O O
because O O
headache B B_DISEASE
- O O
- O O
attributed O O
to O O
its O O
use O O
- O O
- O O
became O O
intolerable O O
. O O

These O O
findings O O
indicate O O
that O O
GTN O O
has O O
a O O
reduced O O
efficacy O O
and O O
tolerability O O
by O O
comparison O O
with O O
DCF O O
in O O
the O O
treatment O O
of O O
primary O O
dysmenorrhea B B_DISEASE/B_LOCATION
. O O

Temocapril O O
, O O
a O O
long O O
- O O
acting O O
non O O
- O O
SH O O
group O O
angiotensin O O
converting O O
enzyme O O
inhibitor O O
, O O
modulates O O
glomerular B B_DISEASE
injury I I_DISEASE
in O O
chronic O O
puromycin O O
aminonucleoside O O
nephrosis B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
purpose O O
of O O
the O O
present O O
study O O
was O O
to O O
determine O O
whether O O
chronic O O
administration O O
of O O
temocapril O O
, O O
a O O
long O O
- O O
acting O O
non O O
- O O
SH O O
group O O
angiotensin O O
converting O O
enzyme O O
( O O
ACE O O
) O O
inhibitor O O
, O O
reduced O O
proteinuria B B_DISEASE/B_GENE
, O O
inhibited O O
glomerular O O
hypertrophy B B_DISEASE
and O O
prevented O O
glomerulosclerosis B B_DISEASE/B_GENE
in O O
chronic O O
puromycin O O
aminonucleoside O O
( O O
PAN O O
) O O
- O O
induced O O
nephrotic B B_DISEASE
rats O O
. O O

Nephrosis B B_DISEASE
was O O
induced O O
by O O
injection O O
of O O
PAN O O
( O O
15mg O O
/ O O
100g O O
body O O
weight O O
) O O
in O O
male O O
Sprague O O
- O O
Dawley O O
( O O
SD O O
) O O
rats O O
. O O

Four O O
groups O O
were O O
used O O
, O O
i O O
) O O
the O O
PAN O O
group O O
( O O
14 O O
) O O
, O O
ii O O
) O O
PAN O O
/ O O
temocapril O O
( O O
13 O O
) O O
, O O
iii O O
) O O
temocapril O O
( O O
14 O O
) O O
and O O
iv O O
) O O
untreated O O
controls O O
( O O
15 O O
) O O
. O O

Temocapril O O
( O O
8 O O
mg O O
/ O O
kg O O
/ O O
day O O
) O O
was O O
administered O O
to O O
the O O
rats O O
which O O
were O O
killed O O
at O O
weeks O O
4 O O
, O O
14 O O
or O O
20 O O
. O O

Temocapril O O
did O O
not O O
attenuate O O
proteinuria B B_DISEASE/B_GENE
at O O
8 O O
days O O
, O O
but O O
it O O
did O O
markedly O O
lower O O
it O O
from O O
weeks O O
4 O O
to O O
20 O O
. O O

The O O
glomerulosclerosis B B_DISEASE_ADJECTIVE[DISEASE]
index O O
( O O
GSI O O
) O O
was O O
6 O O
. O O
21 O O
% O O
at O O
4 O O
weeks O O
and O O
respectively O O
25 O O
. O O
35 O O
% O O
and O O
30 O O
. O O
49 O O
% O O
at O O
14 O O
and O O
20 O O
weeks O O
in O O
the O O
PAN O O
group O O
. O O

It O O
appears O O
that O O
temocapril O O
was O O
effective O O
in O O
retarding O O
renal O O
progression O O
and O O
protected O O
renal O O
function O O
in O O
PAN O O
neprotic B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
rats O O
. O O

Pulmonary B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hypertension I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
ibuprofen O O
prophylaxis O O
in O O
very O O
preterm O O
infants O O
. O O

We O O
report O O
three O O
cases O O
of O O
severe O O
hypoxaemia B B_DISEASE
after O O
ibuprofen O O
administration O O
during O O
a O O
randomised O O
controlled O O
trial O O
of O O
prophylactic O O
treatment O O
of O O
patent B B_DISEASE/B_PERSON
ductus I I_DISEASE/I_PERSON
arteriosus I I_DISEASE/I_PERSON
with O O
ibuprofen O O
in O O
premature O O
infants O O
born O O
at O O
less O O
than O O
28 O O
weeks O O
of O O
gestation O O
. O O

Echocardiography O O
showed O O
severely O O
decreased O O
pulmonary O O
blood O O
flow O O
. O O

We O O
suggest O O
that O O
investigators O O
involved O O
in O O
similar O O
trials O O
pay O O
close O O
attention O O
to O O
pulmonary O O
pressure O O
if O O
hypoxaemia B B_DISEASE/B_LOCATION
occurs O O
after O O
prophylactic O O
administration O O
of O O
ibuprofen O O
. O O

Hyponatremia B B_DISEASE
and O O
syndrome B B_DISEASE
of I I_DISEASE
inappropriate I I_DISEASE
anti I I_DISEASE
- I I_DISEASE
diuretic I I_DISEASE
hormone I I_DISEASE
reported O O
with O O
the O O
use O O
of O O
Vincristine O O
: O O
an O O
over O O
- O O
representation O O
of O O
Asians O O
? O O

PURPOSE O O
: O O
This O O
retrospective O O
study O O
used O O
a O O
pharmaceutical O O
company O O
' O O
s O O
global O O
safety O O
database O O
to O O
determine O O
the O O
reporting O O
rate O O
of O O
hyponatremia B B_DISEASE
and O O
/ O O
or O O
syndrome B B_DISEASE
of I I_DISEASE
inappropriate I I_DISEASE
secretion I I_DISEASE
of I I_DISEASE
anti I I_DISEASE
- I I_DISEASE
diuretic I I_DISEASE
hormone I I_DISEASE
( O O
SIADH B B_DISEASE/B_GENE
) O O
among O O
vincristine O O
- O O
treated O O
patients O O
and O O
to O O
explore O O
the O O
possibility O O
of O O
at O O
- O O
risk O O
population O O
subgroups O O
. O O

METHOD O O
: O O
We O O
searched O O
the O O
Eli O O
Lilly O O
and O O
Company O O
' O O
s O O
computerized O O
adverse O O
event O O
database O O
for O O
all O O
reported O O
cases O O
of O O
hyponatremia B B_DISEASE
and O O
/ O O
or O O
SIADH B B_DISEASE
as O O
of O O
1 O O
November O O
1999 O O
that O O
had O O
been O O
reported O O
during O O
the O O
use O O
of O O
vincristine O O
. O O

RESULTS O O
: O O
A O O
total O O
of O O
76 O O
cases O O
of O O
hyponatremia B B_DISEASE/B_LOCATION
and O O
/ O O
or O O
SIADH B B_DISEASE
associated O O
with O O
vincristine O O
use O O
were O O
identified O O
. O O

The O O
overall O O
reporting O O
rate O O
was O O
estimated O O
to O O
be O O
1 O O
. O O
3 O O
/ O O
100 O O
, O O
000 O O
treated O O
patients O O
. O O

The O O
average O O
age O O
of O O
patients O O
was O O
35 O O
. O O
6 O O
+ O O
/ O O
- O O
28 O O
. O O
3 O O
years O O
, O O
and O O
62 O O
% O O
were O O
males O O
. O O

Approximately O O
75 O O
% O O
of O O
the O O
patients O O
were O O
receiving O O
treatment O O
for O O
leukemia B B_DISEASE
or O O
lymphoma B B_DISEASE
. O O

Among O O
the O O
39 O O
reports O O
that O O
included O O
information O O
on O O
race O O
, O O
the O O
racial O O
distribution O O
was O O
: O O
1 O O
Black O O
, O O
3 O O
Caucasian O O
, O O
and O O
35 O O
Asian O O
. O O

CONCLUSION O O
: O O
Our O O
data O O
suggest O O
that O O
Asian O O
patients O O
may O O
be O O
at O O
increased O O
risk O O
of O O
hyponatremia B B_DISEASE/B_LOCATION
and O O
/ O O
or O O
SIADH B B_DISEASE
associated O O
with O O
vincristine O O
use O O
. O O

Although O O
the O O
overall O O
reported O O
rate O O
of O O
SIADH B B_DISEASE
associated O O
with O O
vincristine O O
is O O
very O O
low O O
, O O
physicians O O
caring O O
for O O
Asian O O
oncology O O
patients O O
should O O
be O O
aware O O
of O O
this O O
potential O O
serious O O
but O O
reversible O O
adverse O O
event O O
. O O

Delayed O O
toxicity B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
cyclophosphamide O O
on O O
the O O
bladder O O
of O O
DBA O O
/ O O
2 O O
and O O
C57BL O O
/ O O
6 O O
female O O
mouse O O
. O O

Inbred O O
DBA O O
/ O O
2 O O
and O O
C57BL O O
/ O O
6 O O
female O O
mice O O
were O O
injected O O
with O O
CY O O
, O O
and O O
the O O
effect O O
of O O
the O O
drug O O
on O O
the O O
bladder O O
was O O
assessed O O
during O O
100 O O
days O O
by O O
light O O
microscopy O O
using O O
different O O
staining O O
procedures O O
, O O
and O O
after O O
30 O O
days O O
by O O
conventional O O
electron O O
microscopy O O
. O O

After O O
30 O O
days O O
of O O
CY O O
injection O O
ulcerous O O
and O O
non O O
- O O
ulcerous O O
forms O O
of O O
chronic O O
cystitis B B_DISEASE
appeared O O
in O O
86 O O
% O O
of O O
DBA O O
/ O O
2 O O
mice O O
but O O
only O O
in O O
4 O O
% O O
of O O
C57BL O O
/ O O
6 O O
mice O O
. O O

Delayed O O
cystitis B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
characterized O O
by O O
infiltration O O
and O O
transepithelial O O
passage O O
into O O
the O O
lumen O O
of O O
inflammatory O O
cells O O
and O O
by O O
frequent O O
exfoliation O O
of O O
the O O
urothelium O O
. O O

Mast O O
cells O O
appeared O O
in O O
the O O
connective O O
and O O
muscular O O
layers O O
of O O
the O O
bladder O O
at O O
a O O
much O O
higher O O
number O O
in O O
DBA O O
/ O O
2 O O
mice O O
than O O
in O O
C57BL O O
/ O O
6 O O
mice O O
or O O
untreated O O
controls O O
. O O

Instead O O
, O O
numerous O O
abnormal O O
vesicles O O
containing O O
one O O
or O O
several O O
dark O O
granules O O
were O O
observed O O
in O O
the O O
cytoplasm O O
of O O
cells O O
from O O
all O O
the O O
epithelial O O
layers O O
. O O

Delayed O O
cystitis B B_DISEASE
still O O
persisted O O
in O O
DBA O O
/ O O
2 O O
mice O O
100 O O
days O O
after O O
treatment O O
. O O

These O O
results O O
indicate O O
that O O
delayed O O
toxicity B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
CY O O
in O O
female O O
DBA O O
/ O O
2 O O
mice O O
causes O O
a O O
bladder O O
pathology O O
that O O
is O O
not O O
observed O O
in O O
C57BL O O
/ O O
6 O O
mice O O
. O O

This O O
pathology O O
resembles O O
interstitial B B_DISEASE/B_LOCATION
cystitis I I_DISEASE/I_LOCATION
in O O
humans O O
and O O
could O O
perhaps O O
be O O
used O O
as O O
an O O
animal O O
model O O
for O O
studies O O
on O O
the O O
disease O O
. O O

High O O
- O O
dose O O
5 O O
- O O
fluorouracil O O
/ O O
folinic O O
acid O O
in O O
combination O O
with O O
three O O
- O O
weekly O O
mitomycin O O
C O O
in O O
the O O
treatment O O
of O O
advanced O O
gastric B B_DISEASE
cancer I I_DISEASE
. O O

A O O
phase O O
II O O
study O O
. O O

BACKGROUND O O
: O O
The O O
24 O O
- O O
hour O O
continuous O O
infusion O O
of O O
5 O O
- O O
fluorouracil O O
( O O
5 O O
- O O
FU O O
) O O
and O O
folinic O O
acid O O
( O O
FA O O
) O O
as O O
part O O
of O O
several O O
new O O
multidrug O O
chemotherapy O O
regimens O O
in O O
advanced O O
gastric B B_DISEASE
cancer I I_DISEASE
( O O
AGC B B_DISEASE/B_LOCATION
) O O
has O O
shown O O
to O O
be O O
effective O O
, O O
with O O
low O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
a O O
previous O O
phase O O
II O O
study O O
with O O
3 O O
- O O
weekly O O
bolus O O
5 O O
- O O
FU O O
, O O
FA O O
and O O
mitomycin O O
C O O
( O O
MMC O O
) O O
we O O
found O O
a O O
low O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rate O O
and O O
response O O
rates O O
comparable O O
to O O
those O O
of O O
regimens O O
such O O
as O O
ELF O O
, O O
FAM O O
or O O
FAMTX O O
, O O
and O O
a O O
promising O O
median O O
overall O O
survival O O
. O O

In O O
order O O
to O O
improve O O
this O O
MMC O O
- O O
dependent O O
schedule O O
we O O
initiated O O
a O O
phase O O
II O O
study O O
with O O
high O O
- O O
dose O O
5 O O
- O O
FU O O
/ O O
FA O O
and O O
3 O O
- O O
weekly O O
bolus O O
MMC O O
. O O

PATIENTS O O
AND O O
METHODS O O
: O O
From O O
February O O
, O O
1998 O O
to O O
September O O
, O O
2000 O O
we O O
recruited O O
33 O O
patients O O
with O O
AGC B B_DISEASE/B_GENE
to O O
receive O O
weekly O O
24 O O
- O O
hour O O
5 O O
- O O
FU O O
2 O O
, O O
600 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
preceded O O
by O O
2 O O
- O O
hour O O
FA O O
500 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
for O O
6 O O
weeks O O
, O O
followed O O
by O O
a O O
2 O O
- O O
week O O
rest O O
period O O
. O O

Bolus O O
MMC O O
10 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
was O O
added O O
in O O
3 O O
- O O
weekly O O
intervals O O
. O O

Treatment O O
given O O
on O O
an O O
outpatient O O
basis O O
, O O
using O O
portable O O
pump O O
systems O O
, O O
was O O
repeated O O
on O O
day O O
57 O O
. O O

Patients O O
' O O
characteristics O O
were O O
: O O
male O O
/ O O
female O O
ratio O O
20 O O
/ O O
13 O O
; O O
median O O
age O O
57 O O
( O O
27 O O
- O O
75 O O
) O O
years O O
; O O
median O O
WHO O O
status O O
1 O O
( O O
0 O O
- O O
2 O O
) O O
. O O

18 O O
patients O O
had O O
a O O
primary O O
AGC B B_DISEASE/B_LOCATION
, O O
and O O
15 O O
showed O O
a O O
relapsed O O
AGC B B_DISEASE
. O O

Median O O
follow O O
- O O
up O O
was O O
11 O O
. O O
8 O O
months O O
( O O
range O O
of O O
those O O
surviving O O
: O O
2 O O
. O O
7 O O
- O O
11 O O
. O O
8 O O
months O O
) O O
. O O

RESULTS O O
: O O
32 O O
patients O O
were O O
evaluable O O
for O O
response O O
- O O
complete O O
remission O O
9 O O
. O O
1 O O
% O O
( O O
n O O
= O O
3 O O
) O O
, O O
partial O O
remission O O
45 O O
. O O
5 O O
% O O
( O O
n O O
= O O
15 O O
) O O
, O O
no O O
change O O
27 O O
. O O
3 O O
% O O
( O O
n O O
= O O
9 O O
) O O
, O O
progressive O O
disease O O
15 O O
. O O
1 O O
% O O
( O O
n O O
= O O
5 O O
) O O
. O O

The O O
worst O O
toxicities B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
% O O
) O O
observed O O
were O O
( O O
CTC O O
- O O
NCI O O
1 O O
/ O O
2 O O
/ O O
3 O O
) O O
: O O
leukopenia B B_DISEASE
45 O O
. O O
5 O O
/ O O
18 O O
. O O
2 O O
/ O O
6 O O
. O O
1 O O
, O O
thrombocytopenia B B_DISEASE
33 O O
. O O
3 O O
/ O O
9 O O
. O O
1 O O
/ O O
6 O O
. O O
1 O O
, O O
vomitus B B_DISEASE
24 O O
. O O
2 O O
/ O O
9 O O
. O O
1 O O
/ O O
0 O O
, O O
diarrhea B B_DISEASE
36 O O
. O O
4 O O
/ O O
6 O O
. O O
1 O O
/ O O
3 O O
. O O
0 O O
, O O
stomatitis B B_DISEASE
18 O O
. O O
2 O O
/ O O
9 O O
. O O
1 O O
/ O O
0 O O
, O O
hand B B_DISEASE
- I I_DISEASE
foot I I_DISEASE
syndrome I I_DISEASE
12 O O
. O O
1 O O
/ O O
0 O O
/ O O
0 O O
. O O

Two O O
patients O O
developed O O
hemolytic B B_DISEASE
- I I_DISEASE
uremic I I_DISEASE
syndrome I I_DISEASE
( O O
HUS B B_MEASURE/B_DISEASE
) O O
. O O

CONCLUSIONS O O
: O O
High O O
- O O
dose O O
5 O O
- O O
FU O O
/ O O
FA O O
/ O O
MMC O O
is O O
an O O
effective O O
and O O
well O O
- O O
tolerated O O
outpatient O O
regimen O O
for O O
AGC B B_DISEASE
( O O
objective O O
response O O
rate O O
54 O O
. O O
6 O O
% O O
) O O
. O O

It O O
may O O
serve O O
as O O
an O O
alternative O O
to O O
cisplatin O O
- O O
containing O O
regimens O O
; O O
however O O
, O O
it O O
has O O
to O O
be O O
considered O O
that O O
possibly O O
HUS B B_DISEASE
may O O
occur O O
. O O

Persistent O O
sterile O O
leukocyturia B B_DISEASE
is O O
associated O O
with O O
impaired B B_DISEASE
renal I I_DISEASE
function I I_DISEASE
in O O
human B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
immunodeficiency I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
virus I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
type I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
1 I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
- I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
infected I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
children O O
treated O O
with O O
indinavir O O
. O O

BACKGROUND O O
: O O
Prolonged O O
administration O O
of O O
indinavir O O
is O O
associated O O
with O O
the O O
occurrence O O
of O O
a O O
variety O O
of O O
renal O O
complications O O
in O O
adults O O
. O O

These O O
well O O
- O O
documented O O
side O O
effects O O
have O O
restricted O O
the O O
use O O
of O O
this O O
potent O O
protease O O
inhibitor O O
in O O
children O O
. O O

DESIGN O O
: O O
A O O
prospective O O
study O O
to O O
monitor O O
indinavir O O
- O O
related O O
nephrotoxicity B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
cohort O O
of O O
30 O O
human B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
immunodeficiency I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
virus I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
type I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
1 I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
- I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
infected I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
children O O
treated O O
with O O
indinavir O O
. O O

METHODS O O
: O O
Urinary O O
pH O O
, O O
albumin O O
, O O
creatinine O O
, O O
the O O
presence O O
of O O
erythrocytes O O
, O O
leukocytes O O
, O O
bacteria O O
and O O
crystals O O
, O O
and O O
culture O O
were O O
analyzed O O
every O O
3 O O
months O O
for O O
96 O O
weeks O O
. O O

Serum O O
creatinine O O
levels O O
were O O
routinely O O
determined O O
at O O
the O O
same O O
time O O
points O O
. O O

Steady O O
- O O
state O O
pharmacokinetics O O
of O O
indinavir O O
were O O
done O O
at O O
week O O
4 O O
after O O
the O O
initiation O O
of O O
indinavir O O
. O O

RESULTS O O
: O O
The O O
cumulative O O
incidence O O
of O O
persistent O O
sterile O O
leukocyturia B B_DISEASE_ADJECTIVE[DISEASE]
( O O
> O O
or O O
= O O
75 O O
cells O O
/ O O
micro O O
L O O
in O O
at O O
least O O
2 O O
consecutive O O
visits O O
) O O
after O O
96 O O
weeks O O
was O O
53 O O
% O O
. O O

Persistent O O
sterile O O
leukocyturia B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
was O O
frequently O O
associated O O
with O O
a O O
mild O O
increase O O
in O O
the O O
urine O O
albumin O O
/ O O
creatinine O O
ratio O O
and O O
by O O
microscopic O O
hematuria B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
cumulative O O
incidence O O
of O O
serum O O
creatinine O O
levels O O
> O O
50 O O
% O O
above O O
normal O O
was O O
33 O O
% O O
after O O
96 O O
weeks O O
. O O

Children O O
with O O
persistent O O
sterile O O
leukocyturia B B_DISEASE
more O O
frequently O O
had O O
serum O O
creatinine O O
levels O O
of O O
50 O O
% O O
above O O
normal O O
than O O
those O O
children O O
without O O
persistent O O
sterile O O
leukocyturia B B_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
children O O
younger O O
than O O
5 O O
. O O
6 O O
years O O
, O O
persistent O O
sterile O O
leukocyturia B B_DISEASE
was O O
significantly O O
more O O
frequent O O
than O O
in O O
older O O
children O O
. O O

A O O
higher O O
cumulative O O
incidence O O
of O O
persistent O O
leukocyturia B B_DISEASE
was O O
found O O
in O O
children O O
with O O
an O O
area O O
under O O
the O O
curve O O
> O O
19 O O
mg O O
/ O O
L O O
x O O
h O O
or O O
a O O
peak O O
serum O O
level O O
of O O
indinavir O O
> O O
12 O O
mg O O
/ O O
L O O
. O O

In O O
4 O O
children O O
, O O
indinavir O O
was O O
discontinued O O
because O O
of O O
nephrotoxicity B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Subsequently O O
, O O
the O O
serum O O
creatinine O O
levels O O
decreased O O
, O O
the O O
urine O O
albumin O O
/ O O
creatinine O O
ratios O O
returned O O
to O O
zero O O
, O O
and O O
the O O
leukocyturia B B_DISEASE
disappeared O O
within O O
3 O O
months O O
. O O

CONCLUSIONS O O
: O O
Children O O
treated O O
with O O
indinavir O O
have O O
a O O
high O O
cumulative O O
incidence O O
of O O
persistent O O
sterile O O
leukocyturia B B_DISEASE_ADJECTIVE[DISEASE]
. O O

Children O O
with O O
persistent O O
sterile O O
leukocyturia B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
more O O
frequently O O
had O O
an O O
increase O O
in O O
serum O O
creatinine O O
levels O O
of O O
> O O
50 O O
% O O
above O O
normal O O
. O O

The O O
impairment B B_DISEASE
of I I_DISEASE
the I I_DISEASE
renal I I_DISEASE
function I I_DISEASE
in O O
these O O
children O O
occurred O O
in O O
the O O
absence O O
of O O
clinical O O
symptoms O O
of O O
nephrolithiasis B B_DISEASE/B_GENE
. O O

Indinavir O O
- O O
associated O O
nephrotoxicity B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
must O O
be O O
monitored O O
closely O O
, O O
especially O O
in O O
children O O
with O O
risk O O
factors O O
such O O
as O O
persistent O O
sterile O O
leukocyturia B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
age O O
< O O
5 O O
. O O
6 O O
years O O
, O O
an O O
area O O
under O O
the O O
curve O O
of O O
indinavir O O
> O O
19 O O
mg O O
/ O O
L O O
x O O
h O O
, O O
and O O
a O O
C O O
( O O
max O O
) O O
> O O
12 O O
mg O O
/ O O
L O O
. O O

Utility O O
of O O
troponin O O
I O O
in O O
patients O O
with O O
cocaine O O
- O O
associated O O
chest B B_DISEASE/B_LOCATION
pain I I_DISEASE/I_LOCATION
. O O

Troponin O O
sampling O O
may O O
offer O O
greater O O
diagnostic O O
utility O O
in O O
these O O
patients O O
. O O

OBJECTIVE O O
: O O
To O O
assess O O
outcomes O O
based O O
on O O
troponin O O
positivity O O
in O O
patients O O
with O O
cocaine O O
chest B B_DISEASE_ADJECTIVE[DISEASE]
pain I I_DISEASE_ADJECTIVE[DISEASE]
admitted O O
for O O
exclusion O O
of O O
MI B B_DISEASE/B_LOCATION
. O O

METHODS O O
: O O
Outcomes O O
were O O
examined O O
in O O
patients O O
admitted O O
for O O
possible O O
MI B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O O
cocaine O O
use O O
. O O

All O O
patients O O
underwent O O
a O O
rapid O O
rule O O
- O O
in O O
protocol O O
that O O
included O O
serial O O
sampling O O
of O O
creatine O O
kinase O O
( O O
CK O O
) O O
, O O
CK O O
- O O
MB O O
, O O
and O O
cardiac O O
troponin O O
I O O
( O O
cTnI O O
) O O
over O O
eight O O
hours O O
. O O

Outcomes O O
included O O
CK O O
- O O
MB O O
MI B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O O
CK O O
- O O
MB O O
> O O
or O O
= O O
8 O O
ng O O
/ O O
mL O O
with O O
a O O
relative O O
index O O
[ O O
( O O
CK O O
- O O
MB O O
x O O
100 O O
) O O
/ O O
total O O
CK O O
] O O
> O O
or O O
= O O
4 O O
, O O
cardiac B B_DISEASE
death I I_DISEASE
, O O
and O O
significant O O
coronary B B_DISEASE/B_LOCATION
disease I I_DISEASE/I_LOCATION
( O O
> O O
or O O
= O O
50 O O
% O O
) O O
. O O

RESULTS O O
: O O
Of O O
the O O
246 O O
admitted O O
patients O O
, O O
34 O O
( O O
14 O O
% O O
) O O
met O O
CK O O
- O O
MB O O
criteria O O
for O O
MI B B_DISEASE/B_LOCATION
and O O
38 O O
( O O
16 O O
% O O
) O O
had O O
cTnI O O
elevations O O
. O O

Three O O
of O O
the O O
four O O
patients O O
without O O
significant O O
disease O O
who O O
had O O
cTnI O O
elevations O O
met O O
CK O O
- O O
MB O O
criteria O O
for O O
MI B B_DISEASE/B_LOCATION
, O O
and O O
the O O
other O O
had O O
a O O
peak O O
CK O O
- O O
MB O O
level O O
of O O
13 O O
ng O O
/ O O
mL O O
. O O

Sensitivities O O
, O O
specificities O O
, O O
and O O
positive O O
and O O
negative O O
likelihood O O
ratios O O
for O O
predicting O O
cardiac B B_DISEASE_ADJECTIVE[DISEASE]
death I I_DISEASE_ADJECTIVE[DISEASE]
or O O
significant O O
disease O O
were O O
high O O
for O O
both O O
CK O O
- O O
MB O O
MI B B_DISEASE/B_PROTEIN[GENE]
and O O
cTnI O O
and O O
were O O
not O O
significantly O O
different O O
. O O

CONCLUSIONS O O
: O O
Most O O
patients O O
with O O
cTnI O O
elevations O O
meet O O
CK O O
- O O
MB O O
criteria O O
for O O
MI B B_DISEASE/B_LOCATION
, O O
as O O
well O O
as O O
have O O
a O O
high O O
incidence O O
of O O
underlying O O
significant O O
disease O O
. O O

Troponin O O
appears O O
to O O
have O O
an O O
equivalent O O
diagnostic O O
accuracy O O
compared O O
with O O
CK O O
- O O
MB O O
for O O
diagnosing O O
necrosis B B_DISEASE/B_LOCATION
in O O
patients O O
with O O
cocaine O O
- O O
associated O O
chest B B_DISEASE/B_LOCATION
pain I I_DISEASE/I_LOCATION
and O O
suspected O O
MI B B_DISEASE
. O O

Acute O O
interstitial B B_DISEASE
nephritis I I_DISEASE
due O O
to O O
nicergoline O O
( O O
Sermion O O
) O O
. O O

A O O
50 O O
- O O
year O O
- O O
old O O
patient O O
admitted O O
to O O
our O O
hospital O O
for O O
fever B B_DISEASE
and O O
acute B B_DISEASE
renal I I_DISEASE
failure I I_DISEASE
. O O

Before O O
admission O O
, O O
he O O
had O O
been O O
taking O O
nicergoline O O
and O O
bendazac O O
lysine O O
due O O
to O O
retinal B B_DISEASE
vein I I_DISEASE
occlusion I I_DISEASE
at O O
ophthalmologic O O
department O O
. O O

Thereafter O O
, O O
he O O
experienced O O
intermittent O O
fever B B_DISEASE
and O O
skin B B_DISEASE
rash I I_DISEASE
. O O

On O O
admission O O
, O O
clinical O O
symptoms O O
( O O
i O O
. O O
e O O
. O O
arthralgia B B_DISEASE
and O O
fever B B_DISEASE
) O O
and O O
laboratory O O
findings O O
( O O
i O O
. O O
e O O
. O O
eosinophilia B B_DISEASE
and O O
renal B B_DISEASE/B_GENE
failure I I_DISEASE/I_GENE
) O O
suggested O O
AIN B B_DISEASE
, O O
and O O
which O O
was O O
confirmed O O
by O O
pathologic O O
findings O O
on O O
renal O O
biopsy O O
. O O

A O O
lymphocyte O O
transformation O O
test O O
demonstrated O O
a O O
positive O O
result O O
against O O
nicergoline O O
. O O

To O O
our O O
knowledge O O
, O O
this O O
is O O
the O O
first O O
report O O
of O O
nicergoline O O
- O O
associated O O
AIN B B_DISEASE/B_GENE
. O O

Neuroleptic B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
malignant I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
syndrome I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
complicated O O
by O O
massive O O
intestinal O O
bleeding B B_DISEASE
in O O
a O O
patient O O
with O O
chronic B B_DISEASE
renal I I_DISEASE
failure I I_DISEASE
. O O

In O O
addition O O
to O O
the O O
typical O O
symptoms O O
of O O
NMS B B_DISEASE/B_GENE
, O O
massive O O
intestinal O O
bleeding B B_DISEASE
was O O
observed O O
during O O
the O O
episode O O
. O O

This O O
report O O
suggests O O
that O O
NMS B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
patient O O
with O O
CRF B B_DISEASE
may O O
be O O
complicated O O
by O O
intestinal O O
bleeding B B_DISEASE
and O O
needs O O
special O O
caution O O
for O O
this O O
complication O O
. O O

Blood O O
brain O O
barrier O O
in O O
right O O
- O O
and O O
left O O
- O O
pawed O O
female O O
rats O O
assessed O O
by O O
a O O
new O O
staining O O
method O O
. O O

The O O
asymmetrical O O
breakdown O O
of O O
the O O
blood O O
- O O
brain O O
barrier O O
( O O
BBB O O
) O O
was O O
studied O O
in O O
female O O
rats O O
. O O

Paw O O
preference O O
was O O
assessed O O
by O O
a O O
food O O
reaching O O
test O O
. O O

Adrenaline O O
- O O
induced O O
hypertension B B_DISEASE
was O O
used O O
to O O
destroy O O
the O O
BBB O O
, O O
which O O
was O O
evaluated O O
using O O
triphenyltetrazolium O O
( O O
TTC O O
) O O
staining O O
of O O
the O O
brain O O
slices O O
just O O
after O O
giving O O
adrenaline O O
for O O
30 O O
s O O
. O O

In O O
normal O O
rats O O
, O O
the O O
whole O O
brain O O
sections O O
exhibited O O
complete O O
staining O O
with O O
TTC O O
. O O

After O O
adrenaline O O
infusion O O
for O O
30 O O
s O O
, O O
there O O
were O O
large O O
unstained O O
areas O O
in O O
the O O
left O O
brain O O
in O O
right O O
- O O
pawed O O
animals O O
, O O
and O O
vice O O
versa O O
in O O
left O O
- O O
pawed O O
animals O O
. O O

Similar O O
results O O
were O O
obtained O O
in O O
seizure B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
induced O O
breakdown O O
of O O
BBB O O
. O O

These O O
results O O
were O O
explained O O
by O O
an O O
asymmetric O O
cerebral O O
blood O O
flow O O
depending O O
upon O O
the O O
paw O O
preference O O
in O O
rats O O
. O O

It O O
was O O
suggested O O
that O O
this O O
new O O
method O O
and O O
the O O
results O O
are O O
consistent O O
with O O
contralateral O O
motor O O
control O O
that O O
may O O
be O O
important O O
in O O
determining O O
the O O
dominant O O
cerebral O O
hemisphere O O
in O O
animals O O
. O O

Carvedilol O O
protects O O
against O O
doxorubicin O O
- O O
induced O O
mitochondrial O O
cardiomyopathy B B_DISEASE
. O O

Several O O
cytopathic O O
mechanisms O O
have O O
been O O
suggested O O
to O O
mediate O O
the O O
dose O O
- O O
limiting O O
cumulative O O
and O O
irreversible O O
cardiomyopathy B B_DISEASE
caused O O
by O O
doxorubicin O O
. O O

Recent O O
evidence O O
indicates O O
that O O
oxidative O O
stress O O
and O O
mitochondrial B B_DISEASE/B_GENE
dysfunction I I_DISEASE/I_GENE
are O O
key O O
factors O O
in O O
the O O
pathogenic O O
process O O
. O O

The O O
objective O O
of O O
this O O
investigation O O
was O O
to O O
test O O
the O O
hypothesis O O
that O O
carvedilol O O
, O O
a O O
nonselective O O
beta O O
- O O
adrenergic O O
receptor O O
antagonist O O
with O O
potent O O
antioxidant O O
properties O O
, O O
protects O O
against O O
the O O
cardiac O O
and O O
hepatic O O
mitochondrial O O
bioenergetic O O
dysfunction O O
associated O O
with O O
subchronic O O
doxorubicin O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Heart O O
and O O
liver O O
mitochondria O O
were O O
isolated O O
from O O
rats O O
treated O O
for O O
7 O O
weeks O O
with O O
doxorubicin O O
( O O
2 O O
mg O O
/ O O
kg O O
sc O O
/ O O
week O O
) O O
, O O
carvedilol O O
( O O
1 O O
mg O O
/ O O
kg O O
ip O O
/ O O
week O O
) O O
, O O
or O O
the O O
combination O O
of O O
the O O
two O O
drugs O O
. O O

Heart O O
mitochondria O O
isolated O O
from O O
doxorubicin O O
- O O
treated O O
rats O O
exhibited O O
depressed O O
rates O O
for O O
state O O
3 O O
respiration O O
( O O
336 O O
+ O O
/ O O
- O O
26 O O
versus O O
425 O O
+ O O
/ O O
- O O
53 O O
natom O O
O O O
/ O O
min O O
/ O O
mg O O
protein O O
) O O
and O O
a O O
lower O O
respiratory O O
control O O
ratio O O
( O O
RCR O O
) O O
( O O
4 O O
. O O
3 O O
+ O O
/ O O
- O O
0 O O
. O O
6 O O
versus O O
5 O O
. O O
8 O O
+ O O
/ O O
- O O
0 O O
. O O
4 O O
) O O
compared O O
with O O
cardiac O O
mitochondria O O
isolated O O
from O O
saline O O
- O O
treated O O
rats O O
. O O

Mitochondrial O O
calcium O O
- O O
loading O O
capacity O O
and O O
the O O
activity O O
of O O
NADH O O
- O O
dehydrogenase O O
were O O
also O O
suppressed O O
in O O
cardiac O O
mitochondria O O
from O O
doxorubicin O O
- O O
treated O O
rats O O
. O O

Doxorubicin O O
treatment O O
also O O
caused O O
a O O
decrease O O
in O O
RCR O O
for O O
liver O O
mitochondria O O
( O O
3 O O
. O O
9 O O
+ O O
/ O O
- O O
0 O O
. O O
9 O O
versus O O
5 O O
. O O
6 O O
+ O O
/ O O
- O O
0 O O
. O O
7 O O
for O O
control O O
rats O O
) O O
and O O
inhibition O O
of O O
hepatic O O
cytochrome O O
oxidase O O
activity O O
. O O

Carvedilol O O
also O O
prevented O O
the O O
decrease O O
in O O
mitochondrial O O
Ca O O
( O O
2 O O
+ O O
) O O
loading O O
capacity O O
and O O
the O O
inhibition O O
of O O
the O O
respiratory O O
complexes O O
of O O
heart O O
mitochondria O O
caused O O
by O O
doxorubicin O O
. O O

Carvedilol O O
by O O
itself O O
did O O
not O O
affect O O
any O O
of O O
the O O
parameters O O
measured O O
for O O
heart O O
or O O
liver O O
mitochondria O O
. O O

It O O
is O O
concluded O O
that O O
this O O
protection O O
by O O
carvedilol O O
against O O
both O O
the O O
structural O O
and O O
functional O O
cardiac O O
tissue O O
damage O O
may O O
afford O O
significant O O
clinical O O
advantage O O
in O O
minimizing O O
the O O
dose O O
- O O
limiting O O
mitochondrial B B_DISEASE
dysfunction I I_DISEASE
and O O
cardiomyopathy B B_DISEASE
that O O
accompanies O O
long O O
- O O
term O O
doxorubicin O O
therapy O O
in O O
cancer B B_DISEASE
patients O O
. O O

Cocaine O O
- O O
induced O O
hyperactivity B B_DISEASE
is O O
more O O
influenced O O
by O O
adenosine O O
receptor O O
agonists O O
than O O
amphetamine O O
- O O
induced O O
hyperactivity B B_DISEASE
. O O

The O O
influence O O
of O O
adenosine O O
receptor O O
agonists O O
and O O
antagonists O O
on O O
cocaine O O
- O O
and O O
amphetamine O O
- O O
induced O O
hyperactivity B B_DISEASE
was O O
examined O O
in O O
mice O O
. O O

All O O
adenosine O O
receptor O O
agonists O O
significantly O O
decreased B B_DISEASE_ADJECTIVE[DISEASE]
the I I_DISEASE_ADJECTIVE[DISEASE]
locomotor I I_DISEASE_ADJECTIVE[DISEASE]
activity I I_DISEASE_ADJECTIVE[DISEASE]
in O O
mice O O
, O O
and O O
the O O
effects O O
were O O
dose O O
- O O
dependent O O
. O O

It O O
seems O O
that O O
adenosine O O
A1 O O
and O O
A2 O O
receptors O O
might O O
be O O
involved O O
in O O
this O O
reaction O O
. O O

These O O
results O O
suggest O O
the O O
involvement O O
of O O
both O O
adenosine O O
receptors O O
in O O
the O O
action O O
of O O
cocaine O O
although O O
agonists O O
of O O
A1 O O
receptors O O
seem O O
to O O
have O O
stronger O O
influence O O
on O O
it O O
. O O

Caffeine O O
had O O
similar O O
action O O
but O O
the O O
effect O O
was O O
not O O
significant O O
. O O

CPT O O
( O O
8 O O
- O O
cyclopentyltheophylline O O
) O O
- O O
- O O
A1 O O
receptor O O
antagonist O O
, O O
did O O
not O O
show O O
any O O
influence O O
in O O
this O O
test O O
. O O

Similarly O O
, O O
all O O
adenosine O O
receptor O O
agonists O O
decreased O O
amphetamine O O
- O O
induced O O
hyperactivity B B_DISEASE
, O O
but O O
at O O
the O O
higher O O
doses O O
than O O
those O O
which O O
were O O
active O O
in O O
cocaine O O
- O O
induced O O
hyperactivity B B_DISEASE
. O O

Our O O
results O O
have O O
shown O O
that O O
all O O
adenosine O O
receptor O O
agonists O O
( O O
A1 O O
and O O
A2 O O
) O O
reduce O O
cocaine O O
- O O
and O O
amphetamine O O
- O O
induced O O
locomotor O O
activity O O
and O O
indicate O O
that O O
cocaine O O
- O O
induced O O
hyperactivity B B_DISEASE
is O O
more O O
influenced O O
by O O
adenosine O O
receptor O O
agonists O O
( O O
particularly O O
A1 O O
receptors O O
) O O
than O O
amphetamine O O
- O O
induced O O
hyperactivity B B_DISEASE
. O O

Amiodarone O O
and O O
the O O
risk O O
of O O
bradyarrhythmia B B_DISEASE
requiring O O
permanent O O
pacemaker O O
in O O
elderly O O
patients O O
with O O
atrial B B_DISEASE/B_GENE
fibrillation I I_DISEASE/I_GENE
and O O
prior O O
myocardial B B_DISEASE
infarction I I_DISEASE
. O O

BACKGROUND O O
: O O
Reports O O
of O O
severe O O
bradyarrhythmia B B_DISEASE
during O O
amiodarone O O
therapy O O
are O O
infrequent O O
and O O
limited O O
to O O
studies O O
assessing O O
the O O
therapy O O
' O O
s O O
use O O
in O O
the O O
management O O
of O O
patients O O
with O O
ventricular B B_DISEASE
arrhythmias I I_DISEASE
. O O

Using O O
a O O
nested O O
case O O
- O O
control O O
design O O
, O O
477 O O
cases O O
of O O
bradyarrhythmia B B_DISEASE
requiring O O
a O O
permanent O O
pacemaker O O
were O O
matched O O
( O O
1 O O
: O O
4 O O
) O O
to O O
1 O O
, O O
908 O O
controls O O
. O O

This O O
effect O O
was O O
modified O O
by O O
gender O O
, O O
with O O
a O O
greater O O
risk O O
in O O
women O O
versus O O
men O O
( O O
OR O O
: O O
3 O O
. O O
86 O O
, O O
95 O O
% O O
CI O O
: O O
1 O O
. O O
70 O O
to O O
8 O O
. O O
75 O O
vs O O
. O O
OR O O
: O O
1 O O
. O O
52 O O
, O O
95 O O
% O O
CI O O
: O O
0 O O
. O O
80 O O
to O O
2 O O
. O O
89 O O
) O O
. O O

CONCLUSIONS O O
: O O
This O O
study O O
suggests O O
that O O
the O O
use O O
of O O
amiodarone O O
in O O
elderly O O
patients O O
with O O
AF B B_DISEASE
and O O
a O O
previous O O
MI B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increases O O
the O O
risk O O
of O O
bradyarrhythmia B B_DISEASE
requiring O O
a O O
permanent O O
pacemaker O O
. O O

Nonsteroidal O O
anti O O
- O O
inflammatory O O
drug O O
- O O
induced O O
cystitis B B_DISEASE
is O O
a O O
poorly O O
recognized O O
and O O
under O O
- O O
reported O O
condition O O
. O O

In O O
addition O O
to O O
tiaprofenic O O
acid O O
, O O
indomethacin O O
has O O
been O O
reported O O
to O O
be O O
associated O O
with O O
this O O
condition O O
. O O

METHODS O O
: O O
Three O O
groups O O
were O O
established O O
: O O
a O O
control O O
group O O
( O O
n O O
= O O
10 O O
) O O
, O O
a O O
high O O
- O O
dose O O
group O O
( O O
n O O
= O O
10 O O
) O O
, O O
treated O O
with O O
one O O
intraperitoneal O O
injection O O
of O O
indomethacin O O
20 O O
mg O O
/ O O
kg O O
, O O
and O O
a O O
therapeutic O O
dose O O
group O O
( O O
n O O
= O O
10 O O
) O O
in O O
which O O
oral O O
indomethacin O O
was O O
administered O O
3 O O
. O O
25 O O
mg O O
/ O O
kg O O
body O O
weight O O
daily O O
for O O
3 O O
weeks O O
. O O

The O O
animals O O
were O O
then O O
killed O O
and O O
the O O
bladders O O
removed O O
for O O
light O O
and O O
electron O O
microscopic O O
studies O O
. O O

When O O
compared O O
with O O
the O O
control O O
group O O
, O O
both O O
indomethacin O O
groups O O
revealed O O
statistically O O
increased O O
numbers O O
of O O
mast O O
cells O O
in O O
the O O
mucosa O O
( O O
P O O
< O O
0 O O
. O O
0001 O O
) O O
and O O
penetration O O
of O O
lanthanum O O
nitrate O O
through O O
intercellular O O
areas O O
of O O
the O O
epithelium O O
. O O

Furthermore O O
, O O
the O O
difference O O
in O O
mast O O
cell O O
counts O O
between O O
the O O
high O O
and O O
therapeutic O O
dose O O
groups O O
was O O
also O O
statistically O O
significant O O
( O O
P O O
< O O
0 O O
. O O
0001 O O
) O O
. O O

CONCLUSIONS O O
: O O
Indomethacin O O
resulted O O
in O O
histopathologic O O
findings O O
typical O O
of O O
interstitial B B_DISEASE/B_LOCATION
cystitis I I_DISEASE/I_LOCATION
, O O
such O O
as O O
leaky O O
bladder O O
epithelium O O
and O O
mucosal O O
mastocytosis B B_DISEASE
. O O

The O O
true O O
incidence O O
of O O
nonsteroidal O O
anti O O
- O O
inflammatory O O
drug O O
- O O
induced O O
cystitis B B_DISEASE
in O O
humans O O
must O O
be O O
clarified O O
by O O
prospective O O
clinical O O
trials O O
. O O

An O O
open O O
- O O
label O O
phase O O
II O O
study O O
of O O
low O O
- O O
dose O O
thalidomide O O
in O O
androgen O O
- O O
independent O O
prostate B B_DISEASE/B_PERSON
cancer I I_DISEASE/I_PERSON
. O O

The O O
antiangiogenic O O
effects O O
of O O
thalidomide O O
have O O
been O O
assessed O O
in O O
clinical O O
trials O O
in O O
patients O O
with O O
various O O
solid O O
and O O
haematological B B_DISEASE
malignancies I I_DISEASE
. O O

Thalidomide O O
blocks O O
the O O
activity O O
of O O
angiogenic O O
agents O O
including O O
bFGF O O
, O O
VEGF O O
and O O
IL O O
- O O
6 O O
. O O

We O O
undertook O O
an O O
open O O
- O O
label O O
study O O
using O O
thalidomide O O
100 O O
mg O O
once O O
daily O O
for O O
up O O
to O O
6 O O
months O O
in O O
20 O O
men O O
with O O
androgen O O
- O O
independent O O
prostate B B_DISEASE
cancer I I_DISEASE
. O O

The O O
mean O O
time O O
of O O
study O O
was O O
109 O O
days O O
( O O
median O O
107 O O
, O O
range O O
4 O O
- O O
184 O O
days O O
) O O
. O O

Patients O O
underwent O O
regular O O
measurement O O
of O O
prostate O O
- O O
specific O O
antigen O O
( O O
PSA O O
) O O
, O O
urea O O
and O O
electrolytes O O
, O O
serum O O
bFGF O O
and O O
VEGF O O
. O O

Of O O
16 O O
men O O
treated O O
for O O
at O O
least O O
2 O O
months O O
, O O
six O O
( O O
37 O O
. O O
5 O O
% O O
) O O
showed O O
a O O
fall O O
in O O
absolute O O
PSA O O
by O O
a O O
median O O
of O O
48 O O
% O O
. O O

Increasing O O
levels O O
of O O
serum O O
bFGF O O
and O O
VEGF O O
were O O
associated O O
with O O
progressive O O
disease O O
; O O
five O O
of O O
six O O
men O O
who O O
demonstrated O O
a O O
fall O O
in O O
PSA O O
also O O
showed O O
a O O
decline O O
in O O
bFGF O O
and O O
VEGF O O
levels O O
, O O
and O O
three O O
of O O
four O O
men O O
with O O
a O O
rising O O
PSA O O
showed O O
an O O
increase O O
in O O
both O O
growth O O
factors O O
. O O

Adverse O O
effects O O
included O O
constipation B B_DISEASE
, O O
morning O O
drowsiness B B_DISEASE
, O O
dizziness B B_DISEASE
and O O
rash B B_DISEASE
, O O
and O O
resulted O O
in O O
withdrawal O O
from O O
the O O
study O O
by O O
three O O
men O O
. O O

Evidence O O
of O O
peripheral B B_DISEASE
sensory I I_DISEASE
neuropathy I I_DISEASE
was O O
found O O
in O O
nine O O
of O O
13 O O
men O O
before O O
treatment O O
. O O

In O O
the O O
seven O O
men O O
who O O
completed O O
six O O
months O O
on O O
thalidomide O O
, O O
subclinical O O
evidence O O
of O O
peripheral B B_DISEASE
neuropathy I I_DISEASE
was O O
found O O
in O O
four O O
before O O
treatment O O
, O O
but O O
in O O
all O O
seven O O
at O O
repeat O O
testing O O
. O O

The O O
findings O O
indicate O O
that O O
thalidomide O O
may O O
be O O
an O O
option O O
for O O
patients O O
who O O
have O O
failed O O
other O O
forms O O
of O O
therapy O O
, O O
provided O O
close O O
follow O O
- O O
up O O
is O O
maintained O O
for O O
development O O
of O O
peripheral B B_DISEASE_ADJECTIVE[DISEASE]
neuropathy I I_DISEASE_ADJECTIVE[DISEASE]
. O O

Central B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nervous I I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system I I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toxicity I I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
following O O
the O O
administration O O
of O O
levobupivacaine O O
for O O
lumbar O O
plexus O O
block O O
: O O
A O O
report O O
of O O
two O O
cases O O
. O O

BACKGROUND O O
AND O O
OBJECTIVES O O
: O O
Central B B_DISEASE
nervous I I_DISEASE
system I I_DISEASE
and I I_DISEASE
cardiac I I_DISEASE
toxicity I I_DISEASE
following O O
the O O
administration O O
of O O
local O O
anesthetics O O
is O O
a O O
recognized O O
complication O O
of O O
regional O O
anesthesia O O
. O O

Levobupivacaine O O
, O O
the O O
pure O O
S O O
( O O
- O O
) O O
enantiomer O O
of O O
bupivacaine O O
, O O
was O O
developed O O
to O O
improve O O
the O O
cardiac O O
safety O O
profile O O
of O O
bupivacaine O O
. O O

We O O
describe O O
2 O O
cases O O
of O O
grand B B_DISEASE
mal I I_DISEASE
seizures I I_DISEASE
following O O
accidental O O
intravascular O O
injection O O
of O O
levobupivacaine O O
. O O

CASE O O
REPORT O O
: O O
Two O O
patients O O
presenting O O
for O O
elective O O
orthopedic O O
surgery O O
of O O
the O O
lower O O
limb O O
underwent O O
blockade O O
of O O
the O O
lumbar O O
plexus O O
via O O
the O O
posterior O O
approach O O
. O O

Immediately O O
after O O
the O O
administration O O
of O O
levobupivacaine O O
0 O O
. O O
5 O O
% O O
with O O
epinephrine O O
2 O O
. O O
5 O O
microgram O O
/ O O
mL O O
, O O
the O O
patients O O
developed O O
grand B B_DISEASE
mal I I_DISEASE
seizures I I_DISEASE
, O O
despite O O
negative O O
aspiration O O
for O O
blood O O
and O O
no O O
clinical O O
signs O O
of O O
intravenous O O
epinephrine O O
administration O O
. O O

The O O
seizures B B_DISEASE/B_PERSON
were O O
successfully O O
treated O O
with O O
sodium O O
thiopental O O
in O O
addition O O
to O O
succinylcholine O O
in O O
1 O O
patient O O
. O O

Neither O O
patient O O
developed O O
signs O O
of O O
cardiovascular B B_DISEASE
toxicity I I_DISEASE
. O O

Both O O
patients O O
were O O
treated O O
preoperatively O O
with O O
beta O O
- O O
adrenergic O O
antagonist O O
medications O O
, O O
which O O
may O O
have O O
masked O O
the O O
cardiovascular O O
signs O O
of O O
the O O
unintentional O O
intravascular O O
administration O O
of O O
levobupivacaine O O
with O O
epinephrine O O
. O O

CONCLUSIONS O O
: O O
Although O O
levobupivacaine O O
may O O
have O O
a O O
safer O O
cardiac B B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
toxicity I I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
profile O O
than O O
racemic O O
bupivacaine O O
, O O
if O O
adequate O O
amounts O O
of O O
levobupivacaine O O
reach O O
the O O
circulation O O
, O O
it O O
will O O
result O O
in O O
convulsions B B_DISEASE
. O O

Plasma O O
concentrations O O
sufficient O O
to O O
result O O
in O O
central B B_DISEASE
nervous I I_DISEASE
system I I_DISEASE
toxicity I I_DISEASE
did O O
not O O
produce O O
manifestations O O
of O O
cardiac B B_DISEASE
toxicity I I_DISEASE
in O O
these O O
2 O O
patients O O
. O O

Amiodarone O O
- O O
induced O O
torsade B B_DISEASE
de I I_DISEASE
pointes I I_DISEASE
during O O
bladder O O
irrigation O O
: O O
an O O
unusual O O
presentation O O
- O O
- O O
a O O
case O O
report O O
. O O

Consistent O O
with O O
other O O
reports O O
this O O
case O O
of O O
TdP B B_DISEASE/B_GENE
occurred O O
in O O
the O O
context O O
of O O
multiple O O
exacerbating O O
factors O O
including O O
hypokalemia B B_DISEASE
and O O
digoxin O O
excess O O
. O O

Transient O O
prolongation O O
of O O
the O O
QT O O
during O O
bladder O O
irrigation O O
prompted O O
the O O
episode O O
of O O
TdP B B_DISEASE/B_GENE
. O O

It O O
is O O
well O O
known O O
that O O
bradycardia B B_DISEASE
exacerbates O O
acquired O O
TdP B B_DISEASE/B_GENE
. O O

The O O
authors O O
speculate O O
that O O
the O O
increased O O
vagal O O
tone O O
during O O
bladder O O
irrigation O O
, O O
a O O
vagal O O
maneuver O O
, O O
in O O
the O O
context O O
of O O
amiodarone O O
therapy O O
resulted O O
in O O
amiodarone O O
- O O
induced O O
proarrhythmia B B_DISEASE
. O O

In O O
the O O
absence O O
of O O
amiodarone O O
therapy O O
, O O
a O O
second O O
bladder O O
irrigation O O
did O O
not O O
induce O O
TdP B B_DISEASE/B_GENE
despite O O
hypokalemia B B_DISEASE
and O O
hypomagnesemia B B_DISEASE
. O O

Anaesthetic O O
complications O O
associated O O
with O O
myotonia B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
congenita I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
case O O
study O O
and O O
comparison O O
with O O
other O O
myotonic B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disorders I I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
describe O O
a O O
previously O O
healthy O O
32 O O
- O O
year O O
- O O
old O O
woman O O
who O O
developed O O
a O O
life O O
- O O
threatening O O
muscle B B_DISEASE
spasm I I_DISEASE
and O O
secondary O O
ventilation O O
difficulties O O
following O O
a O O
preoperative O O
injection O O
of O O
suxamethonium O O
. O O

The O O
muscle B B_DISEASE
spasms I I_DISEASE
disappeared O O
spontaneously O O
and O O
the O O
surgery O O
proceeded O O
without O O
further O O
problems O O
. O O

When O O
subsequently O O
questioned O O
, O O
she O O
reported O O
minor O O
symptoms O O
suggesting O O
a O O
myotonic B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
condition I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Myotonia B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
was O O
found O O
on O O
clinical O O
examination O O
and O O
EMG O O
. O O

Neither O O
the O O
patient O O
nor O O
the O O
anaesthetist O O
were O O
aware O O
of O O
the O O
diagnosis O O
before O O
this O O
potentially O O
lethal O O
complication O O
occurred O O
. O O

We O O
give O O
a O O
brief O O
overview O O
of O O
ion B B_DISEASE_ADJECTIVE[DISEASE]
channel I I_DISEASE_ADJECTIVE[DISEASE]
disorders I I_DISEASE_ADJECTIVE[DISEASE]
including O O
malignant B B_DISEASE/B_PERSON
hyperthermia I I_DISEASE/I_PERSON
and O O
their O O
anaesthetic O O
considerations O O
. O O

Respiratory O O
pattern O O
in O O
a O O
rat O O
model O O
of O O
epilepsy B B_DISEASE/B_LOCATION
. O O

PURPOSE O O
: O O
Apnea B B_DISEASE
is O O
known O O
to O O
occur O O
during O O
seizures B B_DISEASE/B_LOCATION
, O O
but O O
systematic O O
studies O O
of O O
ictal O O
respiratory O O
changes O O
in O O
adults O O
are O O
few O O
. O O

Data O O
regarding O O
respiratory O O
pattern O O
defects O O
during O O
interictal O O
periods O O
also O O
are O O
scarce O O
. O O

Here O O
we O O
sought O O
to O O
generate O O
information O O
with O O
regard O O
to O O
the O O
interictal O O
period O O
in O O
animals O O
with O O
pilocarpine O O
- O O
induced O O
epilepsy B B_DISEASE
. O O

METHODS O O
: O O
Twelve O O
rats O O
( O O
six O O
chronically O O
epileptic B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
animals O O
and O O
six O O
controls O O
) O O
were O O
anesthetized O O
, O O
given O O
tracheotomies O O
, O O
and O O
subjected O O
to O O
hyperventilation B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
hypoventilation O O
conditions O O
. O O

This O O
flow O O
was O O
measured O O
by O O
using O O
a O O
differential O O
pressure O O
transducer O O
, O O
passed O O
through O O
a O O
polygraph O O
, O O
and O O
from O O
this O O
to O O
a O O
computer O O
with O O
custom O O
software O O
that O O
derived O O
ventilation O O
( O O
VE O O
) O O
, O O
tidal O O
volume O O
( O O
VT O O
) O O
, O O
inspiratory O O
time O O
( O O
TI O O
) O O
, O O
expiratory O O
time O O
( O O
TE O O
) O O
, O O
breathing O O
frequency O O
( O O
f O O
) O O
, O O
and O O
mean O O
inspiratory O O
flow O O
( O O
VT O O
/ O O
TI O O
) O O
on O O
a O O
breath O O
- O O
by O O
- O O
breath O O
basis O O
. O O

RESULTS O O
: O O
The O O
hyperventilation B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
maneuver O O
caused O O
a O O
decrease O O
in O O
spontaneous O O
ventilation O O
in O O
pilocarpine O O
- O O
treated O O
and O O
control O O
rats O O
. O O

Although O O
VE O O
had O O
a O O
similar O O
decrease O O
in O O
both O O
groups O O
, O O
in O O
the O O
epileptic B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
group O O
, O O
the O O
decrease O O
in O O
VE O O
was O O
due O O
to O O
a O O
significant O O
( O O
p O O
< O O
0 O O
. O O
05 O O
) O O
increase O O
in O O
TE O O
peak O O
in O O
relation O O
to O O
that O O
of O O
the O O
control O O
animals O O
. O O

The O O
hypoventilation O O
maneuver O O
led O O
to O O
an O O
increase O O
in O O
the O O
arterial O O
Paco2 O O
, O O
followed O O
by O O
an O O
increase O O
in O O
VE O O
. O O

In O O
the O O
epileptic B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
group O O
, O O
the O O
increase O O
in O O
VE O O
was O O
mediated O O
by O O
a O O
significant O O
( O O
p O O
< O O
0 O O
. O O
05 O O
) O O
decrease O O
in O O
TE O O
peak O O
compared O O
with O O
the O O
control O O
group O O
. O O

We O O
speculate O O
on O O
the O O
possible O O
relation O O
of O O
the O O
current O O
findings O O
on O O
treating O O
different O O
epilepsy B B_DISEASE
- O O
associated O O
conditions O O
. O O

Fatal O O
myeloencephalopathy B B_DISEASE_ADJECTIVE[DISEASE]
due O O
to O O
intrathecal O O
vincristine O O
administration O O
. O O

Vincristine O O
was O O
accidentally O O
given O O
intrathecally O O
to O O
a O O
child O O
with O O
leukaemia B B_DISEASE/B_GENE
, O O
producing O O
sensory B B_DISEASE
and I I_DISEASE
motor I I_DISEASE
dysfunction I I_DISEASE
followed O O
by O O
encephalopathy B B_DISEASE
and O O
death O O
. O O

Separate O O
times O O
for O O
administering O O
vincristine O O
and O O
intrathecal O O
therapy O O
is O O
recommended O O
. O O

After O O
determining O O
the O O
bupivacaine O O
AD50 O O
( O O
the O O
concentration O O
of O O
bupivacaine O O
that O O
caused O O
50 O O
% O O
of O O
all O O
beating O O
rat O O
heart O O
myocyte O O
cultures O O
to O O
become O O
arrhythmic B B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
we O O
determined O O
the O O
effect O O
of O O
1 O O
- O O
hour O O
progesterone O O
HCl O O
exposure O O
on O O
myocyte O O
contractile O O
rhythm O O
. O O

Each O O
concentration O O
of O O
progesterone O O
( O O
6 O O
. O O
25 O O
, O O
12 O O
. O O
5 O O
, O O
25 O O
, O O
and O O
50 O O
micrograms O O
/ O O
ml O O
) O O
caused O O
a O O
significant O O
and O O
concentration O O
- O O
dependent O O
reduction O O
in O O
the O O
AD50 O O
for O O
bupivacaine O O
. O O

Estradiol O O
treatment O O
also O O
increased O O
the O O
arrhythmogenicity O O
of O O
bupivacaine O O
in O O
myocyte O O
cultures O O
, O O
but O O
was O O
only O O
one O O
fourth O O
as O O
potent O O
as O O
progesterone O O
. O O

There O O
was O O
a O O
significant O O
decrease O O
in O O
the O O
time O O
to O O
onset O O
of O O
arrhythmia B B_DISEASE
as O O
compared O O
with O O
control O O
nonprogesterone O O
- O O
treated O O
rats O O
( O O
6 O O
. O O
2 O O
+ O O
/ O O
- O O
1 O O
. O O
3 O O
vs O O
. O O
30 O O
. O O
8 O O
+ O O
/ O O
- O O
2 O O
. O O
5 O O
min O O
, O O
mean O O
+ O O
/ O O
- O O
SE O O
) O O
. O O

Potentiation O O
of O O
bupivacaine O O
arrhythmia B B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
myocyte O O
cultures O O
suggests O O
that O O
this O O
effect O O
is O O
at O O
least O O
partly O O
mediated O O
at O O
the O O
myocyte O O
level O O
. O O

Increased O O
serum O O
soluble O O
Fas O O
in O O
patients O O
with O O
acute B B_DISEASE
liver I I_DISEASE
failure I I_DISEASE
due O O
to O O
paracetamol O O
overdose B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

BACKGROUND O O
/ O O
AIMS O O
: O O
Experimental O O
studies O O
have O O
suggested O O
that O O
apoptosis O O
via O O
the O O
Fas O O
/ O O
Fas O O
Ligand O O
signaling O O
system O O
may O O
play O O
an O O
important O O
role O O
in O O
the O O
development O O
of O O
acute B B_DISEASE
liver I I_DISEASE
failure I I_DISEASE
. O O

The O O
aim O O
of O O
the O O
study O O
was O O
to O O
investigate O O
the O O
soluble O O
form O O
of O O
Fas O O
in O O
patients O O
with O O
acute B B_DISEASE/B_LOCATION
liver I I_DISEASE/I_LOCATION
failure I I_DISEASE/I_LOCATION
. O O

METHODOLOGY O O
: O O
Serum O O
levels O O
of O O
sFas O O
( O O
soluble O O
Fas O O
) O O
were O O
measured O O
by O O
ELISA O O
in O O
24 O O
patients O O
with O O
acute B B_DISEASE/B_LOCATION
liver I I_DISEASE/I_LOCATION
failure I I_DISEASE/I_LOCATION
and O O
10 O O
normal O O
control O O
subjects O O
. O O

Serum O O
levels O O
of O O
tumor B B_DISEASE_ADJECTIVE[DISEASE]
necrosis B I_DISEASE_ADJECTIVE[DISEASE]
factor O O
- O O
alpha O O
and O O
interferon O O
- O O
gamma O O
were O O
also O O
determined O O
by O O
ELISA O O
. O O

RESULTS O O
: O O
Serum O O
sFas O O
was O O
significantly O O
increased O O
in O O
patients O O
with O O
acute B B_DISEASE/B_LOCATION
liver I I_DISEASE/I_LOCATION
failure I I_DISEASE/I_LOCATION
( O O
median O O
, O O
26 O O
. O O
8 O O
U O O
/ O O
mL O O
; O O
range O O
, O O
6 O O
. O O
9 O O
- O O
52 O O
. O O
7 O O
U O O
/ O O
mL O O
) O O
compared O O
to O O
the O O
normal O O
controls O O
( O O
median O O
, O O
8 O O
. O O
6 O O
U O O
/ O O
mL O O
; O O
range O O
, O O
6 O O
. O O
5 O O
- O O
12 O O
. O O
0 O O
U O O
/ O O
mL O O
, O O
P O O
< O O
0 O O
. O O
0001 O O
) O O
. O O

Levels O O
were O O
significantly O O
greater O O
in O O
patients O O
with O O
acute B B_DISEASE
liver I I_DISEASE
failure I I_DISEASE
due O O
to O O
paracetamol O O
overdose B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
median O O
, O O
28 O O
. O O
7 O O
U O O
/ O O
mL O O
; O O
range O O
, O O
12 O O
. O O
8 O O
- O O
52 O O
. O O
7 O O
U O O
/ O O
mL O O
, O O
n O O
= O O
17 O O
) O O
than O O
those O O
due O O
to O O
non O O
- O O
A O O
to O O
E O O
hepatitis B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
median O O
, O O
12 O O
. O O
5 O O
U O O
/ O O
mL O O
; O O
range O O
, O O
6 O O
. O O
9 O O
- O O
46 O O
. O O
0 O O
U O O
/ O O
mL O O
, O O
n O O
= O O
7 O O
, O O
P O O
< O O
0 O O
. O O
01 O O
) O O
. O O

A O O
significant O O
correlation O O
was O O
observed O O
between O O
serum O O
sFas O O
levels O O
and O O
aspartate O O
aminotransferase O O
( O O
r O O
= O O
0 O O
. O O
613 O O
, O O
P O O
< O O
0 O O
. O O
01 O O
) O O
. O O

CONCLUSIONS O O
: O O
The O O
increased O O
concentration O O
of O O
sFas O O
in O O
serum O O
of O O
patients O O
with O O
acute B B_DISEASE/B_LOCATION
liver I I_DISEASE/I_LOCATION
failure I I_DISEASE/I_LOCATION
may O O
reflect O O
activation O O
of O O
Fas O O
- O O
mediated O O
apoptosis O O
in O O
the O O
liver O O
and O O
this O O
together O O
with O O
increased O O
tumor B B_DISEASE_ADJECTIVE[DISEASE]
necrosis B I_DISEASE_ADJECTIVE[DISEASE]
factor O O
- O O
alpha O O
may O O
be O O
an O O
important O O
factor O O
in O O
liver O O
cell O O
loss O O
. O O

Bilateral O O
subthalamic O O
nucleus O O
stimulation O O
for O O
Parkinson B B_DISEASE
' I I_DISEASE
s I I_DISEASE
disease I I_DISEASE
. O O

High O O
frequency O O
stimulation O O
of O O
the O O
subthalamic O O
nucleus O O
( O O
STN O O
) O O
is O O
known O O
to O O
ameliorate O O
the O O
signs O O
and O O
symptoms O O
of O O
advanced O O
Parkinson B B_DISEASE
' I I_DISEASE
s I I_DISEASE
disease I I_DISEASE
. O O

AIM O O
: O O
We O O
studied O O
the O O
effect O O
of O O
high O O
frequency O O
STN O O
stimulation O O
in O O
23 O O
patients O O
. O O

METHOD O O
: O O
Twenty O O
- O O
three O O
patients O O
suffering O O
from O O
severe O O
Parkinson B B_DISEASE
' I I_DISEASE
s I I_DISEASE
disease I I_DISEASE
( O O
Stages O O
III O O
- O O
V O O
on O O
Hoehn O O
and O O
Yahr O O
scale O O
) O O
and O O
, O O
particularly O O
bradykinesia B B_DISEASE
, O O
rigidity B B_DISEASE
, O O
and O O
levodopa O O
- O O
induced O O
dyskinesias B B_DISEASE
underwent O O
bilateral O O
implantation O O
of O O
electrodes O O
in O O
the O O
STN O O
. O O

Preoperative O O
and O O
postoperative O O
assessments O O
of O O
these O O
patients O O
at O O
1 O O
, O O
3 O O
, O O
6 O O
and O O
12 O O
months O O
follow O O
- O O
up O O
, O O
in O O
" O O
on O O
" O O
and O O
" O O
off O O
" O O
drug O O
conditions O O
, O O
was O O
carried O O
out O O
using O O
Unified O O
Parkinson B B_DISEASE/B_LOCATION
' I I_DISEASE/I_LOCATION
s I I_DISEASE/I_LOCATION
Disease I I_DISEASE/I_LOCATION
Rating O O
Scale O O
, O O
Hoehn O O
and O O
Yahr O O
staging O O
, O O
England O O
activities O O
of O O
daily O O
living O O
score O O
and O O
video O O
recordings O O
. O O

RESULTS O O
: O O
After O O
one O O
year O O
of O O
electrical O O
stimulation O O
of O O
the O O
STN O O
, O O
the O O
patients O O
' O O
scores O O
for O O
activities O O
of O O
daily O O
living O O
and O O
motor O O
examination O O
scores O O
( O O
Unified O O
Parkinson B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
' I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
s I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
Disease I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
Rating O O
Scale O O
parts O O
II O O
and O O
III O O
) O O
off O O
medication O O
improved O O
by O O
62 O O
% O O
and O O
61 O O
% O O
respectively O O
( O O
p O O
< O O
0 O O
. O O
0005 O O
) O O
. O O

The O O
subscores O O
for O O
the O O
akinesia B B_DISEASE/B_MEASURE
, O O
rigidity B B_DISEASE
, O O
tremor B B_DISEASE
and O O
gait O O
also O O
improved O O
. O O

( O O
p O O
< O O
0 O O
. O O
0005 O O
) O O
. O O

The O O
average O O
levodopa O O
dose O O
decreased O O
from O O
813 O O
mg O O
to O O
359 O O
mg O O
. O O

The O O
cognitive O O
functions O O
remained O O
unchanged O O
. O O

CONCLUSION O O
: O O
Bilateral O O
subthalamic O O
nucleus O O
stimulation O O
is O O
an O O
effective O O
treatment O O
for O O
advanced O O
Parkinson B B_DISEASE/B_GENE
' I I_DISEASE/I_GENE
s I I_DISEASE/I_GENE
disease I I_DISEASE/I_GENE
. O O

The O O
reduction O O
in O O
the O O
levodopa O O
dose O O
is O O
useful O O
in O O
controlling O O
drug B B_DISEASE
- I I_DISEASE
induced I I_DISEASE
dyskinesias I I_DISEASE
. O O

Acute B B_DISEASE_ADJECTIVE[DISEASE]
renal I I_DISEASE_ADJECTIVE[DISEASE]
failure I I_DISEASE_ADJECTIVE[DISEASE]
occurring O O
during O O
intravenous O O
desferrioxamine O O
therapy O O
: O O
recovery O O
after O O
haemodialysis O O
. O O

A O O
patient O O
with O O
transfusion O O
- O O
dependent O O
thalassemia B B_DISEASE/B_GENE
was O O
undergoing O O
home O O
intravenous O O
desferrioxamine O O
( O O
DFX O O
) O O
treatment O O
by O O
means O O
of O O
a O O
totally O O
implanted O O
system O O
because O O
of O O
his O O
poor O O
compliance O O
with O O
the O O
nightly O O
subcutaneous O O
therapy O O
. O O

Due O O
to O O
an O O
accidental O O
malfunctioning O O
of O O
the O O
infusion O O
pump O O
, O O
the O O
patient O O
was O O
inadvertently O O
administered O O
a O O
toxic O O
dosage O O
of O O
the O O
drug O O
which O O
caused O O
renal B B_DISEASE
insufficiency I I_DISEASE
. O O

Given O O
the O O
progressive O O
deterioration O O
of O O
the O O
symptoms O O
and O O
of O O
the O O
laboratory O O
values O O
, O O
despite O O
adequate O O
medical O O
treatment O O
, O O
a O O
decision O O
was O O
made O O
to O O
introduce O O
haemodialytical O O
therapy O O
in O O
order O O
to O O
remove O O
the O O
drug O O
and O O
therapy O O
reduce O O
the O O
nephrotoxicity B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

From O O
the O O
results O O
obtained O O
, O O
haemodialysis O O
can O O
therefore O O
be O O
suggested O O
as O O
a O O
useful O O
therapy O O
in O O
rare O O
cases O O
of O O
progressive O O
acute B B_DISEASE
renal I I_DISEASE
failure I I_DISEASE
caused O O
by O O
desferrioxamine O O
. O O

Ocular O O
motility O O
changes O O
after O O
subtenon O O
carboplatin O O
chemotherapy O O
for O O
retinoblastoma B B_DISEASE
. O O

BACKGROUND O O
: O O
Focal O O
subtenon O O
carboplatin O O
injections O O
have O O
recently O O
been O O
used O O
as O O
a O O
presumably O O
toxicity B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
free O O
adjunct O O
to O O
systemic O O
chemotherapy O O
for O O
intraocular O O
retinoblastoma B B_DISEASE
. O O

OBJECTIVE O O
: O O
To O O
report O O
our O O
clinical O O
experience O O
with O O
abnormal B B_DISEASE
ocular I I_DISEASE
motility I I_DISEASE
in O O
patients O O
treated O O
with O O
subtenon O O
carboplatin O O
chemotherapy O O
. O O

METHODS O O
: O O
We O O
noted O O
abnormal B B_DISEASE_ADJECTIVE[DISEASE]
ocular I I_DISEASE_ADJECTIVE[DISEASE]
motility I I_DISEASE_ADJECTIVE[DISEASE]
in O O
10 O O
consecutive O O
patients O O
with O O
retinoblastoma B B_DISEASE
who O O
had O O
received O O
subtenon O O
carboplatin O O
. O O

During O O
ocular O O
manipulation O O
under O O
general O O
anesthesia O O
, O O
we O O
assessed O O
their O O
eyes O O
by O O
forced O O
duction O O
testing O O
, O O
comparing O O
ocular O O
motility O O
after O O
tumor B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
control O O
with O O
ocular O O
motility O O
at O O
diagnosis O O
. O O

RESULTS O O
: O O
Limitation O O
of O O
ocular O O
motility O O
was O O
detected O O
in O O
all O O
12 O O
eyes O O
of O O
10 O O
patients O O
treated O O
for O O
intraocular O O
retinoblastoma B B_DISEASE
with O O
1 O O
to O O
6 O O
injections O O
of O O
subtenon O O
carboplatin O O
as O O
part O O
of O O
multimodality O O
therapy O O
. O O

Histopathological O O
examination O O
revealed O O
many O O
lipophages O O
in O O
the O O
periorbital O O
fat O O
surrounding O O
the O O
optic O O
nerve O O
in O O
1 O O
eye O O
, O O
indicative O O
of O O
phagocytosis O O
of O O
previously O O
existing O O
fat O O
cells O O
and O O
suggesting O O
prior O O
fat O O
necrosis B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
enucleations O O
were O O
technically O O
difficult O O
and O O
hazardous O O
for O O
globe O O
rupture B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
because O O
of O O
extensive O O
orbital O O
soft O O
tissue O O
adhesions O O
. O O

CONCLUSIONS O O
: O O
Subtenon O O
carboplatin O O
chemotherapy O O
is O O
associated O O
with O O
significant O O
fibrosis B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
orbital O O
soft O O
tissues O O
, O O
leading O O
to O O
mechanical O O
restriction O O
of O O
eye O O
movements O O
and O O
making O O
subsequent O O
enucleation O O
difficult O O
. O O

Subtenon O O
carboplatin O O
is O O
not O O
free O O
of O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
its O O
use O O
is O O
best O O
restricted O O
to O O
specific O O
indications O O
. O O

Ethambutol O O
and O O
optic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
neuropathy I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

PURPOSE O O
: O O
To O O
demonstrate O O
the O O
association O O
between O O
ethambutol O O
and O O
optic B B_DISEASE/B_LOCATION
neuropathy I I_DISEASE/I_LOCATION
. O O

METHOD O O
: O O
Thirteen O O
patients O O
who O O
developed O O
optic B B_DISEASE
neuropathy I I_DISEASE
after O O
being O O
treated O O
with O O
ethambutol O O
for O O
tuberculosis B B_DISEASE/B_LOCATION
of I I_DISEASE/I_LOCATION
the I I_DISEASE/I_LOCATION
lung I I_DISEASE/I_LOCATION
or I I_DISEASE/I_LOCATION
lymph I I_DISEASE/I_LOCATION
node I I_DISEASE/I_LOCATION
at O O
Siriraj O O
Hospital O O
between O O
1997 O O
and O O
2001 O O
were O O
retrospectively O O
reviewed O O
. O O

The O O
clinical O O
characteristics O O
and O O
initial O O
and O O
final O O
visual O O
acuity O O
were O O
analyzed O O
to O O
determine O O
visual O O
outcome O O
. O O

RESULTS O O
: O O
All O O
patients O O
had O O
optic B B_DISEASE
neuropathy I I_DISEASE
between O O
1 O O
to O O
6 O O
months O O
( O O
mean O O
= O O
2 O O
. O O
9 O O
months O O
) O O
after O O
starting O O
ethambutol O O
therapy O O
at O O
a O O
dosage O O
ranging O O
from O O
13 O O
to O O
20 O O
mg O O
/ O O
kg O O
/ O O
day O O
( O O
mean O O
= O O
17 O O
mg O O
/ O O
kg O O
/ O O
day O O
) O O
. O O

Of O O
6 O O
patients O O
with O O
irreversible O O
visual B B_DISEASE
impairment I I_DISEASE
, O O
4 O O
patients O O
had O O
diabetes B B_DISEASE
mellitus I I_DISEASE
, O O
glaucoma B B_DISEASE
and O O
a O O
history O O
of O O
heavy O O
smoking O O
. O O

CONCLUSION O O
: O O
Early O O
recognition O O
of O O
optic B B_DISEASE
neuropathy I I_DISEASE
should O O
be O O
considered O O
in O O
patients O O
with O O
ethambutol O O
therapy O O
. O O

A O O
low O O
dose O O
and O O
prompt O O
discontinuation O O
of O O
the O O
drug O O
is O O
recommended O O
particularly O O
in O O
individuals O O
with O O
diabetes B B_DISEASE
mellitus I I_DISEASE
, O O
glaucoma B B_DISEASE
or O O
who O O
are O O
heavy O O
smokers O O
. O O

Treatment O O
of O O
compensatory O O
gustatory B B_DISEASE
hyperhidrosis I I_DISEASE
with O O
topical O O
glycopyrrolate O O
. O O

Gustatory B B_DISEASE
hyperhidrosis I I_DISEASE
is O O
facial O O
sweating B B_DISEASE
usually O O
associated O O
with O O
the O O
eating O O
of O O
hot O O
spicy O O
food O O
or O O
even O O
smelling O O
this O O
food O O
. O O

Current O O
options O O
of O O
treatment O O
include O O
oral O O
anticholinergic O O
drugs O O
, O O
the O O
topical O O
application O O
of O O
anticholinergics O O
or O O
aluminum O O
chloride O O
, O O
and O O
the O O
injection O O
of O O
botulinum O O
toxin O O
. O O

All O O
patients O O
had O O
gustatory B B_DISEASE
hyperhidrosis I I_DISEASE
, O O
which O O
interfered O O
with O O
their O O
social O O
activities O O
, O O
after O O
transthroacic O O
endoscopic O O
sympathectomy O O
, O O
and O O
which O O
was O O
associated O O
with O O
compensatory O O
focal O O
hyperhidrosis B B_DISEASE
. O O

After O O
applying O O
topical O O
glycopyrrolate O O
, O O
the O O
subjective O O
effect O O
was O O
excellent O O
( O O
no O O
sweating B B_DISEASE
after O O
eating O O
hot O O
spicy O O
food O O
) O O
in O O
10 O O
patients O O
( O O
77 O O
% O O
) O O
, O O
and O O
fair O O
( O O
clearly O O
reduced O O
sweating B B_DISEASE/B_MEASURE
) O O
in O O
3 O O
patients O O
( O O
23 O O
% O O
) O O
. O O

All O O
had O O
reported O O
incidents O O
of O O
being O O
very O O
embarrassed O O
whilst O O
eating O O
hot O O
spicy O O
foods O O
. O O

Adverse O O
effects O O
included O O
a O O
mildly O O
dry B B_DISEASE
mouth I I_DISEASE
and O O
a O O
sore B B_DISEASE
throat I I_DISEASE
in O O
2 O O
patients O O
( O O
2 O O
% O O
glycopyrrolate O O
) O O
, O O
a O O
light O O
headache B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
in O O
1 O O
patient O O
( O O
1 O O
. O O
5 O O
% O O
glycopyrrolate O O
) O O
. O O

The O O
topical O O
application O O
of O O
a O O
glycopyrrolate O O
pad O O
appeared O O
to O O
be O O
safe O O
, O O
efficacious O O
, O O
well O O
tolerated O O
, O O
and O O
a O O
convenient O O
method O O
of O O
treatment O O
for O O
moderate O O
to O O
severe O O
symptoms O O
of O O
gustatory B B_DISEASE
hyperhidrosis I I_DISEASE
in O O
post O O
transthoracic O O
endoscopic O O
sympathectomy O O
or O O
sympathicotomy O O
patients O O
, O O
with O O
few O O
side O O
effects O O
. O O

Neuroleptic O O
- O O
associated O O
hyperprolactinemia B B_DISEASE
. O O

Can O O
it O O
be O O
treated O O
with O O
bromocriptine O O
? O O

Six O O
stable O O
psychiatric O O
outpatients O O
with O O
hyperprolactinemia B B_DISEASE
and O O
amenorrhea B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
/ O O
oligomenorrhea B B_DISEASE
associated O O
with O O
their O O
neuroleptic O O
medications O O
were O O
treated O O
with O O
bromocriptine O O
. O O

Daily O O
dosages O O
of O O
5 O O
- O O
10 O O
mg O O
corrected O O
the O O
hyperprolactinemia B B_DISEASE_ADJECTIVE[DISEASE]
and O O
restored O O
menstruation O O
in O O
four O O
of O O
the O O
six O O
patients O O
. O O

One O O
woman O O
, O O
however O O
, O O
developed O O
worsened O O
psychiatric B B_DISEASE
symptoms I I_DISEASE
while O O
taking O O
bromocriptine O O
, O O
and O O
it O O
was O O
discontinued O O
. O O

This O O
suggests O O
that O O
bromocriptine O O
should O O
be O O
further O O
evaluated O O
as O O
potential O O
therapy O O
for O O
neuroleptic O O
- O O
associated O O
hyperprolactinemia B B_DISEASE
and O O
amenorrhea B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
/ O O
galactorrhea B B_DISEASE/B_BACTERIUM[BIO]
. O O

Ethacrynic O O
acid O O
- O O
induced O O
convulsions B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
brain O O
neurotransmitters O O
in O O
mice O O
. O O

Intracerebroventricular O O
injection O O
of O O
ethacrynic O O
acid O O
( O O
50 O O
% O O
convulsive B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dose O O
; O O
50 O O
micrograms O O
/ O O
mouse O O
) O O
accelerated O O
the O O
synthesis O O
/ O O
turnover O O
of O O
5 O O
- O O
hydroxytryptamine O O
( O O
5 O O
- O O
HT O O
) O O
but O O
suppressed O O
the O O
synthesis O O
of O O
gamma O O
- O O
aminobutyric O O
acid O O
and O O
acetylcholine O O
in O O
mouse O O
brain O O
. O O

These O O
effects O O
were O O
completely O O
antagonized O O
by O O
pretreatment O O
with O O
a O O
glutamate O O
/ O O
N O O
- O O
methyl O O
- O O
D O O
- O O
aspartate O O
antagonist O O
, O O
aminophosphonovaleric O O
acid O O
. O O

In O O
ethacrynic O O
acid O O
- O O
induced O O
convulsions B B_DISEASE
, O O
these O O
neurotransmitter O O
systems O O
may O O
be O O
differentially O O
modulated O O
, O O
probably O O
through O O
activation O O
of O O
glutaminergic O O
neurons O O
in O O
the O O
brain O O
. O O

Pharmacology O O
of O O
gamma O O
- O O
aminobutyric O O
acidA O O
receptor O O
complex O O
after O O
the O O
in O O
vivo O O
administration O O
of O O
the O O
anxioselective O O
and O O
anticonvulsant O O
beta O O
- O O
carboline O O
derivative O O
abecarnil O O
. O O

In O O
rodents O O
, O O
the O O
effect O O
of O O
the O O
beta O O
- O O
carboline O O
derivative O O
isopropyl O O
- O O
6 O O
- O O
benzyloxy O O
- O O
4 O O
- O O
methoxymethyl O O
- O O
beta O O
- O O
carboline O O
- O O
3 O O
- O O
carboxylate O O
( O O
abecarrnil O O
) O O
, O O
a O O
new O O
ligand O O
for O O
benzodiazepine O O
receptors O O
possessing O O
anxiolytic O O
and O O
anticonvulsant O O
properties O O
, O O
was O O
evaluated O O
on O O
the O O
function O O
of O O
central O O
gamma O O
- O O
aminobutyric O O
acid O O
( O O
GABA O O
) O O
A O O
receptor O O
complex O O
, O O
both O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O

Added O O
in O O
vitro O O
to O O
rat O O
cortical O O
membrane O O
preparation O O
, O O
abecarnil O O
increased O O
[ O O
3H O O
] O O
GABA O O
binding O O
, O O
enhanced O O
muscimol O O
- O O
stimulated O O
36Cl O O
- O O
uptake O O
and O O
reduced O O
the O O
binding O O
of O O
t O O
- O O
[ O O
35S O O
] O O
butylbicyclophosphorothionate O O
( O O
[ O O
35S O O
] O O
TBPS O O
) O O
. O O

These O O
effects O O
were O O
similar O O
to O O
those O O
induced O O
by O O
diazepam O O
, O O
whereas O O
the O O
partial O O
agonist O O
Ro O O
16 O O
- O O
6028 O O
( O O
tert O O
- O O
butyl O O
- O O
( O O
S O O
) O O
- O O
8 O O
- O O
bromo O O
- O O
11 O O
, O O
12 O O
, O O
13 O O
, O O
13a O O
- O O
tetrahydro O O
- O O
9 O O
- O O
oxo O O
- O O
9H O O
- O O
imidazo O O
[ O O
1 O O
, O O
5 O O
- O O
a O O
] O O
- O O
pyrrolo O O
- O O
[ O O
2 O O
, O O
1 O O
- O O
c O O
] O O
[ O O
1 O O
, O O
4 O O
] O O
benzodiazepine O O
- O O
1 O O
- O O
carboxylate O O
) O O
showed O O
very O O
weak O O
efficacy O O
in O O
these O O
biochemical O O
tests O O
. O O

After O O
i O O
. O O
p O O
. O O
injection O O
to O O
rats O O
, O O
abecarnil O O
and O O
diazepam O O
decreased O O
in O O
a O O
time O O
- O O
dependent O O
and O O
dose O O
- O O
related O O
( O O
0 O O
. O O
25 O O
- O O
20 O O
mg O O
/ O O
kg O O
i O O
. O O
p O O
. O O
) O O
manner O O
[ O O
35S O O
] O O
TBPS O O
binding O O
measured O O
ex O O
vivo O O
in O O
the O O
cerebral O O
cortex O O
. O O

To O O
better O O
correlate O O
the O O
biochemical O O
and O O
the O O
pharmacological O O
effects O O
, O O
we O O
studied O O
the O O
action O O
of O O
abecarnil O O
on O O
[ O O
35S O O
] O O
TBPS O O
binding O O
, O O
exploratory O O
motility O O
and O O
on O O
isoniazid O O
- O O
induced O O
biochemical O O
and O O
pharmacological O O
effects O O
in O O
mice O O
. O O

In O O
these O O
animals O O
, O O
abecarnil O O
produced O O
a O O
paralleled O O
dose O O
- O O
dependent O O
( O O
0 O O
. O O
05 O O
- O O
1 O O
mg O O
/ O O
kg O O
i O O
. O O
p O O
. O O
) O O
reduction O O
of O O
both O O
motor O O
behavior O O
and O O
cortical O O
[ O O
35S O O
] O O
TBPS O O
binding O O
. O O

Moreover O O
, O O
0 O O
. O O
05 O O
mg O O
/ O O
kg O O
of O O
this O O
beta O O
- O O
carboline O O
reduced O O
markedly O O
the O O
increase O O
of O O
[ O O
35S O O
] O O
TBPS O O
binding O O
and O O
the O O
convulsions B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induced O O
by O O
isoniazid O O
( O O
200 O O
mg O O
/ O O
kg O O
s O O
. O O
c O O
. O O
) O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O

Recurrent O O
myocardial B B_DISEASE
infarction I I_DISEASE
in O O
a O O
postpartum O O
patient O O
receiving O O
bromocriptine O O
. O O

Myocardial B B_DISEASE
infarction I I_DISEASE
in O O
puerperium O O
is O O
infrequently O O
reported O O
. O O

Spasm B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
coronary O O
dissection O O
, O O
or O O
atheromatous O O
etiology O O
has O O
been O O
described O O
. O O

Bromocriptine O O
has O O
been O O
implicated O O
in O O
several O O
previous O O
case O O
reports O O
of O O
myocardial B B_DISEASE
infarction I I_DISEASE
in O O
the O O
puerperium O O
. O O

Our O O
case O O
( O O
including O O
an O O
inadvertent O O
rechallenge O O
) O O
suggests O O
such O O
a O O
relationship O O
. O O

Although O O
generally O O
regarded O O
as O O
" O O
safe O O
, O O
" O O
possible O O
serious O O
cardiac O O
effects O O
of O O
bromocriptine O O
should O O
be O O
acknowledged O O
. O O

Asterixis B B_DISEASE/B_BIO
induced O O
by O O
carbamazepine O O
therapy O O
. O O

There O O
are O O
very O O
few O O
reports O O
about O O
asterixis B B_DISEASE/B_BIO
as O O
a O O
side O O
effect O O
of O O
treatment O O
with O O
psychopharmacologic O O
agents O O
. O O

In O O
this O O
report O O
we O O
present O O
four O O
patients O O
treated O O
with O O
a O O
combination O O
of O O
different O O
psychotropic O O
drugs O O
, O O
in O O
whom O O
asterixis B B_DISEASE/B_BIO
was O O
triggered O O
either O O
by O O
adding O O
carbamazepine O O
( O O
CBZ O O
) O O
to O O
a O O
treatment O O
regimen O O
, O O
or O O
by O O
increasing O O
its O O
dosage O O
. O O

Neither O O
dosage O O
nor O O
serum O O
levels O O
of O O
CBZ O O
were O O
in O O
a O O
higher O O
range O O
. O O

We O O
consider O O
asterixis B B_DISEASE/B_BIO
to O O
be O O
an O O
easily O O
overlooked O O
sign O O
of O O
neurotoxicity B B_DISEASE
, O O
which O O
may O O
occur O O
even O O
at O O
low O O
or O O
moderate O O
dosage O O
levels O O
, O O
if O O
certain O O
drugs O O
as O O
lithium O O
or O O
clozapine O O
are O O
used O O
in O O
combination O O
with O O
CBZ O O
. O O

Stable O O
responders O O
demonstrated O O
a O O
small O O
hypotensive B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
response O O
. O O

Antiparkinsonian O O
effects O O
of O O
levodopa O O
temporally O O
correlated O O
with O O
blood O O
pressure O O
changes O O
. O O

Phenylalanine O O
, O O
a O O
large O O
neutral O O
amino O O
acid O O
( O O
LNAA O O
) O O
competing O O
with O O
levodopa O O
for O O
transport O O
across O O
the O O
blood O O
- O O
brain O O
barrier O O
, O O
reduced O O
the O O
hypotensive B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
antiparkinsonian O O
effects O O
of O O
levodopa O O
. O O

The O O
hypotensive B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effect O O
appears O O
to O O
be O O
related O O
to O O
the O O
higher O O
baseline O O
blood O O
pressure O O
we O O
observed O O
in O O
fluctuating O O
patients O O
relative O O
to O O
stable O O
patients O O
. O O

Syndrome B B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
of I B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
inappropriate I B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
secretion I B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
of I B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
antidiuretic I B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
hormone I B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
after O O
infusional O O
vincristine O O
. O O

A O O
77 O O
- O O
year O O
- O O
old O O
woman O O
with O O
refractory O O
multiple B B_DISEASE/B_GENE
myeloma I I_DISEASE/I_GENE
was O O
treated O O
with O O
a O O
4 O O
- O O
day O O
continuous O O
intravenous O O
infusion O O
of O O
vincristine O O
and O O
doxorubicin O O
and O O
4 O O
days O O
of O O
oral O O
dexamethasone O O
. O O

Nine O O
days O O
after O O
her O O
second O O
cycle O O
she O O
presented O O
with O O
lethargy B B_DISEASE
and O O
weakness B B_DISEASE
associated O O
with O O
hyponatremia B B_DISEASE
. O O

Evaluation O O
revealed O O
the O O
syndrome B B_DISEASE
of I I_DISEASE
inappropriate I I_DISEASE
secretion I I_DISEASE
of I I_DISEASE
antidiuretic I I_DISEASE
hormone I I_DISEASE
, O O
which O O
was O O
attributed O O
to O O
the O O
vincristine O O
infusion O O
. O O

Heart B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
failure I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
to O O
digitalise O O
or O O
not O O
? O O

The O O
view O O
against O O
. O O

Despite O O
extensive O O
clinical O O
experience O O
the O O
role O O
of O O
digoxin O O
is O O
still O O
not O O
well O O
defined O O
. O O

In O O
patients O O
with O O
atrial B B_DISEASE
fibrillation I I_DISEASE
digoxin O O
is O O
beneficial O O
for O O
ventricular O O
rate O O
control O O
. O O

For O O
patients O O
in O O
sinus O O
rhythm O O
and O O
heart B B_DISEASE
failure I I_DISEASE
the O O
situation O O
is O O
less O O
clear O O
. O O

Digoxin O O
has O O
a O O
narrow O O
therapeutic O O
: O O
toxic O O
ratio O O
and O O
concentrations O O
are O O
affected O O
by O O
a O O
number O O
of O O
drugs O O
. O O

Also O O
, O O
digoxin O O
has O O
undesirable O O
effects O O
such O O
as O O
increasing O O
peripheral O O
resistance O O
and O O
myocardial O O
demands O O
, O O
and O O
causing O O
arrhythmias B B_DISEASE
. O O

The O O
trials O O
that O O
are O O
available O O
are O O
generally O O
small O O
with O O
limitations O O
in O O
design O O
and O O
these O O
show O O
variation O O
in O O
patient O O
benefit O O
. O O

Furthermore O O
, O O
no O O
trial O O
has O O
had O O
sufficient O O
power O O
to O O
evaluate O O
mortality O O
. O O

Pooled O O
analysis O O
of O O
the O O
effects O O
of O O
other O O
inotropic O O
drugs O O
shows O O
an O O
excess O O
mortality O O
and O O
there O O
is O O
a O O
possibility O O
that O O
digoxin O O
may O O
increase O O
mortality O O
after O O
myocardial B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
MI B B_DISEASE/B_LOCATION
) O O
. O O

Until O O
then O O
digoxin O O
should O O
be O O
considered O O
a O O
third O O
- O O
line O O
therapy O O
. O O

Isradipine O O
treatment O O
for O O
hypertension B B_DISEASE/B_LOCATION
in O O
general O O
practice O O
in O O
Hong O O
Kong O O
. O O

A O O
6 O O
- O O
week O O
open O O
study O O
of O O
the O O
introduction O O
of O O
isradipine O O
treatment O O
was O O
conducted O O
in O O
general O O
practice O O
in O O
Hong O O
Kong O O
. O O

303 O O
Chinese O O
patients O O
with O O
mild O O
to O O
moderate O O
hypertension B B_DISEASE/B_LOCATION
entered O O
the O O
study O O
. O O

Side O O
effects O O
were O O
reported O O
in O O
21 O O
% O O
of O O
patients O O
and O O
caused O O
withdrawal O O
from O O
the O O
study O O
in O O
3 O O
patients O O
. O O

The O O
main O O
side O O
- O O
effects O O
were O O
headache B B_DISEASE
, O O
dizziness B B_DISEASE
, O O
palpitation B B_DISEASE
and O O
flushing B B_DISEASE
and O O
these O O
were O O
not O O
more O O
frequent O O
than O O
reported O O
in O O
other O O
studies O O
with O O
isradipine O O
or O O
with O O
placebo O O
. O O

Similar O O
reductions O O
occurred O O
in O O
standing O O
blood O O
pressure O O
and O O
there O O
was O O
no O O
evidence O O
of O O
postural B B_DISEASE
hypotension I I_DISEASE
. O O

Dosage O O
was O O
increased O O
from O O
2 O O
. O O
5 O O
mg O O
b O O
. O O
d O O
. O O
to O O
5 O O
mg O O
b O O
. O O
d O O
. O O
at O O
4 O O
weeks O O
in O O
patients O O
with O O
diastolic O O
blood O O
pressure O O
greater O O
than O O
90 O O
mmHg O O
and O O
their O O
further O O
response O O
was O O
greater O O
than O O
those O O
remaining O O
on O O
2 O O
. O O
5 O O
mg O O
b O O
. O O
d O O
. O O

Pharmacological O O
characteristics O O
and O O
side O O
effects O O
of O O
a O O
new O O
galenic O O
formulation O O
of O O
propofol O O
without O O
soyabean O O
oil O O
. O O

We O O
compared O O
the O O
pharmacokinetics O O
, O O
pharmacodynamics O O
and O O
safety O O
profile O O
of O O
a O O
new O O
galenic O O
formulation O O
of O O
propofol O O
( O O
AM149 O O
1 O O
% O O
) O O
, O O
which O O
does O O
not O O
contain O O
soyabean O O
oil O O
, O O
with O O
a O O
standard O O
formulation O O
of O O
propofol O O
( O O
Disoprivan O O
1 O O
% O O
) O O
. O O

In O O
a O O
randomised O O
, O O
double O O
- O O
blind O O
, O O
cross O O
- O O
over O O
study O O
, O O
30 O O
healthy O O
volunteers O O
received O O
a O O
single O O
intravenous O O
bolus O O
injection O O
of O O
2 O O
. O O
5 O O
mg O O
. O O
kg O O
- O O
1 O O
propofol O O
. O O

Plasma O O
propofol O O
levels O O
were O O
measured O O
for O O
48 O O
h O O
following O O
drug O O
administration O O
and O O
evaluated O O
according O O
to O O
a O O
three O O
- O O
compartment O O
model O O
. O O

The O O
pharmacodynamic O O
parameters O O
assessed O O
included O O
induction O O
and O O
emergence O O
times O O
, O O
respiratory O O
and O O
cardiovascular O O
effects O O
, O O
and O O
pain B B_DISEASE/B_MEASURE
on O O
injection O O
. O O

Patients O O
were O O
monitored O O
for O O
side O O
effects O O
over O O
48 O O
h O O
. O O

Owing O O
to O O
a O O
high O O
incidence O O
of O O
thrombophlebitis B B_DISEASE
, O O
the O O
study O O
was O O
terminated O O
prematurely O O
and O O
only O O
the O O
data O O
of O O
the O O
two O O
parallel O O
treatment O O
groups O O
( O O
15 O O
patients O O
in O O
each O O
group O O
) O O
were O O
analysed O O
. O O

Plasma O O
concentrations O O
did O O
not O O
differ O O
significantly O O
between O O
the O O
two O O
formulations O O
. O O

Pain B B_DISEASE
on O O
injection O O
( O O
80 O O
vs O O
. O O
20 O O
% O O
, O O
p O O
< O O
0 O O
. O O
01 O O
) O O
and O O
thrombophlebitis B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
93 O O
. O O
3 O O
vs O O
. O O
6 O O
. O O
6 O O
% O O
, O O
p O O
< O O
0 O O
. O O
001 O O
) O O
occurred O O
more O O
frequently O O
with O O
AM149 O O
than O O
with O O
Disoprivan O O
. O O

Although O O
both O O
formulations O O
had O O
similar O O
pharmacokinetic O O
and O O
pharmacodynamic O O
profiles O O
the O O
new O O
formulation O O
is O O
not O O
suitable O O
for O O
clinical O O
use O O
due O O
to O O
the O O
high O O
incidence O O
of O O
thrombophlebitis B B_DISEASE
produced O O
. O O

Pure B B_DISEASE
red I I_DISEASE
cell I I_DISEASE
aplasia I I_DISEASE
, O O
toxic B B_DISEASE
dermatitis I I_DISEASE
and O O
lymphadenopathy B B_DISEASE
in O O
a O O
patient O O
taking O O
diphenylhydantoin O O
. O O

A O O
patient O O
taking O O
diphenylhydantoin O O
for O O
3 O O
weeks O O
developed O O
a O O
generalized O O
skin B B_DISEASE
rash I I_DISEASE
, O O
lymphadenopathy B B_DISEASE
and O O
pure B B_DISEASE
red I I_DISEASE
cell I I_DISEASE
aplasia I I_DISEASE
. O O

Skin B B_DISEASE
rash I I_DISEASE
is O O
a O O
well O O
- O O
known O O
complication O O
of O O
diphenylhydantoin O O
treatment O O
as O O
is O O
benign O O
and O O
malignant O O
lymphadenopathy B B_DISEASE
. O O

Pure B B_DISEASE
red I I_DISEASE
cell I I_DISEASE
aplasia I I_DISEASE
associated O O
with O O
diphenylhydantoin O O
medication O O
has O O
been O O
reported O O
in O O
3 O O
patients O O
. O O

The O O
exact O O
mechanism O O
by O O
which O O
diphenylhydantoin O O
exerts O O
its O O
toxic O O
effects O O
is O O
not O O
known O O
. O O

In O O
this O O
patient O O
the O O
time O O
relation O O
between O O
the O O
ingestion O O
of O O
diphenylhydantoin O O
and O O
the O O
occurrence O O
of O O
the O O
skin B B_DISEASE
rash I I_DISEASE
, O O
lymphadenopathy B B_DISEASE
and O O
pure B B_DISEASE
red I I_DISEASE
cell I I_DISEASE
aplasia I I_DISEASE
is O O
very O O
suggestive O O
of O O
a O O
direct O O
connection O O
. O O

In O O
order O O
to O O
quantify O O
the O O
incidence O O
of O O
these O O
cardiac O O
events O O
, O O
we O O
performed O O
a O O
meta O O
- O O
analysis O O
of O O
clinical O O
trials O O
comparing O O
VNR O O
with O O
other O O
chemotherapeutic O O
agents O O
in O O
the O O
treatment O O
of O O
various O O
malignancies B B_DISEASE
. O O

Randomized O O
clinical O O
trials O O
comparing O O
VNR O O
with O O
other O O
drugs O O
in O O
the O O
treatment O O
of O O
cancer B B_DISEASE/B_LOCATION
were O O
searched O O
in O O
Medline O O
, O O
Embase O O
, O O
Evidence O O
- O O
based O O
Medicine O O
Reviews O O
databases O O
and O O
the O O
Cochrane O O
library O O
from O O
1987 O O
to O O
2002 O O
. O O

We O O
found O O
19 O O
trials O O
, O O
involving O O
2441 O O
patients O O
treated O O
by O O
VNR O O
and O O
2050 O O
control O O
patients O O
. O O

The O O
risk O O
of O O
VNR O O
cardiac O O
events O O
was O O
similar O O
to O O
vindesine O O
( O O
VDS O O
) O O
and O O
other O O
cardiotoxic B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs O O
[ O O
fluorouracil O O
, O O
anthracyclines O O
, O O
gemcitabine O O
( O O
GEM O O
) O O
em O O
leader O O
] O O
. O O

Even O O
if O O
it O O
did O O
not O O
reach O O
statistical O O
significance O O
because O O
of O O
a O O
few O O
number O O
of O O
cases O O
, O O
the O O
risk O O
was O O
lower O O
in O O
trials O O
excluding O O
patients O O
with O O
cardiac O O
history O O
, O O
and O O
seemed O O
to O O
be O O
higher O O
in O O
trials O O
including O O
patients O O
with O O
pre O O
- O O
existing O O
cardiac B B_DISEASE
diseases I I_DISEASE
. O O

MRI O O
findings O O
of O O
hypoxic O O
cortical O O
laminar O O
necrosis B B_DISEASE/B_MEASURE
in O O
a O O
child O O
with O O
hemolytic B B_DISEASE_ADJECTIVE[DISEASE]
anemia I I_DISEASE_ADJECTIVE[DISEASE]
crisis O O
. O O

We O O
present O O
magnetic O O
resonance O O
imaging O O
findings O O
of O O
a O O
5 O O
- O O
year O O
- O O
old O O
girl O O
who O O
had O O
a O O
rapidly O O
installing O O
hemolytic B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
anemia I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
crisis O O
induced O O
by O O
trimethoprim O O
- O O
sulfomethoxazole O O
, O O
resulting O O
in O O
cerebral B B_DISEASE
anoxia I I_DISEASE
leading O O
to O O
permanent O O
damage O O
. O O

Magnetic O O
Resonance O O
imaging O O
revealed O O
cortical O O
laminar O O
necrosis B B_DISEASE
in O O
arterial O O
border O O
zones O O
in O O
both O O
cerebral O O
hemispheres O O
, O O
ischemic O O
changes O O
in O O
subcortical O O
white O O
matter O O
of O O
left O O
cerebral O O
hemisphere O O
, O O
and O O
in O O
the O O
left O O
putamen O O
. O O

Although O O
cortical O O
laminar O O
necrosis B B_DISEASE
is O O
a O O
classic O O
entity O O
in O O
adulthood O O
related O O
to O O
conditions O O
of O O
energy O O
depletions O O
, O O
there O O
are O O
few O O
reports O O
available O O
in O O
children O O
. O O

A O O
wide O O
review O O
of O O
the O O
literature O O
is O O
also O O
presented O O
. O O

The O O
natural O O
history O O
of O O
Vigabatrin O O
associated O O
visual B B_DISEASE
field I I_DISEASE
defects I I_DISEASE
in O O
patients O O
electing O O
to O O
continue O O
their O O
medication O O
. O O

PURPOSE O O
: O O
To O O
determine O O
the O O
natural O O
history O O
of O O
visual B B_DISEASE
field I I_DISEASE
defects I I_DISEASE
in O O
a O O
group O O
of O O
patients O O
known O O
to O O
have O O
Vigabatrin O O
- O O
associated O O
changes O O
who O O
elected O O
to O O
continue O O
the O O
medication O O
because O O
of O O
good O O
seizure B B_DISEASE
control O O
. O O

METHODS O O
: O O
All O O
patients O O
taking O O
Vigabatrin O O
alone O O
or O O
in O O
combination O O
with O O
other O O
antiepileptic O O
drugs O O
for O O
at O O
least O O
5 O O
years O O
( O O
range O O
5 O O
- O O
12 O O
years O O
) O O
were O O
entered O O
into O O
a O O
visual O O
surveillance O O
programme O O
. O O

Patients O O
were O O
followed O O
up O O
at O O
6 O O
- O O
monthly O O
intervals O O
for O O
not O O
less O O
than O O
18 O O
months O O
( O O
range O O
18 O O
- O O
43 O O
months O O
) O O
. O O

Following O O
already O O
published O O
methodology O O
( O O
Eye O O
2002 O O
; O O
16 O O
; O O
567 O O
- O O
571 O O
) O O
monocular O O
mean O O
radial O O
degrees O O
( O O
MRDs O O
) O O
to O O
the O O
I O O
/ O O
4e O O
isopter O O
on O O
Goldmann O O
perimetry O O
was O O
calculated O O
for O O
the O O
right O O
eye O O
at O O
the O O
time O O
of O O
discovery O O
of O O
a O O
visual B B_DISEASE
field I I_DISEASE
defect I I_DISEASE
and O O
again O O
after O O
not O O
less O O
than O O
18 O O
months O O
follow O O
- O O
up O O
. O O

Only O O
one O O
patient O O
demonstrated O O
a O O
deterioration B B_DISEASE_ADJECTIVE[DISEASE]
in I I_DISEASE_ADJECTIVE[DISEASE]
visual I I_DISEASE_ADJECTIVE[DISEASE]
field I I_DISEASE_ADJECTIVE[DISEASE]
during O O
the O O
study O O
period O O
and O O
discontinued O O
treatment O O
. O O

CONCLUSION O O
: O O
Established O O
visual B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
field I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
defects I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
presumed O O
to O O
be O O
due O O
to O O
Vigabatrin O O
therapy O O
did O O
not O O
usually O O
progress O O
in O O
spite O O
of O O
continuing O O
use O O
of O O
the O O
medication O O
. O O

These O O
data O O
give O O
support O O
to O O
the O O
hypothesis O O
that O O
the O O
pathogenesis O O
of O O
Vigabatrin O O
- O O
associated O O
visual B B_DISEASE
field I I_DISEASE
defects I I_DISEASE
may O O
be O O
an O O
idiosyncratic O O
adverse O O
drug O O
reaction O O
rather O O
than O O
dose O O
- O O
dependent O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Induction O O
of O O
rosaceiform O O
dermatitis B B_DISEASE
during O O
treatment O O
of O O
facial B B_DISEASE/B_GENE
inflammatory I I_DISEASE/I_GENE
dermatoses I I_DISEASE/I_GENE
with O O
tacrolimus O O
ointment O O
. O O

BACKGROUND O O
: O O
Tacrolimus O O
ointment O O
is O O
increasingly O O
used O O
for O O
anti O O
- O O
inflammatory O O
treatment O O
of O O
sensitive O O
areas O O
such O O
as O O
the O O
face O O
, O O
and O O
recent O O
observations O O
indicate O O
that O O
the O O
treatment O O
is O O
effective O O
in O O
steroid O O
- O O
aggravated O O
rosacea B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
perioral B B_DISEASE
dermatitis I I_DISEASE
. O O

We O O
report O O
on O O
rosaceiform O O
dermatitis B B_DISEASE
as O O
a O O
complication O O
of O O
treatment O O
with O O
tacrolimus O O
ointment O O
. O O

OBSERVATIONS O O
: O O
Six O O
adult O O
patients O O
with O O
inflammatory B B_DISEASE/B_PROTEIN[GENE]
facial I B_DISEASE/I_PROTEIN[GENE]
dermatoses I B_DISEASE/I_PROTEIN[GENE]
were O O
treated O O
with O O
tacrolimus O O
ointment O O
because O O
of O O
the O O
ineffectiveness O O
of O O
standard O O
treatments O O
. O O

Within O O
2 O O
to O O
3 O O
weeks O O
of O O
initially O O
effective O O
and O O
well O O
- O O
tolerated O O
treatment O O
, O O
3 O O
patients O O
with O O
a O O
history O O
of O O
rosacea B B_DISEASE
and O O
1 O O
with O O
a O O
history O O
of O O
acne B B_DISEASE
experienced O O
sudden O O
worsening O O
with O O
pustular O O
rosaceiform O O
lesions O O
. O O

In O O
1 O O
patient O O
with O O
eyelid O O
eczema B B_DISEASE
, O O
rosaceiform O O
periocular B B_DISEASE
dermatitis I I_DISEASE
gradually O O
appeared O O
after O O
3 O O
weeks O O
of O O
treatment O O
. O O

In O O
1 O O
patient O O
with O O
atopic B B_DISEASE/B_LOCATION
dermatitis I I_DISEASE/I_LOCATION
, O O
telangiectatic O O
and O O
papular B B_DISEASE
rosacea I I_DISEASE
insidiously O O
appeared O O
after O O
5 O O
months O O
of O O
treatment O O
. O O

CONCLUSIONS O O
: O O
Our O O
observations O O
suggest O O
that O O
the O O
spectrum O O
of O O
rosaceiform O O
dermatitis B B_DISEASE
as O O
a O O
complication O O
of O O
treatment O O
with O O
tacrolimus O O
ointment O O
is O O
heterogeneous O O
. O O

Future O O
studies O O
are O O
needed O O
to O O
identify O O
individual O O
risk O O
factors O O
. O O

Intravascular O O
hemolysis B B_DISEASE
and O O
acute B B_DISEASE
renal I I_DISEASE
failure I I_DISEASE
following O O
intermittent O O
rifampin O O
therapy O O
. O O

Renal B B_DISEASE
failure I I_DISEASE
is O O
a O O
rare O O
complication O O
associated O O
with O O
the O O
use O O
of O O
rifampin O O
. O O

Intravascular O O
hemolysis B B_DISEASE
leading O O
to O O
acute B B_DISEASE
renal I I_DISEASE
failure I I_DISEASE
following O O
rifampin O O
therapy O O
is O O
extremely O O
rare O O
. O O

Two O O
patients O O
with O O
leprosy B B_DISEASE
who O O
developed O O
hemolysis B B_DISEASE
and O O
acute B B_DISEASE
renal I I_DISEASE
failure I I_DISEASE
following O O
rifampin O O
are O O
reported O O
. O O

Structural O O
abnormalities O O
in O O
the O O
brains O O
of O O
human O O
subjects O O
who O O
use O O
methamphetamine O O
. O O

We O O
visualize O O
, O O
for O O
the O O
first O O
time O O
, O O
the O O
profile O O
of O O
structural B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deficits I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
human I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
brain I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
associated O O
with O O
chronic O O
methamphetamine O O
( O O
MA O O
) O O
abuse O O
. O O

Studies O O
of O O
human O O
subjects O O
who O O
have O O
used O O
MA O O
chronically O O
have O O
revealed O O
deficits O O
in O O
dopaminergic O O
and O O
serotonergic O O
systems O O
and O O
cerebral O O
metabolic B B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
abnormalities I B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
. O O

Using O O
magnetic O O
resonance O O
imaging O O
( O O
MRI O O
) O O
and O O
new O O
computational O O
brain O O
- O O
mapping O O
techniques O O
, O O
we O O
determined O O
the O O
pattern O O
of O O
structural O O
brain O O
alterations O O
associated O O
with O O
chronic O O
MA O O
abuse O O
in O O
human O O
subjects O O
and O O
related O O
these O O
deficits O O
to O O
cognitive B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
impairment I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

We O O
used O O
high O O
- O O
resolution O O
MRI O O
and O O
surface O O
- O O
based O O
computational O O
image O O
analyses O O
to O O
map O O
regional O O
abnormalities B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cortex I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hippocampus I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
white I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
matter I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ventricles I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
22 O O
human O O
subjects O O
who O O
used O O
MA O O
and O O
21 O O
age O O
- O O
matched O O
, O O
healthy O O
controls O O
. O O

On O O
average O O
, O O
MA O O
abusers O O
had O O
7 O O
. O O
8 O O
% O O
smaller O O
hippocampal O O
volumes O O
than O O
control O O
subjects O O
( O O
p O O
< O O
0 O O
. O O
01 O O
; O O
left O O
, O O
p O O
= O O
0 O O
. O O
01 O O
; O O
right O O
, O O
p O O
< O O
0 O O
. O O
05 O O
) O O
and O O
significant O O
white O O
- O O
matter O O
hypertrophy B B_DISEASE
( O O
7 O O
. O O
0 O O
% O O
; O O
p O O
< O O
0 O O
. O O
01 O O
) O O
. O O

Hippocampal O O
deficits O O
were O O
mapped O O
and O O
correlated O O
with O O
memory O O
performance O O
on O O
a O O
word O O
- O O
recall O O
test O O
( O O
p O O
< O O
0 O O
. O O
05 O O
) O O
. O O

MRI O O
- O O
based O O
maps O O
suggest O O
that O O
chronic O O
methamphetamine O O
abuse O O
causes O O
a O O
selective O O
pattern O O
of O O
cerebral O O
deterioration O O
that O O
contributes O O
to O O
impaired B B_DISEASE
memory I I_DISEASE
performance I I_DISEASE
. O O

Prominent O O
white O O
- O O
matter O O
hypertrophy B B_DISEASE
may O O
result O O
from O O
altered O O
myelination O O
and O O
adaptive O O
glial O O
changes O O
, O O
including O O
gliosis B B_DISEASE_ADJECTIVE[DISEASE]
secondary O O
to O O
neuronal B B_DISEASE
damage I I_DISEASE
. O O

These O O
brain O O
substrates O O
may O O
help O O
account O O
for O O
the O O
symptoms O O
of O O
MA O O
abuse O O
, O O
providing O O
therapeutic O O
targets O O
for O O
drug O O
- O O
induced O O
brain B B_DISEASE_ADJECTIVE[DISEASE]
injury I I_DISEASE_ADJECTIVE[DISEASE]
. O O

Amiodarone O O
, O O
an O O
efficacious O O
and O O
widely O O
used O O
antiarrhythmic O O
agent O O
, O O
has O O
been O O
reported O O
to O O
cause O O
hepatotoxicity B B_DISEASE
in O O
some O O
patients O O
. O O

To O O
gain O O
insight O O
into O O
the O O
mechanism O O
of O O
this O O
unwanted O O
effect O O
, O O
mice O O
were O O
administered O O
various O O
doses O O
of O O
amiodarone O O
and O O
examined O O
for O O
changes O O
in O O
hepatic O O
histology O O
and O O
gene O O
regulation O O
. O O

Amiodarone O O
induced O O
hepatomegaly B B_DISEASE
, O O
hepatocyte O O
microvesicular O O
lipid O O
accumulation O O
, O O
and O O
a O O
significant O O
decrease O O
in O O
serum O O
triglycerides O O
and O O
glucose O O
. O O

Northern O O
blot O O
analysis O O
of O O
hepatic O O
RNA O O
revealed O O
a O O
dose O O
- O O
dependent O O
increase O O
in O O
the O O
expression O O
of O O
a O O
number O O
of O O
genes O O
critical O O
for O O
fatty O O
acid O O
oxidation O O
, O O
lipoprotein O O
assembly O O
, O O
and O O
lipid O O
transport O O
. O O

Many O O
of O O
these O O
genes O O
are O O
regulated O O
by O O
the O O
peroxisome O O
proliferator O O
- O O
activated O O
receptor O O
- O O
alpha O O
( O O
PPARalpha O O
) O O
, O O
a O O
ligand O O
- O O
activated O O
nuclear O O
hormone O O
receptor O O
transcription O O
factor O O
. O O

The O O
absence O O
of O O
induction O O
of O O
these O O
genes O O
as O O
well O O
as O O
hepatomegaly B B_DISEASE/B_GENE
in O O
PPARalpha O O
knockout O O
[ O O
PPARalpha O O
- O O
/ O O
- O O
] O O
mice O O
indicated O O
that O O
the O O
effects O O
of O O
amiodarone O O
were O O
dependent O O
upon O O
the O O
presence O O
of O O
a O O
functional O O
PPARalpha O O
gene O O
. O O

Compared O O
to O O
wild O O
- O O
type O O
mice O O
, O O
treatment O O
of O O
PPARalpha O O
- O O
/ O O
- O O
mice O O
with O O
amiodarone O O
resulted O O
in O O
an O O
increased O O
rate O O
and O O
extent O O
of O O
total O O
body O O
weight B B_DISEASE
loss I I_DISEASE
. O O

The O O
inability O O
of O O
amiodarone O O
to O O
directly O O
activate O O
either O O
human O O
or O O
mouse O O
PPARalpha O O
transiently O O
expressed O O
in O O
human O O
HepG2 O O
hepatoma B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cells O O
indicates O O
that O O
the O O
effects O O
of O O
amiodarone O O
on O O
the O O
function O O
of O O
this O O
receptor O O
were O O
indirect O O
. O O

Based O O
upon O O
these O O
results O O
, O O
we O O
conclude O O
that O O
amiodarone O O
disrupts O O
hepatic O O
lipid O O
homeostasis O O
and O O
that O O
the O O
increased O O
expression O O
of O O
PPARalpha O O
target O O
genes O O
is O O
secondary O O
to O O
this O O
toxic O O
effect O O
. O O

These O O
results O O
provide O O
important O O
new O O
mechanistic O O
information O O
regarding O O
the O O
hepatotoxic B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O O
of O O
amiodarone O O
and O O
indicate O O
that O O
PPARalpha O O
protects O O
against O O
amiodarone O O
- O O
induced O O
hepatotoxicity B B_DISEASE
. O O

Safety O O
and O O
compliance O O
with O O
once O O
- O O
daily O O
niacin O O
extended O O
- O O
release O O
/ O O
lovastatin O O
as O O
initial O O
therapy O O
in O O
the O O
Impact O O
of O O
Medical O O
Subspecialty O O
on O O
Patient O O
Compliance O O
to O O
Treatment O O
( O O
IMPACT O O
) O O
study O O
. O O

Niacin O O
extended O O
- O O
release O O
/ O O
lovastatin O O
is O O
a O O
new O O
combination O O
product O O
approved O O
for O O
treatment O O
of O O
primary O O
hypercholesterolemia B B_DISEASE
and O O
mixed O O
dyslipidemia B B_DISEASE
. O O

This O O
open O O
- O O
labeled O O
, O O
multicenter O O
study O O
evaluated O O
the O O
safety O O
of O O
bedtime O O
niacin O O
extended O O
- O O
release O O
/ O O
lovastatin O O
when O O
dosed O O
as O O
initial O O
therapy O O
and O O
patient O O
compliance O O
to O O
treatment O O
in O O
various O O
clinical O O
practice O O
settings O O
. O O

A O O
total O O
of O O
4 O O
, O O
499 O O
patients O O
with O O
dyslipidemia B B_DISEASE
requiring O O
drug O O
intervention O O
was O O
enrolled O O
at O O
1 O O
, O O
081 O O
sites O O
. O O

Patients O O
were O O
treated O O
with O O
1 O O
tablet O O
( O O
500 O O
mg O O
of O O
niacin O O
extended O O
- O O
release O O
/ O O
20 O O
mg O O
of O O
lovastatin O O
) O O
once O O
nightly O O
for O O
4 O O
weeks O O
and O O
then O O
2 O O
tablets O O
for O O
8 O O
weeks O O
. O O

Patients O O
also O O
received O O
dietary O O
counseling O O
, O O
educational O O
materials O O
, O O
and O O
reminders O O
to O O
call O O
a O O
toll O O
- O O
free O O
number O O
that O O
provided O O
further O O
education O O
about O O
dyslipidemia B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
niacin O O
extended O O
- O O
release O O
/ O O
lovastatin O O
. O O

Primary O O
end O O
points O O
were O O
study O O
compliance O O
, O O
increases O O
in O O
liver O O
transaminases O O
to O O
> O O
3 O O
times O O
the O O
upper O O
limit O O
of O O
normal O O
, O O
and O O
clinical O O
myopathy B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Final O O
study O O
status O O
was O O
available O O
for O O
4 O O
, O O
217 O O
patients O O
( O O
94 O O
% O O
) O O
. O O

Compliance O O
to O O
niacin O O
extended O O
- O O
release O O
/ O O
lovastatin O O
was O O
77 O O
% O O
, O O
with O O
3 O O
, O O
245 O O
patients O O
completing O O
the O O
study O O
. O O

Patients O O
in O O
the O O
southeast O O
and O O
those O O
enrolled O O
by O O
endocrinologists O O
had O O
the O O
lowest O O
compliance O O
and O O
highest O O
adverse O O
event O O
rates O O
. O O

Flushing B B_DISEASE
was O O
the O O
most O O
common O O
adverse O O
event O O
, O O
reported O O
by O O
18 O O
% O O
of O O
patients O O
and O O
leading O O
to O O
discontinuation O O
by O O
6 O O
% O O
. O O

Incidence O O
of O O
increased O O
aspartate O O
aminotransferase O O
and O O
/ O O
or O O
alanine O O
aminotransferase O O
> O O
3 O O
times O O
the O O
upper O O
limit O O
of O O
normal O O
was O O
< O O
0 O O
. O O
3 O O
% O O
. O O

An O O
increase O O
of O O
creatine O O
phosphokinase O O
to O O
> O O
5 O O
times O O
the O O
upper O O
limit O O
of O O
normal O O
occurred O O
in O O
0 O O
. O O
24 O O
% O O
of O O
patients O O
, O O
and O O
no O O
cases O O
of O O
drug O O
- O O
induced O O
myopathy B B_DISEASE
were O O
observed O O
. O O

Protective O O
effect O O
of O O
Terminalia O O
chebula O O
against O O
experimental O O
myocardial B B_DISEASE
injury I I_DISEASE
induced O O
by O O
isoproterenol O O
. O O

Cardioprotective O O
effect O O
of O O
ethanolic O O
extract O O
of O O
Terminalia O O
chebula O O
fruits O O
( O O
500 O O
mg O O
/ O O
kg O O
body O O
wt O O
) O O
was O O
examined O O
in O O
isoproterenol O O
( O O
200 O O
mg O O
/ O O
kg O O
body O O
wt O O
) O O
induced O O
myocardial B B_DISEASE
damage I I_DISEASE
in O O
rats O O
. O O

In O O
isoproterenol O O
administered O O
rats O O
, O O
the O O
level O O
of O O
lipid O O
peroxides O O
increased O O
significantly O O
in O O
the O O
serum O O
and O O
heart O O
. O O

A O O
significant O O
decrease O O
was O O
observed O O
in O O
the O O
activity O O
of O O
the O O
myocardial O O
marker O O
enzymes O O
with O O
a O O
concomitant O O
increase O O
in O O
their O O
activity O O
in O O
serum O O
. O O

Histopathological O O
examination O O
was O O
carried O O
out O O
to O O
confirm O O
the O O
myocardial O O
necrosis B B_DISEASE
. O O

T O O
. O O
chebula O O
extract O O
pretreatment O O
was O O
found O O
to O O
ameliorate O O
the O O
effect O O
of O O
isoproterenol O O
on O O
lipid O O
peroxide O O
formation O O
and O O
retained O O
the O O
activities O O
of O O
the O O
diagnostic O O
marker O O
enzymes O O
. O O

A O O
case O O
of O O
postoperative O O
anxiety B B_DISEASE
due O O
to O O
low O O
dose O O
droperidol O O
used O O
with O O
patient O O
- O O
controlled O O
analgesia O O
. O O

A O O
multiparous O O
woman O O
in O O
good O O
psychological O O
health O O
underwent O O
urgent O O
caesarean O O
section O O
in O O
labour O O
. O O

Postoperatively O O
, O O
she O O
was O O
given O O
a O O
patient O O
- O O
controlled O O
analgesia O O
device O O
delivering O O
boluses O O
of O O
diamorphine O O
0 O O
. O O
5 O O
mg O O
and O O
droperidol O O
0 O O
. O O
025 O O
mg O O
. O O

Whilst O O
using O O
the O O
device O O
she O O
gradually O O
became O O
anxious O O
, O O
the O O
feeling O O
worsening O O
after O O
each O O
bolus O O
. O O

The O O
diagnosis O O
of O O
droperidol O O
- O O
induced O O
psychological B B_DISEASE
disturbance I I_DISEASE
was O O
not O O
made O O
straight O O
away O O
although O O
on O O
subsequent O O
close O O
questioning O O
the O O
patient O O
gave O O
a O O
very O O
clear O O
history O O
. O O

We O O
feel O O
that O O
, O O
although O O
the O O
dramatic O O
extrapyramidal O O
side O O
effects O O
of O O
dopaminergic O O
antiemetics O O
are O O
well O O
known O O
, O O
more O O
subtle O O
manifestations O O
may O O
easily O O
be O O
overlooked O O
. O O

Accurate O O
patient O O
history O O
contributes O O
to O O
differentiating O O
diabetes B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
insipidus I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
a O O
case O O
study O O
. O O

This O O
case O O
study O O
highlights O O
the O O
important O O
contribution O O
of O O
nursing O O
in O O
obtaining O O
an O O
accurate O O
health O O
history O O
. O O

The O O
case O O
discussed O O
herein O O
initially O O
appeared O O
to O O
be O O
neurogenic B B_DISEASE
diabetes I I_DISEASE
insipidus I I_DISEASE
( O O
DI B B_DISEASE/B_PROTEIN[GENE]
) O O
secondary O O
to O O
a O O
traumatic B B_DISEASE
brain I I_DISEASE
injury I I_DISEASE
. O O

The O O
nursing O O
staff O O
, O O
by O O
reviewing O O
the O O
patient O O
' O O
s O O
health O O
history O O
with O O
his O O
family O O
, O O
discovered O O
a O O
history O O
of O O
polydipsia B B_DISEASE_ADJECTIVE[DISEASE]
and O O
long O O
- O O
standing O O
lithium O O
use O O
. O O

Lithium O O
is O O
implicated O O
in O O
drug O O
- O O
induced O O
nephrogenic B B_DISEASE
DI I I_DISEASE
, O O
and O O
because O O
the O O
patient O O
had O O
not O O
received O O
lithium O O
since O O
being O O
admitted O O
to O O
the O O
hospital O O
, O O
his O O
treatment O O
changed O O
to O O
focus O O
on O O
nephrogenic B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DI I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

By O O
combining O O
information O O
from O O
the O O
patient O O
history O O
, O O
the O O
physical O O
examination O O
, O O
and O O
radiologic O O
and O O
laboratory O O
studies O O
, O O
the O O
critical O O
care O O
team O O
demonstrated O O
that O O
the O O
patient O O
had O O
been O O
self O O
- O O
treating O O
his O O
lithium O O
- O O
induced O O
nephrogenic B B_DISEASE
DI I I_DISEASE
and O O
developed O O
neurogenic B B_DISEASE
DI I I_DISEASE
secondary O O
to O O
brain B B_DISEASE
trauma I I_DISEASE
. O O

Thus O O
successful O O
treatment O O
required O O
that O O
nephrogenic O O
and O O
neurogenic B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
DI I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
be O O
treated O O
concomitantly O O
. O O

Factors O O
contributing O O
to O O
ribavirin O O
- O O
induced O O
anemia B B_DISEASE
. O O

BACKGROUND O O
AND O O
AIM O O
: O O
Interferon O O
and O O
ribavirin O O
combination O O
therapy O O
for O O
chronic B B_DISEASE
hepatitis I I_DISEASE
C I I_DISEASE
produces O O
hemolytic B B_DISEASE_ADJECTIVE[DISEASE]
anemia I I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
study O O
was O O
conducted O O
to O O
identify O O
the O O
factors O O
contributing O O
to O O
ribavirin O O
- O O
induced O O
anemia B B_DISEASE
. O O

METHODS O O
: O O
Eighty O O
- O O
eight O O
patients O O
with O O
chronic B B_DISEASE/B_LOCATION
hepatitis I I_DISEASE/I_LOCATION
C I I_DISEASE/I_LOCATION
who O O
received O O
interferon O O
- O O
alpha O O
- O O
2b O O
at O O
a O O
dose O O
of O O
6 O O
MU O O
administered O O
intramuscularly O O
for O O
24 O O
weeks O O
in O O
combination O O
with O O
ribavirin O O
administered O O
orally O O
at O O
a O O
dose O O
of O O
600 O O
mg O O
or O O
800 O O
mg O O
participated O O
in O O
the O O
study O O
. O O

A O O
hemoglobin O O
concentration O O
of O O
< O O
10 O O
g O O
/ O O
dL O O
was O O
defined O O
as O O
ribavirin O O
- O O
induced O O
anemia B B_DISEASE
. O O

RESULTS O O
: O O
Ribavirin O O
- O O
induced O O
anemia B B_DISEASE
occurred O O
in O O
18 O O
( O O
20 O O
. O O
5 O O
% O O
) O O
patients O O
during O O
treatment O O
. O O

A O O
2 O O
g O O
/ O O
dL O O
decrease O O
in O O
hemoglobin O O
concentrations O O
in O O
patients O O
with O O
anemia B B_DISEASE
was O O
observed O O
at O O
week O O
2 O O
after O O
the O O
start O O
of O O
treatment O O
. O O

The O O
hemoglobin O O
concentration O O
in O O
patients O O
with O O
> O O
or O O
= O O
2 O O
g O O
/ O O
dL O O
decrease O O
at O O
week O O
2 O O
was O O
observed O O
to O O
be O O
significantly O O
lower O O
even O O
after O O
week O O
2 O O
than O O
in O O
patients O O
with O O
< O O
2 O O
g O O
/ O O
dL O O
decrease O O
( O O
P O O
< O O
0 O O
. O O
01 O O
) O O
. O O

A O O
significant O O
relationship O O
was O O
observed O O
between O O
the O O
rate O O
of O O
reduction O O
of O O
hemoglobin O O
concentrations O O
at O O
week O O
2 O O
and O O
the O O
severity O O
of O O
anemia B B_DISEASE
( O O
P O O
< O O
0 O O
. O O
01 O O
) O O
. O O

Such O O
factors O O
as O O
sex O O
( O O
female O O
) O O
, O O
age O O
( O O
> O O
or O O
= O O
60 O O
years O O
old O O
) O O
, O O
and O O
the O O
ribavirin O O
dose O O
by O O
body O O
weight O O
( O O
12 O O
mg O O
/ O O
kg O O
or O O
more O O
) O O
were O O
significant O O
by O O
univariate O O
analysis O O
. O O

CONCLUSIONS O O
: O O
Careful O O
administration O O
is O O
necessary O O
in O O
patients O O
> O O
or O O
= O O
60 O O
years O O
old O O
, O O
in O O
female O O
patients O O
, O O
and O O
in O O
patients O O
receiving O O
a O O
ribavirin O O
dose O O
of O O
12 O O
mg O O
/ O O
kg O O
or O O
more O O
. O O

Patients O O
who O O
experience O O
a O O
fall O O
in O O
hemoglobin O O
concentrations O O
of O O
2 O O
g O O
/ O O
dL O O
or O O
more O O
at O O
week O O
2 O O
after O O
the O O
start O O
of O O
treatment O O
should O O
be O O
monitored O O
with O O
particular O O
care O O
. O O

Zidovudine O O
- O O
induced O O
hepatitis B B_DISEASE
. O O

A O O
case O O
of O O
acute O O
hepatitis B B_DISEASE
induced O O
by O O
zidovudine O O
in O O
a O O
38 O O
- O O
year O O
- O O
old O O
patient O O
with O O
AIDS B B_DISEASE
is O O
presented O O
. O O

The O O
mechanism O O
whereby O O
the O O
hepatitis B B_DISEASE
was O O
induced O O
is O O
not O O
known O O
. O O

However O O
, O O
the O O
patient O O
tolerated O O
well O O
an O O
alternative O O
reverse O O
transcriptase O O
inhibitor O O
, O O
2 O O
' O O
3 O O
' O O
dideoxyinosine O O
. O O

Physicians O O
caring O O
for O O
patients O O
with O O
AIDS B B_DISEASE
should O O
be O O
aware O O
of O O
this O O
hitherto O O
rarely O O
reported O O
complication O O
. O O

Oxidative O O
damage O O
precedes O O
nitrative O O
damage O O
in O O
adriamycin O O
- O O
induced O O
cardiac O O
mitochondrial B B_DISEASE
injury I I_DISEASE
. O O

The O O
purpose O O
of O O
the O O
present O O
study O O
was O O
to O O
determine O O
if O O
elevated O O
reactive O O
oxygen O O
( O O
ROS O O
) O O
/ O O
nitrogen O O
species O O
( O O
RNS O O
) O O
reported O O
to O O
be O O
present O O
in O O
adriamycin O O
( O O
ADR O O
) O O
- O O
induced O O
cardiotoxicity B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
actually O O
resulted O O
in O O
cardiomyocyte O O
oxidative O O
/ O O
nitrative O O
damage O O
, O O
and O O
to O O
quantitatively O O
determine O O
the O O
time O O
course O O
and O O
subcellular O O
localization O O
of O O
these O O
postulated O O
damage O O
products O O
using O O
an O O
in O O
vivo O O
approach O O
. O O

B6C3 O O
mice O O
were O O
treated O O
with O O
a O O
single O O
dose O O
of O O
20 O O
mg O O
/ O O
kg O O
ADR O O
. O O

Ultrastructural O O
damage O O
and O O
levels O O
of O O
4 O O
- O O
hydroxy O O
- O O
2 O O
- O O
nonenal O O
( O O
4HNE O O
) O O
- O O
protein O O
adducts O O
and O O
3 O O
- O O
nitrotyrosine O O
( O O
3NT O O
) O O
were O O
analyzed O O
. O O

Quantitative O O
ultrastructural O O
damage O O
using O O
computerized O O
image O O
techniques O O
showed O O
cardiomyocyte O O
injury O O
as O O
early O O
as O O
3 O O
hours O O
, O O
with O O
mitochondria O O
being O O
the O O
most O O
extensively O O
and O O
progressively O O
injured O O
subcellular O O
organelle O O
. O O

Analysis O O
of O O
4HNE O O
protein O O
adducts O O
by O O
immunogold O O
electron O O
microscopy O O
showed O O
appearance O O
of O O
4HNE O O
protein O O
adducts O O
in O O
mitochondria O O
as O O
early O O
as O O
3 O O
hours O O
, O O
with O O
a O O
peak O O
at O O
6 O O
hours O O
and O O
subsequent O O
decline O O
at O O
24 O O
hours O O
. O O

3NT O O
levels O O
were O O
significantly O O
increased O O
in O O
all O O
subcellular O O
compartments O O
at O O
6 O O
hours O O
and O O
subsequently O O
declined O O
at O O
24 O O
hours O O
. O O

Our O O
data O O
showed O O
ADR O O
induced O O
4HNE O O
- O O
protein O O
adducts O O
in O O
mitochondria O O
at O O
the O O
same O O
time O O
point O O
as O O
when O O
mitochondrial B B_DISEASE
injury I I_DISEASE
initially O O
appeared O O
. O O

These O O
results O O
document O O
for O O
the O O
first O O
time O O
in O O
vivo O O
that O O
mitochondrial B B_DISEASE/B_GENE
oxidative I I_DISEASE/I_GENE
damage I I_DISEASE/I_GENE
precedes O O
nitrative O O
damage O O
. O O

The O O
progressive O O
nature O O
of O O
mitochondrial B B_DISEASE_ADJECTIVE[DISEASE]
injury I I_DISEASE_ADJECTIVE[DISEASE]
suggests O O
that O O
mitochondria O O
, O O
not O O
other O O
subcellular O O
organelles O O
, O O
are O O
the O O
major O O
site O O
of O O
intracellular O O
injury O O
. O O

Sotalol O O
- O O
induced O O
coronary B B_DISEASE
spasm I I_DISEASE
in O O
a O O
patient O O
with O O
dilated B B_DISEASE/B_GENE
cardiomyopathy I I_DISEASE/I_GENE
associated O O
with O O
sustained O O
ventricular B B_DISEASE
tachycardia I I_DISEASE
. O O

A O O
54 O O
- O O
year O O
- O O
old O O
man O O
with O O
severe O O
left O O
ventricular B B_DISEASE/B_LOCATION
dysfunction I I_DISEASE/I_LOCATION
due O O
to O O
dilated B B_DISEASE
cardiomyopathy I I_DISEASE
was O O
referred O O
to O O
our O O
hospital O O
for O O
symptomatic O O
incessant O O
sustained O O
ventricular B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tachycardia I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
VT B B_DISEASE/B_PROTEIN[GENE]
) O O
. O O

After O O
the O O
administration O O
of O O
nifekalant O O
hydrochloride O O
, O O
sustained O O
VT B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
terminated O O
. O O

An O O
alternate O O
class O O
III O O
agent O O
, O O
sotalol O O
, O O
was O O
also O O
effective O O
for O O
the O O
prevention O O
of O O
VT B B_DISEASE
. O O

Coronary B B_DISEASE_ADJECTIVE[DISEASE]
vasospasm I I_DISEASE_ADJECTIVE[DISEASE]
may O O
be O O
induced O O
by O O
the O O
non O O
- O O
selective O O
beta O O
- O O
blocking O O
properties O O
of O O
sotalol O O
. O O

Effects O O
of O O
the O O
antidepressant O O
trazodone O O
, O O
a O O
5 O O
- O O
HT O O
2A O O
/ O O
2C O O
receptor O O
antagonist O O
, O O
on O O
dopamine O O
- O O
dependent O O
behaviors O O
in O O
rats O O
. O O

RATIONALE O O
: O O
5 O O
- O O
Hydroxytryptamine O O
, O O
via O O
stimulation O O
of O O
5 O O
- O O
HT O O
2C O O
receptors O O
, O O
exerts O O
a O O
tonic O O
inhibitory O O
influence O O
on O O
dopaminergic O O
neurotransmission O O
, O O
whereas O O
activation O O
of O O
5 O O
- O O
HT O O
2A O O
receptors O O
enhances O O
stimulated O O
DAergic O O
neurotransmission O O
. O O

The O O
antidepressant O O
trazodone O O
is O O
a O O
5 O O
- O O
HT O O
2A O O
/ O O
2C O O
receptor O O
antagonist O O
. O O

OBJECTIVES O O
: O O
To O O
evaluate O O
the O O
effect O O
of O O
trazodone O O
treatment O O
on O O
behaviors O O
dependent O O
on O O
the O O
functional O O
status O O
of O O
the O O
nigrostriatal O O
DAergic O O
system O O
. O O

METHODS O O
: O O
The O O
effect O O
of O O
pretreatment O O
with O O
trazodone O O
on O O
dexamphetamine O O
- O O
and O O
apomorphine O O
- O O
induced O O
oral B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stereotypies I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
on O O
catalepsy B B_DISEASE
induced O O
by O O
haloperidol O O
and O O
apomorphine O O
( O O
0 O O
. O O
05 O O
mg O O
/ O O
kg O O
, O O
i O O
. O O
p O O
. O O
) O O
, O O
on O O
ergometrine O O
- O O
induced O O
wet O O
dog O O
shake O O
( O O
WDS O O
) O O
behavior O O
and O O
fluoxetine O O
- O O
induced O O
penile O O
erections O O
was O O
studied O O
in O O
rats O O
. O O

We O O
also O O
investigated O O
whether O O
trazodone O O
induces O O
catalepsy B B_DISEASE
in O O
rats O O
. O O

RESULTS O O
: O O
Trazodone O O
at O O
2 O O
. O O
5 O O
- O O
20 O O
mg O O
/ O O
kg O O
i O O
. O O
p O O
. O O
did O O
not O O
induce O O
catalepsy B B_DISEASE
, O O
and O O
did O O
not O O
antagonize O O
apomorphine O O
( O O
1 O O
. O O
5 O O
and O O
3 O O
mg O O
/ O O
kg O O
) O O
stereotypy O O
and O O
apomorphine O O
( O O
0 O O
. O O
05 O O
mg O O
/ O O
kg O O
) O O
- O O
induced O O
catalepsy B B_DISEASE
. O O

However O O
, O O
pretreatment O O
with O O
5 O O
, O O
10 O O
and O O
20 O O
mg O O
/ O O
kg O O
i O O
. O O
p O O
. O O
trazodone O O
enhanced O O
dexamphetamine O O
stereotypy O O
, O O
and O O
antagonized O O
haloperidol O O
catalepsy B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
ergometrine O O
- O O
induced O O
WDS O O
behavior O O
and O O
fluoxetine O O
- O O
induced O O
penile O O
erections O O
. O O

Trazodone O O
at O O
30 O O
, O O
40 O O
and O O
50 O O
mg O O
/ O O
kg O O
i O O
. O O
p O O
. O O
induced O O
catalepsy B B_DISEASE
and O O
antagonized O O
apomorphine O O
and O O
dexamphetamine O O
stereotypies O O
. O O

Furthermore O O
, O O
at O O
5 O O
, O O
10 O O
and O O
20 O O
mg O O
/ O O
kg O O
, O O
trazodone O O
blocks O O
5 O O
- O O
HT O O
2A O O
and O O
5 O O
- O O
HT O O
2C O O
receptors O O
. O O

We O O
suggest O O
that O O
trazodone O O
( O O
5 O O
, O O
10 O O
and O O
20 O O
mg O O
/ O O
kg O O
) O O
, O O
by O O
blocking O O
the O O
5 O O
- O O
HT O O
2C O O
receptors O O
, O O
releases O O
the O O
nigrostriatal O O
DAergic O O
neurons O O
from O O
tonic O O
inhibition O O
caused O O
by O O
5 O O
- O O
HT O O
, O O
and O O
thereby O O
potentiates O O
dexamphetamine O O
stereotypy O O
and O O
antagonizes O O
haloperidol O O
catalepsy B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Swallowing B B_DISEASE
abnormalities I I_DISEASE
and O O
dyskinesia B B_DISEASE
in O O
Parkinson B B_DISEASE/B_PERSON
' I B_DISEASE/I_PERSON
s I B_DISEASE/I_PERSON
disease I B_DISEASE/I_PERSON
. O O

Gastrointestinal B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
abnormalities I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
in O O
Parkinson B B_DISEASE
' I I_DISEASE
s I I_DISEASE
disease I I_DISEASE
( O O
PD B B_DISEASE/B_PROTEIN[GENE]
) O O
have O O
been O O
known O O
for O O
almost O O
two O O
centuries O O
, O O
but O O
many O O
aspects O O
concerning O O
their O O
pathophysiology O O
have O O
not O O
been O O
completely O O
clarified O O
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
characterize O O
the O O
oropharyngeal O O
dynamics O O
in O O
PD B B_DISEASE/B_LOCATION
patients O O
with O O
and O O
without O O
levodopa O O
- O O
induced O O
dyskinesia B B_DISEASE
. O O

Patients O O
were O O
asked O O
about O O
dysphagia B B_DISEASE
and O O
evaluated O O
with O O
the O O
Unified O O
Parkinson B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
' I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
s I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
Disease I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
Rating O O
Scale O O
Parts O O
II O O
and O O
III O O
and O O
the O O
Hoehn O O
and O O
Yahr O O
scale O O
. O O

Nondyskinetic O O
patients O O
, O O
but O O
not O O
the O O
dyskinetic B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
ones O O
, O O
showed O O
less O O
oropharyngeal O O
swallowing O O
efficiency O O
( O O
OPSE O O
) O O
for O O
liquid O O
food O O
than O O
controls O O
( O O
Dunnett O O
, O O
P O O
= O O
0 O O
. O O
02 O O
) O O
. O O

Patients O O
who O O
were O O
using O O
a O O
higher O O
dose O O
of O O
levodopa O O
had O O
a O O
greater O O
OPSE O O
and O O
a O O
trend O O
toward O O
a O O
smaller O O
oral O O
transit O O
time O O
( O O
Pearson O O
' O O
s O O
correlation O O
, O O
P O O
= O O
0 O O
. O O
01 O O
and O O
0 O O
. O O
08 O O
, O O
respectively O O
) O O
. O O

Neither O O
the O O
report O O
of O O
dysphagia B B_DISEASE
nor O O
any O O
of O O
the O O
PD B B_DISEASE
severity O O
parameters O O
correlated O O
to O O
the O O
videofluoroscopic O O
variables O O
. O O

Our O O
results O O
suggest O O
a O O
role O O
for O O
levodopa O O
in O O
the O O
oral O O
phase O O
of O O
deglutition O O
and O O
confirm O O
that O O
dysphagia B B_DISEASE
is O O
not O O
a O O
good O O
predictor O O
of O O
deglutition O O
alterations O O
in O O
PD B B_DISEASE/B_LOCATION
. O O

Inhibition O O
of O O
nuclear O O
factor O O
- O O
kappaB O O
activation O O
attenuates O O
tubulointerstitial B B_DISEASE/B_GENE
nephritis I I_DISEASE/I_GENE
induced O O
by O O
gentamicin O O
. O O

BACKGROUND O O
: O O
Animals O O
treated O O
with O O
gentamicin O O
can O O
show O O
residual O O
areas O O
of O O
interstitial O O
fibrosis B B_DISEASE
in O O
the O O
renal O O
cortex O O
. O O

METHODS O O
: O O
38 O O
female O O
Wistar O O
rats O O
were O O
injected O O
with O O
gentamicin O O
, O O
40 O O
mg O O
/ O O
kg O O
, O O
twice O O
a O O
day O O
for O O
9 O O
days O O
, O O
38 O O
with O O
gentamicin O O
+ O O
PDTC O O
, O O
and O O
28 O O
with O O
0 O O
. O O
15 O O
M O O
NaCl O O
solution O O
. O O

The O O
animals O O
were O O
killed O O
5 O O
and O O
30 O O
days O O
after O O
these O O
injections O O
and O O
the O O
kidneys O O
were O O
removed O O
for O O
histological O O
and O O
immunohistochemical O O
studies O O
. O O

The O O
results O O
of O O
the O O
immunohistochemical O O
studies O O
were O O
scored O O
according O O
to O O
the O O
extent O O
of O O
staining O O
. O O

The O O
fractional O O
interstitial O O
area O O
was O O
determined O O
by O O
morphometry O O
. O O

The O O
animals O O
killed O O
on O O
day O O
30 O O
also O O
presented O O
fibrosis B B_DISEASE
in O O
the O O
renal O O
cortex O O
despite O O
the O O
recovery O O
of O O
renal O O
function O O
. O O

CONCLUSIONS O O
: O O
These O O
data O O
show O O
that O O
inhibition O O
of O O
NF O O
- O O
kappaB O O
activation O O
attenuates O O
tubulointerstitial B B_DISEASE
nephritis I I_DISEASE
induced O O
by O O
gentamicin O O
. O O

Glucose O O
metabolism O O
in O O
patients O O
with O O
schizophrenia B B_DISEASE
treated O O
with O O
atypical O O
antipsychotic O O
agents O O
: O O
a O O
frequently O O
sampled O O
intravenous O O
glucose O O
tolerance O O
test O O
and O O
minimal O O
model O O
analysis O O
. O O

BACKGROUND O O
: O O
While O O
the O O
incidence O O
of O O
new O O
- O O
onset O O
diabetes B B_DISEASE
mellitus I I_DISEASE
may O O
be O O
increasing O O
in O O
patients O O
with O O
schizophrenia B B_DISEASE/B_LOCATION
treated O O
with O O
certain O O
atypical O O
antipsychotic O O
agents O O
, O O
it O O
remains O O
unclear O O
whether O O
atypical O O
agents O O
are O O
directly O O
affecting O O
glucose O O
metabolism O O
or O O
simply O O
increasing O O
known O O
risk O O
factors O O
for O O
diabetes B B_DISEASE
. O O

OBJECTIVE O O
: O O
To O O
study O O
the O O
2 O O
drugs O O
most O O
clearly O O
implicated O O
( O O
clozapine O O
and O O
olanzapine O O
) O O
and O O
risperidone O O
using O O
a O O
frequently O O
sampled O O
intravenous O O
glucose O O
tolerance O O
test O O
. O O

DESIGN O O
: O O
A O O
cross O O
- O O
sectional O O
design O O
in O O
stable O O
, O O
treated O O
patients O O
with O O
schizophrenia B B_DISEASE/B_GENE
evaluated O O
using O O
a O O
frequently O O
sampled O O
intravenous O O
glucose O O
tolerance O O
test O O
and O O
the O O
Bergman O O
minimal O O
model O O
analysis O O
. O O

SETTING O O
: O O
Subjects O O
were O O
recruited O O
from O O
an O O
urban O O
community O O
mental O O
health O O
clinic O O
and O O
were O O
studied O O
at O O
a O O
general O O
clinical O O
research O O
center O O
. O O

Patients O O
Fifty O O
subjects O O
signed O O
informed O O
consent O O
and O O
41 O O
underwent O O
the O O
frequently O O
sampled O O
intravenous O O
glucose O O
tolerance O O
test O O
. O O

Thirty O O
- O O
six O O
nonobese O O
subjects O O
with O O
schizophrenia B B_DISEASE
or O O
schizoaffective B B_DISEASE
disorder I I_DISEASE
, O O
matched O O
by O O
body O O
mass O O
index O O
and O O
treated O O
with O O
either O O
clozapine O O
, O O
olanzapine O O
, O O
or O O
risperidone O O
, O O
were O O
included O O
in O O
the O O
analysis O O
. O O

MAIN O O
OUTCOME O O
MEASURES O O
: O O
Fasting O O
plasma O O
glucose O O
and O O
fasting O O
serum O O
insulin O O
levels O O
, O O
insulin B B_DISEASE/B_MEASURE
sensitivity I I_DISEASE/I_MEASURE
index O O
, O O
homeostasis O O
model O O
assessment O O
of O O
insulin B B_DISEASE/B_ORGANISM_FUNCTION
resistance I I_DISEASE/I_ORGANISM_FUNCTION
, O O
and O O
glucose O O
effectiveness O O
. O O

RESULTS O O
: O O
The O O
mean O O
+ O O
/ O O
- O O
SD O O
duration O O
of O O
treatment O O
with O O
the O O
identified O O
atypical O O
antipsychotic O O
agent O O
was O O
68 O O
. O O
3 O O
+ O O
/ O O
- O O
28 O O
. O O
9 O O
months O O
( O O
clozapine O O
) O O
, O O
29 O O
. O O
5 O O
+ O O
/ O O
- O O
17 O O
. O O
5 O O
months O O
( O O
olanzapine O O
) O O
, O O
and O O
40 O O
. O O
9 O O
+ O O
/ O O
- O O
33 O O
. O O
7 O O
( O O
risperidone O O
) O O
. O O

Fasting O O
serum O O
insulin O O
concentrations O O
differed O O
among O O
groups O O
( O O
F O O
( O O
33 O O
) O O
= O O
3 O O
. O O
35 O O
; O O
P O O
= O O
. O O
047 O O
) O O
( O O
clozapine O O
> O O
olanzapine O O
> O O
risperidone O O
) O O
with O O
significant O O
differences O O
between O O
clozapine O O
and O O
risperidone O O
( O O
t O O
( O O
33 O O
) O O
= O O
2 O O
. O O
32 O O
; O O
P O O
= O O
. O O
03 O O
) O O
and O O
olanzapine O O
and O O
risperidone O O
( O O
t O O
( O O
33 O O
) O O
= O O
2 O O
. O O
15 O O
; O O
P O O
= O O
. O O
04 O O
) O O
. O O

There O O
was O O
a O O
significant O O
difference O O
in O O
insulin B B_DISEASE/B_GENE
sensitivity I I_DISEASE/I_GENE
index O O
among O O
groups O O
( O O
F O O
( O O
33 O O
) O O
= O O
10 O O
. O O
66 O O
; O O
P O O
< O O
. O O
001 O O
) O O
( O O
clozapine O O
< O O
olanzapine O O
< O O
risperidone O O
) O O
, O O
with O O
subjects O O
who O O
received O O
clozapine O O
and O O
olanzapine O O
exhibiting O O
significant O O
insulin B B_DISEASE_ADJECTIVE[DISEASE]
resistance I I_DISEASE_ADJECTIVE[DISEASE]
compared O O
with O O
subjects O O
who O O
were O O
treated O O
with O O
risperidone O O
( O O
clozapine O O
vs O O
risperidone O O
, O O
t O O
( O O
33 O O
) O O
= O O
- O O
4 O O
. O O
29 O O
; O O
P O O
< O O
. O O
001 O O
; O O
olanzapine O O
vs O O
risperidone O O
, O O
t O O
( O O
33 O O
) O O
= O O
- O O
3 O O
. O O
62 O O
; O O
P O O
= O O
. O O
001 O O
[ O O
P O O
< O O
. O O
001 O O
] O O
) O O
. O O

The O O
homeostasis O O
model O O
assessment O O
of O O
insulin B B_DISEASE/B_GENE
resistance I I_DISEASE/I_GENE
also O O
differed O O
significantly O O
among O O
groups O O
( O O
F O O
( O O
33 O O
) O O
= O O
4 O O
. O O
92 O O
; O O
P O O
= O O
. O O
01 O O
) O O
( O O
clozapine O O
> O O
olanzapine O O
> O O
risperidone O O
) O O
( O O
clozapine O O
vs O O
risperidone O O
, O O
t O O
( O O
33 O O
) O O
= O O
2 O O
. O O
94 O O
; O O
P O O
= O O
. O O
006 O O
; O O
olanzapine O O
vs O O
risperidone O O
, O O
t O O
( O O
33 O O
) O O
= O O
2 O O
. O O
42 O O
; O O
P O O
= O O
. O O
02 O O
) O O
. O O

There O O
was O O
a O O
significant O O
difference O O
among O O
groups O O
in O O
glucose O O
effectiveness O O
( O O
F O O
( O O
30 O O
) O O
= O O
4 O O
. O O
18 O O
; O O
P O O
= O O
. O O
02 O O
) O O
( O O
clozapine O O
< O O
olanzapine O O
< O O
risperidone O O
) O O
with O O
significant O O
differences O O
between O O
clozapine O O
and O O
risperidone O O
( O O
t O O
( O O
30 O O
) O O
= O O
- O O
2 O O
. O O
59 O O
; O O
P O O
= O O
. O O
02 O O
) O O
and O O
olanzapine O O
and O O
risperidone O O
( O O
t O O
( O O
30 O O
) O O
= O O
- O O
2 O O
. O O
34 O O
, O O
P O O
= O O
. O O
03 O O
) O O
. O O

CONCLUSIONS O O
: O O
Both O O
nonobese O O
clozapine O O
- O O
and O O
olanzapine O O
- O O
treated O O
groups O O
displayed O O
significant O O
insulin B B_DISEASE_ADJECTIVE[DISEASE]
resistance I I_DISEASE_ADJECTIVE[DISEASE]
and O O
impairment O O
of O O
glucose O O
effectiveness O O
compared O O
with O O
risperidone O O
- O O
treated O O
subjects O O
. O O

Patients O O
taking O O
clozapine O O
and O O
olanzapine O O
must O O
be O O
examined O O
for O O
insulin B B_DISEASE
resistance I I_DISEASE
and O O
its O O
consequences O O
. O O

Thoracic B B_DISEASE
hematomyelia I I_DISEASE
secondary O O
to O O
coumadin O O
anticoagulant O O
therapy O O
: O O
a O O
case O O
report O O
. O O

A O O
case O O
of O O
thoracic B B_DISEASE
hematomyelia I I_DISEASE
secondary O O
to O O
anticoagulant O O
therapy O O
is O O
presented O O
. O O

Clinical O O
features O O
, O O
similar O O
to O O
2 O O
other O O
previously O O
reported O O
cases O O
, O O
are O O
discussed O O
. O O

Mania B B_DISEASE
associated O O
with O O
fluoxetine O O
treatment O O
in O O
adolescents O O
. O O

Fluoxetine O O
, O O
a O O
selective O O
serotonin O O
reuptake O O
inhibitor O O
, O O
is O O
gaining O O
increased O O
acceptance O O
in O O
the O O
treatment O O
of O O
adolescent O O
depression B B_DISEASE
. O O

Generally O O
safe O O
and O O
well O O
tolerated O O
by O O
adults O O
, O O
fluoxetine O O
has O O
been O O
reported O O
to O O
induce O O
mania B B_DISEASE
. O O

The O O
cases O O
of O O
five O O
depressed B B_TIME[MEASURE]/B_DISEASE
adolescents O O
, O O
14 O O
- O O
16 O O
years O O
of O O
age O O
, O O
who O O
developed O O
mania B B_DISEASE
during O O
pharmacotherapy O O
with O O
fluoxetine O O
, O O
are O O
reported O O
here O O
. O O

Apparent O O
risk O O
factors O O
for O O
the O O
development O O
of O O
mania B B_DISEASE
or O O
hypomania B B_DISEASE
during O O
fluoxetine O O
pharmacotherapy O O
in O O
this O O
population O O
were O O
the O O
combination O O
of O O
attention B B_DISEASE
- I I_DISEASE
deficit I I_DISEASE
hyperactivity I I_DISEASE
disorder I I_DISEASE
and O O
affective O O
instability O O
; O O
major O O
depression B B_DISEASE
with O O
psychotic B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
features O O
; O O
a O O
family O O
history O O
of O O
affective B B_DISEASE
disorder I I_DISEASE
, O O
especially O O
bipolar B B_DISEASE/B_PERSON
disorder I I_DISEASE/I_PERSON
; O O
and O O
a O O
diagnosis O O
of O O
bipolar B B_DISEASE
disorder I I_DISEASE
. O O

Further O O
study O O
is O O
needed O O
to O O
determine O O
the O O
optimal O O
dosage O O
and O O
to O O
identify O O
risk O O
factors O O
that O O
increase O O
individual O O
vulnerability O O
to O O
fluoxetine O O
induced O O
mania B B_DISEASE
in O O
adolescents O O
. O O

Acute B B_DISEASE_ADJECTIVE[DISEASE]
renal I I_DISEASE_ADJECTIVE[DISEASE]
insufficiency I I_DISEASE_ADJECTIVE[DISEASE]
after O O
high O O
- O O
dose O O
melphalan O O
in O O
patients O O
with O O
primary B B_DISEASE
systemic I I_DISEASE
amyloidosis I I_DISEASE
during O O
stem O O
cell O O
transplantation O O
. O O

Median O O
survival O O
time O O
from O O
standard O O
treatments O O
is O O
only O O
17 O O
months O O
. O O

High O O
- O O
dose O O
intravenous O O
melphalan O O
followed O O
by O O
peripheral O O
blood O O
stem O O
cell O O
transplant O O
( O O
PBSCT O O
) O O
appears O O
to O O
be O O
the O O
most O O
promising O O
therapy O O
, O O
but O O
treatment O O
mortality O O
can O O
be O O
high O O
. O O

The O O
authors O O
have O O
noted O O
the O O
development O O
of O O
acute B B_DISEASE
renal I I_DISEASE
insufficiency I I_DISEASE
immediately O O
after O O
melphalan O O
conditioning O O
. O O

METHODS O O
: O O
Consecutive O O
AL B B_DISEASE/B_LOCATION
patients O O
who O O
underwent O O
PBSCT O O
were O O
studied O O
retrospectively O O
. O O

Urine O O
sediment O O
score O O
was O O
the O O
sum O O
of O O
the O O
individual O O
types O O
of O O
sediment O O
identified O O
on O O
urine O O
microscopy O O
. O O

RESULTS O O
: O O
Of O O
the O O
80 O O
patients O O
studied O O
, O O
ARI B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
developed O O
in O O
18 O O
. O O
8 O O
% O O
of O O
the O O
patients O O
after O O
high O O
- O O
dose O O
melphalan O O
. O O

Univariate O O
analysis O O
identified O O
age O O
, O O
hypoalbuminemia B B_DISEASE/B_PERSON
, O O
heavy O O
proteinuria B B_DISEASE
, O O
diuretic O O
use O O
, O O
and O O
urine O O
sediment O O
score O O
( O O
> O O
3 O O
) O O
as O O
risk O O
factors O O
. O O

Patients O O
who O O
had O O
ARI B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
high O O
- O O
dose O O
melphalan O O
underwent O O
dialysis O O
more O O
often O O
( O O
P O O
= O O
0 O O
. O O
007 O O
) O O
, O O
and O O
had O O
a O O
worse O O
1 O O
- O O
year O O
survival O O
( O O
P O O
= O O
0 O O
. O O
03 O O
) O O
. O O

CONCLUSION O O
: O O
The O O
timing O O
of O O
renal B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injury I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
strongly O O
suggests O O
melphalan O O
as O O
the O O
causative O O
agent O O
. O O

Ongoing O O
tubular B B_DISEASE
injury I I_DISEASE
may O O
be O O
a O O
prerequisite O O
for O O
renal B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injury I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O O
melphalan O O
as O O
evidenced O O
by O O
the O O
active O O
urinary O O
sediment O O
. O O

Development O O
of O O
ARI B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adversely O O
affected O O
the O O
outcome O O
after O O
PBSCT O O
. O O

Effective O O
preventive O O
measures O O
may O O
help O O
decrease O O
the O O
treatment O O
mortality O O
of O O
PBSCT O O
in O O
AL B B_LOCATION/B_DISEASE
patients O O
. O O

Focal O O
cerebral B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ischemia I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
rats O O
: O O
effect O O
of O O
phenylephrine O O
- O O
induced O O
hypertension B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
during O O
reperfusion O O
. O O

After O O
180 O O
min O O
of O O
temporary O O
middle B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cerebral I B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
artery I B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occlusion I B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
spontaneously O O
hypertensive B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rats O O
, O O
the O O
effect O O
of O O
phenylephrine O O
- O O
induced O O
hypertension B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
on O O
ischemic B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
brain I B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
injury I B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
blood O O
- O O
brain O O
barrier O O
permeability O O
was O O
determined O O
. O O

Part O O
A O O
, O O
for O O
eight O O
rats O O
in O O
each O O
group O O
brain B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
injury I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
was O O
evaluated O O
by O O
staining O O
tissue O O
using O O
2 O O
, O O
3 O O
, O O
5 O O
- O O
triphenyltetrazolium O O
chloride O O
and O O
edema B B_DISEASE
was O O
evaluated O O
by O O
microgravimetry O O
. O O

Brain B B_DISEASE/B_PERSON
injury I I_DISEASE/I_PERSON
( O O
percentage O O
of O O
the O O
ischemic B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
hemisphere I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
) O O
was O O
less O O
in O O
the O O
15 O O
/ O O
HTN B B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
group O O
( O O
16 O O
+ O O
/ O O
- O O
6 O O
, O O
mean O O
+ O O
/ O O
- O O
SD O O
) O O
versus O O
the O O
90 O O
/ O O
HTN B B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
group O O
( O O
30 O O
+ O O
/ O O
- O O
6 O O
) O O
, O O
which O O
was O O
in O O
turn O O
less O O
than O O
the O O
control O O
group O O
( O O
42 O O
+ O O
/ O O
- O O
5 O O
) O O
. O O

Evans O O
Blue O O
( O O
mug O O
g O O
- O O
1 O O
of O O
brain O O
tissue O O
) O O
was O O
greater O O
in O O
the O O
90 O O
/ O O
HTN B B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
group O O
( O O
24 O O
. O O
4 O O
+ O O
/ O O
- O O
6 O O
. O O
0 O O
) O O
versus O O
the O O
control O O
group O O
( O O
12 O O
. O O
3 O O
+ O O
/ O O
- O O
4 O O
. O O
1 O O
) O O
, O O
which O O
was O O
in O O
turn O O
greater O O
than O O
the O O
15 O O
/ O O
HTN B B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
group O O
( O O
7 O O
. O O
3 O O
+ O O
/ O O
- O O
3 O O
. O O
2 O O
) O O
. O O

This O O
study O O
supports O O
a O O
hypothesis O O
that O O
during O O
reperfusion O O
, O O
a O O
short O O
interval O O
of O O
hypertension B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decreases O O
brain B B_DISEASE/B_GENE
injury I I_DISEASE/I_GENE
and O O
edema B B_DISEASE
; O O
and O O
that O O
sustained O O
hypertension B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increases O O
the O O
risk O O
of O O
vasogenic B B_DISEASE
edema I I_DISEASE
. O O

People O O
aged O O
over O O
75 O O
in O O
atrial B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fibrillation I I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
warfarin O O
: O O
the O O
rate O O
of O O
major O O
hemorrhage B B_DISEASE
and O O
stroke B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
more O O
than O O
500 O O
patient O O
- O O
years O O
of O O
follow O O
- O O
up O O
. O O

OBJECTIVES O O
: O O
To O O
determine O O
the O O
incidence O O
of O O
major O O
hemorrhage B B_DISEASE
and O O
stroke B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
people O O
aged O O
76 O O
and O O
older O O
with O O
atrial B B_DISEASE
fibrillation I I_DISEASE
on O O
adjusted O O
- O O
dose O O
warfarin O O
who O O
had O O
been O O
recently O O
been O O
admitted O O
to O O
hospital O O
. O O

DESIGN O O
: O O
A O O
retrospective O O
observational O O
cohort O O
study O O
. O O

SETTING O O
: O O
A O O
major O O
healthcare O O
network O O
involving O O
four O O
tertiary O O
hospitals O O
. O O

PARTICIPANTS O O
: O O
Two O O
hundred O O
thirty O O
- O O
five O O
patients O O
aged O O
76 O O
and O O
older O O
admitted O O
to O O
a O O
major O O
healthcare O O
network O O
between O O
July O O
1 O O
, O O
2001 O O
, O O
and O O
June O O
30 O O
, O O
2002 O O
, O O
with O O
atrial B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fibrillation I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
warfarin O O
were O O
enrolled O O
. O O

MEASUREMENTS O O
: O O
Information O O
regarding O O
major O O
bleeding B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
episodes O O
, O O
strokes B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
warfarin O O
use O O
was O O
obtained O O
from O O
patients O O
, O O
relatives O O
, O O
primary O O
physicians O O
, O O
and O O
medical O O
records O O
. O O

RESULTS O O
: O O
Two O O
hundred O O
twenty O O
- O O
eight O O
patients O O
( O O
42 O O
% O O
men O O
) O O
with O O
a O O
mean O O
age O O
of O O
81 O O
. O O
1 O O
( O O
range O O
76 O O
- O O
94 O O
) O O
were O O
included O O
in O O
the O O
analysis O O
. O O

Total O O
follow O O
- O O
up O O
on O O
warfarin O O
was O O
530 O O
years O O
( O O
mean O O
28 O O
months O O
) O O
. O O

There O O
were O O
53 O O
major O O
hemorrhages B B_DISEASE
, O O
for O O
an O O
annual O O
rate O O
of O O
10 O O
. O O
0 O O
% O O
, O O
including O O
24 O O
( O O
45 O O
. O O
3 O O
% O O
) O O
life O O
- O O
threatening O O
and O O
five O O
( O O
9 O O
. O O
4 O O
% O O
) O O
fatal O O
bleeds O O
. O O

The O O
annual O O
stroke B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rate O O
after O O
initiation O O
of O O
warfarin O O
was O O
2 O O
. O O
6 O O
% O O
. O O

CONCLUSION O O
: O O
The O O
rate O O
of O O
major O O
hemorrhage B B_DISEASE
was O O
high O O
in O O
this O O
old O O
, O O
frail O O
group O O
, O O
but O O
excluding O O
fatalities O O
, O O
resulted O O
in O O
no O O
long O O
- O O
term O O
sequelae O O
, O O
and O O
the O O
stroke B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rate O O
on O O
warfarin O O
was O O
low O O
, O O
demonstrating O O
how O O
effective O O
warfarin O O
treatment O O
is O O
. O O

Safety O O
of O O
celecoxib O O
in O O
patients O O
with O O
adverse O O
skin B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reactions I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
acetaminophen O O
( O O
paracetamol O O
) O O
and O O
nimesulide O O
associated O O
or O O
not O O
with O O
common O O
non O O
- O O
steroidal O O
anti O O
- O O
inflammatory O O
drugs O O
. O O

The O O
rate O O
of O O
adverse O O
hypersensitivity B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
reactions O O
to O O
these O O
agents O O
is O O
generally O O
low O O
. O O

Celecoxib O O
( O O
CE O O
) O O
is O O
a O O
novel O O
drug O O
, O O
with O O
high O O
selectivity O O
and O O
affinity O O
for O O
COX O O
- O O
2 O O
enzyme O O
. O O

OBJECTIVE O O
: O O
We O O
evaluated O O
the O O
tolerability O O
of O O
CE O O
in O O
a O O
group O O
of O O
patients O O
with O O
documented O O
history O O
of O O
adverse O O
cutaneous B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reactions I B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
P O O
and O O
N O O
associated O O
or O O
not O O
to O O
classic O O
NSAIDs O O
. O O

METHODS O O
: O O
We O O
studied O O
9 O O
patients O O
with O O
hypersensitivity B B_DISEASE
to O O
P O O
and O O
N O O
with O O
or O O
without O O
associated O O
reactions O O
to O O
classic O O
NSAIDs O O
. O O

The O O
diagnosis O O
of O O
P O O
and O O
N O O
- O O
induced O O
skin B B_DISEASE
reactions I I_DISEASE
was O O
based O O
in O O
vivo O O
challenge O O
. O O

The O O
placebo O O
was O O
blindly O O
administered O O
at O O
the O O
beginning O O
of O O
each O O
challenge O O
. O O

After O O
three O O
days O O
, O O
a O O
cumulative O O
dosage O O
of O O
200 O O
mg O O
of O O
CE O O
in O O
refracted O O
doses O O
were O O
given O O
. O O

After O O
2 O O
- O O
3 O O
days O O
, O O
a O O
single O O
dose O O
of O O
200 O O
mg O O
was O O
administered O O
. O O

The O O
challenge O O
was O O
considered O O
positive O O
if O O
one O O
or O O
more O O
of O O
the O O
following O O
appeared O O
: O O
erythema B B_DISEASE
, O O
rush O O
or O O
urticaria B B_DISEASE
- O O
angioedema B B_DISEASE_ADJECTIVE[DISEASE]
. O O

Only O O
one O O
patient O O
developed O O
a O O
moderate O O
angioedema B B_DISEASE
of O O
the O O
lips O O
. O O

CONCLUSION O O
: O O
Only O O
one O O
hypersensitivity B B_DISEASE_ADJECTIVE[DISEASE]
reaction O O
to O O
CE O O
was O O
documented O O
among O O
9 O O
P O O
and O O
N O O
- O O
highly O O
NSAIDs O O
intolerant O O
patients O O
. O O

Thus O O
, O O
we O O
conclude O O
that O O
CE O O
is O O
a O O
reasonably O O
safe O O
alternative O O
to O O
be O O
used O O
in O O
subjects O O
who O O
do O O
not O O
tolerate O O
P O O
and O O
N O O
. O O

Case O O
- O O
control O O
study O O
of O O
regular O O
analgesic O O
and O O
nonsteroidal O O
anti O O
- O O
inflammatory O O
use O O
and O O
end B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stage I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
renal I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disease I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

BACKGROUND O O
: O O
Studies O O
on O O
the O O
association O O
between O O
the O O
long O O
- O O
term O O
use O O
of O O
aspirin O O
and O O
other O O
analgesic O O
and O O
nonsteroidal O O
anti O O
- O O
inflammatory O O
drugs O O
( O O
NSAIDs O O
) O O
and O O
end B B_DISEASE
- I I_DISEASE
stage I I_DISEASE
renal I I_DISEASE
disease I I_DISEASE
( O O
ESRD B B_DISEASE
) O O
have O O
given O O
conflicting O O
results O O
. O O

In O O
order O O
to O O
examine O O
this O O
association O O
, O O
a O O
case O O
- O O
control O O
study O O
with O O
incident O O
cases O O
of O O
ESRD B B_DISEASE/B_LOCATION
was O O
carried O O
out O O
. O O

METHODS O O
: O O
The O O
cases O O
were O O
all O O
patients O O
entering O O
the O O
local O O
dialysis O O
program O O
because O O
of O O
ESRD B B_DISEASE
in O O
the O O
study O O
area O O
between O O
June O O
1 O O
, O O
1995 O O
and O O
November O O
30 O O
, O O
1997 O O
. O O

They O O
were O O
classified O O
according O O
to O O
the O O
underlying O O
disease O O
, O O
which O O
had O O
presumably O O
led O O
them O O
to O O
ESRD B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Controls O O
were O O
patients O O
admitted O O
to O O
the O O
same O O
hospitals O O
from O O
where O O
the O O
cases O O
arose O O
, O O
also O O
matched O O
by O O
age O O
and O O
sex O O
. O O

RESULTS O O
: O O
Five O O
hundred O O
and O O
eighty O O
- O O
three O O
cases O O
and O O
1190 O O
controls O O
were O O
included O O
in O O
the O O
analysis O O
. O O

Long O O
- O O
term O O
use O O
of O O
any O O
analgesic O O
was O O
associated O O
with O O
an O O
overall O O
odds O O
ratio O O
of O O
1 O O
. O O
22 O O
( O O
95 O O
% O O
CI O O
, O O
0 O O
. O O
89 O O
- O O
1 O O
. O O
66 O O
) O O
. O O

For O O
specific O O
groups O O
of O O
drugs O O
, O O
the O O
risks O O
were O O
1 O O
. O O
56 O O
( O O
1 O O
. O O
05 O O
- O O
2 O O
. O O
30 O O
) O O
for O O
aspirin O O
, O O
1 O O
. O O
03 O O
( O O
0 O O
. O O
60 O O
- O O
1 O O
. O O
76 O O
) O O
for O O
pyrazolones O O
, O O
0 O O
. O O
80 O O
( O O
0 O O
. O O
39 O O
- O O
1 O O
. O O
63 O O
) O O
for O O
paracetamol O O
, O O
and O O
0 O O
. O O
94 O O
( O O
0 O O
. O O
57 O O
- O O
1 O O
. O O
56 O O
) O O
for O O
nonaspirin O O
NSAIDs O O
. O O

The O O
risk O O
of O O
ESRD B B_DISEASE
associated O O
with O O
aspirin O O
was O O
related O O
to O O
the O O
cumulated O O
dose O O
and O O
duration O O
of O O
use O O
, O O
and O O
it O O
was O O
particularly O O
high O O
among O O
the O O
subset O O
of O O
patients O O
with O O
vascular O O
nephropathy B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
as O O
underlying O O
disease O O
[ O O
2 O O
. O O
35 O O
( O O
1 O O
. O O
17 O O
- O O
4 O O
. O O
72 O O
) O O
] O O
. O O

CONCLUSION O O
: O O
Our O O
data O O
indicate O O
that O O
long O O
- O O
term O O
use O O
of O O
nonaspirin O O
analgesic O O
drugs O O
and O O
NSAIDs O O
is O O
not O O
associated O O
with O O
an O O
increased O O
risk O O
of O O
ESRD B B_DISEASE
. O O

However O O
, O O
the O O
chronic O O
use O O
of O O
aspirin O O
may O O
increase O O
the O O
risk O O
of O O
ESRD B B_DISEASE
. O O

Two O O
cases O O
of O O
amisulpride O O
overdose B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
: O O
a O O
cause O O
for O O
prolonged B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
QT I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
syndrome I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Two O O
cases O O
of O O
deliberate O O
self O O
- O O
poisoning B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
5 O O
g O O
and O O
3 O O
. O O
6 O O
g O O
of O O
amisulpride O O
, O O
respectively O O
, O O
are O O
reported O O
. O O

In O O
both O O
cases O O
, O O
QT B B_DISEASE
prolongation I I_DISEASE
and O O
hypocalcaemia B B_DISEASE
were O O
noted O O
. O O

The O O
QT B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prolongation I I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appeared O O
to O O
respond O O
to O O
administration O O
of O O
i O O
. O O
v O O
. O O
calcium O O
gluconate O O
. O O

Growth O O
- O O
associated O O
protein O O
43 O O
expression O O
in O O
hippocampal O O
molecular O O
layer O O
of O O
chronic O O
epileptic B B_DISEASE
rats O O
treated O O
with O O
cycloheximide O O
. O O

PURPOSE O O
: O O
GAP43 O O
has O O
been O O
thought O O
to O O
be O O
linked O O
with O O
mossy O O
fiber O O
sprouting O O
( O O
MFS O O
) O O
in O O
various O O
experimental O O
models O O
of O O
epilepsy B B_DISEASE
. O O

To O O
investigate O O
how O O
GAP43 O O
expression O O
( O O
GAP43 O O
- O O
ir O O
) O O
correlates O O
with O O
MFS O O
, O O
we O O
assessed O O
the O O
intensity O O
( O O
densitometry O O
) O O
and O O
extension O O
( O O
width O O
) O O
of O O
GAP43 O O
- O O
ir O O
in O O
the O O
inner O O
molecular O O
layer O O
of O O
the O O
dentate O O
gyrus O O
( O O
IML O O
) O O
of O O
rats O O
subject O O
to O O
status B B_DISEASE
epilepticus I I_DISEASE
induced O O
by O O
pilocarpine O O
( O O
Pilo O O
) O O
, O O
previously O O
injected O O
or O O
not O O
with O O
cycloheximide O O
( O O
CHX O O
) O O
, O O
which O O
has O O
been O O
shown O O
to O O
inhibit O O
MFS O O
. O O

METHODS O O
: O O
CHX O O
was O O
injected O O
before O O
the O O
Pilo O O
injection O O
in O O
adult O O
Wistar O O
rats O O
. O O

The O O
Pilo O O
group O O
was O O
injected O O
with O O
the O O
same O O
drugs O O
, O O
except O O
for O O
CHX O O
. O O

Animals O O
were O O
killed O O
between O O
30 O O
and O O
60 O O
days O O
later O O
, O O
and O O
brain O O
sections O O
were O O
processed O O
for O O
GAP43 O O
immunohistochemistry O O
. O O

RESULTS O O
: O O
Densitometry O O
showed O O
no O O
significant O O
difference O O
regarding O O
GAP43 O O
- O O
ir O O
in O O
the O O
IML O O
between O O
Pilo O O
, O O
CHX O O
+ O O
Pilo O O
, O O
and O O
control O O
groups O O
. O O

CONCLUSIONS O O
: O O
Our O O
current O O
finding O O
that O O
animals O O
in O O
the O O
CHX O O
+ O O
Pilo O O
group O O
have O O
a O O
GAP43 O O
- O O
ir O O
band O O
in O O
the O O
IML O O
, O O
similar O O
to O O
that O O
of O O
controls O O
, O O
reinforces O O
prior O O
data O O
on O O
the O O
blockade O O
of O O
MFS O O
in O O
these O O
animals O O
. O O

The O O
change O O
in O O
GAP43 O O
- O O
ir O O
present O O
in O O
Pilo O O
- O O
treated O O
animals O O
was O O
a O O
thinning O O
of O O
the O O
band O O
to O O
a O O
very O O
narrow O O
layer O O
just O O
above O O
the O O
granule O O
cell O O
layer O O
that O O
is O O
likely O O
to O O
be O O
associated O O
with O O
the O O
loss O O
of O O
hilar O O
cell O O
projections O O
that O O
express O O
GAP O O
- O O
43 O O
. O O

RATIONALE O O
: O O
Nicotine O O
and O O
caffeine O O
are O O
widely O O
consumed O O
licit O O
psychoactive O O
drugs O O
worldwide O O
. O O

Epidemiological O O
studies O O
showed O O
that O O
they O O
were O O
generally O O
used O O
concurrently O O
. O O

Although O O
some O O
studies O O
in O O
experimental O O
animals O O
indicate O O
clear O O
pharmacological O O
interactions O O
between O O
them O O
, O O
no O O
studies O O
have O O
shown O O
a O O
specific O O
interaction O O
on O O
anxiety B B_DISEASE_ADJECTIVE[DISEASE]
responses O O
. O O

OBJECTIVES O O
: O O
The O O
present O O
study O O
investigates O O
the O O
effects O O
of O O
nicotine O O
on O O
anxiety B B_DISEASE
induced O O
by O O
caffeine O O
and O O
another O O
anxiogenic O O
drug O O
, O O
pentylenetetrazole O O
, O O
in O O
mice O O
. O O

The O O
elevated O O
plus O O
- O O
maze O O
( O O
EPM O O
) O O
test O O
was O O
used O O
to O O
evaluate O O
the O O
effects O O
of O O
drugs O O
on O O
anxiety B B_DISEASE
. O O

After O O
15 O O
min O O
, O O
mice O O
were O O
evaluated O O
for O O
their O O
open O O
- O O
and O O
closed O O
- O O
arm O O
time O O
and O O
entries O O
on O O
the O O
EPM O O
for O O
a O O
10 O O
- O O
min O O
session O O
. O O

Locomotor O O
activity O O
was O O
recorded O O
for O O
individual O O
groups O O
by O O
using O O
the O O
same O O
treatment O O
protocol O O
with O O
the O O
EPM O O
test O O
. O O

RESULTS O O
: O O
Nicotine O O
( O O
0 O O
. O O
05 O O
- O O
0 O O
. O O
25 O O
mg O O
/ O O
kg O O
) O O
itself O O
did O O
not O O
produce O O
any O O
significant O O
effect O O
in O O
the O O
EPM O O
test O O
, O O
whereas O O
caffeine O O
( O O
70 O O
mg O O
/ O O
kg O O
) O O
and O O
pentylenetetrazole O O
( O O
30 O O
mg O O
/ O O
kg O O
) O O
produced O O
an O O
anxiogenic O O
effect O O
, O O
apparent O O
with O O
decreases O O
in O O
open O O
- O O
arm O O
time O O
and O O
entry O O
. O O

Nicotine O O
( O O
0 O O
. O O
25 O O
mg O O
/ O O
kg O O
) O O
pretreatment O O
blocked O O
the O O
caffeine O O
- O O
but O O
not O O
pentylenetetrazole O O
- O O
induced O O
anxiety B B_DISEASE
. O O

CONCLUSIONS O O
: O O
Our O O
results O O
suggest O O
that O O
the O O
antagonistic O O
effect O O
of O O
nicotine O O
on O O
caffeine O O
- O O
induced O O
anxiety B B_DISEASE
is O O
specific O O
to O O
caffeine O O
, O O
instead O O
of O O
a O O
non O O
- O O
specific O O
anxiolytic O O
effect O O
. O O

Thus O O
, O O
it O O
may O O
extend O O
the O O
current O O
findings O O
on O O
the O O
interaction O O
between O O
nicotine O O
and O O
caffeine O O
. O O

Long O O
term O O
hormone O O
therapy O O
for O O
perimenopausal O O
and O O
postmenopausal O O
women O O
. O O

BACKGROUND O O
: O O
Hormone O O
therapy O O
( O O
HT O O
) O O
is O O
widely O O
used O O
for O O
controlling O O
menopausal B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
symptoms I I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
has O O
also O O
been O O
used O O
for O O
the O O
management O O
and O O
prevention O O
of O O
cardiovascular B B_DISEASE
disease I I_DISEASE
, O O
osteoporosis B B_DISEASE
and O O
dementia B B_DISEASE
in O O
older O O
women O O
but O O
the O O
evidence O O
supporting O O
its O O
use O O
for O O
these O O
indications O O
is O O
largely O O
observational O O
. O O

OBJECTIVES O O
: O O
To O O
assess O O
the O O
effect O O
of O O
long O O
- O O
term O O
HT O O
on O O
mortality O O
, O O
heart B B_DISEASE
disease I I_DISEASE
, O O
venous B B_DISEASE
thromboembolism I I_DISEASE
, O O
stroke B B_DISEASE
, O O
transient B B_DISEASE
ischaemic I I_DISEASE
attacks I I_DISEASE
, O O
breast B B_DISEASE
cancer I I_DISEASE
, O O
colorectal B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cancer I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
ovarian B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cancer I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
endometrial B B_DISEASE
cancer I I_DISEASE
, O O
gallbladder B B_DISEASE
disease I I_DISEASE
, O O
cognitive O O
function O O
, O O
dementia B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
fractures B B_DISEASE
and O O
quality O O
of O O
life O O
. O O

SEARCH O O
STRATEGY O O
: O O
We O O
searched O O
the O O
following O O
databases O O
up O O
to O O
November O O
2004 O O
: O O
the O O
Cochrane O O
Menstrual O O
Disorders O O
and O O
Subfertility O O
Group O O
Trials O O
Register O O
, O O
Cochrane O O
Central O O
Register O O
of O O
Controlled O O
Trials O O
( O O
CENTRAL O O
) O O
, O O
MEDLINE O O
, O O
EMBASE O O
, O O
Biological O O
Abstracts O O
. O O

Relevant O O
non O O
- O O
indexed O O
journals O O
and O O
conference O O
abstracts O O
were O O
also O O
searched O O
. O O

SELECTION O O
CRITERIA O O
: O O
Randomised O O
double O O
- O O
blind O O
trials O O
of O O
HT O O
( O O
oestrogens O O
with O O
or O O
without O O
progestogens O O
) O O
versus O O
placebo O O
, O O
taken O O
for O O
at O O
least O O
one O O
year O O
by O O
perimenopausal O O
or O O
postmenopausal O O
women O O
. O O

DATA O O
COLLECTION O O
AND O O
ANALYSIS O O
: O O
Fifteen O O
RCTs O O
were O O
included O O
. O O

Trials O O
were O O
assessed O O
for O O
quality O O
and O O
two O O
review O O
authors O O
extracted O O
data O O
independently O O
. O O

They O O
calculated O O
risk O O
ratios O O
for O O
dichotomous O O
outcomes O O
and O O
weighted O O
mean O O
differences O O
for O O
continuous O O
outcomes O O
. O O

MAIN O O
RESULTS O O
: O O
All O O
the O O
statistically O O
significant O O
results O O
were O O
derived O O
from O O
the O O
two O O
biggest O O
trials O O
. O O

In O O
relatively O O
healthy O O
women O O
, O O
combined O O
continuous O O
HT O O
significantly O O
increased O O
the O O
risk O O
of O O
venous B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
thromboembolism I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
or O O
coronary O O
event O O
( O O
after O O
one O O
year O O
' O O
s O O
use O O
) O O
, O O
stroke B B_DISEASE
( O O
after O O
3 O O
years O O
) O O
, O O
breast B B_DISEASE
cancer I I_DISEASE
( O O
after O O
5 O O
years O O
) O O
and O O
gallbladder B B_DISEASE
disease I I_DISEASE
. O O

Long O O
- O O
term O O
oestrogen O O
- O O
only O O
HT O O
also O O
significantly O O
increased O O
the O O
risk O O
of O O
stroke B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
gallbladder B B_DISEASE/B_LOCATION
disease I I_DISEASE/I_LOCATION
. O O

Overall O O
, O O
the O O
only O O
statistically O O
significant O O
benefits O O
of O O
HT O O
were O O
a O O
decreased O O
incidence O O
of O O
fractures B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
colon B B_DISEASE
cancer I I_DISEASE
with O O
long O O
- O O
term O O
use O O
. O O

Among O O
relatively O O
healthy O O
women O O
over O O
65 O O
years O O
taking O O
continuous O O
combined O O
HT O O
, O O
there O O
was O O
a O O
statistically O O
significant O O
increase O O
in O O
the O O
incidence O O
of O O
dementia B B_DISEASE
. O O

Among O O
women O O
with O O
cardiovascular B B_DISEASE
disease I I_DISEASE
, O O
long O O
- O O
term O O
use O O
of O O
combined O O
continuous O O
HT O O
significantly O O
increased O O
the O O
risk O O
of O O
venous B B_DISEASE/B_LOCATION
thromboembolism I I_DISEASE/I_LOCATION
. O O

No O O
trials O O
focussed O O
specifically O O
on O O
younger O O
women O O
. O O

However O O
, O O
one O O
trial O O
analysed O O
subgroups O O
of O O
2839 O O
relatively O O
healthy O O
50 O O
to O O
59 O O
year O O
- O O
old O O
women O O
taking O O
combined O O
continuous O O
HT O O
and O O
1637 O O
taking O O
oestrogen O O
- O O
only O O
HT O O
, O O
versus O O
similar O O
- O O
sized O O
placebo O O
groups O O
. O O

The O O
only O O
significantly O O
increased O O
risk O O
reported O O
was O O
for O O
venous B B_DISEASE
thromboembolism I I_DISEASE
in O O
women O O
taking O O
combined O O
continuous O O
HT O O
; O O
their O O
absolute O O
risk O O
remained O O
very O O
low O O
. O O

AUTHORS O O
' O O
CONCLUSIONS O O
: O O
HT O O
is O O
not O O
indicated O O
for O O
the O O
routine O O
management O O
of O O
chronic B B_DISEASE/B_PROTEIN[GENE]
disease I B_DISEASE/I_PROTEIN[GENE]
. O O

We O O
need O O
more O O
evidence O O
on O O
the O O
safety O O
of O O
HT O O
for O O
menopausal O O
symptom O O
control O O
, O O
though O O
short O O
- O O
term O O
use O O
appears O O
to O O
be O O
relatively O O
safe O O
for O O
healthy O O
younger O O
women O O
. O O

Drug B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
liver I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injury I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
an O O
analysis O O
of O O
461 O O
incidences O O
submitted O O
to O O
the O O
Spanish O O
registry O O
over O O
a O O
10 O O
- O O
year O O
period O O
. O O

BACKGROUND O O
& O O
AIMS O O
: O O
Progress O O
in O O
the O O
understanding O O
of O O
susceptibility O O
factors O O
to O O
drug B B_DISEASE
- I I_DISEASE
induced I I_DISEASE
liver I I_DISEASE
injury I I_DISEASE
( O O
DILI B B_DISEASE
) O O
and O O
outcome O O
predictability O O
are O O
hampered O O
by O O
the O O
lack O O
of O O
systematic O O
programs O O
to O O
detect O O
bona O O
fide O O
cases O O
. O O

METHODS O O
: O O
A O O
cooperative O O
network O O
was O O
created O O
in O O
1994 O O
in O O
Spain O O
to O O
identify O O
all O O
suspicions O O
of O O
DILI B B_DISEASE
following O O
a O O
prospective O O
structured O O
report O O
form O O
. O O

The O O
liver B B_DISEASE
damage I I_DISEASE
was O O
characterized O O
according O O
to O O
hepatocellular O O
, O O
cholestatic B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
mixed O O
laboratory O O
criteria O O
and O O
to O O
histologic O O
criteria O O
when O O
available O O
. O O

Further O O
evaluation O O
of O O
causality O O
assessment O O
was O O
centrally O O
performed O O
. O O

RESULTS O O
: O O
Since O O
April O O
1994 O O
to O O
August O O
2004 O O
, O O
461 O O
out O O
of O O
570 O O
submitted O O
cases O O
, O O
involving O O
505 O O
drugs O O
, O O
were O O
deemed O O
to O O
be O O
related O O
to O O
DILI B B_DISEASE
. O O

The O O
antiinfective O O
group O O
of O O
drugs O O
was O O
the O O
more O O
frequently O O
incriminated O O
, O O
amoxicillin O O
- O O
clavulanate O O
accounting O O
for O O
the O O
12 O O
. O O
8 O O
% O O
of O O
the O O
whole O O
series O O
. O O

Indeed O O
, O O
the O O
incidence O O
of O O
liver O O
transplantation O O
and O O
death O O
in O O
this O O
group O O
was O O
11 O O
. O O
7 O O
% O O
if O O
patients O O
had O O
jaundice B B_DISEASE
at O O
presentation O O
, O O
whereas O O
the O O
corresponding O O
figure O O
was O O
3 O O
. O O
8 O O
% O O
in O O
nonjaundiced O O
patients O O
( O O
P O O
< O O
. O O
04 O O
) O O
. O O

Factors O O
associated O O
with O O
the O O
development O O
of O O
fulminant B B_DISEASE
hepatic I I_DISEASE
failure I I_DISEASE
were O O
female O O
sex O O
( O O
OR O O
= O O
25 O O
; O O
95 O O
% O O
CI O O
: O O
4 O O
. O O
1 O O
- O O
151 O O
; O O
P O O
< O O
. O O
0001 O O
) O O
, O O
hepatocellular O O
damage O O
( O O
OR O O
= O O
7 O O
. O O
9 O O
; O O
95 O O
% O O
CI O O
: O O
1 O O
. O O
6 O O
- O O
37 O O
; O O
P O O
< O O
. O O
009 O O
) O O
, O O
and O O
higher O O
baseline O O
plasma O O
bilirubin O O
value O O
( O O
OR O O
= O O
1 O O
. O O
15 O O
; O O
95 O O
% O O
CI O O
: O O
1 O O
. O O
09 O O
- O O
1 O O
. O O
22 O O
; O O
P O O
< O O
. O O
0001 O O
) O O
. O O

CONCLUSIONS O O
: O O
Patients O O
with O O
drug O O
- O O
induced O O
hepatocellular O O
jaundice B B_DISEASE
have O O
11 O O
. O O
7 O O
% O O
chance O O
of O O
progressing O O
to O O
death O O
or O O
transplantation O O
. O O

Amoxicillin O O
- O O
clavulanate O O
stands O O
out O O
as O O
the O O
most O O
common O O
drug O O
related O O
to O O
DILI B B_DISEASE
. O O

Morphological O O
evaluation O O
of O O
the O O
effect O O
of O O
d O O
- O O
ribose O O
on O O
adriamycin O O
- O O
evoked O O
cardiotoxicity B B_DISEASE
in O O
rats O O
. O O

The O O
influence O O
of O O
d O O
- O O
ribose O O
on O O
adriamycin O O
- O O
induced O O
myocardiopathy B B_DISEASE
in O O
rats O O
was O O
studied O O
. O O

Adriamycin O O
in O O
the O O
cumulative O O
dose O O
of O O
25 O O
mg O O
/ O O
kg O O
evoked O O
fully O O
developed O O
cardiac B B_DISEASE
toxicity I I_DISEASE
. O O

D O O
- O O
ribose O O
in O O
the O O
multiple O O
doses O O
of O O
200 O O
mg O O
/ O O
kg O O
did O O
not O O
influence O O
ADR O O
cardiotoxicity B B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
vivo O O
evidences O O
suggesting O O
the O O
role O O
of O O
oxidative O O
stress O O
in O O
pathogenesis O O
of O O
vancomycin O O
- O O
induced O O
nephrotoxicity B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
protection O O
by O O
erdosteine O O
. O O

The O O
aims O O
of O O
this O O
study O O
were O O
to O O
examine O O
vancomycin O O
( O O
VCM O O
) O O
- O O
induced O O
oxidative O O
stress O O
that O O
promotes O O
production O O
of O O
reactive O O
oxygen O O
species O O
( O O
ROS O O
) O O
and O O
to O O
investigate O O
the O O
role O O
of O O
erdosteine O O
, O O
an O O
expectorant O O
agent O O
, O O
which O O
has O O
also O O
antioxidant O O
properties O O
, O O
on O O
kidney O O
tissue O O
against O O
the O O
possible O O
VCM O O
- O O
induced O O
renal B B_DISEASE
impairment I I_DISEASE
in O O
rats O O
. O O

Rats O O
were O O
divided O O
into O O
three O O
groups O O
: O O
sham O O
, O O
VCM O O
and O O
VCM O O
plus O O
erdosteine O O
. O O

Erdosteine O O
was O O
administered O O
orally O O
. O O

VCM O O
administration O O
to O O
control O O
rats O O
significantly O O
increased O O
renal O O
malondialdehyde O O
( O O
MDA O O
) O O
and O O
urinary O O
N O O
- O O
acetyl O O
- O O
beta O O
- O O
d O O
- O O
glucosaminidase O O
( O O
NAG O O
, O O
a O O
marker O O
of O O
renal B B_DISEASE_ADJECTIVE[DISEASE]
tubular I I_DISEASE_ADJECTIVE[DISEASE]
injury I I_DISEASE_ADJECTIVE[DISEASE]
) O O
excretion O O
but O O
decreased O O
superoxide O O
dismutase O O
( O O
SOD O O
) O O
and O O
catalase O O
( O O
CAT O O
) O O
activities O O
. O O

Erdosteine O O
administration O O
with O O
VCM O O
injections O O
caused O O
significantly O O
decreased O O
renal O O
MDA O O
and O O
urinary O O
NAG O O
excretion O O
, O O
and O O
increased O O
SOD O O
activity O O
, O O
but O O
not O O
CAT O O
activity O O
in O O
renal O O
tissue O O
when O O
compared O O
with O O
VCM O O
alone O O
. O O

Erdosteine O O
showed O O
histopathological O O
protection O O
against O O
VCM O O
- O O
induced O O
nephrotoxicity B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

There O O
were O O
a O O
significant O O
dilatation O O
of O O
tubular O O
lumens O O
, O O
extensive O O
epithelial O O
cell O O
vacuolization O O
, O O
atrophy B B_DISEASE
, O O
desquamation B B_DISEASE
, O O
and O O
necrosis B B_DISEASE
in O O
VCM O O
- O O
treated O O
rats O O
more O O
than O O
those O O
of O O
the O O
control O O
and O O
the O O
erdosteine O O
groups O O
. O O

It O O
is O O
concluded O O
that O O
oxidative O O
tubular O O
damage O O
plays O O
an O O
important O O
role O O
in O O
the O O
VCM O O
- O O
induced O O
nephrotoxicity B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
modulation O O
of O O
oxidative O O
stress O O
with O O
erdosteine O O
reduces O O
the O O
VCM O O
- O O
induced O O
kidney B B_DISEASE_ADJECTIVE[DISEASE]
damage I I_DISEASE_ADJECTIVE[DISEASE]
both O O
at O O
the O O
biochemical O O
and O O
histological O O
levels O O
. O O

Gemfibrozil O O
- O O
lovastatin O O
therapy O O
for O O
primary O O
hyperlipoproteinemias B B_DISEASE
. O O

The O O
specific O O
aim O O
of O O
this O O
retrospective O O
, O O
observational O O
study O O
was O O
to O O
assess O O
safety O O
and O O
efficacy O O
of O O
long O O
- O O
term O O
( O O
21 O O
months O O
/ O O
patient O O
) O O
, O O
open O O
- O O
label O O
, O O
gemfibrozil O O
- O O
lovastatin O O
treatment O O
in O O
80 O O
patients O O
with O O
primary O O
mixed O O
hyperlipidemia B B_DISEASE
( O O
68 O O
% O O
of O O
whom O O
had O O
atherosclerotic B B_DISEASE
vascular I I_DISEASE
disease I I_DISEASE
) O O
. O O

Because O O
ideal O O
lipid O O
targets O O
were O O
not O O
reached O O
( O O
low O O
- O O
density O O
lipoprotein O O
( O O
LDL O O
) O O
cholesterol O O
less O O
than O O
130 O O
mg O O
/ O O
dl O O
, O O
high O O
- O O
density O O
lipoprotein O O
( O O
HDL O O
) O O
cholesterol O O
greater O O
than O O
35 O O
mg O O
/ O O
dl O O
, O O
or O O
total O O
cholesterol O O
/ O O
HDL O O
cholesterol O O
less O O
than O O
4 O O
. O O
5 O O
mg O O
/ O O
dl O O
) O O
with O O
diet O O
plus O O
a O O
single O O
drug O O
, O O
gemfibrozil O O
( O O
1 O O
. O O
2 O O
g O O
/ O O
day O O
) O O
- O O
lovastatin O O
( O O
primarily O O
20 O O
or O O
40 O O
mg O O
) O O
treatment O O
was O O
given O O
. O O

Follow O O
- O O
up O O
visits O O
were O O
scheduled O O
with O O
2 O O
- O O
drug O O
therapy O O
every O O
6 O O
to O O
8 O O
weeks O O
, O O
an O O
average O O
of O O
10 O O
. O O
3 O O
visits O O
per O O
patient O O
, O O
with O O
741 O O
batteries O O
of O O
6 O O
liver O O
function O O
tests O O
and O O
714 O O
creatine O O
phosphokinase O O
levels O O
measured O O
. O O

Only O O
1 O O
of O O
the O O
4 O O
, O O
446 O O
liver O O
function O O
tests O O
( O O
0 O O
. O O
02 O O
% O O
) O O
, O O
a O O
gamma O O
glutamyl O O
transferase O O
, O O
was O O
greater O O
than O O
or O O
equal O O
to O O
3 O O
times O O
the O O
upper O O
normal O O
limit O O
. O O

Of O O
the O O
714 O O
creatine O O
phosphokinase O O
levels O O
, O O
9 O O
% O O
were O O
high O O
; O O
only O O
1 O O
( O O
0 O O
. O O
1 O O
% O O
) O O
was O O
greater O O
than O O
or O O
equal O O
to O O
3 O O
times O O
the O O
upper O O
normal O O
limit O O
. O O

With O O
2 O O
- O O
drug O O
therapy O O
, O O
mean O O
total O O
cholesterol O O
decreased O O
22 O O
% O O
from O O
255 O O
to O O
200 O O
mg O O
/ O O
dl O O
, O O
triglyceride O O
levels O O
decreased O O
35 O O
% O O
from O O
236 O O
to O O
154 O O
mg O O
/ O O
dl O O
, O O
LDL O O
cholesterol O O
decreased O O
26 O O
% O O
from O O
176 O O
to O O
131 O O
mg O O
/ O O
dl O O
, O O
and O O
the O O
total O O
cholesterol O O
/ O O
HDL O O
cholesterol O O
ratio O O
decreased O O
24 O O
% O O
from O O
7 O O
. O O
1 O O
to O O
5 O O
. O O
4 O O
, O O
all O O
p O O
less O O
than O O
or O O
equal O O
to O O
0 O O
. O O
0001 O O
. O O

Myositis B B_DISEASE_ADJECTIVE[DISEASE]
, O O
attributable O O
to O O
the O O
drug O O
combination O O
and O O
symptomatic O O
enough O O
to O O
discontinue O O
it O O
, O O
occurred O O
in O O
3 O O
% O O
of O O
patients O O
, O O
and O O
in O O
1 O O
% O O
with O O
concurrent O O
high O O
creatine O O
phosphokinase O O
( O O
769 O O
U O O
/ O O
liter O O
) O O
; O O
no O O
patients O O
had O O
rhabdomyolysis B B_DISEASE
or O O
myoglobinuria B B_DISEASE
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O

Does O O
domperidone O O
potentiate O O
mirtazapine O O
- O O
associated O O
restless B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
legs I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
syndrome I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT

There O O
is O O
now O O
evidence O O
to O O
suggest O O
a O O
central O O
role O O
for O O
the O O
dopaminergic O O
system O O
in O O
restless B B_DISEASE
legs I I_DISEASE
syndrome I I_DISEASE
( O O
RLS B B_DISEASE
) O O
. O O

For O O
example O O
, O O
the O O
symptoms O O
of O O
RLS B B_DISEASE
can O O
be O O
dramatically O O
improved O O
by O O
levodopa O O
and O O
dopamine O O
agonists O O
, O O
whereas O O
central O O
dopamine O O
D2 O O
receptor O O
antagonists O O
can O O
induce O O
or O O
aggravate O O
RLS B B_DISEASE/B_MEASURE
symptoms O O
. O O

To O O
our O O
knowledge O O
, O O
there O O
is O O
no O O
previous O O
report O O
regarding O O
whether O O
domperidone O O
, O O
a O O
peripheral O O
dopamine O O
D2 O O
receptor O O
antagonist O O
, O O
can O O
also O O
induce O O
or O O
aggravate O O
symptoms O O
of O O
RLS B B_DISEASE
. O O

Mirtazapine O O
, O O
the O O
first O O
noradrenergic O O
and O O
specific O O
serotonergic O O
antidepressant O O
( O O
NaSSA O O
) O O
, O O
has O O
been O O
associated O O
with O O
RLS B B_DISEASE
in O O
several O O
recent O O
publications O O
. O O

The O O
authors O O
report O O
here O O
a O O
depressed O O
patient O O
comorbid O O
with O O
postprandial B B_DISEASE
dyspepsia I I_DISEASE
who O O
developed O O
RLS B B_DISEASE
after O O
mirtazapine O O
had O O
been O O
added O O
to O O
his O O
domperidone O O
therapy O O
. O O

Our O O
patient O O
started O O
to O O
have O O
symptoms O O
of O O
RLS B B_DISEASE
only O O
after O O
he O O
had O O
been O O
treated O O
with O O
mirtazapine O O
, O O
and O O
his O O
RLS B B_DISEASE/B_MEASURE
symptoms O O
resolved O O
completely O O
upon O O
discontinuation O O
of O O
his O O
mirtazapine O O
. O O

Such O O
a O O
temporal O O
relationship O O
between O O
the O O
use O O
of O O
mirtazapine O O
and O O
the O O
symptoms O O
of O O
RLS B B_DISEASE
in O O
our O O
patient O O
did O O
not O O
support O O
a O O
potentiating O O
effect O O
of O O
domperione O O
on O O
mirtazapine O O
- O O
associated O O
RLS B B_DISEASE
. O O

However O O
, O O
physicians O O
should O O
be O O
aware O O
of O O
the O O
possibility O O
that O O
mirtazapine O O
can O O
be O O
associated O O
with O O
RLS B B_DISEASE
in O O
some O O
individuals O O
, O O
especially O O
those O O
receiving O O
concomitant O O
dopamine O O
D2 O O
receptor O O
antagonists O O
. O O

Antiandrogenic O O
therapy O O
can O O
cause O O
coronary B B_DISEASE
arterial I I_DISEASE
disease I I_DISEASE
. O O

AIM O O
: O O
To O O
study O O
the O O
change O O
of O O
lipid O O
metabolism O O
by O O
antiandrogen O O
therapy O O
in O O
patients O O
with O O
prostate B B_DISEASE/B_LOCATION
cancer I I_DISEASE/I_LOCATION
. O O

MATERIALS O O
AND O O
METHODS O O
: O O
We O O
studied O O
with O O
a O O
2 O O
. O O
5 O O
years O O
follow O O
- O O
up O O
the O O
changes O O
in O O
plasma O O
cholesterols O O
( O O
C O O
) O O
, O O
triglycerides O O
( O O
TG O O
) O O
, O O
lipoproteins O O
( O O
LP O O
) O O
, O O
and O O
apolipoproteins O O
( O O
Apo O O
) O O
B O O
- O O
100 O O
, O O
A O O
- O O
I O O
, O O
and O O
A O O
- O O
II O O
pro O O
fi O O
les O O
in O O
24 O O
patients O O
of O O
mean O O
age O O
60 O O
years O O
with O O
low O O
risk O O
prostate B B_DISEASE
cancer I I_DISEASE
( O O
stage O O
: O O
T1cN0M0 O O
, O O
Gleason O O
score O O
: O O
2 O O
- O O
5 O O
) O O
during O O
treatment O O
with O O
cyproterone O O
acetate O O
( O O
CPA O O
) O O
without O O
surgical O O
management O O
or O O
radiation O O
therapy O O
. O O

RESULTS O O
: O O
Significant O O
decreases O O
of O O
HDL O O
- O O
C O O
, O O
Apo O O
A O O
- O O
I O O
and O O
Apo O O
A O O
- O O
II O O
and O O
an O O
increase O O
of O O
triglyceride O O
levels O O
in O O
VLDL O O
were O O
induced O O
by O O
CPA O O
. O O

After O O
a O O
period O O
of O O
2 O O
. O O
5 O O
years O O
on O O
CPA O O
treatment O O
, O O
four O O
patients O O
out O O
of O O
twenty O O
- O O
four O O
were O O
found O O
to O O
be O O
affected O O
by O O
coronary B B_DISEASE/B_LOCATION
heart I I_DISEASE/I_LOCATION
disease I I_DISEASE/I_LOCATION
. O O

CONCLUSIONS O O
: O O
Ischaemic O O
coronary B B_DISEASE
arteriosclerosis I I_DISEASE
with O O
an O O
incidence O O
rate O O
of O O
16 O O
. O O
6 O O
% O O
as O O
caused O O
by O O
prolonged O O
CPA O O
therapy O O
is O O
mediated O O
through O O
changes O O
in O O
HDL O O
cholesterol O O
, O O
Apo O O
A O O
- O O
I O O
and O O
Apo O O
A O O
- O O
II O O
pro O O
fi O O
les O O
, O O
other O O
than O O
the O O
well O O
- O O
known O O
hyperglyceridemic B B_DISEASE_ADJECTIVE[DISEASE]
effect I I_DISEASE_ADJECTIVE[DISEASE]
caused O O
by O O
estrogen O O
. O O

5 O O
- O O
Fluorouracil O O
cardiotoxicity B B_DISEASE
induced O O
by O O
alpha O O
- O O
fluoro O O
- O O
beta O O
- O O
alanine O O
. O O

Cardiotoxicity B B_DISEASE
is O O
a O O
rare O O
complication O O
occurring O O
during O O
5 O O
- O O
fluorouracil O O
( O O
5 O O
- O O
FU O O
) O O
treatment O O
for O O
malignancies B B_DISEASE
. O O

We O O
herein O O
report O O
the O O
case O O
of O O
a O O
70 O O
- O O
year O O
- O O
old O O
man O O
with O O
5 O O
- O O
FU O O
- O O
induced O O
cardiotoxicity B B_DISEASE
, O O
in O O
whom O O
a O O
high O O
serum O O
level O O
of O O
alpha O O
- O O
fluoro O O
- O O
beta O O
- O O
alanine O O
( O O
FBAL O O
) O O
was O O
observed O O
. O O

The O O
patient O O
, O O
who O O
had O O
unresectable O O
colon B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cancer I B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
metastases O O
to O O
the O O
liver O O
and O O
lung O O
, O O
was O O
referred O O
to O O
us O O
for O O
chemotherapy O O
from O O
an O O
affiliated O O
hospital O O
; O O
he O O
had O O
no O O
cardiac O O
history O O
. O O

After O O
admission O O
, O O
the O O
patient O O
received O O
a O O
continuous O O
intravenous O O
infusion O O
of O O
5 O O
- O O
FU O O
( O O
1000 O O
mg O O
/ O O
day O O
) O O
, O O
during O O
which O O
precordial B B_DISEASE
pain I I_DISEASE
with O O
right B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
bundle I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
branch I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
block I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occurred O O
concomitantly O O
with O O
a O O
high O O
serum O O
FBAL O O
concentration O O
of O O
1955 O O
ng O O
/ O O
ml O O
. O O

Both O O
the O O
precordial B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pain I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
electrocardiographic O O
changes O O
disappeared O O
spontaneously O O
after O O
the O O
discontinuation O O
of O O
5 O O
- O O
FU O O
. O O

As O O
the O O
precordial B B_DISEASE
pain I I_DISEASE
in O O
this O O
patient O O
was O O
considered O O
to O O
have O O
been O O
due O O
to O O
5 O O
- O O
FU O O
- O O
induced O O
cardiotoxicity B B_DISEASE
, O O
the O O
administration O O
of O O
5 O O
- O O
FU O O
was O O
abandoned O O
. O O

Instead O O
, O O
oral O O
administration O O
of O O
S O O
- O O
1 O O
( O O
a O O
derivative O O
of O O
5 O O
- O O
FU O O
) O O
, O O
at O O
200 O O
mg O O
/ O O
day O O
twice O O
a O O
week O O
, O O
was O O
instituted O O
, O O
because O O
S O O
- O O
1 O O
has O O
a O O
strong O O
inhibitory O O
effect O O
on O O
dihydropyrimidine O O
dehydrogenase O O
, O O
which O O
catalyzes O O
the O O
degradative O O
of O O
5 O O
- O O
FU O O
into O O
FBAL O O
. O O

The O O
serum O O
FBAL O O
concentration O O
subsequently O O
decreased O O
to O O
352 O O
ng O O
/ O O
ml O O
, O O
the O O
same O O
as O O
the O O
value O O
measured O O
on O O
the O O
first O O
day O O
of O O
S O O
- O O
1 O O
administration O O
. O O

Thereafter O O
, O O
no O O
cardiac B B_DISEASE_ADJECTIVE[DISEASE]
symptoms I I_DISEASE_ADJECTIVE[DISEASE]
were O O
observed O O
. O O

The O O
experience O O
of O O
this O O
case O O
, O O
together O O
with O O
a O O
review O O
of O O
the O O
literature O O
, O O
suggests O O
that O O
FBAL O O
is O O
related O O
to O O
5 O O
- O O
FU O O
- O O
induced O O
cardiotoxicity B B_DISEASE
. O O

S O O
- O O
1 O O
may O O
be O O
administered O O
safely O O
to O O
patients O O
with O O
5 O O
- O O
FU O O
- O O
induced O O
cardiotoxicity B B_DISEASE/B_LOCATION
. O O

The O O
case O O
of O O
an O O
11 O O
- O O
year O O
- O O
old O O
boy O O
is O O
reported O O
who O O
was O O
known O O
to O O
have O O
Fanconi B B_DISEASE
' I I_DISEASE
s I I_DISEASE
anemia I I_DISEASE
for O O
3 O O
years O O
and O O
was O O
treated O O
with O O
androgens O O
, O O
corticosteroids O O
and O O
transfusions O O
. O O

Two O O
weeks O O
before O O
his O O
death O O
he O O
was O O
readmitted O O
because O O
of O O
aplastic O O
crisis O O
with O O
septicemia B B_DISEASE
and O O
marked O O
abnormalities O O
in O O
liver O O
function O O
and O O
died O O
of O O
hemorrhagic B B_DISEASE
bronchopneumonia I I_DISEASE
. O O

At O O
autopsy O O
peliosis B B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
and O O
multiple O O
hepatic B B_DISEASE
tumors I I_DISEASE
were O O
found O O
which O O
histologically O O
proved O O
to O O
be O O
well O O
- O O
differentiated O O
hepatocellular B B_DISEASE
carcinoma I I_DISEASE
. O O

This O O
case O O
contributes O O
to O O
the O O
previous O O
observations O O
that O O
non O O
- O O
metastasizing O O
hepatic B B_DISEASE
neoplasms I I_DISEASE
and O O
peliosis B B_DISEASE
can O O
develop O O
in O O
patients O O
with O O
androgen O O
- O O
and O O
corticosteroid O O
- O O
treated O O
Fanconi B B_DISEASE/B_LOCATION
' I I_DISEASE/I_LOCATION
s I I_DISEASE/I_LOCATION
anemia I I_DISEASE/I_LOCATION
. O O

The O O
influence O O
of O O
the O O
time O O
interval O O
between O O
monoHER O O
and O O
doxorubicin O O
administration O O
on O O
the O O
protection O O
against O O
doxorubicin O O
- O O
induced O O
cardiotoxicity B B_DISEASE
in O O
mice O O
. O O

PURPOSE O O
: O O
Despite O O
its O O
well O O
- O O
known O O
cardiotoxicity B B_DISEASE
, O O
the O O
anthracyclin O O
doxorubicin O O
( O O
DOX O O
) O O
continues O O
to O O
be O O
an O O
effective O O
and O O
widely O O
used O O
chemotherapeutic O O
agent O O
. O O

DOX O O
- O O
induced O O
cardiac B B_DISEASE/B_GENE
damage I I_DISEASE/I_GENE
presumably O O
results O O
from O O
the O O
formation O O
of O O
free O O
radicals O O
by O O
DOX O O
. O O

The O O
semisynthetic O O
flavonoid O O
monohydroxyethylrutoside O O
( O O
monoHER O O
) O O
showed O O
cardioprotection O O
against O O
DOX O O
- O O
induced O O
cardiotoxicity B B_DISEASE
through O O
its O O
radical O O
scavenging O O
and O O
iron O O
chelating O O
properties O O
. O O

Because O O
of O O
the O O
relatively O O
short O O
final O O
half O O
- O O
life O O
of O O
monoHER O O
( O O
about O O
30 O O
min O O
) O O
, O O
it O O
is O O
expected O O
that O O
the O O
time O O
interval O O
between O O
monoHER O O
and O O
DOX O O
might O O
be O O
of O O
influence O O
on O O
the O O
cardioprotective O O
effect O O
of O O
monoHER O O
. O O

Therefore O O
, O O
the O O
aim O O
of O O
the O O
present O O
study O O
was O O
to O O
investigate O O
this O O
possible O O
effect O O
. O O

METHODS O O
: O O
Six O O
groups O O
of O O
6 O O
BALB O O
/ O O
c O O
mice O O
were O O
treated O O
with O O
saline O O
, O O
DOX O O
alone O O
or O O
DOX O O
( O O
4 O O
mg O O
/ O O
kg O O
i O O
. O O
v O O
. O O
) O O
preceded O O
by O O
monoHER O O
( O O
500 O O
mg O O
/ O O
kg O O
i O O
. O O
p O O
. O O
) O O
with O O
an O O
interval O O
of O O
10 O O
, O O
30 O O
, O O
60 O O
or O O
120 O O
min O O
. O O

After O O
a O O
6 O O
- O O
week O O
treatment O O
period O O
and O O
additional O O
observation O O
for O O
2 O O
weeks O O
, O O
the O O
mice O O
were O O
sacrificed O O
. O O

Their O O
cardiac O O
tissues O O
were O O
processed O O
for O O
light O O
microscopy O O
, O O
after O O
which O O
cardiomyocyte B B_DISEASE
damage I I_DISEASE
was O O
evaluated O O
according O O
to O O
Billingham O O
( O O
in O O
Cancer B B_DISEASE/B_GENE
Treat O O
Rep O O
62 O O
( O O
6 O O
) O O
: O O
865 O O
- O O
872 O O
, O O
1978 O O
) O O
. O O

Microscopic O O
evaluation O O
revealed O O
that O O
treatment O O
with O O
DOX O O
alone O O
induced O O
significant O O
cardiac B B_DISEASE_ADJECTIVE[DISEASE]
damage I I_DISEASE_ADJECTIVE[DISEASE]
in O O
comparison O O
to O O
the O O
saline O O
control O O
group O O
( O O
P O O
< O O
0 O O
. O O
001 O O
) O O
. O O

RESULTS O O
: O O
The O O
number O O
of O O
damaged O O
cardiomyocytes O O
was O O
9 O O
. O O
6 O O
- O O
fold O O
( O O
95 O O
% O O
CI O O
4 O O
. O O
4 O O
- O O
21 O O
. O O
0 O O
) O O
higher O O
in O O
mice O O
treated O O
with O O
DOX O O
alone O O
than O O
that O O
in O O
animals O O
of O O
the O O
control O O
group O O
. O O

This O O
protective O O
effect O O
did O O
not O O
depend O O
on O O
the O O
time O O
interval O O
between O O
monoHER O O
and O O
DOX O O
administration O O
( O O
P O O
= O O
0 O O
. O O
345 O O
) O O
. O O

CONCLUSION O O
: O O
The O O
results O O
indicate O O
that O O
in O O
an O O
outpatient O O
clinical O O
setting O O
monoHER O O
may O O
be O O
administered O O
shortly O O
before O O
DOX O O
. O O

Clinical O O
evaluation O O
of O O
adverse O O
effects O O
during O O
bepridil O O
administration O O
for O O
atrial B B_DISEASE
fibrillation I I_DISEASE
and I I_DISEASE
flutter I I_DISEASE
. O O

METHODS O O
AND O O
RESULTS O O
: O O
Adverse O O
effects O O
of O O
Bpd O O
requiring O O
discontinuation O O
of O O
treatment O O
were O O
evaluated O O
. O O

Bpd O O
was O O
administered O O
to O O
459 O O
patients O O
( O O
361 O O
males O O
, O O
63 O O
+ O O
/ O O
- O O
12 O O
years O O
old O O
) O O
comprising O O
378 O O
AF B B_DISEASE/B_LOCATION
and O O
81 O O
AFL B B_DISEASE
cases O O
. O O

Mean O O
left O O
ventricular O O
ejection O O
fraction O O
and O O
atrial O O
dimension O O
( O O
LAD O O
) O O
were O O
66 O O
+ O O
/ O O
- O O
11 O O
% O O
and O O
40 O O
+ O O
/ O O
- O O
6 O O
mm O O
, O O
respectively O O
. O O

There O O
was O O
marked O O
QT B B_DISEASE
prolongation I I_DISEASE
greater O O
than O O
0 O O
. O O
55 O O
s O O
in O O
13 O O
patients O O
, O O
bradycardia B B_DISEASE
less O O
than O O
40 O O
beats O O
/ O O
min O O
in O O
6 O O
patients O O
, O O
dizziness B B_DISEASE
and O O
general O O
fatigue B B_DISEASE
in O O
1 O O
patient O O
each O O
. O O

In O O
4 O O
of O O
13 O O
patients O O
with O O
QT B B_DISEASE
prolongation I I_DISEASE
, O O
Tdp B B_DISEASE/B_GENE
occurred O O
. O O

The O O
major O O
triggering O O
factors O O
of O O
Tdp B B_DISEASE/B_GENE
were O O
hypokalemia B B_DISEASE_ADJECTIVE[DISEASE]
and O O
sudden O O
decrease O O
in O O
heart O O
rate O O
. O O

There O O
were O O
no O O
differences O O
in O O
the O O
clinical O O
backgrounds O O
of O O
the O O
patients O O
with O O
and O O
without O O
Tdp B B_DISEASE/B_GENE
other O O
than O O
LAD O O
and O O
age O O
, O O
which O O
were O O
larger O O
and O O
older O O
in O O
the O O
patients O O
with O O
Tdp B B_DISEASE/B_GENE
. O O

CONCLUSION O O
: O O
Careful O O
observation O O
of O O
serum O O
potassium O O
concentration O O
and O O
the O O
ECG O O
should O O
always O O
be O O
done O O
during O O
Bpd O O
administration O O
, O O
particularly O O
in O O
elderly O O
patients O O
. O O

Enhanced O O
isoproterenol O O
- O O
induced O O
cardiac B B_DISEASE/B_GENE
hypertrophy I I_DISEASE/I_GENE
in O O
transgenic O O
rats O O
with O O
low O O
brain O O
angiotensinogen O O
. O O

In O O
this O O
study O O
we O O
aimed O O
at O O
studying O O
the O O
involvement O O
of O O
the O O
brain O O
RAS O O
in O O
the O O
cardiac O O
reactivity O O
to O O
the O O
beta O O
- O O
adrenoceptor O O
( O O
beta O O
- O O
AR O O
) O O
agonist O O
isoproterenol O O
( O O
Iso O O
) O O
. O O

LV B B_DISEASE
hypertrophy I I_DISEASE
induced O O
by O O
Iso O O
treatment O O
was O O
significantly O O
higher O O
in O O
TGR O O
than O O
in O O
SD O O
rats O O
( O O
in O O
g O O
LV O O
wt O O
/ O O
100 O O
g O O
body O O
wt O O
, O O
0 O O
. O O
28 O O
+ O O
/ O O
- O O
0 O O
. O O
004 O O
vs O O
. O O
0 O O
. O O
24 O O
+ O O
/ O O
- O O
0 O O
. O O
004 O O
, O O
respectively O O
) O O
. O O

The O O
greater O O
LV B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hypertrophy I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
TGR O O
rats O O
was O O
associated O O
with O O
more O O
pronounced O O
downregulation O O
of O O
beta O O
- O O
AR O O
and O O
upregulation O O
of O O
LV O O
beta O O
- O O
AR O O
kinase O O
- O O
1 O O
mRNA O O
levels O O
compared O O
with O O
those O O
in O O
SD O O
rats O O
. O O

These O O
results O O
indicate O O
that O O
TGR O O
are O O
more O O
sensitive O O
to O O
beta O O
- O O
AR O O
agonist O O
- O O
induced O O
cardiac B B_DISEASE_ADJECTIVE[DISEASE]
inotropic I I_DISEASE_ADJECTIVE[DISEASE]
response O O
and O O
hypertrophy B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
possibly O O
due O O
to O O
chronically O O
low O O
sympathetic O O
outflow O O
directed O O
to O O
the O O
heart O O
. O O

Drug O O
- O O
induced O O
long B B_DISEASE
QT I I_DISEASE
syndrome I I_DISEASE
in O O
injection O O
drug O O
users O O
receiving O O
methadone O O
: O O
high O O
frequency O O
in O O
hospitalized O O
patients O O
and O O
risk O O
factors O O
. O O

BACKGROUND O O
: O O
Drug O O
- O O
induced O O
long B B_DISEASE
QT I I_DISEASE
syndrome I I_DISEASE
is O O
a O O
serious O O
adverse O O
drug O O
reaction O O
. O O

In O O
the O O
inpatient O O
setting O O
, O O
the O O
frequency O O
of O O
QT B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interval I I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prolongation I I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
methadone O O
treatment O O
, O O
its O O
dose O O
dependence O O
, O O
and O O
the O O
importance O O
of O O
cofactors O O
such O O
as O O
drug O O
- O O
drug O O
interactions O O
remain O O
unknown O O
. O O

METHODS O O
: O O
We O O
performed O O
a O O
systematic O O
, O O
retrospective O O
study O O
comparing O O
active O O
or O O
former O O
intravenous O O
drug O O
users O O
receiving O O
methadone O O
and O O
those O O
not O O
receiving O O
methadone O O
among O O
all O O
patients O O
hospitalized O O
over O O
a O O
5 O O
- O O
year O O
period O O
in O O
a O O
tertiary O O
care O O
hospital O O
. O O

A O O
total O O
of O O
167 O O
patients O O
receiving O O
methadone O O
fulfilled O O
the O O
inclusion O O
criteria O O
and O O
were O O
compared O O
with O O
a O O
control O O
group O O
of O O
80 O O
injection O O
drug O O
users O O
not O O
receiving O O
methadone O O
. O O

In O O
addition O O
to O O
methadone O O
dose O O
, O O
15 O O
demographic O O
, O O
biological O O
, O O
and O O
pharmacological O O
variables O O
were O O
considered O O
as O O
potential O O
risk O O
factors O O
for O O
QT B B_DISEASE
prolongation I I_DISEASE
. O O

RESULTS O O
: O O
Among O O
167 O O
methadone O O
maintenance O O
patients O O
, O O
the O O
prevalence O O
of O O
QTc O O
prolongation O O
to O O
0 O O
. O O
50 O O
second O O
( O O
( O O
1 O O
/ O O
2 O O
) O O
) O O
or O O
longer O O
was O O
16 O O
. O O
2 O O
% O O
compared O O
with O O
0 O O
% O O
in O O
80 O O
control O O
subjects O O
. O O

Six O O
patients O O
( O O
3 O O
. O O
6 O O
% O O
) O O
in O O
the O O
methadone O O
group O O
presented O O
torsades B B_DISEASE
de I I_DISEASE
pointes I I_DISEASE
. O O

Multivariate O O
regression O O
analysis O O
allowed O O
attribution O O
of O O
31 O O
. O O
8 O O
% O O
of O O
QTc O O
variability O O
to O O
methadone O O
dose O O
, O O
cytochrome O O
P O O
- O O
450 O O
3A4 O O
drug O O
- O O
drug O O
interactions O O
, O O
hypokalemia B B_DISEASE/B_PERSON
, O O
and O O
altered O O
liver O O
function O O
. O O

CONCLUSIONS O O
: O O
QT B B_DISEASE
interval I I_DISEASE
prolongation I I_DISEASE
in O O
methadone O O
maintenance O O
patients O O
hospitalized O O
in O O
a O O
tertiary O O
care O O
center O O
is O O
a O O
frequent O O
finding O O
. O O

Methadone O O
dose O O
, O O
presence O O
of O O
cytochrome O O
P O O
- O O
450 O O
3A4 O O
inhibitors O O
, O O
potassium O O
level O O
, O O
and O O
liver O O
function O O
contribute O O
to O O
QT B B_DISEASE
prolongation I I_DISEASE
. O O

Long B B_DISEASE
QT I I_DISEASE
syndrome I I_DISEASE
can O O
occur O O
with O O
low O O
doses O O
of O O
methadone O O
. O O

Mechanisms O O
of O O
hypertension B B_DISEASE
induced O O
by O O
nitric O O
oxide O O
( O O
NO O O
) O O
deficiency O O
: O O
focus O O
on O O
venous O O
function O O
. O O

Loss O O
of O O
endothelial O O
cell O O
- O O
derived O O
nitric O O
oxide O O
( O O
NO O O
) O O
in O O
hypertension B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
is O O
a O O
hallmark O O
of O O
arterial B B_DISEASE
dysfunction I I_DISEASE
. O O

Experimental O O
hypertension B B_DISEASE
created O O
by O O
the O O
removal O O
of O O
NO O O
, O O
however O O
, O O
involves O O
mechanisms O O
in O O
addition O O
to O O
decreased O O
arterial O O
vasodilator O O
activity O O
. O O

We O O
hypothesized O O
that O O
increased O O
venous O O
smooth O O
muscle O O
( O O
venomotor O O
) O O
tone O O
plays O O
a O O
role O O
in O O
Nomega O O
- O O
nitro O O
- O O
L O O
- O O
arginine O O
( O O
LNNA O O
) O O
hypertension B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
through O O
these O O
mechanisms O O
. O O

Rats O O
were O O
treated O O
with O O
the O O
NO O O
synthase O O
inhibitor O O
LNNA O O
( O O
0 O O
. O O
5 O O
g O O
/ O O
L O O
in O O
drinking O O
water O O
) O O
for O O
2 O O
weeks O O
. O O

Carotid O O
arteries O O
and O O
vena O O
cava O O
were O O
removed O O
for O O
measurement O O
of O O
isometric O O
contraction O O
. O O

Maximum O O
contraction O O
of O O
vena O O
cava O O
to O O
norepinephrine O O
( O O
37 O O
% O O
control O O
) O O
also O O
was O O
reduced O O
but O O
no O O
change O O
in O O
response O O
to O O
ET O O
- O O
1 O O
was O O
observed O O
. O O

Similarly O O
, O O
ganglionic O O
blockade O O
with O O
hexamethonium O O
caused O O
a O O
significantly O O
greater O O
fall O O
in O O
LNNA O O
hypertensive B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rats O O
( O O
76 O O
+ O O
/ O O
- O O
9 O O
mm O O
Hg O O
) O O
compared O O
with O O
control O O
rats O O
( O O
35 O O
+ O O
/ O O
- O O
10 O O
mm O O
Hg O O
) O O
. O O

These O O
data O O
suggest O O
that O O
while O O
NO O O
deficiency O O
increases O O
oxidative O O
stress O O
and O O
sympathetic O O
activity O O
in O O
both O O
arterial O O
and O O
venous O O
vessels O O
, O O
the O O
impact O O
on O O
veins O O
does O O
not O O
make O O
a O O
major O O
contribution O O
to O O
this O O
form O O
of O O
hypertension B B_DISEASE
. O O

Association O O
of O O
DRD2 O O
polymorphisms O O
and O O
chlorpromazine O O
- O O
induced O O
extrapyramidal B B_DISEASE
syndrome I I_DISEASE
in O O
Chinese O O
schizophrenic B B_DISEASE/B_PERSON
patients O O
. O O

AIM O O
: O O
Extrapyramidal B B_DISEASE
syndrome I I_DISEASE
( O O
EPS B B_DISEASE
) O O
is O O
most O O
commonly O O
affected O O
by O O
typical O O
antipsychotic O O
drugs O O
that O O
have O O
a O O
high O O
affinity O O
with O O
the O O
D2 O O
receptor O O
. O O

Recently O O
, O O
many O O
research O O
groups O O
have O O
reported O O
on O O
the O O
positive O O
relationship O O
between O O
the O O
genetic O O
variations O O
in O O
the O O
DRD2 O O
gene O O
and O O
the O O
therapeutic O O
response O O
in O O
schizophrenia B B_DISEASE/B_LOCATION
patients O O
as O O
a O O
result O O
of O O
the O O
role O O
of O O
variations O O
in O O
the O O
receptor O O
in O O
modulating O O
receptor O O
expression O O
. O O

In O O
this O O
study O O
, O O
we O O
evaluate O O
the O O
role O O
DRD2 O O
plays O O
in O O
chlorpromazine O O
- O O
induced O O
EPS B B_DISEASE
in O O
schizophrenic B B_DISEASE/B_LOCATION
patients O O
. O O

The O O
alleles O O
of O O
all O O
loci O O
were O O
determined O O
by O O
PCR O O
( O O
polymerase O O
chain O O
reaction O O
) O O
. O O

RESULTS O O
: O O
Polymorphisms O O
TaqID O O
, O O
Ser311Cys O O
and O O
rs6277 O O
were O O
not O O
polymorphic O O
in O O
the O O
population O O
recruited O O
in O O
the O O
present O O
study O O
. O O

No O O
statistical O O
significance O O
was O O
found O O
in O O
the O O
allele O O
distribution O O
of O O
- O O
141Cins O O
> O O
del O O
, O O
TaqIB O O
, O O
rs6275 O O
and O O
TaqIA O O
or O O
in O O
the O O
estimated O O
haplotypes O O
( O O
constituted O O
by O O
TaqIB O O
, O O
rs6275 O O
and O O
TaqIA O O
) O O
in O O
linkage O O
disequilibrium O O
between O O
the O O
two O O
groups O O
. O O

CONCLUSION O O
: O O
Our O O
results O O
did O O
not O O
lend O O
strong O O
support O O
to O O
the O O
view O O
that O O
the O O
genetic O O
variation O O
of O O
the O O
DRD2 O O
gene O O
plays O O
a O O
major O O
role O O
in O O
the O O
individually O O
variable O O
adverse O O
effect O O
induced O O
by O O
chlorpromazine O O
, O O
at O O
least O O
in O O
Chinese O O
patients O O
with O O
schizophrenia B B_DISEASE/B_LOCATION
. O O

Our O O
results O O
confirmed O O
a O O
previous O O
study O O
on O O
the O O
relationship O O
between O O
DRD2 O O
and O O
EPS B B_DISEASE/B_LOCATION
in O O
Caucasians O O
. O O

Physical O O
training O O
decreases O O
susceptibility O O
to O O
subsequent O O
pilocarpine O O
- O O
induced O O
seizures B B_DISEASE
in O O
the O O
rat O O
. O O

Regular O O
motor O O
activity O O
has O O
many O O
benefits O O
for O O
mental O O
and O O
physical O O
condition O O
but O O
its O O
implications O O
for O O
epilepsy B B_DISEASE
are O O
still O O
controversial O O
. O O

In O O
order O O
to O O
elucidate O O
this O O
problem O O
, O O
we O O
have O O
studied O O
the O O
effect O O
of O O
long O O
- O O
term O O
physical O O
activity O O
on O O
susceptibility O O
to O O
subsequent O O
seizures B B_DISEASE
. O O

Male O O
Wistar O O
rats O O
were O O
subjected O O
to O O
repeated O O
training O O
sessions O O
in O O
a O O
treadmill O O
and O O
swimming O O
pool O O
. O O

Thereafter O O
, O O
seizures B B_DISEASE
were O O
induced O O
by O O
pilocarpine O O
injections O O
in O O
trained O O
and O O
non O O
- O O
trained O O
control O O
groups O O
. O O

During O O
the O O
acute O O
period O O
of O O
status B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
epilepticus I B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
we O O
measured O O
: O O
( O O
1 O O
) O O
the O O
latency O O
of O O
the O O
first O O
motor O O
sign O O
, O O
( O O
2 O O
) O O
the O O
intensity O O
of O O
seizures B B_DISEASE
, O O
( O O
3 O O
) O O
the O O
time O O
when O O
it O O
occurred O O
within O O
the O O
6 O O
- O O
h O O
observation O O
period O O
, O O
and O O
( O O
4 O O
) O O
the O O
time O O
when O O
the O O
acute O O
period O O
ended O O
. O O

All O O
these O O
behavioral O O
parameters O O
showed O O
statistically O O
significant O O
changes O O
suggesting O O
that O O
regular O O
physical O O
exercises O O
decrease O O
susceptibility O O
to O O
subsequently O O
induced O O
seizures B B_DISEASE
and O O
ameliorate O O
the O O
course O O
of O O
experimentally O O
induced O O
status B B_DISEASE
epilepticus I I_DISEASE
. O O

Endogenous O O
dopamine O O
plays O O
a O O
central O O
role O O
in O O
salience O O
coding O O
during O O
associative O O
learning O O
. O O

Administration O O
of O O
the O O
dopamine O O
precursor O O
levodopa O O
enhances O O
learning O O
in O O
healthy O O
subjects O O
and O O
stroke B B_DISEASE
patients O O
. O O

We O O
here O O
probed O O
how O O
selective O O
tonic O O
dopaminergic O O
stimulation O O
affects O O
associative O O
learning O O
. O O

Forty O O
healthy O O
subjects O O
were O O
trained O O
in O O
a O O
novel O O
vocabulary O O
of O O
45 O O
concrete O O
nouns O O
over O O
the O O
course O O
of O O
5 O O
consecutive O O
training O O
days O O
in O O
a O O
prospective O O
, O O
randomized O O
, O O
double O O
- O O
blind O O
, O O
placebo O O
- O O
controlled O O
design O O
. O O

Subjects O O
received O O
the O O
tonically O O
stimulating O O
dopamine O O
- O O
receptor O O
agonist O O
pergolide O O
( O O
0 O O
. O O
1 O O
mg O O
) O O
vs O O
placebo O O
120 O O
min O O
before O O
training O O
on O O
each O O
training O O
day O O
. O O

The O O
dopamine O O
agonist O O
significantly O O
impaired B B_DISEASE_ADJECTIVE[DISEASE]
novel I I_DISEASE_ADJECTIVE[DISEASE]
word I I_DISEASE_ADJECTIVE[DISEASE]
learning I I_DISEASE_ADJECTIVE[DISEASE]
compared O O
to O O
placebo O O
. O O

This O O
learning O O
decrement O O
persisted O O
up O O
to O O
the O O
last O O
follow O O
- O O
up O O
4 O O
weeks O O
post O O
- O O
training O O
. O O

Subjects O O
treated O O
with O O
pergolide O O
also O O
showed O O
restricted O O
emotional O O
responses O O
compared O O
to O O
the O O
PLACEBO O O
group O O
. O O

The O O
extent O O
of O O
' O O
flattened O O
' O O
affect O O
with O O
pergolide O O
was O O
related O O
to O O
the O O
degree O O
of O O
learning O O
inhibition O O
. O O

These O O
findings O O
suggest O O
that O O
tonic O O
occupation O O
of O O
dopamine O O
receptors O O
impairs O O
learning O O
by O O
competition O O
with O O
phasic O O
dopamine O O
signals O O
. O O

Thus O O
, O O
phasic O O
signaling O O
seems O O
to O O
be O O
the O O
critical O O
mechanism O O
by O O
which O O
dopamine O O
enhances O O
associative O O
learning O O
in O O
healthy O O
subjects O O
and O O
stroke B B_DISEASE
patients O O
. O O

Minocycline O O
- O O
induced O O
vasculitis B B_DISEASE
fulfilling O O
the O O
criteria O O
of O O
polyarteritis B B_DISEASE
nodosa I I_DISEASE
. O O

A O O
47 O O
- O O
year O O
- O O
old O O
man O O
who O O
had O O
been O O
taking O O
minocycline O O
for O O
palmoplantar B B_DISEASE
pustulosis I I_DISEASE
developed O O
fever B B_DISEASE
, O O
myalgias B B_DISEASE
, O O
polyneuropathy B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
testicular B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pain I I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
with O O
elevated O O
C O O
- O O
reactive O O
protein O O
( O O
CRP O O
) O O
. O O

Neither O O
myeloperoxidase O O
- O O
nor O O
proteinase O O
- O O
3 O O
- O O
antineutrophil O O
cytoplasmic O O
antibody O O
was O O
positive O O
. O O

These O O
manifestations O O
met O O
the O O
American O O
College O O
of O O
Rheumatology O O
1990 O O
criteria O O
for O O
the O O
classification O O
of O O
polyarteritis B B_DISEASE/B_LOCATION
nodosa I I_DISEASE/I_LOCATION
. O O

To O O
our O O
knowledge O O
, O O
this O O
is O O
the O O
second O O
case O O
of O O
minocycline O O
- O O
induced O O
vasculitis B B_DISEASE
satisfying O O
the O O
criteria O O
. O O

Differential O O
diagnosis O O
for O O
drug O O
- O O
induced O O
disease O O
is O O
invaluable O O
even O O
for O O
patients O O
with O O
classical O O
polyarteritis B B_DISEASE
nodosa I I_DISEASE
. O O

Intramuscular O O
hepatitis B B_DISEASE_ADJECTIVE[DISEASE]
B I I_DISEASE_ADJECTIVE[DISEASE]
immune O O
globulin O O
combined O O
with O O
lamivudine O O
in O O
prevention O O
of O O
hepatitis B B_DISEASE
B I I_DISEASE
recurrence O O
after O O
liver O O
transplantation O O
. O O

BACKGROUND O O
: O O
Combined O O
hepatitis B B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
B I B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
immune O O
globulin O O
( O O
HBIg O O
) O O
and O O
lamivudine O O
in O O
prophylaxis O O
of O O
the O O
recurrence O O
of O O
hepatitis B B_DISEASE
B I I_DISEASE
after O O
liver O O
transplantation O O
has O O
significantly O O
improved O O
the O O
survival O O
of O O
HBsAg O O
positive O O
patients O O
. O O

This O O
study O O
was O O
undertaken O O
to O O
evaluate O O
the O O
outcomes O O
of O O
liver O O
transplantation O O
for O O
patients O O
with O O
hepatitis B B_DISEASE
B I I_DISEASE
virus O O
( O O
HBV O O
) O O
. O O

METHODS O O
: O O
A O O
retrospective O O
chart O O
analysis O O
and O O
a O O
review O O
of O O
the O O
organ O O
transplant O O
database O O
identified O O
51 O O
patients O O
( O O
43 O O
men O O
and O O
8 O O
women O O
) O O
transplanted O O
for O O
benign O O
HBV O O
- O O
related O O
cirrhotic B B_DISEASE
diseases I I_DISEASE
between O O
June O O
2002 O O
and O O
December O O
2004 O O
who O O
had O O
survived O O
more O O
than O O
3 O O
months O O
. O O

HBIg O O
was O O
administered O O
intravenously O O
during O O
the O O
first O O
week O O
and O O
intramuscularly O O
thereafter O O
. O O

Intramuscular O O
HBIg O O
was O O
well O O
tolerated O O
in O O
all O O
patients O O
. O O

Anticonvulsant O O
effect O O
of O O
eslicarbazepine O O
acetate O O
( O O
BIA O O
2 O O
- O O
093 O O
) O O
on O O
seizures B B_DISEASE
induced O O
by O O
microperfusion O O
of O O
picrotoxin O O
in O O
the O O
hippocampus O O
of O O
freely O O
moving O O
rats O O
. O O

Eslicarbazepine O O
acetate O O
( O O
BIA O O
2 O O
- O O
093 O O
, O O
S O O
- O O
( O O
- O O
) O O
- O O
10 O O
- O O
acetoxy O O
- O O
10 O O
, O O
11 O O
- O O
dihydro O O
- O O
5H O O
- O O
dibenzo O O
/ O O
b O O
, O O
f O O
/ O O
azepine O O
- O O
5 O O
- O O
carboxamide O O
) O O
is O O
a O O
novel O O
antiepileptic O O
drug O O
, O O
now O O
in O O
Phase O O
III O O
clinical O O
trials O O
, O O
designed O O
with O O
the O O
aim O O
of O O
improving O O
efficacy O O
and O O
safety O O
in O O
comparison O O
with O O
the O O
structurally O O
related O O
drugs O O
carbamazepine O O
( O O
CBZ O O
) O O
and O O
oxcarbazepine O O
( O O
OXC O O
) O O
. O O

We O O
have O O
studied O O
the O O
effects O O
of O O
oral O O
treatment O O
with O O
eslicarbazepine O O
acetate O O
on O O
a O O
whole O O
- O O
animal O O
model O O
in O O
which O O
partial O O
seizures B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
can O O
be O O
elicited O O
repeatedly O O
on O O
different O O
days O O
without O O
changes O O
in O O
threshold O O
or O O
seizure B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
patterns O O
. O O

In O O
the O O
animals O O
treated O O
with O O
threshold O O
doses O O
of O O
picrotoxin O O
, O O
the O O
average O O
number O O
of O O
seizures B B_DISEASE
was O O
2 O O
. O O
3 O O
+ O O
/ O O
- O O
1 O O
. O O
2 O O
, O O
and O O
average O O
seizure B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
duration O O
was O O
39 O O
. O O
5 O O
+ O O
/ O O
- O O
8 O O
. O O
4s O O
. O O

Pre O O
- O O
treatment O O
with O O
a O O
dose O O
of O O
30 O O
mg O O
/ O O
kg O O
2h O O
before O O
picrotoxin O O
microperfusion O O
prevented O O
seizures B B_DISEASE
in O O
the O O
75 O O
% O O
of O O
the O O
rats O O
. O O

Lower O O
doses O O
( O O
3 O O
and O O
10mg O O
/ O O
kg O O
) O O
did O O
not O O
suppress O O
seizures B B_DISEASE
, O O
however O O
, O O
after O O
administration O O
of O O
10mg O O
/ O O
kg O O
, O O
significant O O
reductions O O
in O O
seizures B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
duration O O
( O O
24 O O
. O O
3 O O
+ O O
/ O O
- O O
6 O O
. O O
8s O O
) O O
and O O
seizure B B_DISEASE/B_MEASURE
number O O
( O O
1 O O
. O O
6 O O
+ O O
/ O O
- O O
0 O O
. O O
34 O O
) O O
were O O
found O O
. O O

Acute B B_DISEASE_ADJECTIVE[DISEASE]
renal I I_DISEASE_ADJECTIVE[DISEASE]
failure I I_DISEASE_ADJECTIVE[DISEASE]
associated O O
with O O
prolonged O O
intake O O
of O O
slimming O O
pills O O
containing O O
anthraquinones O O
. O O

Chinese O O
herbal O O
medicine O O
preparations O O
are O O
widely O O
available O O
and O O
often O O
regarded O O
by O O
the O O
public O O
as O O
natural O O
and O O
safe O O
remedies O O
for O O
a O O
variety O O
of O O
medical O O
conditions O O
. O O

Nephropathy B B_DISEASE
caused O O
by O O
Chinese O O
herbs O O
has O O
previously O O
been O O
reported O O
, O O
usually O O
involving O O
the O O
use O O
of O O
aristolochic O O
acids O O
. O O

We O O
report O O
a O O
23 O O
- O O
year O O
- O O
old O O
woman O O
who O O
developed O O
acute B B_DISEASE
renal I I_DISEASE
failure I I_DISEASE
following O O
prolonged O O
use O O
of O O
a O O
proprietary O O
Chinese O O
herbal O O
slimming O O
pill O O
that O O
contained O O
anthraquinone O O
derivatives O O
, O O
extracted O O
from O O
Rhizoma O O
Rhei O O
( O O
rhubarb O O
) O O
. O O

The O O
renal B B_DISEASE_ADJECTIVE[DISEASE]
injury I I_DISEASE_ADJECTIVE[DISEASE]
was O O
probably O O
aggravated O O
by O O
the O O
concomitant O O
intake O O
of O O
a O O
non O O
- O O
steroidal O O
anti O O
- O O
inflammatory O O
drug O O
, O O
diclofenac O O
. O O

Renal O O
pathology O O
was O O
that O O
of O O
hypocellular O O
interstitial O O
fibrosis B B_DISEASE
. O O

Spontaneous O O
renal O O
recovery O O
occurred O O
upon O O
cessation O O
of O O
the O O
slimming O O
pills O O
, O O
but O O
mild O O
interstitial O O
fibrosis B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
tubular O O
atrophy B B_DISEASE
was O O
still O O
evident O O
histologically O O
4 O O
months O O
later O O
. O O

Although O O
a O O
causal O O
relationship O O
between O O
the O O
use O O
of O O
an O O
anthraquinone O O
- O O
containing O O
herbal O O
agent O O
and O O
renal B B_DISEASE
injury I I_DISEASE
remains O O
to O O
be O O
proven O O
, O O
phytotherapy O O
- O O
associated O O
interstitial O O
nephropathy B B_DISEASE
should O O
be O O
considered O O
in O O
patients O O
who O O
present O O
with O O
unexplained O O
renal B B_DISEASE
failure I I_DISEASE
. O O

Chloroacetaldehyde O O
as O O
a O O
sulfhydryl O O
reagent O O
: O O
the O O
role O O
of O O
critical O O
thiol O O
groups O O
in O O
ifosfamide O O
nephropathy B B_DISEASE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
. O O

Chloroacetaldehyde O O
( O O
CAA O O
) O O
is O O
a O O
metabolite O O
of O O
the O O
alkylating O O
agent O O
ifosfamide O O
( O O
IFO O O
) O O
and O O
putatively O O
responsible O O
for O O
renal B B_DISEASE_ADJECTIVE[DISEASE]
damage I I_DISEASE_ADJECTIVE[DISEASE]
following O O
anti O O
- O O
tumor B B_DISEASE/B_GENE
therapy O O
with O O
IFO O O
. O O

Depletion O O
of O O
sulfhydryl O O
( O O
SH O O
) O O
groups O O
has O O
been O O
reported O O
from O O
cell O O
culture O O
, O O
animal O O
and O O
clinical O O
studies O O
. O O

In O O
this O O
work O O
the O O
effect O O
of O O
CAA O O
on O O
human O O
proximal O O
tubule O O
cells O O
in O O
primary O O
culture O O
( O O
hRPTEC O O
) O O
was O O
investigated O O
. O O

Toxicity B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
CAA O O
was O O
determined O O
by O O
protein O O
content O O
, O O
cell O O
number O O
, O O
LDH O O
release O O
, O O
trypan O O
blue O O
exclusion O O
assay O O
and O O
caspase O O
- O O
3 O O
activity O O
. O O

Free O O
thiols O O
were O O
measured O O
by O O
the O O
method O O
of O O
Ellman O O
. O O

CAA O O
reduced O O
hRPTEC O O
cell O O
number O O
and O O
protein O O
, O O
induced O O
a O O
loss O O
in O O
free O O
intracellular O O
thiols O O
and O O
an O O
increase O O
in O O
necrosis B B_DISEASE/B_GENE
markers O O
. O O

CAA O O
but O O
not O O
acrolein O O
inhibited O O
the O O
cysteine O O
proteases O O
caspase O O
- O O
3 O O
, O O
caspase O O
- O O
8 O O
and O O
cathepsin O O
B O O
. O O

In O O
cells O O
stained O O
with O O
fluorescent O O
dyes O O
targeting O O
lysosomes O O
, O O
CAA O O
induced O O
an O O
increase O O
in O O
lysosomal O O
size O O
and O O
lysosomal O O
leakage O O
. O O

The O O
effects O O
of O O
CAA O O
on O O
cysteine O O
protease O O
activities O O
and O O
thiols O O
could O O
be O O
reproduced O O
in O O
cell O O
lysate O O
. O O

Acidification O O
, O O
which O O
slowed O O
the O O
reaction O O
of O O
CAA O O
with O O
thiol O O
donors O O
, O O
could O O
also O O
attenuate O O
effects O O
of O O
CAA O O
on O O
necrosis B B_DISEASE
markers O O
, O O
thiol O O
depletion O O
and O O
cysteine O O
protease O O
inhibition O O
in O O
living O O
cells O O
. O O

This O O
effect O O
can O O
be O O
reduced O O
by O O
acidification O O
. O O

Therefore O O
, O O
urinary O O
acidification O O
could O O
be O O
an O O
option O O
to O O
prevent O O
IFO O O
nephropathy B B_DISEASE
in O O
patients O O
. O O

Stereological O O
methods O O
reveal O O
the O O
robust O O
size O O
and O O
stability O O
of O O
ectopic O O
hilar O O
granule O O
cells O O
after O O
pilocarpine O O
- O O
induced O O
status B B_DISEASE
epilepticus I I_DISEASE
in O O
the O O
adult O O
rat O O
. O O

Following O O
status B B_DISEASE
epilepticus I I_DISEASE
in O O
the O O
rat O O
, O O
dentate O O
granule O O
cell O O
neurogenesis O O
increases O O
greatly O O
, O O
and O O
many O O
of O O
the O O
new O O
neurons O O
appear O O
to O O
develop O O
ectopically O O
, O O
in O O
the O O
hilar O O
region O O
of O O
the O O
hippocampal O O
formation O O
. O O

It O O
has O O
been O O
suggested O O
that O O
the O O
ectopic O O
hilar O O
granule O O
cells O O
could O O
contribute O O
to O O
the O O
spontaneous O O
seizures B B_DISEASE
that O O
ultimately O O
develop O O
after O O
status B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
epilepticus I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

However O O
, O O
the O O
population O O
has O O
never O O
been O O
quantified O O
, O O
so O O
it O O
is O O
unclear O O
whether O O
it O O
is O O
substantial O O
enough O O
to O O
have O O
a O O
strong O O
influence O O
on O O
epileptogenesis O O
. O O

To O O
quantify O O
this O O
population O O
, O O
the O O
total O O
number O O
of O O
ectopic O O
hilar O O
granule O O
cells O O
was O O
estimated O O
using O O
unbiased O O
stereology O O
at O O
different O O
times O O
after O O
pilocarpine O O
- O O
induced O O
status B B_DISEASE
epilepticus I I_DISEASE
. O O

The O O
number O O
of O O
hilar O O
neurons O O
immunoreactive O O
for O O
Prox O O
- O O
1 O O
, O O
a O O
granule O O
- O O
cell O O
- O O
specific O O
marker O O
, O O
was O O
estimated O O
using O O
the O O
optical O O
fractionator O O
method O O
. O O

The O O
results O O
indicate O O
that O O
the O O
size O O
of O O
the O O
hilar O O
ectopic O O
granule O O
cell O O
population O O
after O O
status B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
epilepticus I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
substantial O O
, O O
and O O
stable O O
over O O
time O O
. O O

Interestingly O O
, O O
the O O
size O O
of O O
the O O
population O O
appears O O
to O O
be O O
correlated O O
with O O
the O O
frequency O O
of O O
behavioral O O
seizures B B_DISEASE
, O O
because O O
animals O O
with O O
more O O
ectopic O O
granule O O
cells O O
in O O
the O O
hilus O O
have O O
more O O
frequent O O
behavioral O O
seizures B B_DISEASE
. O O

The O O
hilar O O
ectopic O O
granule O O
cell O O
population O O
does O O
not O O
appear O O
to O O
vary O O
systematically O O
across O O
the O O
septotemporal O O
axis O O
, O O
although O O
it O O
is O O
associated O O
with O O
an O O
increase O O
in O O
volume O O
of O O
the O O
hilus O O
. O O

The O O
results O O
provide O O
new O O
insight O O
into O O
the O O
potential O O
role O O
of O O
ectopic O O
hilar O O
granule O O
cells O O
in O O
the O O
pilocarpine O O
model O O
of O O
temporal B B_DISEASE
lobe I I_DISEASE
epilepsy I I_DISEASE
. O O

A O O
prospective O O
, O O
open O O
- O O
label O O
trial O O
of O O
galantamine O O
in O O
autistic B B_DISEASE/B_LOCATION
disorder I I_DISEASE/I_LOCATION
. O O

OBJECTIVE O O
: O O
Post O O
- O O
mortem O O
studies O O
have O O
reported O O
abnormalities O O
of O O
the O O
cholinergic O O
system O O
in O O
autism B B_DISEASE/B_SPECIES[BIO]
. O O

The O O
purpose O O
of O O
this O O
study O O
was O O
to O O
assess O O
the O O
use O O
of O O
galantamine O O
, O O
an O O
acetylcholinesterase O O
inhibitor O O
and O O
nicotinic O O
receptor O O
modulator O O
, O O
in O O
the O O
treatment O O
of O O
interfering O O
behaviors O O
in O O
children O O
with O O
autism B B_DISEASE/B_LOCATION
. O O

METHODS O O
: O O
Thirteen O O
medication O O
- O O
free O O
children O O
with O O
autism B B_DISEASE
( O O
mean O O
age O O
, O O
8 O O
. O O
8 O O
+ O O
/ O O
- O O
3 O O
. O O
5 O O
years O O
) O O
participated O O
in O O
a O O
12 O O
- O O
week O O
, O O
open O O
- O O
label O O
trial O O
of O O
galantamine O O
. O O

Patients O O
were O O
rated O O
monthly O O
by O O
parents O O
on O O
the O O
Aberrant O O
Behavior O O
Checklist O O
( O O
ABC O O
) O O
and O O
the O O
Conners O O
' O O
Parent O O
Rating O O
Scale O O
- O O
Revised O O
, O O
and O O
by O O
a O O
physician O O
using O O
the O O
Children O O
' O O
s O O
Psychiatric O O
Rating O O
Scale O O
and O O
the O O
Clinical O O
Global O O
Impressions O O
scale O O
. O O

RESULTS O O
: O O
Patients O O
showed O O
a O O
significant O O
reduction O O
in O O
parent O O
- O O
rated O O
irritability B B_DISEASE_ADJECTIVE[DISEASE]
and O O
social O O
withdrawal O O
on O O
the O O
ABC O O
as O O
well O O
as O O
significant O O
improvements O O
in O O
emotional O O
lability O O
and O O
inattention O O
on O O
the O O
Conners O O
' O O
Parent O O
Rating O O
Scale O O
- O O
- O O
Revised O O
. O O

Eight O O
of O O
13 O O
participants O O
were O O
rated O O
as O O
responders O O
on O O
the O O
basis O O
of O O
their O O
improvement O O
scores O O
on O O
the O O
Clinical O O
Global O O
Impressions O O
scale O O
. O O

Overall O O
, O O
galantamine O O
was O O
well O O
- O O
tolerated O O
, O O
with O O
no O O
significant O O
adverse O O
effects O O
apart O O
from O O
headaches B B_DISEASE
in O O
one O O
patient O O
. O O

CONCLUSION O O
: O O
In O O
this O O
open O O
trial O O
, O O
galantamine O O
was O O
well O O
- O O
tolerated O O
and O O
appeared O O
to O O
be O O
beneficial O O
for O O
the O O
treatment O O
of O O
interfering O O
behaviors O O
in O O
children O O
with O O
autism B B_DISEASE
, O O
particularly O O
aggression B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
behavioral B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dyscontrol I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
inattention B B_DISEASE
. O O

Further O O
controlled O O
trials O O
are O O
warranted O O
. O O

Randomized O O
comparison O O
of O O
olanzapine O O
versus O O
risperidone O O
for O O
the O O
treatment O O
of O O
first O O
- O O
episode O O
schizophrenia B B_DISEASE/B_LOCATION
: O O
4 O O
- O O
month O O
outcomes O O
. O O

OBJECTIVE O O
: O O
The O O
authors O O
compared O O
4 O O
- O O
month O O
treatment O O
outcomes O O
for O O
olanzapine O O
versus O O
risperidone O O
in O O
patients O O
with O O
first O O
- O O
episode O O
schizophrenia B B_DISEASE
spectrum O O
disorders O O
. O O

METHOD O O
: O O
One O O
hundred O O
twelve O O
subjects O O
( O O
70 O O
% O O
male O O
; O O
mean O O
age O O
= O O
23 O O
. O O
3 O O
years O O
[ O O
SD O O
= O O
5 O O
. O O
1 O O
] O O
) O O
with O O
first O O
- O O
episode O O
schizophrenia B B_DISEASE
( O O
75 O O
% O O
) O O
, O O
schizophreniform B B_DISEASE
disorder I I_DISEASE
( O O
17 O O
% O O
) O O
, O O
or O O
schizoaffective B B_DISEASE/B_PERSON
disorder I I_DISEASE/I_PERSON
( O O
8 O O
% O O
) O O
were O O
randomly O O
assigned O O
to O O
treatment O O
with O O
olanzapine O O
( O O
2 O O
. O O
5 O O
- O O
20 O O
mg O O
/ O O
day O O
) O O
or O O
risperidone O O
( O O
1 O O
- O O
6 O O
mg O O
/ O O
day O O
) O O
. O O

Among O O
those O O
responding O O
to O O
treatment O O
, O O
more O O
subjects O O
in O O
the O O
olanzapine O O
group O O
( O O
40 O O
. O O
9 O O
% O O
, O O
95 O O
% O O
CI O O
= O O
16 O O
. O O
8 O O
% O O
- O O
65 O O
. O O
0 O O
% O O
) O O
than O O
in O O
the O O
risperidone O O
group O O
( O O
18 O O
. O O
9 O O
% O O
, O O
95 O O
% O O
CI O O
= O O
0 O O
% O O
- O O
39 O O
. O O
2 O O
% O O
) O O
had O O
subsequent O O
ratings O O
not O O
meeting O O
response O O
criteria O O
. O O

Negative O O
symptom O O
outcomes O O
and O O
measures O O
of O O
parkinsonism B B_DISEASE
and O O
akathisia B B_DISEASE
did O O
not O O
differ O O
between O O
medications O O
. O O

Extrapyramidal B B_DISEASE/B_MEASURE
symptom I I_DISEASE/I_MEASURE
severity O O
scores O O
were O O
1 O O
. O O
4 O O
( O O
95 O O
% O O
CI O O
= O O
1 O O
. O O
2 O O
- O O
1 O O
. O O
6 O O
) O O
with O O
risperidone O O
and O O
1 O O
. O O
2 O O
( O O
95 O O
% O O
CI O O
= O O
1 O O
. O O
0 O O
- O O
1 O O
. O O
4 O O
) O O
with O O
olanzapine O O
. O O

Significantly O O
more O O
weight B B_DISEASE
gain I I_DISEASE
occurred O O
with O O
olanzapine O O
than O O
with O O
risperidone O O
: O O
the O O
increase O O
in O O
weight O O
at O O
4 O O
months O O
relative O O
to O O
baseline O O
weight O O
was O O
17 O O
. O O
3 O O
% O O
( O O
95 O O
% O O
CI O O
= O O
14 O O
. O O
2 O O
% O O
- O O
20 O O
. O O
5 O O
% O O
) O O
with O O
olanzapine O O
and O O
11 O O
. O O
3 O O
% O O
( O O
95 O O
% O O
CI O O
= O O
8 O O
. O O
4 O O
% O O
- O O
14 O O
. O O
3 O O
% O O
) O O
with O O
risperidone O O
. O O

CONCLUSIONS O O
: O O
Clinical O O
outcomes O O
with O O
risperidone O O
were O O
equal O O
to O O
those O O
with O O
olanzapine O O
, O O
and O O
response O O
may O O
be O O
more O O
stable O O
. O O

Both O O
medications O O
caused O O
substantial O O
rapid O O
weight B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
gain I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
but O O
weight B B_DISEASE_ADJECTIVE[DISEASE]
gain I I_DISEASE_ADJECTIVE[DISEASE]
was O O
greater O O
with O O
olanzapine O O
. O O

Early O O
paracentral O O
visual B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
field I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
loss I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
patients O O
taking O O
hydroxychloroquine O O
. O O

DESIGN O O
: O O
Retrospective O O
study O O
. O O

Thirty O O
- O O
five O O
patients O O
( O O
13 O O
. O O
4 O O
% O O
) O O
had O O
visual B B_DISEASE
field I I_DISEASE
abnormalities I I_DISEASE
, O O
which O O
were O O
attributed O O
to O O
hydroxychloroquine O O
treatment O O
in O O
4 O O
patients O O
( O O
1 O O
. O O
5 O O
% O O
) O O
. O O

Three O O
of O O
the O O
4 O O
patients O O
were O O
taking O O
less O O
than O O
6 O O
. O O
5 O O
mg O O
/ O O
kg O O
per O O
day O O
and O O
all O O
patients O O
had O O
normal O O
renal O O
and O O
liver O O
function O O
test O O
results O O
. O O

CONCLUSIONS O O
: O O
The O O
current O O
study O O
used O O
a O O
protocol O O
of O O
visual O O
acuity O O
and O O
color O O
vision O O
assessment O O
, O O
funduscopy O O
, O O
and O O
Humphrey O O
10 O O
- O O
2 O O
visual O O
field O O
testing O O
and O O
shows O O
that O O
visual B B_DISEASE_ADJECTIVE[DISEASE]
field I I_DISEASE_ADJECTIVE[DISEASE]
defects I I_DISEASE_ADJECTIVE[DISEASE]
appeared O O
before O O
any O O
corresponding O O
changes O O
in O O
any O O
other O O
tested O O
clinical O O
parameters O O
; O O
the O O
defects O O
were O O
reproducible O O
and O O
the O O
test O O
parameters O O
were O O
reliable O O
. O O

Screening O O
, O O
including O O
Humphrey O O
10 O O
- O O
2 O O
visual O O
field O O
assessment O O
, O O
is O O
recommended O O
2 O O
years O O
after O O
the O O
initial O O
baseline O O
and O O
yearly O O
thereafter O O
. O O

Peri O O
- O O
operative O O
atrioventricular B B_DISEASE
block I I_DISEASE
as O O
a O O
result O O
of O O
chemotherapy O O
with O O
epirubicin O O
and O O
paclitaxel O O
. O O

A O O
47 O O
- O O
year O O
- O O
old O O
woman O O
presented O O
for O O
mastectomy O O
and O O
immediate O O
latissimus O O
dorsi O O
flap O O
reconstruction O O
having O O
been O O
diagnosed O O
with O O
carcinoma B B_DISEASE
of I I_DISEASE
the I I_DISEASE
breast I I_DISEASE
6 O O
months O O
previously O O
. O O

This O O
had O O
been O O
apparently O O
uncomplicated O O
and O O
she O O
had O O
maintained O O
a O O
remarkably O O
high O O
level O O
of O O
physical O O
activity O O
. O O

She O O
was O O
found O O
to O O
be O O
bradycardic B B_DISEASE_ADJECTIVE[DISEASE]
at O O
pre O O
- O O
operative O O
assessment O O
but O O
had O O
no O O
cardiac O O
symptoms O O
. O O

Second O O
degree O O
Mobitz O O
type O O
II O O
atrioventricular B B_DISEASE/B_LOCATION
block I I_DISEASE/I_LOCATION
was O O
diagnosed O O
on O O
electrocardiogram O O
, O O
and O O
temporary O O
transvenous O O
ventricular O O
pacing O O
instituted O O
in O O
the O O
peri O O
- O O
operative O O
period O O
. O O

We O O
discuss O O
how O O
evidence O O
- O O
based O O
guidelines O O
would O O
not O O
have O O
been O O
helpful O O
in O O
this O O
case O O
, O O
and O O
how O O
chemotherapy O O
can O O
exhibit O O
substantial O O
cardiotoxicity B B_DISEASE
that O O
may O O
develop O O
over O O
many O O
years O O
. O O

We O O
suggest O O
that O O
patients O O
who O O
have O O
received O O
chemotherapy O O
at O O
any O O
time O O
should O O
have O O
a O O
pre O O
- O O
operative O O
electrocardiogram O O
even O O
if O O
they O O
are O O
asymptomatic O O
. O O

Risks O O
and O O
benefits O O
of O O
COX O O
- O O
2 O O
inhibitors O O
vs O O
non O O
- O O
selective O O
NSAIDs O O
: O O
does O O
their O O
cardiovascular O O
risk O O
exceed O O
their O O
gastrointestinal O O
benefit O O
? O O

A O O
retrospective O O
cohort O O
study O O
. O O

We O O
aimed O O
to O O
compare O O
the O O
risks O O
of O O
hospitalization O O
for O O
AMI B B_DISEASE
and O O
GI B B_DISEASE
bleeding I I_DISEASE
among O O
elderly O O
patients O O
using O O
COX O O
- O O
2 O O
inhibitors O O
, O O
NS O O
- O O
NSAIDs O O
and O O
acetaminophen O O
. O O

METHODS O O
: O O
We O O
conducted O O
a O O
retrospective O O
cohort O O
study O O
using O O
administrative O O
data O O
of O O
patients O O
> O O
or O O
= O O
65 O O
years O O
of O O
age O O
who O O
filled O O
a O O
prescription O O
for O O
NSAID O O
or O O
acetaminophen O O
during O O
1999 O O
- O O
2002 O O
. O O

Outcomes O O
were O O
compared O O
using O O
Cox O O
regression O O
models O O
with O O
time O O
- O O
dependent O O
exposures O O
. O O

Among O O
users O O
of O O
aspirin O O
, O O
they O O
were O O
: O O
rofecoxib O O
1 O O
. O O
73 O O
( O O
1 O O
. O O
52 O O
, O O
1 O O
. O O
98 O O
) O O
, O O
celecoxib O O
1 O O
. O O
34 O O
( O O
1 O O
. O O
19 O O
, O O
1 O O
. O O
52 O O
) O O
, O O
ibuprofen O O
1 O O
. O O
51 O O
( O O
0 O O
. O O
95 O O
, O O
2 O O
. O O
41 O O
) O O
, O O
diclofenac O O
1 O O
. O O
69 O O
( O O
1 O O
. O O
35 O O
, O O
2 O O
. O O
10 O O
) O O
, O O
naproxen O O
1 O O
. O O
35 O O
( O O
0 O O
. O O
97 O O
, O O
1 O O
. O O
88 O O
) O O
and O O
acetaminophen O O
1 O O
. O O
29 O O
( O O
1 O O
. O O
17 O O
, O O
1 O O
. O O
42 O O
) O O
. O O

CONCLUSION O O
: O O
Among O O
non O O
- O O
users O O
of O O
aspirin O O
, O O
naproxen O O
seemed O O
to O O
carry O O
the O O
highest O O
risk O O
for O O
AMI B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
/ O O
GI B B_DISEASE/B_LOCATION
bleeding I I_DISEASE/I_LOCATION
. O O

The O O
AMI B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
/ O O
GI O O
toxicity B B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
celecoxib O O
was O O
similar O O
to O O
that O O
of O O
acetaminophen O O
and O O
seemed O O
to O O
be O O
better O O
than O O
those O O
of O O
rofecoxib O O
and O O
NS O O
- O O
NSAIDs O O
. O O

Among O O
users O O
of O O
aspirin O O
, O O
both O O
celecoxib O O
and O O
naproxen O O
seemed O O
to O O
be O O
the O O
least O O
toxic O O
. O O

Quinine O O
- O O
induced O O
arrhythmia B B_DISEASE
in O O
a O O
patient O O
with O O
severe B B_DISEASE/B_GENE
malaria I I_DISEASE/I_GENE
. O O

A O O
man O O
, O O
25 O O
years O O
old O O
, O O
was O O
admitted O O
to O O
hospital O O
with O O
high O O
fever B B_DISEASE/B_MEASURE
, O O
chill B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
vomiting B B_DISEASE
, O O
jaundice B B_DISEASE
. O O

The O O
patient O O
was O O
fully O O
conscious O O
, O O
blood O O
pressure O O
120 O O
/ O O
80 O O
mmHg O O
, O O
pulse O O
rate O O
100 O O
x O O
/ O O
minute O O
, O O
regular O O
. O O

On O O
admission O O
, O O
laboratory O O
examination O O
showed O O
Plasmodium O O
falciparum O O
( O O
+ O O
+ O O
+ O O
+ O O
) O O
, O O
total O O
bilirubin O O
8 O O
. O O
25 O O
mg O O
/ O O
dL O O
, O O
conjugated O O
bilirubin O O
4 O O
. O O
36 O O
mg O O
/ O O
dL O O
, O O
unconjugated O O
bilirubin O O
3 O O
. O O
89 O O
mg O O
/ O O
dL O O
, O O
potassium O O
3 O O
. O O
52 O O
meq O O
/ O O
L O O
Patient O O
was O O
diagnosed O O
as O O
severe B B_DISEASE_ADJECTIVE[DISEASE]
malaria I I_DISEASE_ADJECTIVE[DISEASE]
with O O
jaundice B B_DISEASE
and O O
got O O
quinine O O
infusion O O
in O O
dextrose O O
5 O O
% O O
500 O O
mg O O
/ O O
8 O O
hour O O
. O O

On O O
the O O
second O O
day O O
the O O
patient O O
had O O
vomitus B B_DISEASE
, O O
diarrhea B B_DISEASE
, O O
tinnitus B B_DISEASE
, O O
loss B B_DISEASE
of I I_DISEASE
hearing I I_DISEASE
. O O

After O O
30 O O
hours O O
of O O
quinine O O
infusion O O
the O O
patient O O
felt O O
palpitation B B_DISEASE_ADJECTIVE[DISEASE]
and O O
electrocardiography O O
( O O
ECG O O
) O O
recording O O
showed O O
premature B B_DISEASE
ventricular I I_DISEASE
contraction I I_DISEASE
( O O
PVC B B_LOCATION/B_DISEASE
) O O
> O O
5 O O
x O O
/ O O
minute O O
, O O
trigemini O O
, O O
constant O O
type O O
- O O
- O O
sinoatrial B B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
block I B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
, O O
positive O O
U O O
wave O O
. O O

He O O
was O O
treated O O
with O O
lidocaine O O
50 O O
mg O O
intravenously O O
followed O O
by O O
infusion O O
1500 O O
mg O O
in O O
dextrose O O
5 O O
% O O
/ O O
24 O O
hour O O
and O O
potassium O O
aspartate O O
tablet O O
. O O

Quinine O O
infusion O O
was O O
discontinued O O
and O O
changed O O
with O O
sulfate O O
quinine O O
tablets O O
. O O

Three O O
hours O O
later O O
the O O
patient O O
felt O O
better O O
, O O
the O O
frequency O O
of O O
PVC B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
reduced O O
to O O
4 O O
- O O
5 O O
x O O
/ O O
minute O O
and O O
on O O
the O O
third O O
day O O
ECG O O
was O O
normal O O
, O O
potassium O O
level O O
was O O
3 O O
. O O
34 O O
meq O O
/ O O
L O O
. O O

He O O
was O O
discharged O O
on O O
7th O O
day O O
in O O
good O O
condition O O
. O O

Quinine O O
, O O
like O O
quinidine O O
, O O
is O O
a O O
chincona O O
alkaloid O O
that O O
has O O
anti O O
- O O
arrhythmic B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
property O O
, O O
although O O
it O O
also O O
pro O O
- O O
arrhythmic B B_DISEASE_ADJECTIVE[DISEASE]
that O O
can O O
cause O O
various O O
arrhythmias B B_DISEASE
, O O
including O O
severe O O
arrhythmia B B_DISEASE
such O O
as O O
multiple O O
PVC B B_DISEASE
. O O

Penicillamine O O
- O O
related O O
lichenoid B B_DISEASE
dermatitis I I_DISEASE
and O O
utility O O
of O O
zinc O O
acetate O O
in O O
a O O
Wilson B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
disease I B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
patient O O
with O O
hepatic O O
presentation O O
, O O
anxiety B B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
SPECT O O
abnormalities O O
. O O

During O O
the O O
follow O O
- O O
up O O
of O O
our O O
patient O O
, O O
penicillamine O O
was O O
interrupted O O
after O O
the O O
appearance O O
of O O
a O O
lichenoid B B_DISEASE
dermatitis I I_DISEASE
, O O
and O O
zinc O O
acetate O O
permitted O O
to O O
continue O O
the O O
successful O O
treatment O O
of O O
the O O
patient O O
without O O
side O O
- O O
effects O O
. O O

In O O
our O O
case O O
the O O
therapy O O
with O O
zinc O O
acetate O O
represented O O
an O O
effective O O
treatment O O
for O O
a O O
Wilson B B_DISEASE/B_PERSON
' I I_DISEASE/I_PERSON
s I I_DISEASE/I_PERSON
disease I I_DISEASE/I_PERSON
patient O O
in O O
which O O
penicillamine O O
- O O
related O O
side O O
effects O O
appeared O O
. O O

The O O
safety O O
of O O
the O O
zinc O O
acetate O O
allowed O O
us O O
to O O
avoid O O
other O O
potentially O O
toxic O O
chelating O O
drugs O O
; O O
this O O
observation O O
is O O
in O O
line O O
with O O
the O O
growing O O
evidence O O
on O O
the O O
efficacy O O
of O O
the O O
drug O O
in O O
the O O
treatment O O
of O O
Wilson B B_DISEASE
' I I_DISEASE
s I I_DISEASE
disease I I_DISEASE
. O O

Further O O
studies O O
are O O
needed O O
for O O
a O O
better O O
clarification O O
of O O
Wilson B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
' I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
s I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disease I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy O O
, O O
and O O
in O O
particular O O
to O O
differentiate O O
specific O O
therapies O O
for O O
different O O
Wilson B B_DISEASE_ADJECTIVE[DISEASE]
' I I_DISEASE_ADJECTIVE[DISEASE]
s I I_DISEASE_ADJECTIVE[DISEASE]
disease I I_DISEASE_ADJECTIVE[DISEASE]
phenotypes O O
. O O

A O O
dramatic O O
drop B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pressure I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
following O O
prehospital O O
GTN O O
administration O O
. O O

A O O
male O O
in O O
his O O
sixties O O
with O O
no O O
history O O
of O O
cardiac O O
chest B B_DISEASE_ADJECTIVE[DISEASE]
pain I I_DISEASE_ADJECTIVE[DISEASE]
awoke O O
with O O
chest B B_DISEASE
pain I I_DISEASE
following O O
an O O
afternoon O O
sleep O O
. O O

The O O
patient O O
did O O
not O O
self O O
medicate O O
. O O

Several O O
minutes O O
after O O
the O O
GTN O O
the O O
patient O O
experienced O O
a O O
sudden O O
drop B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pressure I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
heart O O
rate O O
, O O
this O O
was O O
rectified O O
by O O
atropine O O
sulphate O O
and O O
a O O
fluid O O
challenge O O
. O O

There O O
was O O
no O O
further O O
deterioration O O
in O O
the O O
patient O O
' O O
s O O
condition O O
during O O
transport O O
to O O
hospital O O
. O O

There O O
are O O
very O O
few O O
documented O O
case O O
like O O
this O O
in O O
the O O
prehospital O O
scientific O O
literature O O
. O O

Prehospital O O
care O O
providers O O
who O O
are O O
managing O O
any O O
patient O O
with O O
a O O
syncopal B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
episode I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
that O O
fails O O
to O O
recover O O
within O O
a O O
reasonable O O
time O O
frame O O
should O O
consider O O
the O O
Bezold O O
- O O
Jarisch O O
reflex O O
as O O
the O O
cause O O
and O O
manage O O
the O O
patient O O
accordingly O O
. O O

Chronic O O
lesion O O
of O O
rostral O O
ventrolateral O O
medulla O O
in O O
spontaneously O O
hypertensive B B_DISEASE/B_ORGANISM_FUNCTION
rats O O
. O O

We O O
studied O O
the O O
effects O O
of O O
chronic O O
selective O O
neuronal O O
lesion O O
of O O
rostral O O
ventrolateral O O
medulla O O
on O O
mean O O
arterial O O
pressure O O
, O O
heart O O
rate O O
, O O
and O O
neurogenic O O
tone O O
in O O
conscious O O
, O O
unrestrained O O
spontaneously O O
hypertensive B B_DISEASE_ADJECTIVE[DISEASE]
rats O O
. O O

The O O
lesions O O
were O O
placed O O
via O O
bilateral O O
microinjections O O
of O O
30 O O
nmol O O
/ O O
200 O O
nl O O
N O O
- O O
methyl O O
- O O
D O O
- O O
aspartic O O
acid O O
. O O

Fifteen O O
days O O
later O O
, O O
the O O
lesioned O O
group O O
still O O
showed O O
values O O
significantly O O
lower O O
than O O
the O O
sham O O
group O O
( O O
150 O O
+ O O
/ O O
- O O
6 O O
versus O O
167 O O
+ O O
/ O O
- O O
5 O O
mm O O
Hg O O
, O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
. O O

No O O
significant O O
heart O O
rate O O
differences O O
were O O
observed O O
between O O
the O O
sham O O
and O O
lesioned O O
groups O O
. O O

The O O
trimethaphan O O
- O O
induced O O
hypotension B B_DISEASE
was O O
accompanied O O
by O O
a O O
significant O O
bradycardia B B_DISEASE
in O O
lesioned O O
rats O O
( O O
- O O
32 O O
+ O O
/ O O
- O O
13 O O
beats O O
per O O
minute O O
) O O
but O O
a O O
tachycardia B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
sham O O
rats O O
( O O
+ O O
33 O O
+ O O
/ O O
- O O
12 O O
beats O O
per O O
minute O O
) O O
1 O O
day O O
postlesion O O
. O O

Therefore O O
, O O
rostral O O
ventrolateral O O
medulla O O
neurons O O
appear O O
to O O
play O O
a O O
significant O O
role O O
in O O
maintaining O O
hypertension B B_DISEASE/B_GENE
in O O
conscious O O
spontaneously O O
hypertensive B B_DISEASE/B_ORGANISM_FUNCTION
rats O O
. O O

Spinal O O
or O O
suprabulbar O O
structures O O
could O O
be O O
responsible O O
for O O
the O O
gradual O O
recovery O O
of O O
the O O
hypertension B B_DISEASE
in O O
the O O
lesioned O O
rats O O
. O O

Acute B B_DISEASE
encephalopathy I I_DISEASE
and O O
cerebral B B_DISEASE
vasospasm I I_DISEASE
after O O
multiagent O O
chemotherapy O O
including O O
PEG O O
- O O
asparaginase O O
and O O
intrathecal O O
cytarabine O O
for O O
the O O
treatment O O
of O O
acute B B_DISEASE
lymphoblastic I I_DISEASE
leukemia I I_DISEASE
. O O

A O O
7 O O
- O O
year O O
- O O
old O O
girl O O
with O O
an O O
unusual O O
reaction O O
to O O
induction O O
chemotherapy O O
for O O
precursor O O
B O O
- O O
cell O O
acute B B_DISEASE
lymphoblastic I I_DISEASE
leukemia I I_DISEASE
( O O
ALL B B_DISEASE
) O O
is O O
described O O
. O O

The O O
patient O O
developed O O
acute B B_DISEASE
encephalopathy I I_DISEASE
evidenced O O
by O O
behavioral O O
changes O O
, O O
aphasia B B_DISEASE
, O O
incontinence B B_DISEASE
, O O
visual B B_DISEASE
hallucinations I I_DISEASE
, O O
and O O
right O O
- O O
sided O O
weakness B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
diffuse O O
cerebral B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
vasospasm I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
on O O
magnetic O O
resonance O O
angiography O O
after O O
the O O
administration O O
of O O
intrathecal O O
cytarabine O O
. O O

Vincristine O O
, O O
dexamethasone O O
, O O
and O O
polyethylene O O
glycol O O
- O O
asparaginase O O
were O O
also O O
administered O O
before O O
the O O
episode O O
as O O
part O O
of O O
induction O O
therapy O O
. O O

Neurologic O O
status O O
returned O O
to O O
baseline O O
within O O
10 O O
days O O
of O O
the O O
acute O O
event O O
, O O
and O O
magnetic O O
resonance O O
angiography O O
findings O O
returned O O
to O O
normal O O
4 O O
months O O
later O O
. O O

Comparison O O
of O O
valsartan O O
/ O O
hydrochlorothiazide O O
combination O O
therapy O O
at O O
doses O O
up O O
to O O
320 O O
/ O O
25 O O
mg O O
versus O O
monotherapy O O
: O O
a O O
double O O
- O O
blind O O
, O O
placebo O O
- O O
controlled O O
study O O
followed O O
by O O
long O O
- O O
term O O
combination O O
therapy O O
in O O
hypertensive B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
adults O O
. O O

BACKGROUND O O
: O O
One O O
third O O
of O O
patients O O
treated O O
for O O
hypertension B B_DISEASE
attain O O
adequate O O
blood O O
pressure O O
( O O
BP O O
) O O
control O O
, O O
and O O
multidrug O O
regimens O O
are O O
often O O
required O O
. O O

Given O O
the O O
lifelong O O
nature O O
of O O
hypertension B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
there O O
is O O
a O O
need O O
to O O
evaluate O O
the O O
long O O
- O O
term O O
efficacy O O
and O O
tolerability O O
of O O
higher O O
doses O O
of O O
combination O O
anti O O
- O O
hypertensive B B_DISEASE/B_GENE
therapies O O
. O O

OBJECTIVE O O
: O O
This O O
study O O
investigated O O
the O O
efficacy O O
and O O
tolerability O O
of O O
valsartan O O
( O O
VAL O O
) O O
or O O
hydrochlorothiazide O O
( O O
HCTZ O O
) O O
- O O
monotherapy O O
and O O
higher O O
- O O
dose O O
combinations O O
in O O
patients O O
with O O
essential B B_DISEASE
hypertension I I_DISEASE
. O O

METHODS O O
: O O
The O O
first O O
part O O
of O O
this O O
study O O
was O O
an O O
8 O O
- O O
week O O
, O O
multicenter O O
, O O
randomized O O
, O O
double O O
- O O
blind O O
, O O
placebo O O
controlled O O
, O O
parallel O O
- O O
group O O
trial O O
. O O

Patients O O
with O O
essential B B_DISEASE
hypertension I I_DISEASE
( O O
mean O O
sitting O O
diastolic O O
BP O O
[ O O
MSDBP O O
] O O
, O O
> O O
or O O
= O O
95 O O
mm O O
Hg O O
and O O
< O O
110 O O
mm O O
Hg O O
) O O
were O O
randomized O O
to O O
1 O O
of O O
8 O O
treatment O O
groups O O
: O O
VAL O O
160 O O
or O O
320 O O
mg O O
; O O
HCTZ O O
12 O O
. O O
5 O O
or O O
25 O O
mg O O
; O O
VAL O O
/ O O
HCTZ O O
160 O O
/ O O
12 O O
. O O
5 O O
, O O
320 O O
/ O O
12 O O
. O O
5 O O
, O O
or O O
320 O O
/ O O
25 O O
mg O O
; O O
or O O
placebo O O
. O O

VAL O O
/ O O
HCTZ O O
320 O O
/ O O
12 O O
. O O
5 O O
and O O
320 O O
/ O O
25 O O
mg O O
were O O
further O O
investigated O O
in O O
a O O
54 O O
- O O
week O O
, O O
open O O
- O O
label O O
extension O O
. O O

Tolerability O O
was O O
assessed O O
by O O
monitoring O O
adverse O O
events O O
at O O
randomization O O
and O O
all O O
subsequent O O
study O O
visits O O
and O O
regular O O
evaluation O O
of O O
hematology O O
and O O
blood O O
chemistry O O
. O O

RESULTS O O
: O O
A O O
total O O
of O O
1346 O O
patients O O
were O O
randomized O O
into O O
the O O
8 O O
- O O
week O O
core O O
study O O
( O O
734 O O
men O O
, O O
612 O O
women O O
; O O
924 O O
white O O
, O O
291 O O
black O O
, O O
23 O O
Asian O O
, O O
108 O O
other O O
; O O
mean O O
age O O
, O O
52 O O
. O O
7 O O
years O O
; O O
mean O O
weight O O
, O O
92 O O
. O O
6 O O
kg O O
) O O
. O O

The O O
incidence O O
of O O
hypokalemia B B_DISEASE
was O O
lower O O
with O O
VAL O O
/ O O
HCTZ O O
combinations O O
( O O
1 O O
. O O
8 O O
% O O
- O O
6 O O
. O O
1 O O
% O O
) O O
than O O
with O O
HCTZ O O
monotherapies O O
( O O
7 O O
. O O
1 O O
% O O
- O O
13 O O
. O O
3 O O
% O O
) O O
. O O

The O O
majority O O
of O O
adverse O O
events O O
in O O
the O O
core O O
study O O
were O O
of O O
mild O O
to O O
moderate O O
severity O O
. O O

CONCLUSIONS O O
: O O
In O O
this O O
study O O
population O O
, O O
combination O O
therapies O O
with O O
VAL O O
/ O O
HCTZ O O
were O O
associated O O
with O O
significantly O O
greater O O
BP O O
reductions O O
compared O O
with O O
either O O
monotherapy O O
, O O
were O O
well O O
tolerated O O
, O O
and O O
were O O
associated O O
with O O
less O O
hypokalemia B B_DISEASE_ADJECTIVE[DISEASE]
than O O
HCTZ O O
alone O O
. O O

Succimer O O
chelation O O
improves O O
learning O O
, O O
attention O O
, O O
and O O
arousal O O
regulation O O
in O O
lead O O
- O O
exposed O O
rats O O
but O O
produces O O
lasting O O
cognitive B B_DISEASE_ADJECTIVE[DISEASE]
impairment I I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
absence O O
of O O
lead O O
exposure O O
. O O

BACKGROUND O O
: O O
There O O
is O O
growing O O
pressure O O
for O O
clinicians O O
to O O
prescribe O O
chelation O O
therapy O O
at O O
only O O
slightly O O
elevated O O
blood O O
lead O O
levels O O
. O O

OBJECTIVES O O
: O O
The O O
present O O
study O O
was O O
designed O O
to O O
answer O O
these O O
questions O O
, O O
using O O
a O O
rodent O O
model O O
of O O
early O O
childhood O O
Pb O O
exposure O O
and O O
treatment O O
with O O
succimer O O
, O O
a O O
widely O O
used O O
chelating O O
agent O O
for O O
the O O
treatment O O
of O O
Pb B B_DISEASE
poisoning I I_DISEASE
. O O

RESULTS O O
: O O
Pb O O
exposure O O
produced O O
lasting O O
impairments B B_DISEASE_ADJECTIVE[DISEASE]
in I I_DISEASE_ADJECTIVE[DISEASE]
learning I I_DISEASE_ADJECTIVE[DISEASE]
, I I_DISEASE_ADJECTIVE[DISEASE]
attention I I_DISEASE_ADJECTIVE[DISEASE]
, I I_DISEASE_ADJECTIVE[DISEASE]
inhibitory I I_DISEASE_ADJECTIVE[DISEASE]
control I I_DISEASE_ADJECTIVE[DISEASE]
, I I_DISEASE_ADJECTIVE[DISEASE]
and I I_DISEASE_ADJECTIVE[DISEASE]
arousal I I_DISEASE_ADJECTIVE[DISEASE]
regulation I I_DISEASE_ADJECTIVE[DISEASE]
, O O
paralleling O O
the O O
areas O O
of O O
dysfunction O O
seen O O
in O O
Pb O O
- O O
exposed O O
children O O
. O O

In O O
contrast O O
, O O
succimer O O
treatment O O
of O O
rats O O
not O O
previously O O
exposed O O
to O O
Pb O O
produced O O
lasting O O
and O O
pervasive O O
cognitive B B_DISEASE
and I I_DISEASE
affective I I_DISEASE
dysfunction I I_DISEASE
comparable O O
in O O
magnitude O O
to O O
that O O
produced O O
by O O
the O O
higher O O
Pb O O
exposure O O
regimen O O
. O O

CONCLUSIONS O O
: O O
These O O
are O O
the O O
first O O
data O O
, O O
to O O
our O O
knowledge O O
, O O
to O O
show O O
that O O
treatment O O
with O O
any O O
chelating O O
agent O O
can O O
alleviate O O
cognitive B B_DISEASE
deficits I I_DISEASE
due O O
to O O
Pb O O
exposure O O
. O O

These O O
findings O O
suggest O O
that O O
it O O
may O O
be O O
possible O O
to O O
identify O O
a O O
succimer O O
treatment O O
protocol O O
that O O
improves O O
cognitive O O
outcomes O O
in O O
Pb O O
- O O
exposed O O
children O O
. O O

However O O
, O O
they O O
also O O
suggest O O
that O O
succimer O O
treatment O O
should O O
be O O
strongly O O
discouraged O O
for O O
children O O
who O O
do O O
not O O
have O O
elevated O O
tissue O O
levels O O
of O O
Pb O O
or O O
other O O
heavy O O
metals O O
. O O

We O O
randomly O O
selected O O
29 O O
patients O O
with O O
PD B B_DISEASE
, O O
27 O O
with O O
MDP B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
25 O O
with O O
major B B_DISEASE
depression I I_DISEASE
without O O
panic B B_DISEASE
attacks I I_DISEASE
( O O
MD B B_DISEASE
) O O
, O O
and O O
28 O O
healthy O O
volunteers O O
. O O

The O O
patients O O
had O O
no O O
psychotropic O O
drug O O
for O O
at O O
least O O
a O O
4 O O
- O O
week O O
period O O
. O O

In O O
a O O
randomized O O
double O O
- O O
blind O O
experiment O O
performed O O
in O O
2 O O
occasions O O
7 O O
days O O
apart O O
, O O
480 O O
mg O O
caffeine O O
and O O
a O O
caffeine O O
- O O
free O O
( O O
placebo O O
) O O
solution O O
were O O
administered O O
in O O
a O O
coffee O O
form O O
and O O
anxiety B B_DISEASE/B_MEASURE
scales O O
were O O
applied O O
before O O
and O O
after O O
each O O
test O O
. O O

A O O
total O O
of O O
58 O O
. O O
6 O O
% O O
( O O
n O O
= O O
17 O O
) O O
of O O
patients O O
with O O
PD B B_DISEASE
, O O
44 O O
. O O
4 O O
% O O
( O O
n O O
= O O
12 O O
) O O
of O O
patients O O
with O O
MDP B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
12 O O
. O O
0 O O
% O O
( O O
n O O
= O O
3 O O
) O O
of O O
patients O O
with O O
MD B B_DISEASE/B_LOCATION
, O O
and O O
7 O O
. O O
1 O O
% O O
( O O
n O O
= O O
2 O O
) O O
of O O
control O O
subjects O O
had O O
a O O
panic B B_DISEASE
attack I I_DISEASE
after O O
the O O
480 O O
- O O
mg O O
caffeine O O
challenge O O
test O O
( O O
chi O O
( O O
2 O O
) O O
( O O
3 O O
) O O
= O O
16 O O
. O O
22 O O
, O O
P O O
= O O
. O O
001 O O
) O O
. O O

No O O
panic B B_DISEASE
attack I I_DISEASE
was O O
observed O O
after O O
the O O
caffeine O O
- O O
free O O
solution O O
intake O O
. O O

The O O
patients O O
with O O
MD B B_DISEASE/B_LOCATION
had O O
a O O
lower O O
heart O O
rate O O
response O O
to O O
the O O
test O O
than O O
all O O
the O O
other O O
groups O O
( O O
2 O O
- O O
way O O
analysis O O
of O O
variance O O
, O O
group O O
by O O
time O O
interaction O O
with O O
Greenhouse O O
- O O
Geisser O O
correction O O
: O O
F O O
( O O
3 O O
, O O
762 O O
) O O
= O O
2 O O
. O O
85 O O
, O O
P O O
= O O
. O O
026 O O
) O O
. O O

Our O O
data O O
suggest O O
that O O
there O O
is O O
an O O
association O O
between O O
panic B B_DISEASE
attacks I I_DISEASE
, O O
no O O
matter O O
if O O
associated O O
with O O
PD B B_DISEASE
or O O
MDP B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
hyperreactivity O O
to O O
an O O
oral O O
caffeine O O
challenge O O
test O O
. O O

Mitral O O
annuloplasty O O
as O O
a O O
ventricular O O
restoration O O
method O O
for O O
the O O
failing B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
left I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
ventricle I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
: O O
a O O
pilot O O
study O O
. O O

However O O
, O O
the O O
direct O O
benefits O O
of O O
this O O
possible O O
reshaping O O
on O O
LV O O
function O O
in O O
the O O
absence O O
of O O
underlying O O
MR B B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remain O O
incompletely O O
understood O O
. O O

The O O
study O O
aim O O
was O O
to O O
identify O O
these O O
benefits O O
in O O
a O O
canine O O
model O O
of O O
acute O O
heart B B_DISEASE/B_LOCATION
failure I I_DISEASE/I_LOCATION
. O O

METHODS O O
: O O
Six O O
dogs O O
underwent O O
MAP O O
with O O
a O O
prosthetic O O
band O O
on O O
the O O
posterior O O
mitral O O
annulus O O
, O O
using O O
four O O
mattress O O
sutures O O
. O O

The O O
sutures O O
were O O
passed O O
individually O O
through O O
four O O
tourniquets O O
and O O
exteriorized O O
untied O O
via O O
the O O
left O O
atriotomy O O
. O O

Sonomicrometry O O
crystals O O
were O O
implanted O O
around O O
the O O
mitral O O
annulus O O
and O O
left O O
ventricle O O
to O O
measure O O
geometry O O
and O O
regional O O
function O O
. O O

Acute O O
heart B B_DISEASE
failure I I_DISEASE
was O O
induced O O
by O O
propranolol O O
and O O
volume O O
loading O O
after O O
weaning O O
from O O
cardiopulmonary O O
bypass O O
; O O
an O O
absence O O
of O O
MR B B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
confirmed O O
by O O
echocardiography O O
. O O

MAP O O
was O O
accomplished O O
by O O
cinching O O
the O O
tourniquets O O
. O O

Data O O
were O O
acquired O O
at O O
baseline O O
, O O
after O O
induction O O
of O O
acute O O
heart B B_DISEASE
failure I I_DISEASE
, O O
and O O
after O O
MAP O O
. O O

RESULTS O O
: O O
MAP O O
decreased O O
mitral O O
annular O O
dimensions O O
in O O
both O O
commissure O O
- O O
commissure O O
and O O
septal O O
- O O
lateral O O
directions O O
. O O

CONCLUSION O O
: O O
The O O
data O O
acquired O O
suggest O O
that O O
isolated O O
MAP O O
may O O
have O O
certain O O
benefits O O
on O O
LV O O
dimension O O
/ O O
function O O
in O O
acute O O
heart B B_DISEASE
failure I I_DISEASE
, O O
even O O
in O O
the O O
absence O O
of O O
MR B B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

However O O
, O O
further O O
investigations O O
are O O
warranted O O
in O O
a O O
model O O
of O O
chronic O O
heart B B_DISEASE
failure I I_DISEASE
. O O

Piperacillin O O
/ O O
tazobactam O O
- O O
induced O O
seizure B B_DISEASE
rapidly O O
reversed O O
by O O
high O O
flux O O
hemodialysis O O
in O O
a O O
patient O O
on O O
peritoneal O O
dialysis O O
. O O

Despite O O
popular O O
use O O
of O O
piperacillin O O
, O O
the O O
dire O O
neurotoxicity B B_DISEASE
associated O O
with O O
piperacillin O O
still O O
goes O O
unrecognized O O
, O O
leading O O
to O O
a O O
delay O O
in O O
appropriate O O
management O O
. O O

The O O
laboratory O O
data O O
revealed O O
normal O O
plasma O O
electrolyte O O
and O O
ammonia O O
levels O O
but O O
leukocytosis B B_DISEASE_ADJECTIVE[DISEASE]
. O O

Neurologic O O
examinations O O
showed O O
dysarthria B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
bilateral O O
Babinski O O
sign O O
. O O

Computed O O
tomography O O
of O O
brain O O
and O O
electroencephalogram O O
were O O
unremarkable O O
. O O

Despite O O
the O O
use O O
of O O
antiepileptic O O
agents O O
, O O
another O O
GTCS B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
episode O O
recurred O O
after O O
the O O
sixth O O
dose O O
of O O
piperacillin O O
/ O O
tazobactam O O
. O O

Brain O O
magnetic O O
resonance O O
imaging O O
did O O
not O O
demonstrate O O
acute O O
infarction B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
organic B B_DISEASE
brain I I_DISEASE
lesions I I_DISEASE
. O O

Piperacillin O O
- O O
induced O O
encephalopathy B B_DISEASE
should O O
be O O
considered O O
in O O
any O O
uremic B B_DISEASE/B_PERSON
patients O O
with O O
unexplained O O
neurological O O
manifestations O O
. O O

CAPD O O
is O O
inefficient O O
in O O
removing O O
piperacillin O O
, O O
whereas O O
hemodialysis O O
can O O
rapidly O O
terminate O O
the O O
piperacillin O O
- O O
induced O O
encephalopathy B B_DISEASE
. O O

Frequency O O
of O O
transient O O
ipsilateral O O
vocal B B_DISEASE
cord I I_DISEASE
paralysis I I_DISEASE
in O O
patients O O
undergoing O O
carotid O O
endarterectomy O O
under O O
local O O
anesthesia O O
. O O

BACKGROUND O O
: O O
Especially O O
because O O
of O O
improvements O O
in O O
clinical O O
neurologic O O
monitoring O O
, O O
carotid O O
endarterectomy O O
done O O
under O O
local O O
anesthesia O O
has O O
become O O
the O O
technique O O
of O O
choice O O
in O O
several O O
centers O O
. O O

Temporary O O
ipsilateral O O
vocal B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nerve I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
palsies I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
due O O
to O O
local O O
anesthetics O O
have O O
been O O
described O O
, O O
however O O
. O O

Such O O
complications O O
are O O
most O O
important O O
in O O
situations O O
where O O
there O O
is O O
a O O
pre O O
- O O
existing O O
contralateral O O
paralysis B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

METHODS O O
: O O
This O O
prospective O O
study O O
included O O
28 O O
patients O O
undergoing O O
carotid O O
endarterectomy O O
under O O
local O O
anesthesia O O
. O O

Vocal O O
cord O O
function O O
was O O
evaluated O O
before O O
, O O
during O O
, O O
and O O
after O O
surgery O O
( O O
postoperative O O
day O O
1 O O
) O O
using O O
flexible O O
laryngoscopy O O
. O O

Anesthesia O O
was O O
performed O O
by O O
injecting O O
20 O O
to O O
40 O O
mL O O
of O O
a O O
mixture O O
of O O
long O O
- O O
acting O O
( O O
ropivacaine O O
) O O
and O O
short O O
- O O
acting O O
( O O
prilocaine O O
) O O
anesthetic O O
. O O

Twelve O O
patients O O
( O O
43 O O
% O O
) O O
were O O
found O O
to O O
have O O
intraoperative O O
ipsilateral O O
vocal B B_DISEASE
cord I I_DISEASE
paralysis I I_DISEASE
. O O

It O O
resolved O O
in O O
all O O
cases O O
< O O
or O O
= O O
24 O O
hours O O
. O O

There O O
were O O
no O O
significant O O
differences O O
in O O
operating O O
time O O
or O O
volume O O
or O O
frequency O O
of O O
anesthetic O O
administration O O
in O O
patients O O
with O O
temporary O O
vocal B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cord I B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
paralysis I B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
compared O O
with O O
those O O
without O O
. O O

CONCLUSION O O
: O O
Local O O
anesthesia O O
led O O
to O O
temporary O O
ipsilateral O O
vocal B B_DISEASE
cord I I_DISEASE
paralysis I I_DISEASE
in O O
almost O O
half O O
of O O
these O O
patients O O
. O O

Because O O
pre O O
- O O
existing O O
paralysis B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
of O O
a O O
relevant O O
frequency O O
( O O
up O O
to O O
3 O O
% O O
) O O
, O O
a O O
preoperative O O
evaluation O O
of O O
vocal O O
cord O O
function O O
before O O
carotid O O
endarterectomy O O
under O O
local O O
anesthesia O O
is O O
recommended O O
to O O
avoid O O
intraoperative O O
bilateral O O
paralysis B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

In O O
patients O O
with O O
preoperative O O
contralateral O O
vocal B B_DISEASE
cord I I_DISEASE
paralysis I I_DISEASE
, O O
surgery O O
under O O
general O O
anesthesia O O
should O O
be O O
considered O O
. O O

Impaired B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fear I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recognition I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
regular O O
recreational O O
cocaine O O
users O O
. O O

INTRODUCTION O O
: O O
The O O
ability O O
to O O
read O O
facial O O
expressions O O
is O O
essential O O
for O O
normal O O
human O O
social O O
interaction O O
. O O

MATERIALS O O
AND O O
METHODS O O
: O O
Three O O
groups O O
, O O
comprised O O
of O O
21 O O
cocaine O O
naive O O
participants O O
( O O
CN O O
) O O
, O O
30 O O
occasional O O
cocaine O O
( O O
OC O O
) O O
, O O
and O O
48 O O
regular O O
recreational O O
cocaine O O
( O O
RC O O
) O O
users O O
, O O
were O O
compared O O
. O O

Mean O O
percent O O
accuracy O O
and O O
latencies O O
for O O
correct O O
responses O O
across O O
eight O O
presentations O O
of O O
each O O
basic O O
emotion O O
were O O
derived O O
. O O

RESULTS O O
: O O
There O O
were O O
no O O
group O O
differences O O
in O O
psychopathology O O
or O O
" O O
eyes O O
task O O
" O O
performance O O
, O O
but O O
the O O
RC O O
group O O
, O O
who O O
otherwise O O
had O O
similar O O
illicit O O
substance O O
use O O
histories O O
to O O
the O O
OC O O
group O O
, O O
exhibited O O
impaired B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
fear I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
recognition I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
accuracy O O
compared O O
to O O
the O O
OC O O
and O O
CN O O
groups O O
. O O

The O O
selective O O
deficit B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in I I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fear I I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recognition I I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
accuracy O O
manifested O O
by O O
the O O
RC O O
group O O
cannot O O
be O O
explained O O
by O O
the O O
subacute O O
effects O O
of O O
cocaine O O
, O O
or O O
ecstasy O O
, O O
because O O
recent O O
and O O
less O O
recent O O
users O O
of O O
these O O
drugs O O
within O O
this O O
group O O
were O O
similarly O O
impaired O O
. O O

Possible O O
parallels O O
between O O
RC O O
users O O
and O O
psychopaths B B_PERSON/B_DISEASE
with O O
respect O O
to O O
impaired B B_DISEASE
fear I I_DISEASE
recognition I I_DISEASE
, O O
amygdala B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dysfunction I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
etiology O O
are O O
discussed O O
. O O

Damage B B_DISEASE_ADJECTIVE[DISEASE]
of I I_DISEASE_ADJECTIVE[DISEASE]
substantia I I_DISEASE_ADJECTIVE[DISEASE]
nigra I I_DISEASE_ADJECTIVE[DISEASE]
pars I I_DISEASE_ADJECTIVE[DISEASE]
reticulata I I_DISEASE_ADJECTIVE[DISEASE]
during O O
pilocarpine O O
- O O
induced O O
status B B_DISEASE
epilepticus I I_DISEASE
in O O
the O O
rat O O
: O O
immunohistochemical O O
study O O
of O O
neurons O O
, O O
astrocytes O O
and O O
serum O O
- O O
protein O O
extravasation O O
. O O

The O O
substantia O O
nigra O O
has O O
a O O
gating O O
function O O
controlling O O
the O O
spread O O
of O O
epileptic B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
seizure I B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
activity O O
. O O

Additionally O O
, O O
in O O
models O O
of O O
prolonged B B_DISEASE
status I I_DISEASE
epilepticus I I_DISEASE
the O O
pars O O
reticulata O O
of O O
substantia O O
nigra O O
( O O
SNR O O
) O O
suffers O O
from O O
a O O
massive O O
lesion O O
which O O
may O O
arise O O
from O O
a O O
massive O O
metabolic B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
derangement I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
hyperexcitation O O
developing O O
in O O
the O O
activated O O
SNR O O
. O O

In O O
this O O
study O O
, O O
status B B_DISEASE
epilepticus I I_DISEASE
was O O
induced O O
by O O
systemic O O
injection O O
of O O
pilocarpine O O
in O O
rats O O
. O O

Animals O O
surviving O O
20 O O
, O O
30 O O
, O O
40 O O
, O O
60 O O
min O O
, O O
2 O O
, O O
3 O O
, O O
6 O O
hours O O
, O O
1 O O
, O O
2 O O
, O O
and O O
3 O O
days O O
after O O
induction O O
of O O
status B B_DISEASE
epilepticus I I_DISEASE
were O O
perfusion O O
- O O
fixed O O
, O O
and O O
brains O O
processed O O
for O O
immunohistochemical O O
staining O O
of O O
SNR O O
. O O

Nissl O O
- O O
staining O O
and O O
antibodies O O
against O O
the O O
neuron O O
- O O
specific O O
calcium O O
- O O
binding O O
protein O O
, O O
parvalbumin O O
, O O
served O O
to O O
detect O O
neuronal B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
damage I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
SNR O O
. O O

Antibodies O O
against O O
the O O
astroglia O O
- O O
specific O O
cytoskeletal O O
protein O O
, O O
glial O O
fibrillary O O
acidic O O
protein O O
( O O
GFAP O O
) O O
, O O
and O O
against O O
the O O
glial O O
calcium O O
- O O
binding O O
protein O O
, O O
S O O
- O O
100 O O
protein O O
, O O
were O O
used O O
to O O
assess O O
the O O
status O O
of O O
astrocytes O O
. O O

Immunohistochemical O O
staining O O
for O O
serum O O
- O O
albumin O O
and O O
immunoglobulins O O
in O O
brain O O
tissue O O
was O O
taken O O
as O O
indicator O O
of O O
blood O O
- O O
brain O O
barrier O O
disturbances O O
and O O
vasogenic B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
edema I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
formation O O
. O O

Immunohistochemical O O
staining O O
indicated O O
loss O O
of O O
GFAP O O
- O O
staining O O
already O O
at O O
30 O O
min O O
after O O
induction O O
of O O
seizures B B_DISEASE/B_GENE
in O O
an O O
oval O O
focus O O
situated O O
in O O
the O O
center O O
of O O
SNR O O
while O O
sparing O O
medial O O
and O O
lateral O O
aspects O O
. O O

At O O
1 O O
h O O
there O O
was O O
additional O O
vacuolation O O
in O O
S O O
- O O
100 O O
protein O O
staining O O
. O O

By O O
2 O O
hours O O
, O O
parvalbumin O O
- O O
staining O O
changed O O
in O O
the O O
central O O
SNR O O
indicating O O
neuronal B B_DISEASE
damage I I_DISEASE
, O O
and O O
Nissl O O
- O O
staining O O
visualized O O
some O O
neuronal O O
distortion O O
. O O

Staining O O
for O O
serum O O
- O O
proteins O O
occurred O O
in O O
a O O
patchy O O
manner O O
throughout O O
the O O
forebrain O O
during O O
the O O
first O O
hours O O
. O O

In O O
a O O
further O O
group O O
of O O
animals O O
surviving O O
1 O O
to O O
5 O O
days O O
, O O
conventional O O
paraffin O O
- O O
sections O O
confirmed O O
the O O
neuronal O O
and O O
glial O O
damage B B_DISEASE
of I I_DISEASE
SNR I I_DISEASE
. O O

Both O O
cell O O
elements O O
may O O
suffer O O
in O O
common O O
from O O
metabolic O O
disturbance O O
and O O
neurotransmitter B B_DISEASE
dysfunction I I_DISEASE
as O O
occur O O
during O O
massive O O
status B B_DISEASE
epilepticus I I_DISEASE
. O O

Neuroprotective O O
effects O O
of O O
melatonin O O
upon O O
the O O
offspring O O
cerebellar O O
cortex O O
in O O
the O O
rat O O
model O O
of O O
BCNU O O
- O O
induced O O
cortical B B_DISEASE
dysplasia I I_DISEASE
. O O

Cortical B B_DISEASE/B_GENE
dysplasia I I_DISEASE/I_GENE
is O O
a O O
malformation O O
characterized O O
by O O
defects O O
in O O
proliferation O O
, O O
migration O O
and O O
maturation O O
. O O

This O O
study O O
was O O
designed O O
to O O
evaluate O O
the O O
alterations O O
in O O
offspring O O
rat O O
cerebellum O O
induced O O
by O O
maternal O O
exposure O O
to O O
carmustine O O
- O O
[ O O
1 O O
, O O
3 O O
- O O
bis O O
( O O
2 O O
- O O
chloroethyl O O
) O O
- O O
1 O O
- O O
nitrosoure O O
] O O
( O O
BCNU O O
) O O
and O O
to O O
investigate O O
the O O
effects O O
of O O
exogenous O O
melatonin O O
upon O O
cerebellar O O
BCNU O O
- O O
induced O O
cortical B B_DISEASE
dysplasia I I_DISEASE
, O O
using O O
histological O O
and O O
biochemical O O
analyses O O
. O O

Pregnant O O
Wistar O O
rats O O
were O O
assigned O O
to O O
five O O
groups O O
: O O
intact O O
- O O
control O O
, O O
saline O O
- O O
control O O
, O O
melatonin O O
- O O
treated O O
, O O
BCNU O O
- O O
exposed O O
and O O
BCNU O O
- O O
exposed O O
plus O O
melatonin O O
. O O

Rats O O
were O O
exposed O O
to O O
BCNU O O
on O O
embryonic O O
day O O
15 O O
and O O
melatonin O O
was O O
given O O
until O O
delivery O O
. O O

Immuno O O
/ O O
histochemistry O O
and O O
electron O O
microscopy O O
were O O
carried O O
out O O
on O O
the O O
offspring O O
cerebellum O O
, O O
and O O
levels O O
of O O
malondialdehyde O O
and O O
superoxide O O
dismutase O O
were O O
determined O O
. O O

Histopathologically O O
, O O
typical O O
findings O O
were O O
observed O O
in O O
the O O
cerebella O O
from O O
the O O
control O O
groups O O
, O O
but O O
the O O
findings O O
consistent O O
with O O
early O O
embryonic O O
development O O
were O O
noted O O
in O O
BCNU O O
- O O
exposed O O
cortical B B_DISEASE/B_PERSON
dysplasia I I_DISEASE/I_PERSON
group O O
. O O

There O O
was O O
a O O
marked O O
increase O O
in O O
the O O
number O O
of O O
TUNEL O O
positive O O
cells O O
and O O
nestin O O
positive O O
cells O O
in O O
BCNU O O
- O O
exposed O O
group O O
, O O
but O O
a O O
decreased O O
immunoreactivity O O
to O O
glial O O
fibrillary O O
acidic O O
protein O O
, O O
synaptophysin O O
and O O
transforming O O
growth O O
factor O O
beta1 O O
was O O
observed O O
, O O
indicating O O
a O O
delayed O O
maturation O O
, O O
and O O
melatonin O O
significantly O O
reversed O O
these O O
changes O O
. O O

Malondialdehyde O O
level O O
in O O
BCNU O O
- O O
exposed O O
group O O
was O O
higher O O
than O O
those O O
in O O
control O O
groups O O
and O O
melatonin O O
decreased O O
malondialdehyde O O
levels O O
in O O
BCNU O O
group O O
( O O
P O O
< O O
0 O O
. O O
01 O O
) O O
, O O
while O O
there O O
were O O
no O O
significant O O
differences O O
in O O
the O O
superoxide O O
dismutase O O
levels O O
between O O
these O O
groups O O
. O O

Reduced O O
cardiotoxicity B B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
doxorubicin O O
given O O
in O O
the O O
form O O
of O O
N O O
- O O
( O O
2 O O
- O O
hydroxypropyl O O
) O O
methacrylamide O O
conjugates O O
: O O
and O O
experimental O O
study O O
in O O
the O O
rat O O
. O O

A O O
rat O O
model O O
was O O
used O O
to O O
evaluate O O
the O O
general O O
acute O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
late O O
cardiotoxicity B B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
4 O O
mg O O
/ O O
kg O O
doxorubicin O O
( O O
DOX O O
) O O
given O O
either O O
as O O
free O O
drug O O
or O O
in O O
the O O
form O O
of O O
three O O
N O O
- O O
( O O
2 O O
- O O
hydroxypropyl O O
) O O
methacrylamide O O
( O O
HPMA O O
) O O
copolymer O O
conjugates O O
. O O

In O O
these O O
HPMA O O
copolymers O O
, O O
DOX O O
was O O
covalently O O
bound O O
via O O
peptide O O
linkages O O
that O O
were O O
either O O
non O O
- O O
biodegradable O O
( O O
Gly O O
- O O
Gly O O
) O O
or O O
degradable O O
by O O
lysosomal O O
proteinases O O
( O O
Gly O O
- O O
Phe O O
- O O
Leu O O
- O O
Gly O O
) O O
. O O

In O O
addition O O
, O O
one O O
biodegradable O O
conjugate O O
containing O O
galactosamine O O
was O O
used O O
; O O
this O O
residue O O
was O O
targeted O O
to O O
the O O
liver O O
. O O

Throughout O O
the O O
study O O
( O O
20 O O
weeks O O
) O O
, O O
deaths O O
related O O
to O O
cardiotoxicity B B_DISEASE
were O O
observed O O
only O O
in O O
animals O O
that O O
received O O
either O O
free O O
DOX O O
or O O
the O O
mixture O O
of O O
HPMA O O
copolymer O O
and O O
free O O
DOX O O
; O O
in O O
these O O
cases O O
, O O
histological O O
investigations O O
revealed O O
marked O O
changes O O
in O O
the O O
heart O O
that O O
were O O
consistent O O
with O O
DOX O O
- O O
induced O O
cardiotoxicity B B_DISEASE
. O O

The O O
heart O O
rate O O
in O O
these O O
animals O O
was O O
approximately O O
12 O O
% O O
lower O O
than O O
that O O
measured O O
in O O
age O O
- O O
matched O O
control O O
rats O O
( O O
P O O
less O O
than O O
0 O O
. O O
05 O O
) O O
. O O

Animals O O
that O O
were O O
given O O
the O O
HPMA O O
copolymer O O
conjugates O O
containing O O
DOX O O
exhibited O O
no O O
significant O O
change O O
in O O
cardiac O O
output O O
throughout O O
the O O
study O O
( O O
P O O
less O O
than O O
0 O O
. O O
05 O O
) O O
. O O

Corneal B B_DISEASE
ulcers I I_DISEASE
associated O O
with O O
aerosolized O O
crack O O
cocaine O O
use O O
. O O

PURPOSE O O
: O O
We O O
report O O
4 O O
cases O O
of O O
corneal B B_DISEASE
ulcers I I_DISEASE
associated O O
with O O
drug B B_DISEASE
abuse I I_DISEASE
. O O

The O O
pathogenesis O O
of O O
these O O
ulcers B B_DISEASE/B_BIO
and O O
management O O
of O O
these O O
patients O O
are O O
also O O
reviewed O O
. O O

METHODS O O
: O O
Review O O
of O O
all O O
cases O O
of O O
corneal B B_DISEASE/B_LOCATION
ulcers I I_DISEASE/I_LOCATION
associated O O
with O O
drug B B_DISEASE
abuse I I_DISEASE
seen O O
at O O
our O O
institution O O
from O O
July O O
2006 O O
to O O
December O O
2006 O O
. O O

RESULTS O O
: O O
Four O O
patients O O
with O O
corneal B B_DISEASE
ulcers I I_DISEASE
associated O O
with O O
crack O O
cocaine O O
use O O
were O O
reviewed O O
. O O

All O O
corneal B B_DISEASE/B_BIO
ulcers I I_DISEASE/I_BIO
were O O
cultured O O
, O O
and O O
the O O
patients O O
were O O
admitted O O
to O O
the O O
hospital O O
for O O
intensive O O
topical O O
antibiotic O O
treatment O O
. O O

Streptococcal O O
organisms O O
were O O
found O O
in O O
3 O O
cases O O
and O O
Capnocytophaga O O
and O O
Brevibacterium O O
casei O O
in O O
1 O O
patient O O
. O O

The O O
infections B B_DISEASE/B_PERSON
responded O O
to O O
antibiotic O O
treatment O O
. O O

Two O O
patients O O
needed O O
a O O
lateral O O
tarsorrhaphy O O
for O O
persistent O O
epithelial B B_DISEASE
defects I I_DISEASE
. O O

CONCLUSIONS O O
: O O
Aerosolized O O
crack O O
cocaine O O
use O O
can O O
be O O
associated O O
with O O
the O O
development O O
of O O
corneal B B_DISEASE/B_LOCATION
ulcers I I_DISEASE/I_LOCATION
. O O

Drug B B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abuse I B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provides O O
additional O O
challenges O O
for O O
management O O
. O O

Not O O
only O O
treatment O O
of O O
their O O
infections B B_DISEASE
but O O
also O O
the O O
overall O O
poor O O
health O O
of O O
the O O
patients O O
and O O
increased O O
risk O O
of O O
noncompliance O O
need O O
to O O
be O O
addressed O O
. O O

Comprehensive O O
care O O
may O O
provide O O
the O O
patient O O
the O O
opportunity O O
to O O
discontinue O O
their O O
substance B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
abuse I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
improve O O
their O O
overall O O
health O O
, O O
and O O
prevent O O
future O O
corneal O O
complications O O
. O O

Topical O O
0 O O
. O O
025 O O
% O O
capsaicin O O
in O O
chronic O O
post B B_DISEASE
- I I_DISEASE
herpetic I I_DISEASE
neuralgia I I_DISEASE
: O O
efficacy O O
, O O
predictors O O
of O O
response O O
and O O
long O O
- O O
term O O
course O O
. O O

In O O
order O O
to O O
evaluate O O
the O O
efficacy O O
, O O
time O O
- O O
course O O
of O O
action O O
and O O
predictors O O
of O O
response O O
to O O
topical O O
capsaicin O O
, O O
39 O O
patients O O
with O O
chronic O O
post B B_DISEASE
- I I_DISEASE
herpetic I I_DISEASE
neuralgia I I_DISEASE
( O O
PHN B B_DISEASE/B_LOCATION
) O O
, O O
median O O
duration O O
24 O O
months O O
, O O
were O O
treated O O
with O O
0 O O
. O O
025 O O
% O O
capsaicin O O
cream O O
for O O
8 O O
weeks O O
. O O

During O O
therapy O O
the O O
patients O O
rated O O
their O O
pain B B_DISEASE
on O O
a O O
visual O O
analogue O O
scale O O
( O O
VAS O O
) O O
and O O
a O O
verbal O O
outcome O O
scale O O
. O O

A O O
follow O O
- O O
up O O
investigation O O
was O O
performed O O
10 O O
- O O
12 O O
months O O
after O O
study O O
onset O O
on O O
the O O
patients O O
who O O
had O O
improved O O
. O O

Nineteen O O
patients O O
( O O
48 O O
. O O
7 O O
% O O
) O O
substantially O O
improved O O
after O O
the O O
8 O O
- O O
week O O
trial O O
; O O
5 O O
( O O
12 O O
. O O
8 O O
% O O
) O O
discontinued O O
therapy O O
due O O
to O O
side O O
- O O
effects O O
such O O
as O O
intolerable O O
capsaicin O O
- O O
induced O O
burning O O
sensations O O
( O O
4 O O
) O O
or O O
mastitis B B_DISEASE
( O O
1 O O
) O O
; O O
15 O O
( O O
38 O O
. O O
5 O O
% O O
) O O
reported O O
no O O
benefit O O
. O O

The O O
decrease O O
in O O
VAS O O
ratings O O
was O O
significant O O
after O O
2 O O
weeks O O
of O O
continuous O O
application O O
. O O

Of O O
the O O
responders O O
72 O O
. O O
2 O O
% O O
were O O
still O O
improved O O
at O O
the O O
follow O O
- O O
up O O
; O O
only O O
one O O
- O O
third O O
of O O
them O O
had O O
continued O O
application O O
irregularly O O
. O O

Treatment O O
effect O O
was O O
not O O
dependent O O
on O O
patient O O
' O O
s O O
age O O
, O O
duration O O
or O O
localization O O
of O O
PHN B B_DISEASE
( O O
trigeminal O O
involvement O O
was O O
excluded O O
) O O
, O O
sensory B B_DISEASE
disturbance I I_DISEASE
or O O
pain B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
character O O
. O O

If O O
confirmed O O
in O O
controlled O O
trials O O
, O O
the O O
long O O
- O O
term O O
results O O
of O O
this O O
open O O
, O O
non O O
- O O
randomized O O
study O O
might O O
indicate O O
that O O
the O O
analgesic O O
effect O O
of O O
capsaicin O O
in O O
PHN B B_DISEASE/B_SPECIES[BIO]
is O O
mediated O O
by O O
both O O
interference O O
with O O
neuropeptide O O
metabolism O O
and O O
morphological O O
changes O O
( O O
perhaps O O
degeneration O O
) O O
of O O
nociceptive O O
afferents O O
. O O

Myo O O
- O O
inositol O O
- O O
1 O O
- O O
phosphate O O
( O O
MIP O O
) O O
synthase O O
inhibition O O
: O O
in O O
- O O
vivo O O
study O O
in O O
rats O O
. O O

Lithium O O
and O O
valproate O O
are O O
the O O
prototypic O O
mood O O
stabilizers O O
and O O
have O O
diverse O O
structures O O
and O O
targets O O
. O O

Both O O
drugs O O
influence O O
inositol O O
metabolism O O
. O O

Lithium O O
inhibits O O
IMPase O O
and O O
valproate O O
inhibits O O
MIP O O
synthase O O
. O O

This O O
study O O
shows O O
that O O
MIP O O
synthase O O
inhibition O O
does O O
not O O
replicate O O
or O O
augment O O
the O O
effects O O
of O O
lithium O O
in O O
the O O
inositol O O
sensitive O O
pilocarpine O O
- O O
induced O O
seizures B B_DISEASE
model O O
. O O

Non O O
- O O
steroidal O O
anti O O
- O O
inflammatory O O
drugs O O
- O O
associated O O
acute O O
interstitial B B_DISEASE
nephritis I I_DISEASE
with O O
granular O O
tubular O O
basement O O
membrane O O
deposits O O
. O O

Acute B B_DISEASE_ADJECTIVE[DISEASE]
tubulo I I_DISEASE_ADJECTIVE[DISEASE]
- I I_DISEASE_ADJECTIVE[DISEASE]
interstitial I I_DISEASE_ADJECTIVE[DISEASE]
nephritis I I_DISEASE_ADJECTIVE[DISEASE]
( O O
ATIN B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
is O O
an O O
important O O
cause O O
of O O
acute B B_DISEASE
renal I I_DISEASE
failure I I_DISEASE
resulting O O
from O O
a O O
variety O O
of O O
insults O O
, O O
including O O
immune O O
complex O O
- O O
mediated O O
tubulo B B_DISEASE
- I I_DISEASE
interstitial I I_DISEASE
injury I I_DISEASE
, O O
but O O
drugs O O
such O O
as O O
non O O
- O O
steroidal O O
anti O O
- O O
inflammatory O O
drugs O O
( O O
NSAIDs O O
) O O
are O O
a O O
far O O
more O O
frequent O O
cause O O
. O O

Overall O O
, O O
as O O
an O O
entity O O
, O O
ATIN B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
remains O O
under O O
- O O
diagnosed O O
, O O
as O O
symptoms O O
resolve O O
spontaneously O O
if O O
the O O
medication O O
is O O
stopped O O
. O O

We O O
report O O
on O O
a O O
14 O O
- O O
year O O
- O O
old O O
boy O O
who O O
developed O O
acute B B_DISEASE
renal I I_DISEASE
failure I I_DISEASE
2 O O
weeks O O
after O O
aortic O O
valve O O
surgery O O
. O O

He O O
was O O
put O O
on O O
aspirin O O
following O O
surgery O O
and O O
took O O
ibuprofen O O
for O O
fever B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
nearly O O
a O O
week O O
prior O O
to O O
presentation O O
. O O

Dialysis O O
was O O
immediately O O
initiated O O
. O O

A O O
kidney O O
biopsy O O
showed O O
inflammatory O O
infiltrate O O
consistent O O
with O O
ATIN B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

His O O
renal O O
recovery O O
and O O
disappearance O O
of O O
proteinuria B B_DISEASE
took O O
a O O
year O O
. O O

In O O
conclusion O O
, O O
this O O
is O O
a O O
first O O
report O O
of O O
NSAIDs O O
- O O
associated O O
ATIN B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
showing O O
deposits O O
of O O
granular O O
immune O O
complex O O
present O O
only O O
in O O
the O O
TBM O O
and O O
not O O
in O O
the O O
glomeruli O O
. O O

Rifampicin O O
- O O
associated O O
segmental O O
necrotizing O O
glomerulonephritis B B_DISEASE
in O O
staphylococcal B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
endocarditis I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

Segmental O O
necrotising O O
glomerulonephritis B B_DISEASE
has O O
been O O
reported O O
as O O
complication O O
of O O
rifampicin O O
therapy O O
in O O
patients O O
receiving O O
treatment O O
for O O
tuberculosis B B_DISEASE/B_GENE
. O O

Changing O O
epidemiology O O
of O O
infections B B_DISEASE/B_BIO
such O O
as O O
infective B B_DISEASE
endocarditis I I_DISEASE
( O O
IE B B_DISEASE/B_LOCATION
) O O
has O O
led O O
to O O
an O O
increase O O
in O O
the O O
use O O
of O O
rifampicin O O
for O O
Staphylococcal B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infections I I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
describe O O
a O O
case O O
of O O
a O O
patient O O
with O O
Staphylococcal B B_DISEASE/B_GENE
IE I I_DISEASE/I_GENE
who O O
developed O O
acute B B_DISEASE
renal I I_DISEASE
failure I I_DISEASE
secondary O O
to O O
a O O
segmental O O
necrotising O O
glomerulonephritis B B_DISEASE
while O O
being O O
treated O O
with O O
rifampicin O O
, O O
and O O
review O O
the O O
literature O O
regarding O O
this O O
complication O O
of O O
rifampicin O O
therapy O O
. O O

Rate O O
of O O
YMDD O O
motif O O
mutants O O
in O O
lamivudine O O
- O O
untreated O O
Iranian O O
patients O O
with O O
chronic B B_DISEASE/B_LOCATION
hepatitis I I_DISEASE/I_LOCATION
B I I_DISEASE/I_LOCATION
virus I I_DISEASE/I_LOCATION
infection I I_DISEASE/I_LOCATION
. O O

BACKGROUND O O
: O O
Lamivudine O O
is O O
used O O
for O O
the O O
treatment O O
of O O
chronic B B_DISEASE/B_PERSON
hepatitis I I_DISEASE/I_PERSON
B I I_DISEASE/I_PERSON
patients O O
. O O

Recent O O
studies O O
show O O
that O O
the O O
YMDD O O
motif O O
mutants O O
( O O
resistant O O
hepatitis B B_DISEASE/B_GENE
B I I_DISEASE/I_GENE
virus O O
) O O
occur O O
as O O
natural O O
genome O O
variability O O
in O O
lamivudine O O
- O O
untreated O O
chronic B B_DISEASE/B_LOCATION
hepatitis I I_DISEASE/I_LOCATION
B I I_DISEASE/I_LOCATION
patients O O
. O O

In O O
this O O
study O O
we O O
aimed O O
to O O
determine O O
the O O
rate O O
of O O
YMDD O O
motif O O
mutants O O
in O O
lamivudine O O
- O O
untreated O O
chronic B B_DISEASE/B_LOCATION
hepatitis I I_DISEASE/I_LOCATION
B I I_DISEASE/I_LOCATION
patients O O
in O O
Iran O O
. O O

PATIENTS O O
AND O O
METHODS O O
: O O
A O O
total O O
of O O
77 O O
chronic B B_DISEASE/B_LOCATION
hepatitis I I_DISEASE/I_LOCATION
B I I_DISEASE/I_LOCATION
patients O O
who O O
had O O
not O O
been O O
treated O O
with O O
lamivudine O O
were O O
included O O
in O O
the O O
study O O
. O O

RESULTS O O
: O O
Of O O
the O O
77 O O
patients O O
enrolled O O
in O O
the O O
study O O
, O O
73 O O
% O O
were O O
male O O
and O O
27 O O
% O O
were O O
female O O
. O O

Mean O O
ALT O O
and O O
AST O O
levels O O
were O O
124 O O
. O O
4 O O
+ O O
/ O O
- O O
73 O O
. O O
4 O O
and O O
103 O O
. O O
1 O O
+ O O
/ O O
- O O
81 O O
IU O O
/ O O
l O O
, O O
respectively O O
. O O

CONCLUSION O O
: O O
Although O O
the O O
natural O O
occurrence O O
of O O
YMDD O O
motif O O
mutants O O
in O O
lamivudine O O
- O O
untreated O O
patients O O
with O O
chronic B B_DISEASE
hepatitis I I_DISEASE
B I I_DISEASE
has O O
been O O
reported O O
, O O
these O O
mutants O O
were O O
not O O
detected O O
in O O
Iranian O O
lamivudine O O
- O O
untreated O O
chronic B B_DISEASE/B_LOCATION
hepatitis I I_DISEASE/I_LOCATION
B I I_DISEASE/I_LOCATION
patients O O
. O O

Branch O O
retinal B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
vein I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occlusion I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
fluoxetine O O
. O O

A O O
case O O
of O O
branch O O
retinal B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
vein I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occlusion I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
associated O O
with O O
fluoxetine O O
- O O
induced O O
secondary O O
hypertension B B_DISEASE
is O O
described O O
. O O

Although O O
an O O
infrequent O O
complication O O
of O O
selective O O
serotonin O O
reuptake O O
inhibitor O O
therapy O O
, O O
it O O
is O O
important O O
that O O
ophthalmologists O O
are O O
aware O O
that O O
these O O
agents O O
can O O
cause O O
hypertension B B_DISEASE
because O O
this O O
class O O
of O O
drugs O O
is O O
widely O O
prescribed O O
. O O

The O O
differential O O
effects O O
of O O
bupivacaine O O
and O O
lidocaine O O
on O O
prostaglandin O O
E2 O O
release O O
, O O
cyclooxygenase O O
gene O O
expression O O
and O O
pain B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
clinical O O
pain B B_DISEASE
model O O
. O O

BACKGROUND O O
: O O
In O O
addition O O
to O O
blocking O O
nociceptive O O
input O O
from O O
surgical O O
sites O O
, O O
long O O
- O O
acting O O
local O O
anesthetics O O
might O O
directly O O
modulate O O
inflammation B B_DISEASE/B_BACTERIUM[BIO]
. O O

In O O
the O O
present O O
study O O
, O O
we O O
describe O O
the O O
proinflammatory O O
effects O O
of O O
bupivacaine O O
on O O
local O O
prostaglandin O O
E2 O O
( O O
PGE2 O O
) O O
production O O
and O O
cyclooxygenase O O
( O O
COX O O
) O O
gene O O
expression O O
that O O
increases O O
postoperative B B_DISEASE_ADJECTIVE[DISEASE]
pain I I_DISEASE_ADJECTIVE[DISEASE]
in O O
human O O
subjects O O
. O O

Oral O O
mucosal O O
biopsies O O
were O O
taken O O
before O O
surgery O O
and O O
48 O O
h O O
after O O
surgery O O
. O O

After O O
extraction O O
, O O
a O O
microdialysis O O
probe O O
was O O
placed O O
at O O
the O O
surgical O O
site O O
for O O
PGE2 O O
and O O
thromboxane O O
B2 O O
( O O
TXB2 O O
) O O
measurements O O
. O O

RESULTS O O
: O O
The O O
bupivacaine O O
/ O O
rofecoxib O O
group O O
reported O O
significantly O O
less O O
pain B B_DISEASE
, O O
as O O
assessed O O
by O O
a O O
visual O O
analog O O
scale O O
, O O
compared O O
with O O
the O O
other O O
three O O
treatment O O
groups O O
over O O
the O O
first O O
4 O O
h O O
. O O

However O O
, O O
the O O
bupivacaine O O
/ O O
placebo O O
group O O
reported O O
significantly O O
more O O
pain B B_DISEASE
at O O
24 O O
h O O
and O O
PGE2 O O
levels O O
during O O
the O O
first O O
4 O O
h O O
were O O
significantly O O
higher O O
than O O
the O O
other O O
three O O
treatment O O
groups O O
. O O

Moreover O O
, O O
bupivacaine O O
significantly O O
increased O O
COX O O
- O O
2 O O
gene O O
expression O O
at O O
48 O O
h O O
as O O
compared O O
with O O
the O O
lidocaine O O
/ O O
placebo O O
group O O
. O O

Thromboxane O O
levels O O
were O O
not O O
significantly O O
affected O O
by O O
any O O
of O O
the O O
treatments O O
, O O
indicating O O
that O O
the O O
effects O O
seen O O
were O O
attributable O O
to O O
inhibition O O
of O O
COX O O
- O O
2 O O
, O O
but O O
not O O
COX O O
- O O
1 O O
. O O

CONCLUSIONS O O
: O O
These O O
results O O
suggest O O
that O O
bupivacaine O O
stimulates O O
COX O O
- O O
2 O O
gene O O
expression O O
after O O
tissue B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injury I B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
which O O
is O O
associated O O
with O O
higher O O
PGE2 O O
production O O
and O O
pain B B_DISEASE
after O O
the O O
local O O
anesthetic O O
effect O O
dissipates O O
. O O

p75NTR O O
expression O O
in O O
rat O O
urinary O O
bladder O O
sensory O O
neurons O O
and O O
spinal O O
cord O O
with O O
cyclophosphamide O O
- O O
induced O O
cystitis B B_DISEASE
. O O

Previous O O
studies O O
have O O
examined O O
the O O
expression O O
and O O
regulation O O
of O O
tyrosine O O
kinase O O
receptors O O
( O O
Trks O O
) O O
in O O
micturition O O
reflexes O O
with O O
urinary B B_DISEASE
bladder I I_DISEASE
inflammation I I_DISEASE
. O O

The O O
present O O
studies O O
examine O O
the O O
expression O O
and O O
regulation O O
of O O
another O O
receptor O O
known O O
to O O
bind O O
NGF O O
, O O
p75 O O
( O O
NTR O O
) O O
, O O
after O O
various O O
durations O O
of O O
bladder B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inflammation I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induced O O
by O O
cyclophosphamide O O
( O O
CYP O O
) O O
. O O

CYP O O
- O O
induced O O
cystitis B B_DISEASE
increased O O
( O O
P O O
< O O
or O O
= O O
0 O O
. O O
001 O O
) O O
p75 O O
( O O
NTR O O
) O O
expression O O
in O O
the O O
superficial O O
lateral O O
and O O
medial O O
dorsal O O
horn O O
in O O
L1 O O
- O O
L2 O O
and O O
L6 O O
- O O
S1 O O
spinal O O
segments O O
. O O

The O O
number O O
of O O
p75 O O
( O O
NTR O O
) O O
- O O
immunoreactive O O
( O O
- O O
IR O O
) O O
cells O O
in O O
the O O
lumbosacral O O
dorsal O O
root O O
ganglia O O
( O O
DRG O O
) O O
also O O
increased O O
( O O
P O O
< O O
or O O
= O O
0 O O
. O O
05 O O
) O O
with O O
CYP O O
- O O
induced O O
cystitis B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
acute O O
, O O
intermediate O O
, O O
and O O
chronic O O
) O O
. O O

Quantitative O O
, O O
real O O
- O O
time O O
polymerase O O
chain O O
reaction O O
also O O
demonstrated O O
significant O O
increases O O
( O O
P O O
< O O
or O O
= O O
0 O O
. O O
01 O O
) O O
in O O
p75 O O
( O O
NTR O O
) O O
mRNA O O
in O O
DRG O O
with O O
intermediate O O
and O O
chronic O O
CYP O O
- O O
induced O O
cystitis B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Retrograde O O
dye O O
- O O
tracing O O
techniques O O
with O O
Fastblue O O
were O O
used O O
to O O
identify O O
presumptive O O
bladder O O
afferent O O
cells O O
in O O
the O O
lumbosacral O O
DRG O O
. O O

In O O
bladder O O
afferent O O
cells O O
in O O
DRG O O
, O O
p75 O O
( O O
NTR O O
) O O
- O O
IR O O
was O O
also O O
increased O O
( O O
P O O
< O O
or O O
= O O
0 O O
. O O
01 O O
) O O
with O O
cystitis B B_DISEASE
. O O

In O O
addition O O
to O O
increases O O
in O O
p75 O O
( O O
NTR O O
) O O
- O O
IR O O
in O O
DRG O O
cell O O
bodies O O
, O O
increases O O
( O O
P O O
< O O
or O O
= O O
0 O O
. O O
001 O O
) O O
in O O
pericellular O O
( O O
encircling O O
DRG O O
cells O O
) O O
p75 O O
( O O
NTR O O
) O O
- O O
IR O O
in O O
DRG O O
also O O
increased O O
. O O

Confocal O O
analyses O O
demonstrated O O
that O O
pericellular O O
p75 O O
( O O
NTR O O
) O O
- O O
IR O O
was O O
not O O
colocalized O O
with O O
the O O
glial O O
marker O O
, O O
glial O O
fibrillary O O
acidic O O
protein O O
( O O
GFAP O O
) O O
. O O

These O O
studies O O
demonstrate O O
that O O
p75 O O
( O O
NTR O O
) O O
expression O O
in O O
micturition O O
reflexes O O
is O O
present O O
constitutively O O
and O O
modified O O
by O O
bladder B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inflammation I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

BACKGROUND O O
: O O
Azathioprine O O
is O O
widely O O
used O O
as O O
an O O
immunosuppressive O O
drug O O
. O O

The O O
side O O
effects O O
of O O
azathioprine O O
include O O
anemia B B_DISEASE
, O O
which O O
has O O
been O O
attributed O O
to O O
bone O O
marrow O O
suppression O O
. O O

Alternatively O O
, O O
anemia B B_DISEASE/B_PERSON
could O O
result O O
from O O
accelerated O O
suicidal O O
erythrocyte O O
death O O
or O O
eryptosis O O
, O O
which O O
is O O
characterized O O
by O O
exposure O O
of O O
phosphatidylserine O O
( O O
PS O O
) O O
at O O
the O O
erythrocyte O O
surface O O
and O O
by O O
cell O O
shrinkage O O
. O O

METHODS O O
: O O
The O O
present O O
experiments O O
explored O O
whether O O
azathioprine O O
influences O O
eryptosis O O
. O O

According O O
to O O
annexin O O
V O O
binding O O
, O O
erythrocytes O O
from O O
patients O O
indeed O O
showed O O
a O O
significant O O
increase O O
of O O
PS O O
exposure O O
within O O
1 O O
week O O
of O O
treatment O O
with O O
azathioprine O O
. O O

In O O
a O O
second O O
series O O
, O O
cytosolic O O
Ca2 O O
+ O O
activity O O
( O O
Fluo3 O O
fluorescence O O
) O O
, O O
cell O O
volume O O
( O O
forward O O
scatter O O
) O O
, O O
and O O
PS O O
- O O
exposure O O
( O O
annexin O O
V O O
binding O O
) O O
were O O
determined O O
by O O
FACS O O
analysis O O
in O O
erythrocytes O O
from O O
healthy O O
volunteers O O
. O O

RESULTS O O
: O O
Exposure O O
to O O
azathioprine O O
( O O
> O O
or O O
= O O
2 O O
microg O O
/ O O
mL O O
) O O
for O O
48 O O
hours O O
increased O O
cytosolic O O
Ca2 O O
+ O O
activity O O
and O O
annexin O O
V O O
binding O O
and O O
decreased O O
forward O O
scatter O O
. O O

The O O
effect O O
of O O
azathioprine O O
on O O
both O O
annexin O O
V O O
binding O O
and O O
forward O O
scatter O O
was O O
significantly O O
blunted O O
in O O
the O O
nominal O O
absence O O
of O O
extracellular O O
Ca2 O O
+ O O
. O O

CONCLUSIONS O O
: O O
Azathioprine O O
triggers O O
suicidal O O
erythrocyte O O
death O O
, O O
an O O
effect O O
presumably O O
contributing O O
to O O
azathioprine O O
- O O
induced O O
anemia B B_DISEASE
. O O

Levetiracetam O O
as O O
an O O
adjunct O O
to O O
phenobarbital O O
treatment O O
in O O
cats O O
with O O
suspected O O
idiopathic B B_DISEASE
epilepsy I I_DISEASE
. O O

OBJECTIVE O O
: O O
To O O
assess O O
pharmacokinetics O O
, O O
efficacy O O
, O O
and O O
tolerability O O
of O O
oral O O
levetiracetam O O
administered O O
as O O
an O O
adjunct O O
to O O
phenobarbital O O
treatment O O
in O O
cats O O
with O O
poorly O O
controlled O O
suspected O O
idiopathic B B_DISEASE
epilepsy I I_DISEASE
. O O

DESIGN O O
- O O
Open O O
- O O
label O O
, O O
noncomparative O O
clinical O O
trial O O
. O O

ANIMALS O O
: O O
12 O O
cats O O
suspected O O
to O O
have O O
idiopathic B B_DISEASE
epilepsy I I_DISEASE
that O O
was O O
poorly O O
controlled O O
with O O
phenobarbital O O
or O O
that O O
had O O
unacceptable O O
adverse O O
effects O O
when O O
treated O O
with O O
phenobarbital O O
. O O

PROCEDURES O O
: O O
Cats O O
were O O
treated O O
with O O
levetiracetam O O
( O O
20 O O
mg O O
/ O O
kg O O
[ O O
9 O O
. O O
1 O O
mg O O
/ O O
lb O O
] O O
, O O
PO O O
, O O
q O O
8 O O
h O O
) O O
. O O

After O O
a O O
minimum O O
of O O
1 O O
week O O
of O O
treatment O O
, O O
serum O O
levetiracetam O O
concentrations O O
were O O
measured O O
before O O
and O O
2 O O
, O O
4 O O
, O O
and O O
6 O O
hours O O
after O O
drug O O
administration O O
, O O
and O O
maximum O O
and O O
minimum O O
serum O O
concentrations O O
and O O
elimination O O
half O O
- O O
life O O
were O O
calculated O O
. O O

Seizure B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
frequencies O O
before O O
and O O
after O O
initiation O O
of O O
levetiracetam O O
treatment O O
were O O
compared O O
, O O
and O O
adverse O O
effects O O
were O O
recorded O O
. O O

RESULTS O O
: O O
Median O O
maximum O O
serum O O
levetiracetam O O
concentration O O
was O O
25 O O
. O O
5 O O
microg O O
/ O O
mL O O
, O O
median O O
minimum O O
serum O O
levetiracetam O O
concentration O O
was O O
8 O O
. O O
3 O O
microg O O
/ O O
mL O O
, O O
and O O
median O O
elimination O O
half O O
- O O
life O O
was O O
2 O O
. O O
9 O O
hours O O
. O O

Median O O
seizure B B_DISEASE
frequency O O
prior O O
to O O
treatment O O
with O O
levetiracetam O O
( O O
2 O O
. O O
1 O O
seizures B B_DISEASE
/ O O
mo O O
) O O
was O O
significantly O O
higher O O
than O O
median O O
seizure B B_DISEASE/B_MEASURE
frequency O O
after O O
initiation O O
of O O
levetiracetam O O
treatment O O
( O O
0 O O
. O O
42 O O
seizures B B_DISEASE
/ O O
mo O O
) O O
, O O
and O O
7 O O
of O O
10 O O
cats O O
were O O
classified O O
as O O
having O O
responded O O
to O O
levetiracetam O O
treatment O O
( O O
ie O O
, O O
reduction O O
in O O
seizure B B_DISEASE
frequency O O
of O O
> O O
or O O
= O O
50 O O
% O O
) O O
. O O

Two O O
cats O O
had O O
transient O O
lethargy B B_DISEASE
and O O
inappetence B B_DISEASE
. O O

CONCLUSIONS O O
AND O O
CLINICAL O O
RELEVANCE O O
: O O
Results O O
suggested O O
that O O
levetiracetam O O
is O O
well O O
tolerated O O
in O O
cats O O
and O O
may O O
be O O
useful O O
as O O
an O O
adjunct O O
to O O
phenobarbital O O
treatment O O
in O O
cats O O
with O O
idiopathic B B_DISEASE
epilepsy I I_DISEASE
. O O

Serotonin O O
reuptake O O
inhibitors O O
, O O
paranoia B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
the O O
ventral O O
basal O O
ganglia O O
. O O

Antidepressants O O
have O O
previously O O
been O O
associated O O
with O O
paranoid B B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
reactions O O
in O O
psychiatric O O
patients O O
. O O

Five O O
cases O O
of O O
paranoid B B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
exacerbation O O
with O O
the O O
serotonin O O
reuptake O O
inhibitors O O
fluoxetine O O
and O O
amitriptyline O O
are O O
reported O O
here O O
. O O

Elements O O
common O O
to O O
these O O
cases O O
included O O
a O O
history O O
of O O
paranoid B B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
symptomatology O O
and O O
the O O
concomitant O O
occurrence O O
of O O
depressive B B_DISEASE
and I I_DISEASE
psychotic I I_DISEASE
symptoms I I_DISEASE
. O O

Complicated O O
depressive B B_DISEASE_ADJECTIVE[DISEASE]
disorders I I_DISEASE_ADJECTIVE[DISEASE]
( O O
including O O
atypicality O O
of O O
course O O
and O O
symptomatology O O
, O O
chronicity O O
, O O
psychosis B B_DISEASE
, O O
bipolarity O O
, O O
and O O
secondary O O
onset O O
in O O
the O O
course O O
of O O
a O O
primary O O
psychosis B B_DISEASE
) O O
may O O
present O O
particular O O
vulnerability O O
to O O
paranoid B B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
exacerbations O O
associated O O
with O O
serotonin O O
reuptake O O
inhibitors O O
. O O

Although O O
the O O
pharmacology O O
and O O
neurobiology O O
of O O
paranoia B B_DISEASE
remain O O
cryptic O O
, O O
several O O
mechanisms O O
, O O
including O O
5HT3 O O
receptor O O
- O O
mediated O O
dopamine O O
release O O
, O O
beta O O
- O O
noradrenergic O O
receptor O O
downregulation O O
, O O
or O O
GABAB O O
receptor O O
upregulation O O
acting O O
in O O
the O O
vicinity O O
of O O
the O O
ventral O O
basal O O
ganglia O O
( O O
possibly O O
in O O
lateral O O
orbitofrontal O O
or O O
anterior O O
cingulate O O
circuits O O
) O O
, O O
might O O
apply O O
to O O
this O O
phenomenon O O
. O O

These O O
cases O O
call O O
attention O O
to O O
possible O O
paranoid B B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
exacerbations O O
with O O
serotonin O O
reuptake O O
blockers O O
in O O
select O O
patients O O
and O O
raise O O
neurobiological O O
considerations O O
regarding O O
paranoia B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

BACKGROUND O O
: O O
Spinal O O
anaesthesia O O
is O O
widely O O
employed O O
in O O
clinical O O
practice O O
but O O
has O O
the O O
main O O
drawback O O
of O O
post O O
- O O
spinal O O
block O O
hypotension B B_DISEASE
. O O

METHODS O O
: O O
With O O
ethical O O
approval O O
, O O
we O O
studied O O
74 O O
American O O
Society O O
of O O
Anesthesiologists O O
( O O
ASA O O
) O O
, O O
physical O O
status O O
class O O
1 O O
and O O
2 O O
patients O O
scheduled O O
for O O
elective O O
unilateral O O
lower O O
limb O O
surgery O O
. O O

Patients O O
were O O
randomly O O
allocated O O
into O O
one O O
of O O
two O O
groups O O
: O O
lateral O O
and O O
conventional O O
spinal O O
anaesthesia O O
groups O O
. O O

In O O
the O O
lateral O O
position O O
with O O
operative O O
side O O
down O O
, O O
patients O O
recived O O
10 O O
mg O O
( O O
2mls O O
) O O
of O O
0 O O
. O O
5 O O
% O O
hyperbaric O O
bupivacaine O O
through O O
a O O
25 O O
- O O
gauge O O
spinal O O
needle O O
. O O

Patients O O
in O O
the O O
unilateral O O
group O O
were O O
maintained O O
in O O
the O O
lateral O O
position O O
for O O
15 O O
minutes O O
following O O
spinal O O
injection O O
while O O
those O O
in O O
the O O
conventional O O
group O O
were O O
turned O O
supine O O
immediately O O
after O O
injection O O
. O O

Blood O O
pressure O O
, O O
heart O O
rate O O
, O O
respiratory O O
rate O O
and O O
oxygen O O
saturation O O
were O O
monitored O O
over O O
1 O O
hour O O
. O O

RESULTS O O
: O O
Three O O
patients O O
( O O
8 O O
. O O
1 O O
% O O
) O O
in O O
the O O
unilateral O O
group O O
and O O
5 O O
( O O
13 O O
. O O
5 O O
% O O
) O O
in O O
the O O
conventional O O
group O O
developed O O
hypotension B B_DISEASE
, O O
P O O
= O O
0 O O
. O O
71 O O
. O O

Four O O
( O O
10 O O
. O O
8 O O
% O O
) O O
patients O O
in O O
the O O
conventional O O
group O O
and O O
1 O O
( O O
2 O O
. O O
7 O O
% O O
) O O
in O O
the O O
unilateral O O
group O O
, O O
P O O
= O O
0 O O
. O O
17 O O
required O O
epinephrine O O
infusion O O
to O O
treat O O
hypotension B B_DISEASE/B_GENE
. O O

The O O
mean O O
respiratory O O
rate O O
and O O
oxygen O O
saturations O O
in O O
the O O
two O O
groups O O
were O O
similar O O
. O O

Also O O
, O O
the O O
type O O
of O O
spinal O O
block O O
instituted O O
affected O O
neither O O
the O O
respiratory O O
rate O O
nor O O
the O O
arterial O O
oxygen O O
saturation O O
. O O

Spectrum O O
of O O
adverse O O
events O O
after O O
generic O O
HAART O O
in O O
southern O O
Indian O O
HIV B B_DISEASE/B_LOCATION
- I I_DISEASE/I_LOCATION
infected I I_DISEASE/I_LOCATION
patients O O
. O O

To O O
determine O O
the O O
incidence O O
of O O
clinically O O
significant O O
adverse O O
events O O
after O O
long O O
- O O
term O O
, O O
fixed O O
- O O
dose O O
, O O
generic O O
highly O O
active O O
antiretroviral O O
therapy O O
( O O
HAART O O
) O O
use O O
among O O
HIV B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
- I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
infected I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
individuals O O
in O O
South O O
India O O
, O O
we O O
examined O O
the O O
experiences O O
of O O
3154 O O
HIV B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
- I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
infected I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
individuals O O
who O O
received O O
a O O
minimum O O
of O O
3 O O
months O O
of O O
generic O O
HAART O O
between O O
February O O
1996 O O
and O O
December O O
2006 O O
at O O
a O O
tertiary O O
HIV O O
care O O
referral O O
center O O
in O O
South O O
India O O
. O O

The O O
most O O
common O O
regimens O O
were O O
3TC O O
+ O O
d4T O O
+ O O
nevirapine O O
( O O
NVP O O
) O O
( O O
54 O O
. O O
8 O O
% O O
) O O
, O O
zidovudine O O
( O O
AZT O O
) O O
+ O O
3TC O O
+ O O
NVP O O
( O O
14 O O
. O O
5 O O
% O O
) O O
, O O
3TC O O
+ O O
d4T O O
+ O O
efavirenz O O
( O O
EFV O O
) O O
( O O
20 O O
. O O
1 O O
% O O
) O O
, O O
and O O
AZT O O
+ O O
3TC O O
+ O O
EFV O O
( O O
5 O O
. O O
4 O O
% O O
) O O
. O O

The O O
most O O
common O O
adverse O O
events O O
and O O
median O O
CD4 O O
at O O
time O O
of O O
event O O
were O O
rash B B_DISEASE
( O O
15 O O
. O O
2 O O
% O O
; O O
CD4 O O
, O O
285 O O
cells O O
/ O O
microL O O
) O O
and O O
peripheral B B_DISEASE
neuropathy I I_DISEASE
( O O
9 O O
. O O
0 O O
% O O
and O O
348 O O
cells O O
/ O O
microL O O
) O O
. O O

Clinically O O
significant O O
anemia B B_DISEASE
( O O
hemoglobin O O
< O O
7 O O
g O O
/ O O
dL O O
) O O
was O O
observed O O
in O O
5 O O
. O O
4 O O
% O O
of O O
patients O O
( O O
CD4 O O
, O O
165 O O
cells O O
/ O O
microL O O
) O O
and O O
hepatitis B B_DISEASE
( O O
clinical O O
jaundice B B_DISEASE
with O O
alanine O O
aminotransferase O O
> O O
5 O O
times O O
upper O O
limits O O
of O O
normal O O
) O O
in O O
3 O O
. O O
5 O O
% O O
of O O
patients O O
( O O
CD4 O O
, O O
260 O O
cells O O
/ O O
microL O O
) O O
. O O

Women O O
were O O
significantly O O
more O O
likely O O
to O O
experience O O
lactic B B_DISEASE
acidosis I I_DISEASE
, O O
while O O
men O O
were O O
significantly O O
more O O
likely O O
to O O
experience O O
immune B B_DISEASE
reconstitution I I_DISEASE
syndrome I I_DISEASE
( O O
p O O
< O O
0 O O
. O O
05 O O
) O O
. O O

Among O O
the O O
patients O O
with O O
1 O O
year O O
of O O
follow O O
- O O
up O O
, O O
NVP O O
therapy O O
was O O
significantly O O
associated O O
with O O
developing O O
rash B B_DISEASE
and O O
d4T O O
therapy O O
with O O
developing O O
peripheral B B_DISEASE
neuropathy I I_DISEASE
( O O
p O O
< O O
0 O O
. O O
05 O O
) O O
. O O

Anemia B B_DISEASE
and O O
hepatitis B B_DISEASE
often O O
occur O O
within O O
12 O O
weeks O O
of O O
initiating O O
generic O O
HAART O O
. O O

Frequent O O
and O O
early O O
monitoring O O
for O O
these O O
toxicities B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
warranted O O
in O O
developing O O
countries O O
where O O
generic O O
HAART O O
is O O
increasingly O O
available O O
. O O

Thalidomide O O
and O O
sensory B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
neurotoxicity I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
: O O
a O O
neurophysiological O O
study O O
. O O

BACKGROUND O O
: O O
Recent O O
studies O O
confirmed O O
a O O
high O O
incidence O O
of O O
sensory B B_DISEASE
axonal I I_DISEASE
neuropathy I I_DISEASE
in O O
patients O O
treated O O
with O O
different O O
doses O O
of O O
thalidomide O O
. O O

PATIENTS O O
AND O O
METHODS O O
: O O
Clinical O O
and O O
electrophysiological O O
data O O
in O O
12 O O
female O O
patients O O
with O O
CLE B B_DISEASE/B_PROTEIN[GENE]
during O O
treatment O O
with O O
thalidomide O O
and O O
up O O
to O O
47 O O
months O O
after O O
discontinuation O O
of O O
treatment O O
were O O
analysed O O
. O O

Sural O O
nerve O O
SAP O O
amplitude O O
reduction O O
> O O
or O O
= O O
40 O O
% O O
was O O
the O O
criteria O O
for O O
discontinuing O O
therapy O O
. O O

One O O
patient O O
showed O O
no O O
changes O O
in O O
SAP O O
amplitude O O
. O O

Five O O
patients O O
complained O O
of O O
paresthesias B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
leg O O
cramps B B_DISEASE
. O O

Five O O
cases O O
of O O
encephalitis B B_DISEASE
during O O
treatment O O
of O O
loiasis B B_DISEASE/B_PERSON
with O O
diethylcarbamazine O O
. O O

Five O O
cases O O
of O O
encephalitis B B_DISEASE
following O O
treatment O O
with O O
diethylcarbamazine O O
( O O
DEC O O
) O O
were O O
observed O O
in O O
Congolese O O
patients O O
with O O
Loa O O
loa O O
filariasis B B_DISEASE
. O O

The O O
relationship O O
between O O
the O O
occurrence O O
of O O
encephalitis B B_DISEASE
and O O
the O O
decrease O O
in O O
microfilaremia B B_DISEASE/B_GENE
is O O
evident O O
. O O

The O O
pathophysiological O O
mechanisms O O
are O O
discussed O O
in O O
the O O
light O O
of O O
these O O
observations O O
and O O
the O O
few O O
other O O
comments O O
on O O
this O O
subject O O
published O O
in O O
the O O
literature O O
. O O

Amiodarone O O
- O O
related O O
pulmonary B B_DISEASE
mass I I_DISEASE
and O O
unique O O
membranous B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glomerulonephritis I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
patient O O
with O O
valvular B B_DISEASE/B_GENE
heart I I_DISEASE/I_GENE
disease I I_DISEASE/I_GENE
: O O
Diagnostic O O
pitfall O O
and O O
new O O
findings O O
. O O

Amiodarone O O
is O O
an O O
anti O O
- O O
arrhythmic B B_DISEASE_ADJECTIVE[DISEASE]
drug O O
for O O
life O O
- O O
threatening O O
tachycardia B B_DISEASE
, O O
but O O
various O O
adverse O O
effects O O
have O O
been O O
reported O O
. O O

Reported O O
herein O O
is O O
an O O
autopsy O O
case O O
of O O
valvular B B_DISEASE
heart I I_DISEASE
disease I I_DISEASE
, O O
in O O
a O O
patient O O
who O O
developed O O
a O O
lung B B_DISEASE
mass I I_DISEASE
( O O
1 O O
. O O
5 O O
cm O O
in O O
diameter O O
) O O
and O O
proteinuria B B_DISEASE
( O O
2 O O
. O O
76 O O
g O O
/ O O
day O O
) O O
after O O
treatment O O
with O O
amiodarone O O
for O O
a O O
long O O
time O O
. O O

The O O
lung B B_DISEASE
mass I I_DISEASE
was O O
highly O O
suspected O O
to O O
be O O
lung B B_DISEASE
cancer I I_DISEASE
on O O
CT O O
and O O
positron O O
emission O O
tomography O O
, O O
but O O
histologically O O
the O O
lesion O O
was O O
composed O O
of O O
lymphoplasmacytic O O
infiltrates O O
in O O
alveolar O O
walls O O
and O O
intra O O
- O O
alveolar O O
accumulation O O
of O O
foamy O O
macrophages O O
containing O O
characteristic O O
myelinoid O O
bodies O O
, O O
indicating O O
that O O
it O O
was O O
an O O
amiodarone O O
- O O
related O O
lesion O O
. O O

In O O
addition O O
, O O
the O O
lung O O
tissue O O
had O O
unevenly O O
distributed O O
hemosiderin B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
deposition O O
, O O
and O O
abnormally O O
tortuous O O
capillaries O O
were O O
seen O O
in O O
the O O
mass O O
and O O
in O O
heavily O O
hemosiderotic B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
lung O O
portions O O
outside O O
the O O
mass O O
. O O

Autoimmune B B_DISEASE/B_MEASURE
diseases I I_DISEASE/I_MEASURE
, O O
viral B B_DISEASE/B_BIO
hepatitis I I_DISEASE/I_BIO
, O O
malignant O O
neoplasms B B_DISEASE
or O O
other O O
diseases O O
with O O
a O O
known O O
relationship O O
to O O
membranous B B_DISEASE
glomerulonephritis I I_DISEASE
were O O
not O O
found O O
. O O

The O O
present O O
case O O
highlights O O
the O O
possibility O O
that O O
differential O O
diagnosis O O
between O O
an O O
amiodarone O O
- O O
related O O
pulmonary B B_DISEASE
lesion I I_DISEASE
and O O
a O O
neoplasm B B_DISEASE
can O O
be O O
very O O
difficult O O
radiologically O O
, O O
and O O
suggests O O
that O O
membranous B B_DISEASE
glomerulonephritis I I_DISEASE
might O O
be O O
another O O
possible O O
complication O O
of O O
amiodarone O O
treatment O O
. O O

Risk O O
of O O
coronary B B_DISEASE
artery I I_DISEASE
disease I I_DISEASE
associated O O
with O O
initial O O
sulphonylurea O O
treatment O O
of O O
patients O O
with O O
type B B_DISEASE
2 I I_DISEASE
diabetes I I_DISEASE
: O O
a O O
matched O O
case O O
- O O
control O O
study O O
. O O

METHODS O O
: O O
In O O
type B B_DISEASE/B_MEASURE
2 I I_DISEASE/I_MEASURE
diabetic I I_DISEASE/I_MEASURE
patients O O
, O O
cases O O
who O O
developed O O
CAD B B_DISEASE
were O O
compared O O
retrospectively O O
with O O
controls O O
that O O
did O O
not O O
. O O

The O O
20 O O
- O O
year O O
risk O O
of O O
CAD B B_DISEASE
at O O
diagnosis O O
of O O
diabetes B B_DISEASE/B_LOCATION
, O O
using O O
the O O
UKPDS O O
risk O O
engine O O
, O O
was O O
used O O
to O O
match O O
cases O O
with O O
controls O O
. O O

RESULTS O O
: O O
The O O
76 O O
cases O O
of O O
CAD B B_DISEASE/B_LOCATION
were O O
compared O O
with O O
152 O O
controls O O
. O O

The O O
hazard O O
of O O
developing O O
CAD B B_DISEASE/B_GENE
( O O
95 O O
% O O
CI O O
) O O
associated O O
with O O
initial O O
treatment O O
increased O O
by O O
2 O O
. O O
4 O O
- O O
fold O O
( O O
1 O O
. O O
3 O O
- O O
4 O O
. O O
3 O O
, O O
P O O
= O O
0 O O
. O O
004 O O
) O O
with O O
glibenclamide O O
; O O
2 O O
- O O
fold O O
( O O
0 O O
. O O
9 O O
- O O
4 O O
. O O
6 O O
, O O
P O O
= O O
0 O O
. O O
099 O O
) O O
with O O
glipizide O O
; O O
2 O O
. O O
9 O O
- O O
fold O O
( O O
1 O O
. O O
6 O O
- O O
5 O O
. O O
1 O O
, O O
P O O
= O O
0 O O
. O O
000 O O
) O O
with O O
either O O
, O O
and O O
was O O
unchanged O O
with O O
metformin O O
. O O

CONCLUSIONS O O
: O O
Initiating O O
treatment O O
of O O
type B B_DISEASE
2 I I_DISEASE
diabetes I I_DISEASE
with O O
glibenclamide O O
or O O
glipizide O O
is O O
associated O O
with O O
increased O O
risk O O
of O O
CAD B B_DISEASE
in O O
comparison O O
to O O
gliclazide O O
or O O
glimepiride O O
. O O

If O O
confirmed O O
, O O
this O O
may O O
be O O
important O O
because O O
most O O
Indian O O
patients O O
receive O O
the O O
cheaper O O
older O O
sulphonylureas O O
, O O
and O O
present O O
guidelines O O
do O O
not O O
distinguish O O
between O O
individual O O
agents O O
. O O

Reduced O O
progression O O
of O O
adriamycin O O
nephropathy B B_DISEASE
in O O
spontaneously O O
hypertensive B B_DISEASE
rats O O
treated O O
by O O
losartan O O
. O O

BACKGROUND O O
: O O
The O O
aim O O
of O O
the O O
study O O
was O O
to O O
investigate O O
the O O
antihypertensive O O
effects O O
of O O
angiotensin O O
II O O
type O O
- O O
1 O O
receptor O O
blocker O O
, O O
losartan O O
, O O
and O O
its O O
potential O O
in O O
slowing O O
down O O
renal B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
disease I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
progression O O
in O O
spontaneously O O
hypertensive B B_DISEASE
rats O O
( O O
SHR O O
) O O
with O O
adriamycin O O
( O O
ADR O O
) O O
nephropathy B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

METHODS O O
: O O
Six O O
- O O
month O O
- O O
old O O
female O O
SHR O O
were O O
randomly O O
selected O O
in O O
six O O
groups O O
. O O

Two O O
control O O
groups O O
( O O
SH O O
( O O
6 O O
) O O
, O O
SH O O
( O O
12 O O
) O O
) O O
received O O
vehicle O O
. O O

Animals O O
were O O
killed O O
after O O
6 O O
or O O
12 O O
weeks O O
, O O
respectively O O
. O O

Haemodynamic O O
measurements O O
were O O
performed O O
on O O
anaesthetized O O
animals O O
, O O
blood O O
and O O
urine O O
samples O O
were O O
taken O O
for O O
biochemical O O
analysis O O
and O O
the O O
left O O
kidney O O
was O O
processed O O
for O O
morphological O O
studies O O
. O O

RESULTS O O
: O O
Short O O
- O O
term O O
losartan O O
treatment O O
, O O
besides O O
antihypertensive O O
effect O O
, O O
improved O O
glomerular O O
filtration O O
rate O O
and O O
ameliorated O O
glomerulosclerosis B B_DISEASE/B_GENE
resulting O O
in O O
decreased O O
proteinuria B B_DISEASE/B_GENE
. O O

Prolonged O O
treatment O O
with O O
losartan O O
showed O O
further O O
reduction O O
of O O
glomerulosclerosis B B_DISEASE/B_GENE
associated O O
with O O
reduced O O
progression O O
of O O
tubular O O
atrophy B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
interstitial B B_DISEASE
fibrosis I I_DISEASE
, O O
thus O O
preventing O O
heavy O O
proteinuria B B_DISEASE
and O O
chronic B B_DISEASE
renal I I_DISEASE
failure I I_DISEASE
. O O

Losartan O O
reduced O O
uraemia B B_DISEASE/B_GENE
and O O
increased O O
urea O O
clearance O O
in O O
advanced O O
ADR O O
nephropathy B B_DISEASE/B_TIME[MEASURE]
in O O
SHR O O
. O O

Histological O O
examination O O
showed O O
that O O
losartan O O
could O O
prevent O O
tubular O O
atrophy B B_DISEASE
, O O
interstitial O O
infiltration O O
and O O
fibrosis B B_DISEASE
in O O
ADR O O
nephropathy B B_DISEASE/B_SPECIES[BIO]
. O O

CONCLUSION O O
: O O
Losartan O O
reduces O O
the O O
rate O O
of O O
progression O O
of O O
ADR O O
- O O
induced O O
focal B B_DISEASE
segmental I I_DISEASE
glomerulosclerosis I I_DISEASE
to O O
end B B_DISEASE/B_LOCATION
- I I_DISEASE/I_LOCATION
stage I I_DISEASE/I_LOCATION
renal I I_DISEASE/I_LOCATION
disease I I_DISEASE/I_LOCATION
in O O
SHR O O
. O O

The O O
risks O O
of O O
aprotinin O O
and O O
tranexamic O O
acid O O
in O O
cardiac O O
surgery O O
: O O
a O O
one O O
- O O
year O O
follow O O
- O O
up O O
of O O
1188 O O
consecutive O O
patients O O
. O O

METHODS O O
: O O
Perioperative O O
data O O
from O O
consecutive O O
cardiac O O
surgery O O
patients O O
were O O
prospectively O O
collected O O
between O O
September O O
2005 O O
and O O
June O O
2006 O O
in O O
a O O
university O O
- O O
affiliated O O
clinic O O
( O O
n O O
= O O
1188 O O
) O O
. O O

During O O
the O O
first O O
5 O O
mo O O
, O O
596 O O
patients O O
received O O
aprotinin O O
( O O
Group O O
A O O
) O O
; O O
in O O
the O O
next O O
5 O O
mo O O
, O O
592 O O
patients O O
were O O
treated O O
with O O
tranexamic O O
acid O O
( O O
Group O O
T O O
) O O
. O O

Except O O
for O O
antifibrinolytic O O
therapy O O
, O O
the O O
anesthetic O O
and O O
surgical O O
protocols O O
remained O O
unchanged O O
. O O

Postoperatively O O
, O O
a O O
significantly O O
higher O O
incidence O O
of O O
seizures B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
found O O
in O O
Group O O
T O O
( O O
4 O O
. O O
6 O O
% O O
vs O O
1 O O
. O O
2 O O
% O O
, O O
P O O
< O O
0 O O
. O O
001 O O
) O O
. O O

This O O
difference O O
was O O
also O O
significant O O
in O O
the O O
primary O O
valve O O
surgery O O
and O O
the O O
high O O
risk O O
surgery O O
subgroups O O
( O O
7 O O
. O O
9 O O
% O O
vs O O
1 O O
. O O
2 O O
% O O
, O O
P O O
= O O
0 O O
. O O
003 O O
; O O
7 O O
. O O
3 O O
% O O
vs O O
2 O O
. O O
4 O O
% O O
, O O
P O O
= O O
0 O O
. O O
035 O O
, O O
respectively O O
) O O
. O O

Persistent O O
atrial O O
fibrillation O O
( O O
7 O O
. O O
9 O O
% O O
vs O O
2 O O
. O O
3 O O
% O O
, O O
P O O
= O O
0 O O
. O O
020 O O
) O O
and O O
renal B B_DISEASE
failure I I_DISEASE
( O O
9 O O
. O O
7 O O
% O O
vs O O
1 O O
. O O
7 O O
% O O
, O O
P O O
= O O
0 O O
. O O
002 O O
) O O
were O O
also O O
more O O
common O O
in O O
Group O O
T O O
, O O
in O O
the O O
primary O O
valve O O
surgery O O
subgroup O O
. O O

On O O
the O O
contrary O O
, O O
among O O
primary O O
coronary O O
artery O O
bypass O O
surgery O O
patients O O
, O O
there O O
were O O
more O O
acute O O
myocardial B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
infarctions I B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
renal B B_DISEASE
dysfunction I I_DISEASE
in O O
Group O O
A O O
( O O
5 O O
. O O
8 O O
% O O
vs O O
2 O O
. O O
0 O O
% O O
, O O
P O O
= O O
0 O O
. O O
027 O O
; O O
22 O O
. O O
5 O O
% O O
vs O O
15 O O
. O O
2 O O
% O O
, O O
P O O
= O O
0 O O
. O O
036 O O
, O O
respectively O O
) O O
. O O

The O O
1 O O
- O O
yr O O
mortality O O
was O O
significantly O O
higher O O
after O O
aprotinin O O
treatment O O
in O O
the O O
high O O
risk O O
surgery O O
group O O
( O O
17 O O
. O O
7 O O
% O O
vs O O
9 O O
. O O
8 O O
% O O
, O O
P O O
= O O
0 O O
. O O
034 O O
) O O
. O O

Administration O O
of O O
aprotinin O O
should O O
be O O
avoided O O
in O O
coronary O O
artery O O
bypass O O
graft O O
and O O
high O O
risk O O
patients O O
, O O
whereas O O
administration O O
of O O
tranexamic O O
acid O O
is O O
not O O
recommended O O
in O O
valve O O
surgery O O
. O O

Delirium B B_DISEASE
in O O
an O O
elderly O O
woman O O
possibly O O
associated O O
with O O
administration O O
of O O
misoprostol O O
. O O

Misoprostol O O
has O O
been O O
associated O O
with O O
adverse O O
reactions O O
, O O
including O O
gastrointestinal O O
symptoms O O
, O O
gynecologic O O
problems O O
, O O
and O O
headache B B_DISEASE
. O O

Changes O O
in O O
mental O O
status O O
, O O
however O O
, O O
have O O
not O O
been O O
reported O O
. O O

We O O
present O O
a O O
case O O
in O O
which O O
an O O
89 O O
- O O
year O O
- O O
old O O
woman O O
in O O
a O O
long O O
- O O
term O O
care O O
facility O O
became O O
confused O O
after O O
the O O
initiation O O
of O O
misoprostol O O
therapy O O
. O O

Her O O
delirium B B_DISEASE
significantly O O
improved O O
after O O
misoprostol O O
was O O
discontinued O O
and O O
her O O
mental O O
status O O
returned O O
to O O
normal O O
within O O
a O O
week O O
. O O

Because O O
no O O
other O O
factors O O
related O O
to O O
this O O
patient O O
changed O O
significantly O O
, O O
the O O
delirium B B_DISEASE
experienced O O
by O O
this O O
patient O O
possibly O O
resulted O O
from O O
misoprostol O O
therapy O O
. O O

The O O
biological O O
properties O O
of O O
the O O
optical O O
isomers O O
of O O
propranolol O O
and O O
their O O
effects O O
on O O
cardiac B B_DISEASE/B_ORGANISM_FUNCTION
arrhythmias I I_DISEASE/I_ORGANISM_FUNCTION
. O O

1 O O
. O O

The O O
optical O O
isomers O O
of O O
propranolol O O
have O O
been O O
compared O O
for O O
their O O
beta O O
- O O
blocking O O
and O O
antiarrhythmic O O
activities O O
. O O
2 O O
. O O

In O O
blocking O O
the O O
positive O O
inotropic O O
and O O
chronotropic O O
responses O O
to O O
isoprenaline O O
, O O
( O O
+ O O
) O O
- O O
propranolol O O
had O O
less O O
than O O
one O O
hundredth O O
the O O
potency O O
of O O
( O O
- O O
) O O
- O O
propranolol O O
. O O

At O O
dose O O
levels O O
of O O
( O O
+ O O
) O O
- O O
propranolol O O
which O O
attenuated O O
the O O
responses O O
to O O
isoprenaline O O
, O O
there O O
was O O
a O O
significant O O
prolongation O O
of O O
the O O
PR O O
interval O O
of O O
the O O
electrocardiogram O O
. O O
3 O O
. O O

The O O
metabolic O O
responses O O
to O O
isoprenaline O O
in O O
dogs O O
( O O
an O O
increase O O
in O O
circulating O O
glucose O O
, O O
lactate O O
and O O
free O O
fatty O O
acids O O
) O O
were O O
all O O
blocked O O
by O O
( O O
- O O
) O O
- O O
propranolol O O
. O O

Both O O
isomers O O
of O O
propranolol O O
possessed O O
similar O O
depressant O O
potency O O
on O O
isolated O O
atrial O O
muscle O O
taken O O
from O O
guinea O O
- O O
pigs O O
. O O
5 O O
. O O

The O O
isomers O O
of O O
propranolol O O
exhibited O O
similar O O
local O O
anaesthetic O O
potencies O O
on O O
an O O
isolated O O
frog O O
nerve O O
preparation O O
at O O
a O O
level O O
approximately O O
three O O
times O O
that O O
of O O
procaine O O
. O O

The O O
racemic O O
compound O O
was O O
significantly O O
less O O
potent O O
than O O
either O O
isomer O O
. O O
6 O O
. O O

Both O O
isomers O O
of O O
propranolol O O
were O O
capable O O
of O O
preventing O O
adrenaline O O
- O O
induced O O
cardiac B B_DISEASE
arrhythmias I I_DISEASE
in O O
cats O O
anaesthetized O O
with O O
halothane O O
, O O
but O O
the O O
mean O O
dose O O
of O O
( O O
- O O
) O O
- O O
propranolol O O
was O O
0 O O
. O O
09 O O
+ O O
/ O O
- O O
0 O O
. O O
02 O O
mg O O
/ O O
kg O O
whereas O O
that O O
of O O
( O O
+ O O
) O O
- O O
propranolol O O
was O O
4 O O
. O O
2 O O
+ O O
/ O O
- O O
1 O O
. O O
2 O O
mg O O
/ O O
kg O O
. O O

At O O
the O O
effective O O
dose O O
level O O
of O O
( O O
+ O O
) O O
- O O
propranolol O O
there O O
was O O
a O O
significant O O
prolongation O O
of O O
the O O
PR O O
interval O O
of O O
the O O
electrocardiogram O O
. O O

Blockade O O
of O O
arrhythmias B B_DISEASE
with O O
both O O
isomers O O
was O O
surmountable O O
by O O
increasing O O
the O O
dose O O
of O O
adrenaline O O
. O O
7 O O
. O O

Both O O
isomers O O
of O O
propranolol O O
were O O
also O O
capable O O
of O O
reversing O O
ventricular B B_DISEASE
tachycardia I I_DISEASE
caused O O
by O O
ouabain O O
in O O
anaesthetized O O
cats O O
and O O
dogs O O
. O O

The O O
dose O O
of O O
( O O
- O O
) O O
- O O
propranolol O O
was O O
significantly O O
smaller O O
than O O
that O O
of O O
( O O
+ O O
) O O
- O O
propranolol O O
in O O
both O O
species O O
but O O
much O O
higher O O
than O O
that O O
required O O
to O O
produce O O
evidence O O
of O O
beta O O
- O O
blockade O O
. O O
8 O O
. O O

The O O
implications O O
of O O
these O O
results O O
are O O
discussed O O
. O O

Topotecan O O
in O O
combination O O
with O O
radiotherapy O O
in O O
unresectable O O
glioblastoma B B_DISEASE
: O O
a O O
phase O O
2 O O
study O O
. O O

Topotecan O O
is O O
an O O
attractive O O
option O O
as O O
it O O
exhibits O O
growth O O
inhibition O O
of O O
human O O
glioma B B_DISEASE
as O O
well O O
as O O
brain O O
penetration O O
. O O

The O O
present O O
study O O
assessed O O
the O O
combination O O
of O O
radiotherapy O O
( O O
60 O O
Gy O O
/ O O
30 O O
fractions O O
/ O O
40 O O
days O O
) O O
and O O
topotecan O O
( O O
0 O O
. O O
9 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
/ O O
day O O
on O O
days O O
1 O O
- O O
5 O O
on O O
weeks O O
1 O O
, O O
3 O O
and O O
5 O O
) O O
in O O
50 O O
adults O O
with O O
histologically O O
proven O O
and O O
untreated O O
GBM B B_DISEASE
. O O

The O O
incidence O O
of O O
non O O
- O O
hematological O O
toxicities B B_DISEASE
was O O
low O O
and O O
grade O O
3 O O
- O O
4 O O
hematological O O
toxicities B B_DISEASE
were O O
reported O O
in O O
20 O O
patients O O
( O O
mainly O O
lymphopenia B B_DISEASE
and O O
neutropenia B B_DISEASE
) O O
. O O

Topotecan O O
in O O
combination O O
with O O
radiotherapy O O
was O O
well O O
tolerated O O
. O O

However O O
, O O
while O O
response O O
and O O
stabilization O O
concerned O O
one O O
- O O
third O O
of O O
the O O
patients O O
, O O
the O O
study O O
did O O
not O O
show O O
increased O O
benefits O O
in O O
terms O O
of O O
survival O O
in O O
patients O O
with O O
unresectable O O
GBM B B_DISEASE
. O O

Long O O
- O O
term O O
lithium O O
therapy O O
leading O O
to O O
hyperparathyroidism B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
: O O
a O O
case O O
report O O
. O O

We O O
examined O O
the O O
case O O
of O O
a O O
lithium O O
- O O
treated O O
patient O O
who O O
had O O
recurrent O O
hypercalcemia B B_DISEASE
to O O
better O O
understand O O
the O O
disease O O
process O O
. O O

CONCLUSION O O
: O O
Primary B B_DISEASE
hyperparathyroidism I I_DISEASE
is O O
a O O
rare O O
but O O
potentially O O
life O O
- O O
threatening O O
side O O
effect O O
of O O
long O O
- O O
term O O
lithium O O
therapy O O
. O O

PRACTICAL O O
IMPLICATIONS O O
: O O
As O O
much O O
as O O
15 O O
% O O
of O O
lithium O O
- O O
treated O O
patients O O
become O O
hypercalcemic B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O O

Comparison O O
of O O
laryngeal O O
mask O O
with O O
endotracheal O O
tube O O
for O O
anesthesia O O
in O O
endoscopic O O
sinus O O
surgery O O
. O O

BACKGROUND O O
: O O
The O O
purpose O O
of O O
this O O
study O O
was O O
to O O
compare O O
surgical O O
conditions O O
, O O
including O O
the O O
amount O O
of O O
intraoperative O O
bleeding B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
as O O
well O O
as O O
intraoperative O O
blood O O
pressure O O
, O O
during O O
functional O O
endoscopic O O
sinus O O
surgery O O
( O O
FESS O O
) O O
using O O
flexible O O
reinforced O O
laryngeal O O
mask O O
airway O O
( O O
FRLMA O O
) O O
versus O O
endotracheal O O
tube O O
( O O
ETT O O
) O O
in O O
maintaining O O
controlled O O
hypotension B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anesthesia O O
induced O O
by O O
propofol O O
- O O
remifentanil O O
total O O
i O O
. O O
v O O
. O O
anesthesia O O
( O O
TIVA O O
) O O
. O O

METHODS O O
: O O
Sixty O O
normotensive O O
American O O
Society O O
of O O
Anesthesiologists O O
I O O
- O O
II O O
adult O O
patients O O
undergoing O O
FESS O O
under O O
controlled O O
hypotension B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anesthesia O O
caused O O
by O O
propofol O O
- O O
remifentanil O O
- O O
TIVA O O
were O O
randomly O O
assigned O O
into O O
two O O
groups O O
: O O
group O O
I O O
, O O
FRLMA O O
; O O
group O O
II O O
, O O
ETT O O
. O O

Hemorrhage B B_DISEASE
was O O
measured O O
and O O
the O O
visibility O O
of O O
the O O
operative O O
field O O
was O O
evaluated O O
according O O
to O O
a O O
six O O
- O O
point O O
scale O O
. O O

RESULTS O O
: O O
Controlled O O
hypotension B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
achieved O O
within O O
a O O
shorter O O
period O O
using O O
laryngeal O O
mask O O
using O O
lower O O
rates O O
of O O
remifentanil O O
infusion O O
and O O
lower O O
total O O
dose O O
of O O
remifentanil O O
. O O

CONCLUSION O O
: O O
In O O
summary O O
, O O
our O O
results O O
indicate O O
that O O
airway O O
management O O
using O O
FRLMA O O
during O O
controlled O O
hypotension B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anesthesia O O
provided O O
better O O
surgical O O
conditions O O
in O O
terms O O
of O O
quality O O
of O O
operative O O
field O O
and O O
blood O O
loss O O
and O O
allowed O O
for O O
convenient O O
induced O O
hypotension B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
low O O
doses O O
of O O
remifentanil O O
during O O
TIVA O O
in O O
patients O O
undergoing O O
FESS O O
. O O

Nonalcoholic B B_DISEASE_ADJECTIVE[DISEASE]
fatty I I_DISEASE_ADJECTIVE[DISEASE]
liver I I_DISEASE_ADJECTIVE[DISEASE]
disease I I_DISEASE_ADJECTIVE[DISEASE]
during O O
valproate O O
therapy O O
. O O

Valproic O O
acid O O
( O O
VPA O O
) O O
is O O
effective O O
for O O
the O O
treatment O O
of O O
many O O
types O O
of O O
epilepsy B B_DISEASE
, O O
but O O
its O O
use O O
can O O
be O O
associated O O
with O O
an O O
increase O O
in O O
body O O
weight O O
. O O

We O O
report O O
a O O
case O O
of O O
nonalcoholic B B_DISEASE
fatty I I_DISEASE
liver I I_DISEASE
disease I I_DISEASE
( O O
NAFLD B B_DISEASE/B_LOCATION
) O O
arising O O
in O O
a O O
child O O
who O O
developed O O
obesity B B_DISEASE/B_GENE
during O O
VPA O O
treatment O O
. O O

Laboratory O O
data O O
revealed O O
hyperinsulinemia B B_DISEASE/B_PERSON
with O O
insulin B B_DISEASE
resistance I I_DISEASE
. O O

After O O
the O O
withdrawal O O
of O O
VPA O O
therapy O O
, O O
our O O
patient O O
showed O O
a O O
significant O O
weight B B_DISEASE_ADJECTIVE[DISEASE]
loss I I_DISEASE_ADJECTIVE[DISEASE]
, O O
a O O
decrease O O
of O O
body O O
mass O O
index O O
, O O
and O O
normalization O O
of O O
metabolic O O
and O O
endocrine O O
parameters O O
; O O
moreover O O
, O O
ultrasound O O
measurements O O
showed O O
a O O
complete O O
normalization O O
. O O

The O O
present O O
case O O
suggests O O
that O O
obesity B B_DISEASE
, O O
hyperinsulinemia B B_DISEASE
, O O
insulin B B_DISEASE
resistance I I_DISEASE
, O O
and O O
long O O
- O O
term O O
treatment O O
with O O
VPA O O
may O O
be O O
all O O
associated O O
with O O
the O O
development O O
of O O
NAFLD B B_DISEASE/B_GENE
; O O
this O O
side O O
effect O O
is O O
reversible O O
after O O
VPA O O
withdrawal O O
. O O

Carbimazole O O
induced O O
ANCA B B_DISEASE/B_GENE
positive I I_DISEASE/I_GENE
vasculitis I I_DISEASE/I_GENE
. O O

Anti O O
- O O
thyroid O O
drugs O O
, O O
like O O
carbimazole O O
and O O
propylthiouracil O O
( O O
PTU O O
) O O
are O O
commonly O O
prescribed O O
for O O
the O O
treatment O O
of O O
hyperthyroidism B B_DISEASE/B_LOCATION
. O O

One O O
should O O
be O O
aware O O
of O O
the O O
side O O
effects O O
of O O
antithyroid O O
medications O O
. O O

Antineutrophil B B_DISEASE/B_GENE
cytoplasmic I I_DISEASE/I_GENE
antibody I I_DISEASE/I_GENE
( I I_DISEASE/I_GENE
ANCA I I_DISEASE/I_GENE
) I I_DISEASE/I_GENE
- I I_DISEASE/I_GENE
- I I_DISEASE/I_GENE
associated I I_DISEASE/I_GENE
vasculitis I I_DISEASE/I_GENE
is O O
a O O
potentially O O
life O O
- O O
threatening O O
adverse O O
effect O O
of O O
antithyroidmedications O O
. O O

We O O
report O O
a O O
patient O O
with O O
Graves B B_DISEASE
' I I_DISEASE
disease I I_DISEASE
who O O
developed O O
ANCA O O
positive O O
carbimazole O O
induced O O
vasculitis B B_DISEASE/B_LOCATION
. O O

The O O
episode O O
was O O
characterized O O
by O O
a O O
vasculitic B B_DISEASE
skin B I_DISEASE
rash I I_DISEASE
associated O O
with O O
large O O
joint O O
arthritis B B_DISEASE
, O O
pyrexia B B_DISEASE
and O O
parotiditis B B_DISEASE
but O O
no O O
renal O O
or O O
pulmonary O O
involvement O O
. O O

He O O
was O O
referred O O
to O O
us O O
for O O
neurological O O
evaluation O O
because O O
he O O
had O O
difficulty O O
in O O
getting O O
up O O
from O O
squatting O O
position O O
and O O
was O O
suspected O O
to O O
have O O
myositis B B_DISEASE
. O O

To O O
the O O
best O O
of O O
our O O
knowledge O O
this O O
is O O
the O O
first O O
ANCA O O
positive O O
carbimazole O O
induced O O
vasculitis B B_DISEASE
case O O
reported O O
from O O
India O O
. O O

Preventive O O
Services O O
Task O O
Force O O
. O O

BACKGROUND O O
: O O
Coronary B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
heart I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
disease I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
cerebrovascular B B_DISEASE
disease I I_DISEASE
are O O
leading O O
causes O O
of O O
death O O
in O O
the O O
United O O
States O O
. O O

In O O
2002 O O
, O O
the O O
U O O
. O O
S O O
. O O

Preventive O O
Services O O
Task O O
Force O O
( O O
USPSTF O O
) O O
strongly O O
recommended O O
that O O
clinicians O O
discuss O O
aspirin O O
with O O
adults O O
who O O
are O O
at O O
increased O O
risk O O
for O O
coronary B B_DISEASE
heart I I_DISEASE
disease I I_DISEASE
. O O

PURPOSE O O
: O O
To O O
determine O O
the O O
benefits O O
and O O
harms O O
of O O
taking O O
aspirin O O
for O O
the O O
primary O O
prevention O O
of O O
myocardial B B_DISEASE
infarctions I I_DISEASE
, O O
strokes B B_DISEASE
, O O
and O O
death O O
. O O

DATA O O
SOURCES O O
: O O
MEDLINE O O
and O O
Cochrane O O
Library O O
( O O
search O O
dates O O
, O O
1 O O
January O O
2001 O O
to O O
28 O O
August O O
2008 O O
) O O
, O O
recent O O
systematic O O
reviews O O
, O O
reference O O
lists O O
of O O
retrieved O O
articles O O
, O O
and O O
suggestions O O
from O O
experts O O
. O O

STUDY O O
SELECTION O O
: O O
English O O
- O O
language O O
randomized O O
, O O
controlled O O
trials O O
( O O
RCTs O O
) O O
; O O
case O O
- O O
control O O
studies O O
; O O
meta O O
- O O
analyses O O
; O O
and O O
systematic O O
reviews O O
of O O
aspirin O O
versus O O
control O O
for O O
the O O
primary O O
prevention O O
of O O
cardiovascular B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
disease I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
CVD B B_DISEASE/B_LOCATION
) O O
were O O
selected O O
to O O
answer O O
the O O
following O O
questions O O
: O O
Does O O
aspirin O O
decrease O O
coronary O O
heart O O
events O O
, O O
strokes B B_DISEASE
, O O
death O O
from O O
coronary O O
heart O O
events O O
or O O
stroke B B_DISEASE
, O O
or O O
all O O
- O O
cause O O
mortality O O
in O O
adults O O
without O O
known O O
CVD B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE

Does O O
aspirin O O
increase O O
gastrointestinal B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
bleeding I I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
or O O
hemorrhagic B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
strokes I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT

DATA O O
EXTRACTION O O
: O O
All O O
studies O O
were O O
reviewed O O
, O O
abstracted O O
, O O
and O O
rated O O
for O O
quality O O
by O O
using O O
predefined O O
USPSTF O O
criteria O O
. O O

DATA O O
SYNTHESIS O O
: O O
New O O
evidence O O
from O O
1 O O
good O O
- O O
quality O O
RCT O O
, O O
1 O O
good O O
- O O
quality O O
meta O O
- O O
analysis O O
, O O
and O O
2 O O
fair O O
- O O
quality O O
subanalyses O O
of O O
RCTs O O
demonstrates O O
that O O
aspirin O O
use O O
reduces O O
the O O
number O O
of O O
CVD B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
events O O
in O O
patients O O
without O O
known O O
CVD B B_DISEASE
. O O

Men O O
in O O
these O O
studies O O
experienced O O
fewer O O
myocardial B B_DISEASE/B_LOCATION
infarctions I I_DISEASE/I_LOCATION
and O O
women O O
experienced O O
fewer O O
ischemic O O
strokes B B_DISEASE
. O O

Aspirin O O
does O O
not O O
seem O O
to O O
affect O O
CVD B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
mortality O O
or O O
all O O
- O O
cause O O
mortality O O
in O O
either O O
men O O
or O O
women O O
. O O

The O O
use O O
of O O
aspirin O O
for O O
primary O O
prevention O O
increases O O
the O O
risk O O
for O O
major O O
bleeding B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
events O O
, O O
primarily O O
gastrointestinal B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
bleeding I I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
events O O
, O O
in O O
both O O
men O O
and O O
women O O
. O O

Men O O
have O O
an O O
increased O O
risk O O
for O O
hemorrhagic B B_DISEASE
strokes I I_DISEASE
with O O
aspirin O O
use O O
. O O

A O O
new O O
RCT O O
and O O
meta O O
- O O
analysis O O
suggest O O
that O O
the O O
risk O O
for O O
hemorrhagic B B_DISEASE
strokes I I_DISEASE
in O O
women O O
is O O
not O O
statistically O O
significantly O O
increased O O
. O O

LIMITATIONS O O
: O O
New O O
evidence O O
on O O
aspirin O O
for O O
the O O
primary O O
prevention O O
of O O
CVD B B_DISEASE/B_LOCATION
is O O
limited O O
. O O

The O O
dose O O
of O O
aspirin O O
used O O
in O O
the O O
RCTs O O
varied O O
, O O
which O O
prevented O O
the O O
estimation O O
of O O
the O O
most O O
appropriate O O
dose O O
for O O
primary O O
prevention O O
. O O

Several O O
of O O
the O O
RCTs O O
were O O
conducted O O
within O O
populations O O
of O O
health O O
professionals O O
, O O
which O O
potentially O O
limits O O
generalizability O O
. O O

CONCLUSION O O
: O O
Aspirin O O
reduces O O
the O O
risk O O
for O O
myocardial B B_DISEASE
infarction I I_DISEASE
in O O
men O O
and O O
strokes B B_DISEASE/B_LOCATION
in O O
women O O
. O O

Aspirin O O
use O O
increases O O
the O O
risk O O
for O O
serious O O
bleeding B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
events O O
. O O

Reducing O O
harm O O
associated O O
with O O
anticoagulation O O
: O O
practical O O
considerations O O
of O O
argatroban O O
therapy O O
in O O
heparin O O
- O O
induced O O
thrombocytopenia B B_DISEASE
. O O

Argatroban O O
is O O
a O O
hepatically O O
metabolized O O
, O O
direct O O
thrombin O O
inhibitor O O
used O O
for O O
prophylaxis O O
or O O
treatment O O
of O O
thrombosis B B_DISEASE
in O O
heparin O O
- O O
induced O O
thrombocytopenia B B_DISEASE
( O O
HIT B B_DISEASE
) O O
and O O
for O O
patients O O
with O O
or O O
at O O
risk O O
of O O
HIT B B_DISEASE/B_LOCATION
undergoing O O
percutaneous O O
coronary O O
intervention O O
( O O
PCI O O
) O O
. O O

The O O
objective O O
of O O
this O O
review O O
is O O
to O O
summarize O O
practical O O
considerations O O
of O O
argatroban O O
therapy O O
in O O
HIT B B_DISEASE/B_GENE
. O O

The O O
US O O
FDA O O
- O O
recommended O O
argatroban O O
dose O O
in O O
HIT B B_GENE/B_DISEASE
is O O
2 O O
microg O O
/ O O
kg O O
/ O O
min O O
( O O
reduced O O
in O O
patients O O
with O O
hepatic B B_DISEASE/B_GENE
impairment I I_DISEASE/I_GENE
and O O
in O O
paediatric O O
patients O O
) O O
, O O
adjusted O O
to O O
achieve O O
activated O O
partial O O
thromboplastin O O
times O O
( O O
aPTTs O O
) O O
1 O O
. O O
5 O O
- O O
3 O O
times O O
baseline O O
( O O
not O O
> O O
100 O O
seconds O O
) O O
. O O

Contemporary O O
experiences O O
indicate O O
that O O
reduced O O
doses O O
are O O
also O O
needed O O
in O O
patients O O
with O O
conditions O O
associated O O
with O O
hepatic O O
hypoperfusion O O
, O O
e O O
. O O
g O O
. O O
heart B B_DISEASE
failure I I_DISEASE
, O O
yet O O
are O O
unnecessary O O
for O O
renal B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
dysfunction I B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O O
adult O O
age O O
, O O
sex O O
, O O
race O O
/ O O
ethnicity O O
or O O
obesity B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
FDA O O
- O O
recommended O O
dose O O
during O O
PCI O O
is O O
25 O O
microg O O
/ O O
kg O O
/ O O
min O O
( O O
350 O O
microg O O
/ O O
kg O O
initial O O
bolus O O
) O O
, O O
adjusted O O
to O O
achieve O O
activated O O
clotting O O
times O O
( O O
ACTs O O
) O O
of O O
300 O O
- O O
450 O O
sec O O
. O O

For O O
PCI O O
, O O
argatroban O O
has O O
not O O
been O O
investigated O O
in O O
hepatically O O
impaired O O
patients O O
; O O
dose O O
adjustment O O
is O O
unnecessary O O
for O O
adult O O
age O O
, O O
sex O O
, O O
race O O
/ O O
ethnicity O O
or O O
obesity B B_DISEASE/B_PERSON
, O O
and O O
lesser O O
doses O O
may O O
be O O
adequate O O
with O O
concurrent O O
glycoprotein O O
IIb O O
/ O O
IIIa O O
inhibition O O
. O O

Argatroban O O
prolongs O O
the O O
International O O
Normalized O O
Ratio O O
, O O
and O O
published O O
approaches O O
for O O
monitoring O O
the O O
argatroban O O
- O O
to O O
- O O
warfarin O O
transition O O
should O O
be O O
followed O O
. O O

Major O O
bleeding B B_DISEASE
with O O
argatroban O O
is O O
0 O O
- O O
10 O O
% O O
in O O
the O O
non O O
- O O
interventional O O
setting O O
and O O
0 O O
- O O
5 O O
. O O
8 O O
% O O
periprocedurally O O
. O O

Improved O O
familiarity O O
of O O
healthcare O O
professionals O O
with O O
argatroban O O
therapy O O
in O O
HIT B B_DISEASE/B_GENE
, O O
including O O
in O O
special O O
populations O O
and O O
during O O
PCI O O
, O O
may O O
facilitate O O
reduction O O
of O O
harm O O
associated O O
with O O
HIT B B_DISEASE
( O O
e O O
. O O
g O O
. O O
fewer O O
thromboses O O
) O O
or O O
its O O
treatment O O
( O O
e O O
. O O
g O O
. O O
fewer O O
argatroban O O
medication O O
errors O O
) O O
. O O

Rhabdomyolysis B B_DISEASE
and O O
brain O O
ischemic B B_DISEASE
stroke I I_DISEASE
in O O
a O O
heroin O O
- O O
dependent O O
male O O
under O O
methadone O O
maintenance O O
therapy O O
. O O

OBJECTIVE O O
: O O
There O O
are O O
several O O
complications O O
associated O O
with O O
heroin B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
abuse I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
some O O
of O O
which O O
are O O
life O O
- O O
threatening O O
. O O

METHOD O O
: O O
A O O
clinical O O
case O O
description O O
. O O

RESULTS O O
: O O
A O O
33 O O
- O O
year O O
- O O
old O O
man O O
presented O O
with O O
rhabdomyolysis B B_DISEASE
and O O
cerebral O O
ischemic B B_DISEASE
stroke I I_DISEASE
after O O
intravenous O O
heroin O O
. O O

He O O
was O O
found O O
unconsciousness B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
at O O
home O O
and O O
was O O
sent O O
to O O
our O O
hospital O O
. O O

In O O
the O O
ER O O
, O O
his O O
opiate O O
level O O
was O O
4497 O O
ng O O
/ O O
ml O O
. O O

In O O
the O O
ICU O O
, O O
we O O
found O O
rhabdomyolysis B B_DISEASE
, O O
acute B B_DISEASE
renal I I_DISEASE
failure I I_DISEASE
and O O
acute O O
respiratory B B_DISEASE
failure I I_DISEASE
. O O

After O O
transfer O O
to O O
an O O
internal O O
ward O O
, O O
we O O
noted O O
aphasia B B_DISEASE
and O O
weakness B B_DISEASE
of O O
his O O
left O O
limbs O O
. O O

After O O
MRI O O
, O O
we O O
found O O
cerebral B B_DISEASE_ADJECTIVE[DISEASE]
ischemic I I_DISEASE_ADJECTIVE[DISEASE]
infarction I I_DISEASE_ADJECTIVE[DISEASE]
. O O

CONCLUSION O O
: O O
Those O O
using O O
methadone O O
and O O
heroin O O
simultaneously O O
may O O
increase O O
risk O O
of O O
rhabdomyolysis B B_DISEASE
and O O
ischemic B B_DISEASE
stroke I I_DISEASE
. O O

Patients O O
under O O
methadone O O
maintenance O O
therapy O O
should O O
be O O
warned O O
regarding O O
these O O
serious O O
adverse O O
events O O
. O O

Hypotheses O O
of O O
heroin O O
- O O
related O O
rhabdomyolysis B B_DISEASE
and O O
stroke B B_DISEASE
in O O
heroin O O
abusers O O
are O O
discussed O O
. O O

Increased O O
vulnerability O O
to O O
6 O O
- O O
hydroxydopamine O O
lesion O O
and O O
reduced O O
development O O
of O O
dyskinesias B B_DISEASE
in O O
mice O O
lacking O O
CB1 O O
cannabinoid O O
receptors O O
. O O

Motor O O
impairment O O
, O O
dopamine O O
( O O
DA O O
) O O
neuronal O O
activity O O
and O O
proenkephalin O O
( O O
PENK O O
) O O
gene O O
expression O O
in O O
the O O
caudate O O
- O O
putamen O O
( O O
CPu O O
) O O
were O O
measured O O
in O O
6 O O
- O O
OHDA O O
- O O
lesioned O O
and O O
treated O O
( O O
L O O
- O O
DOPA O O
+ O O
benserazide O O
) O O
CB1 O O
KO O O
and O O
WT O O
mice O O
. O O

Treatment O O
with O O
L O O
- O O
DOPA O O
+ O O
benserazide O O
( O O
12 O O
weeks O O
) O O
resulted O O
in O O
less O O
severe O O
dyskinesias B B_DISEASE
in O O
CB1 O O
KO O O
than O O
in O O
WT O O
mice O O
. O O

The O O
results O O
revealed O O
that O O
the O O
lack O O
of O O
cannabinoid O O
CB1 O O
receptors O O
increased O O
the O O
severity O O
of O O
motor O O
impairment O O
and O O
DA O O
lesion O O
, O O
and O O
reduced O O
L O O
- O O
DOPA O O
- O O
induced O O
dyskinesias B B_DISEASE
. O O

These O O
results O O
suggest O O
that O O
activation O O
of O O
CB1 O O
receptors O O
offers O O
neuroprotection O O
against O O
dopaminergic O O
lesion O O
and O O
the O O
development O O
of O O
L O O
- O O
DOPA O O
- O O
induced O O
dyskinesias B B_DISEASE
. O O

Hepatocellular O O
oxidant O O
stress O O
following O O
intestinal O O
ischemia B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
reperfusion B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injury I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Reperfusion O O
of O O
ischemic B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
intestine O O
results O O
in O O
acute O O
liver B B_DISEASE
dysfunction I I_DISEASE
characterized O O
by O O
hepatocellular O O
enzyme O O
release O O
into O O
plasma O O
, O O
reduction O O
in O O
bile O O
flow O O
rate O O
, O O
and O O
neutrophil O O
sequestration O O
within O O
the O O
liver O O
. O O

The O O
pathophysiology O O
underlying O O
this O O
acute O O
hepatic B B_DISEASE_ADJECTIVE[DISEASE]
injury I I_DISEASE_ADJECTIVE[DISEASE]
is O O
unknown O O
. O O

This O O
study O O
was O O
undertaken O O
to O O
determine O O
whether O O
oxidants O O
are O O
associated O O
with O O
the O O
hepatic B B_DISEASE_ADJECTIVE[DISEASE]
injury I I_DISEASE_ADJECTIVE[DISEASE]
and O O
to O O
determine O O
the O O
relative O O
value O O
of O O
several O O
indirect O O
methods O O
of O O
assessing O O
oxidant O O
exposure O O
in O O
vivo O O
. O O

Rats O O
were O O
subjected O O
to O O
a O O
standardized O O
intestinal O O
ischemia B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
reperfusion B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injury I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Hepatic O O
tissue O O
was O O
assayed O O
for O O
lipid O O
peroxidation O O
products O O
and O O
oxidized O O
and O O
reduced O O
glutathione O O
. O O

There O O
was O O
no O O
change O O
in O O
hepatic O O
tissue O O
total O O
glutathione O O
following O O
intestinal O O
ischemia B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O O
reperfusion B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injury I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Oxidized O O
glutathione O O
( O O
GSSG O O
) O O
increased O O
significantly O O
following O O
30 O O
and O O
60 O O
min O O
of O O
reperfusion O O
. O O

There O O
was O O
no O O
increase O O
in O O
any O O
of O O
the O O
products O O
of O O
lipid O O
peroxidation O O
associated O O
with O O
this O O
injury O O
. O O

Animal O O
model O O
of O O
mania B B_DISEASE
induced O O
by O O
ouabain O O
: O O
Evidence O O
of O O
oxidative O O
stress O O
in O O
submitochondrial O O
particles O O
of O O
the O O
rat O O
brain O O
. O O

The O O
intracerebroventricular O O
( O O
ICV O O
) O O
administration O O
of O O
ouabain O O
( O O
a O O
Na O O
( O O
+ O O
) O O
/ O O
K O O
( O O
+ O O
) O O
- O O
ATPase O O
inhibitor O O
) O O
in O O
rats O O
has O O
been O O
suggested O O
to O O
mimic O O
some O O
symptoms O O
of O O
human O O
bipolar B B_DISEASE
mania I I_DISEASE
. O O

Clinical O O
studies O O
have O O
shown O O
that O O
bipolar B B_DISEASE/B_GENE
disorder I I_DISEASE/I_GENE
may O O
be O O
related O O
to O O
mitochondrial B B_DISEASE
dysfunction I I_DISEASE
. O O

Herein O O
, O O
we O O
investigated O O
the O O
behavioral O O
and O O
biochemical O O
effects O O
induced O O
by O O
the O O
ICV O O
administration O O
of O O
ouabain O O
in O O
rats O O
. O O

Our O O
findings O O
demonstrated O O
that O O
ouabain O O
at O O
10 O O
( O O
- O O
2 O O
) O O
and O O
10 O O
( O O
- O O
3 O O
) O O
M O O
induced O O
hyperlocomotion B B_DISEASE
in O O
rats O O
, O O
and O O
this O O
response O O
remained O O
up O O
to O O
7 O O
days O O
following O O
a O O
single O O
ICV O O
injection O O
. O O

In O O
addition O O
, O O
we O O
observed O O
that O O
the O O
persistent O O
increase O O
in O O
the O O
rat O O
spontaneous O O
locomotion O O
is O O
associated O O
with O O
increased O O
TBARS O O
levels O O
and O O
superoxide O O
generation O O
in O O
submitochondrial O O
particles O O
in O O
the O O
prefrontal O O
cortex O O
, O O
striatum O O
and O O
amygdala O O
. O O

In O O
conclusion O O
, O O
ouabain O O
- O O
induced O O
mania B B_DISEASE
- O O
like O O
behavior O O
may O O
provide O O
a O O
useful O O
animal O O
model O O
to O O
test O O
the O O
hypothesis O O
of O O
the O O
involvement O O
of O O
oxidative O O
stress O O
in O O
bipolar B B_DISEASE
disorder I I_DISEASE
. O O

Intraoperative O O
dialysis O O
during O O
liver O O
transplantation O O
with O O
citrate O O
dialysate O O
. O O

Liver O O
transplantation O O
for O O
acutely O O
ill O O
patients O O
with O O
fulminant B B_DISEASE
liver I I_DISEASE
failure I I_DISEASE
carries O O
high O O
intraoperative O O
and O O
immediate O O
postoperative O O
risks O O
. O O

These O O
are O O
increased O O
with O O
the O O
presence O O
of O O
concomitant O O
acute B B_DISEASE
kidney I I_DISEASE
injury I I_DISEASE
( O O
AKI B B_DISEASE
) O O
and O O
intraoperative O O
dialysis O O
is O O
sometimes O O
required O O
to O O
allow O O
the O O
transplant O O
to O O
proceed O O
. O O

The O O
derangements O O
in O O
the O O
procoagulant O O
and O O
anticoagulant O O
pathways O O
during O O
fulminant B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
liver I B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
failure I B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
can O O
lead O O
to O O
difficulties O O
with O O
anticoagulation O O
during O O
dialysis O O
, O O
especially O O
when O O
continued O O
in O O
the O O
operating O O
room O O
. O O

Systemic O O
anticoagulation O O
is O O
unsafe O O
and O O
regional O O
citrate O O
anticoagulation O O
in O O
the O O
absence O O
of O O
a O O
functional O O
liver O O
carries O O
the O O
risk O O
of O O
citrate O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Citrate O O
dialysate O O
, O O
a O O
new O O
dialysate O O
with O O
citric O O
acid O O
can O O
be O O
used O O
for O O
anticoagulation O O
in O O
patients O O
who O O
cannot O O
tolerate O O
heparin O O
or O O
regional O O
citrate O O
. O O

We O O
report O O
a O O
case O O
of O O
a O O
40 O O
- O O
year O O
- O O
old O O
female O O
with O O
acetaminophen O O
- O O
induced O O
fulminant B B_DISEASE
liver I I_DISEASE
failure I I_DISEASE
with O O
associated O O
AKI B B_DISEASE
who O O
underwent O O
intraoperative O O
dialytic O O
support O O
during O O
liver O O
transplantation O O
anticoagulated O O
with O O
citrate O O
dialysate O O
during O O
the O O
entire O O
procedure O O
. O O

The O O
patient O O
tolerated O O
the O O
procedure O O
well O O
without O O
any O O
signs O O
of O O
citrate O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
maintained O O
adequate O O
anticoagulation O O
for O O
patency O O
of O O
the O O
dialysis O O
circuit O O
. O O

Citrate O O
dialysate O O
is O O
a O O
safe O O
alternative O O
for O O
intradialytic O O
support O O
of O O
liver O O
transplantation O O
in O O
fulminant B B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
liver I B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
failure I B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
. O O

Delirium B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
patient O O
with O O
toxic O O
flecainide O O
plasma O O
concentrations O O
: O O
the O O
role O O
of O O
a O O
pharmacokinetic O O
drug O O
interaction O O
with O O
paroxetine O O
. O O

OBJECTIVE O O
: O O
To O O
describe O O
a O O
case O O
of O O
flecainide O O
- O O
induced O O
delirium B B_DISEASE
associated O O
with O O
a O O
pharmacokinetic O O
drug O O
interaction O O
with O O
paroxetine O O
. O O

CASE O O
SUMMARY O O
: O O
A O O
69 O O
- O O
year O O
- O O
old O O
white O O
female O O
presented O O
to O O
the O O
emergency O O
department O O
with O O
a O O
history O O
of O O
confusion B B_DISEASE
and O O
paranoia B B_DISEASE
over O O
the O O
past O O
several O O
days O O
. O O

On O O
admission O O
the O O
patient O O
was O O
taking O O
carvedilol O O
12 O O
mg O O
twice O O
daily O O
, O O
warfarin O O
2 O O
mg O O
/ O O
day O O
, O O
folic O O
acid O O
1 O O
mg O O
/ O O
day O O
, O O
levothyroxine O O
100 O O
microg O O
/ O O
day O O
, O O
pantoprazole O O
40 O O
mg O O
/ O O
day O O
, O O
paroxetine O O
40 O O
mg O O
/ O O
day O O
, O O
and O O
flecainide O O
100 O O
mg O O
twice O O
daily O O
. O O

Flecainide O O
had O O
been O O
started O O
2 O O
weeks O O
prior O O
for O O
atrial B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fibrillation I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Laboratory O O
test O O
findings O O
on O O
admission O O
were O O
notable O O
only O O
for O O
a O O
flecainide O O
plasma O O
concentration O O
of O O
1360 O O
microg O O
/ O O
L O O
( O O
reference O O
range O O
200 O O
- O O
1000 O O
) O O
. O O

A O O
metabolic O O
drug O O
interaction O O
between O O
flecainide O O
and O O
paroxetine O O
, O O
which O O
the O O
patient O O
had O O
been O O
taking O O
for O O
more O O
than O O
5 O O
years O O
, O O
was O O
considered O O
. O O

Paroxetine O O
was O O
discontinued O O
and O O
the O O
dose O O
of O O
flecainide O O
was O O
reduced O O
to O O
50 O O
mg O O
twice O O
daily O O
. O O

Her O O
delirium B B_DISEASE
resolved O O
3 O O
days O O
later O O
. O O

DISCUSSION O O
: O O
Flecainide O O
and O O
pharmacologically O O
similar O O
agents O O
that O O
interact O O
with O O
sodium O O
channels O O
may O O
cause O O
delirium B B_DISEASE
in O O
susceptible O O
patients O O
. O O

A O O
MEDLINE O O
search O O
( O O
1966 O O
- O O
January O O
2009 O O
) O O
revealed O O
one O O
in O O
vivo O O
pharmacokinetic O O
study O O
on O O
the O O
interaction O O
between O O
flecainide O O
, O O
a O O
CYP2D6 O O
substrate O O
, O O
and O O
paroxetine O O
, O O
a O O
CYP2D6 O O
inhibitor O O
, O O
as O O
well O O
as O O
3 O O
case O O
reports O O
of O O
flecainide O O
- O O
induced O O
delirium B B_DISEASE
. O O

According O O
to O O
the O O
Naranjo O O
probability O O
scale O O
, O O
flecainide O O
was O O
the O O
probable O O
cause O O
of O O
the O O
patient O O
' O O
s O O
delirium B B_DISEASE
; O O
the O O
Horn O O
Drug O O
Interaction O O
Probability O O
Scale O O
indicates O O
a O O
possible O O
pharmacokinetic O O
drug O O
interaction O O
between O O
flecainide O O
and O O
paroxetine O O
. O O

CONCLUSIONS O O
: O O
Supratherapeutic O O
flecainide O O
plasma O O
concentrations O O
may O O
cause O O
delirium B B_DISEASE
. O O

Because O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
occur O O
when O O
flecainide O O
is O O
prescribed O O
with O O
paroxetine O O
and O O
other O O
potent O O
CYP2D6 O O
inhibitors O O
, O O
flecainide O O
plasma O O
concentrations O O
should O O
be O O
monitored O O
closely O O
with O O
commencement O O
of O O
CYP2D6 O O
inhibitors O O
. O O

Efficacy O O
of O O
everolimus O O
( O O
RAD001 O O
) O O
in O O
patients O O
with O O
advanced O O
NSCLC B B_DISEASE/B_GENE
previously O O
treated O O
with O O
chemotherapy O O
alone O O
or O O
with O O
chemotherapy O O
and O O
EGFR O O
inhibitors O O
. O O

BACKGROUND O O
: O O
Treatment O O
options O O
are O O
scarce O O
in O O
pretreated O O
advanced O O
non B B_DISEASE
- I I_DISEASE
small I I_DISEASE
- I I_DISEASE
cell I I_DISEASE
lung I I_DISEASE
cancer I I_DISEASE
( O O
NSCLC B B_DISEASE
) O O
patients O O
. O O

RAD001 O O
, O O
an O O
oral O O
inhibitor O O
of O O
the O O
mammalian O O
target O O
of O O
rapamycin O O
( O O
mTOR O O
) O O
, O O
has O O
shown O O
phase O O
I O O
efficacy O O
in O O
NSCLC B B_DISEASE
. O O

METHODS O O
: O O
Stage O O
IIIb O O
or O O
IV O O
NSCLC B B_DISEASE/B_LOCATION
patients O O
, O O
with O O
two O O
or O O
fewer O O
prior O O
chemotherapy O O
regimens O O
, O O
one O O
platinum O O
based O O
( O O
stratum O O
1 O O
) O O
or O O
both O O
chemotherapy O O
and O O
epidermal O O
growth O O
factor O O
receptor O O
tyrosine O O
kinase O O
inhibitors O O
( O O
stratum O O
2 O O
) O O
, O O
received O O
RAD001 O O
10 O O
mg O O
/ O O
day O O
until O O
progression O O
or O O
unacceptable O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Analyses O O
of O O
markers O O
associated O O
with O O
the O O
mTOR O O
pathway O O
were O O
carried O O
out O O
on O O
archival O O
tumor B B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
a O O
subgroup O O
using O O
immunohistochemistry O O
( O O
IHC O O
) O O
and O O
direct O O
mutation O O
sequencing O O
. O O

RESULTS O O
: O O
Eighty O O
- O O
five O O
patients O O
were O O
enrolled O O
, O O
42 O O
in O O
stratum O O
1 O O
and O O
43 O O
in O O
stratum O O
. O O

Overall O O
disease O O
control O O
rate O O
was O O
47 O O
. O O
1 O O
% O O
. O O

Common O O
> O O
or O O
= O O
grade O O
3 O O
events O O
were O O
fatigue B B_DISEASE
, O O
dyspnea B B_DISEASE
, O O
stomatitis B B_DISEASE
, O O
anemia B B_DISEASE
, O O
and O O
thrombocytopenia B B_DISEASE
. O O

Pneumonitis B B_DISEASE
, O O
probably O O
or O O
possibly O O
related O O
, O O
mainly O O
grade O O
1 O O
/ O O
2 O O
, O O
occurred O O
in O O
25 O O
% O O
. O O

CONCLUSIONS O O
: O O
RAD001 O O
10 O O
mg O O
/ O O
day O O
was O O
well O O
tolerated O O
, O O
showing O O
modest O O
clinical O O
activity O O
in O O
pretreated O O
NSCLC B B_DISEASE/B_LOCATION
. O O

Evaluation O O
of O O
RAD001 O O
plus O O
standard O O
therapy O O
for O O
metastatic O O
NSCLC B B_DISEASE/B_LOCATION
continues O O
. O O

Posttransplant O O
anemia B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
: O O
the O O
role O O
of O O
sirolimus O O
. O O

Posttransplant O O
anemia B B_DISEASE
is O O
a O O
common O O
problem O O
that O O
may O O
hinder O O
patients O O
' O O
quality O O
of O O
life O O
. O O

It O O
occurs O O
in O O
12 O O
to O O
76 O O
% O O
of O O
patients O O
, O O
and O O
is O O
most O O
common O O
in O O
the O O
immediate O O
posttransplant O O
period O O
. O O

A O O
variety O O
of O O
factors O O
have O O
been O O
identified O O
that O O
increase O O
the O O
risk O O
of O O
posttransplant O O
anemia B B_DISEASE
, O O
of O O
which O O
the O O
level O O
of O O
renal O O
function O O
is O O
most O O
important O O
. O O

Sirolimus O O
, O O
a O O
mammalian O O
target O O
of O O
rapamycin O O
inhibitor O O
, O O
has O O
been O O
implicated O O
as O O
playing O O
a O O
special O O
role O O
in O O
posttransplant O O
anemia B B_DISEASE
. O O

This O O
review O O
considers O O
anemia B B_DISEASE
associated O O
with O O
sirolimus O O
, O O
including O O
its O O
presentation O O
, O O
mechanisms O O
, O O
and O O
management O O
. O O

Coronary O O
computerized O O
tomography O O
angiography O O
for O O
rapid O O
discharge O O
of O O
low O O
- O O
risk O O
patients O O
with O O
cocaine O O
- O O
associated O O
chest B B_DISEASE/B_LOCATION
pain I I_DISEASE/I_LOCATION
. O O

BACKGROUND O O
: O O
Most O O
patients O O
presenting O O
to O O
emergency O O
departments O O
( O O
EDs O O
) O O
with O O
cocaine O O
- O O
associated O O
chest B B_DISEASE/B_LOCATION
pain I I_DISEASE/I_LOCATION
are O O
admitted O O
for O O
at O O
least O O
12 O O
hours O O
and O O
receive O O
a O O
" O O
rule O O
out O O
acute B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coronary I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
syndrome I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
" O O
protocol O O
, O O
often O O
with O O
noninvasive O O
testing O O
prior O O
to O O
discharge O O
. O O

It O O
is O O
unclear O O
whether O O
a O O
coronary O O
CTA O O
strategy O O
would O O
be O O
efficacious O O
in O O
cocaine O O
- O O
associated O O
chest B B_DISEASE/B_LOCATION
pain I I_DISEASE/I_LOCATION
, O O
as O O
coronary B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vasospasm I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
account O O
for O O
some O O
of O O
the O O
ischemia B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
studied O O
whether O O
a O O
negative O O
coronary O O
CTA O O
in O O
patients O O
with O O
cocaine O O
- O O
associated O O
chest B B_DISEASE/B_LOCATION
pain I I_DISEASE/I_LOCATION
could O O
identify O O
a O O
subset O O
safe O O
for O O
discharge O O
. O O

METHODS O O
: O O
We O O
prospectively O O
evaluated O O
the O O
safety O O
of O O
coronary O O
CTA O O
for O O
low O O
- O O
risk O O
patients O O
who O O
presented O O
to O O
the O O
ED O O
with O O
cocaineassociated O O
chest B B_DISEASE
pain I I_DISEASE
( O O
self O O
- O O
reported O O
or O O
positive O O
urine O O
test O O
) O O
. O O

Patients O O
with O O
negative O O
coronary O O
CTA O O
( O O
maximal O O
stenosis B B_DISEASE/B_MEASURE
less O O
than O O
50 O O
% O O
) O O
were O O
discharged O O
. O O

The O O
main O O
outcome O O
was O O
30 O O
- O O
day O O
cardiovascular O O
death O O
or O O
myocardial B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

RESULTS O O
: O O
A O O
total O O
of O O
59 O O
patients O O
with O O
cocaine O O
- O O
associated O O
chest B B_DISEASE
pain I I_DISEASE
were O O
evaluated O O
. O O

Patients O O
had O O
a O O
mean O O
age O O
of O O
45 O O
. O O
6 O O
+ O O
/ O O
- O O
6 O O
. O O
6 O O
yrs O O
and O O
were O O
86 O O
% O O
black O O
, O O
66 O O
% O O
male O O
. O O

Seventy O O
- O O
nine O O
percent O O
had O O
a O O
normal O O
or O O
nonspecific O O
ECG O O
and O O
85 O O
% O O
had O O
a O O
TIMI O O
score O O
< O O
2 O O
. O O

Twenty O O
patients O O
received O O
coronary O O
CTA O O
immediately O O
in O O
the O O
ED O O
, O O
18 O O
of O O
whom O O
were O O
discharged O O
following O O
CTA O O
( O O
90 O O
% O O
) O O
. O O

Thirty O O
- O O
nine O O
received O O
coronary O O
CTA O O
after O O
a O O
brief O O
observation O O
period O O
, O O
with O O
37 O O
discharged O O
home O O
following O O
CTA O O
( O O
95 O O
% O O
) O O
. O O

Six O O
patients O O
had O O
coronary B B_DISEASE
stenosis I I_DISEASE
> O O
or O O
= O O
50 O O
% O O
. O O

During O O
the O O
30 O O
- O O
day O O
follow O O
- O O
up O O
period O O
, O O
no O O
patients O O
died O O
of O O
a O O
cardiovascular O O
event O O
( O O
0 O O
% O O
; O O
95 O O
% O O
CI O O
, O O
0 O O
- O O
6 O O
. O O
1 O O
% O O
) O O
and O O
no O O
patient O O
sustained O O
a O O
nonfatal O O
myocardial B B_DISEASE
infarction I I_DISEASE
( O O
0 O O
% O O
; O O
95 O O
% O O
CI O O
, O O
0 O O
- O O
6 O O
. O O
1 O O
% O O
) O O
. O O

CONCLUSIONS O O
: O O
Although O O
cocaine O O
- O O
associated O O
myocardial B B_DISEASE/B_LOCATION
ischemia I I_DISEASE/I_LOCATION
can O O
result O O
from O O
coronary O O
vasoconstriction O O
, O O
patients O O
with O O
cocaine O O
associated O O
chest B B_DISEASE/B_LOCATION
pain I I_DISEASE/I_LOCATION
, O O
a O O
non O O
- O O
ischemic B B_DISEASE_ADJECTIVE[DISEASE]
ECG O O
, O O
and O O
a O O
TIMI O O
risk O O
score O O
< O O
2 O O
may O O
be O O
safely O O
discharged O O
from O O
the O O
ED O O
after O O
a O O
negative O O
coronary O O
CTA O O
with O O
a O O
low O O
risk O O
of O O
30 O O
- O O
day O O
adverse O O
events O O
. O O

Bilateral O O
haemorrhagic B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
infarction I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
the I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
globus I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
pallidus I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
after O O
cocaine O O
and O O
alcohol O O
intoxication O O
. O O

Cocaine O O
is O O
a O O
risk O O
factor O O
for O O
both O O
ischemic B B_DISEASE_ADJECTIVE[DISEASE]
and I I_DISEASE_ADJECTIVE[DISEASE]
haemorrhagic I I_DISEASE_ADJECTIVE[DISEASE]
stroke I I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
present O O
the O O
case O O
of O O
a O O
31 O O
- O O
year O O
- O O
old O O
man O O
with O O
bilateral O O
ischemia B B_DISEASE
of I I_DISEASE
the I I_DISEASE
globus I I_DISEASE
pallidus I I_DISEASE
after O O
excessive O O
alcohol O O
and O O
intranasal O O
cocaine O O
use O O
. O O

Drug O O
- O O
related O O
globus B B_DISEASE_ADJECTIVE[DISEASE]
pallidus I I_DISEASE_ADJECTIVE[DISEASE]
infarctions I I_DISEASE_ADJECTIVE[DISEASE]
are O O
most O O
often O O
associated O O
with O O
heroin O O
. O O

Bilateral O O
basal B B_DISEASE_ADJECTIVE[DISEASE]
ganglia I I_DISEASE_ADJECTIVE[DISEASE]
infarcts I I_DISEASE_ADJECTIVE[DISEASE]
after O O
the O O
use O O
of O O
cocaine O O
, O O
without O O
concurrent O O
heroin O O
use O O
, O O
have O O
never O O
been O O
reported O O
. O O

In O O
our O O
patient O O
, O O
transient O O
cardiac B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
arrhythmia I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
or O O
respiratory B B_DISEASE
dysfunction I I_DISEASE
related O O
to O O
cocaine O O
and O O
/ O O
or O O
ethanol O O
use O O
were O O
the O O
most O O
likely O O
causes O O
of O O
cerebral B B_DISEASE
hypoperfusion I I_DISEASE
. O O

Late O O
fulminant O O
posterior B B_DISEASE
reversible I I_DISEASE
encephalopathy I I_DISEASE
syndrome I I_DISEASE
after O O
liver O O
transplant O O
. O O

OBJECTIVES O O
: O O
Posterior B B_DISEASE
leukoencephalopathy I I_DISEASE
due O O
to O O
calcineurin O O
- O O
inhibitor O O
- O O
related O O
neurotoxicity B B_DISEASE
is O O
a O O
rare O O
but O O
severe O O
complication O O
that O O
results O O
from O O
treatment O O
with O O
immunosuppressive O O
agents O O
( O O
primarily O O
those O O
administered O O
after O O
a O O
liver O O
or O O
kidney O O
transplant O O
) O O
. O O

CASE O O
: O O
We O O
report O O
the O O
case O O
of O O
a O O
46 O O
- O O
year O O
- O O
old O O
woman O O
who O O
received O O
a O O
liver O O
transplant O O
in O O
our O O
center O O
as O O
treatment O O
for O O
alcoholic B B_DISEASE/B_GENE
cirrhosis I I_DISEASE/I_GENE
and O O
in O O
whom O O
either O O
a O O
fulminant O O
course O O
of O O
posterior B B_DISEASE
leukoencephalopathy I I_DISEASE
or O O
posterior B B_DISEASE
reversible I I_DISEASE
encephalopathy I I_DISEASE
syndrome I I_DISEASE
developed O O
110 O O
days O O
after O O
transplant O O
. O O

Switching O O
the O O
immunosuppressive O O
regimen O O
from O O
tacrolimus O O
to O O
cyclosporine O O
did O O
not O O
improve O O
the O O
clinical O O
situation O O
. O O

CONCLUSIONS O O
: O O
Posterior B B_DISEASE
reversible I I_DISEASE
encephalopathy I I_DISEASE
syndrome I I_DISEASE
after O O
liver O O
transplant O O
is O O
rare O O
. O O

We O O
recommend O O
a O O
complete O O
cessation O O
of O O
any O O
calcineurin O O
inhibitor O O
rather O O
than O O
a O O
dose O O
reduction O O
. O O

Prolonged O O
hypothermia B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
as O O
a O O
bridge O O
to O O
recovery O O
for O O
cerebral B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
edema I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
intracranial B B_DISEASE
hypertension I I_DISEASE
associated O O
with O O
fulminant B B_DISEASE
hepatic I I_DISEASE
failure I I_DISEASE
. O O

METHOD O O
: O O
Case O O
- O O
based O O
observations O O
from O O
a O O
medical O O
intensive O O
care O O
unit O O
( O O
MICU O O
) O O
in O O
a O O
tertiary O O
care O O
facility O O
in O O
a O O
27 O O
- O O
year O O
- O O
old O O
female O O
with O O
FHF B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O O
acetaminophen O O
and O O
resultant O O
cerebral B B_DISEASE_ADJECTIVE[DISEASE]
edema I I_DISEASE_ADJECTIVE[DISEASE]
. O O

RESULTS O O
: O O
Our O O
patient O O
was O O
admitted O O
to O O
the O O
MICU O O
after O O
being O O
found O O
unresponsive O O
with O O
presumed O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
acetaminophen O O
which O O
was O O
ingested O O
over O O
a O O
2 O O
- O O
day O O
period O O
. O O

Initial O O
evaluation O O
confirmed O O
FHF B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O O
acetaminophen O O
and O O
cerebral B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
edema I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
patient O O
was O O
treated O O
with O O
hyperosmolar O O
therapy O O
, O O
hyperventilation B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
sedation O O
, O O
and O O
chemical O O
paralysis B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Her O O
intracranial O O
pressure O O
remained O O
elevated O O
despite O O
maximal O O
medical O O
therapy O O
. O O

At O O
re O O
- O O
warming O O
, O O
patient O O
had O O
resolution O O
of O O
her O O
cerebral B B_DISEASE
edema I I_DISEASE
and O O
intracranial B B_DISEASE
hypertension I I_DISEASE
. O O

At O O
discharge O O
, O O
she O O
had O O
complete O O
recovery O O
of O O
neurological O O
and O O
hepatic O O
functions O O
. O O

CONCLUSION O O
: O O
In O O
patients O O
with O O
FHF B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
cerebral B B_DISEASE
edema I I_DISEASE
from O O
acetaminophen O O
overdose B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
prolonged O O
therapeutic O O
hypothermia B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
could O O
potentially O O
be O O
used O O
as O O
a O O
life O O
saving O O
therapy O O
and O O
a O O
bridge O O
to O O
hepatic O O
and O O
neurological O O
recovery O O
. O O

Binasal B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
visual I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
field I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
defects I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O O
not O O
specific O O
to O O
vigabatrin O O
. O O

This O O
study O O
investigated O O
the O O
visual B B_DISEASE_ADJECTIVE[DISEASE]
defects I I_DISEASE_ADJECTIVE[DISEASE]
associated O O
with O O
the O O
antiepileptic O O
drug O O
vigabatrin O O
( O O
VGB O O
) O O
. O O

Two O O
hundred O O
four O O
people O O
with O O
epilepsy B B_DISEASE
were O O
grouped O O
on O O
the O O
basis O O
of O O
antiepileptic O O
drug O O
therapy O O
( O O
current O O
, O O
previous O O
, O O
or O O
no O O
exposure O O
to O O
VGB O O
) O O
. O O

Groups O O
were O O
matched O O
with O O
respect O O
to O O
age O O
, O O
gender O O
, O O
and O O
seizure B B_DISEASE
frequency O O
. O O

Bilateral B B_DISEASE_ADJECTIVE[DISEASE]
visual I I_DISEASE_ADJECTIVE[DISEASE]
field I I_DISEASE_ADJECTIVE[DISEASE]
abnormalities I I_DISEASE_ADJECTIVE[DISEASE]
are O O
common O O
in O O
the O O
treated O O
epilepsy B B_DISEASE/B_PERSON
population O O
, O O
irrespective O O
of O O
drug O O
history O O
. O O

Assessment O O
by O O
conventional O O
static O O
perimetry O O
may O O
neither O O
be O O
sufficiently O O
sensitive O O
nor O O
specific O O
to O O
reliably O O
identify O O
retinal B B_DISEASE_ADJECTIVE[DISEASE]
toxicity I I_DISEASE_ADJECTIVE[DISEASE]
associated O O
with O O
VGB O O
. O O

Smoking O O
of O O
crack O O
cocaine O O
as O O
a O O
risk O O
factor O O
for O O
HIV B B_DISEASE
infection I I_DISEASE
among O O
people O O
who O O
use O O
injection O O
drugs O O
. O O

BACKGROUND O O
: O O
Little O O
is O O
known O O
about O O
the O O
possible O O
role O O
that O O
smoking O O
crack O O
cocaine O O
has O O
on O O
the O O
incidence O O
of O O
HIV B B_DISEASE
infection I I_DISEASE
. O O

Given O O
the O O
increasing O O
use O O
of O O
crack O O
cocaine O O
, O O
we O O
sought O O
to O O
examine O O
whether O O
use O O
of O O
this O O
illicit O O
drug O O
has O O
become O O
a O O
risk O O
factor O O
for O O
HIV B B_DISEASE
infection I I_DISEASE
. O O

To O O
determine O O
whether O O
the O O
risk O O
of O O
HIV B B_DISEASE
seroconversion I I_DISEASE
among O O
daily O O
smokers O O
of O O
crack O O
cocaine O O
changed O O
over O O
time O O
, O O
we O O
used O O
Cox O O
proportional O O
hazards O O
regression O O
and O O
divided O O
the O O
study O O
into O O
3 O O
periods O O
: O O
May O O
1 O O
, O O
1996 O O
- O O
Nov O O
. O O

30 O O
, O O
1999 O O
( O O
period O O
1 O O
) O O
, O O
Dec O O
. O O

1 O O
, O O
1999 O O
- O O
Nov O O
. O O

30 O O
, O O
2002 O O
( O O
period O O
2 O O
) O O
, O O
and O O
Dec O O
. O O

1 O O
, O O
2002 O O
- O O
Dec O O
. O O

30 O O
, O O
2005 O O
( O O
period O O
3 O O
) O O
. O O

RESULTS O O
: O O
Overall O O
, O O
1048 O O
eligible O O
injection O O
drug O O
users O O
were O O
included O O
in O O
our O O
study O O
. O O

Of O O
these O O
, O O
137 O O
acquired O O
HIV B B_DISEASE/B_GENE
infection I I_DISEASE/I_GENE
during O O
follow O O
- O O
up O O
. O O

The O O
mean O O
proportion O O
of O O
participants O O
who O O
reported O O
daily O O
smoking O O
of O O
crack O O
cocaine O O
increased O O
from O O
11 O O
. O O
6 O O
% O O
in O O
period O O
1 O O
to O O
39 O O
. O O
7 O O
% O O
in O O
period O O
3 O O
. O O

After O O
adjusting O O
for O O
potential O O
confounders O O
, O O
we O O
found O O
that O O
the O O
risk O O
of O O
HIV B B_DISEASE/B_LOCATION
seroconversion I I_DISEASE/I_LOCATION
among O O
participants O O
who O O
were O O
daily O O
smokers O O
of O O
crack O O
cocaine O O
increased O O
over O O
time O O
( O O
period O O
1 O O
: O O
hazard O O
ratio O O
[ O O
HR O O
] O O
1 O O
. O O
03 O O
, O O
95 O O
% O O
confidence O O
interval O O
[ O O
CI O O
] O O
0 O O
. O O
57 O O
- O O
1 O O
. O O
85 O O
; O O
period O O
2 O O
: O O
HR O O
1 O O
. O O
68 O O
, O O
95 O O
% O O
CI O O
1 O O
. O O
01 O O
- O O
2 O O
. O O
80 O O
; O O
and O O
period O O
3 O O
: O O
HR O O
2 O O
. O O
74 O O
, O O
95 O O
% O O
CI O O
1 O O
. O O
06 O O
- O O
7 O O
. O O
11 O O
) O O
. O O

INTERPRETATION O O
: O O
Smoking O O
of O O
crack O O
cocaine O O
was O O
found O O
to O O
be O O
an O O
independent O O
risk O O
factor O O
for O O
HIV B B_DISEASE/B_LOCATION
seroconversion I I_DISEASE/I_LOCATION
among O O
people O O
who O O
were O O
injection O O
drug O O
users O O
. O O

This O O
finding O O
points O O
to O O
the O O
urgent O O
need O O
for O O
evidence O O
- O O
based O O
public O O
health O O
initiatives O O
targeted O O
at O O
people O O
who O O
smoke O O
crack O O
cocaine O O
. O O

Fluoxetine O O
improves O O
the O O
memory B B_DISEASE
deficits I I_DISEASE
caused O O
by O O
the O O
chemotherapy O O
agent O O
5 O O
- O O
fluorouracil O O
. O O

Cancer B B_DISEASE
patients O O
who O O
have O O
been O O
treated O O
with O O
systemic O O
adjuvant O O
chemotherapy O O
have O O
described O O
experiencing O O
deteriorations O O
in O O
cognition O O
. O O

In O O
this O O
investigation O O
the O O
behavioural O O
effects O O
of O O
chronic O O
( O O
two O O
week O O
) O O
treatment O O
with O O
5 O O
- O O
FU O O
and O O
( O O
three O O
weeks O O
) O O
with O O
Fluoxetine O O
either O O
separately O O
or O O
in O O
combination O O
with O O
5 O O
- O O
FU O O
were O O
tested O O
on O O
adult O O
Lister O O
hooded O O
rats O O
. O O

Behavioural O O
effects O O
were O O
tested O O
using O O
a O O
context O O
dependent O O
conditioned O O
emotional O O
response O O
test O O
( O O
CER O O
) O O
which O O
showed O O
that O O
animals O O
treated O O
with O O
5 O O
- O O
FU O O
had O O
a O O
significant O O
reduction O O
in O O
freezing O O
time O O
compared O O
to O O
controls O O
. O O

Animals O O
treated O O
only O O
with O O
5 O O
- O O
FU O O
showed O O
significant O O
deficits O O
in O O
their O O
ability O O
to O O
carry O O
out O O
the O O
OLR O O
task O O
but O O
co O O
administration O O
of O O
Fluoxetine O O
improved O O
their O O
performance O O
. O O

5 O O
- O O
FU O O
chemotherapy O O
caused O O
a O O
significant O O
reduction O O
in O O
the O O
number O O
of O O
proliferating O O
cells O O
in O O
the O O
sub O O
granular O O
zone O O
of O O
the O O
dentate O O
gyrus O O
compared O O
to O O
controls O O
. O O

This O O
reduction O O
was O O
eliminated O O
when O O
Fluoxetine O O
was O O
co O O
administered O O
with O O
5 O O
- O O
FU O O
. O O

Fluoxetine O O
on O O
its O O
own O O
had O O
no O O
effect O O
on O O
proliferating O O
cell O O
number O O
or O O
behaviour O O
. O O

These O O
findings O O
suggest O O
that O O
5 O O
- O O
FU O O
can O O
negatively O O
affect O O
both O O
cell O O
proliferation O O
and O O
hippocampal O O
dependent O O
working O O
memory O O
and O O
that O O
these O O
deficits O O
can O O
be O O
reversed O O
by O O
the O O
simultaneous O O
administration O O
of O O
the O O
antidepressant O O
Fluoxetine O O
. O O

Liver O O
- O O
specific O O
ablation O O
of O O
integrin O O
- O O
linked O O
kinase O O
in O O
mice O O
results O O
in O O
enhanced O O
and O O
prolonged O O
cell O O
proliferation O O
and O O
hepatomegaly B B_DISEASE_ADJECTIVE[DISEASE]
after O O
phenobarbital O O
administration O O
. O O

Livers O O
were O O
harvested O O
on O O
2 O O
, O O
5 O O
, O O
and O O
10 O O
days O O
during O O
PB O O
administration O O
. O O

In O O
the O O
hepatocyte O O
- O O
specific O O
ILK O O
/ O O
liver O O
- O O
/ O O
- O O
mice O O
, O O
the O O
liver O O
: O O
body O O
weight O O
ratio O O
was O O
more O O
than O O
double O O
as O O
compared O O
to O O
0 O O
h O O
at O O
day O O
2 O O
( O O
2 O O
. O O
5 O O
times O O
) O O
, O O
while O O
at O O
days O O
5 O O
and O O
10 O O
, O O
it O O
was O O
enlarged O O
three O O
times O O
. O O

There O O
were O O
slightly O O
increased O O
proliferating O O
cell O O
nuclear O O
antigen O O
- O O
positive O O
cells O O
in O O
the O O
ILK O O
/ O O
liver O O
- O O
/ O O
- O O
animals O O
at O O
day O O
2 O O
as O O
compared O O
to O O
WT O O
after O O
PB O O
administration O O
. O O

In O O
the O O
WT O O
animals O O
, O O
the O O
proliferative O O
response O O
had O O
come O O
back O O
to O O
normal O O
by O O
days O O
5 O O
and O O
10 O O
. O O

In O O
summary O O
, O O
ECM O O
proteins O O
communicate O O
with O O
the O O
signaling O O
machinery O O
of O O
dividing O O
cells O O
via O O
ILK O O
to O O
regulate O O
hepatocyte O O
proliferation O O
and O O
termination O O
of O O
the O O
proliferative O O
response O O
. O O

Decreased O O
Expression O O
of O O
Na O O
/ O O
K O O
- O O
ATPase O O
, O O
NHE3 O O
, O O
NBC1 O O
, O O
AQP1 O O
and O O
OAT O O
in O O
Gentamicin O O
- O O
induced O O
Nephropathy B B_DISEASE/B_GENE
. O O

The O O
present O O
study O O
was O O
aimed O O
to O O
determine O O
whether O O
there O O
is O O
an O O
altered O O
regulation O O
of O O
tubular O O
transporters O O
in O O
gentamicin O O
- O O
induced O O
nephropathy B B_DISEASE
. O O

Sprague O O
- O O
Dawley O O
male O O
rats O O
( O O
200 O O
~ O O
250 O O
g O O
) O O
were O O
subcutaneously O O
injected O O
with O O
gentamicin O O
( O O
100 O O
mg O O
/ O O
kg O O
per O O
day O O
) O O
for O O
7 O O
days O O
, O O
and O O
the O O
expression O O
of O O
tubular O O
transporters O O
was O O
determined O O
by O O
immunoblotting O O
and O O
immunohistochemistry O O
. O O

The O O
mRNA O O
and O O
protein O O
expression O O
of O O
OAT O O
was O O
also O O
determined O O
. O O

Accordingly O O
, O O
the O O
fractional O O
excretion O O
of O O
sodium O O
increased O O
. O O

Urine O O
volume O O
was O O
increased O O
, O O
while O O
urine O O
osmolality O O
and O O
free O O
water O O
reabsorption O O
were O O
decreased O O
. O O

Immunoblotting O O
and O O
immunohistochemistry O O
revealed O O
decreased O O
expression O O
of O O
Na O O
( O O
+ O O
) O O
/ O O
K O O
( O O
+ O O
) O O
- O O
ATPase O O
, O O
NHE3 O O
, O O
NBC1 O O
, O O
and O O
AQP1 O O
in O O
the O O
kidney O O
of O O
gentamicin O O
- O O
treated O O
rats O O
. O O

The O O
expression O O
of O O
OAT1 O O
and O O
OAT3 O O
was O O
also O O
decreased O O
. O O

Gentamicin O O
- O O
induced O O
nephropathy B B_DISEASE
may O O
at O O
least O O
in O O
part O O
be O O
causally O O
related O O
with O O
a O O
decreased O O
expression O O
of O O
Na O O
( O O
+ O O
) O O
/ O O
K O O
( O O
+ O O
) O O
- O O
ATPase O O
, O O
NHE3 O O
, O O
NBC1 O O
, O O
AQP1 O O
and O O
OAT O O
. O O

Acute B B_DISEASE_ADJECTIVE[DISEASE]
renal I I_DISEASE_ADJECTIVE[DISEASE]
failure I I_DISEASE_ADJECTIVE[DISEASE]
after O O
high O O
- O O
dose O O
methotrexate O O
therapy O O
in O O
a O O
patient O O
with O O
ileostomy O O
. O O

High O O
- O O
dose O O
methotrexate O O
( O O
HD O O
- O O
MTX O O
) O O
is O O
an O O
important O O
treatment O O
for O O
Burkitt B B_DISEASE/B_LOCATION
lymphoma I I_DISEASE/I_LOCATION
, O O
but O O
can O O
cause O O
hepatic B B_DISEASE
and I I_DISEASE
renal I I_DISEASE
toxicity I I_DISEASE
when O O
its O O
clearance O O
is O O
delayed O O
. O O

We O O
report O O
a O O
case O O
of O O
acute B B_DISEASE
renal I I_DISEASE
failure I I_DISEASE
after O O
HD O O
- O O
MTX O O
therapy O O
in O O
a O O
patient O O
with O O
ileostomy O O
, O O
The O O
patient O O
was O O
a O O
3 O O
- O O
year O O
- O O
old O O
boy O O
who O O
had O O
received O O
a O O
living O O
- O O
related O O
liver O O
transplantation O O
for O O
congenital O O
biliary B B_DISEASE
atresia I I_DISEASE
. O O

At O O
day O O
833 O O
after O O
the O O
transplantation O O
, O O
he O O
was O O
diagnosed O O
with O O
PTLD B B_DISEASE
( O O
post B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
transplantation I I_DISEASE/I_GENE
lymphoproliferative I I_DISEASE/I_GENE
disorder I I_DISEASE/I_GENE
, O O
Burkitt B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
type I I_DISEASE/I_GENE
malignant I I_DISEASE/I_GENE
lymphoma I I_DISEASE/I_GENE
) O O
. O O

Subsequent O O
HD O O
- O O
MTX O O
therapy O O
caused O O
acute B B_DISEASE
renal I I_DISEASE
failure I I_DISEASE
that O O
required O O
continuous O O
hemodialysis O O
. O O

We O O
supposed O O
that O O
intravascular O O
hypovolemia B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
due O O
to O O
substantial O O
drainage O O
from O O
the O O
ileostoma O O
caused O O
acute B B_DISEASE
prerenal I I_DISEASE
failure I I_DISEASE
. O O

Longitudinal O O
association O O
of O O
alcohol O O
use O O
with O O
HIV B B_DISEASE
disease I I_DISEASE
progression O O
and O O
psychological O O
health O O
of O O
women O O
with O O
HIV O O
. O O

We O O
evaluated O O
the O O
association O O
of O O
alcohol O O
consumption O O
and O O
depression B B_DISEASE
, O O
and O O
their O O
effects O O
on O O
HIV B B_DISEASE
disease I I_DISEASE
progression O O
among O O
women O O
with O O
HIV O O
. O O

The O O
participants O O
had O O
physical O O
examination O O
, O O
medical O O
record O O
extraction O O
, O O
and O O
venipuncture O O
, O O
CD4 O O
+ O O
T O O
- O O
cell O O
counts O O
determination O O
, O O
measurement O O
of O O
depression B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
symptoms O O
( O O
using O O
the O O
self O O
- O O
report O O
Center O O
for O O
Epidemiological O O
Studies O O
- O O
Depression B B_TIME[MEASURE]/B_DISEASE
Scale O O
) O O
, O O
and O O
alcohol O O
use O O
assessment O O
at O O
enrollment O O
, O O
and O O
semiannually O O
until O O
March O O
2000 O O
. O O

Multilevel O O
random O O
coefficient O O
ordinal O O
models O O
as O O
well O O
as O O
multilevel O O
models O O
with O O
joint O O
responses O O
were O O
used O O
in O O
the O O
analysis O O
. O O

There O O
was O O
no O O
significant O O
association O O
between O O
level O O
of O O
alcohol O O
use O O
and O O
CD4 O O
+ O O
T O O
- O O
cell O O
counts O O
. O O

The O O
association O O
between O O
alcohol O O
consumption O O
and O O
depression B B_DISEASE/B_GENE
was O O
significant O O
( O O
p O O
< O O
0 O O
. O O
001 O O
) O O
. O O

Depression B B_TIME[MEASURE]/B_DISEASE
had O O
a O O
significant O O
negative O O
effect O O
on O O
CD4 O O
+ O O
T O O
- O O
cell O O
counts O O
over O O
time O O
regardless O O
of O O
ART O O
use O O
. O O

Our O O
findings O O
suggest O O
that O O
alcohol O O
consumption O O
has O O
a O O
direct O O
association O O
with O O
depression B B_DISEASE/B_LOCATION
. O O

Moreover O O
, O O
depression B B_DISEASE/B_GENE
is O O
associated O O
with O O
HIV B B_DISEASE
disease I I_DISEASE
progression O O
. O O

Chemokine O O
CCL2 O O
and O O
its O O
receptor O O
CCR2 O O
are O O
increased O O
in O O
the O O
hippocampus O O
following O O
pilocarpine O O
- O O
induced O O
status B B_DISEASE
epilepticus I I_DISEASE
. O O

BACKGROUND O O
: O O
Neuroinflammation B B_DISEASE/B_GENE
occurs O O
after O O
seizures B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
is O O
implicated O O
in O O
epileptogenesis O O
. O O

CCR2 O O
is O O
a O O
chemokine O O
receptor O O
for O O
CCL2 O O
and O O
their O O
interaction O O
mediates O O
monocyte O O
infiltration O O
in O O
the O O
neuroinflammatory B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
cascade O O
triggered O O
in O O
different O O
brain O O
pathologies O O
. O O

In O O
this O O
work O O
CCR2 O O
and O O
CCL2 O O
expression O O
were O O
examined O O
following O O
status B B_DISEASE
epilepticus I I_DISEASE
( O O
SE B B_DISEASE/B_LOCATION
) O O
induced O O
by O O
pilocarpine O O
injection O O
. O O

METHODS O O
: O O
SE B B_DISEASE/B_PROTEIN[GENE]
was O O
induced O O
by O O
pilocarpine O O
injection O O
. O O

Control O O
rats O O
were O O
injected O O
with O O
saline O O
instead O O
of O O
pilocarpine O O
. O O

Five O O
days O O
after O O
SE B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
CCR2 O O
staining O O
in O O
neurons O O
and O O
glial O O
cells O O
was O O
examined O O
using O O
imunohistochemical O O
analyses O O
. O O

The O O
number O O
of O O
CCR2 O O
positive O O
cells O O
was O O
determined O O
using O O
stereology O O
probes O O
in O O
the O O
hippocampus O O
. O O

CCL2 O O
expression O O
in O O
the O O
hippocampus O O
was O O
examined O O
by O O
molecular O O
assay O O
. O O

RESULTS O O
: O O
Increased O O
CCR2 O O
was O O
observed O O
in O O
the O O
hippocampus O O
after O O
SE B B_DISEASE
. O O

Seizures B B_DISEASE/B_LOCATION
also O O
resulted O O
in O O
alterations O O
to O O
the O O
cell O O
types O O
expressing O O
CCR2 O O
. O O

Increased O O
numbers O O
of O O
neurons O O
that O O
expressed O O
CCR2 O O
was O O
observed O O
following O O
SE B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Microglial O O
cells O O
were O O
more O O
closely O O
apposed O O
to O O
the O O
CCR2 O O
- O O
labeled O O
cells O O
in O O
SE B B_DISEASE/B_LOCATION
rats O O
. O O

In O O
addition O O
, O O
rats O O
that O O
experienced O O
SE B B_DISEASE
exhibited O O
CCR2 O O
- O O
labeling O O
in O O
populations O O
of O O
hypertrophied B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
astrocytes O O
, O O
especially O O
in O O
CA1 O O
and O O
dentate O O
gyrus O O
. O O

These O O
CCR2 O O
+ O O
astroctytes O O
were O O
not O O
observed O O
in O O
control O O
rats O O
. O O

Examination O O
of O O
CCL2 O O
expression O O
showed O O
that O O
it O O
was O O
elevated O O
in O O
the O O
hippocampus O O
following O O
SE B B_DISEASE
. O O

CONCLUSION O O
: O O
The O O
data O O
show O O
that O O
CCR2 O O
and O O
CCL2 O O
are O O
up O O
- O O
regulated O O
in O O
the O O
hippocampus O O
after O O
pilocarpine O O
- O O
induced O O
SE B B_DISEASE
. O O

Seizures B B_DISEASE/B_LOCATION
also O O
result O O
in O O
changes O O
to O O
CCR2 O O
receptor O O
expression O O
in O O
neurons O O
and O O
astrocytes O O
. O O

These O O
changes O O
might O O
be O O
involved O O
in O O
detrimental O O
neuroplasticity O O
and O O
neuroinflammatory B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
changes O O
that O O
occur O O
following O O
seizures B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Metallothionein O O
induction O O
reduces O O
caspase O O
- O O
3 O O
activity O O
and O O
TNFalpha O O
levels O O
with O O
preservation O O
of O O
cognitive O O
function O O
and O O
intact O O
hippocampal O O
neurons O O
in O O
carmustine O O
- O O
treated O O
rats O O
. O O

The O O
present O O
study O O
aimed O O
to O O
explore O O
the O O
effect O O
of O O
MT O O
induction O O
on O O
carmustine O O
( O O
BCNU O O
) O O
- O O
induced O O
hippocampal O O
cognitive B B_DISEASE
dysfunction I I_DISEASE
in O O
rats O O
. O O

A O O
total O O
of O O
60 O O
male O O
Wistar O O
albino O O
rats O O
were O O
randomly O O
divided O O
into O O
four O O
groups O O
( O O
15 O O
/ O O
group O O
) O O
: O O
The O O
control O O
group O O
injected O O
with O O
single O O
doses O O
of O O
normal O O
saline O O
( O O
i O O
. O O
c O O
. O O
v O O
) O O
followed O O
24 O O
h O O
later O O
by O O
BCNU O O
solvent O O
( O O
i O O
. O O
v O O
) O O
. O O

The O O
second O O
group O O
administered O O
ZnSO O O
( O O
4 O O
) O O
( O O
0 O O
. O O
1 O O
micromol O O
/ O O
10 O O
microl O O
normal O O
saline O O
, O O
i O O
. O O
c O O
. O O
v O O
, O O
once O O
) O O
then O O
BCNU O O
solvent O O
( O O
i O O
. O O
v O O
) O O
after O O
24 O O
h O O
. O O

Fourth O O
group O O
received O O
a O O
single O O
dose O O
of O O
ZnSO O O
( O O
4 O O
) O O
( O O
0 O O
. O O
1 O O
micromol O O
/ O O
10 O O
microl O O
normal O O
saline O O
, O O
i O O
. O O
c O O
. O O
v O O
) O O
then O O
BCNU O O
( O O
20 O O
mg O O
/ O O
kg O O
, O O
i O O
. O O
v O O
, O O
once O O
) O O
after O O
24 O O
h O O
. O O

The O O
obtained O O
data O O
revealed O O
that O O
BCNU O O
administration O O
resulted O O
in O O
deterioration B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
learning I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
short I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
term I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
memory I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
STM O O
) O O
, O O
as O O
measured O O
by O O
using O O
radial O O
arm O O
water O O
maze O O
, O O
accompanied O O
with O O
decreased O O
hippocampal O O
glutathione O O
reductase O O
( O O
GR O O
) O O
activity O O
and O O
reduced O O
glutathione O O
( O O
GSH O O
) O O
content O O
. O O

Also O O
, O O
BCNU O O
administration O O
increased O O
serum O O
tumor B B_DISEASE_ADJECTIVE[DISEASE]
necrosis B I_DISEASE_ADJECTIVE[DISEASE]
factor O O
- O O
alpha O O
( O O
TNFalpha O O
) O O
, O O
hippocampal O O
MT O O
and O O
malondialdehyde O O
( O O
MDA O O
) O O
contents O O
as O O
well O O
as O O
caspase O O
- O O
3 O O
activity O O
in O O
addition O O
to O O
histological O O
alterations O O
. O O

ZnSO O O
( O O
4 O O
) O O
pretreatment O O
counteracted O O
BCNU O O
- O O
induced O O
inhibition O O
of O O
GR O O
and O O
depletion O O
of O O
GSH O O
and O O
resulted O O
in O O
significant O O
reduction O O
in O O
the O O
levels O O
of O O
MDA O O
and O O
TNFalpha O O
as O O
well O O
as O O
the O O
activity O O
of O O
caspase O O
- O O
3 O O
. O O

The O O
histological O O
features O O
were O O
improved O O
in O O
hippocampus O O
of O O
rats O O
treated O O
with O O
ZnSO O O
( O O
4 O O
) O O
+ O O
BCNU O O
compared O O
to O O
only O O
BCNU O O
- O O
treated O O
animals O O
. O O

In O O
conclusion O O
, O O
MT O O
induction O O
halts O O
BCNU O O
- O O
induced O O
hippocampal O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
it O O
prevented O O
GR O O
inhibition O O
and O O
GSH O O
depletion O O
and O O
counteracted O O
the O O
increased O O
levels O O
of O O
TNFalpha O O
, O O
MDA O O
and O O
caspase O O
- O O
3 O O
activity O O
with O O
subsequent O O
preservation O O
of O O
cognition O O
. O O

Fatal O O
carbamazepine O O
induced O O
fulminant B B_DISEASE_ADJECTIVE[DISEASE]
eosinophilic I I_DISEASE_ADJECTIVE[DISEASE]
( O O
hypersensitivity B B_DISEASE/B_PROTEIN[GENE]
) O O
myocarditis B B_DISEASE
: O O
emphasis O O
on O O
anatomical O O
and O O
histological O O
characteristics O O
, O O
mechanisms O O
and O O
genetics O O
of O O
drug B B_DISEASE
hypersensitivity I I_DISEASE
and O O
differential O O
diagnosis O O
. O O

The O O
most O O
severe O O
adverse O O
reactions O O
to O O
carbamazepine O O
have O O
been O O
observed O O
in O O
the O O
haemopoietic O O
system O O
, O O
the O O
liver O O
and O O
the O O
cardiovascular O O
system O O
. O O

A O O
frequently O O
fatal O O
, O O
although O O
exceptionally O O
rare O O
side O O
effect O O
of O O
carbamazepine O O
is O O
necrotizing O O
eosinophilic O O
( O O
hypersensitivity B B_DISEASE/B_LOCATION
) O O
myocarditis B B_DISEASE
. O O

We O O
report O O
a O O
case O O
of O O
hypersensitivity B B_DISEASE
myocarditis B I_DISEASE
secondary O O
to O O
administration O O
of O O
carbamazepine O O
. O O

Acute O O
hypersensitivity B B_DISEASE
myocarditis B I_DISEASE
was O O
not O O
suspected O O
clinically O O
, O O
and O O
the O O
diagnosis O O
was O O
made O O
post O O
- O O
mortem O O
. O O

Clinically O O
, O O
death O O
was O O
due O O
to O O
cardiogenic B B_DISEASE
shock I I_DISEASE
. O O

To O O
best O O
of O O
our O O
knowledge O O
this O O
is O O
the O O
second O O
case O O
of O O
fatal O O
carbamazepine O O
induced O O
myocarditis B B_DISEASE
reported O O
in O O
English O O
literature O O
. O O

Neuropsychiatric O O
behaviors O O
in O O
the O O
MPTP O O
marmoset O O
model O O
of O O
Parkinson B B_DISEASE
' I I_DISEASE
s I I_DISEASE
disease I I_DISEASE
. O O

OBJECTIVES O O
: O O
Neuropsychiatric O O
symptoms O O
are O O
increasingly O O
recognised O O
as O O
a O O
significant O O
problem O O
in O O
patients O O
with O O
Parkinson B B_DISEASE
' I I_DISEASE
s I I_DISEASE
disease I I_DISEASE
( O O
PD B B_DISEASE/B_PROTEIN[GENE]
) O O
. O O

The O O
levodopa O O
- O O
treated O O
MPTP O O
- O O
lesioned O O
marmoset O O
was O O
used O O
as O O
a O O
model O O
of O O
neuropsychiatric B B_DISEASE
symptoms I I_DISEASE
in O O
PD B B_DISEASE/B_LOCATION
patients O O
. O O

Here O O
we O O
compare O O
the O O
time O O
course O O
of O O
levodopa O O
- O O
induced O O
motor O O
fluctuations O O
and O O
neuropsychiatric B B_DISEASE
- I I_DISEASE
like I I_DISEASE
behaviors I I_DISEASE
to O O
determine O O
the O O
relationship O O
between O O
duration O O
of O O
treatment O O
and O O
onset O O
of O O
symptoms O O
. O O

METHODS O O
: O O
Marmosets O O
were O O
administered O O
1 O O
- O O
methyl O O
- O O
4 O O
- O O
phenyl O O
- O O
1 O O
, O O
2 O O
, O O
3 O O
, O O
6 O O
- O O
tetrahydropyridine O O
( O O
2 O O
. O O
0 O O
mg O O
/ O O
kg O O
s O O
. O O
c O O
. O O
) O O
for O O
five O O
days O O
, O O
resulting O O
in O O
stable O O
parkinsonism B B_DISEASE
. O O

Levodopa O O
( O O
15 O O
mg O O
/ O O
kg O O
and O O
benserazide O O
, O O
3 O O
. O O
75 O O
mg O O
/ O O
kg O O
) O O
p O O
. O O
o O O
. O O

b O O
. O O
i O O
. O O
d O O
, O O
was O O
administered O O
for O O
30 O O
days O O
. O O

Animals O O
were O O
evaluated O O
for O O
parkinsonian B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
disability I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
dyskinesia B B_DISEASE/B_MEASURE
and O O
on O O
- O O
time O O
( O O
motor O O
fluctuations O O
) O O
and O O
neuropsychiatric B B_DISEASE
- I I_DISEASE
like I I_DISEASE
behaviors I I_DISEASE
on O O
Day O O
0 O O
( O O
prior O O
to O O
levodopa O O
) O O
and O O
on O O
Days O O
1 O O
, O O
7 O O
, O O
13 O O
, O O
27 O O
and O O
30 O O
of O O
treatment O O
using O O
post O O
hoc O O
DVD O O
analysis O O
by O O
a O O
trained O O
rater O O
, O O
blind O O
to O O
the O O
treatment O O
day O O
. O O

RESULTS O O
: O O
The O O
neuropsychiatric B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
like I B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
behavior I B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
rating O O
scale O O
demonstrated O O
high O O
interrater O O
reliability O O
between O O
three O O
trained O O
raters O O
of O O
differing O O
professional O O
backgrounds O O
. O O

As O O
anticipated O O
, O O
animals O O
exhibited O O
a O O
progressive O O
increase O O
in O O
levodopa O O
- O O
induced O O
motor O O
fluctuations O O
, O O
dyskinesia B B_DISEASE
and O O
wearing O O
- O O
off O O
, O O
that O O
correlated O O
with O O
the O O
duration O O
of O O
levodopa O O
therapy O O
. O O

In O O
contrast O O
, O O
levodopa O O
- O O
induced O O
neuropsychiatric B B_DISEASE
- I I_DISEASE
like I I_DISEASE
behaviors I I_DISEASE
were O O
present O O
on O O
Day O O
1 O O
of O O
levodopa O O
treatment O O
and O O
their O O
severity O O
did O O
not O O
correlate O O
with O O
duration O O
of O O
treatment O O
. O O

CONCLUSIONS O O
: O O
The O O
data O O
suggest O O
that O O
neuropsychiatric B B_DISEASE_ADJECTIVE[DISEASE]
disorders I I_DISEASE_ADJECTIVE[DISEASE]
in O O
PD B B_DISEASE/B_LOCATION
are O O
more O O
likely O O
an O O
interaction O O
between O O
levodopa O O
and O O
the O O
disease O O
state O O
than O O
a O O
consequence O O
of O O
sensitisation O O
to O O
repeated O O
dopaminergic O O
therapy O O
. O O

Contrast O O
medium O O
nephrotoxicity B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
after O O
renal O O
artery O O
and O O
coronary O O
angioplasty O O
. O O

BACKGROUND O O
: O O
Renal B B_DISEASE/B_GENE
dysfunction I I_DISEASE/I_GENE
induced O O
by O O
iodinated O O
contrast O O
medium O O
( O O
CM O O
) O O
administration O O
can O O
minimize O O
the O O
benefit O O
of O O
the O O
interventional O O
procedure O O
in O O
patients O O
undergoing O O
renal O O
angioplasty O O
( O O
PTRA O O
) O O
. O O

PURPOSE O O
: O O
To O O
compare O O
the O O
susceptibility O O
to O O
nephrotoxic B B_DISEASE_ADJECTIVE[DISEASE]
effect O O
of O O
CM O O
in O O
patients O O
undergoing O O
PTRA O O
with O O
that O O
of O O
patients O O
submitted O O
to O O
percutaneous O O
coronary O O
intervention O O
( O O
PCI O O
) O O
. O O

RESULTS O O
: O O
Postprocedural O O
creatinine O O
level O O
decreased O O
nonsignificantly O O
in O O
the O O
PTRA O O
group O O
( O O
1 O O
. O O
46 O O
+ O O
/ O O
- O O
0 O O
. O O
8 O O
vs O O
. O O
1 O O
. O O
34 O O
+ O O
/ O O
- O O
0 O O
. O O
5 O O
mg O O
/ O O
dl O O
, O O
P O O
= O O
NS O O
) O O
and O O
increased O O
significantly O O
in O O
the O O
PCI O O
group O O
( O O
1 O O
. O O
44 O O
+ O O
/ O O
- O O
0 O O
. O O
6 O O
vs O O
. O O
1 O O
. O O
57 O O
+ O O
/ O O
- O O
0 O O
. O O
7 O O
mg O O
/ O O
dl O O
, O O
P O O
< O O
0 O O
. O O
02 O O
) O O
. O O

This O O
difference O O
was O O
not O O
related O O
to O O
either O O
a O O
different O O
clinical O O
risk O O
profile O O
or O O
to O O
the O O
volume O O
of O O
CM O O
administered O O
. O O

CONCLUSION O O
: O O
In O O
this O O
preliminary O O
study O O
patients O O
submitted O O
to O O
PTRA O O
showed O O
a O O
lower O O
susceptibility O O
to O O
renal B B_DISEASE
damage I I_DISEASE
induced O O
by O O
CM O O
administration O O
than O O
PCI O O
patients O O
. O O

Diphenhydramine O O
prevents O O
the O O
haemodynamic O O
changes O O
of O O
cimetidine O O
in O O
ICU O O
patients O O
. O O

This O O
may O O
be O O
because O O
cimetidine O O
acts O O
as O O
a O O
histamine O O
agonist O O
. O O

Each O O
patient O O
was O O
studied O O
on O O
two O O
separate O O
days O O
. O O

In O O
a O O
random O O
fashion O O
, O O
they O O
received O O
cimetidine O O
200 O O
mg O O
iv O O
on O O
one O O
day O O
, O O
and O O
on O O
the O O
other O O
, O O
a O O
pretreatment O O
of O O
diphenhydramine O O
40 O O
mg O O
iv O O
with O O
cimetidine O O
200 O O
mg O O
iv O O
. O O

We O O
conclude O O
that O O
an O O
H1 O O
antagonist O O
may O O
be O O
useful O O
in O O
preventing O O
hypotension B B_DISEASE
caused O O
by O O
iv O O
cimetidine O O
, O O
since O O
the O O
vasodilating O O
activity O O
of O O
cimetidine O O
is O O
mediated O O
, O O
in O O
part O O
, O O
through O O
the O O
H1 O O
receptor O O
. O O

Medical O O
and O O
psychiatric O O
outcomes O O
for O O
patients O O
transplanted O O
for O O
acetaminophen O O
- O O
induced O O
acute B B_DISEASE
liver I I_DISEASE
failure I I_DISEASE
: O O
a O O
case O O
- O O
control O O
study O O
. O O

BACKGROUND O O
: O O
Acetaminophen O O
- O O
induced O O
hepatotoxicity B B_DISEASE
is O O
the O O
most O O
common O O
cause O O
of O O
acute B B_DISEASE
liver I I_DISEASE
failure I I_DISEASE
( O O
ALF B B_DISEASE/B_PROTEIN[GENE]
) O O
in O O
the O O
UK O O
. O O

AIMS O O
AND O O
METHODS O O
: O O
We O O
compared O O
the O O
severity O O
of O O
pretransplant O O
illness O O
, O O
psychiatric O O
co O O
- O O
morbidity O O
, O O
medical O O
and O O
psychosocial O O
outcomes O O
of O O
all O O
patients O O
who O O
had O O
undergone O O
liver O O
transplantation O O
( O O
LT O O
) O O
emergently O O
between O O
1999 O O
- O O
2004 O O
for O O
acetaminophen O O
- O O
induced O O
ALF B B_DISEASE
( O O
n O O
= O O
36 O O
) O O
with O O
age O O
- O O
and O O
sex O O
- O O
matched O O
patients O O
undergoing O O
emergent O O
LT O O
for O O
non O O
- O O
acetaminophen O O
- O O
induced O O
ALF B B_DISEASE
( O O
n O O
= O O
35 O O
) O O
and O O
elective O O
LT O O
for O O
chronic B B_DISEASE
liver I I_DISEASE
disease I I_DISEASE
( O O
CLD B B_DISEASE/B_MEASURE
, O O
n O O
= O O
34 O O
) O O
. O O

RESULTS O O
: O O
Acetaminophen O O
- O O
induced O O
ALF B B_DISEASE
patients O O
undergoing O O
LT O O
had O O
a O O
greater O O
severity O O
of O O
pre O O
- O O
LT O O
illness O O
reflected O O
by O O
higher O O
Acute O O
Physiology O O
and O O
Chronic O O
Health O O
Evaluation O O
II O O
scores O O
and O O
requirement O O
for O O
organ O O
support O O
compared O O
with O O
the O O
other O O
two O O
groups O O
. O O

During O O
follow O O
- O O
up O O
( O O
median O O
5 O O
years O O
) O O
, O O
there O O
were O O
no O O
significant O O
differences O O
in O O
rejection O O
( O O
acute O O
and O O
chronic O O
) O O
, O O
graft O O
failure O O
or O O
survival O O
between O O
the O O
groups O O
( O O
acetaminophen O O
- O O
induced O O
ALF B B_DISEASE/B_LOCATION
1 O O
year O O
87 O O
% O O
, O O
5 O O
years O O
75 O O
% O O
; O O
non O O
- O O
acetaminophen O O
- O O
induced O O
ALF B B_DISEASE
88 O O
% O O
, O O
78 O O
% O O
; O O
CLD B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
93 O O
% O O
, O O
82 O O
% O O
: O O
P O O
> O O
0 O O
. O O
6 O O
log O O
rank O O
) O O
. O O

Two O O
acetaminophen O O
- O O
induced O O
ALF B B_DISEASE
patients O O
reattempted O O
suicide O O
post O O
- O O
LT O O
( O O
one O O
died O O
8 O O
years O O
post O O
- O O
LT O O
) O O
. O O

CONCLUSIONS O O
: O O
Despite O O
a O O
high O O
prevalence O O
of O O
psychiatric O O
disturbance O O
, O O
outcomes O O
for O O
patients O O
transplanted O O
emergently O O
for O O
acetaminophen O O
- O O
induced O O
ALF B B_DISEASE
were O O
comparable O O
to O O
those O O
transplanted O O
for O O
non O O
- O O
acetaminophen O O
- O O
induced O O
ALF B B_DISEASE
and O O
electively O O
for O O
CLD B B_DISEASE
. O O

Antithrombotic O O
drug O O
use O O
, O O
cerebral B B_DISEASE
microbleeds I I_DISEASE
, O O
and O O
intracerebral B B_DISEASE
hemorrhage I I_DISEASE
: O O
a O O
systematic O O
review O O
of O O
published O O
and O O
unpublished O O
studies O O
. O O

We O O
also O O
analyzed O O
published O O
and O O
unpublished O O
follow O O
- O O
up O O
data O O
to O O
determine O O
the O O
risk O O
of O O
ICH B B_DISEASE
in O O
antithrombotic O O
users O O
with O O
MB B B_DISEASE/B_GENE
. O O

In O O
pooled O O
follow O O
- O O
up O O
data O O
for O O
768 O O
antithrombotic O O
users O O
, O O
presence O O
of O O
MB B B_DISEASE/B_GENE
at O O
baseline O O
was O O
associated O O
with O O
a O O
substantially O O
increased O O
risk O O
of O O
subsequent O O
ICH B B_DISEASE
( O O
OR O O
, O O
12 O O
. O O
1 O O
; O O
95 O O
% O O
CI O O
, O O
3 O O
. O O
4 O O
- O O
42 O O
. O O
5 O O
; O O
P O O
< O O
0 O O
. O O
001 O O
) O O
. O O

Limited O O
prospective O O
data O O
corroborate O O
these O O
findings O O
, O O
but O O
larger O O
prospective O O
studies O O
are O O
urgently O O
required O O
. O O

Studies O O
of O O
synergy O O
between O O
morphine O O
and O O
a O O
novel O O
sodium O O
channel O O
blocker O O
, O O
CNSB002 O O
, O O
in O O
rat O O
models O O
of O O
inflammatory O O
and O O
neuropathic B B_DISEASE
pain I I_DISEASE
. O O

OBJECTIVE O O
: O O
This O O
study O O
determined O O
the O O
antihyperalgesic O O
effect O O
of O O
CNSB002 O O
, O O
a O O
sodium O O
channel O O
blocker O O
with O O
antioxidant O O
properties O O
given O O
alone O O
and O O
in O O
combinations O O
with O O
morphine O O
in O O
rat O O
models O O
of O O
inflammatory O O
and O O
neuropathic B B_DISEASE
pain I I_DISEASE
. O O

DESIGN O O
: O O
Dose O O
response O O
curves O O
for O O
nonsedating O O
doses O O
of O O
morphine O O
and O O
CNSB002 O O
given O O
intraperitoneally O O
alone O O
and O O
together O O
in O O
combinations O O
were O O
constructed O O
for O O
antihyperalgesic O O
effect O O
using O O
paw O O
withdrawal O O
from O O
noxious O O
heat O O
in O O
two O O
rat O O
pain B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
models O O
: O O
carrageenan O O
- O O
induced O O
paw O O
inflammation B B_DISEASE/B_BACTERIUM[BIO]
and O O
streptozotocin O O
( O O
STZ O O
) O O
- O O
induced O O
diabetic B B_DISEASE
neuropathy I I_DISEASE
. O O

RESULTS O O
: O O
The O O
maximum O O
nonsedating O O
doses O O
were O O
: O O
morphine O O
, O O
3 O O
. O O
2 O O
mg O O
/ O O
kg O O
; O O
CNSB002 O O
10 O O
. O O
0 O O
mg O O
/ O O
kg O O
; O O
5 O O
. O O
0 O O
mg O O
/ O O
kg O O
CNSB002 O O
with O O
morphine O O
3 O O
. O O
2 O O
mg O O
/ O O
kg O O
in O O
combination O O
. O O

The O O
doses O O
calculated O O
to O O
cause O O
50 O O
% O O
reversal O O
of O O
hyperalgesia B B_DISEASE
( O O
ED50 O O
) O O
were O O
7 O O
. O O
54 O O
( O O
1 O O
. O O
81 O O
) O O
and O O
4 O O
. O O
83 O O
( O O
1 O O
. O O
54 O O
) O O
in O O
the O O
carrageenan O O
model O O
and O O
44 O O
. O O
18 O O
( O O
1 O O
. O O
37 O O
) O O
and O O
9 O O
. O O
14 O O
( O O
1 O O
. O O
24 O O
) O O
in O O
the O O
STZ O O
- O O
induced O O
neuropathy B B_DISEASE
model O O
for O O
CNSB002 O O
and O O
morphine O O
, O O
respectively O O
( O O
mg O O
/ O O
kg O O
; O O
mean O O
, O O
SEM O O
) O O
. O O

These O O
values O O
were O O
greater O O
than O O
the O O
maximum O O
nonsedating O O
doses O O
. O O

The O O
ED50 O O
values O O
for O O
morphine O O
when O O
given O O
in O O
combination O O
with O O
CNSB002 O O
( O O
5 O O
mg O O
/ O O
kg O O
) O O
were O O
less O O
than O O
the O O
maximum O O
nonsedating O O
dose O O
: O O
0 O O
. O O
56 O O
( O O
1 O O
. O O
55 O O
) O O
in O O
the O O
carrageenan O O
model O O
and O O
1 O O
. O O
37 O O
( O O
1 O O
. O O
23 O O
) O O
in O O
the O O
neuropathy B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model O O
( O O
mg O O
/ O O
kg O O
; O O
mean O O
, O O
SEM O O
) O O
. O O

The O O
antinociception O O
after O O
morphine O O
( O O
3 O O
. O O
2 O O
mg O O
/ O O
kg O O
) O O
was O O
increased O O
by O O
co O O
- O O
administration O O
with O O
CNSB002 O O
from O O
28 O O
. O O
0 O O
and O O
31 O O
. O O
7 O O
% O O
to O O
114 O O
. O O
6 O O
and O O
56 O O
. O O
9 O O
% O O
reversal O O
of O O
hyperalgesia B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
inflammatory O O
and O O
neuropathic B B_DISEASE
models O O
, O O
respectively O O
( O O
P O O
< O O
0 O O
. O O
01 O O
; O O
one O O
- O O
way O O
analysis O O
of O O
variance O O
- O O
significantly O O
greater O O
than O O
either O O
drug O O
given O O
alone O O
) O O
. O O

CONCLUSIONS O O
: O O
The O O
maximum O O
antihyperalgesic O O
effect O O
achievable O O
with O O
nonsedating O O
doses O O
of O O
morphine O O
may O O
be O O
increased O O
significantly O O
when O O
the O O
drug O O
is O O
used O O
in O O
combination O O
with O O
CNSB002 O O
. O O

Heparin O O
- O O
induced O O
thrombocytopenia B B_DISEASE
: O O
a O O
practical O O
review O O
. O O

Heparin O O
- O O
induced O O
thrombocytopenia B B_DISEASE
( O O
HIT B B_DISEASE/B_GENE
) O O
remains O O
under O O
- O O
recognized O O
despite O O
its O O
potentially O O
devastating O O
outcomes O O
. O O

It O O
begins O O
when O O
heparin O O
exposure O O
stimulates O O
the O O
formation O O
of O O
heparin O O
- O O
platelet O O
factor O O
4 O O
antibodies O O
, O O
which O O
in O O
turn O O
triggers O O
the O O
release O O
of O O
procoagulant O O
platelet O O
particles O O
. O O

Thrombosis B B_DISEASE
and O O
thrombocytopenia B B_DISEASE
that O O
follow O O
comprise O O
the O O
2 O O
hallmark O O
traits O O
of O O
HIT B B_DISEASE
, O O
with O O
the O O
former O O
largely O O
responsible O O
for O O
significant O O
vascular O O
complications O O
. O O

The O O
prevalence O O
of O O
HIT B B_DISEASE
varies O O
among O O
several O O
subgroups O O
, O O
with O O
greater O O
incidence O O
in O O
surgical O O
as O O
compared O O
with O O
medical O O
populations O O
. O O

HIT B B_DISEASE/B_GENE
must O O
be O O
acknowledged O O
for O O
its O O
intense O O
predilection O O
for O O
thrombosis B B_DISEASE/B_PERSON
and O O
suspected O O
whenever O O
thrombosis B B_DISEASE/B_PERSON
occurs O O
after O O
heparin O O
exposure O O
. O O

The O O
treatment O O
of O O
HIT B B_DISEASE
mandates O O
an O O
immediate O O
cessation O O
of O O
all O O
heparin O O
exposure O O
and O O
the O O
institution O O
of O O
an O O
antithrombotic O O
therapy O O
, O O
most O O
commonly O O
using O O
a O O
direct O O
thrombin O O
inhibitor O O
. O O

Current O O
" O O
diagnostic O O
" O O
tests O O
, O O
which O O
primarily O O
include O O
functional O O
and O O
antigenic O O
assays O O
, O O
have O O
more O O
of O O
a O O
confirmatory O O
than O O
diagnostic O O
role O O
in O O
the O O
management O O
of O O
HIT B B_DISEASE/B_LOCATION
. O O

Special O O
attention O O
must O O
be O O
paid O O
to O O
cardiac O O
patients O O
who O O
are O O
often O O
exposed O O
to O O
heparin O O
multiple O O
times O O
during O O
their O O
course O O
of O O
treatment O O
. O O

Direct O O
thrombin O O
inhibitors O O
are O O
appropriate O O
, O O
evidence O O
- O O
based O O
alternatives O O
to O O
heparin O O
in O O
patients O O
with O O
a O O
history O O
of O O
HIT B B_DISEASE/B_LOCATION
, O O
who O O
need O O
to O O
undergo O O
percutaneous O O
coronary O O
intervention O O
. O O

As O O
heparin O O
remains O O
one O O
of O O
the O O
most O O
frequently O O
used O O
medications O O
today O O
with O O
potential O O
for O O
HIT B B_DISEASE/B_PROTEIN[GENE]
with O O
every O O
heparin O O
exposure O O
, O O
a O O
close O O
vigilance O O
of O O
platelet O O
counts O O
must O O
be O O
practiced O O
whenever O O
heparin O O
is O O
initiated O O
. O O

Abductor O O
paralysis B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
botox O O
injection O O
for O O
adductor B B_DISEASE/B_ORGANISM_FUNCTION
spasmodic I I_DISEASE/I_ORGANISM_FUNCTION
dysphonia I I_DISEASE/I_ORGANISM_FUNCTION
. O O

OBJECTIVES O O
/ O O
HYPOTHESIS O O
: O O
Botulinum O O
toxin O O
( O O
Botox O O
) O O
injections O O
into O O
the O O
thyroarytenoid O O
muscles O O
are O O
the O O
current O O
standard O O
of O O
care O O
for O O
adductor B B_DISEASE
spasmodic I I_DISEASE
dysphonia I I_DISEASE
( O O
ADSD B B_DISEASE
) O O
. O O

Reported O O
adverse O O
effects O O
include O O
a O O
period O O
of O O
breathiness O O
, O O
throat B B_DISEASE
pain I I_DISEASE
, O O
and O O
difficulty O O
with O O
swallowing O O
liquids O O
. O O

Here O O
we O O
report O O
multiple O O
cases O O
of O O
bilateral O O
abductor O O
paralysis B B_DISEASE
following O O
Botox O O
injections O O
for O O
ADSD B B_DISEASE
, O O
a O O
complication O O
previously O O
unreported O O
. O O

STUDY O O
DESIGN O O
: O O
Retrospective O O
case O O
series O O
. O O

METHODS O O
: O O
Patients O O
that O O
received O O
Botox O O
injections O O
for O O
spasmodic B B_DISEASE/B_PROTEIN[GENE]
dysphonia I B_DISEASE/I_PROTEIN[GENE]
between O O
January O O
2000 O O
and O O
October O O
2009 O O
were O O
evaluated O O
. O O

Patients O O
with O O
ADSD B B_DISEASE/B_LOCATION
were O O
identified O O
. O O

For O O
patients O O
with O O
bilateral O O
abductor O O
paralysis B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
age O O
, O O
sex O O
, O O
paralytic O O
Botox O O
dose O O
, O O
prior O O
Botox O O
dose O O
, O O
and O O
course O O
following O O
paralysis B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
were O O
noted O O
. O O

RESULTS O O
: O O
From O O
a O O
database O O
of O O
452 O O
patients O O
receiving O O
Botox O O
, O O
352 O O
patients O O
had O O
been O O
diagnosed O O
with O O
ADSD B B_DISEASE
. O O

Of O O
these O O
352 O O
patients O O
, O O
eight O O
patients O O
suffered O O
bilateral O O
abductor O O
paralysis B B_DISEASE
, O O
and O O
two O O
suffered O O
this O O
complication O O
twice O O
. O O

All O O
affected O O
patients O O
were O O
females O O
over O O
the O O
age O O
of O O
50 O O
years O O
. O O

Most O O
patients O O
had O O
received O O
treatments O O
prior O O
to O O
abductor O O
paralysis B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
continued O O
receiving O O
after O O
paralysis B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Seven O O
patients O O
recovered O O
after O O
a O O
brief O O
period O O
of O O
activity O O
restrictions O O
, O O
and O O
one O O
underwent O O
a O O
tracheotomy O O
. O O

The O O
incidence O O
of O O
abductor O O
paralysis B B_DISEASE
after O O
Botox O O
injection O O
for O O
ADSD B B_DISEASE
was O O
0 O O
. O O
34 O O
% O O
. O O

CONCLUSIONS O O
: O O
Bilateral O O
abductor O O
paralysis B B_DISEASE
is O O
a O O
rare O O
complication O O
of O O
Botox O O
injections O O
for O O
ADSD B B_DISEASE
, O O
causing O O
difficulty O O
with O O
breathing O O
upon O O
exertion O O
. O O

The O O
likely O O
mechanism O O
of O O
paralysis B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
diffusion O O
of O O
Botox O O
around O O
the O O
muscular O O
process O O
of O O
the O O
arytenoid O O
to O O
the O O
posterior O O
cricoarytenoid O O
muscles O O
. O O

The O O
paralysis B B_DISEASE
is O O
temporary O O
, O O
and O O
watchful O O
waiting O O
with O O
restriction O O
of O O
activity O O
is O O
the O O
recommended O O
management O O
. O O

Mitochondrial B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
impairment I I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contributes O O
to O O
cocaine O O
- O O
induced O O
cardiac B B_DISEASE
dysfunction I I_DISEASE
: O O
Prevention O O
by O O
the O O
targeted O O
antioxidant O O
MitoQ O O
. O O

The O O
goal O O
of O O
this O O
study O O
was O O
to O O
assess O O
mitochondrial O O
function O O
and O O
ROS O O
production O O
in O O
an O O
experimental O O
model O O
of O O
cocaine O O
- O O
induced O O
cardiac B B_DISEASE
dysfunction I I_DISEASE
. O O

We O O
hypothesized O O
that O O
cocaine B B_DISEASE
abuse I I_DISEASE
may O O
lead O O
to O O
altered O O
mitochondrial O O
function O O
that O O
in O O
turn O O
may O O
cause O O
left B B_DISEASE
ventricular I I_DISEASE
dysfunction I I_DISEASE
. O O

Seven O O
days O O
of O O
cocaine O O
administration O O
to O O
rats O O
led O O
to O O
an O O
increased O O
oxygen O O
consumption O O
detected O O
in O O
cardiac O O
fibers O O
, O O
specifically O O
through O O
complex O O
I O O
and O O
complex O O
III O O
. O O

ROS O O
levels O O
were O O
increased O O
, O O
specifically O O
in O O
interfibrillar O O
mitochondria O O
. O O

In O O
parallel O O
there O O
was O O
a O O
decrease O O
in O O
ATP O O
synthesis O O
, O O
whereas O O
no O O
difference O O
was O O
observed O O
in O O
subsarcolemmal O O
mitochondria O O
. O O

This O O
uncoupling O O
effect O O
on O O
oxidative O O
phosphorylation O O
was O O
not O O
detectable O O
after O O
short O O
- O O
term O O
exposure O O
to O O
cocaine O O
, O O
suggesting O O
that O O
these O O
mitochondrial B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abnormalities I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
a O O
late O O
rather O O
than O O
a O O
primary O O
event O O
in O O
the O O
pathological O O
response O O
to O O
cocaine O O
. O O

MitoQ O O
, O O
a O O
mitochondrial O O
- O O
targeted O O
antioxidant O O
, O O
was O O
shown O O
to O O
completely O O
prevent O O
these O O
mitochondrial B B_DISEASE_ADJECTIVE[DISEASE]
abnormalities I I_DISEASE_ADJECTIVE[DISEASE]
as O O
well O O
as O O
cardiac B B_DISEASE/B_LOCATION
dysfunction I I_DISEASE/I_LOCATION
characterized O O
here O O
by O O
a O O
diastolic B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dysfunction I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studied O O
with O O
a O O
conductance O O
catheter O O
to O O
obtain O O
pressure O O
- O O
volume O O
data O O
. O O

Taken O O
together O O
, O O
these O O
results O O
extend O O
previous O O
studies O O
and O O
demonstrate O O
that O O
cocaine O O
- O O
induced O O
cardiac B B_DISEASE
dysfunction I I_DISEASE
may O O
be O O
due O O
to O O
a O O
mitochondrial B B_DISEASE
defect I I_DISEASE
. O O

Trimethoprim O O
- O O
induced O O
immune O O
hemolytic B B_DISEASE_ADJECTIVE[DISEASE]
anemia I I_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
pediatric O O
oncology O O
patient O O
presenting O O
as O O
an O O
acute O O
hemolytic O O
transfusion O O
reaction O O
. O O

A O O
10 O O
- O O
year O O
- O O
old O O
male O O
with O O
acute B B_DISEASE
leukemia I I_DISEASE
presented O O
with O O
post O O
- O O
chemotherapy O O
anemia B B_DISEASE
. O O

During O O
red O O
cell O O
transfusion O O
, O O
he O O
developed O O
hemoglobinuria B B_DISEASE
. O O

Transfusion O O
reaction O O
workup O O
was O O
negative O O
. O O

Drug O O
- O O
induced O O
immune O O
hemolytic B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
anemia I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
suspected O O
because O O
of O O
positive O O
direct O O
antiglobulin O O
test O O
, O O
negative O O
eluate O O
, O O
and O O
microspherocytes O O
on O O
smear O O
pre O O
- O O
and O O
post O O
- O O
transfusion O O
. O O

Drug O O
studies O O
using O O
the O O
indirect O O
antiglobulin O O
test O O
were O O
strongly O O
positive O O
with O O
trimethoprim O O
and O O
trimethoprim O O
- O O
sulfamethoxazole O O
but O O
negative O O
with O O
sulfamethoxazole O O
. O O

Other O O
causes O O
of O O
anemia B B_DISEASE
should O O
be O O
considered O O
in O O
patients O O
with O O
worse O O
- O O
than O O
- O O
expected O O
anemia B B_DISEASE
after O O
chemotherapy O O
. O O

Furthermore O O
, O O
hemolysis B B_DISEASE
during O O
transfusion O O
is O O
not O O
always O O
a O O
transfusion O O
reaction O O
. O O

Verapamil O O
stimulation O O
test O O
in O O
hyperprolactinemia B B_PERSON/B_DISEASE
: O O
loss O O
of O O
prolactin O O
response O O
in O O
anatomic O O
or O O
functional O O
stalk O O
effect O O
. O O

AIM O O
: O O
Verapamil O O
stimulation O O
test O O
was O O
previously O O
investigated O O
as O O
a O O
tool O O
for O O
differential O O
diagnosis O O
of O O
hyperprolactinemia B B_DISEASE/B_LOCATION
, O O
but O O
with O O
conflicting O O
results O O
. O O

Macroprolactinemia B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
was O O
never O O
considered O O
in O O
those O O
previous O O
studies O O
. O O

Here O O
, O O
we O O
aimed O O
to O O
re O O
- O O
investigate O O
the O O
diagnostic O O
value O O
of O O
verapamil O O
in O O
a O O
population O O
who O O
were O O
all O O
screened O O
for O O
macroprolactinemia B B_DISEASE
. O O

Prolactin O O
responses O O
to O O
verapamil O O
in O O
65 O O
female O O
patients O O
( O O
age O O
: O O
29 O O
. O O
9 O O
+ O O
/ O O
- O O
8 O O
. O O
1 O O
years O O
) O O
with O O
hyperprolactinemia B B_DISEASE/B_LOCATION
were O O
tested O O
in O O
a O O
descriptive O O
, O O
matched O O
case O O
- O O
control O O
study O O
. O O

METHODS O O
: O O
Verapamil O O
80 O O
mg O O
, O O
p O O
. O O
o O O
. O O
was O O
administered O O
, O O
and O O
then O O
PRL O O
levels O O
were O O
measured O O
at O O
8th O O
and O O
16th O O
hours O O
, O O
by O O
immunometric O O
chemiluminescence O O
. O O

Verapamil O O
responsiveness O O
was O O
determined O O
by O O
peak O O
percent O O
change O O
in O O
basal O O
prolactin O O
levels O O
( O O
PRL O O
) O O
. O O

RESULTS O O
: O O
Verapamil O O
significantly O O
increased O O
PRL O O
levels O O
in O O
healthy O O
controls O O
( O O
N O O
. O O
8 O O
, O O
PRL O O
: O O
183 O O
% O O
) O O
, O O
macroprolactinoma B B_DISEASE
( O O
N O O
. O O
8 O O
, O O
PRL O O
: O O
7 O O
% O O
) O O
, O O
microprolactinoma B B_DISEASE
( O O
N O O
. O O
19 O O
, O O
PRL O O
: O O
21 O O
% O O
) O O
, O O
macroprolactinemia B B_DISEASE
( O O
N O O
. O O
23 O O
, O O
PRL O O
: O O
126 O O
% O O
) O O
, O O
but O O
not O O
in O O
pseudoprolactinoma B B_DISEASE/B_BIO
( O O
N O O
. O O
8 O O
, O O
PRL O O
: O O
0 O O
. O O
8 O O
% O O
) O O
, O O
and O O
risperidone O O
- O O
induced O O
hyperprolactinemia B B_DISEASE
( O O
N O O
. O O
7 O O
, O O
PRL O O
: O O
3 O O
% O O
) O O
. O O

ROC O O
curve O O
analysis O O
revealed O O
that O O
unresponsiveness O O
to O O
verapamil O O
defined O O
as O O
PRL O O
< O O
7 O O
% O O
, O O
discriminated O O
anatomical O O
or O O
functional O O
stalk O O
effect O O
( O O
sensitivity O O
: O O
74 O O
% O O
, O O
specificity O O
: O O
73 O O
% O O
, O O
AUC O O
: O O
0 O O
. O O
855 O O
+ O O
/ O O
- O O
0 O O
. O O
04 O O
, O O
P O O
< O O
0 O O
. O O
001 O O
, O O
CI O O
: O O
0 O O
. O O
768 O O
- O O
0 O O
. O O
942 O O
) O O
associated O O
with O O
pseudoprolactinoma B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
risperidone O O
- O O
induced O O
hyperprolactinemia B B_DISEASE
, O O
respectively O O
. O O

CONCLUSION O O
: O O
Verapamil O O
responsiveness O O
is O O
not O O
a O O
reliable O O
finding O O
for O O
the O O
differential O O
diagnosis O O
of O O
hyperprolactinemia B B_DISEASE
. O O

However O O
, O O
verapamil O O
unresponsiveness O O
discriminates O O
stalk O O
effect O O
( O O
i O O
. O O
e O O
. O O
, O O
anatomically O O
or O O
functionally O O
inhibited O O
dopaminergic O O
tonus O O
) O O
from O O
other O O
causes O O
of O O
hyperprolactinemia B B_DISEASE
with O O
varying O O
degrees O O
of O O
responsiveness O O
. O O

Blockade O O
of O O
endothelial O O
- O O
mesenchymal O O
transition O O
by O O
a O O
Smad3 O O
inhibitor O O
delays O O
the O O
early O O
development O O
of O O
streptozotocin O O
- O O
induced O O
diabetic B B_DISEASE
nephropathy I I_DISEASE
. O O

OBJECTIVE O O
: O O
A O O
multicenter O O
, O O
controlled O O
trial O O
showed O O
that O O
early O O
blockade O O
of O O
the O O
renin O O
- O O
angiotensin O O
system O O
in O O
patients O O
with O O
type B B_DISEASE
1 I I_DISEASE
diabetes I I_DISEASE
and O O
normoalbuminuria O O
did O O
not O O
retard O O
the O O
progression O O
of O O
nephropathy B B_DISEASE
, O O
suggesting O O
that O O
other O O
mechanism O O
( O O
s O O
) O O
are O O
involved O O
in O O
the O O
pathogenesis O O
of O O
early O O
diabetic B B_DISEASE
nephropathy I I_DISEASE
( O O
diabetic B B_DISEASE/B_PROTEIN[GENE]
nephropathy I B_DISEASE/I_PROTEIN[GENE]
) O O
. O O

We O O
have O O
previously O O
demonstrated O O
that O O
endothelial O O
- O O
mesenchymal O O
- O O
transition O O
( O O
EndoMT O O
) O O
contributes O O
to O O
the O O
early O O
development O O
of O O
renal O O
interstitial O O
fibrosis B B_DISEASE
independently O O
of O O
microalbuminuria O O
in O O
mice O O
with O O
streptozotocin O O
( O O
STZ O O
) O O
- O O
induced O O
diabetes B B_DISEASE
. O O

In O O
the O O
present O O
study O O
, O O
we O O
hypothesized O O
that O O
blocking O O
EndoMT O O
reduces O O
the O O
early O O
development O O
of O O
diabetic B B_DISEASE/B_GENE
nephropathy I I_DISEASE/I_GENE
. O O

Phosphorylated O O
Smad3 O O
was O O
detected O O
by O O
immunoprecipitation O O
/ O O
Western O O
blotting O O
and O O
confocal O O
microscopy O O
. O O

Blocking O O
studies O O
using O O
receptor O O
for O O
AGE O O
siRNA O O
and O O
a O O
specific O O
inhibitor O O
of O O
Smad3 O O
( O O
SIS3 O O
) O O
were O O
performed O O
in O O
MMECs O O
and O O
in O O
STZ O O
- O O
induced O O
diabetic B B_DISEASE
nephropathy I I_DISEASE
in O O
Tie2 O O
- O O
Cre O O
; O O
Loxp O O
- O O
EGFP O O
mice O O
. O O

RESULTS O O
: O O
Confocal O O
microscopy O O
and O O
real O O
- O O
time O O
PCR O O
demonstrated O O
that O O
AGEs O O
induced O O
EndoMT O O
in O O
MMECs O O
and O O
in O O
Tie2 O O
- O O
Cre O O
; O O
Loxp O O
- O O
EGFP O O
mice O O
. O O

Immunoprecipitation O O
/ O O
Western O O
blotting O O
showed O O
that O O
Smad3 O O
was O O
activated O O
by O O
AGEs O O
but O O
was O O
inhibited O O
by O O
SIS3 O O
in O O
MMECs O O
and O O
in O O
STZ O O
- O O
induced O O
diabetic B B_DISEASE
nephropathy I I_DISEASE
. O O

Confocal O O
microscopy O O
and O O
real O O
- O O
time O O
PCR O O
further O O
demonstrated O O
that O O
SIS3 O O
abrogated O O
EndoMT O O
, O O
reduced O O
renal O O
fibrosis B B_DISEASE/B_GENE
, O O
and O O
retarded O O
progression O O
of O O
nephropathy B B_DISEASE
. O O

CONCLUSIONS O O
: O O
EndoMT O O
is O O
a O O
novel O O
pathway O O
leading O O
to O O
early O O
development O O
of O O
diabetic B B_DISEASE
nephropathy I I_DISEASE
. O O

Blockade O O
of O O
EndoMT O O
by O O
SIS3 O O
may O O
provide O O
a O O
new O O
strategy O O
to O O
retard O O
the O O
progression O O
of O O
diabetic B B_DISEASE
nephropathy I I_DISEASE
and O O
other O O
diabetes B B_DISEASE
complications I I_DISEASE
. O O

Cytostatic O O
and O O
anti O O
- O O
angiogenic O O
effects O O
of O O
temsirolimus O O
in O O
refractory O O
mantle B B_DISEASE/B_LOCATION
cell I I_DISEASE/I_LOCATION
lymphoma I I_DISEASE/I_LOCATION
. O O

Mantle B B_DISEASE
cell I I_DISEASE
lymphoma I I_DISEASE
( O O
MCL B B_DISEASE
) O O
is O O
a O O
rare O O
and O O
aggressive O O
type O O
of O O
B B B_DISEASE
- I I_DISEASE
cell I I_DISEASE
non I I_DISEASE
- I I_DISEASE
Hodgkin I I_DISEASE
' I I_DISEASE
s I I_DISEASE
lymphoma I I_DISEASE
. O O

However O O
, O O
a O O
38 O O
% O O
remission O O
rate O O
has O O
been O O
recently O O
reported O O
in O O
refractory O O
MCL B B_DISEASE/B_PERSON
treated O O
with O O
temsirolimus O O
, O O
a O O
mTOR O O
inhibitor O O
. O O
Here O O
we O O
had O O
the O O
opportunity O O
to O O
study O O
a O O
case O O
of O O
refractory O O
MCL B B_DISEASE
who O O
had O O
tumor B B_DISEASE
regression O O
two O O
months O O
after O O
temsirolimus O O
treatment O O
, O O
and O O
a O O
progression O O
- O O
free O O
survival O O
of O O
10 O O
months O O
. O O

In O O
this O O
case O O
, O O
lymph O O
node O O
biopsies O O
were O O
performed O O
before O O
and O O
six O O
months O O
after O O
temsirolimus O O
therapy O O
. O O

Comparison O O
of O O
the O O
two O O
biopsies O O
showed O O
that O O
temsirolimus O O
inhibited O O
tumor B B_DISEASE
cell O O
proliferation O O
through O O
cell O O
cycle O O
arrest O O
, O O
but O O
did O O
not O O
induce O O
any O O
change O O
in O O
the O O
number O O
of O O
apoptotic O O
tumor B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cells O O
. O O

Apart O O
from O O
this O O
cytostatic O O
effect O O
, O O
temsirolimus O O
had O O
an O O
antiangiogenic O O
effect O O
with O O
decrease O O
of O O
tumor B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
microvessel O O
density O O
and O O
of O O
VEGF O O
expression O O
. O O

Moreover O O
, O O
numerous O O
patchy O O
, O O
well O O
- O O
limited O O
fibrotic O O
areas O O
, O O
compatible O O
with O O
post O O
- O O
necrotic B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tissue O O
repair O O
, O O
were O O
found O O
after O O
6 O O
- O O
month O O
temsirolimus O O
therapy O O
. O O

Thus O O
, O O
temsirolimus O O
reduced O O
tumor B B_DISEASE
burden O O
through O O
associated O O
cytostatic O O
and O O
anti O O
- O O
angiogenic O O
effects O O
. O O
This O O
dual O O
effect O O
of O O
temsirolimus O O
on O O
tumor B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
tissue O O
could O O
contribute O O
to O O
its O O
recently O O
reported O O
efficiency O O
in O O
refractory O O
MCL B B_DISEASE/B_MEASURE
resistant O O
to O O
conventional O O
chemotherapy O O
. O O

Acute B B_DISEASE
renal I I_DISEASE
failure I I_DISEASE
due O O
to O O
rifampicin O O
. O O

A O O
23 O O
- O O
year O O
- O O
old O O
male O O
patient O O
with O O
bacteriologically O O
proven O O
pulmonary B B_DISEASE
tuberculosis I I_DISEASE
was O O
treated O O
with O O
the O O
various O O
regimens O O
of O O
antituberculosis O O
drugs O O
for O O
nearly O O
15 O O
months O O
. O O

Rifampicin O O
was O O
administered O O
thrice O O
as O O
one O O
of O O
the O O
3 O O
- O O
4 O O
drug O O
regimen O O
and O O
each O O
time O O
he O O
developed O O
untoward O O
side O O
effects O O
like O O
nausea B B_DISEASE
, O O
vomiting B B_DISEASE
and O O
fever B B_DISEASE
with O O
chills O O
and O O
rigors O O
. O O

The O O
patient O O
, O O
however O O
, O O
made O O
a O O
full O O
recovery O O
. O O

Syncope B B_DISEASE
caused O O
by O O
hyperkalemia B B_DISEASE
during O O
use O O
of O O
a O O
combined O O
therapy O O
with O O
the O O
angiotensin O O
- O O
converting O O
enzyme O O
inhibitor O O
and O O
spironolactone O O
. O O

A O O
76 O O
year O O
- O O
old O O
woman O O
with O O
a O O
history O O
of O O
coronary O O
artery O O
bypass O O
grafting O O
and O O
prior O O
myocardial B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction I B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
transferred O O
to O O
the O O
emergency O O
room O O
with O O
loss B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of I B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
consciousness I B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
due O O
to O O
marked O O
bradycardia B B_DISEASE
caused O O
by O O
hyperkalemia B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
cause O O
of O O
hyperkalemia B B_DISEASE
was O O
considered O O
to O O
be O O
several O O
doses O O
of O O
spiranolactone O O
, O O
an O O
aldosterone O O
antagonist O O
, O O
in O O
addition O O
to O O
the O O
long O O
- O O
term O O
intake O O
of O O
ramipril O O
, O O
an O O
ACE O O
inhibitor O O
. O O

Clinicians O O
should O O
be O O
alert O O
to O O
the O O
possibility O O
of O O
hyperkalemia B B_DISEASE
, O O
especially O O
in O O
elderly O O
patients O O
using O O
ACE O O
/ O O
ARB O O
in O O
combination O O
with O O
potassium O O
sparing O O
agents O O
and O O
who O O
have O O
mild O O
renal B B_DISEASE/B_GENE
disturbance I I_DISEASE/I_GENE
. O O

Diffuse O O
skeletal O O
pain B B_DISEASE
after O O
administration O O
of O O
alendronate O O
. O O

BACKGROUND O O
: O O
Osteoporosis B B_DISEASE
is O O
caused O O
by O O
bone O O
resorption O O
in O O
excess O O
of O O
bone O O
formation O O
, O O
and O O
bisphosphonates O O
, O O
are O O
used O O
to O O
inhibit O O
bone O O
resorption O O
. O O

Alendronate O O
, O O
a O O
biphosphonate O O
, O O
is O O
effective O O
for O O
both O O
the O O
treatment O O
and O O
prevention O O
of O O
osteoporosis B B_DISEASE/B_GENE
in O O
postmenopausal O O
women O O
. O O

Side O O
effects O O
are O O
relatively O O
few O O
and O O
prominently O O
gastrointestinal O O
. O O

Musculoskeletal B B_DISEASE
pain I I_DISEASE
may O O
be O O
an O O
important O O
side O O
effect O O
in O O
these O O
patients O O
. O O

We O O
presented O O
a O O
patient O O
admitted O O
to O O
our O O
out O O
- O O
patient O O
clinic O O
with O O
diffuse O O
skeletal O O
pain B B_DISEASE
after O O
three O O
consecutive O O
administration O O
of O O
alendronate O O
. O O

CONCLUSION O O
: O O
We O O
conclude O O
that O O
patients O O
with O O
osteoporosis B B_DISEASE
can O O
report O O
pain B B_DISEASE
, O O
and O O
bisphosphonate O O
- O O
related O O
pain B B_DISEASE
should O O
also O O
be O O
considered O O
before O O
ascribing O O
this O O
complaint O O
to O O
osteoporosis B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Cerebrospinal O O
fluid O O
penetration O O
of O O
high O O
- O O
dose O O
daptomycin O O
in O O
suspected O O
Staphylococcus O O
aureus O O
meningitis B B_DISEASE/B_PERSON
. O O

OBJECTIVE O O
: O O
To O O
report O O
a O O
case O O
of O O
methicillin O O
- O O
sensitive O O
Staphylococcus O O
aureus O O
( O O
MSSA O O
) O O
bacteremia B B_DISEASE/B_PERSON
with O O
suspected O O
MSSA O O
meningitis B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treated O O
with O O
high O O
- O O
dose O O
daptomycin O O
assessed O O
with O O
concurrent O O
serum O O
and O O
cerebrospinal O O
fluid O O
( O O
CSF O O
) O O
concentrations O O
. O O

CASE O O
SUMMARY O O
: O O
A O O
54 O O
- O O
year O O
- O O
old O O
male O O
presented O O
to O O
the O O
emergency O O
department O O
with O O
generalized O O
weakness B B_DISEASE
and O O
presumed O O
health O O
- O O
care O O
- O O
associated O O
pneumonia B B_DISEASE
shown O O
on O O
chest O O
radiograph O O
. O O

Treatment O O
was O O
empirically O O
initiated O O
with O O
vancomycin O O
, O O
levofloxacin O O
, O O
and O O
piperacillin O O
/ O O
tazobactam O O
. O O

Blood O O
cultures O O
revealed O O
S O O
. O O
aureus O O
susceptible O O
to O O
oxacillin O O
. O O

Empiric O O
antibiotic O O
treatment O O
was O O
narrowed O O
to O O
nafcillin O O
on O O
day O O
4 O O
. O O

On O O
day O O
8 O O
, O O
the O O
patient O O
developed O O
acute B B_DISEASE
renal I I_DISEASE
failure I I_DISEASE
( O O
serum O O
creatinine O O
1 O O
. O O
9 O O
mg O O
/ O O
dL O O
, O O
increased O O
from O O
1 O O
. O O
2 O O
mg O O
/ O O
dL O O
the O O
previous O O
day O O
and O O
0 O O
. O O
8 O O
mg O O
/ O O
dL O O
on O O
admission O O
) O O
. O O

The O O
patient O O
' O O
s O O
Glasgow O O
Coma O O
Score O O
was O O
3 O O
, O O
with O O
normal O O
findings O O
shown O O
on O O
computed O O
tomography O O
scan O O
of O O
the O O
head O O
72 O O
hours O O
following O O
an O O
episode O O
of O O
cardiac B B_DISEASE
arrest I I_DISEASE
on O O
day O O
10 O O
. O O

The O O
patient O O
experienced O O
relapsing O O
MSSA O O
bacteremia B B_DISEASE
on O O
day O O
9 O O
, O O
increasing O O
the O O
suspicion O O
for O O
a O O
central O O
nervous O O
system O O
( O O
CNS O O
) O O
infection B B_DISEASE/B_LOCATION
. O O

Nafcillin O O
was O O
discontinued O O
and O O
daptomycin O O
9 O O
mg O O
/ O O
kg O O
daily O O
was O O
initiated O O
for O O
suspected O O
meningitis B B_DISEASE
and O O
was O O
continued O O
until O O
the O O
patient O O
' O O
s O O
death O O
on O O
day O O
16 O O
. O O

Daptomycin O O
serum O O
and O O
CSF O O
trough O O
concentrations O O
were O O
11 O O
. O O
21 O O
ug O O
/ O O
mL O O
and O O
0 O O
. O O
52 O O
ug O O
/ O O
mL O O
, O O
respectively O O
, O O
prior O O
to O O
the O O
third O O
dose O O
. O O

Creatine O O
kinase O O
levels O O
were O O
normal O O
prior O O
to O O
daptomycin O O
therapy O O
and O O
were O O
not O O
reassessed O O
. O O

DISCUSSION O O
: O O
Daptomycin O O
was O O
initiated O O
in O O
our O O
patient O O
secondary O O
to O O
possible O O
nafcillin O O
- O O
induced O O
acute O O
interstitial B B_DISEASE
nephritis I I_DISEASE
and O O
relapsing O O
bacteremia B B_DISEASE
. O O

CONCLUSIONS O O
: O O
High O O
- O O
dose O O
daptomycin O O
may O O
be O O
an O O
alternative O O
option O O
for O O
MSSA O O
bacteremia B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
or O O
without O O
a O O
CNS O O
source O O
in O O
patients O O
who O O
have O O
failed O O
or O O
cannot O O
tolerate O O
standard O O
therapy O O
. O O

Further O O
clinical O O
evaluation O O
in O O
patients O O
with O O
confirmed O O
meningitis B B_DISEASE
is O O
warranted O O
. O O

The O O
role O O
of O O
nitric O O
oxide O O
in O O
convulsions B B_DISEASE
induced O O
by O O
lindane O O
in O O
rats O O
. O O

Lindane O O
is O O
an O O
organochloride O O
pesticide O O
and O O
scabicide O O
. O O

It O O
evokes O O
convulsions B B_DISEASE
mainly O O
trough O O
the O O
blockage O O
of O O
GABA O O
( O O
A O O
) O O
receptors O O
. O O

Nitric O O
oxide O O
( O O
NO O O
) O O
, O O
gaseous O O
neurotransmitter O O
, O O
has O O
contradictor O O
role O O
in O O
epileptogenesis O O
due O O
to O O
opposite O O
effects O O
of O O
L O O
- O O
arginine O O
, O O
precursor O O
of O O
NO O O
syntheses O O
( O O
NOS O O
) O O
, O O
and O O
L O O
- O O
NAME O O
( O O
NOS O O
inhibitor O O
) O O
observed O O
in O O
different O O
epilepsy B B_DISEASE
models O O
. O O

The O O
aim O O
of O O
the O O
current O O
study O O
was O O
to O O
determine O O
the O O
effects O O
of O O
NO O O
on O O
the O O
behavioral O O
and O O
EEG O O
characteristics O O
of O O
lindane O O
- O O
induced O O
epilepsy B B_DISEASE
in O O
male O O
Wistar O O
albino O O
rats O O
. O O

The O O
administration O O
of O O
L O O
- O O
arginine O O
( O O
600 O O
, O O
800 O O
and O O
1000 O O
mg O O
/ O O
kg O O
, O O
i O O
. O O
p O O
. O O
) O O
in O O
dose O O
- O O
dependent O O
manner O O
significantly O O
increased O O
convulsion B B_DISEASE
incidence O O
and O O
severity O O
and O O
shortened O O
latency O O
time O O
to O O
first O O
convulsion B B_DISEASE_ADJECTIVE[DISEASE]
elicited O O
by O O
lower O O
lindane O O
dose O O
( O O
4 O O
mg O O
/ O O
kg O O
, O O
i O O
. O O
p O O
. O O
) O O
. O O

On O O
the O O
contrary O O
, O O
pretreatment O O
with O O
L O O
- O O
NAME O O
( O O
500 O O
, O O
700 O O
and O O
900 O O
mg O O
/ O O
kg O O
, O O
i O O
. O O
p O O
. O O
) O O
decreased O O
convulsion B B_DISEASE
incidence O O
and O O
severity O O
and O O
prolonged O O
latency O O
time O O
to O O
convulsion B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
following O O
injection O O
with O O
a O O
convulsive B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
dose O O
of O O
lindane O O
( O O
8 O O
mg O O
/ O O
kg O O
, O O
i O O
. O O
p O O
. O O
) O O
. O O

These O O
results O O
support O O
the O O
conclusion O O
that O O
NO O O
plays O O
a O O
role O O
of O O
endogenous O O
convulsant O O
in O O
rat O O
model O O
of O O
lindane O O
seizures B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Severe O O
polyneuropathy B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
motor O O
loss O O
after O O
intrathecal O O
thiotepa O O
combination O O
chemotherapy O O
: O O
description O O
of O O
two O O
cases O O
. O O

Two O O
cases O O
of O O
severe O O
delayed O O
neurologic B B_DISEASE
toxicity I I_DISEASE
related O O
to O O
the O O
administration O O
of O O
intrathecal O O
( O O
IT O O
) O O
combination O O
chemotherapy O O
including O O
thiotepa O O
( O O
TSPA O O
) O O
are O O
presented O O
. O O

Both O O
cases O O
developed O O
axonal B B_DISEASE/B_LOCATION
neuropathy I I_DISEASE/I_LOCATION
with O O
motor O O
predominance O O
in O O
the O O
lower O O
extremities O O
1 O O
and O O
6 O O
months O O
after O O
IT O O
chemotherapy O O
was O O
administered O O
. O O

Neurologic B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
toxicities I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
have O O
been O O
described O O
with O O
IT O O
- O O
methotrexate O O
, O O
IT O O
- O O
cytosine O O
arabinoside O O
and O O
IT O O
- O O
TSPA O O
. O O

To O O
our O O
knowledge O O
, O O
however O O
, O O
axonal B B_DISEASE
neuropathy I I_DISEASE
following O O
administration O O
of O O
these O O
three O O
agents O O
has O O
not O O
been O O
previously O O
described O O
. O O

In O O
spite O O
of O O
the O O
fact O O
that O O
TSPA O O
is O O
a O O
useful O O
IT O O
agent O O
, O O
its O O
combination O O
with O O
MTX O O
, O O
ara O O
- O O
C O O
and O O
radiotherapy O O
could O O
cause O O
severe O O
neurotoxicity B B_DISEASE
. O O

This O O
unexpected O O
complication O O
indicates O O
the O O
need O O
for O O
further O O
toxicology O O
research O O
on O O
IT O O
- O O
TSPA O O
. O O

Effects O O
of O O
cromakalim O O
and O O
pinacidil O O
on O O
large O O
epicardial O O
and O O
small O O
coronary O O
arteries O O
in O O
conscious O O
dogs O O
. O O

Vasodilation O O
of O O
large O O
and O O
small O O
coronary O O
vessels O O
and O O
hypotension B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induced O O
by O O
cromakalim O O
and O O
pinacidil O O
were O O
not O O
affected O O
by O O
prior O O
combined O O
beta O O
adrenergic O O
and O O
muscarinic O O
receptors O O
blockade O O
but O O
drug O O
- O O
induced O O
tachycardia B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
abolished O O
. O O

Mefenamic O O
acid O O
- O O
induced O O
neutropenia B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
renal B B_DISEASE
failure I I_DISEASE
in O O
elderly O O
females O O
with O O
hypothyroidism B B_DISEASE
. O O

We O O
report O O
mefenamic O O
acid O O
- O O
induced O O
non O O
- O O
oliguric O O
renal B B_DISEASE
failure I I_DISEASE
and O O
severe O O
neutropenia B B_DISEASE
occurring O O
simultaneously O O
in O O
two O O
elderly O O
females O O
. O O

The O O
neutropenia B B_DISEASE
was O O
due O O
to O O
maturation O O
arrest O O
of O O
the O O
myeloid O O
series O O
in O O
one O O
patient O O
. O O

Both O O
patients O O
were O O
also O O
hypothyroid B B_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
it O O
is O O
not O O
clear O O
whether O O
this O O
was O O
a O O
predisposing O O
factor O O
to O O
the O O
development O O
of O O
these O O
adverse O O
reactions O O
. O O

However O O
, O O
it O O
would O O
seem O O
prudent O O
not O O
to O O
use O O
mefenamic O O
acid O O
in O O
hypothyroid B B_DISEASE/B_PERSON
patients O O
until O O
the O O
hypothyroidism B B_DISEASE/B_MEASURE
has O O
been O O
corrected O O
. O O

Etiology O O
of O O
hypercalcemia B B_DISEASE
in O O
hemodialysis O O
patients O O
on O O
calcium O O
carbonate O O
therapy O O
. O O

Fourteen O O
of O O
39 O O
dialysis O O
patients O O
( O O
36 O O
% O O
) O O
became O O
hypercalcemic B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
after O O
switching O O
to O O
calcium O O
carbonate O O
as O O
their O O
principal O O
phosphate O O
binder O O
. O O

In O O
order O O
to O O
identify O O
risk O O
factors O O
associated O O
with O O
the O O
development O O
of O O
hypercalcemia B B_DISEASE
, O O
indirect O O
parameters O O
of O O
intestinal O O
calcium O O
reabsorption O O
and O O
bone O O
turnover O O
rate O O
in O O
these O O
14 O O
patients O O
were O O
compared O O
with O O
results O O
in O O
14 O O
eucalcemic O O
patients O O
matched O O
for O O
age O O
, O O
sex O O
, O O
length O O
of O O
time O O
on O O
dialysis O O
, O O
and O O
etiology O O
of O O
renal B B_DISEASE
disease I I_DISEASE
. O O

In O O
addition O O
to O O
experiencing O O
hypercalcemic B B_DISEASE_ADJECTIVE[DISEASE]
episodes O O
with O O
peak O O
calcium O O
values O O
of O O
2 O O
. O O
7 O O
to O O
3 O O
. O O
8 O O
mmol O O
/ O O
L O O
( O O
10 O O
. O O
7 O O
to O O
15 O O
. O O
0 O O
mg O O
/ O O
dL O O
) O O
, O O
patients O O
in O O
the O O
hypercalcemic B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
group O O
exhibited O O
a O O
significant O O
increase O O
in O O
the O O
mean O O
calcium O O
concentration O O
obtained O O
during O O
6 O O
months O O
before O O
the O O
switch O O
, O O
compared O O
with O O
the O O
mean O O
value O O
obtained O O
during O O
the O O
7 O O
months O O
of O O
observation O O
after O O
the O O
switch O O
( O O
2 O O
. O O
4 O O
+ O O
/ O O
- O O
0 O O
. O O
03 O O
to O O
2 O O
. O O
5 O O
+ O O
/ O O
- O O
0 O O
. O O
03 O O
mmol O O
/ O O
L O O
[ O O
9 O O
. O O
7 O O
+ O O
/ O O
- O O
0 O O
. O O
2 O O
to O O
10 O O
. O O
2 O O
+ O O
/ O O
- O O
0 O O
. O O
1 O O
mg O O
/ O O
dL O O
] O O
, O O
P O O
= O O
0 O O
. O O
006 O O
) O O
. O O

In O O
contrast O O
, O O
eucalcemic O O
patients O O
exhibited O O
no O O
change O O
in O O
mean O O
calcium O O
values O O
over O O
the O O
same O O
time O O
period O O
( O O
2 O O
. O O
3 O O
+ O O
/ O O
- O O
0 O O
. O O
05 O O
to O O
2 O O
. O O
3 O O
+ O O
/ O O
- O O
0 O O
. O O
05 O O
mmol O O
/ O O
L O O
[ O O
9 O O
. O O
2 O O
+ O O
/ O O
- O O
0 O O
. O O
2 O O
to O O
9 O O
. O O
2 O O
+ O O
/ O O
- O O
0 O O
. O O
2 O O
mg O O
/ O O
dL O O
] O O
) O O
. O O

CaCO3 O O
dosage O O
, O O
calculated O O
dietary O O
calcium O O
intake O O
, O O
and O O
circulating O O
levels O O
of O O
vitamin O O
D O O
metabolites O O
were O O
similar O O
in O O
both O O
groups O O
. O O

Physical O O
activity O O
index O O
and O O
predialysis O O
serum O O
bicarbonate O O
levels O O
also O O
were O O
similar O O
in O O
both O O
groups O O
. O O

Late O O
- O O
onset O O
scleroderma B B_DISEASE
renal I I_DISEASE
crisis I I_DISEASE
induced O O
by O O
tacrolimus O O
and O O
prednisolone O O
: O O
a O O
case O O
report O O
. O O

Moderate O O
to O O
high O O
dose O O
corticosteroid O O
use O O
is O O
recognized O O
as O O
a O O
major O O
risk O O
factor O O
for O O
SRC B B_DISEASE/B_GENE
. O O

Furthermore O O
, O O
there O O
have O O
been O O
reports O O
of O O
thrombotic B B_DISEASE
microangiopathy I I_DISEASE
precipitated O O
by O O
cyclosporine O O
in O O
patients O O
with O O
SSc B B_DISEASE/B_LOCATION
. O O

In O O
this O O
article O O
, O O
we O O
report O O
a O O
patient O O
with O O
SRC B B_GENE/B_DISEASE
induced O O
by O O
tacrolimus O O
and O O
corticosteroids O O
. O O

The O O
aim O O
of O O
this O O
work O O
is O O
to O O
call O O
attention O O
to O O
the O O
risk O O
of O O
tacrolimus O O
use O O
in O O
patients O O
with O O
SSc B B_DISEASE/B_GENE
. O O

Methyldopa O O
- O O
induced O O
hemolytic B B_DISEASE/B_LOCATION
anemia I I_DISEASE/I_LOCATION
in O O
a O O
15 O O
year O O
old O O
presenting O O
as O O
near O O
- O O
syncope B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O O

Methyldopa O O
is O O
an O O
antihypertensive O O
medication O O
which O O
is O O
available O O
generically O O
and O O
under O O
the O O
trade O O
name O O
Aldomet O O
that O O
is O O
widely O O
prescribed O O
in O O
the O O
adult O O
population O O
and O O
infrequently O O
used O O
in O O
children O O
. O O

Methyldopa O O
causes O O
an O O
autoimmune B B_DISEASE
hemolytic I I_DISEASE
anemia I I_DISEASE
in O O
a O O
small O O
percentage O O
of O O
patients O O
who O O
take O O
the O O
drug O O
. O O

The O O
boy O O
had O O
been O O
treated O O
with O O
intravenous O O
methyldopa O O
during O O
a O O
trauma B B_DISEASE_ADJECTIVE[DISEASE]/B_SEQUENCE[MEASURE]
admission O O
seven O O
weeks O O
prior O O
to O O
presentation O O
. O O

Transfusion O O
and O O
corticosteroid O O
therapy O O
resulted O O
in O O
a O O
complete O O
recovery O O
of O O
the O O
patient O O
. O O

A O O
brief O O
review O O
of O O
autoimmune O O
and O O
drug O O
- O O
induced O O
hemolytic B B_DISEASE
anemias I I_DISEASE
is O O
provided O O
. O O

The O O
risk O O
and O O
associated O O
factors O O
of O O
methamphetamine O O
psychosis B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
methamphetamine O O
- O O
dependent O O
patients O O
in O O
Malaysia O O
. O O

OBJECTIVE O O
: O O
The O O
objective O O
of O O
this O O
study O O
was O O
to O O
determine O O
the O O
risk O O
of O O
lifetime O O
and O O
current O O
methamphetamine O O
- O O
induced O O
psychosis B B_DISEASE
in O O
patients O O
with O O
methamphetamine O O
dependence O O
. O O

The O O
association O O
between O O
psychiatric O O
co O O
- O O
morbidity O O
and O O
methamphetamine O O
- O O
induced O O
psychosis B B_DISEASE/B_LOCATION
was O O
also O O
studied O O
. O O

METHODS O O
: O O
This O O
was O O
a O O
cross O O
- O O
sectional O O
study O O
conducted O O
concurrently O O
at O O
a O O
teaching O O
hospital O O
and O O
a O O
drug O O
rehabilitation O O
center O O
in O O
Malaysia O O
. O O

Patients O O
with O O
the O O
diagnosis O O
of O O
methamphetamine O O
based O O
on O O
DSM O O
- O O
IV O O
were O O
interviewed O O
using O O
the O O
Mini O O
International O O
Neuropsychiatric O O
Interview O O
( O O
M O O
. O O
I O O
. O O
N O O
. O O
I O O
. O O
) O O
for O O
methamphetamine O O
- O O
induced O O
psychosis B B_DISEASE
and O O
other O O
Axis O O
I O O
psychiatric B B_DISEASE
disorders I I_DISEASE
. O O

The O O
information O O
on O O
sociodemographic O O
background O O
and O O
drug O O
use O O
history O O
was O O
obtained O O
from O O
interview O O
or O O
medical O O
records O O
. O O

RESULTS O O
: O O
Of O O
292 O O
subjects O O
, O O
47 O O
. O O
9 O O
% O O
of O O
the O O
subjects O O
had O O
a O O
past O O
history O O
of O O
psychotic B B_DISEASE
symptoms I I_DISEASE
and O O
13 O O
. O O
0 O O
% O O
of O O
the O O
patients O O
were O O
having O O
current O O
psychotic B B_DISEASE
symptoms I I_DISEASE
. O O

Co O O
- O O
morbid O O
major O O
depressive B B_DISEASE
disorder I I_DISEASE
( O O
OR O O
= O O
7 O O
. O O
18 O O
, O O
95 O O
CI O O
= O O
2 O O
. O O
612 O O
- O O
19 O O
. O O
708 O O
) O O
, O O
bipolar B B_DISEASE
disorder I I_DISEASE
( O O
OR O O
= O O
13 O O
. O O
807 O O
, O O
95 O O
CI O O
= O O
5 O O
. O O
194 O O
- O O
36 O O
. O O
706 O O
) O O
, O O
antisocial B B_DISEASE
personality I I_DISEASE
disorder I I_DISEASE
( O O
OR O O
= O O
12 O O
. O O
619 O O
, O O
95 O O
CI O O
= O O
6 O O
. O O
702 O O
- O O
23 O O
. O O
759 O O
) O O
and O O
heavy O O
methamphetamine O O
uses O O
were O O
significantly O O
associated O O
with O O
lifetime O O
methamphetamine O O
- O O
induced O O
psychosis B B_DISEASE/B_LOCATION
after O O
adjusted O O
for O O
other O O
factors O O
. O O

Major B B_DISEASE/B_PERSON
depressive I I_DISEASE/I_PERSON
disorder I I_DISEASE/I_PERSON
( O O
OR O O
= O O
2 O O
. O O
870 O O
, O O
CI O O
= O O
1 O O
. O O
154 O O
- O O
7 O O
. O O
142 O O
) O O
and O O
antisocial B B_DISEASE/B_PERSON
personality I I_DISEASE/I_PERSON
disorder I I_DISEASE/I_PERSON
( O O
OR O O
= O O
3 O O
. O O
299 O O
, O O
95 O O
CI O O
= O O
1 O O
. O O
375 O O
- O O
7 O O
. O O
914 O O
) O O
were O O
the O O
only O O
factors O O
associated O O
with O O
current O O
psychosis B B_DISEASE
. O O

CONCLUSION O O
: O O
There O O
was O O
a O O
high O O
risk O O
of O O
psychosis B B_DISEASE
in O O
patients O O
with O O
methamphetamine O O
dependence O O
. O O

It O O
was O O
associated O O
with O O
co O O
- O O
morbid O O
affective B B_DISEASE
disorder I I_DISEASE
, O O
antisocial B B_DISEASE
personality I I_DISEASE
, O O
and O O
heavy O O
methamphetamine O O
use O O
. O O

It O O
is O O
recommended O O
that O O
all O O
cases O O
of O O
methamphetamine O O
dependence O O
should O O
be O O
screened O O
for O O
psychotic B B_DISEASE/B_LOCATION
symptoms I I_DISEASE/I_LOCATION
. O O

Cerebellar O O
sensory O O
processing O O
alterations O O
impact O O
motor O O
cortical O O
plasticity O O
in O O
Parkinson B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
' I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
s I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
disease I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
: O O
clues O O
from O O
dyskinetic B B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
patients O O
. O O

The O O
plasticity O O
of O O
primary O O
motor O O
cortex O O
( O O
M1 O O
) O O
in O O
patients O O
with O O
Parkinson B B_DISEASE
' I I_DISEASE
s I I_DISEASE
disease I I_DISEASE
( O O
PD B B_DISEASE/B_PROTEIN[GENE]
) O O
and O O
levodopa O O
- O O
induced O O
dyskinesias B B_DISEASE_ADJECTIVE[DISEASE]
( O O
LIDs B B_DISEASE/B_PROTEIN[GENE]
) O O
is O O
severely O O
impaired O O
. O O

This O O
study O O
demonstrates O O
that O O
the O O
deficient O O
sensorimotor O O
M1 O O
plasticity O O
in O O
16 O O
patients O O
with O O
LIDs B B_DISEASE
could O O
be O O
reinstated O O
by O O
a O O
single O O
session O O
of O O
real O O
inhibitory O O
cerebellar O O
stimulation O O
but O O
not O O
sham O O
stimulation O O
. O O

The O O
benefit O O
of O O
inhibitory O O
cerebellar O O
stimulation O O
on O O
LIDs B B_DISEASE
is O O
known O O
. O O

To O O
explore O O
whether O O
this O O
benefit O O
is O O
linked O O
to O O
the O O
restoration O O
of O O
sensorimotor O O
plasticity O O
of O O
M1 O O
, O O
we O O
conducted O O
an O O
additional O O
study O O
looking O O
at O O
changes O O
in O O
LIDs B B_DISEASE_ADJECTIVE[DISEASE]
and O O
PAS O O
- O O
induced O O
plasticity O O
after O O
10 O O
sessions O O
of O O
either O O
bilateral O O
, O O
real O O
inhibitory O O
cerebellar O O
stimulation O O
or O O
sham O O
stimulation O O
. O O

Only O O
real O O
and O O
not O O
sham O O
stimulation O O
had O O
an O O
antidyskinetic O O
effect O O
and O O
it O O
was O O
paralleled O O
by O O
a O O
resurgence O O
in O O
the O O
sensorimotor O O
plasticity O O
of O O
M1 O O
. O O

These O O
results O O
suggest O O
that O O
alterations O O
in O O
cerebellar O O
sensory O O
processing O O
function O O
, O O
occurring O O
secondary O O
to O O
abnormal O O
basal O O
ganglia O O
signals O O
reaching O O
it O O
, O O
may O O
be O O
an O O
important O O
element O O
contributing O O
to O O
the O O
maladaptive O O
sensorimotor O O
plasticity O O
of O O
M1 O O
and O O
the O O
emergence O O
of O O
abnormal B B_DISEASE
involuntary I I_DISEASE
movements I I_DISEASE
. O O

The O O
long O O
- O O
term O O
safety O O
of O O
danazol O O
in O O
women O O
with O O
hereditary B B_DISEASE/B_LOCATION
angioedema I I_DISEASE/I_LOCATION
. O O

Although O O
the O O
short O O
- O O
term O O
safety O O
( O O
less O O
than O O
or O O
equal O O
to O O
6 O O
months O O
) O O
of O O
danazol O O
has O O
been O O
established O O
in O O
a O O
variety O O
of O O
settings O O
, O O
no O O
information O O
exists O O
as O O
to O O
its O O
long O O
- O O
term O O
safety O O
. O O

We O O
therefore O O
investigated O O
the O O
long O O
- O O
term O O
safety O O
of O O
danazol O O
by O O
performing O O
a O O
retrospective O O
chart O O
review O O
of O O
60 O O
female O O
patients O O
with O O
hereditary B B_DISEASE/B_LOCATION
angioedema I I_DISEASE/I_LOCATION
treated O O
with O O
danazol O O
for O O
a O O
continuous O O
period O O
of O O
6 O O
months O O
or O O
longer O O
. O O

The O O
mean O O
age O O
of O O
the O O
patients O O
was O O
35 O O
. O O
2 O O
years O O
and O O
the O O
mean O O
duration O O
of O O
therapy O O
was O O
59 O O
. O O
7 O O
months O O
. O O

Virtually O O
all O O
patients O O
experienced O O
one O O
or O O
more O O
adverse O O
reactions O O
. O O

Menstrual B B_DISEASE
abnormalities I I_DISEASE
( O O
79 O O
% O O
) O O
, O O
weight B B_DISEASE
gain I I_DISEASE
( O O
60 O O
% O O
) O O
, O O
muscle B B_DISEASE
cramps I I_DISEASE
/ O O
myalgias B B_DISEASE
( O O
40 O O
% O O
) O O
, O O
and O O
transaminase O O
elevations O O
( O O
40 O O
% O O
) O O
were O O
the O O
most O O
common O O
adverse O O
reactions O O
. O O

No O O
patient O O
has O O
died O O
or O O
suffered O O
any O O
apparent O O
long O O
- O O
term O O
sequelae O O
that O O
were O O
directly O O
attributable O O
to O O
the O O
drug O O
. O O

The O O
function O O
of O O
P2X3 O O
receptor O O
and O O
NK1 O O
receptor O O
antagonists O O
on O O
cyclophosphamide O O
- O O
induced O O
cystitis B B_DISEASE
in O O
rats O O
. O O

PURPOSE O O
: O O
The O O
purpose O O
of O O
the O O
study O O
is O O
to O O
explore O O
the O O
function O O
of O O
P2X3 O O
and O O
NK1 O O
receptors O O
antagonists O O
on O O
cyclophosphamide O O
( O O
CYP O O
) O O
- O O
induced O O
cystitis B B_DISEASE
in O O
rats O O
. O O

METHODS O O
: O O
Sixty O O
female O O
Sprague O O
- O O
Dawley O O
( O O
SD O O
) O O
rats O O
were O O
randomly O O
divided O O
into O O
three O O
groups O O
. O O

The O O
rats O O
in O O
the O O
control O O
group O O
were O O
intraperitoneally O O
( O O
i O O
. O O
p O O
. O O
) O O
injected O O
with O O
0 O O
. O O
9 O O
% O O
saline O O
( O O
4 O O
ml O O
/ O O
kg O O
) O O
; O O
the O O
rats O O
in O O
the O O
model O O
group O O
were O O
i O O
. O O
p O O
. O O
injected O O
with O O
CYP O O
( O O
150 O O
mg O O
/ O O
kg O O
) O O
; O O
and O O
the O O
rats O O
in O O
the O O
intervention O O
group O O
were O O
i O O
. O O
p O O
. O O
injected O O
with O O
CYP O O
with O O
subsequently O O
perfusion O O
of O O
bladder O O
with O O
P2X3 O O
and O O
NK1 O O
receptors O O
' O O
antagonists O O
, O O
Suramin O O
and O O
GR O O
82334 O O
. O O

Spontaneous O O
pain B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
behaviors O O
following O O
the O O
administration O O
of O O
CYP O O
were O O
observed O O
. O O

Pathological O O
changes O O
in O O
bladder O O
tissue O O
were O O
observed O O
. O O

Immunofluorescence O O
was O O
used O O
to O O
detect O O
the O O
expression O O
of O O
P2X3 O O
and O O
NK1 O O
receptors O O
in O O
bladder O O
. O O

RESULTS O O
: O O
Cyclophosphamide O O
treatment O O
increased O O
the O O
spontaneous O O
pain B B_DISEASE/B_ORGANISM_FUNCTION
behaviors O O
scores O O
. O O

Histological O O
changes O O
evident O O
in O O
model O O
and O O
intervention O O
groups O O
rats O O
' O O
bladder O O
included O O
edema B B_DISEASE
, O O
vasodilation O O
, O O
and O O
infiltration O O
of O O
inflammatory O O
cells O O
. O O

In O O
model O O
group O O
, O O
the O O
expression O O
of O O
P2X3 O O
receptor O O
increased O O
in O O
urothelium O O
and O O
suburothelium O O
, O O
and O O
NK1 O O
receptor O O
increased O O
in O O
suburothelium O O
, O O
while O O
the O O
expression O O
of O O
them O O
in O O
intervention O O
group O O
was O O
lower O O
. O O

CONCLUSIONS O O
: O O
In O O
CYP O O
- O O
induced O O
cystitis B B_DISEASE
, O O
the O O
expression O O
of O O
P2X3 O O
and O O
NK1 O O
receptors O O
increased O O
in O O
urothelium O O
and O O
/ O O
or O O
suburothelium O O
. O O

Patient O O
tolerance O O
study O O
of O O
topical O O
chlorhexidine O O
diphosphanilate O O
: O O
a O O
new O O
topical O O
agent O O
for O O
burns B B_DISEASE
. O O

Effective O O
topical O O
antimicrobial O O
agents O O
decrease O O
infection B B_DISEASE
and O O
mortality O O
in O O
burn B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
patients O O
. O O

Chlorhexidine O O
phosphanilate O O
( O O
CHP O O
) O O
, O O
a O O
new O O
broad O O
- O O
spectrum O O
antimicrobial O O
agent O O
, O O
has O O
been O O
evaluated O O
as O O
a O O
topical O O
burn B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
wound O O
dressing O O
in O O
cream O O
form O O
, O O
but O O
preliminary O O
clinical O O
trials O O
reported O O
that O O
it O O
was O O
painful O O
upon O O
application O O
. O O

This O O
study O O
compared O O
various O O
concentrations O O
of O O
CHP O O
to O O
determine O O
if O O
a O O
tolerable O O
concentration O O
could O O
be O O
identified O O
with O O
retention O O
of O O
antimicrobial O O
efficacy O O
. O O

Twenty O O
- O O
nine O O
burn B B_DISEASE/B_PERSON
patients O O
, O O
each O O
with O O
two O O
similar O O
burns B B_PERSON/B_DISEASE
which O O
could O O
be O O
separately O O
treated O O
, O O
were O O
given O O
pairs O O
of O O
treatments O O
at O O
successive O O
12 O O
- O O
h O O
intervals O O
over O O
a O O
3 O O
- O O
day O O
period O O
. O O

One O O
burn B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site O O
was O O
treated O O
with O O
each O O
of O O
four O O
different O O
CHP O O
concentrations O O
, O O
from O O
0 O O
. O O
25 O O
per O O
cent O O
to O O
2 O O
per O O
cent O O
, O O
their O O
vehicle O O
, O O
and O O
1 O O
per O O
cent O O
silver O O
sulphadiazine O O
( O O
AgSD O O
) O O
cream O O
, O O
an O O
antimicrobial O O
agent O O
frequently O O
used O O
for O O
topical O O
treatment O O
of O O
burn B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
wounds O O
. O O

The O O
other O O
site O O
was O O
always O O
treated O O
with O O
AgSD O O
cream O O
. O O

There O O
was O O
a O O
direct O O
relationship O O
between O O
CHP O O
concentration O O
and O O
patients O O
' O O
ratings O O
of O O
pain B B_DISEASE
on O O
an O O
analogue O O
scale O O
. O O

The O O
0 O O
. O O
25 O O
per O O
cent O O
CHP O O
cream O O
was O O
closest O O
to O O
AgSD O O
in O O
pain B B_DISEASE
tolerance O O
; O O
however O O
, O O
none O O
of O O
the O O
treatments O O
differed O O
statistically O O
from O O
AgSD O O
or O O
from O O
each O O
other O O
. O O

In O O
addition O O
, O O
ease O O
of O O
application O O
of O O
CHP O O
creams O O
was O O
less O O
satisfactory O O
than O O
that O O
of O O
AgSD O O
. O O

It O O
was O O
concluded O O
that O O
formulations O O
at O O
or O O
below O O
0 O O
. O O
5 O O
per O O
cent O O
CHP O O
may O O
prove O O
acceptable O O
for O O
wound O O
care O O
, O O
but O O
the O O
vehicle O O
system O O
needs O O
pharmaceutical O O
improvement O O
to O O
render O O
it O O
more O O
tolerable O O
and O O
easier O O
to O O
use O O
. O O

Acute O O
hepatitis B B_DISEASE
associated O O
with O O
clopidogrel O O
: O O
a O O
case O O
report O O
and O O
review O O
of O O
the O O
literature O O
. O O

Drug O O
- O O
induced O O
hepatotoxicity B B_DISEASE
is O O
a O O
common O O
cause O O
of O O
acute O O
hepatitis B B_DISEASE
, O O
and O O
the O O
recognition O O
of O O
the O O
responsible O O
drug O O
may O O
be O O
difficult O O
. O O

We O O
describe O O
a O O
case O O
of O O
clopidogrel O O
- O O
related O O
acute O O
hepatitis B B_DISEASE
. O O

The O O
diagnosis O O
is O O
strongly O O
suggested O O
by O O
an O O
accurate O O
medical O O
history O O
and O O
liver O O
biopsy O O
. O O

Reports O O
about O O
cases O O
of O O
hepatotoxicity B B_DISEASE
due O O
to O O
clopidogrel O O
are O O
increasing O O
in O O
the O O
last O O
few O O
years O O
, O O
after O O
the O O
increased O O
use O O
of O O
this O O
drug O O
. O O

In O O
conclusion O O
, O O
we O O
believe O O
that O O
physicians O O
should O O
carefully O O
consider O O
the O O
risk O O
of O O
drug O O
- O O
induced O O
hepatic B B_DISEASE
injury I I_DISEASE
when O O
clopidogrel O O
is O O
prescribed O O
. O O

Bortezomib O O
and O O
dexamethasone O O
as O O
salvage O O
therapy O O
in O O
patients O O
with O O
relapsed O O
/ O O
refractory O O
multiple B B_DISEASE
myeloma I I_DISEASE
: O O
analysis O O
of O O
long O O
- O O
term O O
clinical O O
outcomes O O
. O O

This O O
retrospective O O
study O O
investigated O O
the O O
combination O O
of O O
bort O O
( O O
1 O O
. O O
3 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
on O O
days O O
1 O O
, O O
4 O O
, O O
8 O O
, O O
and O O
11 O O
every O O
3 O O
weeks O O
) O O
and O O
dex O O
( O O
20 O O
mg O O
on O O
the O O
day O O
of O O
and O O
the O O
day O O
after O O
bort O O
) O O
as O O
salvage O O
treatment O O
in O O
85 O O
patients O O
with O O
R O O
/ O O
R O O
MM B B_DISEASE
after O O
prior O O
autologous O O
stem O O
cell O O
transplantation O O
or O O
conventional O O
chemotherapy O O
. O O

The O O
median O O
number O O
of O O
prior O O
lines O O
of O O
therapy O O
was O O
2 O O
. O O

Eighty O O
- O O
seven O O
percent O O
of O O
the O O
patients O O
had O O
received O O
immunomodulatory O O
drugs O O
included O O
in O O
some O O
line O O
of O O
therapy O O
before O O
bort O O
- O O
dex O O
. O O

The O O
median O O
number O O
of O O
bort O O
- O O
dex O O
cycles O O
was O O
6 O O
, O O
up O O
to O O
a O O
maximum O O
of O O
12 O O
cycles O O
. O O

Median O O
durations O O
of O O
response O O
, O O
time O O
to O O
next O O
therapy O O
and O O
treatment O O
- O O
free O O
interval O O
were O O
8 O O
, O O
11 O O
. O O
2 O O
, O O
and O O
5 O O
. O O
1 O O
months O O
, O O
respectively O O
. O O

The O O
most O O
relevant O O
adverse O O
event O O
was O O
peripheral B B_DISEASE
neuropathy I I_DISEASE
, O O
which O O
occurred O O
in O O
78 O O
% O O
of O O
the O O
patients O O
( O O
grade O O
II O O
, O O
38 O O
% O O
; O O
grade O O
III O O
, O O
21 O O
% O O
) O O
and O O
led O O
to O O
treatment O O
discontinuation O O
in O O
6 O O
% O O
. O O

Bort O O
- O O
dex O O
was O O
an O O
effective O O
salvage O O
treatment O O
for O O
MM B B_TIME[MEASURE]/B_DISEASE
patients O O
, O O
particularly O O
for O O
those O O
in O O
first O O
relapse O O
. O O

Pubertal O O
exposure O O
to O O
Bisphenol O O
A O O
increases O O
anxiety B B_DISEASE
- O O
like O O
behavior O O
and O O
decreases O O
acetylcholinesterase O O
activity O O
of O O
hippocampus O O
in O O
adult O O
male O O
mice O O
. O O

The O O
negative O O
effects O O
of O O
Bisphenol O O
A O O
( O O
BPA O O
) O O
on O O
neurodevelopment O O
and O O
behaviors O O
have O O
been O O
well O O
established O O
. O O

Acetylcholinesterase O O
( O O
AChE O O
) O O
is O O
a O O
regulatory O O
enzyme O O
which O O
is O O
involved O O
in O O
anxiety B B_DISEASE
- O O
like O O
behavior O O
. O O

On O O
postnatal O O
day O O
( O O
PND O O
) O O
35 O O
, O O
male O O
mice O O
were O O
exposed O O
to O O
50mg O O
BPA O O
/ O O
kg O O
diet O O
per O O
day O O
for O O
a O O
period O O
of O O
35 O O
days O O
. O O

In O O
addition O O
, O O
AChE O O
activity O O
was O O
measured O O
in O O
the O O
prefrontal O O
cortex O O
, O O
hypothalamus O O
, O O
cerebellum O O
and O O
hippocampus O O
. O O

Results O O
from O O
our O O
behavioral O O
phenotyping O O
indicated O O
that O O
anxiety B B_DISEASE
- O O
like O O
behavior O O
was O O
increased O O
in O O
mice O O
exposed O O
to O O
BPA O O
. O O

Our O O
findings O O
showed O O
that O O
pubertal O O
BPA O O
exposure O O
increased O O
anxiety B B_DISEASE
- O O
like O O
behavior O O
, O O
which O O
may O O
be O O
associated O O
with O O
decreased O O
AChE O O
activity O O
of O O
the O O
hippocampus O O
in O O
adult O O
male O O
mice O O
. O O

Further O O
studies O O
are O O
necessary O O
to O O
investigate O O
the O O
cholinergic O O
signaling O O
of O O
the O O
hippocampus O O
in O O
PBE O O
induced O O
anxiety B B_DISEASE
- O O
like O O
behaviors O O
. O O

Biochemical O O
effects O O
of O O
Solidago O O
virgaurea O O
extract O O
on O O
experimental O O
cardiotoxicity B B_DISEASE
. O O

Cardiovascular B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
diseases I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
CVDs B B_DISEASE/B_LOCATION
) O O
are O O
the O O
major O O
health O O
problem O O
of O O
advanced O O
as O O
well O O
as O O
developing O O
countries O O
of O O
the O O
world O O
. O O

The O O
aim O O
of O O
the O O
present O O
study O O
was O O
to O O
investigate O O
the O O
protective O O
effect O O
of O O
the O O
Solidago O O
virgaurea O O
extract O O
on O O
isoproterenol O O
- O O
induced O O
cardiotoxicity B B_DISEASE
in O O
rats O O
. O O

The O O
subcutaneous O O
injection O O
of O O
isoproterenol O O
( O O
30 O O
mg O O
/ O O
kg O O
) O O
into O O
rats O O
twice O O
at O O
an O O
interval O O
of O O
24 O O
h O O
, O O
for O O
two O O
consecutive O O
days O O
, O O
led O O
to O O
a O O
significant O O
increase O O
in O O
serum O O
lactate O O
dehydrogenase O O
, O O
creatine O O
phosphokinase O O
, O O
alanine O O
transaminase O O
, O O
aspartate O O
transaminase O O
, O O
and O O
angiotensin O O
- O O
converting O O
enzyme O O
activities O O
, O O
total O O
cholesterol O O
, O O
triglycerides O O
, O O
free O O
serum O O
fatty O O
acid O O
, O O
cardiac O O
tissue O O
malondialdehyde O O
( O O
MDA O O
) O O
, O O
and O O
nitric O O
oxide O O
levels O O
and O O
a O O
significant O O
decrease O O
in O O
levels O O
of O O
glutathione O O
and O O
superoxide O O
dismutase O O
in O O
cardiac O O
tissue O O
as O O
compared O O
to O O
the O O
normal O O
control O O
group O O
( O O
P O O
< O O
0 O O
. O O
05 O O
) O O
. O O

Captopril O O
( O O
50 O O
mg O O
/ O O
kg O O
/ O O
day O O
, O O
given O O
orally O O
) O O
, O O
an O O
inhibitor O O
of O O
angiotensin O O
- O O
converting O O
enzyme O O
used O O
as O O
a O O
standard O O
cardioprotective O O
drug O O
, O O
was O O
used O O
as O O
a O O
positive O O
control O O
in O O
this O O
study O O
. O O

The O O
data O O
of O O
the O O
present O O
study O O
suggest O O
that O O
S O O
. O O
virgaurea O O
extract O O
exerts O O
its O O
protective O O
effect O O
by O O
decreasing O O
MDA O O
level O O
and O O
increasing O O
the O O
antioxidant O O
status O O
in O O
isoproterenol O O
- O O
treated O O
rats O O
. O O

The O O
study O O
emphasizes O O
the O O
beneficial O O
action O O
of O O
S O O
. O O
virgaurea O O
extract O O
as O O
a O O
cardioprotective O O
agent O O
. O O

" O O
Real O O
- O O
world O O
" O O
data O O
on O O
the O O
efficacy O O
and O O
safety O O
of O O
lenalidomide O O
and O O
dexamethasone O O
in O O
patients O O
with O O
relapsed O O
/ O O
refractory O O
multiple B B_DISEASE/B_LOCATION
myeloma I I_DISEASE/I_LOCATION
who O O
were O O
treated O O
according O O
to O O
the O O
standard O O
clinical O O
practice O O
: O O
a O O
study O O
of O O
the O O
Greek O O
Myeloma B B_DISEASE
Study O O
Group O O
. O O

Lenalidomide O O
and O O
dexamethasone O O
( O O
RD O O
) O O
is O O
a O O
standard O O
of O O
care O O
for O O
relapsed O O
/ O O
refractory O O
multiple B B_DISEASE/B_LOCATION
myeloma I I_DISEASE/I_LOCATION
( O O
RRMM B B_DISEASE/B_LOCATION
) O O
, O O
but O O
there O O
is O O
limited O O
published O O
data O O
on O O
its O O
efficacy O O
and O O
safety O O
in O O
the O O
" O O
real O O
world O O
" O O
( O O
RW O O
) O O
, O O
according O O
to O O
the O O
International O O
Society O O
of O O
Pharmacoeconomics O O
and O O
Outcomes O O
Research O O
definition O O
. O O

We O O
studied O O
212 O O
RRMM B B_DISEASE/B_MEASURE
patients O O
who O O
received O O
RD O O
in O O
RW O O
. O O

Objective O O
response O O
( O O
> O O
PR O O
( O O
partial O O
response O O
) O O
) O O
rate O O
was O O
77 O O
. O O
4 O O
% O O
( O O
complete O O
response O O
( O O
CR O O
) O O
, O O
20 O O
. O O
2 O O
% O O
) O O
. O O

Median O O
time O O
to O O
first O O
and O O
best O O
response O O
was O O
2 O O
and O O
5 O O
months O O
, O O
respectively O O
. O O

Quality O O
of O O
response O O
was O O
independent O O
of O O
previous O O
lines O O
of O O
therapies O O
or O O
previous O O
exposure O O
to O O
thalidomide O O
or O O
bortezomib O O
. O O

Median O O
duration O O
of O O
response O O
was O O
34 O O
. O O
4 O O
months O O
, O O
and O O
it O O
was O O
higher O O
in O O
patients O O
who O O
received O O
RD O O
until O O
progression O O
( O O
not O O
reached O O
versus O O
19 O O
months O O
, O O
p O O
< O O
0 O O
. O O
001 O O
) O O
. O O

Adverse O O
events O O
were O O
reported O O
in O O
68 O O
. O O
9 O O
% O O
of O O
patients O O
( O O
myelosuppression B B_DISEASE_ADJECTIVE[DISEASE]
in O O
49 O O
. O O
4 O O
% O O
) O O
and O O
12 O O
. O O
7 O O
% O O
of O O
patients O O
needed O O
hospitalization O O
. O O

Peripheral B B_DISEASE
neuropathy I I_DISEASE
was O O
observed O O
only O O
in O O
2 O O
. O O
5 O O
% O O
of O O
patients O O
and O O
deep B B_DISEASE
vein I I_DISEASE
thrombosis I I_DISEASE
in O O
5 O O
. O O
7 O O
% O O
. O O

Dose O O
reductions O O
were O O
needed O O
in O O
31 O O
% O O
of O O
patients O O
and O O
permanent O O
discontinuation O O
in O O
38 O O
. O O
9 O O
% O O
. O O

Performance O O
status O O
( O O
PS O O
) O O
and O O
initial O O
lenalidomide O O
dose O O
predicted O O
for O O
treatment O O
discontinuation O O
. O O

Our O O
study O O
confirms O O
that O O
RD O O
is O O
effective O O
and O O
safe O O
in O O
RRMM B B_DISEASE/B_PERSON
in O O
the O O
RW O O
; O O
it O O
produces O O
durable O O
responses O O
especially O O
in O O
patients O O
who O O
continue O O
on O O
treatment O O
till O O
progression O O
and O O
improves O O
humoral O O
immunity O O
even O O
in O O
patients O O
with O O
stable O O
disease O O
. O O

Ifosfamide O O
( O O
IFO O O
) O O
is O O
an O O
alkylating O O
nitrogen O O
mustard O O
, O O
administrated O O
as O O
an O O
antineoplasmic O O
agent O O
. O O

It O O
is O O
characterized O O
by O O
its O O
intense O O
urotoxic O O
action O O
, O O
leading O O
to O O
hemorrhagic B B_DISEASE
cystitis I I_DISEASE
. O O

IFO O O
and O O
Mesna O O
were O O
administrated O O
separately O O
on O O
rabbit O O
' O O
s O O
lymphocytes O O
in O O
vivo O O
, O O
which O O
were O O
later O O
developed O O
in O O
vitro O O
. O O

Cytogenetic O O
markers O O
for O O
sister O O
chromatid O O
exchanges O O
( O O
SCEs O O
) O O
, O O
proliferation O O
rate O O
index O O
( O O
PRI O O
) O O
and O O
Mitotic O O
Index O O
were O O
recorded O O
. O O

In O O
addition O O
to O O
this O O
, O O
when O O
high O O
concentrations O O
of O O
Mesna O O
were O O
administered O O
alone O O
significant O O
reductions O O
of O O
the O O
PRI O O
were O O
noted O O
, O O
than O O
with O O
IFO O O
acting O O
at O O
the O O
same O O
concentration O O
on O O
the O O
lymphocytes O O
. O O

Mesna O O
significantly O O
reduces O O
IFO O O
' O O
s O O
genotoxicity B B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
while O O
when O O
administered O O
in O O
high O O
concentrations O O
it O O
acts O O
in O O
an O O
inhibitory O O
fashion O O
on O O
the O O
cytostatic O O
action O O
of O O
the O O
drug O O
. O O

Risk O O
factors O O
and O O
predictors O O
of O O
levodopa O O
- O O
induced O O
dyskinesia B B_DISEASE
among O O
multiethnic O O
Malaysians O O
with O O
Parkinson B B_DISEASE
' I I_DISEASE
s I I_DISEASE
disease I I_DISEASE
. O O

Chronic O O
pulsatile O O
levodopa O O
therapy O O
for O O
Parkinson B B_DISEASE
' I I_DISEASE
s I I_DISEASE
disease I I_DISEASE
( O O
PD B B_DISEASE/B_PROTEIN[GENE]
) O O
leads O O
to O O
the O O
development O O
of O O
motor O O
fluctuations O O
and O O
dyskinesia B B_DISEASE
. O O

We O O
studied O O
the O O
prevalence O O
and O O
predictors O O
of O O
levodopa O O
- O O
induced O O
dyskinesia B B_DISEASE
among O O
multiethnic O O
Malaysian O O
patients O O
with O O
PD B B_DISEASE
. O O

METHODS O O
: O O
This O O
is O O
a O O
cross O O
- O O
sectional O O
study O O
involving O O
95 O O
patients O O
with O O
PD B B_DISEASE
on O O
uninterrupted O O
levodopa O O
therapy O O
for O O
at O O
least O O
6 O O
months O O
. O O

The O O
instrument O O
used O O
was O O
the O O
UPDRS O O
questionnaires O O
. O O

The O O
predictors O O
of O O
dyskinesia B B_DISEASE
were O O
determined O O
using O O
multivariate O O
logistic O O
regression O O
analysis O O
. O O

RESULTS O O
: O O
The O O
mean O O
age O O
was O O
65 O O
. O O
6 O O
+ O O
8 O O
. O O
5 O O
years O O
. O O

The O O
mean O O
onset O O
age O O
was O O
58 O O
. O O
5 O O
+ O O
9 O O
. O O
8 O O
years O O
. O O

The O O
median O O
disease O O
duration O O
was O O
6 O O
( O O
7 O O
) O O
years O O
. O O

Dyskinesia B B_DISEASE
was O O
present O O
in O O
44 O O
% O O
( O O
n O O
= O O
42 O O
) O O
with O O
median O O
levodopa O O
therapy O O
of O O
3 O O
years O O
. O O

There O O
were O O
64 O O
. O O
3 O O
% O O
Chinese O O
, O O
31 O O
% O O
Malays O O
, O O
and O O
3 O O
. O O
7 O O
% O O
Indians O O
and O O
other O O
ethnic O O
groups O O
. O O

Eighty O O
- O O
one O O
percent O O
of O O
patients O O
with O O
dyskinesia B B_DISEASE
had O O
clinical O O
fluctuations O O
. O O

Patients O O
with O O
dyskinesia B B_DISEASE
had O O
lower O O
onset O O
age O O
( O O
p O O
< O O
0 O O
. O O
001 O O
) O O
, O O
longer O O
duration O O
of O O
levodopa O O
therapy O O
( O O
p O O
< O O
0 O O
. O O
001 O O
) O O
, O O
longer O O
disease O O
duration O O
( O O
p O O
< O O
0 O O
. O O
001 O O
) O O
, O O
higher O O
total O O
daily O O
levodopa O O
dose O O
( O O
p O O
< O O
0 O O
. O O
001 O O
) O O
, O O
and O O
higher O O
total O O
UPDRS O O
scores O O
( O O
p O O
= O O
0 O O
. O O
005 O O
) O O
than O O
patients O O
without O O
dyskinesia B B_DISEASE
. O O

The O O
three O O
significant O O
predictors O O
of O O
dyskinesia B B_DISEASE
were O O
duration O O
of O O
levodopa O O
therapy O O
, O O
onset O O
age O O
, O O
and O O
total O O
daily O O
levodopa O O
dose O O
. O O

CONCLUSIONS O O
: O O
The O O
prevalence O O
of O O
levodopa O O
- O O
induced O O
dyskinesia B B_DISEASE
in O O
our O O
patients O O
was O O
44 O O
% O O
. O O

The O O
most O O
significant O O
predictors O O
were O O
duration O O
of O O
levodopa O O
therapy O O
, O O
total O O
daily O O
levodopa O O
dose O O
, O O
and O O
onset O O
age O O
. O O

Dose O O
- O O
dependent O O
neurotoxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
high O O
- O O
dose O O
busulfan O O
in O O
children O O
: O O
a O O
clinical O O
and O O
pharmacological O O
study O O
. O O

We O O
report O O
here O O
a O O
retrospective O O
study O O
of O O
123 O O
children O O
( O O
median O O
age O O
, O O
6 O O
. O O
5 O O
years O O
) O O
receiving O O
high O O
- O O
dose O O
busulfan O O
in O O
combined O O
chemotherapy O O
before O O
bone O O
marrow O O
transplantation O O
for O O
malignant O O
solid O O
tumors B B_DISEASE
, O O
brain B B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
tumors I B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
excluded O O
. O O

Busulfan O O
was O O
given O O
p O O
. O O
o O O
. O O
, O O
every O O
6 O O
hours O O
for O O
16 O O
doses O O
over O O
4 O O
days O O
. O O

Two O O
total O O
doses O O
were O O
consecutively O O
used O O
: O O
16 O O
mg O O
/ O O
kg O O
, O O
then O O
600 O O
mg O O
/ O O
m2 O O
. O O

The O O
dose O O
calculation O O
on O O
the O O
basis O O
of O O
body O O
surface O O
area O O
results O O
in O O
higher O O
doses O O
in O O
young O O
children O O
than O O
in O O
older O O
patients O O
( O O
16 O O
to O O
28 O O
mg O O
/ O O
kg O O
) O O
. O O

Ninety O O
- O O
six O O
patients O O
were O O
not O O
given O O
anticonvulsive O O
prophylaxis O O
; O O
7 O O
( O O
7 O O
. O O
5 O O
% O O
) O O
developed O O
seizures B B_DISEASE
during O O
the O O
4 O O
days O O
of O O
the O O
busulfan O O
course O O
or O O
within O O
24 O O
h O O
after O O
the O O
last O O
dosing O O
. O O

When O O
the O O
total O O
busulfan O O
dose O O
was O O
taken O O
into O O
account O O
, O O
there O O
was O O
a O O
significant O O
difference O O
in O O
terms O O
of O O
neurotoxicity B B_DISEASE
incidence O O
among O O
patients O O
under O O
16 O O
mg O O
/ O O
kg O O
( O O
1 O O
of O O
57 O O
, O O
1 O O
. O O
7 O O
% O O
) O O
and O O
patients O O
under O O
600 O O
mg O O
/ O O
m2 O O
( O O
6 O O
of O O
39 O O
, O O
15 O O
. O O
4 O O
% O O
) O O
( O O
P O O
less O O
than O O
0 O O
. O O
02 O O
) O O
. O O

Twenty O O
- O O
seven O O
patients O O
were O O
given O O
a O O
600 O O
- O O
mg O O
/ O O
m2 O O
busulfan O O
total O O
dose O O
with O O
continuous O O
i O O
. O O
v O O
. O O
infusion O O
of O O
clonazepam O O
; O O
none O O
had O O
any O O
neurological B B_DISEASE
symptoms I I_DISEASE
. O O

Busulfan O O
levels O O
were O O
measured O O
by O O
a O O
gas O O
chromatographic O O
- O O
mass O O
spectrometry O O
assay O O
in O O
the O O
plasma O O
and O O
cerebrospinal O O
fluid O O
of O O
9 O O
children O O
without O O
central B B_DISEASE
nervous I I_DISEASE
system I I_DISEASE
disease I I_DISEASE
under O O
600 O O
mg O O
/ O O
m2 O O
busulfan O O
with O O
clonazepam O O
: O O
busulfan O O
cerebrospinal O O
fluid O O
: O O
plasma O O
ratio O O
was O O
1 O O
. O O
39 O O
. O O

This O O
was O O
significantly O O
different O O
( O O
P O O
less O O
than O O
0 O O
. O O
02 O O
) O O
from O O
the O O
cerebrospinal O O
fluid O O
: O O
plasma O O
ratio O O
previously O O
defined O O
in O O
children O O
receiving O O
a O O
16 O O
- O O
mg O O
/ O O
kg O O
total O O
dose O O
of O O
busulfan O O
. O O

This O O
study O O
shows O O
that O O
busulfan O O
neurotoxicity B B_DISEASE
is O O
dose O O
- O O
dependent O O
in O O
children O O
and O O
efficiently O O
prevented O O
by O O
clonazepam O O
. O O

A O O
busulfan O O
dose O O
calculated O O
on O O
the O O
basis O O
of O O
body O O
surface O O
area O O
, O O
resulting O O
in O O
higher O O
doses O O
in O O
young O O
children O O
, O O
was O O
followed O O
by O O
increased O O
neurotoxicity B B_DISEASE
, O O
close O O
to O O
neurotoxicity B B_DISEASE/B_MEASURE
incidence O O
observed O O
in O O
adults O O
. O O

The O O
busulfan O O
dose O O
in O O
children O O
and O O
infants O O
undergoing O O
bone O O
marrow O O
transplantation O O
should O O
be O O
reconsidered O O
on O O
the O O
basis O O
of O O
pharmacokinetic O O
studies O O
. O O

An O O
unexpected O O
diagnosis O O
in O O
a O O
renal O O
- O O
transplant O O
patient O O
with O O
proteinuria B B_DISEASE
treated O O
with O O
everolimus O O
: O O
AL B B_DISEASE_ADJECTIVE[DISEASE]
amyloidosis B I_DISEASE_ADJECTIVE[DISEASE]
. O O

Proteinuria B B_DISEASE
is O O
an O O
expected O O
complication O O
in O O
transplant O O
patients O O
treated O O
with O O
mammalian O O
target O O
of O O
rapamycin O O
inhibitors O O
( O O
mTOR O O
- O O
i O O
) O O
. O O

However O O
, O O
clinical O O
suspicion O O
should O O
always O O
be O O
supported O O
by O O
histological O O
evidence O O
in O O
order O O
to O O
investigate O O
potential O O
alternate O O
diagnoses O O
such O O
as O O
acute O O
or O O
chronic O O
rejection O O
, O O
interstitial O O
fibrosis B B_DISEASE
and O O
tubular O O
atrophy B B_DISEASE
, O O
or O O
recurrent O O
or O O
de O O
novo O O
glomerulopathy B B_DISEASE
. O O

In O O
this O O
case O O
we O O
report O O
the O O
unexpected O O
diagnosis O O
of O O
amyloidosis B B_DISEASE
in O O
a O O
renal O O
- O O
transplant O O
patient O O
with O O
pre O O
- O O
transplant O O
monoclonal O O
gammapathy O O
of O O
undetermined O O
significance O O
who O O
developed O O
proteinuria B B_DISEASE
after O O
conversion O O
from O O
tacrolimus O O
to O O
everolimus O O
. O O

Long O O
- O O
term O O
oral O O
galactose O O
treatment O O
prevents O O
cognitive B B_DISEASE
deficits I I_DISEASE
in O O
male O O
Wistar O O
rats O O
treated O O
intracerebroventricularly O O
with O O
streptozotocin O O
. O O

Basic O O
and O O
clinical O O
research O O
has O O
demonstrated O O
that O O
dementia B B_DISEASE
of O O
sporadic O O
Alzheimer B B_DISEASE/B_MEASURE
' I I_DISEASE/I_MEASURE
s I I_DISEASE/I_MEASURE
disease I I_DISEASE/I_MEASURE
( O O
sAD O O
) O O
type O O
is O O
associated O O
with O O
dysfunction O O
of O O
the O O
insulin O O
- O O
receptor O O
( O O
IR O O
) O O
system O O
followed O O
by O O
decreased O O
glucose O O
transport O O
via O O
glucose O O
transporter O O
GLUT4 O O
and O O
decreased O O
glucose O O
metabolism O O
in O O
brain O O
cells O O
. O O

An O O
alternative O O
source O O
of O O
energy O O
is O O
d O O
- O O
galactose O O
( O O
the O O
C O O
- O O
4 O O
- O O
epimer O O
of O O
d O O
- O O
glucose O O
) O O
which O O
is O O
transported O O
into O O
the O O
brain O O
by O O
insulin O O
- O O
independent O O
GLUT3 O O
transporter O O
where O O
it O O
might O O
be O O
metabolized O O
to O O
glucose O O
via O O
the O O
Leloir O O
pathway O O
. O O

Exclusively O O
parenteral O O
daily O O
injections O O
of O O
galactose O O
induce O O
memory B B_DISEASE
deterioration I I_DISEASE
in O O
rodents O O
and O O
are O O
used O O
to O O
generate O O
animal O O
aging O O
model O O
, O O
but O O
the O O
effects O O
of O O
oral O O
galactose O O
treatment O O
on O O
cognitive O O
functions O O
have O O
never O O
been O O
tested O O
. O O

We O O
have O O
investigated O O
the O O
effects O O
of O O
continuous O O
daily O O
oral O O
galactose O O
( O O
200 O O
mg O O
/ O O
kg O O
/ O O
day O O
) O O
treatment O O
on O O
cognitive B B_DISEASE_ADJECTIVE[DISEASE]
deficits I I_DISEASE_ADJECTIVE[DISEASE]
in O O
streptozotocin O O
- O O
induced O O
( O O
STZ O O
- O O
icv O O
) O O
rat O O
model O O
of O O
sAD O O
, O O
tested O O
by O O
Morris O O
Water O O
Maze O O
and O O
Passive O O
Avoidance O O
test O O
, O O
respectively O O
. O O

One O O
month O O
of O O
oral O O
galactose O O
treatment O O
initiated O O
immediately O O
after O O
the O O
STZ O O
- O O
icv O O
administration O O
, O O
successfully O O
prevented O O
development O O
of O O
the O O
STZ O O
- O O
icv O O
- O O
induced O O
cognitive B B_DISEASE
deficits I I_DISEASE
. O O

Beneficial O O
effect O O
of O O
oral O O
galactose O O
was O O
independent O O
of O O
the O O
rat O O
age O O
and O O
of O O
the O O
galactose O O
dose O O
ranging O O
from O O
100 O O
to O O
300 O O
mg O O
/ O O
kg O O
/ O O
day O O
. O O

The O O
increase O O
of O O
galactose O O
concentration O O
in O O
the O O
cerebrospinal O O
fluid O O
was O O
several O O
times O O
lower O O
after O O
oral O O
than O O
after O O
parenteral O O
administration O O
of O O
the O O
same O O
galactose O O
dose O O
. O O

Oral O O
galactose O O
exposure O O
might O O
have O O
beneficial O O
effects O O
on O O
learning O O
and O O
memory O O
ability O O
and O O
could O O
be O O
worth O O
investigating O O
for O O
improvement O O
of O O
cognitive B B_DISEASE_ADJECTIVE[DISEASE]
deficits I I_DISEASE_ADJECTIVE[DISEASE]
associated O O
with O O
glucose B B_DISEASE/B_LOCATION
hypometabolism I I_DISEASE/I_LOCATION
in O O
AD B B_DISEASE/B_LOCATION
. O O

An O O
investigation O O
of O O
the O O
pattern O O
of O O
kidney B B_DISEASE
injury I I_DISEASE
in O O
HIV O O
- O O
positive O O
persons O O
exposed O O
to O O
tenofovir O O
disoproxil O O
fumarate O O
: O O
an O O
examination O O
of O O
a O O
large O O
population O O
database O O
( O O
MHRA O O
database O O
) O O
. O O

The O O
potential O O
for O O
tenofovir O O
to O O
cause O O
a O O
range O O
of O O
kidney O O
syndromes O O
has O O
been O O
established O O
from O O
mechanistic O O
and O O
randomised O O
clinical O O
trials O O
. O O

However O O
, O O
the O O
exact O O
pattern O O
of O O
kidney O O
involvement O O
is O O
still O O
uncertain O O
. O O

Reports O O
that O O
satisfy O O
defined O O
criteria O O
were O O
classified O O
as O O
acute B B_DISEASE
kidney I I_DISEASE
injury I I_DISEASE
, O O
kidney B B_DISEASE
tubular I I_DISEASE
dysfunction I I_DISEASE
and O O
Fanconi B B_DISEASE/B_PERSON
syndrome I I_DISEASE/I_PERSON
. O O

Of O O
the O O
407 O O
Yellow O O
Card O O
records O O
analysed O O
, O O
106 O O
satisfied O O
criteria O O
for O O
TDF O O
- O O
related O O
kidney B B_DISEASE_ADJECTIVE[DISEASE]
disease I I_DISEASE_ADJECTIVE[DISEASE]
, O O
of O O
which O O
53 O O
( O O
50 O O
% O O
) O O
had O O
features O O
of O O
kidney B B_DISEASE
tubular I I_DISEASE
dysfunction I I_DISEASE
, O O
35 O O
( O O
33 O O
% O O
) O O
were O O
found O O
to O O
have O O
features O O
of O O
glomerular B B_DISEASE
dysfunction I I_DISEASE
and O O
18 O O
( O O
17 O O
% O O
) O O
had O O
Fanconi B B_DISEASE/B_LOCATION
syndrome I I_DISEASE/I_LOCATION
. O O

The O O
median O O
TDF O O
exposure O O
was O O
316 O O
days O O
( O O
interquartile O O
range O O
120 O O
- O O
740 O O
) O O
. O O

The O O
incidence O O
of O O
hospitalisation O O
for O O
TDF O O
kidney O O
adverse O O
effects O O
was O O
high O O
, O O
particularly O O
amongst O O
patients O O
with O O
features O O
of O O
Fanconi B B_DISEASE/B_GENE
syndrome I I_DISEASE/I_GENE
. O O

The O O
pattern O O
of O O
kidney O O
syndromes O O
in O O
this O O
population O O
series O O
mirrors O O
that O O
reported O O
in O O
randomised O O
clinical O O
trials O O
. O O

Incidence O O
of O O
postoperative B B_DISEASE/B_LOCATION
delirium I I_DISEASE/I_LOCATION
is O O
high O O
even O O
in O O
a O O
population O O
without O O
known O O
risk O O
factors O O
. O O

PURPOSE O O
: O O
Postoperative B B_DISEASE/B_GENE
delirium I I_DISEASE/I_GENE
is O O
a O O
recognized O O
complication O O
in O O
populations O O
at O O
risk O O
. O O

The O O
aim O O
of O O
this O O
study O O
is O O
to O O
assess O O
the O O
prevalence O O
of O O
early O O
postoperative B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
delirium I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
a O O
population O O
without O O
known O O
risk O O
factors O O
admitted O O
to O O
the O O
ICU O O
for O O
postoperative O O
monitoring O O
after O O
elective O O
major O O
surgery O O
. O O

The O O
secondary O O
outcome O O
investigated O O
is O O
to O O
identify O O
eventual O O
independent O O
risk O O
factors O O
among O O
demographic O O
data O O
and O O
anesthetic O O
drugs O O
used O O
. O O

METHODS O O
: O O
An O O
observational O O
, O O
prospective O O
study O O
was O O
conducted O O
on O O
a O O
consecutive O O
cohort O O
of O O
patients O O
admitted O O
to O O
our O O
ICU O O
within O O
and O O
for O O
at O O
least O O
24 O O
h O O
after O O
major O O
surgical O O
procedures O O
. O O

Exclusion O O
criteria O O
were O O
any O O
preexisting O O
predisposing O O
factor O O
for O O
delirium B B_DISEASE
or O O
other O O
potentially O O
confounding O O
neurological B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dysfunctions I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Patients O O
were O O
assessed O O
daily O O
using O O
the O O
confusion B B_DISEASE/B_MEASURE
assessment O O
method O O
for O O
the O O
ICU O O
scale O O
for O O
3 O O
days O O
after O O
the O O
surgical O O
procedure O O
. O O

Early O O
postoperative B B_DISEASE/B_ORGANISM_FUNCTION
delirium I I_DISEASE/I_ORGANISM_FUNCTION
incidence O O
risk O O
factors O O
were O O
then O O
assessed O O
through O O
three O O
different O O
multiple O O
regression O O
models O O
. O O

RESULTS O O
: O O
According O O
to O O
the O O
confusion O O
assessment O O
method O O
for O O
the O O
ICU O O
scale O O
, O O
28 O O
% O O
of O O
patients O O
were O O
diagnosed O O
with O O
early O O
postoperative B B_DISEASE
delirium I I_DISEASE
. O O

The O O
use O O
of O O
thiopentone O O
was O O
significantly O O
associated O O
with O O
an O O
eight O O
- O O
fold O O
- O O
higher O O
risk O O
for O O
delirium B B_DISEASE
compared O O
to O O
propofol O O
( O O
57 O O
. O O
1 O O
% O O
vs O O
. O O
7 O O
. O O
1 O O
% O O
, O O
RR O O
= O O
8 O O
. O O
0 O O
, O O
X2 O O
= O O
4 O O
. O O
256 O O
; O O
df O O
= O O
1 O O
; O O
0 O O
. O O
05 O O
< O O
p O O
< O O
0 O O
. O O
02 O O
) O O
. O O

CONCLUSION O O
: O O
In O O
this O O
study O O
early O O
postoperative B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
delirium I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
found O O
to O O
be O O
a O O
very O O
common O O
complication O O
after O O
major O O
surgery O O
, O O
even O O
in O O
a O O
population O O
without O O
known O O
risk O O
factors O O
. O O

A O O
single O O
neurotoxic B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose O O
of O O
methamphetamine O O
induces O O
a O O
long O O
- O O
lasting O O
depressive B B_DISEASE
- O O
like O O
behaviour O O
in O O
mice O O
. O O

Methamphetamine O O
( O O
METH O O
) O O
triggers O O
a O O
disruption O O
of O O
the O O
monoaminergic O O
system O O
and O O
METH O O
abuse O O
leads O O
to O O
negative O O
emotional O O
states O O
including O O
depressive B B_DISEASE
symptoms I I_DISEASE
during O O
drug O O
withdrawal O O
. O O

However O O
, O O
it O O
is O O
currently O O
unknown O O
if O O
the O O
acute O O
toxic O O
dosage O O
of O O
METH O O
also O O
causes O O
a O O
long O O
- O O
lasting O O
depressive B B_DISEASE
phenotype O O
and O O
persistent O O
monoaminergic O O
deficits O O
. O O

Thus O O
, O O
we O O
now O O
assessed O O
the O O
depressive B B_DISEASE
- O O
like O O
behaviour O O
in O O
mice O O
at O O
early O O
and O O
long O O
- O O
term O O
periods O O
following O O
a O O
single O O
high O O
METH O O
dose O O
( O O
30 O O
mg O O
/ O O
kg O O
, O O
i O O
. O O
p O O
. O O
) O O
. O O

METH O O
did O O
not O O
alter O O
the O O
motor O O
function O O
and O O
procedural O O
memory O O
of O O
mice O O
as O O
assessed O O
by O O
swimming O O
speed O O
and O O
escape O O
latency O O
to O O
find O O
the O O
platform O O
in O O
a O O
cued O O
version O O
of O O
the O O
water O O
maze O O
task O O
. O O

This O O
depressive B B_DISEASE
- O O
like O O
profile O O
induced O O
by O O
METH O O
was O O
accompanied O O
by O O
a O O
marked O O
depletion O O
of O O
frontostriatal O O
dopaminergic O O
and O O
serotonergic O O
neurotransmission O O
, O O
indicated O O
by O O
a O O
reduction O O
in O O
the O O
levels O O
of O O
dopamine O O
, O O
DOPAC O O
and O O
HVA O O
, O O
tyrosine O O
hydroxylase O O
and O O
serotonin O O
, O O
observed O O
at O O
both O O
3 O O
and O O
49 O O
days O O
post O O
- O O
administration O O
. O O

In O O
parallel O O
, O O
another O O
neurochemical O O
feature O O
of O O
depression B B_DISEASE
- O O
- O O
astroglial O O
dysfunction O O
- O O
- O O
was O O
unaffected O O
in O O
the O O
cortex O O
and O O
the O O
striatal O O
levels O O
of O O
the O O
astrocytic O O
protein O O
marker O O
, O O
glial O O
fibrillary O O
acidic O O
protein O O
, O O
were O O
only O O
transiently O O
increased O O
at O O
3 O O
days O O
. O O

These O O
findings O O
demonstrate O O
for O O
the O O
first O O
time O O
that O O
a O O
single O O
high O O
dose O O
of O O
METH O O
induces O O
long O O
- O O
lasting O O
depressive B B_DISEASE
- O O
like O O
behaviour O O
in O O
mice O O
associated O O
with O O
a O O
persistent O O
disruption O O
of O O
frontostriatal O O
dopaminergic O O
and O O
serotonergic O O
homoeostasis O O
. O O

Linezolid O O
- O O
induced O O
optic B B_DISEASE
neuropathy I I_DISEASE
. O O

We O O
describe O O
a O O
case O O
of O O
progressive O O
loss B B_DISEASE
of I I_DISEASE
vision I I_DISEASE
associated O O
with O O
linezolid O O
therapy O O
. O O

A O O
45 O O
- O O
year O O
- O O
old O O
male O O
patient O O
who O O
was O O
on O O
treatment O O
with O O
multiple O O
second O O
- O O
line O O
anti O O
- O O
tuberculous O O
drugs O O
including O O
linezolid O O
and O O
ethambutol O O
for O O
extensively B B_DISEASE
drug I I_DISEASE
- I I_DISEASE
resistant I I_DISEASE
tuberculosis I I_DISEASE
( O O
XDR B B_DISEASE
- I I_DISEASE
TB I I_DISEASE
) O O
presented O O
to O O
us O O
with O O
painless O O
progressive O O
loss B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
of I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
vision I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
both O O
eyes O O
. O O

Color O O
vision O O
was O O
defective O O
and O O
fundus O O
examination O O
revealed O O
optic B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
disc I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
edema I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
both O O
eyes O O
. O O

Ethambutol O O
- O O
induced O O
toxic B B_DISEASE
optic I I_DISEASE
neuropathy I I_DISEASE
was O O
suspected O O
and O O
tablet O O
ethambutol O O
was O O
withdrawn O O
. O O

Deterioration B B_DISEASE/B_PERSON
of I I_DISEASE/I_PERSON
vision I I_DISEASE/I_PERSON
occurred O O
despite O O
withdrawal O O
of O O
ethambutol O O
. O O

Resuscitation O O
with O O
lipid O O
, O O
epinephrine O O
, O O
or O O
both O O
in O O
levobupivacaine O O
- O O
induced O O
cardiac B B_DISEASE
toxicity I I_DISEASE
in O O
newborn O O
piglets O O
. O O

BACKGROUND O O
: O O
The O O
optimal O O
dosing O O
regimens O O
of O O
lipid O O
emulsion O O
, O O
epinephrine O O
, O O
or O O
both O O
are O O
not O O
yet O O
determined O O
in O O
neonates O O
in O O
cases O O
of O O
local O O
anaesthetic O O
systemic O O
toxicity B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O O
LAST O O
) O O
. O O

METHODS O O
: O O
Newborn O O
piglets O O
received O O
levobupivacaine O O
until O O
cardiovascular B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
collapse I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occurred O O
. O O

Standard O O
cardiopulmonary O O
resuscitation O O
was O O
started O O
and O O
electrocardiogram O O
( O O
ECG O O
) O O
was O O
monitored O O
for O O
ventricular B B_DISEASE
tachycardia I I_DISEASE
, O O
fibrillation B B_DISEASE
, O O
or O O
QRS O O
prolongation O O
. O O

Piglets O O
were O O
then O O
randomly O O
allocated O O
to O O
four O O
groups O O
: O O
control O O
( O O
saline O O
) O O
, O O
Intralipid O O
( O O
) O O
alone O O
, O O
epinephrine O O
alone O O
, O O
or O O
a O O
combination O O
of O O
Intralipd O O
plus O O
epinephrine O O
. O O

RESULTS O O
: O O
ROSC O O
was O O
achieved O O
in O O
only O O
one O O
of O O
the O O
control O O
piglets O O
compared O O
with O O
most O O
of O O
the O O
treated O O
piglets O O
. O O

CONCLUSIONS O O
: O O
Lipid O O
emulsion O O
with O O
or O O
without O O
epinephrine O O
, O O
or O O
epinephrine O O
alone O O
were O O
equally O O
effective O O
in O O
achieving O O
a O O
return O O
to O O
spontaneous O O
circulation O O
in O O
this O O
model O O
of O O
LAST O O
. O O

Incidence O O
of O O
heparin O O
- O O
induced O O
thrombocytopenia B B_DISEASE
type I I_DISEASE
II I I_DISEASE
and O O
postoperative O O
recovery O O
of O O
platelet O O
count O O
in O O
liver O O
graft O O
recipients O O
: O O
a O O
retrospective O O
cohort O O
analysis O O
. O O

BACKGROUND O O
: O O
Thrombocytopenia B B_DISEASE
in O O
patients O O
with O O
end B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
stage I I_DISEASE/I_GENE
liver I I_DISEASE/I_GENE
disease I I_DISEASE/I_GENE
is O O
a O O
common O O
disorder O O
caused O O
mainly O O
by O O
portal B B_DISEASE
hypertension I I_DISEASE
, O O
low O O
levels O O
of O O
thrombopoetin O O
, O O
and O O
endotoxemia B B_DISEASE
. O O

The O O
impact O O
of O O
immune O O
- O O
mediated O O
heparin O O
- O O
induced O O
thrombocytopenia B B_DISEASE
type I I_DISEASE
II I I_DISEASE
( O O
HIT B B_DISEASE/B_GENE
type I B_DISEASE/I_GENE
II I B_DISEASE/I_GENE
) O O
as O O
a O O
cause O O
of O O
thrombocytopenia B B_DISEASE
after O O
liver O O
transplantation O O
is O O
not O O
yet O O
understood O O
, O O
with O O
few O O
literature O O
citations O O
reporting O O
contradictory O O
results O O
. O O

The O O
aim O O
of O O
our O O
study O O
was O O
to O O
demonstrate O O
the O O
perioperative O O
course O O
of O O
thrombocytopenia B B_DISEASE
after O O
liver O O
transplantation O O
and O O
determine O O
the O O
occurrence O O
of O O
clinical O O
HIT B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
type I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

METHOD O O
: O O
We O O
retrospectively O O
evaluated O O
the O O
medical O O
records O O
of O O
205 O O
consecutive O O
adult O O
patients O O
who O O
underwent O O
full O O
- O O
size O O
liver O O
transplantation O O
between O O
January O O
2006 O O
and O O
December O O
2010 O O
due O O
to O O
end B B_DISEASE
- I I_DISEASE
stage I I_DISEASE
or I I_DISEASE
malignant I I_DISEASE
liver I I_DISEASE
disease I I_DISEASE
. O O

Preoperative O O
platelet O O
count O O
, O O
postoperative O O
course O O
of O O
platelets O O
, O O
and O O
clinical O O
signs O O
of O O
HIT B B_DISEASE
type I I_DISEASE
II I I_DISEASE
were O O
analyzed O O
. O O

RESULTS O O
: O O
A O O
total O O
of O O
155 O O
( O O
75 O O
. O O
6 O O
% O O
) O O
of O O
205 O O
patients O O
had O O
thrombocytopenia B B_DISEASE
before O O
transplantation O O
, O O
significantly O O
influenced O O
by O O
Model O O
of O O
End B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
Stage I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
Liver I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
Disease I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
score O O
and O O
liver B B_DISEASE_ADJECTIVE[DISEASE]
cirrhosis I I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
platelet O O
count O O
exceeded O O
100 O O
, O O
000 O O
/ O O
uL O O
in O O
most O O
of O O
the O O
patients O O
( O O
n O O
= O O
193 O O
) O O
at O O
a O O
medium O O
of O O
7 O O
d O O
. O O

Regarding O O
HIT B B_DISEASE/B_PERSON
II I I_DISEASE/I_PERSON
, O O
there O O
were O O
four O O
( O O
1 O O
. O O
95 O O
% O O
) O O
patients O O
with O O
a O O
background O O
of O O
HIT B B_DISEASE
type I I_DISEASE
II I I_DISEASE
. O O

CONCLUSIONS O O
: O O
The O O
incidence O O
of O O
HIT B B_DISEASE/B_GENE
in O O
patients O O
with O O
end B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
stage I I_DISEASE/I_GENE
hepatic I I_DISEASE/I_GENE
failure I I_DISEASE/I_GENE
is O O
, O O
with O O
about O O
1 O O
. O O
95 O O
% O O
, O O
rare O O
. O O

For O O
further O O
reduction O O
of O O
HIT B B_DISEASE_ADJECTIVE[DISEASE]
type I I_DISEASE_ADJECTIVE[DISEASE]
II I I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
use O O
of O O
intravenous O O
heparin O O
should O O
be O O
avoided O O
and O O
the O O
prophylactic O O
anticoagulation O O
should O O
be O O
performed O O
with O O
low O O
- O O
molecular O O
- O O
weight O O
heparin O O
after O O
normalization O O
of O O
platelet O O
count O O
. O O

Takotsubo B B_DISEASE
syndrome I I_DISEASE
( O O
or O O
apical B B_DISEASE
ballooning I I_DISEASE
syndrome I I_DISEASE
) O O
secondary O O
to O O
Zolmitriptan O O
. O O

We O O
report O O
a O O
case O O
of O O
54 O O
- O O
year O O
- O O
old O O
woman O O
with O O
medical O O
history O O
of O O
mitral B B_DISEASE
valve I I_DISEASE
prolapse I I_DISEASE
and O O
migraines B B_DISEASE/B_LOCATION
, O O
who O O
was O O
admitted O O
to O O
the O O
hospital O O
for O O
substernal O O
chest B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pain I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
electrocardiogram O O
demonstrated O O
1 O O
/ O O
2 O O
mm O O
ST O O
- O O
segment O O
elevation O O
in O O
leads O O
II O O
, O O
III O O
, O O
aVF O O
, O O
V5 O O
, O O
and O O
V6 O O
and O O
positive O O
troponin O O
I O O
. O O

Emergent O O
coronary O O
angiogram O O
revealed O O
normal O O
coronary O O
arteries O O
with O O
moderately O O
reduced O O
left O O
ventricular O O
ejection O O
fraction O O
with O O
wall O O
motion O O
abnormalities O O
consistent O O
with O O
TS B B_DISEASE
. O O

Detailed O O
history O O
obtained O O
retrospectively O O
revealed O O
that O O
the O O
patient O O
took O O
zolmitriptan O O
sparingly O O
only O O
when O O
she O O
had O O
migraines B B_DISEASE
. O O

But O O
before O O
this O O
event O O
, O O
she O O
was O O
taking O O
zolmitriptan O O
2 O O
- O O
3 O O
times O O
daily O O
for O O
several O O
days O O
because O O
of O O
a O O
persistent O O
migraine B B_DISEASE
headache I I_DISEASE
. O O

She O O
otherwise O O
reported O O
that O O
she O O
is O O
quite O O
active O O
, O O
rides O O
horses O O
, O O
and O O
does O O
show O O
jumping O O
without O O
any O O
limitations O O
in O O
her O O
physical O O
activity O O
. O O

There O O
was O O
no O O
evidence O O
of O O
any O O
recent O O
stress O O
or O O
status B B_DISEASE
migrainosus I I_DISEASE
. O O

Extensive O O
literature O O
search O O
revealed O O
multiple O O
cases O O
of O O
coronary B B_DISEASE
artery I I_DISEASE
vasospasm I I_DISEASE
secondary O O
to O O
zolmitriptan O O
, O O
but O O
none O O
of O O
the O O
cases O O
were O O
associated O O
with O O
TS B B_DISEASE
. O O

Depression B B_DISEASE
, O O
impulsiveness B B_DISEASE
, O O
sleep O O
, O O
and O O
memory O O
in O O
past O O
and O O
present O O
polydrug O O
users O O
of O O
3 O O
, O O
4 O O
- O O
methylenedioxymethamphetamine O O
( O O
MDMA O O
, O O
ecstasy O O
) O O
. O O

Unfortunately O O
, O O
the O O
results O O
from O O
human O O
research O O
investigating O O
its O O
psychological O O
effects O O
have O O
been O O
inconsistent O O
. O O

OBJECTIVES O O
: O O
The O O
present O O
study O O
aimed O O
to O O
be O O
the O O
largest O O
to O O
date O O
in O O
sample O O
size O O
and O O
5HT O O
- O O
related O O
behaviors O O
; O O
the O O
first O O
to O O
compare O O
present O O
ecstasy O O
users O O
with O O
past O O
users O O
after O O
an O O
abstinence O O
of O O
4 O O
or O O
more O O
years O O
, O O
and O O
the O O
first O O
to O O
include O O
robust O O
controls O O
for O O
other O O
recreational O O
substances O O
. O O

Participants O O
completed O O
a O O
drug O O
history O O
questionnaire O O
, O O
Beck O O
Depression B B_DISEASE
Inventory O O
, O O
Barratt O O
Impulsiveness B B_DISEASE_ADJECTIVE[DISEASE]
Scale O O
, O O
Pittsburgh O O
Sleep O O
Quality O O
Index O O
, O O
and O O
Wechsler O O
Memory O O
Scale O O
- O O
Revised O O
which O O
, O O
in O O
total O O
, O O
provided O O
13 O O
psychometric O O
measures O O
. O O

Compared O O
with O O
present O O
ecstasy O O
users O O
, O O
the O O
past O O
users O O
showed O O
no O O
change O O
for O O
ten O O
measures O O
, O O
increased O O
impairment O O
for O O
two O O
measures O O
, O O
and O O
improvement O O
on O O
just O O
one O O
measure O O
. O O

CONCLUSIONS O O
: O O
Given O O
this O O
record O O
of O O
impaired B B_DISEASE_ADJECTIVE[DISEASE]
memory I I_DISEASE_ADJECTIVE[DISEASE]
and O O
clinically O O
significant O O
levels O O
of O O
depression B B_DISEASE
, O O
impulsiveness B B_DISEASE
, O O
and O O
sleep B B_DISEASE_ADJECTIVE[DISEASE]
disturbance I I_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
prognosis O O
for O O
the O O
current O O
generation O O
of O O
ecstasy O O
users O O
is O O
a O O
major O O
cause O O
for O O
concern O O
. O O

Association O O
of O O
common O O
genetic O O
variants O O
of O O
HOMER1 O O
gene O O
with O O
levodopa O O
adverse O O
effects O O
in O O
Parkinson B B_DISEASE/B_LOCATION
' I I_DISEASE/I_LOCATION
s I I_DISEASE/I_LOCATION
disease I I_DISEASE/I_LOCATION
patients O O
. O O

Levodopa O O
is O O
the O O
most O O
effective O O
symptomatic O O
therapy O O
for O O
Parkinson B B_DISEASE
' I I_DISEASE
s I I_DISEASE
disease I I_DISEASE
, O O
but O O
its O O
chronic O O
use O O
could O O
lead O O
to O O
chronic O O
adverse O O
outcomes O O
, O O
such O O
as O O
motor O O
fluctuations O O
, O O
dyskinesia B B_DISEASE
and O O
visual B B_DISEASE
hallucinations I I_DISEASE
. O O

A O O
total O O
of O O
205 O O
patients O O
with O O
idiopathic B B_DISEASE/B_LOCATION
Parkinson I I_DISEASE/I_LOCATION
' I I_DISEASE/I_LOCATION
s I I_DISEASE/I_LOCATION
disease I I_DISEASE/I_LOCATION
were O O
investigated O O
. O O

Patients O O
were O O
genotyped O O
for O O
rs4704559 O O
, O O
rs10942891 O O
and O O
rs4704560 O O
by O O
allelic O O
discrimination O O
with O O
Taqman O O
assays O O
. O O

The O O
rs4704559 O O
G O O
allele O O
was O O
associated O O
with O O
a O O
lower O O
prevalence O O
of O O
dyskinesia B B_DISEASE
( O O
prevalence O O
ratio O O
( O O
PR O O
) O O
= O O
0 O O
. O O
615 O O
, O O
95 O O
% O O
confidence O O
interval O O
( O O
CI O O
) O O
0 O O
. O O
426 O O
- O O
0 O O
. O O
887 O O
, O O
P O O
= O O
0 O O
. O O
009 O O
) O O
and O O
visual B B_DISEASE
hallucinations I I_DISEASE
( O O
PR O O
= O O
0 O O
. O O
515 O O
, O O
95 O O
% O O
CI O O
0 O O
. O O
295 O O
- O O
0 O O
. O O
899 O O
, O O
P O O
= O O
0 O O
. O O
020 O O
) O O
. O O

INTRODUCTION O O
: O O
Diazinon O O
Yis O O
one O O
of O O
the O O
most O O
broadly O O
used O O
organophosphorus O O
insecticides O O
in O O
agriculture O O
. O O

It O O
has O O
been O O
shown O O
that O O
exposure O O
to O O
diazinon O O
may O O
interfere O O
with O O
lipid O O
metabolism O O
. O O

Moreover O O
, O O
the O O
hypolipidemic O O
effect O O
of O O
crocin O O
has O O
been O O
established O O
. O O

Earlier O O
studies O O
revealed O O
the O O
major O O
role O O
of O O
Extracellular O O
signal O O
- O O
regulated O O
kinase O O
( O O
ERK O O
) O O
pathways O O
in O O
low O O
- O O
density O O
lipoprotein O O
receptor O O
( O O
LDLr O O
) O O
expression O O
. O O

The O O
levels O O
of O O
cholesterol O O
, O O
triglyceride O O
and O O
LDL O O
in O O
blood O O
of O O
rats O O
were O O
analyzed O O
. O O

RESULTS O O
: O O
Our O O
data O O
showed O O
that O O
subacute O O
exposure O O
to O O
diazinon O O
significantly O O
increased O O
concentrations O O
of O O
cholesterol O O
, O O
triglyceride O O
and O O
LDL O O
. O O

Moreover O O
diazinon O O
decreased O O
ERK1 O O
/ O O
2 O O
protein O O
phosphorylation O O
and O O
LDLr O O
transcript O O
. O O

Crocin O O
reduced O O
inhibition O O
of O O
ERK O O
activation O O
and O O
diazinon O O
- O O
induced O O
hyperlipemia B B_DISEASE/B_GENE
and O O
increased O O
levels O O
of O O
LDLr O O
transcript O O
. O O

CONCLUSIONS O O
: O O
Crocin O O
may O O
be O O
considered O O
as O O
a O O
novel O O
protective O O
agent O O
in O O
diazinon O O
- O O
induced O O
hyperlipemia B B_DISEASE/B_GENE
through O O
modulating O O
of O O
ERK O O
pathway O O
and O O
increase O O
of O O
LDLr O O
expression O O
. O O

GEM O O
- O O
P O O
chemotherapy O O
is O O
active O O
in O O
the O O
treatment O O
of O O
relapsed O O
Hodgkin B B_DISEASE/B_GENE
lymphoma I I_DISEASE/I_GENE
. O O

Hodgkin B B_DISEASE
lymphoma I I_DISEASE
( O O
HL B B_PROTEIN[GENE]/B_DISEASE
) O O
is O O
a O O
relatively O O
chemosensitive O O
malignancy B B_DISEASE/B_MEASURE
. O O

However O O
, O O
for O O
those O O
who O O
relapse O O
, O O
high O O
- O O
dose O O
chemotherapy O O
with O O
autologous O O
stem O O
cell O O
transplant O O
is O O
the O O
treatment O O
of O O
choice O O
which O O
relies O O
on O O
adequate O O
disease O O
control O O
with O O
salvage O O
chemotherapy O O
. O O

Regimens O O
commonly O O
used O O
often O O
require O O
inpatient O O
administration O O
and O O
can O O
be O O
difficult O O
to O O
deliver O O
due O O
to O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Gemcitabine O O
and O O
cisplatin O O
have O O
activity O O
in O O
HL B B_DISEASE
, O O
non O O
- O O
overlapping O O
toxicity B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
first O O
- O O
line O O
chemotherapeutics O O
, O O
and O O
may O O
be O O
delivered O O
in O O
an O O
outpatient O O
setting O O
. O O

In O O
this O O
retrospective O O
single O O
- O O
centre O O
analysis O O
, O O
patients O O
with O O
relapsed O O
or O O
refractory O O
HL B B_DISEASE/B_GENE
treated O O
with O O
gemcitabine O O
1 O O
, O O
000 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
day O O
( O O
D O O
) O O
1 O O
, O O
D8 O O
and O O
D15 O O
; O O
methylprednisolone O O
1 O O
, O O
000 O O
mg O O
D1 O O
- O O
5 O O
; O O
and O O
cisplatin O O
100 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
D15 O O
, O O
every O O
28 O O
days O O
( O O
GEM O O
- O O
P O O
) O O
were O O
included O O
. O O

Demographic O O
, O O
survival O O
, O O
response O O
and O O
toxicity B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data O O
were O O
recorded O O
. O O

Forty O O
- O O
one O O
eligible O O
patients O O
were O O
identified O O
: O O
median O O
age O O
27 O O
. O O

One O O
hundred O O
and O O
twenty O O
- O O
two O O
cycles O O
of O O
GEM O O
- O O
P O O
were O O
administered O O
in O O
total O O
( O O
median O O
3 O O
cycles O O
; O O
range O O
1 O O
- O O
6 O O
) O O
. O O

Twenty O O
of O O
41 O O
( O O
48 O O
% O O
) O O
patients O O
received O O
GEM O O
- O O
P O O
as O O
second O O
- O O
line O O
treatment O O
and O O
11 O O
/ O O
41 O O
( O O
27 O O
% O O
) O O
as O O
third O O
- O O
line O O
therapy O O
. O O

The O O
most O O
common O O
grade O O
3 O O
/ O O
4 O O
toxicities B B_DISEASE
were O O
haematological O O
: O O
neutropenia B B_DISEASE
54 O O
% O O
and O O
thrombocytopenia B B_DISEASE
51 O O
% O O
. O O

Median O O
follow O O
- O O
up O O
from O O
the O O
start O O
of O O
GEM O O
- O O
P O O
was O O
4 O O
. O O
5 O O
years O O
. O O

Fourteen O O
of O O
41 O O
patients O O
proceeded O O
directly O O
to O O
autologous O O
transplant O O
. O O

GEM O O
- O O
P O O
is O O
a O O
salvage O O
chemotherapy O O
with O O
relatively O O
high O O
response O O
rates O O
, O O
leading O O
to O O
successful O O
transplantation O O
in O O
appropriate O O
patients O O
, O O
in O O
the O O
treatment O O
of O O
relapsed O O
or O O
refractory O O
HL B B_DISEASE/B_PERSON
. O O

Basal O O
functioning O O
of O O
the O O
hypothalamic O O
- O O
pituitary O O
- O O
adrenal O O
( O O
HPA O O
) O O
axis O O
and O O
psychological O O
distress O O
in O O
recreational O O
ecstasy O O
polydrug O O
users O O
. O O

RATIONALE O O
: O O
Ecstasy O O
( O O
MDMA O O
) O O
is O O
a O O
psychostimulant O O
drug O O
which O O
is O O
increasingly O O
associated O O
with O O
psychobiological B B_DISEASE
dysfunction I I_DISEASE
. O O

METHOD O O
: O O
Seventy O O
- O O
six O O
participants O O
( O O
21 O O
nonusers O O
, O O
29 O O
light O O
ecstasy O O
- O O
polydrug O O
users O O
, O O
26 O O
heavy O O
ecstasy O O
- O O
polydrug O O
users O O
) O O
completed O O
a O O
substance O O
use O O
inventory O O
and O O
measures O O
of O O
psychological O O
distress O O
at O O
baseline O O
, O O
then O O
two O O
consecutive O O
days O O
of O O
cortisol O O
sampling O O
( O O
on O O
awakening O O
, O O
30 O O
min O O
post O O
awakening O O
, O O
between O O
1400 O O
and O O
1600 O O
hours O O
and O O
pre O O
bedtime O O
) O O
. O O

On O O
day O O
2 O O
, O O
participants O O
also O O
attended O O
the O O
laboratory O O
to O O
complete O O
a O O
20 O O
- O O
min O O
multitasking O O
stressor O O
. O O

RESULTS O O
: O O
Both O O
user O O
groups O O
exhibited O O
significantly O O
greater O O
levels O O
of O O
anxiety B B_DISEASE
and O O
depression B B_DISEASE
than O O
nonusers O O
. O O

CONCLUSIONS O O
: O O
The O O
increases O O
in O O
anxiety B B_DISEASE
and O O
depression B B_DISEASE
are O O
in O O
line O O
with O O
previous O O
observations O O
in O O
recreational O O
ecstasy O O
- O O
polydrug O O
users O O
. O O

Ifosfamide O O
related O O
encephalopathy B B_DISEASE
: O O
the O O
need O O
for O O
a O O
timely O O
EEG O O
evaluation O O
. O O

BACKGROUND O O
: O O
Ifosfamide O O
is O O
an O O
alkylating O O
agent O O
useful O O
in O O
the O O
treatment O O
of O O
a O O
wide O O
range O O
of O O
cancers B B_DISEASE
including O O
sarcomas B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
lymphoma B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
gynecologic B B_DISEASE
and I I_DISEASE
testicular I I_DISEASE
cancers I I_DISEASE
. O O

Encephalopathy B B_DISEASE
has O O
been O O
reported O O
in O O
10 O O
- O O
40 O O
% O O
of O O
patients O O
receiving O O
high O O
- O O
dose O O
IV O O
ifosfamide O O
. O O

OBJECTIVE O O
: O O
To O O
highlight O O
the O O
role O O
of O O
electroencephalogram O O
( O O
EEG O O
) O O
in O O
the O O
early O O
detection O O
and O O
management O O
of O O
ifosfamide O O
related O O
encephalopathy B B_DISEASE
. O O

METHODS O O
: O O
Retrospective O O
chart O O
review O O
including O O
clinical O O
data O O
and O O
EEG O O
recordings O O
was O O
done O O
on O O
five O O
patients O O
, O O
admitted O O
to O O
MD O O
Anderson O O
Cancer B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
Center O O
between O O
years O O
2009 O O
and O O
2012 O O
, O O
who O O
developed O O
ifosfamide O O
related O O
acute O O
encephalopathy B B_DISEASE
. O O

RESULTS O O
: O O
All O O
five O O
patients O O
experienced O O
symptoms O O
of O O
encephalopathy B B_DISEASE
soon O O
after O O
( O O
within O O
12 O O
h O O
- O O
2 O O
days O O
) O O
receiving O O
ifosfamide O O
. O O

Two O O
patients O O
developed O O
generalized O O
convulsions B B_DISEASE
while O O
one O O
patient O O
developed O O
continuous O O
non B B_DISEASE
- I I_DISEASE
convulsive I I_DISEASE
status I I_DISEASE
epilepticus I I_DISEASE
( O O
NCSE B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
that O O
required O O
ICU O O
admission O O
and O O
intubation O O
. O O

Mixed O O
pattern O O
with O O
the O O
presence O O
of O O
both O O
sharps O O
and O O
triphasic O O
waves O O
were O O
also O O
noted O O
. O O

Repeat O O
EEGs O O
within O O
24 O O
_ O O
h O O
of O O
symptom O O
onset O O
showed O O
marked O O
improvement O O
that O O
was O O
correlated O O
with O O
clinical O O
improvement O O
. O O

CONCLUSIONS O O
: O O
Severity O O
of O O
ifosfamide O O
related O O
encephalopathy B B_DISEASE
correlates O O
with O O
EEG O O
changes O O
. O O

We O O
suggest O O
a O O
timely O O
EEG O O
evaluation O O
for O O
patients O O
receiving O O
ifosfamide O O
who O O
develop O O
features O O
of O O
encephalopathy B B_DISEASE
. O O

Incidence O O
of O O
contrast O O
- O O
induced O O
nephropathy B B_DISEASE
in O O
hospitalised O O
patients O O
with O O
cancer B B_DISEASE
. O O

OBJECTIVES O O
: O O
To O O
determine O O
the O O
frequency O O
of O O
and O O
possible O O
factors O O
related O O
to O O
contrast O O
- O O
induced O O
nephropathy B B_DISEASE
( O O
CIN O O
) O O
in O O
hospitalised O O
patients O O
with O O
cancer B B_DISEASE
. O O

METHODS O O
: O O
Ninety O O
adult O O
patients O O
were O O
enrolled O O
. O O

Patients O O
with O O
risk O O
factors O O
for O O
acute B B_DISEASE
renal I I_DISEASE
failure I I_DISEASE
were O O
excluded O O
. O O

Blood O O
samples O O
were O O
examined O O
the O O
day O O
before O O
contrast O O
- O O
enhanced O O
computed O O
tomography O O
( O O
CT O O
) O O
and O O
serially O O
for O O
3 O O
days O O
thereafter O O
. O O

CIN O O
was O O
significantly O O
more O O
after O O
treatment O O
with O O
bevacizumab O O
/ O O
irinotecan O O
( O O
P O O
= O O
0 O O
. O O
021 O O
) O O
and O O
in O O
patients O O
with O O
hypertension B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O O
P O O
= O O
0 O O
. O O
044 O O
) O O
. O O

CIN O O
developed O O
4 O O
. O O
5 O O
- O O
times O O
more O O
frequently O O
in O O
patients O O
with O O
cancer B B_DISEASE/B_LOCATION
who O O
had O O
undergone O O
recent O O
chemotherapy O O
. O O

Hypertension B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
combination O O
of O O
bevacizumab O O
/ O O
irinotecan O O
may O O
be O O
additional O O
risk O O
factors O O
for O O
CIN O O
development O O
. O O

KEY O O
POINTS O O
: O O
. O O

Contrast O O
- O O
induced O O
nephropathy B B_DISEASE
( O O
CIN O O
) O O
is O O
a O O
concern O O
for O O
oncological O O
patients O O
undergoing O O
CT O O
. O O

. O O
Hypertension B B_DISEASE
and O O
treatment O O
with O O
bevacizumab O O
appear O O
to O O
be O O
additional O O
risk O O
factors O O
. O O

Syndrome B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inappropriate I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antidiuretic I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
hormone I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
secretion O O
associated O O
with O O
desvenlafaxine O O
. O O

OBJECTIVE O O
: O O
To O O
report O O
a O O
case O O
of O O
syndrome B B_DISEASE
of I I_DISEASE
inappropriate I I_DISEASE
anti I I_DISEASE
- I I_DISEASE
diuretic I I_DISEASE
hormone I I_DISEASE
( O O
SIADH B B_DISEASE/B_GENE
) O O
secretion O O
associated O O
with O O
desvenlafaxine O O
. O O

CASE O O
SUMMARY O O
: O O
A O O
57 O O
- O O
year O O
old O O
female O O
with O O
hyponatraemia B B_DISEASE
. O O

Her O O
medications O O
included O O
desvenlafaxine O O
, O O
and O O
symptoms O O
included O O
nausea B B_DISEASE
, O O
anxiety B B_DISEASE
and O O
confusion B B_DISEASE
. O O

The O O
serum O O
sodium O O
at O O
this O O
time O O
was O O
120 O O
mmol O O
/ O O
L O O
, O O
serum O O
osmolality O O
was O O
263 O O
mosmol O O
/ O O
kg O O
, O O
urine O O
osmolality O O
410 O O
mosmol O O
/ O O
kg O O
and O O
urine O O
sodium O O
63 O O
mmol O O
/ O O
L O O
, O O
consistent O O
with O O
a O O
diagnosis O O
of O O
SIADH B B_DISEASE
. O O

Desvenlafaxine O O
was O O
ceased O O
and O O
fluid O O
restriction O O
implemented O O
. O O

During O O
her O O
further O O
3 O O
weeks O O
inpatient O O
admission O O
the O O
serum O O
sodium O O
ranged O O
from O O
134 O O
to O O
137 O O
mmol O O
/ O O
L O O
during O O
treatment O O
with O O
mirtazapine O O
. O O

DISCUSSION O O
: O O
SIADH B B_DISEASE
has O O
been O O
widely O O
reported O O
with O O
a O O
range O O
of O O
antidepressants O O
. O O

This O O
case O O
report O O
suggests O O
that O O
desvenlafaxine O O
might O O
cause O O
clinically O O
significant O O
hyponatremia B B_DISEASE
. O O

CONCLUSIONS O O
: O O
Clinicians O O
should O O
be O O
aware O O
of O O
the O O
potential O O
for O O
antidepressants O O
to O O
cause O O
hyponatremia B B_DISEASE
, O O
and O O
take O O
appropriate O O
corrective O O
action O O
where O O
necessary O O
. O O

Oxidative O O
stress O O
on O O
cardiotoxicity B B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
after O O
treatment O O
with O O
single O O
and O O
multiple O O
doses O O
of O O
doxorubicin O O
. O O

The O O
mechanism O O
of O O
doxorubicin O O
( O O
DOX O O
) O O
- O O
induced O O
cardiotoxicity B B_DISEASE/B_GENE
remains O O
controversial O O
. O O

Wistar O O
rats O O
( O O
n O O
= O O
66 O O
) O O
received O O
DOX O O
injections O O
intraperitoneally O O
and O O
were O O
randomly O O
assigned O O
to O O
2 O O
experimental O O
protocols O O
: O O
( O O
1 O O
) O O
rats O O
were O O
killed O O
before O O
( O O
- O O
24 O O
h O O
, O O
n O O
= O O
8 O O
) O O
and O O
24 O O
h O O
after O O
( O O
+ O O
24 O O
h O O
, O O
n O O
= O O
8 O O
) O O
a O O
single O O
dose O O
of O O
DOX O O
( O O
4 O O
mg O O
/ O O
kg O O
body O O
weight O O
) O O
to O O
determine O O
the O O
DOX O O
acute O O
effect O O
and O O
( O O
2 O O
) O O
rats O O
( O O
n O O
= O O
58 O O
) O O
received O O
4 O O
injections O O
of O O
DOX O O
( O O
4 O O
mg O O
/ O O
kg O O
body O O
weight O O
/ O O
week O O
) O O
and O O
were O O
killed O O
before O O
the O O
first O O
injection O O
( O O
M0 O O
) O O
and O O
1 O O
week O O
after O O
each O O
injection O O
( O O
M1 O O
, O O
M2 O O
, O O
M3 O O
, O O
and O O
M4 O O
) O O
to O O
determine O O
the O O
chronological O O
effects O O
. O O

Animals O O
used O O
at O O
M0 O O
( O O
n O O
= O O
8 O O
) O O
were O O
also O O
used O O
at O O
moment O O
- O O
24 O O
h O O
of O O
acute O O
study O O
. O O

Cardiac O O
total O O
antioxidant O O
performance O O
( O O
TAP O O
) O O
, O O
DNA O O
damage O O
, O O
and O O
morphology O O
analyses O O
were O O
carried O O
out O O
at O O
each O O
time O O
point O O
. O O

Single O O
dose O O
of O O
DOX O O
was O O
associated O O
with O O
increased O O
cardiac B B_DISEASE/B_GENE
disarrangement I I_DISEASE/I_GENE
, O O
necrosis B B_DISEASE/B_GENE
, O O
and O O
DNA O O
damage O O
( O O
strand O O
breaks O O
( O O
SBs O O
) O O
and O O
oxidized O O
pyrimidines O O
) O O
and O O
decreased O O
TAP O O
. O O

The O O
chronological O O
study O O
showed O O
an O O
effect O O
of O O
a O O
cumulative O O
dose O O
on O O
body O O
weight O O
( O O
R O O
= O O
- O O
0 O O
. O O
99 O O
, O O
p O O
= O O
0 O O
. O O
011 O O
) O O
, O O
necrosis B B_DISEASE/B_GENE
( O O
R O O
= O O
1 O O
. O O
00 O O
, O O
p O O
= O O
0 O O
. O O
004 O O
) O O
, O O
TAP O O
( O O
R O O
= O O
0 O O
. O O
95 O O
, O O
p O O
= O O
0 O O
. O O
049 O O
) O O
, O O
and O O
DNA O O
SBs O O
( O O
R O O
= O O
- O O
0 O O
. O O
95 O O
, O O
p O O
= O O
0 O O
. O O
049 O O
) O O
. O O

DNA O O
SBs O O
damage O O
was O O
negatively O O
associated O O
with O O
TAP O O
( O O
R O O
= O O
- O O
0 O O
. O O
98 O O
, O O
p O O
= O O
0 O O
. O O
018 O O
) O O
, O O
and O O
necrosis B B_DISEASE/B_GENE
( O O
R O O
= O O
- O O
0 O O
. O O
97 O O
, O O
p O O
= O O
0 O O
. O O
027 O O
) O O
. O O

Our O O
results O O
suggest O O
that O O
oxidative O O
damage O O
is O O
associated O O
with O O
acute O O
cardiotoxicity B B_DISEASE
induced O O
by O O
a O O
single O O
dose O O
of O O
DOX O O
only O O
. O O

Increased O O
resistance O O
to O O
the O O
oxidative O O
stress O O
is O O
plausible O O
for O O
the O O
multiple O O
dose O O
of O O
DOX O O
. O O

Thus O O
, O O
different O O
mechanisms O O
may O O
be O O
involved O O
in O O
acute O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
versus O O
chronic O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Tacrolimus O O
- O O
related O O
seizure B B_DISEASE
after O O
pediatric O O
liver O O
transplantation O O
- O O
- O O
a O O
single O O
- O O
center O O
experience O O
. O O

To O O
identify O O
the O O
risk O O
factors O O
for O O
new O O
- O O
onset O O
seizures B B_DISEASE
after O O
pediatric O O
LT O O
and O O
to O O
assess O O
their O O
clinical O O
implications O O
and O O
long O O
- O O
term O O
prognosis O O
. O O

The O O
clinical O O
and O O
laboratory O O
data O O
of O O
27 O O
consecutive O O
children O O
who O O
underwent O O
LT O O
from O O
January O O
2007 O O
to O O
December O O
2010 O O
in O O
our O O
center O O
were O O
analyzed O O
retrospectively O O
. O O

Patients O O
were O O
divided O O
into O O
seizures B B_DISEASE
group O O
and O O
a O O
non O O
- O O
seizures B B_DISEASE
group O O
. O O

Seizures B B_DISEASE
occurred O O
in O O
four O O
children O O
, O O
an O O
incidence O O
of O O
14 O O
. O O
8 O O
% O O
. O O

All O O
exhibited O O
generalized O O
tonic B B_DISEASE
- I I_DISEASE
clonic I I_DISEASE
seizures I I_DISEASE
within O O
the O O
first O O
two O O
wk O O
after O O
LT O O
. O O

Univariate O O
analysis O O
showed O O
that O O
the O O
risk O O
factors O O
associated O O
with O O
seizures B B_DISEASE/B_GENE
after O O
pediatric O O
LT O O
included O O
gender O O
, O O
pediatric O O
end B B_DISEASE_ADJECTIVE[DISEASE]
- I I_DISEASE_ADJECTIVE[DISEASE]
stage I I_DISEASE_ADJECTIVE[DISEASE]
liver I I_DISEASE_ADJECTIVE[DISEASE]
disease I I_DISEASE_ADJECTIVE[DISEASE]
score O O
before O O
surgery O O
, O O
Child O O
- O O
Pugh O O
score O O
before O O
surgery O O
, O O
serum O O
total O O
bilirubin O O
after O O
surgery O O
, O O
and O O
trough O O
TAC O O
level O O
. O O

Multivariate O O
analysis O O
showed O O
that O O
trough O O
TAC O O
level O O
was O O
the O O
only O O
independent O O
risk O O
factor O O
associated O O
with O O
the O O
seizures B B_DISEASE
. O O

All O O
children O O
who O O
experienced O O
seizures B B_DISEASE
survived O O
with O O
good O O
graft O O
function O O
and O O
remained O O
seizure B B_DISEASE
- O O
free O O
without O O
anti O O
- O O
epileptic B B_DISEASE/B_GENE
drugs O O
over O O
a O O
mean O O
follow O O
- O O
up O O
period O O
of O O
33 O O
. O O
7 O O
+ O O
14 O O
. O O
6 O O
months O O
. O O

High O O
trough O O
TAC O O
level O O
was O O
the O O
predominant O O
factor O O
that O O
contributed O O
to O O
seizures B B_DISEASE
in O O
the O O
early O O
post O O
- O O
operative O O
period O O
after O O
pediatric O O
LT O O
. O O

High O O
PELD O O
and O O
Child O O
- O O
Pugh O O
scores O O
before O O
LT O O
and O O
high O O
post O O
- O O
operative O O
serum O O
Tbil O O
may O O
be O O
contributory O O
risk O O
factors O O
for O O
TAC O O
- O O
related O O
seizures B B_DISEASE
. O O

The O O
flavonoid O O
apigenin O O
delays O O
forgetting O O
of O O
passive O O
avoidance O O
conditioning O O
in O O
rats O O
. O O

The O O
present O O
experiments O O
were O O
performed O O
to O O
study O O
the O O
effect O O
of O O
the O O
flavonoid O O
apigenin O O
( O O
20 O O
mg O O
/ O O
kg O O
intraperitoneally O O
( O O
i O O
. O O
p O O
. O O
) O O
, O O
1 O O
h O O
before O O
acquisition O O
) O O
, O O
on O O
24 O O
h O O
retention O O
performance O O
and O O
forgetting O O
of O O
a O O
step O O
- O O
through O O
passive O O
avoidance O O
task O O
, O O
in O O
young O O
male O O
Wistar O O
rats O O
. O O

There O O
were O O
no O O
differences O O
between O O
saline O O
- O O
and O O
apigenin O O
- O O
treated O O
groups O O
in O O
the O O
24 O O
h O O
retention O O
trial O O
. O O

Furthermore O O
, O O
apigenin O O
did O O
not O O
prevent O O
the O O
amnesia B B_DISEASE_ADJECTIVE[DISEASE]
induced O O
by O O
scopolamine O O
( O O
1mg O O
/ O O
kg O O
, O O
i O O
. O O
p O O
. O O
, O O
30 O O
min O O
before O O
the O O
acquisition O O
) O O
. O O

The O O
saline O O
- O O
and O O
apigenin O O
- O O
treated O O
rats O O
that O O
did O O
not O O
step O O
through O O
into O O
the O O
dark O O
compartment O O
during O O
the O O
cut O O
- O O
off O O
time O O
( O O
540 O O
s O O
) O O
were O O
retested O O
weekly O O
for O O
up O O
to O O
eight O O
weeks O O
. O O

In O O
the O O
saline O O
treated O O
group O O
, O O
the O O
first O O
significant O O
decline O O
in O O
passive O O
avoidance O O
response O O
was O O
observed O O
at O O
four O O
weeks O O
, O O
and O O
complete O O
memory B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
loss I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
found O O
five O O
weeks O O
after O O
the O O
acquisition O O
of O O
the O O
passive O O
avoidance O O
task O O
. O O

At O O
the O O
end O O
of O O
the O O
experimental O O
period O O
, O O
60 O O
% O O
of O O
the O O
animals O O
treated O O
with O O
apigenin O O
still O O
did O O
not O O
step O O
through O O
. O O

These O O
data O O
suggest O O
that O O
1 O O
) O O
apigenin O O
delays O O
the O O
long O O
- O O
term O O
forgetting O O
but O O
did O O
not O O
modulate O O
the O O
24 O O
h O O
retention O O
of O O
fear O O
memory O O
and O O
2 O O
) O O
the O O
obtained O O
beneficial O O
effect O O
of O O
apigenin O O
on O O
the O O
passive O O
avoidance O O
conditioning O O
is O O
mediated O O
by O O
mechanisms O O
that O O
do O O
not O O
implicate O O
its O O
action O O
on O O
the O O
muscarinic O O
cholinergic O O
system O O
. O O

Histamine O O
antagonists O O
and O O
d O O
- O O
tubocurarine O O
- O O
induced O O
hypotension B B_DISEASE
in O O
cardiac O O
surgical O O
patients O O
. O O

H1 O O
- O O
and O O
H2 O O
- O O
histamine O O
antagonists O O
or O O
placebo O O
were O O
given O O
before O O
dosing O O
with O O
d O O
- O O
tubocurarine O O
in O O
a O O
randomized O O
double O O
- O O
blind O O
fashion O O
to O O
four O O
groups O O
: O O
group O O
1 O O
- O O
- O O
placebo O O
; O O
group O O
2 O O
- O O
- O O
cimetidine O O
, O O
4 O O
mg O O
/ O O
kg O O
, O O
plus O O
placebo O O
; O O
group O O
3 O O
- O O
- O O
chlorpheniramine O O
, O O
0 O O
. O O
1 O O
mg O O
/ O O
kg O O
, O O
plus O O
placebo O O
; O O
and O O
group O O
4 O O
- O O
- O O
cimetidine O O
plus O O
chlorpheniramine O O
. O O

Group O O
1 O O
had O O
a O O
moderate O O
negative O O
correlation O O
between O O
plasma O O
histamine O O
change O O
and O O
systemic O O
vascular O O
resistance O O
( O O
r O O
= O O
0 O O
. O O
58 O O
; O O
P O O
less O O
than O O
0 O O
. O O
05 O O
) O O
not O O
present O O
in O O
group O O
4 O O
. O O

Thus O O
prior O O
dosing O O
with O O
H1 O O
- O O
and O O
H2 O O
- O O
antagonists O O
provides O O
only O O
partial O O
protection O O
. O O

Cholecystokinin O O
- O O
octapeptide O O
restored O O
morphine O O
- O O
induced O O
hippocampal O O
long O O
- O O
term O O
potentiation O O
impairment O O
in O O
rats O O
. O O

We O O
have O O
previously O O
reported O O
that O O
CCK O O
- O O
8 O O
significantly O O
alleviated O O
morphine O O
- O O
induced O O
amnesia B B_DISEASE
and O O
reversed O O
spine O O
density O O
decreases O O
in O O
the O O
CA1 O O
region O O
of O O
the O O
hippocampus O O
in O O
morphine O O
- O O
treated O O
animals O O
. O O

Pre O O
- O O
treatment O O
of O O
the O O
CCK2 O O
receptor O O
antagonist O O
L O O
- O O
365 O O
, O O
260 O O
( O O
10ug O O
, O O
i O O
. O O
c O O
. O O
v O O
) O O
reversed O O
the O O
effects O O
of O O
CCK O O
- O O
8 O O
, O O
but O O
the O O
CCK1 O O
receptor O O
antagonist O O
L O O
- O O
364 O O
, O O
718 O O
( O O
10ug O O
, O O
i O O
. O O
c O O
. O O
v O O
) O O
did O O
not O O
. O O

The O O
present O O
results O O
demonstrate O O
that O O
CCK O O
- O O
8 O O
attenuates O O
the O O
effect O O
of O O
morphine O O
on O O
hippocampal O O
LTP O O
through O O
CCK2 O O
receptors O O
and O O
suggest O O
an O O
ameliorative O O
function O O
of O O
CCK O O
- O O
8 O O
on O O
morphine O O
- O O
induced O O
memory B B_DISEASE
impairment I I_DISEASE
. O O

Glial O O
activation O O
and O O
post O O
- O O
synaptic O O
neurotoxicity B B_DISEASE
: O O
the O O
key O O
events O O
in O O
Streptozotocin O O
( O O
ICV O O
) O O
induced O O
memory B B_DISEASE
impairment I I_DISEASE
in O O
rats O O
. O O

In O O
the O O
present O O
study O O
the O O
role O O
of O O
glial O O
activation O O
and O O
post O O
synaptic O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
ICV O O
Streptozotocin O O
( O O
STZ O O
) O O
induced O O
memory B B_DISEASE
impaired I I_DISEASE
rats O O
was O O
explored O O
. O O

In O O
experiment O O
set O O
up O O
1 O O
: O O
Memory B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
deficit I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
was O O
found O O
in O O
Morris O O
water O O
maze O O
test O O
on O O
14 O O
- O O
16 O O
days O O
after O O
STZ O O
( O O
ICV O O
; O O
3mg O O
/ O O
Kg O O
) O O
administration O O
. O O

STZ O O
causes O O
increased O O
expression O O
of O O
GFAP O O
, O O
CD11b O O
and O O
TNF O O
- O O
a O O
indicating O O
glial O O
activation O O
and O O
neuroinflammation B B_DISEASE
. O O

STZ O O
also O O
significantly O O
increased O O
the O O
level O O
of O O
ROS O O
, O O
nitrite O O
, O O
Ca O O
( O O
2 O O
+ O O
) O O
and O O
reduced O O
the O O
mitochondrial O O
activity O O
in O O
synaptosomal O O
preparation O O
illustrating O O
free O O
radical O O
generation O O
and O O
excitotoxicity B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Increased O O
expression O O
and O O
activity O O
of O O
Caspase O O
- O O
3 O O
was O O
also O O
observed O O
in O O
STZ O O
treated O O
rat O O
which O O
specify O O
apoptotic O O
cell O O
death O O
in O O
hippocampus O O
and O O
cortex O O
. O O

STZ O O
treatment O O
showed O O
decrease O O
expression O O
of O O
post O O
synaptic O O
markers O O
CaMKIIa O O
and O O
PSD O O
- O O
95 O O
, O O
while O O
, O O
expression O O
of O O
pre O O
synaptic O O
markers O O
( O O
synaptophysin O O
and O O
SNAP O O
- O O
25 O O
) O O
remains O O
unaltered O O
indicating O O
selective O O
post O O
synaptic O O
neurotoxicity B B_DISEASE
. O O

Oral O O
treatment O O
with O O
Memantine O O
( O O
10mg O O
/ O O
kg O O
) O O
and O O
Ibuprofen O O
( O O
50 O O
mg O O
/ O O
kg O O
) O O
daily O O
for O O
13 O O
days O O
attenuated O O
STZ O O
induced O O
glial O O
activation O O
, O O
apoptotic O O
cell O O
death O O
and O O
post O O
synaptic O O
neurotoxicity B B_DISEASE
in O O
rat O O
brain O O
. O O

Further O O
, O O
in O O
experiment O O
set O O
up O O
2 O O
: O O
where O O
memory O O
function O O
was O O
not O O
affected O O
i O O
. O O
e O O
. O O
7 O O
- O O
9 O O
days O O
after O O
STZ O O
treatment O O
. O O

The O O
level O O
of O O
GFAP O O
, O O
CD11b O O
, O O
TNF O O
- O O
a O O
, O O
ROS O O
and O O
nitrite O O
levels O O
were O O
increased O O
. O O

On O O
the O O
other O O
hand O O
, O O
apoptotic O O
marker O O
, O O
synaptic O O
markers O O
, O O
mitochondrial O O
activity O O
and O O
Ca O O
( O O
2 O O
+ O O
) O O
levels O O
remained O O
unaffected O O
. O O

Collective O O
data O O
indicates O O
that O O
neuroinflammatory B B_DISEASE_ADJECTIVE[DISEASE]
process O O
and O O
oxidative O O
stress O O
occurs O O
earlier O O
to O O
apoptosis O O
and O O
does O O
not O O
affect O O
memory O O
function O O
. O O

Present O O
study O O
clearly O O
suggests O O
that O O
glial O O
activation O O
and O O
post O O
synaptic O O
neurotoxicity B B_DISEASE
are O O
the O O
key O O
factors O O
in O O
STZ O O
induced O O
memory B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
impairment I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
neuronal O O
cell O O
death O O
. O O

Comparison O O
of O O
effects O O
of O O
isotonic O O
sodium O O
chloride O O
with O O
diltiazem O O
in O O
prevention O O
of O O
contrast O O
- O O
induced O O
nephropathy B B_DISEASE
. O O

INTRODUCTION O O
AND O O
OBJECTIVE O O
: O O
Contrast O O
- O O
induced O O
nephropathy B B_DISEASE
( O O
CIN O O
) O O
significantly O O
increases O O
the O O
morbidity O O
and O O
mortality O O
of O O
patients O O
. O O

MATERIALS O O
AND O O
METHODS O O
: O O
Our O O
study O O
included O O
patients O O
who O O
were O O
administered O O
30 O O
- O O
60 O O
mL O O
of O O
iodinated O O
contrast O O
agent O O
for O O
percutaneous O O
coronary O O
angiography O O
( O O
PCAG O O
) O O
, O O
all O O
with O O
creatinine O O
values O O
between O O
1 O O
. O O
1 O O
and O O
3 O O
. O O
1 O O
mg O O
/ O O
dL O O
. O O

Patients O O
were O O
divided O O
into O O
three O O
groups O O
and O O
each O O
group O O
had O O
20 O O
patients O O
. O O

The O O
first O O
group O O
of O O
patients O O
was O O
administered O O
isotonic O O
sodium O O
chloride O O
; O O
the O O
second O O
group O O
was O O
administered O O
a O O
solution O O
that O O
of O O
5 O O
% O O
dextrose O O
and O O
sodium O O
bicarbonate O O
, O O
while O O
the O O
third O O
group O O
was O O
administered O O
isotonic O O
sodium O O
chloride O O
before O O
and O O
after O O
the O O
contrast O O
injection O O
. O O

The O O
third O O
group O O
received O O
an O O
additional O O
injection O O
of O O
diltiazem O O
the O O
day O O
before O O
and O O
first O O
2 O O
days O O
after O O
the O O
contrast O O
injection O O
. O O

All O O
of O O
the O O
patients O O
' O O
plasma O O
blood O O
urea O O
nitrogen O O
( O O
BUN O O
) O O
and O O
creatinine O O
levels O O
were O O
measured O O
on O O
the O O
second O O
and O O
seventh O O
day O O
after O O
the O O
administration O O
of O O
intravenous O O
contrast O O
material O O
. O O

RESULTS O O
: O O
The O O
basal O O
creatinine O O
levels O O
were O O
similar O O
for O O
all O O
three O O
groups O O
( O O
p O O
> O O
0 O O
. O O
05 O O
) O O
. O O

Among O O
a O O
total O O
of O O
60 O O
patients O O
included O O
in O O
the O O
study O O
, O O
16 O O
patients O O
developed O O
acute B B_DISEASE
renal I I_DISEASE
failure I I_DISEASE
( O O
ARF B B_DISEASE/B_GENE
) O O
on O O
the O O
second O O
day O O
after O O
contrast O O
material O O
was O O
injected O O
( O O
26 O O
. O O
6 O O
% O O
) O O
. O O

The O O
number O O
of O O
patients O O
who O O
developed O O
ARF B B_DISEASE
on O O
the O O
second O O
day O O
after O O
the O O
injection O O
in O O
the O O
first O O
group O O
was O O
five O O
( O O
25 O O
% O O
) O O
, O O
in O O
the O O
second O O
group O O
was O O
six O O
( O O
30 O O
% O O
) O O
and O O
the O O
third O O
group O O
was O O
five O O
( O O
25 O O
% O O
) O O
( O O
p O O
> O O
0 O O
. O O
05 O O
) O O
. O O

Neurocognitive O O
and O O
neuroradiologic O O
central O O
nervous O O
system O O
late O O
effects O O
in O O
children O O
treated O O
on O O
Pediatric O O
Oncology O O
Group O O
( O O
POG O O
) O O
P9605 O O
( O O
standard O O
risk O O
) O O
and O O
P9201 O O
( O O
lesser O O
risk O O
) O O
acute B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lymphoblastic I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
leukemia I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
protocols O O
( O O
ACCL0131 O O
) O O
: O O
a O O
methotrexate O O
consequence O O
? O O

A O O
report O O
from O O
the O O
Children O O
' O O
s O O
Oncology O O
Group O O
. O O

Concerns O O
about O O
long O O
- O O
term O O
methotrexate O O
( O O
MTX O O
) O O
neurotoxicity B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
1990s O O
led O O
to O O
modifications O O
in O O
intrathecal O O
( O O
IT O O
) O O
therapy O O
, O O
leucovorin O O
rescue O O
, O O
and O O
frequency O O
of O O
systemic O O
MTX O O
administration O O
in O O
children O O
with O O
acute B B_DISEASE
lymphoblastic I I_DISEASE
leukemia I I_DISEASE
. O O

In O O
this O O
study O O
, O O
neurocognitive O O
outcomes O O
and O O
neuroradiologic O O
evidence O O
of O O
leukoencephalopathy B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
compared O O
in O O
children O O
treated O O
with O O
intense O O
central O O
nervous O O
system O O
( O O
CNS O O
) O O
- O O
directed O O
therapy O O
( O O
P9605 O O
) O O
versus O O
those O O
receiving O O
fewer O O
CNS O O
- O O
directed O O
treatment O O
days O O
during O O
intensive O O
consolidation O O
( O O
P9201 O O
) O O
. O O

A O O
total O O
of O O
66 O O
children O O
from O O
16 O O
Pediatric O O
Oncology O O
Group O O
institutions O O
with O O
" O O
standard O O
- O O
risk O O
" O O
acute B B_DISEASE
lymphoblastic I I_DISEASE
leukemia I I_DISEASE
, O O
1 O O
. O O
00 O O
to O O
9 O O
. O O
99 O O
years O O
at O O
diagnosis O O
, O O
without O O
evidence O O
of O O
CNS O O
leukemia B B_DISEASE
at O O
diagnosis O O
were O O
enrolled O O
on O O
ACCL0131 O O
: O O
28 O O
from O O
P9201 O O
and O O
38 O O
from O O
P9605 O O
. O O

Magnetic O O
resonance O O
imaging O O
scans O O
and O O
standard O O
neuropsychological O O
tests O O
were O O
performed O O
> O O
2 O O
. O O
6 O O
years O O
after O O
the O O
end O O
of O O
treatment O O
. O O

Significantly O O
more O O
P9605 O O
patients O O
developed O O
leukoencephalopathy B B_DISEASE
compared O O
with O O
P9201 O O
patients O O
( O O
68 O O
% O O
, O O
95 O O
% O O
confidence O O
interval O O
49 O O
% O O
- O O
83 O O
% O O
vs O O
. O O
22 O O
% O O
, O O
95 O O
% O O
confidence O O
interval O O
5 O O
% O O
- O O
44 O O
% O O
; O O
P O O
= O O
0 O O
. O O
001 O O
) O O
identified O O
as O O
late O O
as O O
7 O O
. O O
7 O O
years O O
after O O
the O O
end O O
of O O
treatment O O
. O O

Overall O O
, O O
40 O O
% O O
of O O
patients O O
scored O O
< O O
85 O O
on O O
either O O
Verbal O O
or O O
Performance O O
IQ O O
. O O

Children O O
on O O
both O O
studies O O
had O O
significant O O
attention B B_DISEASE_ADJECTIVE[DISEASE]
problems I I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
P9605 O O
children O O
scored O O
below O O
average O O
on O O
more O O
neurocognitive O O
measures O O
than O O
those O O
treated O O
on O O
P9201 O O
( O O
82 O O
% O O
, O O
14 O O
/ O O
17 O O
measures O O
vs O O
. O O
24 O O
% O O
, O O
4 O O
/ O O
17 O O
measures O O
) O O
. O O

Tranexamic O O
acid O O
overdosage O O
- O O
induced O O
generalized O O
seizure B B_DISEASE
in O O
renal B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
failure I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

We O O
report O O
a O O
45 O O
- O O
year O O
- O O
old O O
lady O O
with O O
chronic B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
kidney I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
disease I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
stage O O
4 O O
due O O
to O O
chronic O O
tubulointerstial B B_DISEASE
disease I I_DISEASE
. O O

She O O
was O O
admitted O O
to O O
our O O
center O O
for O O
severe O O
anemia B B_DISEASE
due O O
to O O
menorrhagia B B_DISEASE
and O O
deterioration B B_DISEASE
of I I_DISEASE
renal I I_DISEASE
function I I_DISEASE
. O O

She O O
was O O
infused O O
three O O
units O O
of O O
packed O O
cells O O
during O O
a O O
session O O
of O O
hemodialysis O O
. O O

Tranexamic O O
acid O O
( O O
TNA O O
) O O
1 O O
g O O
8 O O
- O O
hourly O O
was O O
administered O O
to O O
her O O
to O O
control O O
bleeding B B_DISEASE
per O O
vaginum O O
. O O

Two O O
hours O O
after O O
the O O
sixth O O
dose O O
of O O
TNA O O
, O O
she O O
had O O
an O O
episode O O
of O O
generalized O O
tonic B B_DISEASE
clonic I I_DISEASE
convulsions I I_DISEASE
. O O

TNA O O
was O O
discontinued O O
. O O

Investigations O O
of O O
the O O
patient O O
revealed O O
no O O
biochemical O O
or O O
structural O O
central O O
nervous B B_DISEASE_ADJECTIVE[DISEASE]
system I I_DISEASE_ADJECTIVE[DISEASE]
abnormalities I I_DISEASE_ADJECTIVE[DISEASE]
that O O
could O O
have O O
provoked O O
the O O
convulsions B B_DISEASE
. O O

She O O
did O O
not O O
require O O
any O O
further O O
dialytic O O
support O O
. O O

She O O
had O O
no O O
further O O
episodes O O
of O O
convulsion B B_DISEASE
till O O
dis O O
- O O
charge O O
and O O
during O O
the O O
two O O
months O O
of O O
follow O O
- O O
up O O
. O O

Thus O O
, O O
the O O
precipitating O O
cause O O
of O O
convulsions B B_DISEASE
was O O
believed O O
to O O
be O O
an O O
overdose B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
TNA O O
. O O

Pre O O
- O O
treatment O O
of O O
bupivacaine O O
- O O
induced O O
cardiovascular B B_DISEASE
depression I I_DISEASE
using O O
different O O
lipid O O
formulations O O
of O O
propofol O O
. O O

BACKGROUND O O
: O O
Pre O O
- O O
treatment O O
with O O
lipid O O
emulsions O O
has O O
been O O
shown O O
to O O
increase O O
lethal O O
doses O O
of O O
bupivacaine O O
, O O
and O O
the O O
lipid O O
content O O
of O O
propofol O O
may O O
alleviate O O
bupivacaine O O
- O O
induced O O
cardiotoxicity B B_DISEASE
. O O

The O O
aim O O
of O O
this O O
study O O
is O O
to O O
investigate O O
the O O
effects O O
of O O
propofol O O
in O O
intralipid O O
or O O
medialipid O O
emulsions O O
on O O
bupivacaine O O
- O O
induced O O
cardiotoxicity B B_DISEASE
. O O

METHODS O O
: O O
Rats O O
were O O
anaesthetised O O
with O O
ketamine O O
and O O
were O O
given O O
0 O O
. O O
5 O O
mg O O
/ O O
kg O O
/ O O
min O O
propofol O O
in O O
intralipid O O
( O O
Group O O
P O O
) O O
, O O
propofol O O
in O O
medialipid O O
( O O
Group O O
L O O
) O O
, O O
or O O
saline O O
( O O
Group O O
C O O
) O O
over O O
20 O O
min O O
. O O

Thereafter O O
, O O
2 O O
mg O O
/ O O
kg O O
/ O O
min O O
bupivacaine O O
0 O O
. O O
5 O O
% O O
was O O
infused O O
. O O

We O O
recorded O O
time O O
to O O
first O O
dysrhythmia B B_DISEASE
occurrence O O
, O O
respective O O
times O O
to O O
25 O O
% O O
and O O
50 O O
% O O
reduction O O
of O O
the O O
heart O O
rate O O
( O O
HR O O
) O O
and O O
mean O O
arterial O O
pressure O O
, O O
and O O
time O O
to O O
asystole B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
total O O
amount O O
of O O
bupivacaine O O
consumption O O
. O O

Blood O O
and O O
tissue O O
samples O O
were O O
collected O O
following O O
asystole B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

RESULTS O O
: O O
The O O
time O O
to O O
first O O
dysrhythmia B B_DISEASE
occurrence O O
, O O
time O O
to O O
25 O O
% O O
and O O
50 O O
% O O
reductions O O
in O O
HR O O
, O O
and O O
time O O
to O O
asystole B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
longer O O
in O O
Group O O
P O O
than O O
the O O
other O O
groups O O
. O O

The O O
cumulative O O
bupivacaine O O
dose O O
given O O
at O O
those O O
time O O
points O O
was O O
higher O O
in O O
Group O O
P O O
. O O
Plasma O O
bupivacaine O O
levels O O
were O O
significantly O O
lower O O
in O O
Group O O
P O O
than O O
in O O
Group O O
C O O
. O O
Bupivacaine O O
levels O O
in O O
the O O
brain O O
and O O
heart O O
were O O
significantly O O
lower O O
in O O
Group O O
P O O
and O O
Group O O
L O O
than O O
in O O
Group O O
C O O
. O O

CONCLUSION O O
: O O
We O O
conclude O O
that O O
pre O O
- O O
treatment O O
with O O
propofol O O
in O O
intralipid O O
, O O
compared O O
with O O
propofol O O
in O O
medialipid O O
or O O
saline O O
, O O
delayed O O
the O O
onset O O
of O O
bupivacaine O O
- O O
induced O O
cardiotoxic B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O O
as O O
well O O
as O O
reduced O O
plasma O O
bupivacaine O O
levels O O
. O O

Further O O
studies O O
are O O
needed O O
to O O
explore O O
tissue O O
bupivacaine O O
levels O O
of O O
propofol O O
in O O
medialipid O O
and O O
adapt O O
these O O
results O O
to O O
clinical O O
practice O O
. O O

Drug B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Induced I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Acute I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Liver I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Injury I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Within O O
12 O O
Hours O O
After O O
Fluvastatin O O
Therapy O O
. O O

Although O O
statins O O
are O O
generally O O
well O O
- O O
tolerated O O
drugs O O
, O O
recent O O
cases O O
of O O
drug B B_DISEASE
- I I_DISEASE
induced I I_DISEASE
liver I I_DISEASE
injury I I_DISEASE
associated O O
with O O
their O O
use O O
have O O
been O O
reported O O
. O O

A O O
52 O O
- O O
year O O
- O O
old O O
Chinese O O
man O O
reported O O
with O O
liver B B_DISEASE
damage I I_DISEASE
, O O
which O O
appeared O O
12 O O
hours O O
after O O
beginning O O
treatment O O
with O O
fluvastatin O O
. O O

Patient O O
presented O O
with O O
complaints O O
of O O
increasing O O
nausea B B_DISEASE/B_MEASURE
, O O
anorexia B B_DISEASE
, O O
and O O
upper O O
abdominal B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
pain I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

His O O
laboratory O O
values O O
showed O O
elevated O O
creatine O O
kinase O O
and O O
transaminases O O
. O O

The O O
liver O O
biochemistries O O
eventually O O
normalized O O
within O O
3 O O
weeks O O
of O O
stopping O O
the O O
fluvastatin O O
. O O

Therefore O O
, O O
when O O
prescribing O O
statins O O
, O O
the O O
possibility O O
of O O
hepatic B B_DISEASE
damage I I_DISEASE
should O O
be O O
taken O O
into O O
account O O
. O O

Fluconazole O O
associated O O
agranulocytosis B B_DISEASE
and O O
thrombocytopenia B B_DISEASE
. O O

CASE O O
: O O
We O O
describe O O
a O O
second O O
case O O
of O O
fluconazole O O
associated O O
agranulocytosis B B_DISEASE/B_GENE
with O O
thrombocytopenia B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
recovery O O
upon O O
discontinuation O O
of O O
therapy O O
. O O

The O O
patient O O
began O O
to O O
have O O
changes O O
in O O
white O O
blood O O
cells O O
and O O
platelets O O
within O O
48 O O
h O O
of O O
administration O O
of O O
fluconazole O O
and O O
began O O
to O O
recover O O
with O O
48 O O
h O O
of O O
discontinuation O O
. O O

This O O
case O O
highlights O O
that O O
drug O O
- O O
induced O O
blood B B_DISEASE
dyscrasias I I_DISEASE
can O O
occur O O
unexpectedly O O
as O O
a O O
result O O
of O O
treatment O O
with O O
a O O
commonly O O
used O O
drug O O
thought O O
to O O
be O O
" O O
safe O O
" O O
. O O

CONCLUSION O O
: O O
According O O
to O O
Naranjo O O
' O O
s O O
algorithm O O
the O O
likelihood O O
that O O
our O O
patient O O
' O O
s O O
agranulocytosis B B_DISEASE
and O O
thrombocytopenia B B_DISEASE
occurred O O
as O O
a O O
result O O
of O O
therapy O O
with O O
fluconazole O O
is O O
probable O O
, O O
with O O
a O O
total O O
of O O
six O O
points O O
. O O

We O O
feel O O
that O O
the O O
weight O O
of O O
the O O
overall O O
evidence O O
of O O
this O O
evidence O O
is O O
strong O O
. O O

In O O
particular O O
the O O
temporal O O
relationship O O
of O O
bone B B_DISEASE_ADJECTIVE[DISEASE]
marrow I I_DISEASE_ADJECTIVE[DISEASE]
suppression I I_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
initiation O O
of O O
fluconazole O O
and O O
the O O
abatement O O
of O O
symptoms O O
that O O
rapidly O O
reversed O O
immediately O O
following O O
discontinuation O O
. O O

Two O O
- O O
dimensional O O
speckle O O
tracking O O
echocardiography O O
combined O O
with O O
high O O
- O O
sensitive O O
cardiac O O
troponin O O
T O O
in O O
early O O
detection O O
and O O
prediction O O
of O O
cardiotoxicity B B_DISEASE
during O O
epirubicine O O
- O O
based O O
chemotherapy O O
. O O

AIMS O O
: O O
To O O
investigate O O
whether O O
alterations O O
of O O
myocardial B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
strain I B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
high O O
- O O
sensitive O O
cardiac O O
troponin O O
T O O
( O O
cTnT O O
) O O
could O O
predict O O
future O O
cardiac B B_DISEASE
dysfunction I I_DISEASE
in O O
patients O O
after O O
epirubicin O O
exposure O O
. O O

METHODS O O
: O O
Seventy O O
- O O
five O O
patients O O
with O O
non B B_DISEASE/B_LOCATION
- I I_DISEASE/I_LOCATION
Hodgkin I I_DISEASE/I_LOCATION
lymphoma I I_DISEASE/I_LOCATION
treated O O
with O O
epirubicin O O
were O O
studied O O
. O O

Blood O O
collection O O
and O O
echocardiography O O
were O O
performed O O
at O O
baseline O O
, O O
1 O O
day O O
after O O
the O O
third O O
cycle O O
, O O
and O O
1 O O
day O O
after O O
completion O O
of O O
chemotherapy O O
. O O

Patients O O
were O O
studied O O
using O O
echocardiography O O
during O O
follow O O
- O O
up O O
. O O

Global O O
longitudinal O O
( O O
GLS O O
) O O
, O O
circumferential O O
( O O
GCS O O
) O O
, O O
and O O
radial O O
strain O O
( O O
GRS O O
) O O
were O O
calculated O O
using O O
speckle O O
tracking O O
echocardiography O O
. O O

Left O O
ventricular O O
ejection O O
fraction O O
was O O
analysed O O
by O O
real O O
- O O
time O O
3D O O
echocardiography O O
. O O

Cardiotoxicity B B_DISEASE/B_LOCATION
was O O
defined O O
as O O
a O O
reduction O O
of O O
the O O
LVEF O O
of O O
> O O
5 O O
% O O
to O O
< O O
55 O O
% O O
with O O
symptoms O O
of O O
heart B B_DISEASE
failure I I_DISEASE
or O O
an O O
asymptomatic O O
reduction O O
of O O
the O O
LVEF O O
of O O
> O O
10 O O
% O O
to O O
< O O
55 O O
% O O
. O O

RESULTS O O
: O O
Fourteen O O
patients O O
( O O
18 O O
. O O
67 O O
% O O
) O O
developed O O
cardiotoxicity B B_DISEASE/B_GENE
after O O
treatment O O
. O O

GLS O O
( O O
- O O
18 O O
. O O
48 O O
+ O O
1 O O
. O O
72 O O
% O O
vs O O
. O O
- O O
15 O O
. O O
96 O O
+ O O
1 O O
. O O
6 O O
% O O
) O O
, O O
GCS O O
( O O
- O O
20 O O
. O O
93 O O
+ O O
2 O O
. O O
86 O O
% O O
vs O O
. O O
- O O
19 O O
. O O
20 O O
+ O O
3 O O
. O O
21 O O
% O O
) O O
, O O
and O O
GRS O O
( O O
39 O O
. O O
23 O O
+ O O
6 O O
. O O
44 O O
% O O
vs O O
. O O
34 O O
. O O
98 O O
+ O O
6 O O
. O O
2 O O
% O O
) O O
were O O
markedly O O
reduced O O
and O O
cTnT O O
was O O
elevated O O
from O O
0 O O
. O O
0010 O O
+ O O
0 O O
. O O
0020 O O
to O O
0 O O
. O O
0073 O O
+ O O
0 O O
. O O
0038 O O
ng O O
/ O O
mL O O
( O O
P O O
all O O
< O O
0 O O
. O O
01 O O
) O O
at O O
the O O
completion O O
of O O
chemotherapy O O
compared O O
with O O
baseline O O
values O O
. O O

A O O
> O O
15 O O
. O O
9 O O
% O O
decrease O O
in O O
GLS O O
[ O O
sensitivity O O
, O O
86 O O
% O O
; O O
specificity O O
, O O
75 O O
% O O
; O O
area O O
under O O
the O O
curve O O
( O O
AUC O O
) O O
= O O
0 O O
. O O
815 O O
; O O
P O O
= O O
0 O O
. O O
001 O O
] O O
and O O
a O O
> O O
0 O O
. O O
004 O O
ng O O
/ O O
mL O O
elevation O O
in O O
cTnT O O
( O O
sensitivity O O
, O O
79 O O
% O O
; O O
specificity O O
, O O
64 O O
% O O
; O O
AUC O O
= O O
0 O O
. O O
757 O O
; O O
P O O
= O O
0 O O
. O O
005 O O
) O O
from O O
baseline O O
to O O
the O O
third O O
cycle O O
of O O
chemotherapy O O
predicted O O
later O O
cardiotoxicity B B_DISEASE
. O O

The O O
decrease O O
in O O
GLS O O
remained O O
the O O
only O O
independent O O
predictor O O
of O O
cardiotoxicity B B_DISEASE
( O O
P O O
= O O
0 O O
. O O
000 O O
) O O
. O O

CONCLUSIONS O O
: O O
GLS O O
combined O O
with O O
cTnT O O
may O O
provide O O
a O O
reliable O O
and O O
non O O
- O O
invasive O O
method O O
to O O
predict O O
cardiac B B_DISEASE
dysfunction I I_DISEASE
in O O
patients O O
receiving O O
anthracycline O O
- O O
based O O
chemotherapy O O
. O O

Prevention O O
of O O
etomidate O O
- O O
induced O O
myoclonus B B_DISEASE
: O O
which O O
is O O
superior O O
: O O
Fentanyl O O
, O O
midazolam O O
, O O
or O O
a O O
combination O O
? O O

A O O
Retrospective O O
comparative O O
study O O
. O O

BACKGROUND O O
: O O
In O O
this O O
retrospective O O
comparative O O
study O O
, O O
we O O
aimed O O
to O O
compare O O
the O O
effectiveness O O
of O O
fentanyl O O
, O O
midazolam O O
, O O
and O O
a O O
combination O O
of O O
fentanyl O O
and O O
midazolam O O
to O O
prevent O O
etomidate O O
- O O
induced O O
myoclonus B B_DISEASE
. O O

MATERIAL O O
AND O O
METHODS O O
: O O
This O O
study O O
was O O
performed O O
based O O
on O O
anesthesia O O
records O O
. O O

Depending O O
on O O
the O O
drugs O O
that O O
would O O
be O O
given O O
before O O
the O O
induction O O
of O O
anesthesia O O
with O O
etomidate O O
, O O
the O O
patients O O
were O O
separated O O
into O O
4 O O
groups O O
: O O
no O O
pretreatment O O
( O O
Group O O
NP O O
) O O
, O O
fentanyl O O
1 O O
ug O O
. O O
kg O O
- O O
1 O O
( O O
Group O O
F O O
) O O
, O O
midazolam O O
0 O O
. O O
03 O O
mg O O
. O O
kg O O
- O O
1 O O
( O O
Group O O
M O O
) O O
, O O
and O O
midazolam O O
0 O O
. O O
015 O O
mg O O
. O O
kg O O
- O O
1 O O
+ O O
fentanyl O O
0 O O
. O O
5 O O
ug O O
. O O
kg O O
- O O
1 O O
( O O
Group O O
FM O O
) O O
. O O

Patients O O
who O O
received O O
the O O
same O O
anesthetic O O
procedure O O
were O O
selected O O
: O O
2 O O
minutes O O
after O O
intravenous O O
injections O O
of O O
the O O
pretreatment O O
drugs O O
, O O
anesthesia O O
is O O
induced O O
with O O
0 O O
. O O
3 O O
mg O O
. O O
kg O O
- O O
1 O O
etomidate O O
injected O O
intravenously O O
over O O
a O O
period O O
of O O
20 O O
- O O
30 O O
seconds O O
. O O

Myoclonic B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
movements I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O O
evaluated O O
, O O
which O O
were O O
observed O O
and O O
graded O O
according O O
to O O
clinical O O
severity O O
during O O
the O O
2 O O
minutes O O
after O O
etomidate O O
injection O O
. O O

The O O
severity O O
of O O
pain B B_DISEASE
due O O
to O O
etomidate O O
injection O O
, O O
mean O O
arterial O O
pressure O O
, O O
heart O O
rate O O
, O O
and O O
adverse O O
effects O O
were O O
also O O
evaluated O O
. O O

RESULTS O O
: O O
Study O O
results O O
showed O O
that O O
myoclonus B B_DISEASE/B_GENE
incidence O O
was O O
85 O O
% O O
, O O
40 O O
% O O
, O O
70 O O
% O O
, O O
and O O
25 O O
% O O
in O O
Group O O
NP O O
, O O
Group O O
F O O
, O O
Group O O
M O O
, O O
and O O
Group O O
FM O O
, O O
respectively O O
, O O
and O O
were O O
significantly O O
lower O O
in O O
Group O O
F O O
and O O
Group O O
FM O O
. O O

CONCLUSIONS O O
: O O
We O O
conclude O O
that O O
pretreatment O O
with O O
fentanyl O O
or O O
combination O O
of O O
fentanyl O O
and O O
midazolam O O
was O O
effective O O
in O O
preventing O O
etomidate O O
- O O
induced O O
myoclonus B B_DISEASE
. O O

Convulsant O O
effect O O
of O O
lindane O O
and O O
regional O O
brain O O
concentration O O
of O O
GABA O O
and O O
dopamine O O
. O O

We O O
studied O O
the O O
effect O O
of O O
lindane O O
( O O
150 O O
mg O O
/ O O
kg O O
) O O
on O O
the O O
GABAergic O O
and O O
dopaminergic O O
systems O O
by O O
measuring O O
the O O
concentration O O
of O O
GABA O O
, O O
dopamine O O
and O O
its O O
metabolites O O
in O O
7 O O
brain O O
areas O O
at O O
the O O
onset O O
of O O
seizures B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

All O O
animals O O
suffered O O
tonic O O
convulsions B B_DISEASE
at O O
18 O O
. O O
3 O O
+ O O
/ O O
- O O
1 O O
. O O
4 O O
min O O
after O O
lindane O O
administration O O
. O O

The O O
concentration O O
of O O
GABA O O
was O O
only O O
slightly O O
but O O
significantly O O
decreased O O
in O O
the O O
colliculi O O
without O O
modifications O O
in O O
the O O
other O O
areas O O
. O O

The O O
concentration O O
of O O
dopamine O O
was O O
increased O O
in O O
the O O
mesencephalon O O
and O O
that O O
of O O
its O O
metabolite O O
DOPAC O O
was O O
also O O
increased O O
in O O
the O O
mesencephalon O O
and O O
the O O
striatum O O
. O O

Cholestatic B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
presentation O O
of O O
yellow O O
phosphorus O O
poisoning B B_DISEASE
. O O

Yellow O O
phosphorus O O
, O O
a O O
component O O
of O O
certain O O
pesticide O O
pastes O O
and O O
fireworks O O
, O O
is O O
well O O
known O O
to O O
cause O O
hepatotoxicity B B_DISEASE
. O O

Poisoning B B_DISEASE/B_PERSON
with O O
yellow O O
phosphorus O O
classically O O
manifests O O
with O O
acute B B_DISEASE
hepatitis I I_DISEASE
leading O O
to O O
acute B B_DISEASE
liver I I_DISEASE
failure I I_DISEASE
which O O
may O O
need O O
liver O O
transplantation O O
. O O

We O O
present O O
a O O
case O O
of O O
yellow O O
phosphorus O O
poisoning B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
which O O
a O O
patient O O
presented O O
with O O
florid O O
clinical O O
features O O
of O O
cholestasis B B_DISEASE
highlighting O O
the O O
fact O O
that O O
cholestasis B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
can O O
rarely O O
be O O
a O O
presenting O O
feature O O
of O O
yellow O O
phosphorus O O
hepatotoxicity B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Vasovagal B B_DISEASE_ADJECTIVE[DISEASE]
syncope I I_DISEASE_ADJECTIVE[DISEASE]
and O O
severe O O
bradycardia B B_DISEASE
following O O
intranasal O O
dexmedetomidine O O
for O O
pediatric O O
procedural O O
sedation O O
. O O

We O O
report O O
syncope B B_DISEASE
and O O
bradycardia B B_DISEASE
in O O
an O O
11 O O
- O O
year O O
- O O
old O O
girl O O
following O O
administration O O
of O O
intranasal O O
dexmedetomidine O O
for O O
sedation O O
for O O
a O O
voiding O O
cystourethrogram O O
. O O

The O O
primary O O
abnormality O O
found O O
was O O
persistent O O
bradycardia B B_DISEASE
, O O
and O O
she O O
was O O
admitted O O
to O O
the O O
hospital O O
for O O
telemetric O O
observation O O
. O O

The O O
bradycardia B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lasted O O
~ O O
2 O O
h O O
, O O
and O O
further O O
cardiac O O
workup O O
revealed O O
no O O
underlying O O
abnormality O O
. O O

Unanticipated O O
and O O
previously O O
unreported O O
outcomes O O
may O O
be O O
witnessed O O
as O O
we O O
expand O O
the O O
use O O
of O O
certain O O
sedatives O O
to O O
alternative O O
routes O O
of O O
administration O O
. O O

Paradoxical O O
severe O O
agitation B B_DISEASE
induced O O
by O O
add O O
- O O
on O O
high O O
- O O
doses O O
quetiapine O O
in O O
schizo B B_DISEASE/B_PERSON
- I I_DISEASE/I_PERSON
affective I I_DISEASE/I_PERSON
disorder I I_DISEASE/I_PERSON
. O O

We O O
report O O
the O O
case O O
of O O
a O O
35 O O
- O O
year O O
- O O
old O O
patient O O
suffering O O
from O O
schizo B B_DISEASE/B_LOCATION
- I I_DISEASE/I_LOCATION
affective I I_DISEASE/I_LOCATION
disorder I I_DISEASE/I_LOCATION
since O O
the O O
age O O
of O O
19 O O
years O O
, O O
treated O O
by O O
a O O
combination O O
of O O
first O O
- O O
generation O O
antipsychotics O O
, O O
zuclopenthixol O O
( O O
100 O O
mg O O
/ O O
day O O
) O O
and O O
lithium O O
( O O
1200 O O
mg O O
/ O O
day O O
) O O
( O O
serum O O
lithium O O
= O O
0 O O
. O O
85 O O
mEq O O
/ O O
l O O
) O O
. O O

This O O
patient O O
had O O
no O O
associated O O
personality B B_DISEASE_ADJECTIVE[DISEASE]
disorder I I_DISEASE_ADJECTIVE[DISEASE]
( O O
particularly O O
no O O
antisocial B B_DISEASE
disorder I I_DISEASE
) O O
and O O
no O O
substance B B_DISEASE
abuse I I_DISEASE
disorder I I_DISEASE
. O O

Within O O
the O O
48 O O
h O O
following O O
the O O
gradual O O
introduction O O
of O O
quetiapine O O
( O O
up O O
to O O
600 O O
mg O O
/ O O
day O O
) O O
, O O
the O O
patient O O
presented O O
severe O O
agitation B B_DISEASE
without O O
an O O
environmental O O
explanation O O
, O O
contrasting O O
with O O
the O O
absence O O
of O O
a O O
history O O
of O O
aggressiveness B B_DISEASE
or O O
personality B B_DISEASE
disorder I I_DISEASE
. O O

The O O
diagnoses O O
of O O
manic B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
shift O O
and O O
akathisia B B_DISEASE
were O O
dismissed O O
. O O

The O O
withdrawal O O
and O O
the O O
gradual O O
reintroduction O O
of O O
quetiapine O O
2 O O
weeks O O
later O O
, O O
which O O
led O O
to O O
another O O
severe O O
agitation B B_DISEASE/B_TIME[MEASURE]
, O O
enabled O O
us O O
to O O
attribute O O
the O O
agitation B B_DISEASE/B_TIME[MEASURE]
specifically O O
to O O
quetiapine O O
. O O

Antioxidant O O
effects O O
of O O
bovine O O
lactoferrin O O
on O O
dexamethasone O O
- O O
induced O O
hypertension B B_DISEASE
in O O
rat O O
. O O

Dexamethasone O O
- O O
( O O
Dex O O
- O O
) O O
induced O O
hypertension B B_DISEASE
is O O
associated O O
with O O
enhanced O O
oxidative O O
stress O O
. O O

Lactoferrin O O
( O O
LF O O
) O O
is O O
an O O
iron O O
- O O
binding O O
glycoprotein O O
with O O
antihypertensive O O
properties O O
. O O

In O O
this O O
study O O
, O O
we O O
investigated O O
the O O
effect O O
of O O
chronic O O
administration O O
of O O
LF O O
on O O
oxidative O O
stress O O
and O O
hypertension B B_DISEASE/B_GENE
upon O O
Dex O O
administration O O
. O O

Male O O
Wistar O O
rats O O
were O O
treated O O
by O O
Dex O O
( O O
30 O O
u O O
g O O
/ O O
kg O O
/ O O
day O O
subcutaneously O O
) O O
or O O
saline O O
for O O
14 O O
days O O
. O O

Oral O O
bovine O O
LF O O
( O O
30 O O
, O O
100 O O
, O O
300 O O
mg O O
/ O O
kg O O
) O O
was O O
given O O
from O O
day O O
8 O O
to O O
14 O O
in O O
a O O
reversal O O
study O O
. O O

In O O
a O O
prevention O O
study O O
, O O
rats O O
received O O
4 O O
days O O
of O O
LF O O
treatment O O
followed O O
by O O
Dex O O
and O O
continued O O
during O O
the O O
test O O
period O O
. O O

Thymus O O
weight O O
was O O
used O O
as O O
a O O
marker O O
of O O
glucocorticoid O O
activity O O
. O O

Plasma O O
hydrogen O O
peroxide O O
( O O
H2O2 O O
) O O
concentration O O
and O O
ferric O O
reducing O O
antioxidant O O
power O O
( O O
FRAP O O
) O O
value O O
were O O
determined O O
. O O

LF O O
lowered O O
( O O
P O O
< O O
0 O O
. O O
01 O O
) O O
and O O
dose O O
dependently O O
prevented O O
( O O
P O O
< O O
0 O O
. O O
001 O O
) O O
Dex O O
- O O
induced O O
hypertension B B_DISEASE
. O O

LF O O
prevented O O
body O O
weight B B_DISEASE/B_MEASURE
loss I I_DISEASE/I_MEASURE
and O O
significantly O O
reduced O O
the O O
elevated O O
plasma O O
H2O2 O O
and O O
increased O O
FRAP O O
values O O
. O O

Chronic O O
administration O O
of O O
LF O O
strongly O O
reduced O O
the O O
blood O O
pressure O O
and O O
production O O
of O O
ROS O O
and O O
improved O O
antioxidant O O
capacity O O
in O O
Dex O O
- O O
induced O O
hypertension B B_DISEASE
, O O
suggesting O O
the O O
role O O
of O O
inhibition O O
of O O
oxidative O O
stress O O
as O O
another O O
mechanism O O
of O O
antihypertensive O O
action O O
of O O
LF O O
. O O

The O O
association O O
between O O
tranexamic O O
acid O O
and O O
convulsive B B_DISEASE_ADJECTIVE[DISEASE]
seizures B I_DISEASE_ADJECTIVE[DISEASE]
after O O
cardiac O O
surgery O O
: O O
a O O
multivariate O O
analysis O O
in O O
11 O O
529 O O
patients O O
. O O

Because O O
of O O
a O O
lack O O
of O O
contemporary O O
data O O
regarding O O
seizures B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O O
cardiac O O
surgery O O
, O O
we O O
undertook O O
a O O
retrospective O O
analysis O O
of O O
prospectively O O
collected O O
data O O
from O O
11 O O
529 O O
patients O O
in O O
whom O O
cardiopulmonary O O
bypass O O
was O O
used O O
from O O
January O O
2004 O O
to O O
December O O
2010 O O
. O O

A O O
convulsive B B_DISEASE
seizure B I_DISEASE
was O O
defined O O
as O O
a O O
transient O O
episode O O
of O O
disturbed O O
brain O O
function O O
characterised O O
by O O
abnormal B B_DISEASE
involuntary I I_DISEASE
motor I I_DISEASE
movements I I_DISEASE
. O O

Multivariate O O
regression O O
analysis O O
was O O
performed O O
to O O
identify O O
independent O O
predictors O O
of O O
postoperative O O
seizures B B_DISEASE
. O O

A O O
total O O
of O O
100 O O
( O O
0 O O
. O O
9 O O
% O O
) O O
patients O O
developed O O
postoperative O O
convulsive B B_DISEASE
seizures B I_DISEASE
. O O

Generalised B B_DISEASE/B_PERSON
and I I_DISEASE/I_PERSON
focal I I_DISEASE/I_PERSON
seizures I I_DISEASE/I_PERSON
were O O
identified O O
in O O
68 O O
and O O
32 O O
patients O O
, O O
respectively O O
. O O

The O O
median O O
( O O
IQR O O
[ O O
range O O
] O O
) O O
time O O
after O O
surgery O O
when O O
the O O
seizure B B_DISEASE
occurred O O
was O O
7 O O
( O O
6 O O
- O O
12 O O
[ O O
1 O O
- O O
216 O O
] O O
) O O
h O O
and O O
8 O O
( O O
6 O O
- O O
11 O O
[ O O
4 O O
- O O
18 O O
] O O
) O O
h O O
, O O
respectively O O
. O O

Epileptiform O O
findings O O
on O O
electroencephalography O O
were O O
seen O O
in O O
19 O O
patients O O
. O O

Independent O O
predictors O O
of O O
postoperative O O
seizures B B_DISEASE
included O O
age O O
, O O
female O O
sex O O
, O O
redo O O
cardiac O O
surgery O O
, O O
calcification O O
of O O
ascending O O
aorta O O
, O O
congestive B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
heart I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
failure I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
deep O O
hypothermic B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
circulatory O O
arrest O O
, O O
duration O O
of O O
aortic O O
cross O O
- O O
clamp O O
and O O
tranexamic O O
acid O O
. O O

When O O
tested O O
in O O
a O O
multivariate O O
regression O O
analysis O O
, O O
tranexamic O O
acid O O
was O O
a O O
strong O O
independent O O
predictor O O
of O O
seizures B B_DISEASE
( O O
OR O O
14 O O
. O O
3 O O
, O O
95 O O
% O O
CI O O
5 O O
. O O
5 O O
- O O
36 O O
. O O
7 O O
; O O
p O O
< O O
0 O O
. O O
001 O O
) O O
. O O

Patients O O
with O O
convulsive B B_DISEASE
seizures B I_DISEASE
had O O
2 O O
. O O
5 O O
times O O
higher O O
in O O
- O O
hospital O O
mortality O O
rates O O
and O O
twice O O
the O O
length O O
of O O
hospital O O
stay O O
compared O O
with O O
patients O O
without O O
convulsive B B_DISEASE/B_PERSON
seizures B I_DISEASE/I_PERSON
. O O

Mean O O
( O O
IQR O O
[ O O
range O O
] O O
) O O
length O O
of O O
stay O O
in O O
the O O
intensive O O
care O O
unit O O
was O O
115 O O
( O O
49 O O
- O O
228 O O
[ O O
32 O O
- O O
481 O O
] O O
) O O
h O O
in O O
patients O O
with O O
convulsive B B_DISEASE
seizures B I_DISEASE
compared O O
with O O
26 O O
( O O
22 O O
- O O
69 O O
[ O O
14 O O
- O O
1080 O O
] O O
) O O
h O O
in O O
patients O O
without O O
seizures B B_DISEASE/B_PERSON
( O O
p O O
< O O
0 O O
. O O
001 O O
) O O
. O O

Convulsive B B_DISEASE_ADJECTIVE[DISEASE]
seizures B I_DISEASE_ADJECTIVE[DISEASE]
are O O
a O O
serious O O
postoperative B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complication I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
cardiac O O
surgery O O
. O O

As O O
tranexamic O O
acid O O
is O O
the O O
only O O
modifiable O O
factor O O
, O O
its O O
administration O O
, O O
particularly O O
in O O
doses O O
exceeding O O
80 O O
mg O O
. O O
kg O O
( O O
- O O
1 O O
) O O
, O O
should O O
be O O
weighed O O
against O O
the O O
risk O O
of O O
postoperative O O
seizures B B_DISEASE
. O O

Dysfunctional B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
overnight I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
memory I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
consolidation O O
in O O
ecstasy O O
users O O
. O O

Previous O O
studies O O
indicate O O
that O O
ecstasy O O
users O O
have O O
marked O O
and O O
persistent O O
neurocognitive O O
and O O
sleep B B_DISEASE_ADJECTIVE[DISEASE]
- I I_DISEASE_ADJECTIVE[DISEASE]
related I I_DISEASE_ADJECTIVE[DISEASE]
impairments I I_DISEASE_ADJECTIVE[DISEASE]
. O O

Memory O O
recall O O
of O O
word O O
pairs O O
was O O
evaluated O O
before O O
and O O
after O O
a O O
period O O
of O O
sleep O O
, O O
with O O
and O O
without O O
interference O O
prior O O
to O O
testing O O
. O O

In O O
addition O O
, O O
we O O
assessed O O
neurocognitive O O
performances O O
across O O
tasks O O
of O O
learning O O
, O O
memory O O
and O O
executive O O
functioning O O
. O O

Ecstasy O O
users O O
demonstrated O O
impaired B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
overnight I I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
memory I I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
consolidation O O
, O O
a O O
finding O O
that O O
was O O
more O O
pronounced O O
following O O
associative O O
interference O O
. O O

Additionally O O
, O O
ecstasy O O
users O O
demonstrated O O
impairments O O
on O O
tasks O O
recruiting O O
frontostriatal O O
and O O
hippocampal O O
neural O O
circuitry O O
, O O
in O O
the O O
domains O O
of O O
proactive O O
interference O O
memory O O
, O O
long O O
- O O
term O O
memory O O
, O O
encoding O O
, O O
working O O
memory O O
and O O
complex O O
planning O O
. O O

We O O
suggest O O
that O O
ecstasy O O
- O O
associated O O
dysfunction O O
in O O
fronto O O
- O O
temporal O O
circuitry O O
may O O
underlie O O
overnight O O
consolidation O O
memory B B_DISEASE_ADJECTIVE[DISEASE]
impairments I I_DISEASE_ADJECTIVE[DISEASE]
in O O
regular O O
ecstasy O O
users O O
. O O

Normoammonemic O O
encephalopathy B B_DISEASE
: O O
solely O O
valproate O O
induced O O
or O O
multiple O O
mechanisms O O
? O O

A O O
77 O O
- O O
year O O
- O O
old O O
woman O O
presented O O
with O O
subacute O O
onset O O
progressive O O
confusion B B_DISEASE
, O O
aggression B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
auditory B B_DISEASE
hallucinations I I_DISEASE
and O O
delusions B B_DISEASE
. O O

In O O
the O O
preceding O O
months O O
, O O
the O O
patient O O
had O O
a O O
number O O
of O O
admissions O O
with O O
transient O O
unilateral O O
hemiparesis B B_DISEASE
with O O
facial O O
droop O O
, O O
and O O
had O O
been O O
started O O
on O O
valproate O O
for O O
presumed O O
hemiplegic B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
migraine I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Valproate O O
was O O
withdrawn O O
soon O O
after O O
admission O O
and O O
her O O
cognitive O O
abilities O O
have O O
gradually O O
improved O O
over O O
3 O O
months O O
of O O
follow O O
- O O
up O O
. O O

Valproate O O
levels O O
taken O O
prior O O
to O O
withdrawal O O
were O O
subtherapeutic O O
and O O
the O O
patient O O
was O O
normoammonaemic O O
. O O

EEG O O
undertaken O O
during O O
inpatient O O
stay O O
showed O O
changes O O
consistent O O
with O O
encephalopathy B B_DISEASE
, O O
and O O
low O O
titre O O
N O O
- O O
methyl O O
- O O
D O O
- O O
aspartate O O
( O O
NMDA O O
) O O
receptor O O
antibodies O O
were O O
present O O
in O O
this O O
patient O O
. O O

The O O
possible O O
aetiologies O O
of O O
valproate O O
- O O
induced O O
encephalopathy B B_DISEASE
and O O
NMDA O O
receptor O O
- O O
associated O O
encephalitis B B_DISEASE
present O O
a O O
diagnostic O O
dilemma O O
. O O

We O O
present O O
a O O
putative O O
combinatorial O O
hypothesis O O
to O O
explain O O
this O O
patient O O
' O O
s O O
symptoms O O
. O O

Cerebellar B B_DISEASE
and I I_DISEASE
oculomotor I I_DISEASE
dysfunction I I_DISEASE
induced O O
by O O
rapid O O
infusion O O
of O O
pethidine O O
. O O

Pethidine O O
is O O
an O O
opioid O O
that O O
gains O O
its O O
popularity O O
for O O
the O O
effective O O
pain B B_DISEASE
control O O
through O O
acting O O
on O O
the O O
opioid O O
- O O
receptors O O
. O O

However O O
, O O
rapid O O
pain B B_DISEASE
relief O O
sometimes O O
brings O O
about O O
unfavourable O O
side O O
effects O O
that O O
largely O O
limit O O
its O O
clinical O O
utility O O
. O O

Common O O
side O O
effects O O
include O O
nausea B B_DISEASE
, O O
vomiting B B_DISEASE
and O O
hypotension B B_DISEASE
. O O

In O O
patients O O
with O O
impaired B B_DISEASE
renal I I_DISEASE
and I I_DISEASE
liver I I_DISEASE
function I I_DISEASE
, O O
and O O
those O O
who O O
need O O
long O O
- O O
term O O
pain B B_DISEASE
control O O
, O O
pethidine O O
may O O
cause O O
excitatory O O
central O O
nervous O O
system O O
( O O
CNS O O
) O O
effects O O
through O O
its O O
neurotoxic B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
metabolite O O
, O O
norpethidine O O
, O O
resulting O O
in O O
irritability B B_DISEASE
and O O
seizure B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
attack O O
. O O

In O O
this O O
case O O
report O O
, O O
we O O
highlight O O
opioid O O
' O O
s O O
inhibitory O O
side O O
effects O O
on O O
the O O
cerebellar O O
structure O O
that O O
causes O O
dysmetria B B_DISEASE
, O O
dysarthria B B_DISEASE/B_LOCATION
, O O
reduced O O
smooth O O
pursuit O O
gain O O
and O O
decreased O O
saccadic O O
velocity O O
. O O

Baboon B B_DISEASE
syndrome I I_DISEASE
induced O O
by O O
ketoconazole O O
. O O

A O O
27 O O
- O O
year O O
- O O
old O O
male O O
patient O O
presented O O
with O O
a O O
maculopapular B B_DISEASE/B_LOCATION
eruption I I_DISEASE/I_LOCATION
on O O
the O O
flexural O O
areas O O
and O O
buttocks O O
after O O
using O O
oral O O
ketoconazole O O
. O O

The O O
patient O O
was O O
diagnosed O O
with O O
drug O O
- O O
induced O O
baboon B B_DISEASE
syndrome I I_DISEASE
based O O
on O O
his O O
history O O
, O O
which O O
included O O
prior O O
sensitivity O O
to O O
topical O O
ketoconazole O O
, O O
a O O
physical O O
examination O O
, O O
and O O
histopathological O O
findings O O
. O O

Baboon B B_DISEASE/B_PROTEIN[GENE]
syndrome I B_DISEASE/I_PROTEIN[GENE]
is O O
a O O
drug O O
- O O
or O O
contact O O
allergen O O
- O O
related O O
maculopapular B B_DISEASE
eruption I I_DISEASE
that O O
typically O O
involves O O
the O O
flexural O O
and O O
gluteal O O
areas O O
. O O

To O O
the O O
best O O
of O O
our O O
knowledge O O
, O O
this O O
is O O
the O O
first O O
reported O O
case O O
of O O
ketoconazole O O
- O O
induced O O
baboon B B_DISEASE
syndrome I I_DISEASE
in O O
the O O
English O O
literature O O
. O O

A O O
Case O O
of O O
Sudden B B_DISEASE
Cardiac I I_DISEASE
Death I I_DISEASE
due O O
to O O
Pilsicainide O O
- O O
Induced O O
Torsades B B_DISEASE
de I I_DISEASE
Pointes I I_DISEASE
. O O

An O O
84 O O
- O O
year O O
- O O
old O O
male O O
received O O
oral O O
pilsicainide O O
, O O
a O O
pure O O
sodium O O
channel O O
blocker O O
with O O
slow O O
recovery O O
kinetics O O
, O O
to O O
convert O O
his O O
paroxysmal O O
atrial B B_DISEASE
fibrillation I I_DISEASE
to O O
a O O
sinus O O
rhythm O O
; O O
the O O
patient O O
developed O O
sudden B B_DISEASE
cardiac I I_DISEASE
death I I_DISEASE
two O O
days O O
later O O
. O O

The O O
Holter O O
electrocardiogram O O
, O O
which O O
was O O
worn O O
by O O
chance O O
, O O
revealed O O
torsade B B_DISEASE/B_LOCATION
de I I_DISEASE/I_LOCATION
pointes I I_DISEASE/I_LOCATION
with O O
gradually O O
prolonged O O
QT O O
intervals O O
. O O

Although O O
the O O
patient O O
' O O
s O O
renal O O
function O O
was O O
not O O
highly O O
impaired O O
and O O
the O O
dose O O
of O O
pilsicainide O O
was O O
low O O
, O O
the O O
plasma O O
concentration O O
of O O
pilsicainide O O
may O O
have O O
been O O
high O O
, O O
which O O
can O O
produce O O
torsades B B_DISEASE
de I I_DISEASE
pointes I I_DISEASE
in O O
the O O
octogenarian O O
. O O

Although O O
the O O
oral O O
administration O O
of O O
class O O
IC O O
drugs O O
, O O
including O O
pilsicainide O O
, O O
is O O
effective O O
to O O
terminate O O
atrial B B_DISEASE
fibrillation I I_DISEASE
, O O
careful O O
consideration O O
must O O
be O O
taken O O
before O O
giving O O
these O O
drugs O O
to O O
octogenarians O O
. O O

All O O
- O O
trans O O
retinoic O O
acid O O
- O O
induced O O
inflammatory O O
myositis B B_DISEASE
in O O
a O O
patient O O
with O O
acute B B_DISEASE/B_LOCATION
promyelocytic I I_DISEASE/I_LOCATION
leukemia I I_DISEASE/I_LOCATION
. O O

Only O O
a O O
handful O O
of O O
cases O O
of O O
ATRA O O
- O O
induced O O
myositis B B_DISEASE
in O O
children O O
have O O
been O O
reported O O
, O O
and O O
none O O
in O O
the O O
radiology O O
literature O O
. O O

We O O
present O O
such O O
a O O
case O O
in O O
a O O
15 O O
- O O
year O O
- O O
old O O
boy O O
with O O
APL B B_DISEASE/B_GENE
, O O
where O O
recognition O O
of O O
imaging O O
findings O O
played O O
a O O
crucial O O
role O O
in O O
making O O
the O O
diagnosis O O
and O O
facilitated O O
prompt O O
, O O
effective O O
treatment O O
. O O

Tolerability O O
of O O
lomustine O O
in O O
combination O O
with O O
cyclophosphamide O O
in O O
dogs O O
with O O
lymphoma B B_DISEASE
. O O

This O O
retrospective O O
study O O
describes O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
associated O O
with O O
a O O
protocol O O
of O O
lomustine O O
( O O
CCNU O O
) O O
and O O
cyclophosphamide O O
( O O
CTX O O
) O O
in O O
dogs O O
with O O
lymphoma B B_DISEASE
. O O

CCNU O O
was O O
administered O O
per O O
os O O
( O O
PO O O
) O O
at O O
a O O
targeted O O
dosage O O
of O O
60 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
body O O
surface O O
area O O
on O O
day O O
0 O O
, O O
CTX O O
was O O
administered O O
PO O O
at O O
a O O
targeted O O
dosage O O
of O O
250 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
divided O O
over O O
days O O
0 O O
through O O
4 O O
, O O
and O O
all O O
dogs O O
received O O
prophylactic O O
antibiotics O O
. O O

Ninety O O
treatments O O
were O O
given O O
to O O
the O O
57 O O
dogs O O
included O O
in O O
the O O
study O O
. O O

Neutropenia B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
the O O
principal O O
toxic O O
effect O O
, O O
and O O
the O O
overall O O
frequency O O
of O O
grade O O
4 O O
neutropenia B B_DISEASE
after O O
the O O
first O O
treatment O O
of O O
CCNU O O
/ O O
CTX O O
was O O
30 O O
% O O
( O O
95 O O
% O O
confidence O O
interval O O
, O O
19 O O
- O O
43 O O
% O O
) O O
. O O

The O O
mean O O
body O O
weight O O
of O O
dogs O O
with O O
grade O O
4 O O
neutropenia B B_DISEASE
( O O
19 O O
. O O
7 O O
kg O O
+ O O
13 O O
. O O
4 O O
kg O O
) O O
was O O
significantly O O
less O O
than O O
the O O
mean O O
body O O
weight O O
of O O
dogs O O
that O O
did O O
not O O
develop O O
grade O O
4 O O
neutropenia B B_DISEASE
( O O
31 O O
. O O
7 O O
kg O O
+ O O
12 O O
. O O
4 O O
kg O O
; O O
P O O
= O O
. O O
005 O O
) O O
. O O

One O O
dog O O
( O O
3 O O
% O O
) O O
developed O O
hematologic O O
changes O O
suggestive O O
of O O
hepatotoxicity B B_DISEASE
. O O

No O O
dogs O O
had O O
evidence O O
of O O
either O O
renal B B_DISEASE_ADJECTIVE[DISEASE]
toxicity I I_DISEASE_ADJECTIVE[DISEASE]
or O O
hemorrhagic B B_DISEASE
cystitis I I_DISEASE
. O O

Adverse O O
gastrointestinal O O
effects O O
were O O
uncommon O O
. O O

On O O
the O O
basis O O
of O O
the O O
findings O O
reported O O
herein O O
, O O
a O O
dose O O
of O O
60 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
of O O
CCNU O O
combined O O
with O O
250 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
of O O
CTX O O
( O O
divided O O
over O O
5 O O
days O O
) O O
q O O
4 O O
wk O O
is O O
tolerable O O
in O O
tumor B B_DISEASE/B_LOCATION
- O O
bearing O O
dogs O O
. O O

Nelarabine O O
neurotoxicity B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
concurrent O O
intrathecal O O
chemotherapy O O
: O O
Case O O
report O O
and O O
review O O
of O O
literature O O
. O O

Severe O O
nelarabine O O
neurotoxicity B B_DISEASE
in O O
a O O
patient O O
who O O
received O O
concurrent O O
intrathecal O O
( O O
IT O O
) O O
chemotherapy O O
is O O
reported O O
. O O

A O O
37 O O
- O O
year O O
- O O
old O O
Caucasian O O
woman O O
with O O
a O O
history O O
of O O
T B B_DISEASE
- I I_DISEASE
cell I I_DISEASE
lymphoblastic I I_DISEASE
lymphoma I I_DISEASE
was O O
admitted O O
for O O
relapsed O O
disease O O
. O O

She O O
was O O
originally O O
treated O O
with O O
induction O O
chemotherapy O O
followed O O
by O O
an O O
autologous O O
transplant O O
. O O

She O O
developed O O
relapsed O O
disease O O
10 O O
months O O
later O O
with O O
leukemic B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
involvement O O
. O O

She O O
was O O
re O O
- O O
induced O O
with O O
nelarabine O O
1500 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
on O O
days O O
1 O O
, O O
3 O O
, O O
and O O
5 O O
with O O
1 O O
dose O O
of O O
IT O O
cytarabine O O
100 O O
mg O O
on O O
day O O
2 O O
as O O
central O O
nervous O O
system O O
( O O
CNS O O
) O O
prophylaxis O O
. O O

At O O
the O O
time O O
of O O
treatment O O
, O O
she O O
was O O
on O O
continuous O O
renal O O
replacement O O
therapy O O
due O O
to O O
sequelae O O
of O O
tumor B B_DISEASE
lysis I I_DISEASE
syndrome I I_DISEASE
( O O
TLS B B_DISEASE/B_GENE
) O O
. O O

She O O
received O O
a O O
second O O
cycle O O
of O O
nelarabine O O
without O O
additional O O
IT O O
prophylaxis O O
one O O
month O O
later O O
. O O

Predominantly O O
sensory O O
, O O
though O O
also O O
motor O O
and O O
autonomic O O
, O O
peripheral B B_DISEASE_ADJECTIVE[DISEASE]
neuropathy I I_DISEASE_ADJECTIVE[DISEASE]
started O O
in O O
her O O
feet O O
, O O
ascended O O
proximally O O
to O O
the O O
mid O O
- O O
thoracic O O
region O O
, O O
and O O
eventually O O
included O O
her O O
distal O O
upper O O
extremities O O
. O O

Her O O
neuropathy B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
stabilized O O
and O O
showed O O
slight O O
improvement O O
and O O
ultimately O O
received O O
an O O
unrelated O O
, O O
reduced O O
- O O
intensity O O
allogeneic O O
transplant O O
while O O
in O O
complete O O
remission O O
, O O
but O O
relapsed O O
disease O O
10 O O
weeks O O
later O O
. O O

She O O
is O O
currently O O
being O O
treated O O
with O O
best O O
supportive O O
care O O
. O O

To O O
our O O
knowledge O O
, O O
this O O
is O O
the O O
first O O
published O O
case O O
report O O
of O O
severe O O
neurotoxicity B B_DISEASE
caused O O
by O O
nelarabine O O
in O O
a O O
patient O O
who O O
received O O
concurrent O O
IT O O
chemotherapy O O
. O O

Valproate O O
- O O
induced O O
hyperammonemic B B_DISEASE
encephalopathy B I_DISEASE
in O O
a O O
renal O O
transplanted O O
patient O O
. O O

Neurological B B_DISEASE
complications I I_DISEASE
after O O
renal O O
transplantation O O
constitute O O
an O O
important O O
cause O O
of O O
morbidity O O
and O O
mortality O O
. O O

Their O O
differential O O
diagnosis O O
is O O
difficult O O
and O O
essential O O
for O O
subsequent O O
patient O O
' O O
s O O
management O O
. O O

Valproate O O
- O O
induced O O
hyperammonemic B B_DISEASE
encephalopathy B I_DISEASE
is O O
an O O
uncommon O O
but O O
serious O O
effect O O
of O O
valproate O O
treatment O O
. O O

Here O O
, O O
we O O
describe O O
the O O
case O O
of O O
a O O
15 O O
- O O
year O O
- O O
old O O
girl O O
who O O
was O O
on O O
a O O
long O O
- O O
term O O
therapy O O
with O O
valproate O O
due O O
to O O
epilepsy B B_DISEASE
and O O
revealed O O
impaired B B_DISEASE_ADJECTIVE[DISEASE]
consciousness I I_DISEASE_ADJECTIVE[DISEASE]
with O O
hyperammonemia B B_DISEASE
12 O O
days O O
after O O
renal O O
transplantation O O
. O O

Clinicians O O
should O O
increase O O
their O O
awareness O O
for O O
potential O O
complication O O
of O O
valproate O O
, O O
especially O O
in O O
transplanted O O
patients O O
. O O

Necrotising B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fasciitis I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O O
bortezomib O O
and O O
dexamethasone O O
- O O
containing O O
regimen O O
in O O
an O O
elderly O O
patient O O
of O O
Waldenstrom B B_DISEASE/B_LOCATION
macroglobulinaemia I I_DISEASE/I_LOCATION
. O O

Bortezomib O O
and O O
high O O
- O O
dose O O
dexamethasone O O
- O O
containing O O
regimens O O
are O O
considered O O
to O O
be O O
generally O O
tolerable O O
with O O
few O O
severe O O
bacterial B B_DISEASE
infections I I_DISEASE
in O O
patients O O
with O O
B O O
- O O
cell O O
malignancies B B_DISEASE
. O O

However O O
, O O
information O O
is O O
limited O O
concerning O O
the O O
safety O O
of O O
the O O
regimen O O
in O O
elderly O O
patients O O
. O O

We O O
report O O
a O O
case O O
of O O
a O O
76 O O
- O O
year O O
- O O
old O O
man O O
with O O
Waldenstrom B B_DISEASE/B_LOCATION
macroglobulinaemia I I_DISEASE/I_LOCATION
who O O
suffered O O
necrotising B B_DISEASE
fasciitis I I_DISEASE
without O O
neutropenia B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O O
the O O
combination O O
treatment O O
with O O
bortezomib O O
, O O
high O O
- O O
dose O O
dexamethasone O O
and O O
rituximab O O
. O O

Physicians O O
should O O
recognise O O
the O O
possibility O O
of O O
fatal O O
bacterial B B_DISEASE
infections I I_DISEASE
related O O
to O O
bortezomib O O
plus O O
high O O
- O O
dose O O
dexamethasone O O
in O O
elderly O O
patients O O
, O O
and O O
we O O
believe O O
this O O
case O O
warrants O O
further O O
investigation O O
. O O

An O O
integrated O O
characterization O O
of O O
serological O O
, O O
pathological O O
, O O
and O O
functional O O
events O O
in O O
doxorubicin O O
- O O
induced O O
cardiotoxicity B B_DISEASE
. O O

Many O O
efficacious O O
cancer B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatments O O
cause O O
significant O O
cardiac O O
morbidity O O
, O O
yet O O
biomarkers O O
or O O
functional O O
indices O O
of O O
early O O
damage O O
, O O
which O O
would O O
allow O O
monitoring O O
and O O
intervention O O
, O O
are O O
lacking O O
. O O

In O O
this O O
study O O
, O O
we O O
have O O
utilized O O
a O O
rat O O
model O O
of O O
progressive O O
doxorubicin O O
( O O
DOX O O
) O O
- O O
induced O O
cardiomyopathy B B_DISEASE
, O O
applying O O
multiple O O
approaches O O
, O O
including O O
cardiac O O
magnetic O O
resonance O O
imaging O O
( O O
MRI O O
) O O
, O O
to O O
provide O O
the O O
most O O
comprehensive O O
characterization O O
to O O
date O O
of O O
the O O
timecourse O O
of O O
serological O O
, O O
pathological O O
, O O
and O O
functional O O
events O O
underlying O O
this O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Hannover O O
Wistar O O
rats O O
were O O
dosed O O
with O O
1 O O
. O O
25 O O
mg O O
/ O O
kg O O
DOX O O
weekly O O
for O O
8 O O
weeks O O
followed O O
by O O
a O O
4 O O
week O O
off O O
- O O
dosing O O
" O O
recovery O O
" O O
period O O
. O O

Electron O O
microscopy O O
of O O
the O O
myocardium O O
revealed O O
subcellular B B_DISEASE_ADJECTIVE[DISEASE]
degeneration I I_DISEASE_ADJECTIVE[DISEASE]
and O O
marked O O
mitochondrial O O
changes O O
after O O
a O O
single O O
dose O O
. O O

Histopathological O O
analysis O O
revealed O O
progressive O O
cardiomyocyte B B_DISEASE
degeneration I I_DISEASE
, O O
hypertrophy B B_DISEASE
/ O O
cytomegaly O O
, O O
and O O
extensive O O
vacuolation O O
after O O
two O O
doses O O
. O O

Extensive O O
replacement O O
fibrosis B B_DISEASE
( O O
quantified O O
by O O
Sirius O O
red O O
staining O O
) O O
developed O O
during O O
the O O
off O O
- O O
dosing O O
period O O
. O O

Functional O O
indices O O
assessed O O
by O O
cardiac O O
MRI O O
( O O
including O O
left O O
ventricular O O
ejection O O
fraction O O
( O O
LVEF O O
) O O
, O O
cardiac O O
output O O
, O O
and O O
E O O
/ O O
A O O
ratio O O
) O O
declined O O
progressively O O
, O O
reaching O O
statistical O O
significance O O
after O O
two O O
doses O O
and O O
culminating O O
in O O
" O O
clinical O O
" O O
LV B B_DISEASE_ADJECTIVE[DISEASE]
dysfunction I I_DISEASE_ADJECTIVE[DISEASE]
by O O
12 O O
weeks O O
. O O

Troponin O O
I O O
levels O O
positively O O
correlated O O
with O O
delayed O O
and O O
peak O O
gadolinium O O
contrast O O
enhancement O O
, O O
histopathological O O
grading O O
, O O
and O O
diastolic B B_DISEASE/B_MEASURE
dysfunction I I_DISEASE/I_MEASURE
. O O

In O O
summary O O
, O O
subcellular O O
cardiomyocyte B B_DISEASE
degeneration I I_DISEASE
was O O
the O O
earliest O O
marker O O
, O O
followed O O
by O O
progressive O O
functional O O
decline O O
and O O
histopathological O O
manifestations O O
. O O

However O O
, O O
all O O
indices O O
predated O O
" O O
clinical O O
" O O
LV B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dysfunction I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
thus O O
warrant O O
further O O
evaluation O O
as O O
predictive O O
biomarkers O O
. O O

Intradermal O O
glutamate O O
and O O
capsaicin O O
injections O O
: O O
intra O O
- O O
and O O
interindividual O O
variability O O
of O O
provoked O O
hyperalgesia B B_DISEASE/B_MEASURE
and O O
allodynia B B_DISEASE
. O O

Intradermal O O
injections O O
of O O
glutamate O O
and O O
capsaicin O O
are O O
attractive O O
to O O
use O O
in O O
human O O
experimental O O
pain B B_DISEASE
models O O
because O O
hyperalgesia B B_DISEASE
and O O
allodynia B B_DISEASE
mimic O O
isolated O O
aspects O O
of O O
clinical O O
pain B B_DISEASE
disorders I I_DISEASE
. O O

The O O
aim O O
of O O
the O O
present O O
study O O
was O O
to O O
investigate O O
the O O
reproducibility O O
of O O
these O O
models O O
. O O

Twenty O O
healthy O O
male O O
volunteers O O
( O O
mean O O
age O O
24 O O
years O O
; O O
range O O
18 O O
- O O
38 O O
years O O
) O O
received O O
intradermal O O
injections O O
of O O
glutamate O O
and O O
capsaicin O O
in O O
the O O
volar O O
forearm O O
. O O

Magnitudes O O
of O O
secondary O O
pinprick O O
hyperalgesia B B_DISEASE
and O O
brush O O
- O O
evoked O O
allodynia B B_DISEASE
were O O
investigated O O
using O O
von O O
Frey O O
filaments O O
( O O
gauges O O
10 O O
, O O
15 O O
, O O
60 O O
and O O
100 O O
g O O
) O O
and O O
brush O O
strokes O O
. O O

Areas O O
of O O
secondary B B_DISEASE
hyperalgesia I I_DISEASE
and O O
allodynia B B_DISEASE
were O O
quantified O O
immediately O O
after O O
injection O O
and O O
after O O
15 O O
, O O
30 O O
and O O
60 O O
min O O
. O O

Two O O
identical O O
experiments O O
separated O O
by O O
at O O
least O O
7 O O
days O O
were O O
performed O O
. O O

Reproducibility O O
across O O
and O O
within O O
volunteers O O
( O O
inter O O
- O O
and O O
intra O O
- O O
individual O O
variation O O
, O O
respectively O O
) O O
was O O
assessed O O
using O O
intraclass O O
correlation O O
coefficient O O
( O O
ICC O O
) O O
and O O
coefficient O O
of O O
variation O O
( O O
CV O O
) O O
. O O

Secondary O O
pinprick O O
hyperalgesia B B_DISEASE
was O O
observed O O
as O O
a O O
marked O O
increase O O
in O O
the O O
visual O O
analogue O O
scale O O
( O O
VAS O O
) O O
response O O
to O O
von O O
Frey O O
gauges O O
60 O O
and O O
100 O O
g O O
( O O
P O O
< O O
0 O O
. O O
001 O O
) O O
after O O
glutamate O O
injection O O
. O O

For O O
capsaicin O O
, O O
secondary O O
pinprick O O
hyperalgesia B B_DISEASE
was O O
detected O O
with O O
all O O
von O O
Frey O O
gauges O O
( O O
P O O
< O O
0 O O
. O O
001 O O
) O O
. O O

Glutamate O O
evoked O O
reproducible O O
VAS O O
response O O
to O O
all O O
von O O
Frey O O
gauges O O
( O O
ICC O O
> O O
0 O O
. O O
60 O O
) O O
and O O
brush O O
strokes O O
( O O
ICC O O
> O O
0 O O
. O O
83 O O
) O O
. O O

Capsaicin O O
injection O O
was O O
reproducible O O
for O O
secondary B B_DISEASE
hyperalgesia I I_DISEASE
( O O
ICC O O
> O O
0 O O
. O O
70 O O
) O O
and O O
allodynia B B_DISEASE
( O O
ICC O O
> O O
0 O O
. O O
71 O O
) O O
. O O

Intra O O
- O O
individual O O
variability O O
was O O
generally O O
lower O O
for O O
the O O
VAS O O
response O O
to O O
von O O
Frey O O
and O O
brush O O
compared O O
with O O
areas O O
of O O
secondary B B_DISEASE
hyperalgesia I I_DISEASE
and O O
allodynia B B_DISEASE
. O O

In O O
conclusion O O
, O O
glutamate O O
and O O
capsaicin O O
yield O O
reproducible O O
hyperalgesic B B_DISEASE_ADJECTIVE[DISEASE]
and O O
allodynic B B_DISEASE_ADJECTIVE[DISEASE]
responses O O
, O O
and O O
the O O
present O O
model O O
is O O
well O O
suited O O
for O O
basic O O
research O O
, O O
as O O
well O O
as O O
for O O
assessing O O
the O O
modulation O O
of O O
central O O
phenomena O O
. O O

Ocular O O
- O O
specific O O
ER O O
stress O O
reduction O O
rescues O O
glaucoma B B_DISEASE
in O O
murine O O
glucocorticoid O O
- O O
induced O O
glaucoma B B_DISEASE
. O O

Administration O O
of O O
glucocorticoids O O
induces O O
ocular B B_DISEASE
hypertension I I_DISEASE
in O O
some O O
patients O O
. O O

The O O
underlying O O
pathology O O
of O O
glucocorticoid O O
- O O
induced O O
glaucoma B B_DISEASE
is O O
not O O
fully O O
understood O O
, O O
due O O
in O O
part O O
to O O
lack O O
of O O
an O O
appropriate O O
animal O O
model O O
. O O

Here O O
, O O
we O O
developed O O
a O O
murine O O
model O O
of O O
glucocorticoid O O
- O O
induced O O
glaucoma B B_DISEASE
that O O
exhibits O O
glaucoma B B_DISEASE
features O O
that O O
are O O
observed O O
in O O
patients O O
. O O

Treatment O O
of O O
WT O O
mice O O
with O O
topical O O
ocular O O
0 O O
. O O
1 O O
% O O
dexamethasone O O
led O O
to O O
elevation O O
of O O
intraocular O O
pressure O O
( O O
IOP O O
) O O
, O O
functional O O
and O O
structural O O
loss O O
of O O
retinal B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ganglion I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
cells O O
, O O
and O O
axonal B B_DISEASE
degeneration I I_DISEASE
, O O
resembling O O
glucocorticoid O O
- O O
induced O O
glaucoma B B_DISEASE
in O O
human O O
patients O O
. O O

Furthermore O O
, O O
dexamethasone O O
- O O
induced O O
ocular B B_DISEASE/B_GENE
hypertension I I_DISEASE/I_GENE
was O O
associated O O
with O O
chronic O O
ER O O
stress O O
of O O
the O O
trabecular O O
meshwork O O
( O O
TM O O
) O O
. O O

Dexamethasone O O
induced O O
the O O
transcriptional O O
factor O O
CHOP O O
, O O
a O O
marker O O
for O O
chronic O O
ER O O
stress O O
, O O
in O O
the O O
anterior O O
segment O O
tissues O O
, O O
and O O
Chop O O
deletion O O
reduced O O
ER O O
stress O O
in O O
these O O
tissues O O
and O O
prevented O O
dexamethasone O O
- O O
induced O O
ocular B B_DISEASE/B_GENE
hypertension I I_DISEASE/I_GENE
. O O

Furthermore O O
, O O
reduction O O
of O O
ER O O
stress O O
in O O
the O O
TM O O
with O O
sodium O O
4 O O
- O O
phenylbutyrate O O
prevented O O
dexamethasone O O
- O O
induced O O
ocular B B_DISEASE/B_GENE
hypertension I I_DISEASE/I_GENE
in O O
WT O O
mice O O
. O O

Our O O
data O O
indicate O O
that O O
ER O O
stress O O
contributes O O
to O O
glucocorticoid O O
- O O
induced O O
ocular B B_DISEASE/B_GENE
hypertension I I_DISEASE/I_GENE
and O O
suggest O O
that O O
reducing O O
ER O O
stress O O
has O O
potential O O
as O O
a O O
therapeutic O O
strategy O O
for O O
treating O O
glucocorticoid O O
- O O
induced O O
glaucoma B B_DISEASE
. O O

Effects O O
of O O
ginsenosides O O
on O O
opioid O O
- O O
induced O O
hyperalgesia B B_DISEASE
in O O
mice O O
. O O

Opioid O O
- O O
induced O O
hyperalgesia B B_DISEASE
( O O
OIH B B_DISEASE/B_LOCATION
) O O
is O O
characterized O O
by O O
nociceptive O O
sensitization O O
caused O O
by O O
the O O
cessation O O
of O O
chronic O O
opioid O O
use O O
. O O

OIH B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
can O O
limit O O
the O O
clinical O O
use O O
of O O
opioid O O
analgesics O O
and O O
complicate O O
withdrawal O O
from O O
opioid B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
addiction I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
this O O
study O O
, O O
we O O
investigated O O
the O O
effects O O
of O O
Re O O
, O O
Rg1 O O
, O O
and O O
Rb1 O O
ginsenosides O O
, O O
the O O
bioactive O O
components O O
of O O
ginseng O O
, O O
on O O
OIH B B_DISEASE/B_GENE
. O O

OIH B B_DISEASE
was O O
achieved O O
in O O
mice O O
after O O
subcutaneous O O
administration O O
of O O
morphine O O
for O O
7 O O
consecutive O O
days O O
three O O
times O O
per O O
day O O
. O O

During O O
withdrawal O O
( O O
days O O
8 O O
and O O
9 O O
) O O
, O O
these O O
mice O O
were O O
administered O O
Re O O
, O O
Rg1 O O
, O O
or O O
Rb1 O O
intragastrically O O
two O O
times O O
per O O
day O O
. O O

Re O O
( O O
300 O O
mg O O
/ O O
kg O O
) O O
inhibited O O
OIH B B_DISEASE
in O O
both O O
the O O
thermal O O
sensitivity O O
test O O
and O O
the O O
acetic O O
acid O O
- O O
induced O O
writhing O O
test O O
. O O

However O O
, O O
the O O
Rg1 O O
and O O
Rb1 O O
ginsenosides O O
failed O O
to O O
prevent O O
OIH B B_DISEASE
in O O
either O O
test O O
. O O

Furthermore O O
, O O
Rg1 O O
showed O O
a O O
tendency O O
to O O
aggravate O O
OIH B B_DISEASE
in O O
the O O
acetic O O
acid O O
- O O
induced O O
writhing O O
test O O
. O O

Our O O
data O O
suggested O O
that O O
the O O
ginsenoside O O
Re O O
, O O
but O O
not O O
Rg1 O O
or O O
Rb1 O O
, O O
may O O
contribute O O
toward O O
reversal O O
of O O
OIH B B_DISEASE/B_GENE
. O O

A O O
comparison O O
of O O
severe O O
hemodynamic O O
disturbances O O
between O O
dexmedetomidine O O
and O O
propofol O O
for O O
sedation O O
in O O
neurocritical O O
care O O
patients O O
. O O

OBJECTIVE O O
: O O
Dexmedetomidine O O
and O O
propofol O O
are O O
commonly O O
used O O
sedatives O O
in O O
neurocritical O O
care O O
as O O
they O O
allow O O
for O O
frequent O O
neurologic O O
examinations O O
. O O

DESIGN O O
: O O
Multicenter O O
, O O
retrospective O O
, O O
propensity O O
- O O
matched O O
cohort O O
study O O
. O O

SETTING O O
: O O
Neurocritical O O
care O O
units O O
at O O
two O O
academic O O
medical O O
centers O O
with O O
dedicated O O
neurocritical O O
care O O
teams O O
and O O
board O O
- O O
certified O O
neurointensivists O O
. O O

PATIENTS O O
: O O
Neurocritical O O
care O O
patients O O
admitted O O
between O O
July O O
2009 O O
and O O
September O O
2012 O O
were O O
evaluated O O
and O O
then O O
matched O O
1 O O
: O O
1 O O
based O O
on O O
propensity O O
scoring O O
of O O
baseline O O
characteristics O O
. O O

INTERVENTIONS O O
: O O
Continuous O O
sedation O O
with O O
dexmedetomidine O O
or O O
propofol O O
. O O

MEASUREMENTS O O
AND O O
MAIN O O
RESULTS O O
: O O
A O O
total O O
of O O
342 O O
patients O O
( O O
105 O O
dexmedetomidine O O
and O O
237 O O
propofol O O
) O O
were O O
included O O
in O O
the O O
analysis O O
, O O
with O O
190 O O
matched O O
( O O
95 O O
in O O
each O O
group O O
) O O
by O O
propensity O O
score O O
. O O

The O O
primary O O
outcome O O
of O O
this O O
study O O
was O O
a O O
composite O O
of O O
severe O O
hypotension B B_DISEASE
( O O
mean O O
arterial O O
pressure O O
< O O
60 O O
mm O O
Hg O O
) O O
and O O
bradycardia B B_DISEASE
( O O
heart O O
rate O O
< O O
50 O O
beats O O
/ O O
min O O
) O O
during O O
sedative O O
infusion O O
. O O

When O O
analyzed O O
separately O O
, O O
no O O
differences O O
could O O
be O O
found O O
in O O
the O O
prevalence O O
of O O
severe O O
hypotension B B_DISEASE
or O O
bradycardia B B_DISEASE
in O O
either O O
the O O
unmatched O O
or O O
matched O O
cohorts O O
. O O

CONCLUSIONS O O
: O O
Severe O O
hypotension B B_DISEASE
and O O
bradycardia B B_DISEASE
occur O O
at O O
similar O O
prevalence O O
in O O
neurocritical O O
care O O
patients O O
who O O
receive O O
dexmedetomidine O O
or O O
propofol O O
. O O

Providers O O
should O O
similarly O O
consider O O
the O O
likelihood O O
of O O
hypotension B B_DISEASE
or O O
bradycardia B B_DISEASE
before O O
starting O O
either O O
sedative O O
. O O

Hydroxytyrosol O O
ameliorates O O
oxidative O O
stress O O
and O O
mitochondrial B B_DISEASE_ADJECTIVE[DISEASE]
dysfunction I I_DISEASE_ADJECTIVE[DISEASE]
in O O
doxorubicin O O
- O O
induced O O
cardiotoxicity B B_DISEASE/B_GENE
in O O
rats O O
with O O
breast B B_DISEASE
cancer I I_DISEASE
. O O

Oxidative O O
stress O O
is O O
involved O O
in O O
several O O
processes O O
including O O
cancer B B_DISEASE/B_ORGANISM_FUNCTION
, O O
aging O O
and O O
cardiovascular B B_DISEASE
disease I I_DISEASE
, O O
and O O
has O O
been O O
shown O O
to O O
potentiate O O
the O O
therapeutic O O
effect O O
of O O
drugs O O
such O O
as O O
doxorubicin O O
. O O

Doxorubicin O O
causes O O
significant O O
cardiotoxicity B B_DISEASE
characterized O O
by O O
marked O O
increases O O
in O O
oxidative O O
stress O O
and O O
mitochondrial B B_DISEASE/B_GENE
dysfunction I I_DISEASE/I_GENE
. O O

Herein O O
, O O
we O O
investigate O O
whether O O
doxorubicin O O
- O O
associated O O
chronic O O
cardiac B B_DISEASE
toxicity I I_DISEASE
can O O
be O O
ameliorated O O
with O O
the O O
antioxidant O O
hydroxytyrosol O O
in O O
rats O O
with O O
breast B B_DISEASE/B_GENE
cancer I I_DISEASE/I_GENE
. O O

Thirty O O
- O O
six O O
rats O O
bearing O O
breast B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tumors I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
chemically O O
were O O
divided O O
into O O
4 O O
groups O O
: O O
control O O
, O O
hydroxytyrosol O O
( O O
0 O O
. O O
5mg O O
/ O O
kg O O
, O O
5days O O
/ O O
week O O
) O O
, O O
doxorubicin O O
( O O
1mg O O
/ O O
kg O O
/ O O
week O O
) O O
, O O
and O O
doxorubicin O O
plus O O
hydroxytyrosol O O
. O O

Cardiac B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disturbances I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
the O O
cellular O O
and O O
mitochondrial O O
level O O
, O O
mitochondrial O O
electron O O
transport O O
chain O O
complexes O O
I O O
- O O
IV O O
and O O
apoptosis O O
- O O
inducing O O
factor O O
, O O
and O O
oxidative O O
stress O O
markers O O
have O O
been O O
analyzed O O
. O O

Hydroxytyrosol O O
improved O O
the O O
cardiac B B_DISEASE_ADJECTIVE[DISEASE]
disturbances I I_DISEASE_ADJECTIVE[DISEASE]
enhanced O O
by O O
doxorubicin O O
by O O
significantly O O
reducing O O
the O O
percentage O O
of O O
altered O O
mitochondria O O
and O O
oxidative O O
damage O O
. O O

This O O
study O O
demonstrates O O
that O O
hydroxytyrosol O O
protect O O
rat O O
heart B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
damage I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
provoked O O
by O O
doxorubicin O O
decreasing O O
oxidative O O
damage O O
and O O
mitochondrial O O
alterations O O
. O O

Amiodarone O O
- O O
induced O O
myxoedema B B_DISEASE
coma I I_DISEASE
. O O

A O O
62 O O
- O O
year O O
- O O
old O O
man O O
was O O
found O O
to O O
have O O
bradycardia B B_DISEASE
, O O
hypothermia B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
respiratory B B_DISEASE
failure I I_DISEASE
3 O O
weeks O O
after O O
initiation O O
of O O
amiodarone O O
therapy O O
for O O
atrial B B_DISEASE
fibrillation I I_DISEASE
. O O

Thyroid O O
- O O
stimulating O O
hormone O O
was O O
found O O
to O O
be O O
168 O O
uIU O O
/ O O
mL O O
( O O
nl O O
. O O
0 O O
. O O
3 O O
- O O
5 O O
uIU O O
/ O O
mL O O
) O O
and O O
free O O
thyroxine O O
( O O
FT4 O O
) O O
was O O
< O O
0 O O
. O O
2 O O
ng O O
/ O O
dL O O
( O O
nl O O
. O O
0 O O
. O O
8 O O
- O O
1 O O
. O O
8 O O
ng O O
/ O O
dL O O
) O O
. O O

He O O
received O O
intravenous O O
fluids O O
, O O
vasopressor O O
therapy O O
and O O
stress O O
dose O O
steroids O O
; O O
he O O
was O O
intubated O O
and O O
admitted O O
to O O
the O O
intensive O O
care O O
unit O O
. O O

He O O
received O O
500 O O
ug O O
of O O
intravenous O O
levothyroxine O O
in O O
the O O
first O O
18 O O
h O O
of O O
therapy O O
, O O
and O O
150 O O
ug O O
intravenous O O
daily O O
thereafter O O
. O O

Twelve O O
hours O O
after O O
the O O
initiation O O
of O O
therapy O O
, O O
FT4 O O
was O O
0 O O
. O O
96 O O
ng O O
/ O O
dL O O
. O O

The O O
patient O O
was O O
maintained O O
on O O
levothyroxine O O
175 O O
( O O
g O O
POorally O O
daily O O
. O O

The O O
24 O O
hour O O
excretion O O
of O O
iodine O O
was O O
3657 O O
( O O
mcg O O
( O O
25 O O
- O O
756 O O
( O O
mcg O O
) O O
. O O

The O O
only O O
two O O
cases O O
of O O
amiodarone O O
- O O
induced O O
myxoedema B B_DISEASE
coma I I_DISEASE
in O O
the O O
literature O O
report O O
patient O O
death O O
despite O O
supportive O O
therapy O O
and O O
thyroid O O
hormone O O
replacement O O
. O O

This O O
case O O
represents O O
the O O
most O O
thoroughly O O
investigated O O
case O O
of O O
amiodarone O O
- O O
induced O O
myxoedema B B_DISEASE
coma I I_DISEASE
with O O
a O O
history O O
significant O O
for O O
subclinical O O
thyroid B B_DISEASE
disease I I_DISEASE
. O O

Use O O
of O O
argatroban O O
and O O
catheter O O
- O O
directed O O
thrombolysis B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O O
alteplase O O
in O O
an O O
oncology O O
patient O O
with O O
heparin O O
- O O
induced O O
thrombocytopenia B B_DISEASE
with O O
thrombosis B B_DISEASE
. O O

SUMMARY O O
: O O
A O O
63 O O
- O O
year O O
- O O
old O O
Caucasian O O
man O O
with O O
renal O O
amyloidosis B B_DISEASE
undergoing O O
peripheral O O
blood O O
stem O O
cell O O
collection O O
for O O
an O O
autologous O O
stem O O
cell O O
transplant O O
developed O O
extensive O O
bilateral O O
upper B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
extremity I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
deep I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
venous I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
thrombosis I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
DVT B B_DISEASE/B_LOCATION
) O O
and O O
pulmonary B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
embolism I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
secondary O O
to O O
heparin O O
- O O
induced O O
thrombocytopenia B B_DISEASE
. O O

A O O
continuous O O
i O O
. O O
v O O
. O O
infusion O O
of O O
argatroban O O
was O O
initiated O O
, O O
and O O
the O O
patient O O
was O O
managed O O
on O O
the O O
general O O
medical O O
floor O O
. O O

After O O
one O O
week O O
of O O
therapy O O
, O O
he O O
was O O
transferred O O
to O O
the O O
intensive O O
care O O
unit O O
with O O
cardiopulmonary O O
compromise O O
related O O
to O O
superior B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
vena I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cava I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
SVC I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
syndrome I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

A O O
percutaneous O O
mechanical O O
thrombectomy O O
and O O
CDT O O
with O O
alteplase O O
were O O
attempted O O
, O O
but O O
the O O
procedure O O
was O O
aborted O O
due O O
to O O
epistaxis B B_DISEASE
. O O

The O O
epistaxis B B_DISEASE
resolved O O
the O O
next O O
day O O
, O O
and O O
the O O
patient O O
was O O
restarted O O
on O O
argatroban O O
. O O

Alteplase O O
was O O
discontinued O O
, O O
and O O
the O O
patient O O
was O O
reinitiated O O
on O O
argatroban O O
; O O
ultimately O O
, O O
he O O
was O O
transitioned O O
to O O
warfarin O O
for O O
long O O
- O O
term O O
anticoagulation O O
. O O

Although O O
the O O
patient O O
recovered O O
, O O
he O O
experienced O O
permanent O O
vision B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and I I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hearing I I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
loss I I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
well O O
as O O
end B B_DISEASE
- I I_DISEASE
stage I I_DISEASE
renal I I_DISEASE
disease I I_DISEASE
. O O

CONCLUSION O O
: O O
A O O
63 O O
- O O
year O O
- O O
old O O
man O O
with O O
renal O O
amyloidosis B B_DISEASE
and O O
SVC B B_DISEASE
syndrome I I_DISEASE
secondary O O
to O O
HITT B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
successfully O O
treated O O
with O O
argatroban O O
and O O
CDT O O
with O O
alteplase O O
. O O

Effects O O
of O O
dehydroepiandrosterone O O
in O O
amphetamine O O
- O O
induced O O
schizophrenia B B_DISEASE
models O O
in O O
mice O O
. O O

OBJECTIVE O O
: O O
To O O
examine O O
the O O
effects O O
of O O
dehydroepiandrosterone O O
( O O
DHEA O O
) O O
on O O
animal O O
models O O
of O O
schizophrenia B B_DISEASE
. O O

METHODS O O
: O O
Seventy O O
Swiss O O
albino O O
female O O
mice O O
( O O
25 O O
- O O
35 O O
g O O
) O O
were O O
divided O O
into O O
4 O O
groups O O
: O O
amphetamine O O
- O O
free O O
( O O
control O O
) O O
, O O
amphetamine O O
, O O
50 O O
, O O
and O O
100 O O
mg O O
/ O O
kg O O
DHEA O O
. O O

The O O
DHEA O O
was O O
administered O O
intraperitoneally O O
( O O
ip O O
) O O
for O O
5 O O
days O O
. O O

Amphetamine O O
( O O
3 O O
mg O O
/ O O
kg O O
ip O O
) O O
induced O O
hyper B B_DISEASE_ADJECTIVE[DISEASE]
locomotion O O
, O O
apomorphine O O
( O O
1 O O
. O O
5 O O
mg O O
/ O O
kg O O
subcutaneously O O
[ O O
sc O O
] O O
) O O
induced O O
climbing O O
, O O
and O O
haloperidol O O
( O O
1 O O
. O O
5 O O
mg O O
/ O O
kg O O
sc O O
) O O
induced O O
catalepsy B B_DISEASE_ADJECTIVE[DISEASE]
tests O O
were O O
used O O
as O O
animal O O
models O O
of O O
schizophrenia B B_DISEASE
. O O

The O O
study O O
was O O
conducted O O
at O O
the O O
Animal O O
Experiment O O
Laboratories O O
, O O
Department O O
of O O
Pharmacology O O
, O O
Medical O O
School O O
, O O
Eskisehir O O
Osmangazi O O
University O O
, O O
Eskisehir O O
, O O
Turkey O O
between O O
March O O
and O O
May O O
2012 O O
. O O

RESULTS O O
: O O
In O O
the O O
amphetamine O O
- O O
induced O O
locomotion O O
test O O
, O O
there O O
were O O
significant O O
increases O O
in O O
all O O
movements O O
compared O O
with O O
the O O
amphetamine O O
- O O
free O O
group O O
. O O

Both O O
DHEA O O
50 O O
mg O O
/ O O
kg O O
( O O
p O O
< O O
0 O O
. O O
05 O O
) O O
, O O
and O O
100 O O
mg O O
/ O O
kg O O
( O O
p O O
< O O
0 O O
. O O
01 O O
) O O
significantly O O
decreased O O
all O O
movements O O
compared O O
with O O
the O O
amphetamine O O
- O O
induced O O
locomotion O O
group O O
. O O

There O O
was O O
a O O
significant O O
difference O O
between O O
groups O O
in O O
the O O
haloperidol O O
- O O
induced O O
catalepsy B B_DISEASE_ADJECTIVE[DISEASE]
test O O
( O O
p O O
< O O
0 O O
. O O
05 O O
) O O
. O O

There O O
was O O
no O O
significant O O
difference O O
between O O
groups O O
in O O
terms O O
of O O
total O O
climbing O O
time O O
in O O
the O O
apomorphine O O
- O O
induced O O
climbing O O
test O O
( O O
p O O
> O O
0 O O
. O O
05 O O
) O O
. O O

CONCLUSION O O
: O O
We O O
observed O O
that O O
DHEA O O
reduced O O
locomotor O O
activity O O
and O O
increased O O
catalepsy B B_DISEASE/B_ORGANISM_FUNCTION
at O O
both O O
doses O O
, O O
while O O
it O O
had O O
no O O
effect O O
on O O
climbing O O
behavior O O
. O O

We O O
suggest O O
that O O
DHEA O O
displays O O
typical O O
neuroleptic O O
- O O
like O O
effects O O
, O O
and O O
may O O
be O O
used O O
in O O
the O O
treatment O O
of O O
schizophrenia B B_DISEASE
. O O

Availability O O
of O O
human O O
induced O O
pluripotent O O
stem O O
cell O O
- O O
derived O O
cardiomyocytes O O
in O O
assessment O O
of O O
drug O O
potential O O
for O O
QT B B_DISEASE
prolongation I I_DISEASE
. O O

However O O
, O O
there O O
is O O
no O O
report O O
showing O O
that O O
this O O
technique O O
can O O
be O O
used O O
to O O
predict O O
multichannel O O
blocker O O
potential O O
for O O
QT B B_DISEASE
prolongation I I_DISEASE
. O O

The O O
aim O O
of O O
this O O
study O O
is O O
to O O
show O O
that O O
FPD O O
from O O
MEA O O
( O O
Multielectrode O O
array O O
) O O
of O O
hiPS O O
- O O
CMs O O
can O O
detect O O
QT B B_DISEASE
prolongation I I_DISEASE
induced O O
by O O
multichannel O O
blockers O O
. O O

hiPS O O
- O O
CMs O O
were O O
seeded O O
onto O O
MEA O O
and O O
FPD O O
was O O
measured O O
for O O
2min O O
every O O
10min O O
for O O
30min O O
after O O
drug O O
exposure O O
for O O
the O O
vehicle O O
and O O
each O O
drug O O
concentration O O
. O O

IKr O O
and O O
IKs O O
blockers O O
concentration O O
- O O
dependently O O
prolonged O O
corrected O O
FPD O O
( O O
FPDc O O
) O O
, O O
whereas O O
Ca O O
( O O
2 O O
+ O O
) O O
channel O O
blockers O O
concentration O O
- O O
dependently O O
shortened O O
FPDc O O
. O O

Finally O O
, O O
the O O
IKr O O
blockers O O
, O O
Terfenadine O O
and O O
Citalopram O O
, O O
which O O
are O O
reported O O
to O O
cause O O
Torsade B B_DISEASE
de I I_DISEASE
Pointes I I_DISEASE
( O O
TdP B B_PROTEIN[GENE]/B_DISEASE
) O O
in O O
clinical O O
practice O O
, O O
produced O O
early O O
afterdepolarization O O
( O O
EAD O O
) O O
. O O

Dermal O O
developmental O O
toxicity B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
N O O
- O O
phenylimide O O
herbicides O O
in O O
rats O O
. O O

BACKGROUND O O
: O O
S O O
- O O
53482 O O
and O O
S O O
- O O
23121 O O
are O O
N O O
- O O
phenylimide O O
herbicides O O
and O O
produced O O
embryolethality B B_DISEASE/B_ORGANISM_FUNCTION
, O O
teratogenicity B B_DISEASE
( O O
mainly O O
ventricular B B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
septal I I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
defects I I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
and O O
wavy O O
ribs O O
) O O
, O O
and O O
growth B B_DISEASE/B_ORGANISM_FUNCTION
retardation I I_DISEASE/I_ORGANISM_FUNCTION
in O O
rats O O
in O O
conventional O O
oral O O
developmental O O
toxicity B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
studies O O
. O O

Our O O
objective O O
in O O
this O O
study O O
was O O
to O O
investigate O O
whether O O
the O O
compounds O O
induce O O
developmental O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
via O O
the O O
dermal O O
route O O
, O O
which O O
is O O
more O O
relevant O O
to O O
occupational O O
exposure O O
, O O
hence O O
better O O
addressing O O
human O O
health O O
risks O O
. O O

METHODS O O
: O O
S O O
- O O
53482 O O
was O O
administered O O
dermally O O
to O O
rats O O
at O O
30 O O
, O O
100 O O
, O O
and O O
300 O O
mg O O
/ O O
kg O O
during O O
organogenesis O O
, O O
and O O
S O O
- O O
23121 O O
was O O
administered O O
at O O
200 O O
, O O
400 O O
, O O
and O O
800 O O
mg O O
/ O O
kg O O
( O O
the O O
maximum O O
applicable O O
dose O O
level O O
) O O
. O O

Fetuses O O
were O O
obtained O O
by O O
a O O
Cesarean O O
section O O
and O O
examined O O
for O O
external O O
, O O
visceral O O
, O O
and O O
skeletal O O
alterations O O
. O O

RESULTS O O
: O O
Dermal O O
exposure O O
of O O
rats O O
to O O
S O O
- O O
53482 O O
at O O
300 O O
mg O O
/ O O
kg O O
produced O O
patterns O O
of O O
developmental O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
similar O O
to O O
those O O
resulting O O
from O O
oral O O
exposure O O
. O O

Toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
included O O
embryolethality B B_DISEASE
, O O
teratogenicity B B_DISEASE
, O O
and O O
growth B B_DISEASE/B_ORGANISM_FUNCTION
retardation I I_DISEASE/I_ORGANISM_FUNCTION
. O O

Dermal O O
administration O O
of O O
S O O
- O O
23121 O O
at O O
800 O O
mg O O
/ O O
kg O O
resulted O O
in O O
an O O
increased O O
incidence O O
of O O
embryonic B B_DISEASE
death I I_DISEASE
and O O
ventricular B B_DISEASE
septal I I_DISEASE
defect I I_DISEASE
, O O
but O O
retarded O O
fetal O O
growth O O
was O O
not O O
observed O O
as O O
it O O
was O O
following O O
oral O O
exposure O O
to O O
S O O
- O O
23121 O O
. O O

CONCLUSIONS O O
: O O
Based O O
on O O
the O O
results O O
, O O
S O O
- O O
53482 O O
and O O
S O O
- O O
23121 O O
were O O
teratogenic B B_DISEASE_ADJECTIVE[DISEASE]
when O O
administered O O
dermally O O
to O O
pregnant O O
rats O O
as O O
were O O
the O O
compounds O O
administered O O
orally O O
. O O

Thus O O
, O O
investigation O O
of O O
the O O
mechanism O O
and O O
its O O
human O O
relevancy O O
become O O
more O O
important O O
. O O

Rates O O
of O O
Renal B B_DISEASE
Toxicity I I_DISEASE
in O O
Cancer B B_DISEASE/B_PERSON
Patients O O
Receiving O O
Cisplatin O O
With O O
and O O
Without O O
Mannitol O O
. O O

BACKGROUND O O
: O O
Cisplatin O O
is O O
a O O
widely O O
used O O
antineoplastic O O
. O O

One O O
of O O
the O O
major O O
complications O O
of O O
cisplatin O O
use O O
is O O
dose O O
- O O
limiting O O
nephrotoxicity B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

There O O
are O O
many O O
strategies O O
to O O
prevent O O
this O O
toxicity B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
including O O
the O O
use O O
of O O
mannitol O O
as O O
a O O
nephroprotectant O O
in O O
combination O O
with O O
hydration O O
. O O

OBJECTIVE O O
: O O
We O O
aimed O O
to O O
evaluate O O
the O O
rates O O
of O O
cisplatin O O
- O O
induced O O
nephrotoxicity B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
cancer B B_DISEASE/B_PERSON
patients O O
receiving O O
single O O
- O O
agent O O
cisplatin O O
with O O
and O O
without O O
mannitol O O
. O O

METHODS O O
: O O
This O O
single O O
- O O
center O O
retrospective O O
analysis O O
was O O
a O O
quasi O O
experiment O O
created O O
by O O
the O O
national O O
mannitol O O
shortage O O
. O O

Data O O
were O O
collected O O
on O O
adult O O
cancer B B_DISEASE/B_LOCATION
patients O O
receiving O O
single O O
- O O
agent O O
cisplatin O O
as O O
an O O
outpatient O O
from O O
January O O
2011 O O
to O O
September O O
2012 O O
. O O

The O O
primary O O
outcome O O
was O O
acute B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
kidney I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
injury I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
AKI B B_DISEASE/B_GENE
) O O
. O O

RESULTS O O
: O O
We O O
evaluated O O
143 O O
patients O O
who O O
received O O
single O O
- O O
agent O O
cisplatin O O
; O O
97 O O
. O O
2 O O
% O O
of O O
patients O O
had O O
head B B_DISEASE
and I I_DISEASE
neck I I_DISEASE
cancer I I_DISEASE
as O O
their O O
primary O O
malignancy B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Patients O O
who O O
did O O
not O O
receive O O
mannitol O O
were O O
more O O
likely O O
to O O
develop O O
nephrotoxicity B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
odds O O
ratio O O
[ O O
OR O O
] O O
= O O
2 O O
. O O
646 O O
( O O
95 O O
% O O
CI O O
= O O
1 O O
. O O
008 O O
, O O
6 O O
. O O
944 O O
; O O
P O O
= O O
0 O O
. O O
048 O O
) O O
. O O

Patients O O
who O O
received O O
the O O
100 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
dosing O O
and O O
patients O O
who O O
had O O
a O O
history O O
of O O
hypertension B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
also O O
had O O
a O O
higher O O
likelihood O O
of O O
developing O O
nephrotoxicity B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
OR O O
= O O
11 O O
. O O
494 O O
( O O
95 O O
% O O
CI O O
= O O
4 O O
. O O
149 O O
, O O
32 O O
. O O
258 O O
; O O
P O O
< O O
0 O O
. O O
0001 O O
) O O
and O O
OR O O
= O O
3 O O
. O O
219 O O
( O O
95 O O
% O O
CI O O
= O O
1 O O
. O O
228 O O
, O O
8 O O
. O O
439 O O
; O O
P O O
= O O
0 O O
. O O
017 O O
) O O
, O O
respectively O O
. O O

CONCLUSIONS O O
: O O
When O O
limited O O
quantities O O
of O O
mannitol O O
are O O
available O O
, O O
it O O
should O O
preferentially O O
be O O
given O O
to O O
patients O O
at O O
particularly O O
high O O
risk O O
of O O
nephrotoxicity B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Our O O
analysis O O
suggests O O
that O O
those O O
patients O O
receiving O O
the O O
dosing O O
schedule O O
of O O
100 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
cisplatin O O
every O O
3 O O
weeks O O
and O O
those O O
with O O
hypertension B B_DISEASE
are O O
at O O
the O O
greatest O O
risk O O
of O O
nephrotoxicity B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
would O O
benefit O O
from O O
the O O
addition O O
of O O
mannitol O O
. O O

Metformin O O
protects O O
against O O
seizures B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
learning B B_DISEASE
and I I_DISEASE
memory I I_DISEASE
impairments I I_DISEASE
and O O
oxidative O O
damage O O
induced O O
by O O
pentylenetetrazole O O
- O O
induced O O
kindling O O
in O O
mice O O
. O O

Cognitive B B_DISEASE
impairment I I_DISEASE
, O O
the O O
most O O
common O O
and O O
severe O O
comorbidity O O
of O O
epilepsy B B_DISEASE/B_LOCATION
, O O
greatly O O
diminishes O O
the O O
quality O O
of O O
life O O
. O O

However O O
, O O
current O O
therapeutic O O
interventions O O
for O O
epilepsy B B_DISEASE/B_LOCATION
can O O
also O O
cause O O
untoward O O
cognitive O O
effects O O
. O O

Thus O O
, O O
there O O
is O O
an O O
urgent O O
need O O
for O O
new O O
kinds O O
of O O
agents O O
targeting O O
both O O
seizures B B_DISEASE
and O O
cognition B B_DISEASE
deficits I I_DISEASE
. O O

Oxidative O O
stress O O
is O O
considered O O
to O O
play O O
an O O
important O O
role O O
in O O
epileptogenesis O O
and O O
cognitive B B_DISEASE/B_ORGANISM_FUNCTION
deficits I I_DISEASE/I_ORGANISM_FUNCTION
, O O
and O O
antioxidants O O
have O O
a O O
putative O O
antiepileptic O O
potential O O
. O O

Metformin O O
, O O
the O O
most O O
commonly O O
prescribed O O
antidiabetic O O
oral O O
drug O O
, O O
has O O
antioxidant O O
properties O O
. O O

This O O
study O O
was O O
designed O O
to O O
evaluate O O
the O O
ameliorative O O
effects O O
of O O
metformin O O
on O O
seizures B B_DISEASE
, O O
cognitive B B_DISEASE_ADJECTIVE[DISEASE]
impairment I I_DISEASE_ADJECTIVE[DISEASE]
and O O
brain O O
oxidative O O
stress O O
markers O O
observed O O
in O O
pentylenetetrazole O O
- O O
induced O O
kindling O O
animals O O
. O O

Male O O
C57BL O O
/ O O
6 O O
mice O O
were O O
administered O O
with O O
subconvulsive O O
dose O O
of O O
pentylenetetrazole O O
( O O
37 O O
mg O O
/ O O
kg O O
, O O
i O O
. O O
p O O
. O O
) O O
every O O
other O O
day O O
for O O
14 O O
injections O O
. O O

Metformin O O
was O O
injected O O
intraperitoneally O O
in O O
dose O O
of O O
200mg O O
/ O O
kg O O
along O O
with O O
alternate O O
- O O
day O O
PTZ O O
. O O

We O O
found O O
that O O
metformin O O
suppressed O O
the O O
progression O O
of O O
kindling O O
, O O
ameliorated O O
the O O
cognitive B B_DISEASE
impairment I I_DISEASE
and O O
decreased O O
brain O O
oxidative O O
stress O O
. O O

Thus O O
the O O
present O O
study O O
concluded O O
that O O
metformin O O
may O O
be O O
a O O
potential O O
agent O O
for O O
the O O
treatment O O
of O O
epilepsy B B_DISEASE
as O O
well O O
as O O
a O O
protective O O
medicine O O
against O O
cognitive B B_DISEASE
impairment I I_DISEASE
induced O O
by O O
seizures B B_DISEASE
. O O

P53 O O
inhibition O O
exacerbates O O
late O O
- O O
stage O O
anthracycline O O
cardiotoxicity B B_DISEASE
. O O

AIMS O O
: O O
Doxorubicin O O
( O O
DOX O O
) O O
is O O
an O O
effective O O
anti O O
- O O
cancer B B_DISEASE
therapeutic O O
, O O
but O O
is O O
associated O O
with O O
both O O
acute O O
and O O
late O O
- O O
stage O O
cardiotoxicity B B_DISEASE
. O O

Children O O
are O O
particularly O O
sensitive O O
to O O
DOX O O
- O O
induced O O
heart B B_DISEASE/B_GENE
failure I I_DISEASE/I_GENE
. O O

Here O O
, O O
the O O
impact O O
of O O
p53 O O
inhibition O O
on O O
acute O O
vs O O
. O O
late O O
- O O
stage O O
DOX O O
cardiotoxicity B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
examined O O
in O O
a O O
juvenile O O
model O O
. O O

Furthermore O O
, O O
these O O
data O O
suggest O O
an O O
explanation O O
as O O
to O O
how O O
p53 O O
inhibition O O
can O O
result O O
in O O
cardioprotection O O
during O O
drug O O
treatment O O
and O O
, O O
paradoxically O O
, O O
enhanced O O
cardiotoxicity B B_DISEASE
long O O
after O O
the O O
cessation O O
of O O
drug O O
treatment O O
. O O

Metronidazole O O
- O O
induced O O
encephalopathy B B_DISEASE
: O O
an O O
uncommon O O
scenario O O
. O O

We O O
present O O
a O O
case O O
where O O
a O O
patient O O
developed O O
features O O
of O O
encephalopathy B B_DISEASE
following O O
prolonged O O
metronidazole O O
intake O O
. O O

The O O
diagnosis O O
of O O
metronidazole O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
made O O
by O O
the O O
MRI O O
findings O O
and O O
supported O O
clinically O O
. O O

Aconitine O O
- O O
induced O O
Ca2 O O
+ O O
overload O O
causes O O
arrhythmia B B_DISEASE/B_GENE
and O O
triggers O O
apoptosis O O
through O O
p38 O O
MAPK O O
signaling O O
pathway O O
in O O
rats O O
. O O

Aconitine O O
is O O
a O O
major O O
bioactive O O
diterpenoid O O
alkaloid O O
with O O
high O O
content O O
derived O O
from O O
herbal O O
aconitum O O
plants O O
. O O

Emerging O O
evidence O O
indicates O O
that O O
voltage O O
- O O
dependent O O
Na O O
( O O
+ O O
) O O
channels O O
have O O
pivotal O O
roles O O
in O O
the O O
cardiotoxicity B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
aconitine O O
. O O

However O O
, O O
no O O
reports O O
are O O
available O O
on O O
the O O
role O O
of O O
Ca O O
( O O
2 O O
+ O O
) O O
in O O
aconitine O O
poisoning B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
this O O
study O O
, O O
we O O
explored O O
the O O
importance O O
of O O
pathological O O
Ca O O
( O O
2 O O
+ O O
) O O
signaling O O
in O O
aconitine O O
poisoning B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
vitro O O
and O O
in O O
vivo O O
. O O

We O O
found O O
that O O
Ca O O
( O O
2 O O
+ O O
) O O
overload O O
lead O O
to O O
accelerated O O
beating O O
rhythm O O
in O O
adult O O
rat O O
ventricular O O
myocytes O O
and O O
caused O O
arrhythmia B B_DISEASE
in O O
conscious O O
freely O O
moving O O
rats O O
. O O

To O O
investigate O O
effects O O
of O O
aconitine O O
on O O
myocardial B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
injury I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
we O O
performed O O
cytotoxicity B B_DISEASE/B_GENE
assay O O
in O O
neonatal O O
rat O O
ventricular O O
myocytes O O
( O O
NRVMs O O
) O O
, O O
as O O
well O O
as O O
measured O O
lactate O O
dehydrogenase O O
level O O
in O O
the O O
culture O O
medium O O
of O O
NRVMs O O
and O O
activities O O
of O O
serum O O
cardiac O O
enzymes O O
in O O
rats O O
. O O

The O O
results O O
showed O O
that O O
aconitine O O
resulted O O
in O O
myocardial B B_DISEASE/B_GENE
injury I I_DISEASE/I_GENE
and O O
reduced O O
NRVMs O O
viability O O
dose O O
- O O
dependently O O
. O O

The O O
results O O
showed O O
that O O
aconitine O O
stimulated O O
apoptosis O O
time O O
- O O
dependently O O
. O O

Hence O O
, O O
our O O
results O O
suggest O O
that O O
aconitine O O
significantly O O
aggravates O O
Ca O O
( O O
2 O O
+ O O
) O O
overload O O
and O O
causes O O
arrhythmia B B_DISEASE/B_GENE
and O O
finally O O
promotes O O
apoptotic O O
development O O
via O O
phosphorylation O O
of O O
P38 O O
mitogen O O
- O O
activated O O
protein O O
kinase O O
. O O

Chronic O O
treatment O O
with O O
metformin O O
suppresses O O
toll O O
- O O
like O O
receptor O O
4 O O
signaling O O
and O O
attenuates O O
left B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ventricular I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dysfunction I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
following O O
myocardial B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Acute O O
treatment O O
with O O
metformin O O
has O O
a O O
protective O O
effect O O
in O O
myocardial B B_DISEASE
infarction I I_DISEASE
by O O
suppression O O
of O O
inflammatory O O
responses O O
due O O
to O O
activation O O
of O O
AMP O O
- O O
activated O O
protein O O
kinase O O
( O O
AMPK O O
) O O
. O O

In O O
the O O
present O O
study O O
, O O
the O O
effect O O
of O O
chronic O O
pre O O
- O O
treatment O O
with O O
metformin O O
on O O
cardiac B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
dysfunction I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O O
toll O O
- O O
like O O
receptor O O
4 O O
( O O
TLR4 O O
) O O
activities O O
following O O
myocardial B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
their O O
relation O O
with O O
AMPK O O
were O O
assessed O O
. O O

Isoproterenol O O
( O O
100mg O O
/ O O
kg O O
) O O
was O O
injected O O
subcutaneously O O
on O O
the O O
13th O O
and O O
14th O O
days O O
to O O
induce O O
acute B B_DISEASE
myocardial I I_DISEASE
infarction I I_DISEASE
. O O

Isoproterenol O O
alone O O
decreased O O
left O O
ventricular O O
systolic O O
pressure O O
and O O
myocardial O O
contractility O O
indexed O O
as O O
LVdp O O
/ O O
dtmax O O
and O O
LVdp O O
/ O O
dtmin O O
. O O

The O O
left B B_DISEASE/B_MEASURE
ventricular I I_DISEASE/I_MEASURE
dysfunction I I_DISEASE/I_MEASURE
was O O
significantly O O
lower O O
in O O
the O O
groups O O
treated O O
with O O
25 O O
and O O
50mg O O
/ O O
kg O O
of O O
metformin O O
. O O

Metfromin O O
markedly O O
lowered O O
isoproterenol O O
- O O
induced O O
elevation O O
in O O
the O O
levels O O
of O O
TLR4 O O
mRNA O O
, O O
myeloid O O
differentiation O O
protein O O
88 O O
( O O
MyD88 O O
) O O
, O O
tumor B B_DISEASE_ADJECTIVE[DISEASE]
necrosis B I_DISEASE_ADJECTIVE[DISEASE]
factor O O
- O O
alpha O O
( O O
TNF O O
- O O
a O O
) O O
, O O
and O O
interleukin O O
6 O O
( O O
IL O O
- O O
6 O O
) O O
in O O
the O O
heart O O
tissues O O
. O O

Similar O O
changes O O
were O O
also O O
seen O O
in O O
the O O
serum O O
levels O O
of O O
TNF O O
- O O
a O O
and O O
IL O O
- O O
6 O O
. O O

However O O
, O O
the O O
lower O O
doses O O
of O O
25 O O
and O O
50mg O O
/ O O
kg O O
were O O
more O O
effective O O
than O O
100mg O O
/ O O
kg O O
. O O

Phosphorylated O O
AMPKa O O
( O O
p O O
- O O
AMPK O O
) O O
in O O
the O O
myocardium O O
was O O
significantly O O
elevated O O
by O O
25mg O O
/ O O
kg O O
of O O
metformin O O
, O O
slightly O O
by O O
50mg O O
/ O O
kg O O
, O O
but O O
not O O
by O O
100mg O O
/ O O
kg O O
. O O

Chronic O O
pre O O
- O O
treatment O O
with O O
metformin O O
reduces O O
post O O
- O O
myocardial B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cardiac O O
dysfunction O O
and O O
suppresses O O
inflammatory O O
responses O O
, O O
possibly O O
through O O
inhibition O O
of O O
TLR4 O O
activities O O
. O O

This O O
mechanism O O
can O O
be O O
considered O O
as O O
a O O
target O O
to O O
protect O O
infarcted O O
myocardium O O
. O O

Unusual O O
complications O O
of O O
antithyroid O O
drug O O
therapy O O
: O O
four O O
case O O
reports O O
and O O
review O O
of O O
literature O O
. O O

Two O O
cases O O
of O O
propylthiouracil O O
- O O
associated O O
acute O O
hepatitis B B_DISEASE
, O O
one O O
case O O
of O O
fatal O O
methimazole O O
- O O
associated O O
hepatocellular B B_DISEASE
necrosis I I_DISEASE
and O O
one O O
case O O
of O O
propylthiouracil O O
- O O
associated O O
lupus B B_DISEASE
- I I_DISEASE
like I I_DISEASE
syndrome I I_DISEASE
are O O
described O O
. O O

It O O
is O O
concluded O O
that O O
in O O
most O O
circumstances O O
131I O O
is O O
the O O
therapy O O
of O O
choice O O
for O O
hyperthyroidism B B_DISEASE/B_PERSON
. O O

Neuroleptic B B_DISEASE
malignant I I_DISEASE
syndrome I I_DISEASE
induced O O
by O O
combination O O
therapy O O
with O O
tetrabenazine O O
and O O
tiapride O O
in O O
a O O
Japanese O O
patient O O
with O O
Huntington B B_DISEASE
' I I_DISEASE
s I I_DISEASE
disease I I_DISEASE
at O O
the O O
terminal O O
stage O O
of O O
recurrent O O
breast B B_DISEASE
cancer I I_DISEASE
. O O

We O O
herein O O
describe O O
the O O
case O O
of O O
an O O
81 O O
- O O
year O O
- O O
old O O
Japanese O O
woman O O
with O O
neuroleptic B B_DISEASE
malignant I I_DISEASE
syndrome I I_DISEASE
that O O
occurred O O
36 O O
days O O
after O O
the O O
initiation O O
of O O
combination O O
therapy O O
with O O
tiapride O O
( O O
75 O O
mg O O
/ O O
day O O
) O O
and O O
tetrabenazine O O
( O O
12 O O
. O O
5 O O
mg O O
/ O O
day O O
) O O
for O O
Huntington B B_DISEASE
' I I_DISEASE
s I I_DISEASE
disease I I_DISEASE
. O O

The O O
patient O O
had O O
been O O
treated O O
with O O
tiapride O O
or O O
tetrabenazine O O
alone O O
without O O
any O O
adverse O O
effects O O
before O O
the O O
administration O O
of O O
the O O
combination O O
therapy O O
. O O

She O O
also O O
had O O
advanced O O
breast B B_DISEASE
cancer I I_DISEASE
when O O
the O O
combination O O
therapy O O
was O O
initiated O O
. O O

To O O
the O O
best O O
of O O
our O O
knowledge O O
, O O
the O O
occurrence O O
of O O
neuroleptic B B_DISEASE
malignant I I_DISEASE
syndrome I I_DISEASE
due O O
to O O
combination O O
therapy O O
with O O
tetrabenazine O O
and O O
tiapride O O
has O O
not O O
been O O
previously O O
reported O O
. O O

A O O
metoprolol O O
- O O
terbinafine O O
combination O O
induced O O
bradycardia B B_DISEASE
. O O

To O O
report O O
a O O
sinus B B_DISEASE/B_BIO
bradycardia I I_DISEASE/I_BIO
induced O O
by O O
metoprolol O O
and O O
terbinafine O O
drug O O
- O O
drug O O
interaction O O
and O O
its O O
management O O
. O O

A O O
63 O O
year O O
- O O
old O O
Caucasian O O
man O O
on O O
metoprolol O O
200 O O
mg O O
/ O O
day O O
for O O
stable O O
coronary B B_DISEASE
artery I I_DISEASE
disease I I_DISEASE
was O O
prescribed O O
a O O
90 O O
- O O
day O O
course O O
of O O
oral O O
terbinafine O O
250 O O
mg O O
/ O O
day O O
for O O
onychomycosis B B_DISEASE
. O O

On O O
the O O
49th O O
day O O
of O O
terbinafine O O
therapy O O
, O O
he O O
was O O
brought O O
to O O
the O O
emergency O O
room O O
for O O
a O O
decrease O O
of O O
his O O
global O O
health O O
status O O
, O O
confusion B B_DISEASE
and O O
falls O O
. O O

The O O
electrocardiogram O O
revealed O O
a O O
37 O O
beats O O
/ O O
min O O
sinus B B_DISEASE/B_MEASURE
bradycardia I I_DISEASE/I_MEASURE
. O O

A O O
score O O
of O O
7 O O
on O O
the O O
Naranjo O O
adverse B B_DISEASE_ADJECTIVE[DISEASE]
drug I I_DISEASE_ADJECTIVE[DISEASE]
reaction I I_DISEASE_ADJECTIVE[DISEASE]
probability O O
scale O O
indicates O O
a O O
probable O O
relationship O O
between O O
the O O
patient O O
' O O
s O O
sinus B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bradycardia I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
drug O O
interaction O O
between O O
metoprolol O O
and O O
terbinafine O O
. O O

It O O
was O O
subsequently O O
changed O O
to O O
bisoprolol O O
and O O
the O O
heart O O
rate O O
remained O O
normal O O
. O O

By O O
inhibiting O O
the O O
cytochrome O O
P450 O O
2D6 O O
, O O
terbinafine O O
had O O
decreased O O
metoprolol O O
' O O
s O O
clearance O O
, O O
leading O O
in O O
metoprolol O O
accumulation O O
which O O
has O O
resulted O O
in O O
clinically O O
significant O O
sinus B B_DISEASE
bradycardia I I_DISEASE
. O O

Optochiasmatic O O
and O O
peripheral B B_DISEASE/B_LOCATION
neuropathy I I_DISEASE/I_LOCATION
due O O
to O O
ethambutol O O
overtreatment O O
. O O

Ethambutol O O
is O O
known O O
to O O
cause O O
optic B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
neuropathy I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
, O O
more O O
rarely O O
, O O
axonal O O
polyneuropathy B B_DISEASE
. O O

We O O
characterize O O
the O O
clinical O O
, O O
neurophysiological O O
, O O
and O O
neuroimaging O O
findings O O
in O O
a O O
72 O O
- O O
year O O
- O O
old O O
man O O
who O O
developed O O
visual B B_DISEASE
loss I I_DISEASE
and O O
paresthesias B B_DISEASE
after O O
11 O O
weeks O O
of O O
exposure O O
to O O
a O O
supratherapeutic O O
dose O O
of O O
ethambutol O O
. O O

This O O
case O O
demonstrates O O
the O O
selective O O
vulnerability O O
of O O
the O O
anterior O O
visual O O
pathways O O
and O O
peripheral O O
nerves O O
to O O
ethambutol O O
toxicity B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

Testosterone O O
ameliorates O O
streptozotocin O O
- O O
induced O O
memory B B_DISEASE
impairment I I_DISEASE
in O O
male O O
rats O O
. O O

AIM O O
: O O
To O O
study O O
the O O
effects O O
of O O
testosterone O O
on O O
streptozotocin O O
( O O
STZ O O
) O O
- O O
induced O O
memory B B_DISEASE
impairment I I_DISEASE
in O O
male O O
rats O O
. O O

METHODS O O
: O O
Adult O O
male O O
Wistar O O
rats O O
were O O
intracerebroventricularly O O
( O O
icv O O
) O O
infused O O
with O O
STZ O O
( O O
750 O O
ug O O
) O O
on O O
d O O
1 O O
and O O
d O O
3 O O
, O O
and O O
a O O
passive O O
avoidance O O
task O O
was O O
assessed O O
2 O O
weeks O O
after O O
the O O
first O O
injection O O
of O O
STZ O O
. O O

Castration O O
surgery O O
was O O
performed O O
in O O
another O O
group O O
of O O
rats O O
, O O
and O O
the O O
passive O O
avoidance O O
task O O
was O O
assessed O O
4 O O
weeks O O
after O O
the O O
operation O O
. O O

Testosterone O O
( O O
1 O O
mg O O
. O O
kg O O
( O O
- O O
1 O O
) O O
. O O
d O O
( O O
- O O
1 O O
) O O
, O O
sc O O
) O O
, O O
the O O
androgen O O
receptor O O
antagonist O O
flutamide O O
( O O
10 O O
mg O O
. O O
kg O O
( O O
- O O
1 O O
) O O
. O O
d O O
( O O
- O O
1 O O
) O O
, O O
ip O O
) O O
, O O
the O O
estrogen O O
receptor O O
antagonist O O
tamoxifen O O
( O O
1 O O
mg O O
. O O
kg O O
( O O
- O O
1 O O
) O O
. O O
d O O
( O O
- O O
1 O O
) O O
, O O
ip O O
) O O
or O O
the O O
aromatase O O
inhibitor O O
letrozole O O
( O O
4 O O
mg O O
. O O
kg O O
( O O
- O O
1 O O
) O O
. O O
d O O
( O O
- O O
1 O O
) O O
, O O
ip O O
) O O
were O O
administered O O
for O O
6 O O
d O O
after O O
the O O
first O O
injection O O
of O O
STZ O O
. O O

Testosterone O O
replacement O O
almost O O
restored O O
the O O
STL1 O O
and O O
STL2 O O
in O O
castrated O O
rats O O
, O O
and O O
significantly O O
prolonged O O
the O O
STL1 O O
and O O
STL2 O O
in O O
STZ O O
- O O
treated O O
rats O O
. O O

Administration O O
of O O
flutamide O O
, O O
letrozole O O
or O O
tamoxifen O O
significantly O O
impaired B B_DISEASE_ADJECTIVE[DISEASE]
the I I_DISEASE_ADJECTIVE[DISEASE]
memory I I_DISEASE_ADJECTIVE[DISEASE]
in O O
intact O O
rats O O
, O O
and O O
significantly O O
attenuated O O
the O O
testosterone O O
replacement O O
in O O
improving O O
STZ O O
- O O
and O O
castration O O
- O O
induced O O
memory B B_DISEASE
impairment I I_DISEASE
. O O

CONCLUSION O O
: O O
Testosterone O O
administration O O
ameliorates O O
STZ O O
- O O
and O O
castration O O
- O O
induced O O
memory B B_DISEASE
impairment I I_DISEASE
in O O
male O O
Wistar O O
rats O O
. O O

Behavioral O O
and O O
neurochemical O O
studies O O
in O O
mice O O
pretreated O O
with O O
garcinielliptone O O
FC O O
in O O
pilocarpine O O
- O O
induced O O
seizures B B_DISEASE
. O O

Garcinielliptone O O
FC O O
( O O
GFC O O
) O O
isolated O O
from O O
hexanic O O
fraction O O
seed O O
extract O O
of O O
species O O
Platonia O O
insignis O O
Mart O O
. O O

It O O
is O O
widely O O
used O O
in O O
folk O O
medicine O O
to O O
treat O O
skin B B_DISEASE
diseases I I_DISEASE
in O O
both O O
humans O O
and O O
animals O O
as O O
well O O
as O O
the O O
seed O O
decoction O O
has O O
been O O
used O O
to O O
treat O O
diarrheas B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
inflammatory B B_DISEASE
diseases I I_DISEASE
. O O

However O O
, O O
there O O
is O O
no O O
research O O
on O O
GFC O O
effects O O
in O O
the O O
central O O
nervous O O
system O O
of O O
rodents O O
. O O

The O O
present O O
study O O
aimed O O
to O O
evaluate O O
the O O
GFC O O
effects O O
at O O
doses O O
of O O
25 O O
, O O
50 O O
or O O
75 O O
mg O O
/ O O
kg O O
on O O
seizure B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
parameters O O
to O O
determine O O
their O O
anticonvulsant O O
activity O O
and O O
its O O
effects O O
on O O
amino O O
acid O O
( O O
r O O
- O O
aminobutyric O O
acid O O
( O O
GABA O O
) O O
, O O
glutamine O O
, O O
aspartate O O
and O O
glutathione O O
) O O
levels O O
as O O
well O O
as O O
on O O
acetylcholinesterase O O
( O O
AChE O O
) O O
activity O O
in O O
mice O O
hippocampus O O
after O O
seizures B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

GFC O O
produced O O
an O O
increased O O
latency O O
to O O
first O O
seizure B B_DISEASE
, O O
at O O
doses O O
25mg O O
/ O O
kg O O
( O O
20 O O
. O O
12 O O
+ O O
2 O O
. O O
20 O O
min O O
) O O
, O O
50mg O O
/ O O
kg O O
( O O
20 O O
. O O
95 O O
+ O O
2 O O
. O O
21 O O
min O O
) O O
or O O
75 O O
mg O O
/ O O
kg O O
( O O
23 O O
. O O
43 O O
+ O O
1 O O
. O O
99 O O
min O O
) O O
when O O
compared O O
with O O
seized O O
mice O O
. O O

In O O
aspartate O O
, O O
glutamine O O
and O O
glutamate O O
levels O O
detected O O
a O O
decrease O O
of O O
5 O O
. O O
21 O O
% O O
, O O
13 O O
. O O
55 O O
% O O
and O O
21 O O
. O O
80 O O
% O O
, O O
respectively O O
in O O
mice O O
hippocampus O O
treated O O
with O O
GFC75 O O
plus O O
P400 O O
when O O
compared O O
with O O
seized O O
mice O O
. O O

The O O
results O O
indicate O O
that O O
GFC O O
can O O
exert O O
anticonvulsant O O
activity O O
and O O
reduce O O
the O O
frequency O O
of O O
installation O O
of O O
pilocarpine O O
- O O
induced O O
status B B_DISEASE
epilepticus I I_DISEASE
, O O
as O O
demonstrated O O
by O O
increase O O
in O O
latency O O
to O O
first O O
seizure B B_DISEASE
and O O
decrease O O
in O O
mortality O O
rate O O
of O O
animals O O
. O O

Standard O O
operating O O
procedures O O
for O O
antibiotic O O
therapy O O
and O O
the O O
occurrence O O
of O O
acute B B_DISEASE
kidney I I_DISEASE
injury I I_DISEASE
: O O
a O O
prospective O O
, O O
clinical O O
, O O
non O O
- O O
interventional O O
, O O
observational O O
study O O
. O O

INTRODUCTION O O
: O O
Acute B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
kidney I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
injury I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
AKI B B_DISEASE/B_GENE
) O O
occurs O O
in O O
7 O O
% O O
of O O
hospitalized O O
and O O
66 O O
% O O
of O O
Intensive O O
Care O O
Unit O O
( O O
ICU O O
) O O
patients O O
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
investigate O O
, O O
whether O O
there O O
is O O
an O O
association O O
between O O
adherence O O
to O O
guidelines O O
( O O
standard O O
operating O O
procedures O O
( O O
SOP O O
) O O
) O O
for O O
potentially O O
nephrotoxic B B_DISEASE_ADJECTIVE[DISEASE]
antibiotics O O
and O O
the O O
occurrence O O
of O O
AKI B B_DISEASE
. O O

Data O O
collection O O
was O O
performed O O
over O O
a O O
total O O
of O O
170 O O
days O O
in O O
three O O
ICUs O O
at O O
Charite O O
- O O
Universitaetsmedizin O O
Berlin O O
. O O

A O O
total O O
of O O
675 O O
patients O O
were O O
included O O
; O O
163 O O
of O O
these O O
had O O
therapy O O
with O O
vancomycin O O
, O O
gentamicin O O
, O O
or O O
tobramycin O O
; O O
were O O
> O O
18 O O
years O O
; O O
and O O
treated O O
in O O
the O O
ICU O O
for O O
> O O
24 O O
hours O O
. O O

Patients O O
with O O
an O O
adherence O O
to O O
SOP O O
> O O
70 O O
% O O
were O O
classified O O
into O O
the O O
high O O
adherence O O
group O O
( O O
HAG O O
) O O
and O O
patients O O
with O O
an O O
adherence O O
of O O
< O O
70 O O
% O O
into O O
the O O
low O O
adherence O O
group O O
( O O
LAG O O
) O O
. O O

AKI B B_DISEASE
was O O
defined O O
according O O
to O O
RIFLE O O
criteria O O
. O O

Adherence O O
to O O
SOPs O O
was O O
evaluated O O
by O O
retrospective O O
expert O O
audit O O
. O O

Development O O
of O O
AKI B B_DISEASE
was O O
compared O O
between O O
groups O O
with O O
exact O O
Chi2 O O
- O O
test O O
and O O
multivariate O O
logistic O O
regression O O
analysis O O
( O O
two O O
- O O
sided O O
P O O
< O O
0 O O
. O O
05 O O
) O O
. O O

RESULTS O O
: O O
LAG O O
consisted O O
of O O
75 O O
patients O O
( O O
46 O O
% O O
) O O
versus O O
88 O O
HAG O O
patients O O
( O O
54 O O
% O O
) O O
. O O

AKI B B_DISEASE/B_GENE
occurred O O
significantly O O
more O O
often O O
in O O
LAG O O
with O O
36 O O
% O O
versus O O
21 O O
% O O
in O O
HAG O O
( O O
P O O
= O O
0 O O
. O O
035 O O
) O O
. O O

Basic O O
characteristics O O
were O O
comparable O O
, O O
except O O
an O O
increased O O
rate O O
of O O
soft O O
tissue O O
infections B B_DISEASE
in O O
LAG O O
. O O

Multivariate O O
analysis O O
revealed O O
an O O
odds O O
ratio O O
of O O
2 O O
. O O
5 O O
- O O
fold O O
for O O
LAG O O
to O O
develop O O
AKI B B_DISEASE
compared O O
with O O
HAG O O
( O O
95 O O
% O O
confidence O O
interval O O
1 O O
. O O
195 O O
to O O
5 O O
. O O
124 O O
, O O
P O O
= O O
0 O O
. O O
039 O O
) O O
. O O

CONCLUSION O O
: O O
Low O O
adherence O O
to O O
SOPs O O
for O O
potentially O O
nephrotoxic B B_DISEASE_ADJECTIVE[DISEASE]
antibiotics O O
was O O
associated O O
with O O
a O O
higher O O
occurrence O O
of O O
AKI B B_DISEASE
. O O

TRIAL O O
REGISTRATION O O
: O O
Current O O
Controlled O O
Trials O O
ISRCTN54598675 O O
. O O

Registered O O
17 O O
August O O
2007 O O
. O O

Rhabdomyolysis B B_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
hepatitis B B_DISEASE/B_LOCATION
C I I_DISEASE/I_LOCATION
virus I I_DISEASE/I_LOCATION
infected I I_DISEASE/I_LOCATION
patient O O
treated O O
with O O
telaprevir O O
and O O
simvastatin O O
. O O

A O O
46 O O
- O O
year O O
old O O
man O O
with O O
a O O
chronic O O
hepatitis B B_DISEASE
C I I_DISEASE
virus I I_DISEASE
infection I I_DISEASE
received O O
triple O O
therapy O O
with O O
ribavirin O O
, O O
pegylated O O
interferon O O
and O O
telaprevir O O
. O O

The O O
patient O O
also O O
received O O
simvastatin O O
. O O

One O O
month O O
after O O
starting O O
the O O
antiviral O O
therapy O O
, O O
the O O
patient O O
was O O
admitted O O
to O O
the O O
hospital O O
because O O
he O O
developed O O
rhabdomyolysis B B_DISEASE
. O O

At O O
admission O O
simvastatin O O
and O O
all O O
antiviral O O
drugs O O
were O O
discontinued O O
because O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
due O O
to O O
a O O
drug O O
- O O
drug O O
interaction O O
was O O
suspected O O
. O O

The O O
creatine O O
kinase O O
peaked O O
at O O
62 O O
, O O
246 O O
IU O O
/ O O
L O O
and O O
the O O
patient O O
was O O
treated O O
with O O
intravenous O O
normal O O
saline O O
. O O

The O O
patient O O
' O O
s O O
renal O O
function O O
remained O O
unaffected O O
. O O

Fourteen O O
days O O
after O O
hospitalization O O
, O O
creatine O O
kinase O O
level O O
had O O
returned O O
to O O
230 O O
IU O O
/ O O
L O O
and O O
the O O
patient O O
was O O
discharged O O
. O O

Telaprevir O O
was O O
considered O O
the O O
probable O O
causative O O
agent O O
of O O
an O O
interaction O O
with O O
simvastatin O O
according O O
to O O
the O O
Drug O O
Interaction O O
Probability O O
Scale O O
. O O

The O O
interaction O O
is O O
due O O
to O O
inhibition O O
of O O
CYP3A4 O O
- O O
mediated O O
simvastatin O O
clearance O O
. O O

Simvastatin O O
plasma O O
concentration O O
increased O O
30 O O
times O O
in O O
this O O
patient O O
and O O
statin O O
induced O O
muscle B B_DISEASE
toxicity I I_DISEASE
is O O
related O O
to O O
the O O
concentration O O
of O O
the O O
statin O O
in O O
blood O O
. O O

In O O
conclusion O O
, O O
with O O
this O O
case O O
we O O
illustrate O O
that O O
telaprevir O O
as O O
well O O
as O O
statins O O
are O O
susceptible O O
to O O
clinical O O
relevant O O
drug O O
- O O
drug O O
interactions O O
. O O

Combination O O
of O O
bortezomib O O
, O O
thalidomide O O
, O O
and O O
dexamethasone O O
( O O
VTD O O
) O O
as O O
a O O
consolidation O O
therapy O O
after O O
autologous O O
stem O O
cell O O
transplantation O O
for O O
symptomatic O O
multiple B B_DISEASE/B_LOCATION
myeloma I I_DISEASE/I_LOCATION
in O O
Japanese O O
patients O O
. O O

In O O
this O O
study O O
, O O
we O O
retrospectively O O
analyzed O O
the O O
safety O O
and O O
efficacy O O
of O O
combination O O
regimen O O
of O O
bortezomib O O
, O O
thalidomide O O
, O O
and O O
dexamethasone O O
( O O
VTD O O
) O O
as O O
consolidation O O
therapy O O
in O O
24 O O
Japanese O O
patients O O
with O O
newly O O
diagnosed O O
MM B B_DISEASE/B_LOCATION
. O O

VTD O O
consisted O O
of O O
bortezomib O O
at O O
a O O
dose O O
of O O
1 O O
. O O
3 O O
mg O O
/ O O
m O O
( O O
2 O O
) O O
and O O
dexamethasone O O
at O O
a O O
dose O O
of O O
40 O O
mg O O
/ O O
day O O
on O O
days O O
1 O O
, O O
8 O O
, O O
15 O O
, O O
and O O
22 O O
of O O
a O O
35 O O
- O O
day O O
cycle O O
, O O
with O O
daily O O
oral O O
thalidomide O O
at O O
a O O
dose O O
of O O
100 O O
mg O O
/ O O
day O O
. O O

Grade O O
3 O O
- O O
4 O O
neutropenia B B_DISEASE
and O O
thrombocytopenia B B_DISEASE
were O O
documented O O
in O O
four O O
and O O
three O O
patients O O
( O O
17 O O
and O O
13 O O
% O O
) O O
, O O
respectively O O
, O O
but O O
drug O O
dose O O
reduction O O
due O O
to O O
cytopenia B B_DISEASE
was O O
not O O
required O O
in O O
any O O
case O O
. O O

Peripheral B B_DISEASE
neuropathy I I_DISEASE
was O O
common O O
( O O
63 O O
% O O
) O O
, O O
but O O
severe O O
grade O O
3 O O
- O O
4 O O
peripheral B B_DISEASE
neuropathy I I_DISEASE
was O O
not O O
observed O O
. O O

Very O O
good O O
partial O O
response O O
or O O
better O O
response O O
( O O
> O O
VGPR O O
) O O
rates O O
before O O
and O O
after O O
consolidation O O
therapy O O
were O O
54 O O
and O O
79 O O
% O O
, O O
respectively O O
. O O

Patients O O
had O O
a O O
significant O O
probability O O
of O O
improving O O
from O O
< O O
VGPR O O
before O O
consolidation O O
therapy O O
to O O
> O O
VGPR O O
after O O
consolidation O O
therapy O O
( O O
p O O
= O O
0 O O
. O O
041 O O
) O O
. O O

Conversion O O
to O O
sirolimus O O
ameliorates O O
cyclosporine O O
- O O
induced O O
nephropathy B B_DISEASE
in O O
the O O
rat O O
: O O
focus O O
on O O
serum O O
, O O
urine O O
, O O
gene O O
, O O
and O O
protein O O
renal O O
expression O O
biomarkers O O
. O O

Protocols O O
of O O
conversion O O
from O O
cyclosporin O O
A O O
( O O
CsA O O
) O O
to O O
sirolimus O O
( O O
SRL O O
) O O
have O O
been O O
widely O O
used O O
in O O
immunotherapy O O
after O O
transplantation O O
to O O
prevent O O
CsA O O
- O O
induced O O
nephropathy B B_DISEASE
, O O
but O O
the O O
molecular O O
mechanisms O O
underlying O O
these O O
protocols O O
remain O O
nuclear O O
. O O

Classical O O
and O O
emergent O O
serum O O
, O O
urinary O O
, O O
and O O
kidney O O
tissue O O
( O O
gene O O
and O O
protein O O
expression O O
) O O
markers O O
were O O
assessed O O
. O O

Renal B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
lesions I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O O
analyzed O O
in O O
hematoxylin O O
and O O
eosin O O
, O O
periodic O O
acid O O
- O O
Schiff O O
, O O
and O O
Masson O O
' O O
s O O
trichrome O O
stains O O
. O O

SRL O O
- O O
treated O O
rats O O
presented O O
proteinuria B B_DISEASE/B_GENE
and O O
NGAL O O
( O O
serum O O
and O O
urinary O O
) O O
as O O
the O O
best O O
markers O O
of O O
renal B B_DISEASE/B_GENE
impairment I I_DISEASE/I_GENE
. O O

Short O O
CsA O O
treatment O O
presented O O
slight O O
or O O
even O O
absent O O
kidney B B_DISEASE_ADJECTIVE[DISEASE]
lesions I I_DISEASE_ADJECTIVE[DISEASE]
and O O
TGF O O
- O O
b O O
, O O
NF O O
- O O
kb O O
, O O
mTOR O O
, O O
PCNA O O
, O O
TP53 O O
, O O
KIM O O
- O O
1 O O
, O O
and O O
CTGF O O
as O O
relevant O O
gene O O
and O O
protein O O
changes O O
. O O

Prolonged O O
CsA O O
exposure O O
aggravated O O
renal B B_DISEASE/B_LOCATION
damage I I_DISEASE/I_LOCATION
, O O
without O O
clear O O
changes O O
on O O
the O O
traditional O O
markers O O
, O O
but O O
with O O
changes O O
in O O
serums O O
TGF O O
- O O
b O O
and O O
IL O O
- O O
7 O O
, O O
TBARs O O
clearance O O
, O O
and O O
kidney O O
TGF O O
- O O
b O O
and O O
mTOR O O
. O O

Conversion O O
to O O
SRL O O
prevented O O
CsA O O
- O O
induced O O
renal B B_DISEASE_ADJECTIVE[DISEASE]
damage I I_DISEASE_ADJECTIVE[DISEASE]
evolution O O
( O O
absent O O
/ O O
mild O O
grade O O
lesions O O
) O O
, O O
while O O
NGAL O O
( O O
serum O O
versus O O
urine O O
) O O
seems O O
to O O
be O O
a O O
feasible O O
biomarker O O
of O O
CsA O O
replacement O O
to O O
SRL O O
. O O

Kinin O O
B2 O O
receptor O O
deletion O O
and O O
blockage O O
ameliorates O O
cisplatin O O
- O O
induced O O
acute B B_DISEASE/B_GENE
renal I I_DISEASE/I_GENE
injury I I_DISEASE/I_GENE
. O O

Cisplatin O O
treatment O O
has O O
been O O
adopted O O
in O O
some O O
chemotherapies O O
; O O
however O O
, O O
this O O
drug O O
can O O
induce O O
acute B B_DISEASE
kidney I I_DISEASE
injury I I_DISEASE
due O O
its O O
ability O O
to O O
negatively O O
affect O O
renal O O
function O O
, O O
augment O O
serum O O
levels O O
of O O
creatinine O O
and O O
urea O O
, O O
increase O O
the O O
acute B B_DISEASE_ADJECTIVE[DISEASE]
tubular I I_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_DISEASE_ADJECTIVE[DISEASE]
score O O
and O O
up O O
- O O
regulate O O
cytokines O O
( O O
e O O
. O O
g O O
. O O
, O O
IL O O
- O O
1b O O
and O O
TNF O O
- O O
a O O
) O O
. O O

The O O
kinin O O
B2 O O
receptor O O
has O O
been O O
associated O O
with O O
the O O
inflammation B B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
process O O
, O O
as O O
well O O
as O O
the O O
regulation O O
of O O
cytokine O O
expression O O
, O O
and O O
its O O
deletion O O
resulted O O
in O O
an O O
improvement O O
in O O
the O O
diabetic B B_DISEASE_ADJECTIVE[DISEASE]
nephropathy I I_DISEASE_ADJECTIVE[DISEASE]
status O O
. O O

To O O
examine O O
the O O
role O O
of O O
the O O
kinin O O
B2 O O
receptor O O
in O O
cisplatin O O
- O O
induced O O
acute B B_DISEASE
kidney I I_DISEASE
injury I I_DISEASE
, O O
kinin O O
B2 O O
receptor O O
knockout O O
mice O O
were O O
challenged O O
with O O
cisplatin O O
. O O

Additionally O O
, O O
WT O O
mice O O
were O O
treated O O
with O O
a O O
B2 O O
receptor O O
antagonist O O
after O O
cisplatin O O
administration O O
. O O

B2 O O
receptor O O
- O O
deficient O O
mice O O
were O O
less O O
sensitive O O
to O O
this O O
drug O O
than O O
the O O
WT O O
mice O O
, O O
as O O
shown O O
by O O
reduced O O
weight B B_DISEASE/B_GENE
loss I I_DISEASE/I_GENE
, O O
better O O
preservation O O
of O O
kidney O O
function O O
, O O
down O O
regulation O O
of O O
inflammatory O O
cytokines O O
and O O
less O O
acute B B_DISEASE
tubular I I_DISEASE
necrosis I I_DISEASE
. O O

Moreover O O
, O O
treatment O O
with O O
the O O
kinin O O
B2 O O
receptor O O
antagonist O O
effectively O O
reduced O O
the O O
levels O O
of O O
serum O O
creatinine O O
and O O
blood O O
urea O O
after O O
cisplatin O O
administration O O
. O O

Thus O O
, O O
our O O
data O O
suggest O O
that O O
the O O
kinin O O
B2 O O
receptor O O
is O O
involved O O
in O O
cisplatin O O
- O O
induced O O
acute B B_DISEASE
kidney I I_DISEASE
injury I I_DISEASE
by O O
mediating O O
the O O
necrotic B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
process O O
and O O
the O O
expression O O
of O O
inflammatory O O
cytokines O O
, O O
thus O O
resulting O O
in O O
declined O O
renal O O
function O O
. O O

These O O
results O O
highlight O O
the O O
kinin O O
B2 O O
receptor O O
antagonist O O
treatment O O
in O O
amelioration O O
of O O
nephrotoxicity B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
by O O
cisplatin O O
therapy O O
. O O

Safety O O
and O O
efficacy O O
of O O
fluocinolone O O
acetonide O O
intravitreal O O
implant O O
( O O
0 O O
. O O
59 O O
mg O O
) O O
in O O
birdshot B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
retinochoroidopathy I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

PURPOSE O O
: O O
To O O
report O O
the O O
treatment O O
outcomes O O
of O O
the O O
fluocinolone O O
acetonide O O
intravitreal O O
implant O O
( O O
0 O O
. O O
59 O O
mg O O
) O O
in O O
patients O O
with O O
birdshot B B_DISEASE/B_LOCATION
retinochoroidopathy I I_DISEASE/I_LOCATION
whose O O
disease O O
is O O
refractory O O
or O O
intolerant O O
to O O
conventional O O
immunomodulatory O O
therapy O O
. O O

METHODS O O
: O O
A O O
retrospective O O
case O O
series O O
involving O O
11 O O
birdshot B B_DISEASE/B_PERSON
retinochoroidopathy I I_DISEASE/I_PERSON
patients O O
( O O
11 O O
eyes O O
) O O
. O O

Eleven O O
patients O O
( O O
11 O O
eyes O O
) O O
underwent O O
surgery O O
for O O
fluocinolone O O
acetonide O O
implant O O
( O O
0 O O
. O O
59 O O
mg O O
) O O
. O O

Treatment O O
outcomes O O
of O O
interest O O
were O O
noted O O
at O O
baseline O O
, O O
before O O
fluocinolone O O
acetonide O O
implant O O
, O O
and O O
then O O
at O O
6 O O
months O O
, O O
1 O O
year O O
, O O
2 O O
years O O
, O O
3 O O
years O O
, O O
and O O
beyond O O
3 O O
years O O
. O O

Disease O O
activity O O
markers O O
, O O
including O O
signs O O
of O O
ocular O O
inflammation B B_DISEASE/B_BACTERIUM[BIO]
, O O
evidence O O
of O O
retinal B B_DISEASE
vasculitis I I_DISEASE
, O O
Swedish O O
interactive O O
threshold O O
algorithm O O
- O O
short O O
wavelength O O
automated O O
perimetry O O
Humphrey O O
visual O O
field O O
analysis O O
, O O
electroretinographic O O
parameters O O
, O O
and O O
optical O O
coherence O O
tomography O O
were O O
recorded O O
. O O

Data O O
on O O
occurrence O O
of O O
cataract B B_DISEASE
and O O
raised B B_DISEASE
intraocular I I_DISEASE
pressure I I_DISEASE
were O O
collected O O
in O O
all O O
eyes O O
. O O

RESULTS O O
: O O
Intraocular O O
inflammation B B_DISEASE/B_BACTERIUM[BIO]
was O O
present O O
in O O
54 O O
. O O
5 O O
, O O
9 O O
. O O
9 O O
, O O
11 O O
. O O
1 O O
, O O
and O O
0 O O
% O O
of O O
patients O O
at O O
baseline O O
, O O
6 O O
months O O
, O O
1 O O
year O O
, O O
2 O O
years O O
, O O
3 O O
years O O
, O O
and O O
beyond O O
3 O O
years O O
after O O
receiving O O
the O O
implant O O
, O O
respectively O O
. O O

Active O O
vasculitis B B_DISEASE/B_LOCATION
was O O
noted O O
in O O
36 O O
. O O
3 O O
% O O
patients O O
at O O
baseline O O
and O O
0 O O
% O O
at O O
3 O O
years O O
of O O
follow O O
- O O
up O O
. O O

More O O
than O O
20 O O
% O O
( O O
47 O O
. O O
61 O O
- O O
67 O O
. O O
2 O O
% O O
) O O
reduction O O
in O O
central O O
retinal O O
thickness O O
was O O
noted O O
in O O
all O O
patients O O
with O O
cystoid B B_DISEASE/B_LOCATION
macular I I_DISEASE/I_LOCATION
edema I I_DISEASE/I_LOCATION
at O O
6 O O
months O O
, O O
1 O O
year O O
, O O
2 O O
years O O
, O O
and O O
3 O O
years O O
postimplant O O
. O O

At O O
baseline O O
, O O
54 O O
. O O
5 O O
% O O
patients O O
were O O
on O O
immunomodulatory O O
agents O O
. O O

This O O
percentage O O
decreased O O
to O O
45 O O
. O O
45 O O
, O O
44 O O
. O O
4 O O
, O O
and O O
14 O O
. O O
28 O O
% O O
at O O
1 O O
year O O
, O O
2 O O
years O O
, O O
and O O
3 O O
years O O
postimplant O O
, O O
respectively O O
. O O

Adverse O O
events O O
included O O
increased B B_DISEASE
intraocular I I_DISEASE
pressure I I_DISEASE
( O O
54 O O
. O O
5 O O
% O O
) O O
and O O
cataract B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
formation O O
( O O
100 O O
% O O
) O O
. O O

CONCLUSION O O
: O O
The O O
data O O
suggest O O
that O O
fluocinolone O O
acetonide O O
implant O O
( O O
0 O O
. O O
59 O O
mg O O
) O O
helps O O
to O O
control O O
inflammation B B_DISEASE/B_BACTERIUM[BIO]
in O O
otherwise O O
treatment O O
- O O
refractory O O
cases O O
of O O
birdshot B B_DISEASE/B_LOCATION
retinochoroidopathy I I_DISEASE/I_LOCATION
. O O

It O O
is O O
associated O O
with O O
significant O O
side O O
effects O O
of O O
cataract B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
ocular B B_DISEASE
hypertension I I_DISEASE
requiring O O
treatment O O
. O O

Optimal O O
precurarizing O O
dose O O
of O O
rocuronium O O
to O O
decrease O O
fasciculation B B_DISEASE
and O O
myalgia B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
following O O
succinylcholine O O
administration O O
. O O

BACKGROUND O O
: O O
Succinylcholine O O
commonly O O
produces O O
frequent O O
adverse O O
effects O O
, O O
including O O
muscle B B_DISEASE
fasciculation I I_DISEASE
and O O
myalgia B B_DISEASE
. O O

The O O
current O O
study O O
identified O O
the O O
optimal O O
dose O O
of O O
rocuronium O O
to O O
prevent O O
succinylcholine O O
- O O
induced O O
fasciculation B B_DISEASE
and O O
myalgia B B_DISEASE
and O O
evaluated O O
the O O
influence O O
of O O
rocuronium O O
on O O
the O O
speed O O
of O O
onset O O
produced O O
by O O
succinylcholine O O
. O O

METHODS O O
: O O
This O O
randomized O O
, O O
double O O
- O O
blinded O O
study O O
was O O
conducted O O
in O O
100 O O
patients O O
randomly O O
allocated O O
into O O
five O O
groups O O
of O O
20 O O
patients O O
each O O
. O O

Patients O O
were O O
randomized O O
to O O
receive O O
0 O O
. O O
02 O O
, O O
0 O O
. O O
03 O O
, O O
0 O O
. O O
04 O O
, O O
0 O O
. O O
05 O O
and O O
0 O O
. O O
06 O O
mg O O
/ O O
kg O O
rocuronium O O
as O O
a O O
precurarizing O O
dose O O
. O O

Neuromuscular O O
monitoring O O
after O O
each O O
precurarizing O O
dose O O
was O O
recorded O O
from O O
the O O
adductor O O
pollicis O O
muscle O O
using O O
acceleromyography O O
with O O
train O O
- O O
of O O
- O O
four O O
stimulation O O
of O O
the O O
ulnar O O
nerve O O
. O O

All O O
patients O O
received O O
succinylcholine O O
1 O O
. O O
5 O O
mg O O
/ O O
kg O O
at O O
2 O O
minutes O O
after O O
the O O
precurarization O O
, O O
and O O
were O O
assessed O O
the O O
incidence O O
and O O
severity O O
of O O
fasciculations B B_DISEASE
, O O
while O O
myalgia B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
assessed O O
at O O
24 O O
hours O O
after O O
surgery O O
. O O

RESULTS O O
: O O
The O O
incidence O O
and O O
severity O O
of O O
visible O O
muscle B B_DISEASE_ADJECTIVE[DISEASE]
fasciculation I I_DISEASE_ADJECTIVE[DISEASE]
was O O
significantly O O
less O O
with O O
increasing O O
the O O
amount O O
of O O
precurarizing O O
dose O O
of O O
rocuronium O O
( O O
P O O
< O O
0 O O
. O O
001 O O
) O O
. O O

Those O O
of O O
myalgia B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tend O O
to O O
decrease O O
according O O
to O O
increasing O O
the O O
amount O O
of O O
precurarizing O O
dose O O
of O O
rocuronium O O
, O O
but O O
there O O
was O O
no O O
significance O O
( O O
P O O
= O O
0 O O
. O O
072 O O
) O O
. O O

The O O
onset O O
time O O
of O O
succinylcholine O O
was O O
significantly O O
longer O O
with O O
increasing O O
the O O
amount O O
of O O
precurarizing O O
dose O O
of O O
rocuronium O O
( O O
P O O
< O O
0 O O
. O O
001 O O
) O O
. O O

CONCLUSIONS O O
: O O
Precurarization O O
with O O
0 O O
. O O
04 O O
mg O O
/ O O
kg O O
rocuronium O O
was O O
the O O
optimal O O
dose O O
considering O O
the O O
reduction O O
in O O
the O O
incidence O O
and O O
severity O O
of O O
fasciculation B B_DISEASE
and O O
myalgia B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
acceptable O O
onset O O
time O O
, O O
and O O
the O O
safe O O
and O O
effective O O
precurarization O O
. O O

Absence O O
of O O
PKC O O
- O O
alpha O O
attenuates O O
lithium O O
- O O
induced O O
nephrogenic B B_DISEASE
diabetes I I_DISEASE
insipidus I I_DISEASE
. O O

Lithium O O
, O O
an O O
effective O O
antipsychotic O O
, O O
induces O O
nephrogenic B B_DISEASE
diabetes I I_DISEASE
insipidus I I_DISEASE
( O O
NDI B B_DISEASE/B_PROTEIN[GENE]
) O O
in O O
40 O O
% O O
of O O
patients O O
. O O

The O O
decreased O O
capacity O O
to O O
concentrate O O
urine O O
is O O
likely O O
due O O
to O O
lithium O O
acutely O O
disrupting O O
the O O
cAMP O O
pathway O O
and O O
chronically O O
reducing O O
urea O O
transporter O O
( O O
UT O O
- O O
A1 O O
) O O
and O O
water O O
channel O O
( O O
AQP2 O O
) O O
expression O O
in O O
the O O
inner O O
medulla O O
. O O

Targeting O O
an O O
alternative O O
signaling O O
pathway O O
, O O
such O O
as O O
PKC O O
- O O
mediated O O
signaling O O
, O O
may O O
be O O
an O O
effective O O
method O O
of O O
treating O O
lithium O O
- O O
induced O O
polyuria B B_DISEASE
. O O

WT O O
mice O O
had O O
increased O O
urine O O
output O O
and O O
lowered O O
urine O O
osmolality O O
after O O
3 O O
and O O
5 O O
days O O
of O O
treatment O O
whereas O O
PKCa O O
KO O O
mice O O
had O O
no O O
change O O
in O O
urine O O
output O O
or O O
concentration O O
. O O

Western O O
blot O O
analysis O O
revealed O O
that O O
AQP2 O O
expression O O
in O O
medullary O O
tissues O O
was O O
lowered O O
after O O
3 O O
and O O
5 O O
days O O
in O O
WT O O
mice O O
; O O
however O O
, O O
AQP2 O O
was O O
unchanged O O
in O O
PKCa O O
KO O O
. O O

Similar O O
results O O
were O O
observed O O
with O O
UT O O
- O O
A1 O O
expression O O
. O O

Animals O O
were O O
also O O
treated O O
with O O
lithium O O
for O O
6 O O
weeks O O
. O O

Lithium O O
- O O
treated O O
WT O O
mice O O
had O O
19 O O
- O O
fold O O
increased O O
urine O O
output O O
whereas O O
treated O O
PKCa O O
KO O O
animals O O
had O O
a O O
4 O O
- O O
fold O O
increase O O
in O O
output O O
. O O

AQP2 O O
and O O
UT O O
- O O
A1 O O
expression O O
was O O
lowered O O
in O O
6 O O
week O O
lithium O O
- O O
treated O O
WT O O
animals O O
whereas O O
in O O
treated O O
PKCa O O
KO O O
mice O O
, O O
AQP2 O O
was O O
only O O
reduced O O
by O O
2 O O
- O O
fold O O
and O O
UT O O
- O O
A1 O O
expression O O
was O O
unaffected O O
. O O

Urinary O O
sodium O O
, O O
potassium O O
and O O
calcium O O
were O O
elevated O O
in O O
lithium O O
- O O
fed O O
WT O O
but O O
not O O
in O O
lithium O O
- O O
fed O O
PKCa O O
KO O O
mice O O
. O O

Our O O
data O O
show O O
that O O
ablation O O
of O O
PKCa O O
preserves O O
AQP2 O O
and O O
UT O O
- O O
A1 O O
protein O O
expression O O
and O O
localization O O
in O O
lithium O O
- O O
induced O O
NDI B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
prevents O O
the O O
development O O
of O O
the O O
severe O O
polyuria B B_DISEASE_ADJECTIVE[DISEASE]
associated O O
with O O
lithium O O
therapy O O
. O O

A O O
very O O
rare O O
side O O
- O O
effect O O
of O O
amlodipine O O
is O O
dysguesia B B_DISEASE
. O O

A O O
review O O
of O O
the O O
literature O O
produced O O
only O O
one O O
case O O
. O O

We O O
report O O
a O O
case O O
about O O
a O O
female O O
with O O
essential O O
hypertension B B_DISEASE
on O O
drug O O
treatment O O
with O O
amlodipine O O
developed O O
loss B B_DISEASE/B_GENE
of I I_DISEASE/I_GENE
taste I I_DISEASE/I_GENE
sensation I I_DISEASE/I_GENE
. O O

Condition O O
moderately O O
improved O O
on O O
stoppage O O
of O O
the O O
drug O O
for O O
25 O O
days O O
. O O

We O O
conclude O O
that O O
amlodipine O O
can O O
cause O O
dysguesia B B_DISEASE
. O O

Here O O
, O O
we O O
describe O O
the O O
clinical O O
presentation O O
and O O
review O O
the O O
relevant O O
literature O O
on O O
amlodipine O O
and O O
dysguesia B B_DISEASE/B_LOCATION
. O O

Rhabdomyolysis B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
association O O
with O O
simvastatin O O
and O O
dosage O O
increment O O
in O O
clarithromycin O O
. O O

This O O
particular O O
case O O
is O O
of O O
interest O O
as O O
rhabdomyolysis B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
only O O
occurred O O
after O O
an O O
increase O O
in O O
the O O
dose O O
of O O
clarithromycin O O
. O O

The O O
patient O O
developed O O
raised O O
cardiac O O
biomarkers O O
without O O
any O O
obvious O O
cardiac O O
issues O O
, O O
a O O
phenomenon O O
that O O
has O O
been O O
linked O O
to O O
rhabdomyolysis B B_DISEASE
previously O O
. O O

To O O
date O O
, O O
there O O
has O O
been O O
no O O
reported O O
effect O O
of O O
rhabdomyolysis B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
structure O O
and O O
function O O
of O O
cardiac O O
muscle O O
. O O

Clinicians O O
need O O
to O O
be O O
aware O O
of O O
prescribing O O
concomitant O O
medications O O
that O O
increase O O
the O O
risk O O
of O O
myopathy B B_DISEASE/B_GENE
or O O
inhibit O O
the O O
CYP3A4 O O
enzyme O O
. O O

Our O O
case O O
suggests O O
that O O
troponin O O
elevation O O
could O O
be O O
associated O O
with O O
statin O O
induced O O
rhabdomyolysis B B_DISEASE
, O O
which O O
may O O
warrant O O
further O O
studies O O
. O O

Characterization O O
of O O
a O O
novel O O
BCHE O O
" O O
silent O O
" O O
allele O O
: O O
point O O
mutation O O
( O O
p O O
. O O
Val204Asp O O
) O O
causes O O
loss O O
of O O
activity O O
and O O
prolonged O O
apnea B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
suxamethonium O O
. O O

Butyrylcholinesterase B B_DISEASE/B_LOCATION
deficiency I I_DISEASE/I_LOCATION
is O O
characterized O O
by O O
prolonged O O
apnea B B_DISEASE
after O O
the O O
use O O
of O O
muscle O O
relaxants O O
( O O
suxamethonium O O
or O O
mivacurium O O
) O O
in O O
patients O O
who O O
have O O
mutations O O
in O O
the O O
BCHE O O
gene O O
. O O

Electrophoretic O O
analysis O O
of O O
plasma O O
BChE O O
of O O
the O O
proband O O
and O O
his O O
mother O O
showed O O
that O O
patient O O
has O O
a O O
reduced O O
amount O O
of O O
tetrameric O O
enzyme O O
in O O
plasma O O
and O O
that O O
minor O O
fast O O
- O O
moving O O
BChE O O
components O O
: O O
monomer O O
, O O
dimer O O
, O O
and O O
monomer O O
- O O
albumin O O
conjugate O O
are O O
missing O O
. O O

Kinetic O O
analysis O O
showed O O
that O O
the O O
p O O
. O O
Val204Asp O O
/ O O
p O O
. O O
Asp70Gly O O
- O O
p O O
. O O
Ala539Thr O O
BChE O O
displays O O
a O O
pure O O
Michaelian O O
behavior O O
with O O
BTC O O
as O O
the O O
substrate O O
. O O

Both O O
catalytic O O
parameters O O
Km O O
= O O
265 O O
uM O O
for O O
BTC O O
, O O
two O O
times O O
higher O O
than O O
that O O
of O O
the O O
atypical O O
enzyme O O
, O O
and O O
a O O
low O O
Vmax O O
are O O
consistent O O
with O O
the O O
absence O O
of O O
activity O O
against O O
suxamethonium O O
. O O

This O O
fits O O
with O O
the O O
reduced O O
concentration O O
of O O
p O O
. O O
Ala204Asp O O
/ O O
p O O
. O O
Asp70Gly O O
- O O
p O O
. O O
Ala539Thr O O
tetrameric O O
enzyme O O
in O O
the O O
plasma O O
and O O
non O O
- O O
detectable O O
fast O O
moving O O
- O O
bands O O
on O O
electrophoresis O O
gels O O
. O O

Delayed O O
anemia B B_DISEASE
after O O
treatment O O
with O O
injectable O O
artesunate O O
in O O
the O O
Democratic O O
Republic O O
of O O
the O O
Congo O O
: O O
a O O
manageable O O
issue O O
. O O

Cases O O
of O O
delayed O O
hemolytic B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
anemia I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
have O O
been O O
described O O
after O O
treatment O O
with O O
injectable O O
artesunate O O
, O O
the O O
current O O
World O O
Health O O
Organization O O
( O O
WHO O O
) O O
- O O
recommended O O
first O O
- O O
line O O
drug O O
for O O
the O O
treatment O O
of O O
severe O O
malaria B B_DISEASE
. O O

A O O
total O O
of O O
350 O O
patients O O
( O O
215 O O
[ O O
61 O O
. O O
4 O O
% O O
] O O
< O O
5 O O
years O O
of O O
age O O
and O O
135 O O
[ O O
38 O O
. O O
6 O O
% O O
] O O
> O O
5 O O
years O O
of O O
age O O
) O O
were O O
followed O O
- O O
up O O
after O O
treatment O O
with O O
injectable O O
artesunate O O
for O O
severe O O
malaria B B_DISEASE
in O O
hospitals O O
and O O
health O O
centers O O
of O O
the O O
Democratic O O
Republic O O
of O O
the O O
Congo O O
. O O

Complete O O
series O O
of O O
hemoglobin O O
( O O
Hb O O
) O O
measurements O O
were O O
available O O
for O O
201 O O
patients O O
. O O

A O O
decrease O O
in O O
Hb O O
levels O O
between O O
2 O O
and O O
5 O O
g O O
/ O O
dL O O
was O O
detected O O
in O O
23 O O
( O O
11 O O
. O O
4 O O
% O O
) O O
patients O O
during O O
the O O
follow O O
- O O
up O O
period O O
. O O

For O O
five O O
patients O O
, O O
Hb O O
levels O O
decreased O O
below O O
5 O O
g O O
/ O O
dL O O
during O O
at O O
least O O
one O O
follow O O
- O O
up O O
visit O O
. O O

All O O
cases O O
of O O
delayed O O
anemia B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
clinically O O
manageable O O
and O O
resolved O O
within O O
one O O
month O O
. O O

Regulation O O
of O O
signal O O
transducer O O
and O O
activator O O
of O O
transcription O O
3 O O
and O O
apoptotic O O
pathways O O
by O O
betaine O O
attenuates O O
isoproterenol O O
- O O
induced O O
acute O O
myocardial B B_DISEASE
injury I I_DISEASE
in O O
rats O O
. O O

The O O
present O O
study O O
was O O
designed O O
to O O
investigate O O
the O O
cardioprotective O O
effects O O
of O O
betaine O O
on O O
acute O O
myocardial B B_DISEASE
ischemia I I_DISEASE
induced O O
experimentally O O
in O O
rats O O
focusing O O
on O O
regulation O O
of O O
signal O O
transducer O O
and O O
activator O O
of O O
transcription O O
3 O O
( O O
STAT3 O O
) O O
and O O
apoptotic O O
pathways O O
as O O
the O O
potential O O
mechanism O O
underlying O O
the O O
drug O O
effect O O
. O O

Male O O
Sprague O O
Dawley O O
rats O O
were O O
treated O O
with O O
betaine O O
( O O
100 O O
, O O
200 O O
, O O
and O O
400 O O
mg O O
/ O O
kg O O
) O O
orally O O
for O O
40 O O
days O O
. O O

Acute O O
myocardial B B_DISEASE
ischemic I I_DISEASE
injury I I_DISEASE
was O O
induced O O
in O O
rats O O
by O O
subcutaneous O O
injection O O
of O O
isoproterenol O O
( O O
85 O O
mg O O
/ O O
kg O O
) O O
, O O
for O O
two O O
consecutive O O
days O O
. O O

Serum O O
cardiac O O
marker O O
enzyme O O
, O O
histopathological O O
variables O O
and O O
expression O O
of O O
protein O O
levels O O
were O O
analyzed O O
. O O

Oral O O
administration O O
of O O
betaine O O
( O O
200 O O
and O O
400 O O
mg O O
/ O O
kg O O
) O O
significantly O O
reduced O O
the O O
level O O
of O O
cardiac O O
marker O O
enzyme O O
in O O
the O O
serum O O
and O O
prevented O O
left O O
ventricular B B_DISEASE
remodeling I I_DISEASE
. O O

Western O O
blot O O
analysis O O
showed O O
that O O
isoproterenol O O
- O O
induced O O
phosphorylation O O
of O O
STAT3 O O
was O O
maintained O O
or O O
further O O
enhanced O O
by O O
betaine O O
treatment O O
in O O
myocardium O O
. O O

Furthermore O O
, O O
betaine O O
( O O
200 O O
and O O
400 O O
mg O O
/ O O
kg O O
) O O
treatment O O
increased O O
the O O
ventricular O O
expression O O
of O O
Bcl O O
- O O
2 O O
and O O
reduced O O
the O O
level O O
of O O
Bax O O
, O O
therefore O O
causing O O
a O O
significant O O
increase O O
in O O
the O O
ratio O O
of O O
Bcl O O
- O O
2 O O
/ O O
Bax O O
. O O

The O O
protective O O
role O O
of O O
betaine O O
on O O
myocardial B B_DISEASE
damage I I_DISEASE
was O O
further O O
confirmed O O
by O O
histopathological O O
examination O O
. O O

In O O
summary O O
, O O
our O O
results O O
showed O O
that O O
betaine O O
pretreatment O O
attenuated O O
isoproterenol O O
- O O
induced O O
acute O O
myocardial B B_DISEASE
ischemia I I_DISEASE
via O O
the O O
regulation O O
of O O
STAT3 O O
and O O
apoptotic O O
pathways O O
. O O

Quetiapine O O
- O O
induced O O
neutropenia B B_DISEASE
in O O
a O O
bipolar B B_DISEASE/B_MEASURE
patient O O
with O O
hepatocellular B B_DISEASE
carcinoma I I_DISEASE
. O O

OBJECTIVE O O
: O O
Quetiapine O O
is O O
a O O
dibenzothiazepine O O
derivative O O
, O O
similar O O
to O O
clozapine O O
, O O
which O O
has O O
the O O
highest O O
risk O O
of O O
causing O O
blood B B_DISEASE
dyscrasias I I_DISEASE
, O O
especially O O
neutropenia B B_DISEASE
. O O

There O O
are O O
some O O
case O O
reports O O
about O O
this O O
side O O
effect O O
of O O
quetiapine O O
, O O
but O O
possible O O
risk O O
factors O O
are O O
seldom O O
discussed O O
and O O
identified O O
. O O

A O O
case O O
of O O
a O O
patient O O
with O O
hepatocellular B B_DISEASE/B_LOCATION
carcinoma I I_DISEASE/I_LOCATION
that O O
developed O O
neutropenia B B_DISEASE
after O O
treatment O O
with O O
quetiapine O O
is O O
described O O
here O O
. O O

CASE O O
REPORT O O
: O O
A O O
62 O O
- O O
year O O
- O O
old O O
Taiwanese O O
widow O O
with O O
bipolar B B_DISEASE
disorder I I_DISEASE
was O O
diagnosed O O
with O O
hepatocellular B B_DISEASE
carcinoma I I_DISEASE
at O O
age O O
60 O O
. O O

She O O
developed O O
leucopenia B B_DISEASE
after O O
being O O
treated O O
with O O
quetiapine O O
. O O

After O O
quetiapine O O
was O O
discontinued O O
, O O
her O O
white O O
blood O O
cell O O
count O O
returned O O
to O O
normal O O
. O O

CONCLUSIONS O O
: O O
Although O O
neutropenia B B_DISEASE
is O O
not O O
a O O
common O O
side O O
effect O O
of O O
quetiapine O O
, O O
physicians O O
should O O
be O O
cautious O O
about O O
its O O
presentation O O
and O O
associated O O
risk O O
factors O O
. O O

Hepatic B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dysfunction I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
may O O
be O O
one O O
of O O
the O O
possible O O
risk O O
factors O O
, O O
and O O
concomitant O O
fever B B_DISEASE
may O O
be O O
a O O
diagnostic O O
marker O O
for O O
adverse O O
reaction O O
to O O
quetiapine O O
. O O

Lateral O O
antebrachial O O
cutaneous O O
neuropathy B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O O
steroid O O
injection O O
at O O
lateral O O
epicondyle O O
. O O

BACKGROUND O O
AND O O
OBJECTIVES O O
: O O
This O O
report O O
aimed O O
to O O
present O O
a O O
case O O
of O O
lateral O O
antebrachial O O
cutaneous O O
neuropathy B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
LACNP O O
) O O
that O O
occurred O O
after O O
a O O
steroid O O
injection O O
in O O
the O O
lateral O O
epicondyle O O
to O O
treat O O
lateral B B_DISEASE/B_LOCATION
epicondylitis I I_DISEASE/I_LOCATION
in O O
a O O
40 O O
- O O
year O O
- O O
old O O
woman O O
. O O

MATERIAL O O
AND O O
METHOD O O
: O O
A O O
40 O O
- O O
year O O
- O O
old O O
woman O O
presented O O
with O O
decreased O O
sensation O O
and O O
paresthesia B B_DISEASE/B_MEASURE
over O O
her O O
right O O
lateral O O
forearm O O
; O O
the O O
paresthesia B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O O
occurred O O
after O O
a O O
steroid O O
injection O O
in O O
the O O
right O O
lateral O O
epicondyle O O
3 O O
months O O
before O O
. O O

Her O O
sensation O O
of O O
light O O
touch O O
and O O
pain B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
diminished O O
over O O
the O O
lateral O O
side O O
of O O
the O O
right O O
forearm O O
and O O
wrist O O
area O O
. O O

The O O
difference O O
of O O
amplitude O O
between O O
both O O
sides O O
was O O
significant O O
because O O
there O O
was O O
more O O
than O O
a O O
50 O O
% O O
reduction O O
. O O

CONCLUSION O O
: O O
This O O
report O O
describes O O
the O O
case O O
of O O
a O O
woman O O
with O O
LACNP O O
that O O
developed O O
after O O
a O O
steroid O O
injection O O
for O O
the O O
treatment O O
of O O
lateral B B_DISEASE/B_GENE
epicondylitis I I_DISEASE/I_GENE
. O O

Curcumin O O
prevents O O
maleate O O
- O O
induced O O
nephrotoxicity B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
relation O O
to O O
hemodynamic O O
alterations O O
, O O
oxidative O O
stress O O
, O O
mitochondrial O O
oxygen O O
consumption O O
and O O
activity O O
of O O
respiratory O O
complex O O
I O O
. O O

The O O
potential O O
protective O O
effect O O
of O O
the O O
dietary O O
antioxidant O O
curcumin O O
( O O
120 O O
mg O O
/ O O
Kg O O
/ O O
day O O
for O O
6 O O
days O O
) O O
against O O
the O O
renal B B_DISEASE
injury I I_DISEASE
induced O O
by O O
maleate O O
was O O
evaluated O O
. O O

Tubular O O
proteinuria B B_DISEASE
and O O
oxidative O O
stress O O
were O O
induced O O
by O O
a O O
single O O
injection O O
of O O
maleate O O
( O O
400 O O
mg O O
/ O O
kg O O
) O O
in O O
rats O O
. O O

Maleate O O
- O O
induced O O
renal B B_DISEASE
injury I I_DISEASE
included O O
increase O O
in O O
renal O O
vascular O O
resistance O O
and O O
in O O
the O O
urinary O O
excretion O O
of O O
total O O
protein O O
, O O
glucose O O
, O O
sodium O O
, O O
neutrophil O O
gelatinase O O
- O O
associated O O
lipocalin O O
( O O
NGAL O O
) O O
and O O
N O O
- O O
acetyl O O
b O O
- O O
D O O
- O O
glucosaminidase O O
( O O
NAG O O
) O O
, O O
upregulation O O
of O O
kidney B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
injury I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
molecule O O
( O O
KIM O O
) O O
- O O
1 O O
, O O
decrease O O
in O O
renal O O
blood O O
flow O O
and O O
claudin O O
- O O
2 O O
expression O O
besides O O
of O O
necrosis B B_DISEASE/B_GENE
and O O
apoptosis O O
of O O
tubular O O
cells O O
on O O
24 O O
h O O
. O O

Studies O O
were O O
also O O
conducted O O
in O O
renal O O
epithelial O O
LLC O O
- O O
PK1 O O
cells O O
and O O
in O O
mitochondria O O
isolated O O
from O O
kidneys O O
of O O
all O O
the O O
experimental O O
groups O O
. O O

In O O
addition O O
, O O
maleate O O
treatment O O
reduced O O
oxygen O O
consumption O O
in O O
ADP O O
- O O
stimulated O O
mitochondria O O
and O O
diminished O O
respiratory O O
control O O
index O O
when O O
using O O
malate O O
/ O O
glutamate O O
as O O
substrate O O
. O O

The O O
activities O O
of O O
both O O
complex O O
I O O
and O O
aconitase O O
were O O
also O O
diminished O O
. O O

All O O
the O O
above O O
- O O
described O O
alterations O O
were O O
prevented O O
by O O
curcumin O O
. O O

It O O
is O O
concluded O O
that O O
curcumin O O
is O O
able O O
to O O
attenuate O O
in O O
vivo O O
maleate O O
- O O
induced O O
nephropathy B B_DISEASE
and O O
in O O
vitro O O
cell O O
damage O O
. O O

Anticonvulsant O O
actions O O
of O O
MK O O
- O O
801 O O
on O O
the O O
lithium O O
- O O
pilocarpine O O
model O O
of O O
status B B_DISEASE
epilepticus I I_DISEASE
in O O
rats O O
. O O

MK O O
- O O
801 O O
, O O
a O O
noncompetitive O O
N O O
- O O
methyl O O
- O O
D O O
- O O
aspartate O O
( O O
NMDA O O
) O O
receptor O O
antagonist O O
, O O
was O O
tested O O
for O O
anticonvulsant O O
effects O O
in O O
rats O O
using O O
two O O
seizure B B_DISEASE
models O O
, O O
coadministration O O
of O O
lithium O O
and O O
pilocarpine O O
and O O
administration O O
of O O
a O O
high O O
dose O O
of O O
pilocarpine O O
alone O O
. O O

Three O O
major O O
results O O
are O O
reported O O
. O O

First O O
, O O
pretreatment O O
with O O
MK O O
- O O
801 O O
produced O O
an O O
effective O O
and O O
dose O O
- O O
dependent O O
anticonvulsant O O
action O O
with O O
the O O
lithium O O
- O O
pilocarpine O O
model O O
but O O
not O O
with O O
rats O O
treated O O
with O O
pilocarpine O O
alone O O
, O O
suggesting O O
that O O
different O O
biochemical O O
mechanisms O O
control O O
seizures B B_DISEASE
in O O
these O O
two O O
models O O
. O O

Second O O
, O O
the O O
anticonvulsant O O
effect O O
of O O
MK O O
- O O
801 O O
in O O
the O O
lithium O O
- O O
pilocarpine O O
model O O
only O O
occurred O O
after O O
initial O O
periods O O
of O O
seizure B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O O
. O O

This O O
observation O O
is O O
suggested O O
to O O
be O O
an O O
in O O
vivo O O
demonstration O O
of O O
the O O
conclusion O O
derived O O
from O O
in O O
vitro O O
experiments O O
that O O
MK O O
- O O
801 O O
binding O O
requires O O
agonist O O
- O O
induced O O
opening O O
of O O
the O O
channel O O
sites O O
of O O
the O O
NMDA O O
receptor O O
. O O

Third O O
, O O
although O O
it O O
is O O
relatively O O
easy O O
to O O
block O O
seizures B B_DISEASE
induced O O
by O O
lithium O O
and O O
pilocarpine O O
by O O
administration O O
of O O
anticonvulsants O O
prior O O
to O O
pilocarpine O O
, O O
it O O
is O O
more O O
difficult O O
to O O
terminate O O
ongoing O O
status B B_DISEASE
epilepticus I I_DISEASE
and O O
block O O
the O O
lethality O O
of O O
the O O
seizures B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Administration O O
of O O
MK O O
- O O
801 O O
30 O O
or O O
60 O O
min O O
after O O
pilocarpine O O
, O O
i O O
. O O
e O O
. O O
, O O
during O O
status B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
epilepticus I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
gradually O O
reduced O O
electrical O O
and O O
behavioral O O
seizure B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
activity O O
and O O
greatly O O
enhanced O O
the O O
survival O O
rate O O
. O O

These O O
results O O
suggest O O
that O O
activation O O
of O O
NMDA O O
receptors O O
plays O O
an O O
important O O
role O O
in O O
status B B_DISEASE
epilepticus I I_DISEASE
and O O
brain B B_DISEASE
damage I I_DISEASE
in O O
the O O
lithium O O
- O O
pilocarpine O O
model O O
. O O

This O O
was O O
further O O
supported O O
by O O
results O O
showing O O
that O O
nonconvulsive O O
doses O O
of O O
NMDA O O
and O O
pilocarpine O O
were O O
synergistic O O
, O O
resulting O O
in O O
status B B_DISEASE
epilepticus I I_DISEASE
and O O
subsequent O O
mortality O O
. O O

Continuous O O
infusion O O
tobramycin O O
combined O O
with O O
carbenicillin O O
for O O
infections B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
cancer B B_DISEASE/B_PERSON
patients O O
. O O

The O O
cure O O
rate O O
of O O
infections B B_DISEASE
in O O
cancer B B_DISEASE/B_PERSON
patients O O
is O O
adversely O O
affected O O
by O O
neutropenia B B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O O
less O O
than O O
1 O O
, O O
000 O O
/ O O
mm3 O O
) O O
. O O

In O O
particular O O
, O O
patients O O
with O O
severe O O
neutropenia B B_DISEASE
( O O
less O O
than O O
100 O O
/ O O
mm3 O O
) O O
have O O
shown O O
a O O
poor O O
response O O
to O O
antibiotics O O
. O O

To O O
overcome O O
the O O
adverse O O
effects O O
of O O
neutropenia B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
tobramycin O O
was O O
given O O
by O O
continuous O O
infusion O O
and O O
combined O O
with O O
intermittent O O
carbenicillin O O
. O O

Tobramycin O O
was O O
given O O
to O O
a O O
total O O
daily O O
dose O O
of O O
300 O O
mg O O
/ O O
m2 O O
and O O
carbenicillin O O
was O O
given O O
at O O
a O O
dose O O
of O O
5 O O
gm O O
every O O
four O O
hours O O
. O O

There O O
were O O
125 O O
infectious O O
episodes O O
in O O
116 O O
cancer B B_DISEASE
patients O O
receiving O O
myelosuppressive O O
chemotherapy O O
. O O

The O O
overall O O
cure O O
rate O O
was O O
70 O O
% O O
. O O

Pneumonia B B_DISEASE
was O O
the O O
most O O
common O O
infection B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
61 O O
% O O
of O O
59 O O
episodes O O
were O O
cured O O
. O O

Gram O O
- O O
negative O O
bacilli O O
were O O
the O O
most O O
common O O
causative O O
organisms O O
and O O
69 O O
% O O
of O O
these O O
infections B B_DISEASE/B_BIO
were O O
cured O O
. O O

The O O
most O O
common O O
pathogen O O
was O O
Klebsiella O O
pneumoniae B B_BACTERIUM[BIO]/B_DISEASE
and O O
this O O
, O O
together O O
with O O
Escherichia O O
coli O O
and O O
Pseudomonas O O
aeruginosa O O
, O O
accounted O O
for O O
74 O O
% O O
of O O
all O O
gram B B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
- I B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
negative I B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
bacillary I B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
infections I B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O O

Response O O
was O O
not O O
influenced O O
by O O
the O O
initial O O
neutrophil O O
count O O
, O O
with O O
a O O
62 O O
% O O
cure O O
rate O O
for O O
39 O O
episodes O O
associated O O
with O O
severe O O
neutropenia B B_DISEASE
. O O

However O O
, O O
failure O O
of O O
the O O
neutrophil O O
count O O
to O O
increase O O
during O O
therapy O O
adversely O O
affected O O
response O O
. O O

Azotemia B B_DISEASE
was O O
the O O
major O O
side O O
effect O O
recognized O O
, O O
and O O
it O O
occurred O O
in O O
11 O O
% O O
of O O
episodes O O
. O O

Major O O
azotemia B B_DISEASE
( O O
serum O O
creatinine O O
greater O O
than O O
2 O O
. O O
5 O O
mg O O
/ O O
dl O O
or O O
BUN O O
greater O O
than O O
50 O O
mg O O
/ O O
dl O O
) O O
occurred O O
in O O
only O O
2 O O
% O O
. O O

Azotemia B B_DISEASE_ADJECTIVE[DISEASE]
was O O
not O O
related O O
to O O
duration O O
of O O
therapy O O
or O O
serum O O
tobramycin O O
concentration O O
. O O

This O O
antibiotic O O
regimen O O
showed O O
both O O
therapeutic O O
efficacy O O
and O O
acceptable O O
renal B B_DISEASE_ADJECTIVE[DISEASE]
toxicity I I_DISEASE_ADJECTIVE[DISEASE]
for O O
these O O
patients O O
. O O

Incidence O O
of O O
solid O O
tumours B B_DISEASE
among O O
pesticide O O
applicators O O
exposed O O
to O O
the O O
organophosphate O O
insecticide O O
diazinon O O
in O O
the O O
Agricultural O O
Health O O
Study O O
: O O
an O O
updated O O
analysis O O
. O O

OBJECTIVE O O
: O O
Diazinon O O
, O O
a O O
common O O
organophosphate O O
insecticide O O
with O O
genotoxic O O
properties O O
, O O
was O O
previously O O
associated O O
with O O
lung B B_DISEASE
cancer I I_DISEASE
in O O
the O O
Agricultural O O
Health O O
Study O O
( O O
AHS O O
) O O
cohort O O
, O O
but O O
few O O
other O O
epidemiological O O
studies O O
have O O
examined O O
diazinon O O
- O O
associated O O
cancer B B_DISEASE
risk O O
. O O

We O O
used O O
updated O O
diazinon O O
exposure O O
and O O
cancer B B_DISEASE/B_MEASURE
incidence O O
information O O
to O O
evaluate O O
solid O O
tumour B B_DISEASE
risk O O
in O O
the O O
AHS O O
. O O

METHODS O O
: O O
Male O O
pesticide O O
applicators O O
in O O
Iowa O O
and O O
North O O
Carolina O O
reported O O
lifetime O O
diazinon O O
use O O
at O O
enrolment O O
( O O
1993 O O
- O O
1997 O O
) O O
and O O
follow O O
- O O
up O O
( O O
1998 O O
- O O
2005 O O
) O O
; O O
cancer B B_DISEASE/B_MEASURE
incidence O O
was O O
assessed O O
through O O
2010 O O
( O O
North O O
Carolina O O
) O O
/ O O
2011 O O
( O O
Iowa O O
) O O
. O O

Among O O
applicators O O
with O O
usage O O
information O O
sufficient O O
to O O
evaluate O O
exposure O O
- O O
response O O
patterns O O
, O O
we O O
used O O
Poisson O O
regression O O
to O O
estimate O O
adjusted O O
rate O O
ratios O O
( O O
RRs O O
) O O
and O O
95 O O
% O O
CI O O
for O O
cancer B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sites O O
with O O
> O O
10 O O
exposed O O
cases O O
for O O
both O O
lifetime O O
( O O
LT O O
) O O
exposure O O
days O O
and O O
intensity O O
- O O
weighted O O
( O O
IW O O
) O O
lifetime O O
exposure O O
days O O
( O O
accounting O O
for O O
factors O O
impacting O O
exposure O O
) O O
. O O

RESULTS O O
: O O
We O O
observed O O
elevated O O
lung B B_DISEASE/B_MEASURE
cancer I I_DISEASE/I_MEASURE
risks O O
( O O
N O O
= O O
283 O O
) O O
among O O
applicators O O
with O O
the O O
greatest O O
number O O
of O O
LT O O
( O O
RR O O
= O O
1 O O
. O O
60 O O
; O O
95 O O
% O O
CI O O
1 O O
. O O
11 O O
to O O
2 O O
. O O
31 O O
; O O
Ptrend O O
= O O
0 O O
. O O
02 O O
) O O
and O O
IW O O
days O O
of O O
diazinon O O
use O O
( O O
RR O O
= O O
1 O O
. O O
41 O O
; O O
95 O O
% O O
CI O O
0 O O
. O O
98 O O
to O O
2 O O
. O O
04 O O
; O O
Ptrend O O
= O O
0 O O
. O O
08 O O
) O O
. O O

Kidney B B_DISEASE/B_MEASURE
cancer I I_DISEASE/I_MEASURE
( O O
N O O
= O O
94 O O
) O O
risks O O
were O O
non O O
- O O
significantly O O
elevated O O
( O O
RRLT O O
days O O
= O O
1 O O
. O O
77 O O
; O O
95 O O
% O O
CI O O
0 O O
. O O
90 O O
to O O
3 O O
. O O
51 O O
; O O
Ptrend O O
= O O
0 O O
. O O
09 O O
; O O
RRIW O O
days O O
1 O O
. O O
37 O O
; O O
95 O O
% O O
CI O O
0 O O
. O O
64 O O
to O O
2 O O
. O O
92 O O
; O O
Ptrend O O
= O O
0 O O
. O O
50 O O
) O O
, O O
as O O
were O O
risks O O
for O O
aggressive O O
prostate B B_DISEASE
cancer I I_DISEASE
( O O
N O O
= O O
656 O O
) O O
. O O

CONCLUSIONS O O
: O O
Our O O
updated O O
evaluation O O
of O O
diazinon O O
provides O O
additional O O
evidence O O
of O O
an O O
association O O
with O O
lung B B_DISEASE
cancer I I_DISEASE
risk O O
. O O

Newly O O
identified O O
links O O
to O O
kidney B B_DISEASE/B_LOCATION
cancer I I_DISEASE/I_LOCATION
and O O
associations O O
with O O
aggressive O O
prostate B B_DISEASE
cancer I I_DISEASE
require O O
further O O
evaluation O O
. O O

Associations O O
of O O
Ozone O O
and O O
PM2 O O
. O O
5 O O
Concentrations O O
With O O
Parkinson B B_DISEASE/B_LOCATION
' I I_DISEASE/I_LOCATION
s I I_DISEASE/I_LOCATION
Disease I I_DISEASE/I_LOCATION
Among O O
Participants O O
in O O
the O O
Agricultural O O
Health O O
Study O O
. O O

OBJECTIVE O O
: O O
This O O
study O O
describes O O
associations O O
of O O
ozone O O
and O O
fine O O
particulate O O
matter O O
with O O
Parkinson B B_DISEASE
' I I_DISEASE
s I I_DISEASE
disease I I_DISEASE
observed O O
among O O
farmers O O
in O O
North O O
Carolina O O
and O O
Iowa O O
. O O

METHODS O O
: O O
We O O
used O O
logistic O O
regression O O
to O O
determine O O
the O O
associations O O
of O O
these O O
pollutants O O
with O O
self O O
- O O
reported O O
, O O
doctor O O
- O O
diagnosed O O
Parkinson B B_DISEASE
' I I_DISEASE
s I I_DISEASE
disease I I_DISEASE
. O O

Daily O O
predicted O O
pollutant O O
concentrations O O
were O O
used O O
to O O
derive O O
surrogates O O
of O O
long O O
- O O
term O O
exposure O O
and O O
link O O
them O O
to O O
study O O
participants O O
' O O
geocoded O O
addresses O O
. O O

RESULTS O O
: O O
We O O
observed O O
positive O O
associations O O
of O O
Parkinson B B_DISEASE
' I I_DISEASE
s I I_DISEASE
disease I I_DISEASE
with O O
ozone O O
( O O
odds O O
ratio O O
= O O
1 O O
. O O
39 O O
; O O
95 O O
% O O
CI O O
: O O
0 O O
. O O
98 O O
to O O
1 O O
. O O
98 O O
) O O
and O O
fine O O
particulate O O
matter O O
( O O
odds O O
ratio O O
= O O
1 O O
. O O
34 O O
; O O
95 O O
% O O
CI O O
: O O
0 O O
. O O
93 O O
to O O
1 O O
. O O
93 O O
) O O
in O O
North O O
Carolina O O
but O O
not O O
in O O
Iowa O O
. O O

CONCLUSIONS O O
: O O
The O O
plausibility O O
of O O
an O O
effect O O
of O O
ambient O O
concentrations O O
of O O
these O O
pollutants O O
on O O
Parkinson B B_DISEASE
' I I_DISEASE
s I I_DISEASE
disease I I_DISEASE
risk O O
is O O
supported O O
by O O
experimental O O
data O O
demonstrating O O
damage O O
to O O
dopaminergic O O
neurons O O
at O O
relevant O O
concentrations O O
. O O

Additional O O
studies O O
are O O
needed O O
to O O
address O O
uncertainties O O
related O O
to O O
confounding O O
and O O
to O O
examine O O
temporal O O
aspects O O
of O O
the O O
associations O O
we O O
observed O O
. O O

Low O O
functional O O
programming O O
of O O
renal O O
AT2R O O
mediates O O
the O O
developmental O O
origin O O
of O O
glomerulosclerosis B B_DISEASE
in O O
adult O O
offspring O O
induced O O
by O O
prenatal O O
caffeine O O
exposure O O
. O O

UNASSIGNED O O
: O O
Our O O
previous O O
study O O
has O O
indicated O O
that O O
prenatal O O
caffeine O O
exposure O O
( O O
PCE O O
) O O
could O O
induce O O
intrauterine B B_DISEASE/B_ORGANISM_FUNCTION
growth I I_DISEASE/I_ORGANISM_FUNCTION
retardation I I_DISEASE/I_ORGANISM_FUNCTION
( O O
IUGR B B_DISEASE/B_GENE
) O O
of O O
offspring O O
. O O

Recent O O
research O O
suggested O O
that O O
IUGR B B_DISEASE
is O O
a O O
risk O O
factor O O
for O O
glomerulosclerosis B B_DISEASE
. O O

However O O
, O O
whether O O
PCE O O
could O O
induce O O
glomerulosclerosis B B_DISEASE/B_GENE
and O O
its O O
underlying O O
mechanisms O O
remain O O
unknown O O
. O O

This O O
study O O
aimed O O
to O O
demonstrate O O
the O O
induction O O
to O O
glomerulosclerosis B B_DISEASE/B_ORGANISM_FUNCTION
in O O
adult O O
offspring O O
by O O
PCE O O
and O O
its O O
intrauterine O O
programming O O
mechanisms O O
. O O

A O O
rat O O
model O O
of O O
IUGR B B_DISEASE
was O O
established O O
by O O
PCE O O
, O O
male O O
fetuses O O
and O O
adult O O
offspring O O
at O O
the O O
age O O
of O O
postnatal O O
week O O
24 O O
were O O
euthanized O O
. O O

The O O
results O O
revealed O O
that O O
the O O
adult O O
offspring O O
kidneys O O
in O O
the O O
PCE O O
group O O
exhibited O O
glomerulosclerosis B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
as O O
well O O
as O O
interstitial B B_DISEASE
fibrosis I I_DISEASE
, O O
accompanied O O
by O O
elevated O O
levels O O
of O O
serum O O
creatinine O O
and O O
urine O O
protein O O
. O O

Moreover O O
, O O
AT2R O O
gene O O
and O O
protein O O
expressions O O
in O O
fetal O O
kidneys O O
were O O
inhibited O O
by O O
PCE O O
, O O
associated O O
with O O
the O O
repression O O
of O O
the O O
gene O O
expression O O
of O O
glial O O
- O O
cell O O
- O O
line O O
- O O
derived O O
neurotrophic O O
factor O O
( O O
GDNF O O
) O O
/ O O
tyrosine O O
kinase O O
receptor O O
( O O
c O O
- O O
Ret O O
) O O
signaling O O
pathway O O
. O O

These O O
results O O
demonstrated O O
that O O
PCE O O
could O O
induce O O
dysplasia B B_DISEASE/B_GENE
of I I_DISEASE/I_GENE
fetal I I_DISEASE/I_GENE
kidneys I I_DISEASE/I_GENE
as O O
well O O
as O O
glomerulosclerosis B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
of O O
adult O O
offspring O O
, O O
and O O
the O O
low O O
functional O O
programming O O
of O O
renal O O
AT2R O O
might O O
mediate O O
the O O
developmental O O
origin O O
of O O
adult O O
glomerulosclerosis B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

1 O O
, O O
3 O O
- O O
Butadiene O O
, O O
CML B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
the O O
t O O
( O O
9 O O
: O O
22 O O
) O O
translocation O O
: O O
A O O
reality O O
check O O
. O O

UNASSIGNED O O
: O O
Epidemiological O O
studies O O
of O O
1 O O
, O O
3 O O
- O O
butadiene O O
have O O
suggest O O
that O O
exposures O O
to O O
humans O O
are O O
associated O O
with O O
chronic B B_DISEASE
myeloid I I_DISEASE
leukemia I I_DISEASE
( O O
CML B B_DISEASE/B_LOCATION
) O O
. O O

CML B B_DISEASE/B_LOCATION
has O O
a O O
well O O
- O O
documented O O
association O O
with O O
ionizing O O
radiation O O
, O O
but O O
reports O O
of O O
associations O O
with O O
chemical O O
exposures O O
have O O
been O O
questioned O O
. O O

We O O
have O O
used O O
ionizing O O
radiation O O
to O O
develop O O
such O O
a O O
control O O
. O O

Conditions O O
that O O
will O O
be O O
required O O
for O O
studies O O
of O O
1 O O
, O O
3 O O
- O O
butadiene O O
are O O
discussed O O
. O O

Cancer B B_DISEASE
incidence O O
and O O
metolachlor O O
use O O
in O O
the O O
Agricultural O O
Health O O
Study O O
: O O
An O O
update O O
. O O

UNASSIGNED O O
: O O
Metolachlor O O
, O O
a O O
widely O O
used O O
herbicide O O
, O O
is O O
classified O O
as O O
a O O
Group O O
C O O
carcinogen O O
by O O
the O O
U O O
. O O
S O O
. O O

Environmental O O
Protection O O
Agency O O
based O O
on O O
increased O O
liver B B_DISEASE/B_ORGANISM_FUNCTION
neoplasms I I_DISEASE/I_ORGANISM_FUNCTION
in O O
female O O
rats O O
. O O

Epidemiologic O O
studies O O
of O O
the O O
health O O
effects O O
of O O
metolachlor O O
have O O
been O O
limited O O
. O O

The O O
Agricultural O O
Health O O
Study O O
( O O
AHS O O
) O O
is O O
a O O
prospective O O
cohort O O
study O O
including O O
licensed O O
private O O
and O O
commercial O O
pesticide O O
applicators O O
in O O
Iowa O O
and O O
North O O
Carolina O O
enrolled O O
1993 O O
- O O
1997 O O
. O O

We O O
evaluated O O
cancer B B_DISEASE
incidence O O
through O O
2010 O O
/ O O
2011 O O
( O O
NC O O
/ O O
IA O O
) O O
for O O
49 O O
, O O
616 O O
applicators O O
, O O
53 O O
% O O
of O O
whom O O
reported O O
ever O O
using O O
metolachlor O O
. O O

We O O
used O O
Poisson O O
regression O O
to O O
evaluate O O
relations O O
between O O
two O O
metrics O O
of O O
metolachlor O O
use O O
( O O
lifetime O O
days O O
, O O
intensity O O
- O O
weighted O O
lifetime O O
days O O
) O O
and O O
cancer B B_DISEASE
incidence O O
. O O

We O O
saw O O
no O O
association O O
between O O
metolachlor O O
use O O
and O O
incidence O O
of O O
all O O
cancers B B_DISEASE
combined O O
( O O
n O O
= O O
5 O O
, O O
701 O O
with O O
a O O
5 O O
- O O
year O O
lag O O
) O O
or O O
most O O
site O O
- O O
specific O O
cancers B B_DISEASE
. O O

For O O
liver B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
cancer I B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O O
in O O
analyses O O
restricted O O
to O O
exposed O O
workers O O
, O O
elevations O O
observed O O
at O O
higher O O
categories O O
of O O
use O O
were O O
not O O
statistically O O
significant O O
. O O

A O O
similar O O
pattern O O
was O O
observed O O
for O O
follicular B B_DISEASE
cell I I_DISEASE
lymphoma I I_DISEASE
, O O
but O O
no O O
other O O
lymphoma B B_DISEASE
subtypes O O
. O O

An O O
earlier O O
suggestion O O
of O O
increased O O
lung B B_DISEASE/B_GENE
cancer I I_DISEASE/I_GENE
risk O O
at O O
high O O
levels O O
of O O
metolachlor O O
use O O
in O O
this O O
cohort O O
was O O
not O O
confirmed O O
in O O
this O O
update O O
. O O

This O O
suggestion O O
of O O
an O O
association O O
between O O
metolachlor O O
and O O
liver B B_DISEASE
cancer I I_DISEASE
among O O
pesticide O O
applicators O O
is O O
a O O
novel O O
finding O O
and O O
echoes O O
observation O O
of O O
increased O O
liver B B_DISEASE_ADJECTIVE[DISEASE]
neoplasms I I_DISEASE_ADJECTIVE[DISEASE]
in O O
some O O
animal O O
studies O O
. O O

However O O
, O O
our O O
findings O O
for O O
both O O
liver B B_DISEASE
cancer I I_DISEASE
and O O
follicular O O
cell O O
lymphoma B B_DISEASE
warrant O O
follow O O
- O O
up O O
to O O
better O O
differentiate O O
effects O O
of O O
metolachlor O O
use O O
from O O
other O O
factors O O
. O O

BACKGROUND O O
: O O
Millions O O
of O O
individuals O O
worldwide O O
, O O
particularly O O
those O O
living O O
in O O
rural O O
and O O
developing O O
areas O O
, O O
are O O
exposed O O
to O O
harmful O O
levels O O
of O O
inorganic O O
arsenic O O
( O O
iAs O O
) O O
in O O
their O O
drinking O O
water O O
. O O

Inorganic O O
As O O
exposure O O
during O O
key O O
developmental O O
periods O O
is O O
associated O O
with O O
a O O
variety O O
of O O
adverse O O
health O O
effects O O
including O O
those O O
that O O
are O O
evident O O
in O O
adulthood O O
. O O

There O O
is O O
considerable O O
interest O O
in O O
identifying O O
the O O
molecular O O
mechanisms O O
that O O
relate O O
early O O
- O O
life O O
iAs O O
exposure O O
to O O
the O O
development O O
of O O
these O O
latent O O
diseases O O
, O O
particularly O O
in O O
relationship O O
to O O
cancer B B_DISEASE
. O O

OBJECTIVES O O
: O O
This O O
work O O
summarizes O O
research O O
on O O
the O O
molecular O O
mechanisms O O
that O O
underlie O O
the O O
increased O O
risk O O
of O O
cancer B B_DISEASE
development O O
in O O
adulthood O O
that O O
is O O
associated O O
with O O
early O O
- O O
life O O
iAs O O
exposure O O
. O O

DISCUSSION O O
: O O
Epigenetic O O
reprogramming O O
that O O
imparts O O
functional O O
changes O O
in O O
gene O O
expression O O
, O O
the O O
development O O
of O O
cancer B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
stem O O
cells O O
, O O
and O O
immunomodulation O O
are O O
plausible O O
underlying O O
mechanisms O O
by O O
which O O
early O O
- O O
life O O
iAs O O
exposure O O
elicits O O
latent O O
carcinogenic O O
effects O O
. O O

CONCLUSIONS O O
: O O
Evidence O O
is O O
mounting O O
that O O
relates O O
early O O
- O O
life O O
iAs O O
exposure O O
and O O
cancer B B_DISEASE/B_PERSON
development O O
later O O
in O O
life O O
. O O

Future O O
research O O
should O O
include O O
animal O O
studies O O
that O O
address O O
mechanistic O O
hypotheses O O
and O O
studies O O
of O O
human O O
populations O O
that O O
integrate O O
early O O
- O O
life O O
exposure O O
, O O
molecular O O
alterations O O
, O O
and O O
latent O O
disease O O
outcomes O O
. O O

Nifedipine O O
induced O O
bradycardia B B_DISEASE
in O O
a O O
patient O O
with O O
autonomic B B_DISEASE/B_LOCATION
neuropathy I I_DISEASE/I_LOCATION
. O O

He O O
was O O
found O O
to O O
have O O
atrial B B_DISEASE
flutter I I_DISEASE
at O O
a O O
ventricular O O
rate O O
of O O
70 O O
/ O O
min O O
which O O
slowed O O
down O O
to O O
30 O O
- O O
40 O O
/ O O
min O O
when O O
nifedipine O O
( O O
60 O O
mg O O
) O O
in O O
3 O O
divided O O
doses O O
, O O
during O O
which O O
he O O
was O O
paced O O
at O O
a O O
rate O O
of O O
70 O O
/ O O
min O O
. O O

This O O
is O O
inconsistent O O
with O O
the O O
well O O
- O O
established O O
finding O O
that O O
nifedipine O O
induces O O
tachycardia B B_DISEASE
in O O
normally O O
innervated O O
hearts O O
. O O

However O O
, O O
in O O
hearts O O
deprived O O
of O O
compensatory O O
sympathetic O O
drive O O
, O O
it O O
may O O
lead O O
to O O
bradycardia B B_DISEASE
. O O

The O O
effect O O
of O O
haloperidol O O
in O O
cocaine O O
and O O
amphetamine O O
intoxication O O
. O O

The O O
effectiveness O O
of O O
haloperidol O O
pretreatment O O
in O O
preventing O O
the O O
toxic O O
effects O O
of O O
high O O
doses O O
of O O
amphetamine O O
and O O
cocaine O O
was O O
studied O O
in O O
rats O O
. O O

In O O
this O O
model O O
, O O
toxic O O
effects O O
were O O
induced O O
by O O
intraperitoneal O O
( O O
i O O
. O O
p O O
. O O
) O O
injection O O
of O O
amphetamine O O
75 O O
mg O O
/ O O
kg O O
( O O
100 O O
% O O
death O O
rate O O
) O O
or O O
cocaine O O
70 O O
mg O O
/ O O
kg O O
( O O
82 O O
% O O
death O O
rate O O
) O O
. O O

Haloperidol O O
failed O O
to O O
prevent O O
amphetamine O O
- O O
induced O O
seizures B B_DISEASE
, O O
but O O
did O O
lower O O
the O O
mortality O O
rate O O
at O O
most O O
doses O O
tested O O
. O O

Haloperidol O O
decreased O O
the O O
incidence O O
of O O
cocaine O O
- O O
induced O O
seizures B B_DISEASE
at O O
the O O
two O O
highest O O
doses O O
, O O
but O O
the O O
lowering O O
of O O
the O O
mortality O O
rate O O
did O O
not O O
reach O O
statistical O O
significance O O
at O O
any O O
dose O O
. O O

These O O
data O O
suggest O O
a O O
protective O O
role O O
for O O
the O O
central O O
dopamine O O
blocker O O
haloperidol O O
against O O
death O O
from O O
high O O
- O O
dose O O
amphetamine O O
exposure O O
without O O
reducing O O
the O O
incidence O O
of O O
seizures B B_DISEASE
. O O

In O O
contrast O O
, O O
haloperidol O O
demonstrated O O
an O O
ability O O
to O O
reduce O O
cocaine O O
- O O
induced O O
seizures B B_DISEASE
without O O
significantly O O
reducing O O
mortality O O
. O O

Autoradiographic O O
evidence O O
of O O
estrogen O O
binding O O
sites O O
in O O
nuclei O O
of O O
diethylstilbesterol O O
induced O O
hamster O O
renal B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
carcinomas I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Estrogen O O
binding O O
sites O O
were O O
demonstrated O O
by O O
autoradiography O O
in O O
one O O
transplantable O O
and O O
five O O
primary O O
diethylstilbesterol O O
induced O O
renal B B_DISEASE/B_LOCATION
carcinomas I I_DISEASE/I_LOCATION
in O O
three O O
hamsters O O
. O O

Radiolabelling O O
, O O
following O O
the O O
in O O
vivo O O
injection O O
of O O
3H O O
- O O
17 O O
beta O O
estradiol O O
, O O
was O O
increased O O
only O O
over O O
the O O
nuclei O O
of O O
tumor B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
cells O O
; O O
stereologic O O
analysis O O
revealed O O
a O O
4 O O
. O O
5 O O
- O O
to O O
6 O O
. O O
7 O O
- O O
times O O
higher O O
concentration O O
of O O
reduced O O
silver O O
grains O O
over O O
nuclei O O
than O O
cytoplasm O O
of O O
these O O
cells O O
. O O

Despite O O
rapid O O
tubular O O
excretion O O
of O O
estradiol O O
which O O
peaked O O
in O O
less O O
than O O
1 O O
h O O
, O O
the O O
normal O O
cells O O
did O O
not O O
appear O O
to O O
bind O O
the O O
ligand O O
. O O

This O O
is O O
the O O
first O O
published O O
report O O
documenting O O
the O O
preferential O O
in O O
vivo O O
binding O O
of O O
estrogen O O
to O O
nuclei O O
of O O
cells O O
in O O
estrogen O O
induced O O
hamster O O
renal B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
carcinomas I B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Bradycardia B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
due O O
to O O
biperiden O O
. O O

In O O
a O O
38 O O
- O O
year O O
- O O
old O O
male O O
patient O O
suffering O O
from O O
a O O
severe O O
postzosteric B B_DISEASE
trigeminal B I_DISEASE
neuralgia I I_DISEASE
, O O
intravenous O O
application O O
of O O
10 O O
mg O O
biperiden O O
lactate O O
led O O
to O O
a O O
long O O
- O O
lasting O O
paradoxical O O
reaction O O
characterized O O
by O O
considerable O O
bradycardia B B_DISEASE
, O O
dysarthria B B_DISEASE
, O O
and O O
dysphagia B B_DISEASE
. O O

The O O
heart O O
rate O O
was O O
back O O
to O O
normal O O
within O O
12 O O
hours O O
upon O O
administration O O
of O O
orciprenaline O O
under O O
cardiac O O
monitoring O O
in O O
an O O
intensive O O
care O O
unit O O
. O O

Bradycardia B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induced O O
by O O
biperiden O O
is O O
attributed O O
to O O
the O O
speed O O
of O O
injection O O
and O O
to O O
a O O
dose O O
- O O
related O O
dual O O
effect O O
of O O
atropine O O
- O O
like O O
drugs O O
on O O
muscarine O O
receptors O O
. O O

Deliberate O O
hypotension B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
by O O
labetalol O O
with O O
halothane O O
, O O
enflurane O O
or O O
isoflurane O O
for O O
middle O O
- O O
ear O O
surgery O O
. O O

The O O
mean O O
H O O
concentration O O
during O O
hypotension B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
inspiratory O O
gas O O
was O O
0 O O
. O O
7 O O
+ O O
/ O O
- O O
0 O O
. O O
1 O O
vol O O
% O O
, O O
the O O
mean O O
E O O
concentration O O
1 O O
. O O
6 O O
+ O O
/ O O
- O O
0 O O
. O O
2 O O
vol O O
% O O
, O O
and O O
the O O
mean O O
I O O
concentration O O
1 O O
. O O
0 O O
+ O O
/ O O
- O O
0 O O
. O O
1 O O
vol O O
% O O
. O O

In O O
addition O O
, O O
the O O
patients O O
received O O
fentanyl O O
and O O
d O O
- O O
tubocurarine O O
. O O

During O O
hypotension B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
the O O
heart O O
rate O O
was O O
stable O O
without O O
tachy B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- I B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or I B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
bradycardia I B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
operating O O
conditions O O
regarding O O
bleeding B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
estimated O O
in O O
a O O
double O O
- O O
blind O O
manner O O
, O O
and O O
did O O
not O O
differ O O
significantly O O
between O O
the O O
groups O O
. O O

During O O
hypotension B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
the O O
serum O O
creatinine O O
concentration O O
rose O O
significantly O O
in O O
all O O
groups O O
from O O
the O O
values O O
before O O
hypotension B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
returned O O
postoperatively O O
to O O
the O O
initial O O
level O O
in O O
the O O
other O O
groups O O
, O O
except O O
the O O
isoflurane O O
group O O
. O O

After O O
hypotension B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
there O O
was O O
no O O
rebound O O
phenomenon O O
in O O
either O O
blood O O
pressure O O
or O O
heart O O
rate O O
. O O

These O O
results O O
indicate O O
that O O
labetalol O O
induces O O
easily O O
adjustable O O
hypotension B B_DISEASE
without O O
compensatory O O
tachycardia B B_DISEASE
and O O
rebound O O
hypertension B B_DISEASE
. O O

Convulsion B B_DISEASE_ADJECTIVE[DISEASE]
following O O
intravenous O O
fluorescein O O
angiography O O
. O O

Tonic B B_DISEASE/B_PERSON
- I I_DISEASE/I_PERSON
clonic I I_DISEASE/I_PERSON
seizures I I_DISEASE/I_PERSON
followed O O
intravenous O O
fluorescein O O
injection O O
for O O
fundus O O
angiography O O
in O O
a O O
47 O O
- O O
year O O
- O O
old O O
male O O
. O O

Despite O O
precautions O O
this O O
adverse O O
reaction O O
recurred O O
on O O
re O O
- O O
exposure O O
to O O
intravenous O O
fluorescein O O
. O O

ACC O O
- O O
9653 O O
, O O
the O O
disodium O O
phosphate O O
ester O O
of O O
3 O O
- O O
hydroxymethyl O O
- O O
5 O O
, O O
5 O O
- O O
diphenylhydantoin O O
, O O
is O O
a O O
prodrug O O
of O O
phenytoin O O
with O O
advantageous O O
physicochemical O O
properties O O
. O O

ACC O O
- O O
9653 O O
is O O
rapidly O O
converted O O
enzymatically O O
to O O
phenytoin O O
in O O
vivo O O
. O O

ACC O O
- O O
9653 O O
and O O
phenytoin O O
sodium O O
have O O
equivalent O O
anticonvulsant O O
activity O O
against O O
seizures B B_DISEASE/B_LOCATION
induced O O
by O O
maximal O O
electroshock O O
( O O
MES O O
) O O
in O O
mice O O
following O O
i O O
. O O
p O O
. O O
, O O
oral O O
, O O
or O O
i O O
. O O
v O O
. O O
administration O O
. O O

ACC O O
- O O
9653 O O
and O O
phenytoin O O
sodium O O
have O O
similar O O
antiarrhythmic O O
activity O O
against O O
ouabain O O
- O O
induced O O
ventricular B B_DISEASE
tachycardia I I_DISEASE
in O O
anesthetized O O
dogs O O
. O O

The O O
total O O
doses O O
of O O
ACC O O
- O O
9653 O O
or O O
phenytoin O O
sodium O O
necessary O O
to O O
convert O O
the O O
arrhythmia B B_DISEASE
to O O
a O O
normal O O
sinus O O
rhythm O O
were O O
24 O O
+ O O
/ O O
- O O
6 O O
and O O
14 O O
+ O O
/ O O
- O O
3 O O
mg O O
/ O O
kg O O
, O O
respectively O O
. O O

Only O O
phenytoin O O
sodium O O
displayed O O
in O O
vitro O O
antiarrhythmic O O
activity O O
against O O
strophanthidin O O
- O O
induced O O
arrhythmias B B_DISEASE
in O O
guinea O O
pig O O
right O O
atria O O
. O O

In O O
anesthetized O O
dogs O O
, O O
a O O
high O O
dose O O
of O O
ACC O O
- O O
9653 O O
( O O
31 O O
mg O O
/ O O
kg O O
) O O
was O O
infused O O
over O O
15 O O
, O O
20 O O
, O O
and O O
30 O O
min O O
and O O
the O O
responses O O
were O O
compared O O
to O O
an O O
equimolar O O
dose O O
of O O
phenytoin O O
sodium O O
( O O
21 O O
mg O O
/ O O
kg O O
) O O
. O O

The O O
ACC O O
- O O
9653 O O
and O O
phenytoin O O
sodium O O
treatments O O
produced O O
similar O O
marked O O
reductions O O
in O O
diastolic O O
blood O O
pressure O O
and O O
contractile O O
force O O
( O O
LVdP O O
/ O O
dt O O
) O O
. O O

The O O
maximum O O
effects O O
of O O
each O O
treatment O O
occurred O O
at O O
the O O
time O O
of O O
maximum O O
phenytoin O O
sodium O O
levels O O
. O O

Acute O O
toxicity B B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
studies O O
of O O
ACC O O
- O O
9653 O O
and O O
phenytoin O O
sodium O O
were O O
carried O O
out O O
in O O
mice O O
, O O
rats O O
, O O
rabbits O O
, O O
and O O
dogs O O
by O O
i O O
. O O
v O O
. O O
, O O
i O O
. O O
m O O
. O O
, O O
and O O
i O O
. O O
p O O
. O O
routes O O
of O O
administration O O
. O O

The O O
systemic O O
toxic O O
signs O O
of O O
both O O
agents O O
were O O
similar O O
and O O
occurred O O
at O O
approximately O O
equivalent O O
doses O O
. O O

Tachyphylaxis O O
to O O
systemic O O
but O O
not O O
to O O
airway O O
responses O O
during O O
prolonged O O
therapy O O
with O O
high O O
dose O O
inhaled O O
salbutamol O O
in O O
asthmatics B B_DISEASE/B_PERSON
. O O

High O O
doses O O
of O O
inhaled O O
salbutamol O O
produce O O
substantial O O
improvements O O
in O O
airway O O
response O O
in O O
patients O O
with O O
asthma B B_DISEASE/B_LOCATION
, O O
and O O
are O O
associated O O
with O O
dose O O
- O O
dependent O O
systemic O O
beta O O
- O O
adrenoceptor O O
responses O O
. O O

Twelve O O
asthmatic B B_DISEASE/B_PERSON
patients O O
( O O
FEV1 O O
, O O
81 O O
+ O O
/ O O
- O O
4 O O
% O O
predicted O O
) O O
, O O
requiring O O
only O O
occasional O O
inhaled O O
beta O O
- O O
agonists O O
as O O
their O O
sole O O
therapy O O
, O O
were O O
given O O
a O O
14 O O
- O O
day O O
treatment O O
with O O
high O O
dose O O
inhaled O O
salbutamol O O
( O O
HDS O O
) O O
, O O
4 O O
, O O
000 O O
micrograms O O
daily O O
, O O
low O O
dose O O
inhaled O O
salbutamol O O
( O O
LDS O O
) O O
, O O
800 O O
micrograms O O
daily O O
, O O
or O O
placebo O O
( O O
PI O O
) O O
by O O
metered O O
- O O
dose O O
inhaler O O
in O O
a O O
double O O
- O O
blind O O
, O O
randomized O O
crossover O O
design O O
. O O

During O O
the O O
14 O O
- O O
day O O
run O O
- O O
in O O
and O O
during O O
washout O O
periods O O
, O O
inhaled O O
beta O O
- O O
agonists O O
were O O
withheld O O
and O O
ipratropium O O
bromide O O
was O O
substituted O O
for O O
rescue O O
purposes O O
. O O

At O O
the O O
end O O
of O O
each O O
14 O O
- O O
day O O
treatment O O
, O O
a O O
dose O O
- O O
response O O
curve O O
( O O
DRC O O
) O O
was O O
performed O O
, O O
and O O
airway O O
( O O
FEV1 O O
, O O
FEF25 O O
- O O
75 O O
) O O
chronotropic O O
( O O
HR O O
) O O
, O O
tremor B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
metabolic O O
( O O
K O O
, O O
Glu O O
) O O
responses O O
were O O
measured O O
at O O
each O O
step O O
( O O
from O O
100 O O
to O O
4 O O
, O O
000 O O
micrograms O O
) O O
. O O

DRC O O
for O O
HR O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
, O O
K O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
, O O
and O O
Glu O O
( O O
p O O
less O O
than O O
0 O O
. O O
005 O O
) O O
were O O
attenuated O O
after O O
treatment O O
with O O
HDS O O
compared O O
with O O
PI O O
. O O

Frequency O O
and O O
severity O O
of O O
subjective O O
adverse O O
effects O O
were O O
also O O
reduced O O
after O O
HDS O O
: O O
tremor B B_DISEASE
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
, O O
palpitations B B_DISEASE
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O

Phenytoin O O
induced O O
fatal O O
hepatic B B_DISEASE
injury I I_DISEASE
. O O

A O O
61 O O
year O O
old O O
female O O
developed O O
fatal O O
hepatic B B_DISEASE
failure I I_DISEASE
after O O
phenytoin O O
administration O O
. O O

A O O
typical O O
multisystem O O
clinical O O
pattern O O
precedes O O
the O O
manifestations O O
of O O
hepatic B B_DISEASE/B_LOCATION
injury I I_DISEASE/I_LOCATION
. O O

The O O
hematologic O O
, O O
biochemical O O
and O O
pathologic O O
features O O
indicate O O
a O O
mixed O O
hepatocellular B B_DISEASE
damage I I_DISEASE
due O O
to O O
drug B B_DISEASE
hypersensitivity I I_DISEASE
. O O

We O O
studied O O
mortality O O
after O O
pertussis B B_DISEASE
immunization O O
in O O
the O O
mouse O O
. O O

Without O O
treatment O O
, O O
73 O O
of O O
92 O O
animals O O
( O O
80 O O
% O O
) O O
died O O
after O O
injection O O
of O O
bovine O O
serum O O
albumin O O
( O O
BSA O O
) O O
on O O
day O O
+ O O
7 O O
of O O
pertussis B B_DISEASE
immunization O O
. O O

After O O
pretreatment O O
with O O
3 O O
mg O O
of O O
cyproheptadine O O
, O O
2 O O
mg O O
mianserin O O
, O O
or O O
2 O O
mg O O
chlorpheniramine O O
, O O
only O O
5 O O
of O O
105 O O
animals O O
( O O
5 O O
% O O
) O O
died O O
after O O
receiving O O
BSA O O
on O O
day O O
+ O O
7 O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
. O O

Blockade O O
of O O
histamine O O
H1 O O
receptors O O
may O O
reduce O O
mortality O O
in O O
pertussis B B_DISEASE/B_BIO
immunization O O
- O O
induced O O
encephalopathy B B_DISEASE
in O O
mice O O
. O O

Support O O
for O O
adrenaline O O
- O O
hypertension B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hypothesis O O
: O O
18 O O
hour O O
pressor O O
effect O O
after O O
6 O O
hours O O
adrenaline O O
infusion O O
. O O

In O O
a O O
double O O
blind O O
, O O
crossover O O
study O O
6 O O
h O O
infusions O O
of O O
adrenaline O O
( O O
15 O O
ng O O
/ O O
kg O O
/ O O
min O O
; O O
1 O O
ng O O
= O O
5 O O
. O O
458 O O
pmol O O
) O O
, O O
noradrenaline O O
( O O
30 O O
ng O O
/ O O
kg O O
/ O O
min O O
; O O
1 O O
ng O O
= O O
5 O O
. O O
911 O O
pmol O O
) O O
, O O
and O O
a O O
5 O O
% O O
dextrose O O
solution O O
( O O
5 O O
. O O
4 O O
ml O O
/ O O
h O O
) O O
, O O
were O O
given O O
to O O
ten O O
healthy O O
volunteers O O
in O O
random O O
order O O
2 O O
weeks O O
apart O O
. O O

Adrenaline O O
, O O
but O O
not O O
noradrenaline O O
, O O
caused O O
a O O
delayed O O
and O O
protracted O O
pressor O O
effect O O
. O O

Over O O
the O O
total O O
postinfusion O O
period O O
systolic O O
and O O
diastolic O O
arterial O O
pressure O O
were O O
6 O O
( O O
SEM O O
2 O O
) O O
% O O
and O O
7 O O
( O O
2 O O
) O O
% O O
, O O
respectively O O
, O O
higher O O
than O O
after O O
dextrose O O
infusion O O
( O O
ANOVA O O
, O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
. O O

Thus O O
, O O
" O O
stress O O
" O O
levels O O
of O O
adrenaline O O
( O O
230 O O
pg O O
/ O O
ml O O
) O O
for O O
6 O O
h O O
cause O O
a O O
delayed O O
and O O
protracted O O
pressor O O
effect O O
. O O

These O O
findings O O
are O O
strong O O
support O O
for O O
the O O
adrenaline O O
- O O
hypertension B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hypothesis O O
in O O
man O O
. O O

Effect O O
of O O
alkylxanthines O O
on O O
gentamicin O O
- O O
induced O O
acute B B_DISEASE
renal I I_DISEASE
failure I I_DISEASE
in O O
the O O
rat O O
. O O

Adenosine O O
antagonists O O
have O O
been O O
previously O O
shown O O
to O O
be O O
of O O
benefit O O
in O O
some O O
ischaemic B B_DISEASE_ADJECTIVE[DISEASE]
and O O
nephrotoxic B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
models O O
of O O
acute B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
renal I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
failure I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
ARF B B_DISEASE/B_GENE
) O O
. O O

In O O
the O O
present O O
study O O
, O O
the O O
effects O O
of O O
three O O
alkylxanthines O O
with O O
different O O
potencies O O
as O O
adenosine O O
antagonists O O
8 O O
- O O
phenyltheophylline O O
, O O
theophylline O O
and O O
enprofylline O O
, O O
were O O
examined O O
in O O
rats O O
developing O O
acute B B_DISEASE
renal I I_DISEASE
failure I I_DISEASE
after O O
4 O O
daily O O
injections O O
of O O
gentamicin O O
( O O
200 O O
mg O O
kg O O
- O O
1 O O
) O O
. O O

Renal O O
function O O
was O O
assessed O O
by O O
biochemical O O
( O O
plasma O O
urea O O
and O O
creatinine O O
) O O
, O O
functional O O
( O O
urine O O
analysis O O
and O O
[ O O
3H O O
] O O
inulin O O
and O O
[ O O
14C O O
] O O
p O O
- O O
aminohippuric O O
acid O O
clearances O O
) O O
and O O
morphological O O
( O O
degree O O
of O O
necrosis B B_DISEASE
) O O
indices O O
. O O

However O O
, O O
any O O
improvement O O
produced O O
by O O
drug O O
treatment O O
was O O
largely O O
a O O
result O O
of O O
a O O
beneficial O O
effect O O
exerted O O
by O O
its O O
vehicle O O
( O O
polyethylene O O
glycol O O
and O O
NaOH O O
) O O
. O O

The O O
lack O O
of O O
any O O
consistent O O
protective O O
effect O O
noted O O
with O O
the O O
alkylxanthines O O
tested O O
in O O
the O O
present O O
study O O
indicates O O
that O O
adenosine O O
plays O O
little O O
, O O
if O O
any O O
, O O
pathophysiological O O
role O O
in O O
gentamicin O O
- O O
induced O O
ARF B B_DISEASE
. O O

A O O
total O O
of O O
261 O O
adverse O O
ocular O O
reactions O O
occurred O O
in O O
237 O O
patients O O
who O O
received O O
isotretinoin O O
, O O
a O O
commonly O O
used O O
drug O O
in O O
the O O
treatment O O
of O O
severe O O
cystic O O
acne B B_DISEASE
. O O

Blepharoconjunctivitis B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
subjective O O
complaints O O
of O O
dry B B_DISEASE
eyes I I_DISEASE
, O O
blurred B B_DISEASE
vision I I_DISEASE
, O O
contact O O
lens O O
intolerance O O
, O O
and O O
photodermatitis B B_DISEASE
are O O
reversible O O
side O O
effects O O
. O O

More O O
serious O O
ocular O O
adverse O O
reactions O O
include O O
papilledema B B_DISEASE
, O O
pseudotumor B B_DISEASE
cerebri I I_DISEASE
, O O
and O O
white O O
or O O
gray O O
subepithelial O O
corneal B B_DISEASE
opacities I I_DISEASE
; O O
all O O
of O O
these O O
are O O
reversible O O
if O O
the O O
drug O O
is O O
discontinued O O
. O O

Isotretinoin O O
is O O
contraindicated O O
in O O
pregnancy O O
because O O
of O O
the O O
many O O
reported O O
congenital B B_DISEASE_ADJECTIVE[DISEASE]
abnormalities I I_DISEASE_ADJECTIVE[DISEASE]
after O O
maternal O O
use O O
( O O
including O O
microphthalmos B B_DISEASE
, O O
orbital O O
hypertelorism B B_DISEASE
, O O
and O O
optic B B_DISEASE
nerve I I_DISEASE
hypoplasia I I_DISEASE
) O O
. O O

Procaterol O O
and O O
terbutaline O O
in O O
bronchial B B_DISEASE/B_PERSON
asthma I B_DISEASE/I_PERSON
. O O

A O O
double O O
- O O
blind O O
, O O
placebo O O
- O O
controlled O O
, O O
cross O O
- O O
over O O
study O O
. O O

Procaterol O O
, O O
a O O
new O O
beta O O
- O O
2 O O
adrenoceptor O O
stimulant O O
, O O
was O O
studied O O
in O O
a O O
double O O
- O O
blind O O
, O O
placebo O O
- O O
controlled O O
, O O
cross O O
- O O
over O O
trial O O
in O O
patients O O
with O O
bronchial B B_DISEASE
asthma I I_DISEASE
. O O

Oral O O
procaterol O O
50 O O
micrograms O O
b O O
. O O
d O O
. O O
, O O
procaterol O O
100 O O
micrograms O O
b O O
. O O
d O O
. O O
, O O
and O O
terbutaline O O
5 O O
mg O O
t O O
. O O
i O O
. O O
d O O
. O O
, O O
were O O
compared O O
when O O
given O O
randomly O O
in O O
1 O O
- O O
week O O
treatment O O
periods O O
. O O

The O O
best O O
clinical O O
effect O O
was O O
found O O
with O O
terbutaline O O
. O O

Both O O
anti O O
- O O
asthmatic B B_DISEASE
and O O
tremorgenic B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O O
of O O
procaterol O O
were O O
dose O O
- O O
related O O
. O O

Procaterol O O
appeared O O
effective O O
in O O
the O O
doses O O
tested O O
, O O
and O O
a O O
twice O O
daily O O
regimen O O
would O O
appear O O
to O O
be O O
suitable O O
with O O
this O O
drug O O
. O O

Subacute O O
effects O O
of O O
propranolol O O
and O O
B O O
24 O O
/ O O
76 O O
on O O
isoproterenol O O
- O O
induced O O
rat O O
heart B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
hypertrophy I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
correlation O O
with O O
blood O O
pressure O O
. O O

The O O
studies O O
were O O
performed O O
using O O
an O O
experimental O O
model O O
of O O
isoproterenol O O
- O O
induced O O
heart B B_DISEASE/B_LOCATION
hypertrophy I I_DISEASE/I_LOCATION
in O O
rats O O
. O O

A O O
correlation O O
of O O
the O O
blood O O
pressure O O
was O O
neither O O
found O O
in O O
the O O
development O O
nor O O
in O O
the O O
attempt O O
to O O
suppress O O
the O O
development O O
of O O
heart B B_DISEASE/B_GENE
hypertrophy I I_DISEASE/I_GENE
with O O
the O O
two O O
beta O O
- O O
receptor O O
blockers O O
. O O

Both O O
beta O O
- O O
blockers O O
influenced O O
the O O
development O O
of O O
hypertrophy B B_DISEASE
to O O
a O O
different O O
, O O
but O O
not O O
reproducible O O
extent O O
. O O

It O O
was O O
possible O O
to O O
suppress O O
the O O
increased O O
ornithine O O
decarboxylase O O
activity O O
with O O
both O O
beta O O
- O O
blockers O O
in O O
hypertrophied B B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
hearts I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
, O O
but O O
there O O
was O O
no O O
effect O O
on O O
the O O
heart O O
mass O O
. O O

Neither O O
propranolol O O
nor O O
B O O
24 O O
/ O O
76 O O
could O O
stop O O
the O O
changes O O
in O O
the O O
characteristic O O
myosin O O
isoenzyme O O
pattern O O
of O O
the O O
hypertrophied B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
rat O O
heart O O
. O O

Thus O O
, O O
the O O
investigations O O
did O O
not O O
provide O O
any O O
evidence O O
that O O
the O O
beta O O
- O O
receptor O O
blockers O O
propranolol O O
and O O
B O O
24 O O
/ O O
76 O O
have O O
the O O
potency O O
to O O
prevent O O
isoproterenol O O
from O O
producing O O
heart B B_DISEASE/B_GENE
hypertrophy I I_DISEASE/I_GENE
. O O

Increased O O
anxiogenic O O
effects O O
of O O
caffeine O O
in O O
panic B B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
disorders I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O O

The O O
effects O O
of O O
oral O O
administration O O
of O O
caffeine O O
( O O
10 O O
mg O O
/ O O
kg O O
) O O
on O O
behavioral O O
ratings O O
, O O
somatic O O
symptoms O O
, O O
blood O O
pressure O O
and O O
plasma O O
levels O O
of O O
3 O O
- O O
methoxy O O
- O O
4 O O
- O O
hydroxyphenethyleneglycol O O
( O O
MHPG O O
) O O
and O O
cortisol O O
were O O
determined O O
in O O
17 O O
healthy O O
subjects O O
and O O
21 O O
patients O O
meeting O O
DSM O O
- O O
III O O
criteria O O
for O O
agoraphobia B B_DISEASE/B_PERSON
with O O
panic B B_DISEASE
attacks I I_DISEASE
or O O
panic B B_DISEASE
disorder I I_DISEASE
. O O

Caffeine O O
produced O O
significantly O O
greater O O
increases O O
in O O
subject O O
- O O
rated O O
anxiety B B_DISEASE
, O O
nervousness O O
, O O
fear O O
, O O
nausea B B_DISEASE
, O O
palpitations B B_DISEASE
, O O
restlessness B B_DISEASE
, O O
and O O
tremors B B_DISEASE
in O O
the O O
patients O O
compared O O
with O O
healthy O O
subjects O O
. O O

Seventy O O
- O O
one O O
percent O O
of O O
the O O
patients O O
reported O O
that O O
the O O
behavioral O O
effects O O
of O O
caffeine O O
were O O
similar O O
to O O
those O O
experienced O O
during O O
panic B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
attacks I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Because O O
caffeine O O
is O O
an O O
adenosine O O
receptor O O
antagonist O O
, O O
these O O
results O O
suggest O O
that O O
some O O
panic B B_DISEASE/B_GENE
disorder I I_DISEASE/I_GENE
patients O O
may O O
have O O
abnormalities B B_DISEASE_ADJECTIVE[DISEASE]
in I I_DISEASE_ADJECTIVE[DISEASE]
neuronal I I_DISEASE_ADJECTIVE[DISEASE]
systems I I_DISEASE_ADJECTIVE[DISEASE]
involving O O
adenosine O O
. O O

Patients O O
with O O
anxiety B B_DISEASE
disorders I I_DISEASE
may O O
benefit O O
by O O
avoiding O O
caffeine O O
- O O
containing O O
foods O O
and O O
beverages O O
. O O

Comparison O O
of O O
the O O
effect O O
of O O
oxitropium O O
bromide O O
and O O
of O O
slow O O
- O O
release O O
theophylline O O
on O O
nocturnal O O
asthma B B_DISEASE
. O O

The O O
effects O O
of O O
a O O
new O O
inhaled O O
antimuscarinic O O
drug O O
, O O
oxitropium O O
bromide O O
, O O
and O O
of O O
a O O
slow O O
- O O
release O O
theophylline O O
preparation O O
upon O O
nocturnal O O
asthma B B_DISEASE
were O O
compared O O
in O O
a O O
placebo O O
- O O
controlled O O
double O O
- O O
blind O O
study O O
. O O

Two O O
samples O O
were O O
studied O O
: O O
12 O O
patients O O
received O O
oxitropium O O
at O O
600 O O
micrograms O O
( O O
6 O O
subjects O O
) O O
or O O
at O O
400 O O
micrograms O O
t O O
. O O
i O O
. O O
d O O
. O O

No O O
significant O O
difference O O
was O O
noticed O O
between O O
results O O
obtained O O
with O O
either O O
active O O
drug O O
, O O
as O O
well O O
as O O
with O O
either O O
dosage O O
of O O
oxitropium O O
. O O

No O O
subject O O
reported O O
side O O
effects O O
of O O
oxitropium O O
, O O
as O O
compared O O
to O O
three O O
subjects O O
reporting O O
nausea B B_DISEASE
, O O
vomiting B B_DISEASE
and O O
tremors B B_DISEASE
after O O
theophylline O O
. O O

Oxitropium O O
proves O O
to O O
be O O
a O O
valuable O O
alternative O O
to O O
theophylline O O
in O O
nocturnal O O
asthma B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
since O O
it O O
is O O
equally O O
potent O O
, O O
safer O O
and O O
does O O
not O O
require O O
the O O
titration O O
of O O
dosage O O
. O O

Penicillin O O
anaphylaxis B B_DISEASE/B_MEASURE
. O O

A O O
case O O
of O O
oral O O
penicillin O O
anaphylaxis B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
described O O
, O O
and O O
the O O
terminology O O
, O O
occurrence O O
, O O
clinical O O
manifestations O O
, O O
pathogenesis O O
, O O
prevention O O
, O O
and O O
treatment O O
of O O
anaphylaxis B B_DISEASE
are O O
reviewed O O
. O O

Emergency O O
physicians O O
should O O
be O O
aware O O
of O O
oral O O
penicillin O O
anaphylaxis B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
order O O
to O O
prevent O O
its O O
occurrence O O
by O O
prescribing O O
the O O
antibiotic O O
judiciously O O
and O O
knowledgeably O O
and O O
to O O
offer O O
optimal O O
medical O O
therapy O O
once O O
this O O
life O O
- O O
threatening O O
reaction O O
has O O
begun O O
. O O

Reversible O O
valproic O O
acid O O
- O O
induced O O
dementia B B_DISEASE
: O O
a O O
case O O
report O O
. O O

Reversible O O
valproic O O
acid O O
- O O
induced O O
dementia B B_DISEASE
was O O
documented O O
in O O
a O O
21 O O
- O O
year O O
- O O
old O O
man O O
with O O
epilepsy B B_DISEASE/B_GENE
who O O
had O O
a O O
3 O O
- O O
year O O
history O O
of O O
insidious O O
progressive O O
decline O O
in O O
global O O
cognitive O O
abilities O O
documented O O
by O O
serial O O
neuropsychological O O
studies O O
. O O

Repeat O O
neuropsychological O O
testing O O
7 O O
weeks O O
after O O
discontinuation O O
of O O
the O O
drug O O
revealed O O
dramatic O O
improvement O O
in O O
IQ O O
, O O
memory O O
, O O
naming O O
, O O
and O O
other O O
tasks O O
commensurate O O
with O O
clinical O O
recovery O O
in O O
his O O
intellectual O O
capacity O O
. O O

Possible O O
pathophysiological O O
mechanisms O O
which O O
may O O
have O O
been O O
operative O O
in O O
this O O
case O O
include O O
: O O
a O O
direct O O
central O O
nervous O O
system O O
( O O
CNS O O
) O O
toxic O O
effect O O
of O O
valproic O O
acid O O
; O O
a O O
paradoxical O O
epileptogenic O O
effect O O
secondary O O
to O O
the O O
drug O O
; O O
and O O
an O O
indirect O O
CNS O O
toxic O O
effect O O
mediated O O
through O O
valproic O O
acid O O
- O O
induced O O
hyperammonemia B B_DISEASE
. O O

Reversal O O
of O O
scopolamine O O
- O O
induced O O
amnesia B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
passive O O
avoidance O O
by O O
pre O O
- O O
and O O
post O O
- O O
training O O
naloxone O O
. O O

In O O
a O O
series O O
of O O
five O O
experiments O O
, O O
the O O
modulating O O
role O O
of O O
naloxone O O
on O O
a O O
scopolamine O O
- O O
induced O O
retention B B_DISEASE
deficit I I_DISEASE
in O O
a O O
passive O O
avoidance O O
paradigm O O
was O O
investigated O O
in O O
mice O O
. O O

Scopolamine O O
, O O
but O O
not O O
methyl O O
scopolamine O O
( O O
1 O O
and O O
3 O O
mg O O
/ O O
kg O O
) O O
, O O
induced O O
an O O
amnesia B B_DISEASE_ADJECTIVE[DISEASE]
as O O
measured O O
by O O
latency O O
and O O
duration O O
parameters O O
. O O

Naloxone O O
( O O
0 O O
. O O
3 O O
, O O
1 O O
, O O
3 O O
, O O
and O O
10 O O
mg O O
/ O O
kg O O
) O O
injected O O
prior O O
to O O
training O O
attenuated O O
the O O
retention B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
deficit I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
with O O
a O O
peak O O
of O O
activity O O
at O O
3 O O
mg O O
/ O O
kg O O
. O O

The O O
effect O O
of O O
naloxone O O
could O O
be O O
antagonized O O
with O O
morphine O O
( O O
1 O O
, O O
3 O O
, O O
and O O
10 O O
mg O O
/ O O
kg O O
) O O
, O O
demonstrating O O
the O O
opioid O O
specificity O O
of O O
the O O
naloxone O O
effect O O
. O O

Post O O
- O O
training O O
administration O O
of O O
naloxone O O
( O O
3 O O
mg O O
/ O O
kg O O
) O O
as O O
a O O
single O O
or O O
as O O
a O O
split O O
dose O O
also O O
attenuated O O
the O O
scopolamine O O
- O O
induced O O
amnesia B B_DISEASE_ADJECTIVE[DISEASE]
. O O

Control O O
experiments O O
indicated O O
that O O
neither O O
an O O
increase O O
in O O
pain B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensitivity O O
( O O
pre O O
- O O
training O O
naloxone O O
) O O
nor O O
an O O
induced O O
aversive O O
state O O
( O O
post O O
- O O
training O O
naloxone O O
) O O
appear O O
to O O
be O O
responsible O O
for O O
the O O
influence O O
of O O
naloxone O O
on O O
the O O
scopolamine O O
- O O
induced O O
retention B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
deficit I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

A O O
possible O O
mechanism O O
for O O
this O O
interaction O O
involving O O
the O O
septo O O
- O O
hippocampal O O
cholinergic O O
pathway O O
is O O
discussed O O
. O O

Electron O O
microscopic O O
investigations O O
of O O
the O O
cyclophosphamide O O
- O O
induced O O
lesions B B_DISEASE
of I I_DISEASE
the I I_DISEASE
urinary I I_DISEASE
bladder I I_DISEASE
of O O
the O O
rat O O
and O O
their O O
prevention O O
by O O
mesna O O
. O O

Fully O O
developed O O
cyclophosphamide O O
- O O
induced O O
cystitis B B_DISEASE
is O O
characterized O O
by O O
nearly O O
complete O O
detachment O O
of O O
the O O
urothelium O O
, O O
severe O O
submucosal O O
edema B B_DISEASE
owing O O
to O O
damage O O
to O O
the O O
microvascular O O
bed O O
and O O
focal O O
muscle O O
necroses B B_DISEASE
. O O

The O O
initial O O
response O O
to O O
the O O
primary O O
attack O O
by O O
the O O
cyclophosphamide O O
metabolites O O
seems O O
to O O
be O O
fragmentation O O
of O O
the O O
luminal O O
membrane O O
. O O

Subsequent O O
breaks O O
in O O
the O O
lateral O O
cell O O
membranes O O
of O O
the O O
superficial O O
cells O O
and O O
in O O
all O O
the O O
plasma O O
membranes O O
of O O
the O O
intermediate O O
and O O
basal O O
cells O O
, O O
intercellular O O
and O O
intracellular O O
edema B B_DISEASE
and O O
disintegration O O
of O O
the O O
desmosomes O O
and O O
hemidesmosomes O O
lead O O
to O O
progressive O O
degeneration O O
and O O
detachment O O
of O O
the O O
epithelial O O
cells O O
with O O
exposure O O
and O O
splitting O O
of O O
the O O
basal O O
membrane O O
. O O

Increase O O
in O O
intragastric O O
pressure O O
during O O
suxamethonium O O
- O O
induced O O
muscle B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
fasciculations I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
children O O
: O O
inhibition O O
by O O
alfentanil O O
. O O

Changes O O
in O O
intragastric O O
pressure O O
after O O
the O O
administration O O
of O O
suxamethonium O O
1 O O
. O O
5 O O
mg O O
kg O O
- O O
1 O O
i O O
. O O
v O O
. O O
were O O
studied O O
in O O
32 O O
children O O
( O O
mean O O
age O O
6 O O
. O O
9 O O
yr O O
) O O
pretreated O O
with O O
either O O
physiological O O
saline O O
or O O
alfentanil O O
50 O O
micrograms O O
kg O O
- O O
1 O O
. O O

Anaesthesia O O
was O O
induced O O
with O O
thiopentone O O
5 O O
mg O O
kg O O
- O O
1 O O
. O O

The O O
incidence O O
and O O
intensity O O
of O O
muscle B B_DISEASE
fasciculations I I_DISEASE
caused O O
by O O
suxamethonium O O
were O O
significantly O O
greater O O
in O O
the O O
control O O
than O O
in O O
the O O
alfentanil O O
group O O
. O O

The O O
intragastric O O
pressure O O
during O O
muscle B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
fasciculations I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
significantly O O
higher O O
in O O
the O O
control O O
group O O
( O O
16 O O
+ O O
/ O O
- O O
0 O O
. O O
7 O O
( O O
SEM O O
) O O
cm O O
H2O O O
) O O
than O O
in O O
the O O
alfentanil O O
group O O
( O O
7 O O
. O O
7 O O
+ O O
/ O O
- O O
1 O O
. O O
5 O O
( O O
SEM O O
) O O
cm O O
H2O O O
) O O
. O O

The O O
increase O O
in O O
intragastric O O
pressure O O
was O O
directly O O
related O O
to O O
the O O
intensity O O
of O O
muscle B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
fasciculations I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
regression O O
line O O
: O O
y O O
= O O
0 O O
. O O
5 O O
+ O O
4 O O
. O O
78x O O
with O O
r O O
of O O
0 O O
. O O
78 O O
) O O
. O O

It O O
is O O
concluded O O
that O O
intragastric O O
pressure O O
increases O O
significantly O O
during O O
muscle B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
fasciculations I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
caused O O
by O O
suxamethonium O O
in O O
healthy O O
children O O
. O O

Alfentanil O O
50 O O
micrograms O O
kg O O
- O O
1 O O
effectively O O
inhibits O O
the O O
incidence O O
and O O
intensity O O
of O O
suxamethonium O O
- O O
induced O O
muscle B B_DISEASE
fasciculations I I_DISEASE
; O O
moreover O O
, O O
intragastric O O
pressure O O
remains O O
at O O
its O O
control O O
value O O
. O O

Acute O O
insulin O O
treatment O O
normalizes O O
the O O
resistance O O
to O O
the O O
cardiotoxic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effect O O
of O O
isoproterenol O O
in O O
streptozotocin O O
diabetic B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rats O O
. O O

A O O
morphometric O O
study O O
of O O
isoproterenol O O
induced O O
myocardial O O
fibrosis B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
acute O O
effect O O
of O O
insulin O O
treatment O O
on O O
the O O
earlier O O
reported O O
protective O O
effect O O
of O O
streptozotocin O O
diabetes B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
against O O
the O O
cardiotoxic B B_DISEASE_ADJECTIVE[DISEASE]
effect O O
of O O
high O O
doses O O
of O O
isoproterenol O O
( O O
ISO O O
) O O
was O O
investigated O O
in O O
rats O O
. O O

Thirty O O
to O O
135 O O
min O O
after O O
the O O
injection O O
of O O
crystalline O O
insulin O O
, O O
ISO O O
was O O
given O O
subcutaneously O O
and O O
when O O
ISO O O
induced O O
fibrosis B B_DISEASE
in O O
the O O
myocardium O O
was O O
morphometrically O O
analyzed O O
7 O O
days O O
later O O
, O O
a O O
highly O O
significant O O
correlation O O
( O O
r O O
= O O
0 O O
. O O
83 O O
, O O
2 O O
p O O
= O O
0 O O
. O O
006 O O
) O O
to O O
the O O
slope O O
of O O
the O O
fall O O
in O O
blood O O
glucose O O
after O O
insulin O O
treatment O O
appeared O O
. O O

The O O
myocardial O O
content O O
of O O
catecholamines O O
was O O
estimated O O
in O O
these O O
8 O O
day O O
diabetic B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
rats O O
. O O

The O O
norepinephrine O O
content O O
was O O
significantly O O
increased O O
while O O
epinephrine O O
remained O O
unchanged O O
. O O

An O O
enhanced O O
sympathetic O O
nervous O O
system O O
activity O O
with O O
a O O
consequent O O
down O O
regulation O O
of O O
the O O
myocardial O O
beta O O
- O O
adrenergic O O
receptors O O
could O O
, O O
therefore O O
, O O
explain O O
this O O
catecholamine O O
resistance O O
. O O

The O O
rapid O O
reversion O O
after O O
insulin O O
treatment O O
excludes O O
the O O
possibility O O
that O O
streptozotocin O O
in O O
itself O O
causes O O
the O O
ISO O O
resistance O O
and O O
points O O
towards O O
a O O
direct O O
insulin O O
effect O O
on O O
myocardial O O
catecholamine O O
sensitivity O O
in O O
diabetic B B_DISEASE/B_PERSON
rats O O
. O O

The O O
phenomenon O O
described O O
might O O
elucidate O O
pathogenetic O O
mechanisms O O
behind O O
toxic O O
myocardial O O
cell O O
degeneration O O
and O O
may O O
possibly O O
have O O
relevance O O
for O O
acute O O
cardiovascular O O
complications O O
in O O
diabetic B B_DISEASE/B_PERSON
patients O O
. O O

Differential O O
effects O O
of O O
non O O
- O O
steroidal O O
anti O O
- O O
inflammatory O O
drugs O O
on O O
seizures B B_DISEASE
produced O O
by O O
pilocarpine O O
in O O
rats O O
. O O

The O O
muscarinic O O
cholinergic O O
agonist O O
pilocarpine O O
induces O O
in O O
rats O O
seizures B B_DISEASE
and O O
status B B_DISEASE
epilepticus I I_DISEASE
followed O O
by O O
widespread O O
damage O O
to O O
the O O
forebrain O O
. O O

The O O
present O O
study O O
was O O
designed O O
to O O
investigate O O
the O O
effect O O
of O O
5 O O
non O O
- O O
steroidal O O
anti O O
- O O
inflammatory O O
drugs O O
, O O
sodium O O
salicylate O O
, O O
phenylbutazone O O
, O O
indomethacin O O
, O O
ibuprofen O O
and O O
mefenamic O O
acid O O
, O O
on O O
seizures B B_DISEASE
produced O O
by O O
pilocarpine O O
. O O

Indomethacin O O
, O O
1 O O
- O O
10 O O
mg O O
/ O O
kg O O
, O O
and O O
ibuprofen O O
, O O
10 O O
- O O
100 O O
mg O O
/ O O
kg O O
, O O
failed O O
to O O
modulate O O
seizures B B_DISEASE
produced O O
by O O
pilocarpine O O
. O O

Mefenamic O O
acid O O
, O O
26 O O
( O O
22 O O
- O O
30 O O
) O O
mg O O
/ O O
kg O O
, O O
prevented O O
seizures B B_DISEASE
and O O
protected O O
rats O O
from O O
seizure B B_DISEASE
- O O
related O O
brain B B_DISEASE_ADJECTIVE[DISEASE]
damage I I_DISEASE_ADJECTIVE[DISEASE]
induced O O
by O O
pilocarpine O O
, O O
380 O O
mg O O
/ O O
kg O O
. O O

These O O
results O O
indicate O O
that O O
non O O
- O O
steroidal O O
anti O O
- O O
inflammatory O O
drugs O O
differentially O O
modulate O O
the O O
threshold O O
for O O
pilocarpine O O
- O O
induced O O
seizures B B_DISEASE
. O O

Acute B B_DISEASE_ADJECTIVE[DISEASE]
neurologic I I_DISEASE_ADJECTIVE[DISEASE]
dysfunction I I_DISEASE_ADJECTIVE[DISEASE]
after O O
high O O
- O O
dose O O
etoposide O O
therapy O O
for O O
malignant B B_DISEASE
glioma I I_DISEASE
. O O

Etoposide O O
( O O
VP O O
- O O
16 O O
- O O
213 O O
) O O
has O O
been O O
used O O
in O O
the O O
treatment O O
of O O
many O O
solid O O
tumors B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
hematologic B B_DISEASE
malignancies I I_DISEASE
. O O

When O O
used O O
in O O
high O O
doses O O
and O O
in O O
conjunction O O
with O O
autologous O O
bone O O
marrow O O
transplantation O O
, O O
this O O
agent O O
has O O
activity O O
against O O
several O O
treatment O O
- O O
resistant O O
cancers B B_DISEASE
including O O
malignant B B_DISEASE
glioma I I_DISEASE
. O O

In O O
six O O
of O O
eight O O
patients O O
( O O
75 O O
% O O
) O O
who O O
we O O
treated O O
for O O
recurrent O O
or O O
resistant O O
glioma B B_DISEASE
, O O
sudden O O
severe O O
neurologic B B_DISEASE
deterioration I I_DISEASE
occurred O O
. O O

This O O
developed O O
a O O
median O O
of O O
9 O O
days O O
after O O
initiation O O
of O O
high O O
- O O
dose O O
etoposide O O
therapy O O
. O O

Significant O O
clinical O O
manifestations O O
have O O
included O O
confusion B B_DISEASE
, O O
papilledema B B_DISEASE
, O O
somnolence B B_DISEASE
, O O
exacerbation O O
of O O
motor B B_DISEASE
deficits I I_DISEASE
, O O
and O O
sharp O O
increase O O
in O O
seizure B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
activity O O
. O O

These O O
abnormalities O O
resolved O O
rapidly O O
after O O
initiation O O
of O O
high O O
- O O
dose O O
intravenous O O
dexamethasone O O
therapy O O
. O O

In O O
all O O
patients O O
, O O
computerized O O
tomographic O O
( O O
CT O O
) O O
brain O O
scans O O
demonstrated O O
stability O O
in O O
tumor B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
size O O
and O O
peritumor O O
edema B B_DISEASE/B_MEASURE
when O O
compared O O
with O O
pretransplant O O
scans O O
. O O

This O O
complication O O
appears O O
to O O
represent O O
a O O
significant O O
new O O
toxicity B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
high O O
- O O
dose O O
etoposide O O
therapy O O
for O O
malignant B B_DISEASE
glioma I I_DISEASE
. O O

Progressive O O
bile B B_DISEASE
duct I I_DISEASE
injury I I_DISEASE
after O O
thiabendazole O O
administration O O
. O O

A O O
27 O O
- O O
yr O O
- O O
old O O
man O O
developed O O
jaundice B B_DISEASE
2 O O
wk O O
after O O
exposure O O
to O O
thiabendazole O O
. O O

Cholestasis B B_DISEASE/B_PERSON
persisted O O
for O O
3 O O
yr O O
, O O
at O O
which O O
time O O
a O O
liver O O
transplant O O
was O O
performed O O
. O O

Prominent O O
fibrosis B B_DISEASE
and O O
hepatocellular O O
regeneration O O
were O O
also O O
present O O
; O O
however O O
, O O
the O O
lobular O O
architecture O O
was O O
preserved O O
. O O

This O O
case O O
represents O O
an O O
example O O
of O O
" O O
idiosyncratic O O
" O O
drug B B_DISEASE
- I I_DISEASE
induced I I_DISEASE
liver I I_DISEASE
damage I I_DISEASE
in O O
which O O
the O O
primary O O
target O O
of O O
injury O O
is O O
the O O
bile O O
duct O O
. O O

An O O
autoimmune O O
pathogenesis O O
of O O
the O O
bile B B_DISEASE/B_BIO
duct I I_DISEASE/I_BIO
destruction I I_DISEASE/I_BIO
is O O
suggested O O
. O O

Differential O O
effects O O
of O O
1 O O
, O O
4 O O
- O O
dihydropyridine O O
calcium O O
channel O O
blockers O O
: O O
therapeutic O O
implications O O
. O O

Increasing O O
recognition O O
of O O
the O O
importance O O
of O O
calcium O O
in O O
the O O
pathogenesis O O
of O O
cardiovascular B B_DISEASE
disease I I_DISEASE
has O O
stimulated O O
research O O
into O O
the O O
use O O
of O O
calcium O O
channel O O
blocking O O
agents O O
for O O
treatment O O
of O O
a O O
variety O O
of O O
cardiovascular B B_DISEASE_ADJECTIVE[DISEASE]
diseases I I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
favorable O O
efficacy O O
and O O
tolerability O O
profiles O O
of O O
these O O
agents O O
make O O
them O O
attractive O O
therapeutic O O
modalities O O
. O O

Clinical O O
applications O O
of O O
calcium O O
channel O O
blockers O O
parallel O O
their O O
tissue O O
selectivity O O
. O O

In O O
contrast O O
to O O
verapamil O O
and O O
diltiazem O O
, O O
which O O
are O O
roughly O O
equipotent O O
in O O
their O O
actions O O
on O O
the O O
heart O O
and O O
vascular O O
smooth O O
muscle O O
, O O
the O O
dihydropyridine O O
calcium O O
channel O O
blockers O O
are O O
a O O
group O O
of O O
potent O O
peripheral O O
vasodilator O O
agents O O
that O O
exert O O
minimal O O
electrophysiologic O O
effects O O
on O O
cardiac O O
nodal O O
or O O
conduction O O
tissue O O
. O O

As O O
the O O
first O O
dihydropyridine O O
available O O
for O O
use O O
in O O
the O O
United O O
States O O
, O O
nifedipine O O
controls O O
angina B B_DISEASE
and O O
hypertension B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
minimal O O
depression O O
of O O
cardiac O O
function O O
. O O

Additional O O
members O O
of O O
this O O
group O O
of O O
calcium O O
channel O O
blockers O O
have O O
been O O
studied O O
for O O
a O O
variety O O
of O O
indications O O
for O O
which O O
they O O
may O O
offer O O
advantages O O
over O O
current O O
therapy O O
. O O

Once O O
or O O
twice O O
daily O O
dosage O O
possible O O
with O O
nitrendipine O O
and O O
nisoldipine O O
offers O O
a O O
convenient O O
administration O O
schedule O O
, O O
which O O
encourages O O
patient O O
compliance O O
in O O
long O O
- O O
term O O
therapy O O
of O O
hypertension B B_DISEASE
. O O

The O O
coronary O O
vasodilating O O
properties O O
of O O
nisoldipine O O
have O O
led O O
to O O
the O O
investigation O O
of O O
this O O
agent O O
for O O
use O O
in O O
angina B B_DISEASE/B_PERSON
. O O

Selectivity O O
for O O
the O O
cerebrovascular O O
bed O O
makes O O
nimodipine O O
potentially O O
useful O O
in O O
the O O
treatment O O
of O O
subarachnoid B B_DISEASE
hemorrhage I I_DISEASE
, O O
migraine B B_DISEASE
headache I I_DISEASE
, O O
dementia B B_DISEASE
, O O
and O O
stroke B B_DISEASE
. O O

In O O
general O O
, O O
the O O
dihydropyridine O O
calcium O O
channel O O
blockers O O
are O O
usually O O
well O O
tolerated O O
, O O
with O O
headache B B_DISEASE
, O O
facial O O
flushing B B_DISEASE
, O O
palpitations B B_DISEASE
, O O
edema B B_DISEASE
, O O
nausea B B_DISEASE
, O O
anorexia B B_DISEASE
, O O
and O O
dizziness B B_DISEASE
being O O
the O O
more O O
common O O
adverse O O
effects O O
. O O

The O O
enhancement O O
of O O
aminonucleoside O O
nephrosis B B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
by O O
the O O
co O O
- O O
administration O O
of O O
protamine O O
. O O

An O O
experimental O O
model O O
of O O
focal B B_DISEASE
segmental I I_DISEASE
glomerular I I_DISEASE
sclerosis I I_DISEASE
( O O
FSGS B B_LOCATION/B_DISEASE
) O O
was O O
developed O O
in O O
rats O O
by O O
the O O
combined O O
administration O O
of O O
puromycin O O
- O O
aminonucleoside O O
( O O
AMNS O O
) O O
and O O
protamine O O
sulfate O O
( O O
PS O O
) O O
. O O

Male O O
Sprague O O
- O O
Dawley O O
rats O O
, O O
uninephrectomized O O
three O O
weeks O O
before O O
, O O
received O O
daily O O
injections O O
of O O
subcutaneous O O
AMNS O O
( O O
1 O O
mg O O
/ O O
100 O O
g O O
body O O
wt O O
) O O
and O O
intravenous O O
PS O O
( O O
2 O O
separated O O
doses O O
of O O
2 O O
. O O
5 O O
mg O O
/ O O
100 O O
g O O
body O O
wt O O
) O O
for O O
four O O
days O O
. O O

The O O
series O O
of O O
injections O O
were O O
repeated O O
another O O
three O O
times O O
at O O
10 O O
day O O
intervals O O
. O O

The O O
animals O O
were O O
sacrificed O O
on O O
days O O
24 O O
, O O
52 O O
, O O
and O O
80 O O
. O O

They O O
developed O O
nephrotic B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
syndrome I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
finally O O
renal B B_DISEASE
failure I I_DISEASE
. O O

The O O
time O O
- O O
course O O
curve O O
of O O
creatinine O O
clearance O O
dropped O O
and O O
showed O O
significant O O
difference O O
( O O
P O O
less O O
than O O
0 O O
. O O
01 O O
) O O
from O O
that O O
of O O
each O O
control O O
group O O
, O O
such O O
as O O
, O O
AMNS O O
alone O O
, O O
PS O O
alone O O
or O O
saline O O
injected O O
. O O

Their O O
glomeruli O O
showed O O
changes O O
of O O
progressive O O
FSGS B B_DISEASE
. O O

The O O
ultrastructural O O
studies O O
in O O
the O O
initial O O
stage O O
revealed O O
significant O O
lack O O
of O O
particles O O
of O O
perfused O O
ruthenium O O
red O O
on O O
the O O
lamina O O
rara O O
externa O O
and O O
marked O O
changes O O
in O O
epithelial O O
cell O O
cytoplasm O O
. O O

Theophylline O O
neurotoxicity B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
pregnant O O
rats O O
. O O

The O O
purpose O O
of O O
this O O
investigation O O
was O O
to O O
determine O O
whether O O
the O O
neurotoxicity B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
theophylline O O
is O O
altered O O
in O O
advanced O O
pregnancy O O
. O O

Sprague O O
- O O
Dawley O O
rats O O
that O O
were O O
20 O O
days O O
pregnant O O
and O O
nonpregnant O O
rats O O
of O O
the O O
same O O
age O O
and O O
strain O O
received O O
infusions O O
of O O
aminophylline O O
until O O
onset O O
of O O
maximal O O
seizures B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
which O O
occurred O O
after O O
28 O O
and O O
30 O O
minutes O O
respectively O O
. O O

Theophylline O O
concentrations O O
at O O
this O O
endpoint O O
in O O
serum O O
( O O
total O O
) O O
and O O
CSF O O
were O O
similar O O
but O O
serum O O
( O O
free O O
) O O
and O O
brain O O
concentrations O O
were O O
slightly O O
different O O
in O O
pregnant O O
rats O O
. O O

Theophylline O O
serum O O
protein O O
binding O O
determined O O
by O O
equilibrium O O
dialysis O O
was O O
lower O O
in O O
pregnant O O
rats O O
. O O

Fetal O O
serum O O
concentrations O O
at O O
onset O O
of O O
seizures B B_DISEASE/B_ORGANISM_FUNCTION
in O O
the O O
mother O O
were O O
similar O O
to O O
maternal O O
brain O O
and O O
CSF O O
concentrations O O
and O O
correlated O O
significantly O O
with O O
the O O
former O O
. O O

Hyperkalemia B B_DISEASE/B_LOCATION
induced O O
by O O
indomethacin O O
and O O
naproxen O O
and O O
reversed O O
by O O
fludrocortisone O O
. O O

We O O
have O O
described O O
a O O
patient O O
with O O
severe O O
rheumatoid B B_DISEASE
arthritis I I_DISEASE
and O O
a O O
history O O
of O O
mefenamic O O
acid O O
nephropathy B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
whom O O
hyperkalemia B B_DISEASE
and O O
inappropriate O O
hypoaldosteronism B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
caused O O
by O O
both O O
indomethacin O O
and O O
naproxen O O
, O O
without O O
major O O
decline O O
in O O
renal O O
function O O
. O O

It O O
is O O
likely O O
that O O
preexisting O O
renal B B_DISEASE
disease I I_DISEASE
predisposed O O
this O O
patient O O
to O O
type B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
IV I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
renal I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tubular I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
acidosis I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
prostaglandin O O
synthetase O O
inhibitors O O
. O O

Because O O
he O O
was O O
unable O O
to O O
discontinue O O
nonsteroidal O O
anti O O
- O O
inflammatory O O
drug O O
therapy O O
, O O
fludrocortisone O O
was O O
added O O
, O O
correcting O O
the O O
hyperkalemia B B_DISEASE
and O O
allowing O O
indomethacin O O
therapy O O
to O O
be O O
continued O O
safely O O
. O O

Hypotension B B_DISEASE
as O O
a O O
manifestation O O
of O O
cardiotoxicity B B_DISEASE
in O O
three O O
patients O O
receiving O O
cisplatin O O
and O O
5 O O
- O O
fluorouracil O O
. O O

Cardiac O O
symptoms O O
, O O
including O O
hypotension B B_DISEASE
, O O
developed O O
in O O
three O O
patients O O
with O O
advanced O O
colorectal B B_DISEASE/B_GENE
carcinoma I I_DISEASE/I_GENE
while O O
being O O
treated O O
with O O
cisplatin O O
( O O
CDDP O O
) O O
and O O
5 O O
- O O
fluorouracil O O
( O O
5 O O
- O O
FU O O
) O O
. O O

In O O
two O O
patients O O
, O O
hypotension B B_DISEASE
was O O
associated O O
with O O
severe O O
left B B_DISEASE
ventricular I I_DISEASE
dysfunction I I_DISEASE
. O O

All O O
three O O
patients O O
required O O
therapy O O
discontinuation O O
. O O

Cardiac O O
enzymes O O
remained O O
normal O O
despite O O
transient O O
electrocardiographic O O
( O O
EKG O O
) O O
changes O O
. O O

The O O
presentation O O
and O O
cardiac O O
evaluation O O
( O O
hemodynamic O O
, O O
echocardiographic O O
, O O
and O O
scintigraphic O O
) O O
of O O
these O O
patients O O
suggest O O
new O O
manifestations O O
of O O
5 O O
- O O
FU O O
cardiotoxicity B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
that O O
may O O
be O O
influenced O O
by O O
CDDP O O
. O O

The O O
possible O O
pathophysiologic O O
mechanisms O O
are O O
discussed O O
. O O

Fatal O O
aplastic B B_DISEASE
anemia I I_DISEASE
in O O
a O O
patient O O
treated O O
with O O
carbamazepine O O
. O O

A O O
case O O
of O O
fatal O O
aplastic B B_DISEASE
anemia I I_DISEASE
due O O
to O O
carbamazepine O O
treatment O O
in O O
an O O
epileptic B B_DISEASE/B_PERSON
woman O O
is O O
reported O O
. O O

Despite O O
concerns O O
of O O
fatal O O
bone B B_DISEASE
marrow I I_DISEASE
toxicity I I_DISEASE
due O O
to O O
carbamazepine O O
, O O
this O O
is O O
only O O
the O O
fourth O O
documented O O
and O O
published O O
report O O
. O O

Carbamazepine O O
is O O
a O O
safe O O
drug O O
, O O
but O O
physicians O O
and O O
patients O O
should O O
be O O
aware O O
of O O
the O O
exceedingly O O
rare O O
but O O
potentially O O
fatal O O
side O O
effects O O
, O O
better O O
prevented O O
by O O
clinical O O
than O O
by O O
laboratory O O
monitoring O O
. O O

Participation O O
of O O
a O O
bulbospinal O O
serotonergic O O
pathway O O
in O O
the O O
rat O O
brain O O
in O O
clonidine O O
- O O
induced O O
hypotension B B_DISEASE
and O O
bradycardia B B_DISEASE
. O O

Intramedullary O O
administration O O
of O O
clonidine O O
, O O
but O O
not O O
saline O O
vehicle O O
, O O
caused O O
a O O
dose O O
- O O
dependent O O
decrease O O
in O O
both O O
the O O
mean O O
arterial O O
pressure O O
and O O
the O O
heart O O
rate O O
. O O

The O O
clonidine O O
- O O
induced O O
hypotension B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
antagonized O O
by O O
prior O O
spinal O O
transection O O
, O O
but O O
not O O
bilateral O O
vagotomy O O
. O O

On O O
the O O
other O O
hand O O
, O O
the O O
clonidine O O
- O O
induced O O
bradycardia B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
antagonized O O
by O O
prior O O
bilateral O O
vagotomy O O
, O O
but O O
not O O
spinal O O
transection O O
. O O

Furthermore O O
, O O
selective O O
destruction O O
of O O
the O O
spinal O O
5 O O
- O O
HT O O
nerves O O
, O O
produced O O
by O O
bilateral O O
spinal O O
injection O O
of O O
5 O O
, O O
7 O O
- O O
dihydroxytryptamine O O
, O O
reduced O O
the O O
magnitude O O
of O O
the O O
vasodepressor O O
or O O
the O O
bradycardiac B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses O O
to O O
clonidine O O
microinjected O O
into O O
the O O
area O O
near O O
the O O
ventrolateral O O
surface O O
of O O
the O O
medulla O O
oblongata O O
in O O
rats O O
. O O

The O O
data O O
indicate O O
that O O
a O O
bulbospinal O O
serotonergic O O
pathway O O
is O O
involved O O
in O O
development O O
of O O
clonidine O O
- O O
induced O O
hypotension B B_DISEASE
and O O
bradycardia B B_DISEASE
. O O

The O O
induced O O
hypotension B B_DISEASE
is O O
brought O O
about O O
by O O
a O O
decrease O O
in O O
sympathetic O O
efferent O O
activity O O
, O O
whereas O O
the O O
induced O O
bradycardia B B_DISEASE
was O O
due O O
to O O
an O O
increase O O
in O O
vagal O O
efferent O O
activity O O
. O O

Hypertension B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
neuroblastoma B B_DISEASE/B_BIO
induced O O
by O O
imipramine O O
. O O

Hypertension B B_DISEASE/B_GENE
is O O
a O O
well O O
- O O
known O O
finding O O
in O O
some O O
patients O O
with O O
neuroblastoma B B_DISEASE/B_LOCATION
. O O

However O O
, O O
it O O
has O O
not O O
previously O O
been O O
described O O
in O O
association O O
with O O
the O O
use O O
of O O
Imipramine O O
. O O

We O O
report O O
the O O
occurrence O O
of O O
severe O O
hypertension B B_DISEASE
( O O
blood O O
pressure O O
190 O O
/ O O
160 O O
) O O
in O O
a O O
4 O O
- O O
year O O
- O O
old O O
girl O O
with O O
neuroblastoma B B_DISEASE/B_LOCATION
who O O
was O O
given O O
Imipramine O O
to O O
control O O
a O O
behavior B B_DISEASE
disorder I I_DISEASE
. O O

It O O
was O O
determined O O
later O O
that O O
this O O
patient O O
' O O
s O O
tumor B B_DISEASE
was O O
recurring O O
at O O
the O O
time O O
of O O
her O O
hypertensive B B_DISEASE
episode O O
. O O

Since O O
she O O
had O O
no O O
blood O O
pressure O O
elevation O O
at O O
initial O O
diagnosis O O
and O O
none O O
following O O
discontinuation O O
of O O
the O O
Imipramine O O
( O O
when O O
she O O
was O O
in O O
florid O O
relapse O O
) O O
, O O
we O O
believe O O
that O O
this O O
drug O O
rather O O
than O O
her O O
underlying O O
disease O O
alone O O
caused O O
her O O
hypertension B B_DISEASE
. O O

The O O
mechanism O O
for O O
this O O
reaction O O
is O O
believed O O
to O O
be O O
increased O O
levels O O
of O O
vasoactive O O
catecholamines O O
due O O
to O O
interference O O
of O O
their O O
physiologic O O
inactivation O O
by O O
Imipramine O O
. O O

From O O
this O O
experience O O
, O O
we O O
urge O O
extreme O O
caution O O
in O O
the O O
use O O
of O O
tricyclic O O
antidepressants O O
in O O
children O O
with O O
active O O
neuroblastoma B B_DISEASE
. O O

Rechallenge O O
of O O
patients O O
who O O
developed O O
oral B B_DISEASE
candidiasis I I_DISEASE
or O O
hoarseness B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
beclomethasone O O
dipropionate O O
. O O

Of O O
158 O O
asthmatic B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O O
who O O
were O O
placed O O
on O O
inhaled O O
beclomethasone O O
, O O
15 O O
( O O
9 O O
. O O
5 O O
% O O
) O O
developed O O
either O O
hoarseness B B_DISEASE
( O O
8 O O
) O O
, O O
oral O O
thrush B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
6 O O
) O O
, O O
or O O
both O O
( O O
1 O O
) O O
. O O

These O O
included O O
five O O
cases O O
who O O
developed O O
hoarseness B B_DISEASE
and O O
three O O
who O O
developed O O
Candidiasis B B_DISEASE
. O O

One O O
patient O O
had O O
both O O
. O O

Oral O O
thrush B B_DISEASE
did O O
not O O
recur O O
, O O
but O O
60 O O
% O O
( O O
3 O O
/ O O
5 O O
) O O
of O O
patients O O
with O O
hoarseness B B_DISEASE
had O O
recurrence O O
. O O

We O O
conclude O O
that O O
patients O O
may O O
be O O
restarted O O
on O O
inhaled O O
beclomethasone O O
when O O
clinically O O
indicated O O
; O O
however O O
, O O
because O O
of O O
the O O
high O O
recurrence O O
rate O O
, O O
patients O O
who O O
develop O O
hoarseness B B_DISEASE
should O O
not O O
be O O
re O O
- O O
challenged O O
. O O

Concomitant O O
use O O
of O O
oral O O
prednisone O O
and O O
topical O O
beclomethasone O O
may O O
increase O O
the O O
risk O O
of O O
developing O O
hoarseness B B_DISEASE
or O O
candidiasis B B_DISEASE
. O O

Cyclophosphamide O O
cardiotoxicity B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
: O O
an O O
analysis O O
of O O
dosing O O
as O O
a O O
risk O O
factor O O
. O O

Patients O O
who O O
undergo O O
bone O O
marrow O O
transplantation O O
are O O
generally O O
immunosuppressed O O
with O O
a O O
dose O O
of O O
cyclophosphamide O O
( O O
CYA O O
) O O
which O O
is O O
usually O O
calculated O O
based O O
on O O
the O O
patient O O
' O O
s O O
weight O O
. O O

At O O
these O O
high O O
doses O O
of O O
CYA O O
, O O
serious O O
cardiotoxicity B B_DISEASE
may O O
occur O O
, O O
but O O
definitive O O
risk O O
factors O O
for O O
the O O
development O O
of O O
such O O
cardiotoxicity B B_DISEASE
have O O
not O O
been O O
described O O
. O O

Since O O
chemotherapeutic O O
agent O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
generally O O
correlates O O
with O O
dose O O
per O O
body O O
surface O O
area O O
, O O
we O O
retrospectively O O
calculated O O
the O O
dose O O
of O O
CYA O O
in O O
patients O O
transplanted O O
at O O
our O O
institution O O
to O O
determine O O
whether O O
the O O
incidence O O
of O O
CYA O O
cardiotoxicity B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
correlated O O
with O O
the O O
dose O O
per O O
body O O
surface O O
area O O
. O O

Eighty O O
patients O O
who O O
were O O
to O O
receive O O
CYA O O
50 O O
mg O O
/ O O
kg O O
/ O O
d O O
for O O
four O O
days O O
as O O
preparation O O
for O O
marrow O O
grafting O O
underwent O O
a O O
total O O
of O O
84 O O
transplants O O
for O O
aplastic B B_DISEASE
anemia I I_DISEASE
, O O
Wiskott B B_DISEASE
- I I_DISEASE
Aldrich I I_DISEASE
syndrome I I_DISEASE
, O O
or O O
severe B B_DISEASE
combined I I_DISEASE
immunodeficiency I I_DISEASE
syndrome I I_DISEASE
. O O

Fourteen O O
of O O
84 O O
( O O
17 O O
% O O
) O O
patients O O
had O O
symptoms O O
and O O
signs O O
consistent O O
with O O
CYA O O
cardiotoxicity B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
within O O
ten O O
days O O
of O O
receiving O O
1 O O
to O O
4 O O
doses O O
of O O
CYA O O
. O O

Six O O
of O O
the O O
14 O O
patients O O
died O O
with O O
congestive B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
heart I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
failure I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
dose O O
of O O
CYA O O
per O O
body O O
surface O O
area O O
was O O
calculated O O
for O O
all O O
patients O O
and O O
the O O
patients O O
were O O
divided O O
into O O
two O O
groups O O
based O O
on O O
daily O O
CYA O O
dose O O
: O O
Group O O
1 O O
, O O
CYA O O
less O O
than O O
or O O
equal O O
to O O
1 O O
. O O
55 O O
g O O
/ O O
m2 O O
/ O O
d O O
; O O
Group O O
2 O O
, O O
CYA O O
greater O O
than O O
1 O O
. O O
55 O O
g O O
/ O O
m2 O O
/ O O
d O O
. O O

Cardiotoxicity B B_DISEASE
that O O
was O O
thought O O
to O O
be O O
related O O
to O O
CYA O O
occurred O O
in O O
1 O O
/ O O
32 O O
( O O
3 O O
% O O
) O O
of O O
patients O O
in O O
Group O O
1 O O
and O O
in O O
13 O O
/ O O
52 O O
( O O
25 O O
% O O
) O O
patients O O
in O O
Group O O
2 O O
( O O
P O O
less O O
than O O
0 O O
. O O
025 O O
) O O
. O O

Congestive B B_DISEASE/B_LOCATION
heart I I_DISEASE/I_LOCATION
failure I I_DISEASE/I_LOCATION
caused O O
or O O
contributed O O
to O O
death O O
in O O
0 O O
/ O O
32 O O
patients O O
in O O
Group O O
1 O O
v O O
6 O O
/ O O
52 O O
( O O
12 O O
% O O
) O O
of O O
patients O O
in O O
Group O O
2 O O
( O O
P O O
less O O
than O O
0 O O
. O O
25 O O
) O O
. O O

There O O
was O O
no O O
difference O O
in O O
the O O
rate O O
of O O
engraftment O O
of O O
evaluable O O
patients O O
in O O
the O O
two O O
groups O O
( O O
P O O
greater O O
than O O
0 O O
. O O
5 O O
) O O
. O O

We O O
conclude O O
that O O
the O O
CYA O O
cardiotoxicity B B_DISEASE/B_MEASURE
correlates O O
with O O
CYA O O
dosage O O
as O O
calculated O O
by O O
body O O
surface O O
area O O
, O O
and O O
that O O
patients O O
with O O
aplastic B B_DISEASE
anemia I I_DISEASE
and O O
immunodeficiencies B B_DISEASE
can O O
be O O
effectively O O
prepared O O
for O O
bone O O
marrow O O
grafting O O
at O O
a O O
CYA O O
dose O O
of O O
1 O O
. O O
55 O O
g O O
/ O O
m2 O O
/ O O
d O O
for O O
four O O
days O O
with O O
a O O
lower O O
incidence O O
of O O
cardiotoxicity B B_DISEASE
than O O
patients O O
whose O O
CYA O O
dosage O O
is O O
calculated O O
based O O
on O O
weight O O
. O O

Studies O O
of O O
risk O O
factors O O
for O O
aminoglycoside O O
nephrotoxicity B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
epidemiology O O
of O O
aminoglycoside O O
- O O
induced O O
nephrotoxicity B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
not O O
fully O O
understood O O
. O O

Experimental O O
studies O O
in O O
healthy O O
human O O
volunteers O O
indicate O O
aminoglycosides O O
cause O O
proximal O O
tubular O O
damage O O
in O O
most O O
patients O O
, O O
but O O
rarely O O
, O O
if O O
ever O O
, O O
cause O O
glomerular B B_DISEASE
or I I_DISEASE
tubular I I_DISEASE
dysfunction I I_DISEASE
. O O

Clinical O O
trials O O
of O O
aminoglycosides O O
in O O
seriously O O
ill O O
patients O O
indicate O O
that O O
the O O
relative O O
risk O O
for O O
developing O O
acute B B_DISEASE
renal I I_DISEASE
failure I I_DISEASE
during O O
therapy O O
ranges O O
from O O
8 O O
to O O
10 O O
and O O
that O O
the O O
attributable O O
risk O O
is O O
70 O O
% O O
to O O
80 O O
% O O
. O O

Further O O
analysis O O
of O O
these O O
data O O
suggests O O
that O O
the O O
duration O O
of O O
therapy O O
, O O
plasma O O
aminoglycoside O O
levels O O
, O O
liver B B_DISEASE
disease I I_DISEASE
, O O
advanced O O
age O O
, O O
high O O
initial O O
estimated O O
creatinine O O
clearance O O
and O O
, O O
possibly O O
, O O
female O O
gender O O
all O O
increase O O
the O O
risk O O
for O O
nephrotoxicity B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Other O O
causes O O
of O O
acute B B_DISEASE
renal I I_DISEASE
failure I I_DISEASE
, O O
such O O
as O O
shock B B_DISEASE
, O O
appear O O
to O O
have O O
an O O
additive O O
effect O O
. O O

Predictive O O
models O O
have O O
been O O
developed O O
from O O
these O O
analyses O O
that O O
should O O
be O O
useful O O
for O O
identifying O O
patients O O
at O O
high O O
risk O O
. O O

These O O
models O O
may O O
also O O
be O O
useful O O
in O O
developing O O
insights O O
into O O
the O O
pathophysiology O O
of O O
aminoglycoside O O
- O O
induced O O
nephrotoxicity B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Central O O
action O O
of O O
narcotic O O
analgesics O O
. O O

Part O O
IV O O
. O O

Noradrenergic O O
influences O O
on O O
the O O
activity O O
of O O
analgesics O O
in O O
rats O O
. O O

The O O
effect O O
of O O
clonidine O O
, O O
naphazoline O O
and O O
xylometazoline O O
on O O
analgesia O O
induced O O
by O O
morphine O O
, O O
codeine O O
, O O
fentanyl O O
and O O
pentazocine O O
, O O
and O O
on O O
cataleptic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effect O O
of O O
morphine O O
, O O
codine O O
and O O
fentanyl O O
was O O
studied O O
in O O
rats O O
. O O

The O O
biochemical O O
assays O O
on O O
the O O
influence O O
of O O
four O O
analgesics O O
on O O
the O O
brain O O
concentration O O
and O O
turnover O O
of O O
noradrenaline O O
( O O
NA O O
) O O
were O O
also O O
performed O O
. O O

It O O
was O O
found O O
that O O
three O O
drugs O O
stimulating O O
central O O
NA O O
receptors O O
failed O O
to O O
affect O O
the O O
analgesic O O
ED50 O O
of O O
all O O
antinociceptive O O
agents O O
and O O
they O O
enhanced O O
catalepsy B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
by O O
morphine O O
and O O
fentanyl O O
. O O

Codeine O O
catalepsy B B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
was O O
increased O O
by O O
clonidine O O
and O O
decreased O O
by O O
naphazoline O O
and O O
xylometazoline O O
. O O

The O O
brain O O
concentration O O
of O O
NA O O
was O O
not O O
changed O O
by O O
morphine O O
and O O
fentanyl O O
, O O
but O O
one O O
of O O
the O O
doses O O
of O O
codeine O O
( O O
45 O O
mg O O
/ O O
kg O O
) O O
slightly O O
enhanced O O
it O O
. O O

Pentazocine O O
dose O O
- O O
dependently O O
decreased O O
the O O
brain O O
level O O
of O O
NA O O
. O O

The O O
rate O O
of O O
NA O O
turnover O O
was O O
not O O
altered O O
by O O
analgesics O O
except O O
for O O
the O O
higher O O
dose O O
of O O
fentanyl O O
( O O
0 O O
. O O
2 O O
mg O O
/ O O
kg O O
) O O
following O O
which O O
the O O
disappearance O O
of O O
NA O O
from O O
the O O
brain O O
was O O
diminished O O
. O O

It O O
is O O
suggested O O
that O O
in O O
rats O O
the O O
brain O O
NA O O
plays O O
a O O
less O O
important O O
function O O
than O O
the O O
other O O
monoamines O O
in O O
the O O
behavioural O O
activity O O
of O O
potent O O
analgesics O O
. O O

Flurothyl O O
seizure B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thresholds O O
in O O
mice O O
treated O O
neonatally O O
with O O
a O O
single O O
injection O O
of O O
monosodium O O
glutamate O O
( O O
MSG O O
) O O
: O O
evaluation O O
of O O
experimental O O
parameters O O
in O O
flurothyl O O
seizure B B_DISEASE
testing O O
. O O

Monosodium O O
glutamate O O
( O O
MSG O O
) O O
administration O O
to O O
neonatal O O
rodents O O
produces O O
convulsions B B_DISEASE
and O O
results O O
in O O
numerous O O
biochemical O O
and O O
behavioral O O
deficits O O
. O O

These O O
studies O O
were O O
undertaken O O
to O O
determine O O
if O O
neonatal O O
administration O O
of O O
MSG O O
produced O O
permanent O O
alterations O O
in O O
seizure B B_DISEASE
susceptibility O O
, O O
since O O
previous O O
investigations O O
were O O
inconclusive O O
. O O

A O O
flurothyl O O
ether O O
seizure B B_DISEASE
screening O O
technique O O
was O O
used O O
to O O
evaluate O O
seizure B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
susceptibility O O
in O O
adult O O
mice O O
that O O
received O O
neonatal O O
injections O O
of O O
MSG O O
( O O
4 O O
mg O O
/ O O
g O O
and O O
1 O O
mg O O
/ O O
g O O
) O O
. O O

MSG O O
treatment O O
resulted O O
in O O
significant O O
reductions O O
in O O
whole O O
brain O O
weight O O
but O O
did O O
not O O
alter O O
seizure B B_DISEASE
threshold O O
. O O

A O O
naloxone O O
( O O
5 O O
mg O O
/ O O
kg O O
) O O
challenge O O
was O O
also O O
ineffective O O
in O O
altering O O
the O O
seizure B B_DISEASE
thresholds O O
of O O
either O O
control O O
of O O
MSG O O
- O O
treated O O
mice O O
. O O

Flurothyl O O
ether O O
produced O O
hypothermia B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
which O O
was O O
correlated O O
with O O
the O O
duration O O
of O O
flurothyl O O
exposure O O
; O O
however O O
, O O
the O O
relationship O O
of O O
hypothermia B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O O
seizure B B_DISEASE
induction O O
was O O
unclear O O
. O O

Flurothyl O O
seizure B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
testing O O
proved O O
to O O
be O O
a O O
rapid O O
and O O
reliable O O
technique O O
with O O
which O O
to O O
evaluate O O
seizure B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
susceptibility O O
. O O

Susceptibility O O
to O O
seizures B B_DISEASE
produced O O
by O O
pilocarpine O O
in O O
rats O O
after O O
microinjection O O
of O O
isoniazid O O
or O O
gamma O O
- O O
vinyl O O
- O O
GABA O O
into O O
the O O
substantia O O
nigra O O
. O O

Pilocarpine O O
, O O
given O O
intraperitoneally O O
to O O
rats O O
, O O
reproduces O O
the O O
neuropathological O O
sequelae O O
of O O
temporal B B_DISEASE
lobe I I_DISEASE
epilepsy I I_DISEASE
and O O
provides O O
a O O
relevant O O
animal O O
model O O
for O O
studying O O
mechanisms O O
of O O
buildup O O
of O O
convulsive B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
activity O O
and O O
pathways O O
operative O O
in O O
the O O
generalization O O
and O O
propagation O O
of O O
seizures B B_DISEASE
within O O
the O O
forebrain O O
. O O

In O O
the O O
present O O
study O O
, O O
the O O
effects O O
of O O
manipulating O O
the O O
activity O O
of O O
the O O
gamma O O
- O O
aminobutyric O O
acid O O
( O O
GABA O O
) O O
- O O
mediated O O
synaptic O O
inhibition O O
within O O
the O O
substantia O O
nigra O O
on O O
seizures B B_DISEASE
produced O O
by O O
pilocarpine O O
in O O
rats O O
, O O
were O O
investigated O O
. O O

In O O
animals O O
pretreated O O
with O O
microinjections O O
of O O
isoniazid O O
, O O
150 O O
micrograms O O
, O O
an O O
inhibitor O O
of O O
activity O O
of O O
the O O
GABA O O
- O O
synthesizing O O
enzyme O O
, O O
L O O
- O O
glutamic O O
acid O O
decarboxylase O O
, O O
into O O
the O O
substantia O O
nigra O O
pars O O
reticulata O O
( O O
SNR O O
) O O
, O O
bilaterally O O
, O O
non O O
- O O
convulsant O O
doses O O
of O O
pilocarpine O O
, O O
100 O O
and O O
200 O O
mg O O
/ O O
kg O O
, O O
resulted O O
in O O
severe O O
motor O O
limbic O O
seizures B B_DISEASE
and O O
status B B_DISEASE
epilepticus I I_DISEASE
. O O

Electroencephalographic O O
and O O
behavioral O O
monitoring O O
revealed O O
a O O
profound O O
reduction O O
of O O
the O O
threshold O O
for O O
pilocarpine O O
- O O
induced O O
convulsions B B_DISEASE
. O O

Morphological O O
analysis O O
of O O
frontal O O
forebrain O O
sections O O
with O O
light O O
microscopy O O
revealed O O
seizure B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
related O O
damage O O
to O O
the O O
hippocampal O O
formation O O
, O O
thalamus O O
, O O
amygdala O O
, O O
olfactory O O
cortex O O
, O O
substantia O O
nigra O O
and O O
neocortex O O
, O O
which O O
is O O
typically O O
observed O O
with O O
pilocarpine O O
in O O
doses O O
exceeding O O
350 O O
mg O O
/ O O
kg O O
. O O

Bilateral O O
intrastriatal O O
injections O O
of O O
isoniazid O O
did O O
not O O
augment O O
seizures B B_DISEASE
produced O O
by O O
pilocarpine O O
, O O
200 O O
mg O O
/ O O
kg O O
. O O

Application O O
of O O
an O O
irreversible O O
inhibitor O O
of O O
GABA O O
transaminase O O
, O O
gamma O O
- O O
vinyl O O
- O O
GABA O O
( O O
D O O
, O O
L O O
- O O
4 O O
- O O
amino O O
- O O
hex O O
- O O
5 O O
- O O
enoic O O
acid O O
) O O
, O O
5 O O
micrograms O O
, O O
into O O
the O O
SNR O O
, O O
bilaterally O O
, O O
suppressed O O
the O O
appearance O O
of O O
electrographic O O
and O O
behavioral O O
seizures B B_DISEASE
produced O O
by O O
pilocarpine O O
, O O
380 O O
mg O O
/ O O
kg O O
. O O

This O O
treatment O O
was O O
also O O
sufficient O O
to O O
protect O O
animals O O
from O O
the O O
occurrence O O
of O O
brain B B_DISEASE
damage I I_DISEASE
. O O

Microinjections O O
of O O
gamma O O
- O O
vinyl O O
- O O
GABA O O
, O O
5 O O
micrograms O O
, O O
into O O
the O O
dorsal O O
striatum O O
, O O
bilaterally O O
, O O
failed O O
to O O
prevent O O
the O O
development O O
of O O
convulsions B B_DISEASE
produced O O
by O O
pilocarpine O O
, O O
380 O O
mg O O
/ O O
kg O O
. O O

The O O
results O O
demonstrate O O
that O O
the O O
threshold O O
for O O
pilocarpine O O
- O O
induced O O
seizures B B_DISEASE
in O O
rats O O
is O O
subjected O O
to O O
the O O
regulation O O
of O O
the O O
GABA O O
- O O
mediated O O
synaptic O O
inhibition O O
within O O
the O O
substantia O O
nigra O O
. O O

Human O O
and O O
canine O O
ventricular O O
vasoactive O O
intestinal O O
polypeptide O O
: O O
decrease O O
with O O
heart B B_DISEASE
failure I I_DISEASE
. O O

Vasoactive O O
intestinal O O
polypeptide O O
( O O
VIP O O
) O O
is O O
a O O
systemic O O
and O O
coronary O O
vasodilator O O
that O O
may O O
have O O
positive O O
inotropic O O
properties O O
. O O

Myocardial O O
levels O O
of O O
VIP O O
were O O
assayed O O
before O O
and O O
after O O
the O O
development O O
of O O
heart B B_DISEASE
failure I I_DISEASE
in O O
two O O
canine O O
models O O
. O O

In O O
the O O
first O O
, O O
cobalt O O
cardiomyopathy B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
induced O O
in O O
eight O O
dogs O O
; O O
VIP O O
( O O
by O O
radioimmunoassay O O
) O O
decreased O O
from O O
35 O O
+ O O
/ O O
- O O
11 O O
pg O O
/ O O
mg O O
protein O O
( O O
mean O O
+ O O
/ O O
- O O
SD O O
) O O
to O O
5 O O
+ O O
/ O O
- O O
4 O O
pg O O
/ O O
mg O O
protein O O
( O O
P O O
less O O
than O O
0 O O
. O O
05 O O
) O O
. O O

In O O
six O O
dogs O O
with O O
doxorubicin O O
- O O
induced O O
heart B B_DISEASE
failure I I_DISEASE
, O O
VIP O O
decreased O O
from O O
31 O O
+ O O
/ O O
- O O
7 O O
to O O
11 O O
+ O O
/ O O
- O O
4 O O
pg O O
/ O O
mg O O
protein O O
( O O
P O O
less O O
than O O
0 O O
. O O
05 O O
) O O
. O O

In O O
addition O O
, O O
VIP O O
content O O
of O O
left O O
ventricular O O
muscle O O
of O O
resected O O
failing O O
hearts O O
in O O
10 O O
patients O O
receiving O O
a O O
heart O O
transplant O O
was O O
compared O O
with O O
the O O
papillary O O
muscles O O
in O O
14 O O
patients O O
( O O
five O O
with O O
rheumatic B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
disease I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
nine O O
with O O
myxomatous B B_DISEASE
degeneration I I_DISEASE
) O O
receiving O O
mitral O O
valve O O
prostheses O O
. O O

The O O
lowest O O
myocardial O O
VIP O O
concentration O O
was O O
found O O
in O O
the O O
hearts O O
of O O
patients O O
with O O
coronary B B_DISEASE
disease I I_DISEASE
( O O
one O O
patient O O
receiving O O
a O O
transplant O O
and O O
three O O
receiving O O
mitral O O
prostheses O O
) O O
( O O
6 O O
. O O
3 O O
+ O O
/ O O
- O O
1 O O
. O O
9 O O
pg O O
/ O O
mg O O
protein O O
) O O
. O O

The O O
other O O
patients O O
undergoing O O
transplantation O O
had O O
an O O
average O O
ejection O O
fraction O O
of O O
17 O O
% O O
+ O O
/ O O
- O O
6 O O
% O O
and O O
a O O
VIP O O
level O O
of O O
8 O O
. O O
8 O O
+ O O
/ O O
- O O
3 O O
. O O
9 O O
pg O O
/ O O
mg O O
protein O O
. O O

The O O
hearts O O
without O O
coronary B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
artery I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disease I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
average O O
ejection O O
fraction O O
of O O
this O O
group O O
62 O O
% O O
+ O O
/ O O
- O O
10 O O
% O O
) O O
had O O
a O O
VIP O O
concentration O O
of O O
14 O O
. O O
1 O O
+ O O
/ O O
- O O
7 O O
. O O
9 O O
pg O O
/ O O
mg O O
protein O O
, O O
and O O
this O O
was O O
greater O O
than O O
in O O
hearts O O
of O O
the O O
patients O O
with O O
coronary B B_DISEASE
disease I I_DISEASE
and O O
the O O
hearts O O
of O O
patients O O
receiving O O
a O O
transplant O O
( O O
P O O
less O O
than O O
0 O O
. O O
05 O O
) O O
. O O

Myocardial O O
catecholamines O O
were O O
also O O
determined O O
in O O
14 O O
subjects O O
; O O
a O O
weak O O
correlation O O
( O O
r O O
= O O
0 O O
. O O
57 O O
, O O
P O O
less O O
than O O
0 O O
. O O
05 O O
) O O
between O O
the O O
tissue O O
concentrations O O
of O O
VIP O O
and O O
norepinephrine O O
was O O
noted O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O

Non O O
- O O
invasive O O
detection O O
of O O
coronary B B_DISEASE
artery I I_DISEASE
disease I I_DISEASE
by O O
body O O
surface O O
electrocardiographic O O
mapping O O
after O O
dipyridamole O O
infusion O O
. O O

Electrocardiographic O O
changes O O
after O O
dipyridamole O O
infusion O O
( O O
0 O O
. O O
568 O O
mg O O
/ O O
kg O O
/ O O
4 O O
min O O
) O O
were O O
studied O O
in O O
41 O O
patients O O
with O O
coronary B B_DISEASE
artery I I_DISEASE
disease I I_DISEASE
and O O
compared O O
with O O
those O O
after O O
submaximal O O
treadmill O O
exercise O O
by O O
use O O
of O O
the O O
body O O
surface O O
mapping O O
technique O O
. O O

Eighty O O
- O O
seven O O
unipolar O O
electrocardiograms O O
( O O
ECGs O O
) O O
distributed O O
over O O
the O O
entire O O
thoracic O O
surface O O
were O O
simultaneously O O
recorded O O
. O O

Exercise O O
- O O
induced O O
ST O O
depression B B_DISEASE_ADJECTIVE[DISEASE]
was O O
observed O O
in O O
84 O O
% O O
of O O
the O O
non O O
- O O
MI B B_DISEASE/B_LOCATION
group O O
, O O
43 O O
% O O
of O O
the O O
ANT B B_LOCATION/B_DISEASE
- I I_LOCATION/I_DISEASE
MI I I_LOCATION/I_DISEASE
group O O
, O O
38 O O
% O O
of O O
the O O
INF B B_DISEASE/B_LOCATION
- I I_DISEASE/I_LOCATION
MI I I_DISEASE/I_LOCATION
group O O
and O O
61 O O
% O O
of O O
the O O
total O O
. O O

For O O
individual O O
patients O O
, O O
there O O
were O O
no O O
obvious O O
differences O O
between O O
the O O
body O O
surface O O
distribution O O
of O O
ST O O
depression B B_DISEASE
in O O
both O O
tests O O
. O O

The O O
data O O
suggest O O
that O O
the O O
dipyridamole O O
- O O
induced O O
myocardial B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ischemia I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
caused O O
by O O
the O O
inhomogenous O O
distribution O O
of O O
myocardial O O
blood O O
flow O O
. O O

We O O
conclude O O
that O O
the O O
dipyridamole O O
ECG O O
test O O
is O O
as O O
useful O O
as O O
the O O
exercise O O
ECG O O
test O O
for O O
the O O
assessment O O
of O O
coronary B B_DISEASE/B_LOCATION
artery I I_DISEASE/I_LOCATION
disease I I_DISEASE/I_LOCATION
. O O

Bradycardia B B_DISEASE
after O O
high O O
- O O
dose O O
intravenous O O
methylprednisolone O O
therapy O O
. O O

In O O
5 O O
consecutive O O
patients O O
with O O
rheumatoid B B_DISEASE/B_LOCATION
arthritis I I_DISEASE/I_LOCATION
who O O
received O O
intravenous O O
high O O
- O O
dose O O
methylprednisolone O O
( O O
MP O O
) O O
therapy O O
( O O
1 O O
g O O
daily O O
for O O
2 O O
or O O
3 O O
consecutive O O
days O O
) O O
, O O
a O O
decline O O
in O O
pulse O O
rate O O
was O O
observed O O
, O O
most O O
pronounced O O
on O O
day O O
4 O O
. O O

In O O
one O O
of O O
the O O
5 O O
patients O O
the O O
bradycardia B B_DISEASE
was O O
associated O O
with O O
complaints O O
of O O
substernal O O
pressure O O
. O O

Reversal O O
to O O
normal O O
heart O O
rate O O
was O O
found O O
on O O
day O O
7 O O
. O O

Electrocardiographic O O
registrations O O
showed O O
sinus B B_DISEASE_ADJECTIVE[DISEASE]
bradycardia I I_DISEASE_ADJECTIVE[DISEASE]
in O O
all O O
cases O O
. O O

No O O
significant O O
changes O O
in O O
plasma O O
concentrations O O
of O O
electrolytes O O
were O O
found O O
. O O

Careful O O
observation O O
of O O
patients O O
receiving O O
high O O
- O O
dose O O
MP O O
is O O
recommended O O
. O O

High O O
- O O
dose O O
MP O O
may O O
be O O
contraindicated O O
in O O
patients O O
with O O
known O O
heart B B_DISEASE/B_LOCATION
disease I I_DISEASE/I_LOCATION
. O O

Two O O
cases O O
of O O
downbeat B B_DISEASE
nystagmus I I_DISEASE
and O O
oscillopsia B B_DISEASE
associated O O
with O O
carbamazepine O O
. O O

Downbeat B B_DISEASE/B_LOCATION
nystagmus I I_DISEASE/I_LOCATION
is O O
often O O
associated O O
with O O
structural O O
lesions O O
at O O
the O O
craniocervical O O
junction O O
, O O
but O O
has O O
occasionally O O
been O O
reported O O
as O O
a O O
manifestation O O
of O O
metabolic O O
imbalance O O
or O O
drug O O
intoxication O O
. O O

We O O
recorded O O
the O O
eye O O
movements O O
of O O
two O O
patients O O
with O O
reversible O O
downbeat B B_DISEASE
nystagmus I I_DISEASE
related O O
to O O
carbamazepine O O
therapy O O
. O O

The O O
nystagmus B B_DISEASE
of O O
both O O
patients O O
resolved O O
after O O
reduction O O
of O O
the O O
serum O O
carbamazepine O O
levels O O
. O O

In O O
patients O O
with O O
downbeat B B_DISEASE/B_LOCATION
nystagmus I I_DISEASE/I_LOCATION
who O O
are O O
taking O O
anticonvulsant O O
medications O O
, O O
consideration O O
should O O
be O O
given O O
to O O
reduction O O
in O O
dose O O
before O O
further O O
investigation O O
is O O
undertaken O O
. O O

Improvement O O
by O O
denopamine O O
( O O
TA O O
- O O
064 O O
) O O
of O O
pentobarbital O O
- O O
induced O O
cardiac B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
failure I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
the O O
dog O O
heart O O
- O O
lung O O
preparation O O
. O O

The O O
efficacy O O
of O O
denopamine O O
, O O
an O O
orally O O
active O O
beta O O
1 O O
- O O
adrenoceptor O O
agonist O O
, O O
in O O
improving O O
cardiac B B_DISEASE
failure I I_DISEASE
was O O
assessed O O
in O O
dog O O
heart O O
- O O
lung O O
preparations O O
. O O

Cardiac O O
functions O O
depressed O O
by O O
pentobarbital O O
( O O
118 O O
+ O O
/ O O
- O O
28 O O
mg O O
; O O
mean O O
value O O
+ O O
/ O O
- O O
SD O O
) O O
such O O
that O O
cardiac O O
output O O
and O O
maximum O O
rate O O
of O O
rise O O
of O O
left O O
ventricular O O
pressure O O
( O O
LV O O
dP O O
/ O O
dt O O
max O O
) O O
had O O
been O O
reduced O O
by O O
about O O
35 O O
% O O
and O O
26 O O
% O O
of O O
the O O
respective O O
controls O O
were O O
improved O O
by O O
denopamine O O
( O O
10 O O
- O O
300 O O
micrograms O O
) O O
in O O
a O O
dose O O
- O O
dependent O O
manner O O
. O O

No O O
arrhythmias B B_DISEASE
were O O
induced O O
by O O
these O O
doses O O
of O O
denopamine O O
. O O

The O O
results O O
warrant O O
clinical O O
trials O O
of O O
denopamine O O
in O O
the O O
treatment O O
of O O
cardiac B B_DISEASE/B_LOCATION
failure I I_DISEASE/I_LOCATION
. O O

Clonazepam O O
monotherapy O O
for O O
epilepsy B B_DISEASE
in O O
childhood O O
. O O

Sixty O O
patients O O
( O O
age O O
- O O
range O O
one O O
month O O
to O O
14 O O
years O O
) O O
with O O
other O O
types O O
of O O
epilepsy B B_DISEASE/B_MEASURE
than O O
infantile B B_DISEASE/B_PERSON
spasms I B_DISEASE/I_PERSON
were O O
treated O O
with O O
clonazepam O O
. O O

Disappearance O O
of O O
seizures B B_DISEASE
and O O
normalization O O
of O O
abnormal O O
EEG O O
with O O
disappearance O O
of O O
seizures B B_DISEASE
were O O
recognized O O
in O O
77 O O
% O O
and O O
50 O O
% O O
, O O
respectively O O
. O O

Seizures B B_DISEASE/B_PERSON
disappeared O O
in O O
71 O O
% O O
of O O
the O O
patients O O
with O O
generalized O O
seizures B B_DISEASE
and O O
89 O O
% O O
of O O
partial O O
seizures B B_DISEASE/B_LOCATION
. O O

In O O
excellent O O
cases O O
, O O
mean O O
effective O O
dosages O O
were O O
0 O O
. O O
086 O O
+ O O
/ O O
- O O
0 O O
. O O
021 O O
mg O O
/ O O
kg O O
/ O O
day O O
in O O
infants O O
and O O
0 O O
. O O
057 O O
+ O O
/ O O
- O O
0 O O
. O O
022 O O
mg O O
/ O O
kg O O
/ O O
day O O
in O O
schoolchildren O O
, O O
this O O
difference O O
was O O
statistically O O
significant O O
( O O
p O O
less O O
than O O
0 O O
. O O
005 O O
) O O
. O O

The O O
incidence O O
of O O
side O O
effects O O
such O O
as O O
drowsiness B B_DISEASE
and O O
ataxia B B_DISEASE
was O O
only O O
5 O O
% O O
. O O

Postmarketing O O
study O O
of O O
timolol O O
- O O
hydrochlorothiazide O O
antihypertensive O O
therapy O O
. O O

Data O O
on O O
9 O O
, O O
037 O O
patients O O
were O O
collected O O
by O O
1 O O
, O O
455 O O
participating O O
physicians O O
. O O

The O O
antihypertensive O O
effect O O
of O O
the O O
drug O O
was O O
greater O O
in O O
patients O O
with O O
more O O
severe O O
hypertension B B_DISEASE
. O O

Overall O O
, O O
1 O O
, O O
453 O O
patients O O
experienced O O
a O O
total O O
of O O
2 O O
, O O
658 O O
adverse O O
events O O
, O O
the O O
most O O
common O O
being O O
fatigue B B_DISEASE
, O O
dizziness B B_DISEASE
, O O
and O O
weakness B B_DISEASE
. O O

Salicylate O O
nephropathy B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
Gunn O O
rat O O
: O O
potential O O
role O O
of O O
prostaglandins O O
. O O

We O O
examined O O
the O O
potential O O
role O O
of O O
prostaglandins O O
in O O
the O O
development O O
of O O
analgesic O O
nephropathy B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
Gunn O O
strain O O
of O O
rat O O
. O O

The O O
homozygous O O
Gunn O O
rats O O
have O O
unconjugated O O
hyperbilirubinemia B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
due O O
to O O
the O O
absence O O
of O O
glucuronyl O O
transferase O O
, O O
leading O O
to O O
marked O O
bilirubin O O
deposition O O
in O O
renal O O
medulla O O
and O O
papilla O O
. O O

These O O
rats O O
are O O
also O O
highly O O
susceptible O O
to O O
develop O O
papillary B B_DISEASE
necrosis I I_DISEASE
with O O
analgesic O O
administration O O
. O O

We O O
used O O
homozygous O O
( O O
jj O O
) O O
and O O
phenotypically O O
normal O O
heterozygous O O
( O O
jJ O O
) O O
animals O O
. O O

Four O O
groups O O
of O O
rats O O
( O O
n O O
= O O
7 O O
) O O
were O O
studied O O
: O O
jj O O
and O O
jJ O O
rats O O
treated O O
either O O
with O O
aspirin O O
300 O O
mg O O
/ O O
kg O O
every O O
other O O
day O O
or O O
sham O O
- O O
treated O O
. O O

After O O
one O O
week O O
, O O
slices O O
of O O
cortex O O
, O O
outer O O
and O O
inner O O
medulla O O
from O O
one O O
kidney O O
were O O
incubated O O
in O O
buffer O O
and O O
prostaglandin O O
synthesis O O
was O O
determined O O
by O O
radioimmunoassay O O
. O O

The O O
other O O
kidney O O
was O O
examined O O
histologically O O
. O O

A O O
marked O O
corticomedullary O O
gradient O O
of O O
prostaglandin O O
synthesis O O
was O O
observed O O
in O O
all O O
groups O O
. O O

PGE2 O O
synthesis O O
was O O
significantly O O
higher O O
in O O
outer O O
medulla O O
, O O
but O O
not O O
cortex O O
or O O
inner O O
medulla O O
, O O
of O O
jj O O
( O O
38 O O
+ O O
/ O O
- O O
6 O O
ng O O
/ O O
mg O O
prot O O
) O O
than O O
jJ O O
rats O O
( O O
15 O O
+ O O
/ O O
- O O
3 O O
) O O
( O O
p O O
less O O
than O O
0 O O
. O O
01 O O
) O O
. O O

The O O
changes O O
in O O
renal O O
prostaglandin O O
synthesis O O
were O O
accompanied O O
by O O
evidence O O
of O O
renal B B_DISEASE/B_GENE
damage I I_DISEASE/I_GENE
in O O
aspirin O O
- O O
treated O O
jj O O
but O O
not O O
jJ O O
rats O O
as O O
evidenced O O
by O O
: O O
increased O O
incidence O O
and O O
severity O O
of O O
hematuria B B_DISEASE/B_GENE
( O O
p O O
less O O
than O O
0 O O
. O O
01 O O
) O O
; O O
increased O O
serum O O
creatinine O O
( O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
; O O
and O O
increase O O
in O O
outer O O
medullary O O
histopathologic O O
lesions O O
( O O
p O O
less O O
than O O
0 O O
. O O
005 O O
compared O O
to O O
either O O
sham O O
- O O
treated O O
jj O O
or O O
aspirin O O
- O O
treated O O
jJ O O
) O O
. O O

These O O
results O O
suggest O O
that O O
enhanced O O
prostaglandin O O
synthesis O O
contributes O O
to O O
maintenance O O
of O O
renal O O
function O O
and O O
morphological O O
integrity O O
, O O
and O O
that O O
inhibition O O
of O O
prostaglandin O O
synthesis O O
may O O
lead O O
to O O
pathological B B_DISEASE
renal I I_DISEASE
medullary I I_DISEASE
lesions I I_DISEASE
and O O
deterioration B B_DISEASE
of I I_DISEASE
renal I I_DISEASE
function I I_DISEASE
. O O

Prophylactic O O
lidocaine O O
in O O
the O O
early O O
phase O O
of O O
suspected O O
myocardial B B_DISEASE
infarction I I_DISEASE
. O O

Four O O
hundred O O
two O O
patients O O
with O O
suspected O O
myocardial B B_DISEASE/B_LOCATION
infarction I I_DISEASE/I_LOCATION
seen O O
within O O
6 O O
hours O O
of O O
the O O
onset O O
of O O
symptoms O O
entered O O
a O O
double O O
- O O
blind O O
randomized O O
trial O O
of O O
lidocaine O O
vs O O
placebo O O
. O O

During O O
the O O
1 O O
hour O O
after O O
administration O O
of O O
the O O
drug O O
the O O
incidence O O
of O O
ventricular B B_DISEASE_ADJECTIVE[DISEASE]
fibrillation I I_DISEASE_ADJECTIVE[DISEASE]
or O O
sustained O O
ventricular B B_DISEASE
tachycardia I I_DISEASE
among O O
the O O
204 O O
patients O O
with O O
acute O O
myocardial B B_DISEASE
infarction I I_DISEASE
was O O
low O O
, O O
1 O O
. O O
5 O O
% O O
. O O

Lidocaine O O
, O O
given O O
in O O
a O O
300 O O
mg O O
dose O O
intramuscularly O O
followed O O
by O O
100 O O
mg O O
intravenously O O
, O O
did O O
not O O
prevent O O
sustained O O
ventricular B B_DISEASE
tachycardia I I_DISEASE
, O O
although O O
there O O
was O O
a O O
significant O O
reduction O O
in O O
the O O
number O O
of O O
patients O O
with O O
warning O O
arrhythmias B B_DISEASE
between O O
15 O O
and O O
45 O O
minutes O O
after O O
the O O
administration O O
of O O
lidocaine O O
( O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
. O O

The O O
average O O
plasma O O
lidocaine O O
level O O
10 O O
minutes O O
after O O
administration O O
for O O
patients O O
without O O
a O O
myocardial B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
significantly O O
higher O O
than O O
that O O
for O O
patients O O
with O O
an O O
acute O O
infarction B B_DISEASE
. O O

The O O
mean O O
plasma O O
lidocaine O O
level O O
of O O
patients O O
on O O
beta O O
- O O
blocking O O
agents O O
was O O
no O O
different O O
from O O
that O O
in O O
patients O O
not O O
on O O
beta O O
blocking O O
agents O O
. O O

During O O
the O O
1 O O
- O O
hour O O
study O O
period O O
, O O
the O O
incidence O O
of O O
central O O
nervous O O
system O O
side O O
effects O O
was O O
significantly O O
greater O O
in O O
the O O
lidocaine O O
group O O
, O O
hypotension B B_DISEASE
occurred O O
in O O
11 O O
patients O O
, O O
nine O O
of O O
whom O O
had O O
received O O
lidocaine O O
, O O
and O O
four O O
patients O O
died O O
from O O
asystole B B_DISEASE
, O O
three O O
of O O
whom O O
had O O
had O O
lidocaine O O
. O O

We O O
cannot O O
advocate O O
the O O
administration O O
of O O
lidocaine O O
prophylactically O O
in O O
the O O
early O O
hours O O
of O O
suspected O O
myocardial B B_DISEASE/B_LOCATION
infarction I I_DISEASE/I_LOCATION
. O O

Evidence O O
for O O
a O O
cholinergic O O
role O O
in O O
haloperidol O O
- O O
induced O O
catalepsy B B_DISEASE
. O O

Experiments O O
in O O
mice O O
tested O O
previous O O
evidence O O
that O O
activation O O
of O O
cholinergic O O
systems O O
promotes O O
catalepsy B B_DISEASE
and O O
that O O
cholinergic O O
mechanisms O O
need O O
to O O
be O O
intact O O
for O O
full O O
expression O O
of O O
neuroleptic O O
- O O
induced O O
catalepsy B B_DISEASE
. O O

Large O O
doses O O
of O O
the O O
cholinomimetic O O
, O O
pilocarpine O O
, O O
could O O
induce O O
catalepsy B B_DISEASE
when O O
peripheral O O
cholinergic O O
receptors O O
were O O
blocked O O
. O O

Low O O
doses O O
of O O
pilocarpine O O
caused O O
a O O
pronounced O O
enhancement O O
of O O
the O O
catalepsy B B_DISEASE
that O O
was O O
induced O O
by O O
the O O
dopaminergic O O
blocker O O
, O O
haloperidol O O
. O O

A O O
muscarinic O O
receptor O O
blocker O O
, O O
atropine O O
, O O
disrupted O O
haloperidol O O
- O O
induced O O
catalepsy B B_DISEASE
. O O

Intracranial O O
injection O O
of O O
an O O
acetylcholine O O
- O O
synthesis O O
inhibitor O O
, O O
hemicholinium O O
, O O
prevented O O
the O O
catalepsy B B_DISEASE
that O O
is O O
usually O O
induced O O
by O O
haloperidol O O
. O O

These O O
findings O O
suggest O O
the O O
hypothesis O O
that O O
the O O
catalepsy B B_DISEASE
that O O
is O O
produced O O
by O O
neuroleptics O O
such O O
as O O
haloperidol O O
is O O
actually O O
mediated O O
by O O
intrinsic O O
central O O
cholinergic O O
systems O O
. O O

Alternatively O O
, O O
activation O O
of O O
central O O
cholinergic O O
systems O O
could O O
promote O O
catalepsy B B_DISEASE/B_ORGANISM_FUNCTION
by O O
suppression O O
of O O
dopaminergic O O
systems O O
. O O

Cardiovascular B B_DISEASE
dysfunction I I_DISEASE
and O O
hypersensitivity B B_DISEASE
to O O
sodium O O
pentobarbital O O
induced O O
by O O
chronic O O
barium O O
chloride O O
ingestion O O
. O O

Barium O O
- O O
supplemented O O
Long O O
- O O
Evans O O
hooded O O
rats O O
were O O
characterized O O
by O O
a O O
persistent O O
hypertension B B_DISEASE
that O O
was O O
evident O O
after O O
1 O O
month O O
of O O
barium O O
( O O
100 O O
micrograms O O
/ O O
ml O O
mineral O O
fortified O O
water O O
) O O
treatment O O
. O O

Analysis O O
of O O
in O O
vivo O O
myocardial O O
excitability O O
, O O
contractility O O
, O O
and O O
metabolic O O
characteristics O O
at O O
16 O O
months O O
revealed O O
other O O
significant O O
barium O O
- O O
induced O O
disturbances B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
within I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
the I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cardiovascular I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
system I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
most O O
distinctive O O
aspect O O
of O O
the O O
barium O O
effect O O
was O O
a O O
demonstrated O O
hypersensitivity B B_DISEASE
of O O
the O O
cardiovascular O O
system O O
to O O
sodium O O
pentobarbital O O
. O O

The O O
lack O O
of O O
a O O
similar O O
response O O
to O O
ketamine O O
and O O
xylazine O O
anesthesia O O
revealed O O
that O O
the O O
cardiovascular O O
actions O O
of O O
sodium O O
pentobarbital O O
in O O
barium O O
- O O
treated O O
rats O O
were O O
linked O O
specifically O O
to O O
this O O
anesthetic O O
, O O
and O O
were O O
not O O
representative O O
of O O
a O O
generalized O O
anesthetic O O
response O O
. O O

Other O O
myocardial O O
pathophysiologic O O
and O O
metabolic O O
changes O O
induced O O
by O O
barium O O
were O O
manifest O O
, O O
irrespective O O
of O O
the O O
anesthetic O O
employed O O
. O O

The O O
contractile O O
element O O
shortening O O
velocity O O
of O O
the O O
cardiac O O
muscle O O
fibers O O
was O O
significantly O O
slower O O
in O O
both O O
groups O O
of O O
barium O O
- O O
treated O O
rats O O
relative O O
to O O
the O O
control O O
groups O O
, O O
irrespective O O
of O O
the O O
anesthetic O O
regimen O O
. O O

Similarly O O
, O O
significant O O
disturbances O O
in O O
myocardial O O
energy O O
metabolism O O
were O O
detected O O
in O O
the O O
barium O O
- O O
exposed O O
rats O O
which O O
were O O
consistent O O
with O O
the O O
reduced O O
contractile O O
element O O
shortening O O
velocity O O
. O O

In O O
addition O O
, O O
the O O
excitability O O
of O O
the O O
cardiac O O
conduction O O
system O O
was O O
depressed O O
preferentially O O
in O O
the O O
atrioventricular O O
nodal O O
region O O
of O O
hearts O O
from O O
barium O O
- O O
exposed O O
rats O O
. O O

Overall O O
, O O
the O O
altered O O
cardiac O O
contractility O O
and O O
excitability O O
characteristics O O
, O O
the O O
myocardial O O
metabolic B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
disturbances I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
the O O
hypersensitivity B B_DISEASE
of O O
the O O
cardiovascular O O
system O O
to O O
sodium O O
pentobarbital O O
suggest O O
the O O
existence O O
of O O
a O O
heretofore O O
undescribed O O
cardiomyopathic B B_DISEASE_ADJECTIVE[DISEASE]
disorder I I_DISEASE_ADJECTIVE[DISEASE]
induced O O
by O O
chronic O O
barium O O
exposure O O
. O O

These O O
experimental O O
findings O O
represent O O
the O O
first O O
indication O O
that O O
life O O
- O O
long O O
barium O O
ingestion O O
may O O
have O O
significant O O
adverse O O
effects O O
on O O
the O O
mammalian O O
cardiovascular O O
system O O
. O O

Propranolol O O
antagonism O O
of O O
phenylpropanolamine O O
- O O
induced O O
hypertension B B_DISEASE
. O O

Phenylpropanolamine O O
( O O
PPA O O
) O O
overdose B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
can O O
cause O O
severe O O
hypertension B B_DISEASE
, O O
intracerebral B B_DISEASE
hemorrhage I I_DISEASE
, O O
and O O
death O O
. O O

We O O
studied O O
the O O
efficacy O O
and O O
safety O O
of O O
propranolol O O
in O O
the O O
treatment O O
of O O
PPA O O
- O O
induced O O
hypertension B B_DISEASE
. O O

Left O O
ventricular O O
function O O
( O O
assessed O O
by O O
echocardiography O O
) O O
showed O O
that O O
PPA O O
increased O O
the O O
stroke B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
volume O O
30 O O
% O O
( O O
from O O
62 O O
. O O
5 O O
+ O O
/ O O
- O O
20 O O
. O O
9 O O
to O O
80 O O
. O O
8 O O
+ O O
/ O O
- O O
22 O O
. O O
4 O O
ml O O
) O O
, O O
the O O
ejection O O
fraction O O
9 O O
% O O
( O O
from O O
64 O O
% O O
+ O O
/ O O
- O O
10 O O
% O O
to O O
70 O O
% O O
+ O O
/ O O
- O O
7 O O
% O O
) O O
, O O
and O O
cardiac O O
output O O
14 O O
% O O
( O O
from O O
3 O O
. O O
6 O O
+ O O
/ O O
- O O
0 O O
. O O
6 O O
to O O
4 O O
. O O
1 O O
+ O O
/ O O
- O O
1 O O
. O O
0 O O
L O O
/ O O
min O O
) O O
. O O

Intravenous O O
propranolol O O
reversed O O
these O O
effects O O
. O O

That O O
propranolol O O
antagonizes O O
the O O
pressor O O
effect O O
of O O
PPA O O
is O O
in O O
contrast O O
to O O
the O O
interaction O O
in O O
which O O
propranolol O O
enhances O O
the O O
pressor O O
effect O O
of O O
norepinephrine O O
. O O

This O O
is O O
probably O O
because O O
PPA O O
has O O
less O O
beta O O
2 O O
activity O O
than O O
does O O
norepinephrine O O
. O O

Mesangial O O
function O O
and O O
glomerular B B_DISEASE
sclerosis I I_DISEASE
in O O
rats O O
with O O
aminonucleoside O O
nephrosis B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
possible O O
relationship O O
between O O
mesangial B B_DISEASE/B_GENE
dysfunction I I_DISEASE/I_GENE
and O O
development O O
of O O
glomerular B B_DISEASE
sclerosis I I_DISEASE
was O O
studied O O
in O O
the O O
puromycin O O
aminonucleoside O O
( O O
PAN O O
) O O
model O O
. O O

Five O O
male O O
Wistar O O
rats O O
received O O
repeated O O
subcutaneous O O
PAN O O
injections O O
; O O
five O O
controls O O
received O O
saline O O
only O O
. O O

After O O
4 O O
weeks O O
the O O
PAN O O
rats O O
were O O
severely O O
proteinuric B B_DISEASE_ADJECTIVE[DISEASE]
( O O
190 O O
+ O O
/ O O
- O O
80 O O
mg O O
/ O O
24 O O
hr O O
) O O
, O O
and O O
all O O
rats O O
were O O
given O O
colloidal O O
carbon O O
( O O
CC O O
) O O
intravenously O O
. O O

At O O
5 O O
months O O
glomerular B B_DISEASE/B_GENE
sclerosis I I_DISEASE/I_GENE
was O O
found O O
in O O
7 O O
. O O
6 O O
+ O O
/ O O
- O O
3 O O
. O O
4 O O
% O O
of O O
the O O
glomeruli O O
of O O
PAN O O
rats O O
; O O
glomeruli O O
of O O
the O O
controls O O
were O O
normal O O
. O O

Glomeruli O O
of O O
PAN O O
rats O O
contained O O
significantly O O
more O O
CC O O
than O O
glomeruli O O
of O O
controls O O
. O O

Glomeruli O O
with O O
sclerosis B B_DISEASE
contained O O
significantly O O
more O O
CC O O
than O O
non O O
- O O
sclerotic O O
glomeruli O O
in O O
the O O
same O O
kidneys O O
. O O

CC O O
was O O
preferentially O O
localized O O
within O O
the O O
sclerotic O O
areas O O
of O O
the O O
affected O O
glomeruli O O
. O O

Since O O
mesangial O O
CC O O
clearance O O
from O O
the O O
mesangium O O
did O O
not O O
change O O
during O O
chronic O O
PAN O O
treatment O O
, O O
we O O
conclude O O
that O O
this O O
preferential O O
CC O O
localization O O
within O O
the O O
lesions O O
is O O
caused O O
by O O
an O O
increased O O
CC O O
uptake O O
shortly O O
after O O
injection O O
in O O
apparent O O
vulnerable O O
areas O O
where O O
sclerosis B B_DISEASE
will O O
develop O O
subsequently O O
. O O

Similar O O
to O O
the O O
remnant O O
kidney O O
model O O
in O O
PAN O O
nephrosis B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
the O O
development O O
of O O
glomerular B B_DISEASE
sclerosis I I_DISEASE
may O O
be O O
related O O
to O O
" O O
mesangial O O
overloading O O
. O O
" O O

Relationship O O
between O O
nicotine O O
- O O
induced O O
seizures B B_DISEASE
and O O
hippocampal O O
nicotinic O O
receptors O O
. O O

A O O
controversy O O
has O O
existed O O
for O O
several O O
years O O
concerning O O
the O O
physiological O O
relevance O O
of O O
the O O
nicotinic O O
receptor O O
measured O O
by O O
alpha O O
- O O
bungarotoxin O O
binding O O
. O O

Using O O
mice O O
derived O O
from O O
a O O
classical O O
F2 O O
and O O
backcross O O
genetic O O
design O O
, O O
a O O
relationship O O
between O O
nicotine O O
- O O
induced O O
seizures B B_DISEASE
and O O
alpha O O
- O O
bungarotoxin O O
nicotinic O O
receptor O O
concentration O O
was O O
found O O
. O O

Mice O O
sensitive O O
to O O
the O O
convulsant O O
effects O O
of O O
nicotine O O
had O O
greater O O
alpha O O
- O O
bungarotoxin O O
binding O O
in O O
the O O
hippocampus O O
than O O
seizure B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
insensitive O O
mice O O
. O O

The O O
binding O O
sites O O
from O O
seizure B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
sensitive O O
and O O
resistant O O
mice O O
were O O
equally O O
affected O O
by O O
treatment O O
with O O
dithiothreitol O O
, O O
trypsin O O
or O O
heat O O
. O O

Thus O O
it O O
appears O O
that O O
the O O
difference O O
between O O
seizure B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
sensitive O O
and O O
insensitive O O
animals O O
may O O
be O O
due O O
to O O
a O O
difference O O
in O O
hippocampal O O
nicotinic O O
receptor O O
concentration O O
as O O
measured O O
with O O
alpha O O
- O O
bungarotoxin O O
binding O O
. O O

Acetaminophen O O
( O O
APAP O O
) O O
produces O O
proximal O O
tubular B B_DISEASE
necrosis I I_DISEASE
in O O
Fischer O O
344 O O
( O O
F344 O O
) O O
rats O O
. O O

Recently O O
, O O
p O O
- O O
aminophenol O O
( O O
PAP O O
) O O
, O O
a O O
known O O
potent O O
nephrotoxicant O O
, O O
was O O
identified O O
as O O
a O O
metabolite O O
of O O
APAP O O
in O O
F344 O O
rats O O
. O O

The O O
purpose O O
of O O
this O O
study O O
was O O
to O O
determine O O
if O O
PAP O O
formation O O
is O O
a O O
requisite O O
step O O
in O O
APAP O O
- O O
induced O O
nephrotoxicity B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

BNPP O O
( O O
1 O O
to O O
8 O O
mM O O
) O O
reduced O O
APAP O O
deacetylation O O
and O O
covalent O O
binding O O
in O O
F344 O O
renal O O
cortical O O
homogenates O O
in O O
a O O
concentration O O
- O O
dependent O O
manner O O
. O O

Pretreatment O O
of O O
animals O O
with O O
BNPP O O
prior O O
to O O
APAP O O
or O O
PAP O O
administration O O
resulted O O
in O O
marked O O
reduction O O
of O O
APAP O O
( O O
900 O O
mg O O
/ O O
kg O O
) O O
nephrotoxicity B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O O
not O O
PAP O O
nephrotoxicity B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

This O O
result O O
was O O
not O O
due O O
to O O
altered O O
disposition O O
of O O
either O O
APAP O O
or O O
acetylated O O
metabolites O O
in O O
plasma O O
or O O
renal O O
cortical O O
and O O
hepatic O O
tissue O O
. O O

Rather O O
, O O
BNPP O O
pretreatment O O
reduced O O
the O O
fraction O O
of O O
APAP O O
excreted O O
as O O
PAP O O
by O O
64 O O
and O O
75 O O
% O O
after O O
APAP O O
doses O O
of O O
750 O O
and O O
900 O O
mg O O
/ O O
kg O O
. O O

Therefore O O
, O O
the O O
BNPP O O
- O O
induced O O
reduction O O
in O O
APAP O O
- O O
induced O O
nephrotoxicity B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appears O O
to O O
be O O
due O O
to O O
inhibition O O
of O O
APAP O O
deacetylation O O
. O O

It O O
is O O
concluded O O
that O O
PAP O O
formation O O
, O O
in O O
vivo O O
, O O
accounts O O
, O O
at O O
least O O
in O O
part O O
, O O
for O O
APAP O O
- O O
induced O O
renal B B_DISEASE
tubular I I_DISEASE
necrosis I I_DISEASE
. O O

Morphine O O
- O O
induced O O
seizures B B_DISEASE
in O O
newborn O O
infants O O
. O O

Two O O
neonates O O
suffered O O
from O O
generalized O O
seizures B B_DISEASE
during O O
the O O
course O O
of O O
intravenous O O
morphine O O
sulfate O O
for O O
post O O
- O O
operative O O
analgesia O O
. O O

They O O
received O O
morphine O O
in O O
doses O O
of O O
32 O O
micrograms O O
/ O O
kg O O
/ O O
hr O O
and O O
40 O O
micrograms O O
/ O O
kg O O
/ O O
hr O O
larger O O
than O O
a O O
group O O
of O O
10 O O
neonates O O
who O O
received O O
6 O O
- O O
24 O O
micrograms O O
/ O O
kg O O
/ O O
hr O O
and O O
had O O
no O O
seizures B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Plasma O O
concentrations O O
of O O
morphine O O
in O O
these O O
neonates O O
was O O
excessive O O
( O O
60 O O
and O O
90 O O
mg O O
/ O O
ml O O
) O O
. O O

Other O O
known O O
reasons O O
for O O
seizures B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
ruled O O
out O O
and O O
the O O
convulsions B B_DISEASE
stopped O O
a O O
few O O
hours O O
after O O
cessation O O
of O O
morphine O O
and O O
did O O
not O O
reoccur O O
in O O
the O O
subsequent O O
8 O O
months O O
. O O

Indomethacin O O
induced O O
hypotension B B_DISEASE
in O O
sodium O O
and O O
volume O O
depleted O O
rats O O
. O O

After O O
a O O
single O O
oral O O
dose O O
of O O
4 O O
mg O O
/ O O
kg O O
indomethacin O O
( O O
IDM O O
) O O
to O O
sodium O O
and O O
volume O O
depleted O O
rats O O
plasma O O
renin O O
activity O O
( O O
PRA O O
) O O
and O O
systolic O O
blood O O
pressure O O
fell O O
significantly O O
within O O
four O O
hours O O
. O O

Thus O O
, O O
indomethacin O O
by O O
inhibition O O
of O O
prostaglandin O O
synthesis O O
may O O
diminish O O
the O O
blood O O
pressure O O
maintaining O O
effect O O
of O O
the O O
stimulated O O
renin O O
- O O
angiotensin O O
system O O
in O O
sodium O O
and O O
volume O O
depletion O O
. O O

On O O
the O O
antiarrhythmic O O
activity O O
of O O
one O O
N O O
- O O
substituted O O
piperazine O O
derivative O O
of O O
trans O O
- O O
2 O O
- O O
amino O O
- O O
3 O O
- O O
hydroxy O O
- O O
1 O O
, O O
2 O O
, O O
3 O O
, O O
4 O O
- O O
tetrahydroanaphthalene O O
. O O

The O O
antiarrhythmic O O
activity O O
of O O
the O O
compound O O
N O O
- O O
( O O
trans O O
- O O
3 O O
- O O
hydroxy O O
- O O
1 O O
, O O
2 O O
, O O
3 O O
, O O
4 O O
- O O
tetrahydro O O
- O O
2 O O
- O O
naphthyl O O
) O O
- O O
N O O
- O O
( O O
3 O O
- O O
oxo O O
- O O
3 O O
- O O
phenyl O O
- O O
2 O O
- O O
methylpropyl O O
) O O
- O O
piperazine O O
hydrochloride O O
, O O
referred O O
to O O
as O O
P11 O O
, O O
is O O
studied O O
on O O
anaesthesized O O
cats O O
and O O
Wistar O O
albino O O
rats O O
, O O
as O O
well O O
as O O
on O O
non O O
- O O
anaesthesized O O
rabbits O O
. O O

Four O O
types O O
of O O
experimental O O
arrhythmia B B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O O
used O O
- O O
- O O
with O O
BaCl2 O O
, O O
with O O
chloroform O O
- O O
adrenaline O O
, O O
with O O
strophantine O O
G O O
and O O
with O O
aconitine O O
. O O

The O O
compound O O
P11 O O
is O O
introduced O O
in O O
doses O O
of O O
0 O O
. O O
25 O O
and O O
0 O O
. O O
50 O O
mg O O
/ O O
kg O O
intravenously O O
and O O
10 O O
mg O O
/ O O
kg O O
orally O O
. O O

The O O
compound O O
manifests O O
antiarrhythmic O O
activity O O
in O O
all O O
models O O
of O O
experimental O O
arrhythmia B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
used O O
, O O
causing O O
greatest O O
inhibition O O
on O O
the O O
arrhythmia B B_DISEASE
induced O O
by O O
chloroform O O
- O O
adrenaline O O
( O O
in O O
90 O O
per O O
cent O O
) O O
and O O
with O O
BaCl2 O O
( O O
in O O
84 O O
per O O
cent O O
) O O
. O O

The O O
results O O
obtained O O
are O O
associated O O
with O O
the O O
beta O O
- O O
adrenoblocking O O
and O O
with O O
the O O
membrane O O
- O O
stabilizing O O
action O O
of O O
the O O
compound O O
. O O

Recurrent O O
subarachnoid B B_DISEASE
hemorrhage I I_DISEASE
associated O O
with O O
aminocaproic O O
acid O O
therapy O O
and O O
acute B B_DISEASE
renal I I_DISEASE
artery I I_DISEASE
thrombosis I I_DISEASE
. O O

Case O O
report O O
. O O

Epsilon O O
aminocaproic O O
acid O O
( O O
EACA O O
) O O
has O O
been O O
used O O
to O O
prevent O O
rebleeding O O
in O O
patients O O
with O O
subarachnoid B B_DISEASE
hemorrhage I I_DISEASE
( O O
SAH B B_DISEASE
) O O
. O O

Although O O
this O O
agent O O
does O O
decrease O O
the O O
frequency O O
of O O
rebleeding O O
, O O
several O O
reports O O
have O O
described O O
thrombotic B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
complications O O
of O O
EACA O O
therapy O O
. O O

These O O
complications O O
have O O
included O O
clinical O O
deterioration O O
and O O
intracranial B B_DISEASE
vascular I I_DISEASE
thrombosis I I_DISEASE
in O O
patients O O
with O O
SAH B B_DISEASE
, O O
arteriolar O O
and O O
capillary O O
fibrin O O
thrombi B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
patients O O
with O O
fibrinolytic O O
syndromes O O
treated O O
with O O
EACA O O
, O O
or O O
other O O
thromboembolic B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
phenomena I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Since O O
intravascular O O
fibrin O O
thrombi B B_DISEASE
are O O
often O O
observed O O
in O O
patients O O
with O O
fibrinolytic O O
disorders O O
, O O
EACA O O
should O O
not O O
be O O
implicated O O
in O O
the O O
pathogenesis O O
of O O
fibrin O O
thrombi B B_DISEASE
in O O
patients O O
with O O
disseminated B B_DISEASE
intravascular I I_DISEASE
coagulation I I_DISEASE
or O O
other O O
" O O
consumption B B_DISEASE
coagulopathies I I_DISEASE
. O O
" O O
This O O
report O O
describes O O
subtotal O O
infarction B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
kidney O O
due O O
to O O
thrombosis B B_DISEASE
of I I_DISEASE
a I I_DISEASE
normal I I_DISEASE
renal I I_DISEASE
artery I I_DISEASE
. O O

This O O
occlusion O O
occurred O O
after O O
EACA O O
therapy O O
in O O
a O O
patient O O
with O O
SAH B B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
histopathological O O
documentation O O
of O O
recurrent O O
SAH B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
corresponding O O
clinical O O
event O O
was O O
characterized O O
by O O
marked O O
hypertension B B_DISEASE
and O O
abrupt O O
neurological O O
deterioration O O
. O O

Effect O O
of O O
vincristine O O
sulfate O O
on O O
Pseudomonas B B_DISEASE
infections I I_DISEASE
in O O
monkeys O O
. O O

Leukocytosis B B_DISEASE_ADJECTIVE[DISEASE]
was O O
observed O O
in O O
all O O
monkeys O O
. O O

Intravenous O O
or O O
intratracheal O O
inoculation O O
of O O
2 O O
. O O
0 O O
to O O
2 O O
. O O
5 O O
mg O O
of O O
vincristine O O
sulfate O O
was O O
followed O O
by O O
leukopenia B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
4 O O
to O O
5 O O
days O O
. O O

Intravenous O O
inoculation O O
of O O
4 O O
. O O
2 O O
x O O
10 O O
( O O
10 O O
) O O
to O O
7 O O
. O O
8 O O
x O O
10 O O
( O O
10 O O
) O O
pyocin O O
type O O
6 O O
Pseudomonas O O
organisms O O
in O O
monkeys O O
given O O
vincristine O O
sulfate O O
4 O O
days O O
previously O O
resulted O O
in O O
fatal O O
infection B B_DISEASE
in O O
11 O O
of O O
14 O O
monkeys O O
, O O
whereas O O
none O O
of O O
four O O
receiving O O
Pseudomonas O O
alone O O
died O O
. O O

These O O
studies O O
suggest O O
that O O
an O O
antimetabolite O O
- O O
induced O O
leukopenia B B_DISEASE
predisposes O O
to O O
severe O O
Pseudomonas O O
sepsis B B_DISEASE
and O O
that O O
such O O
monkeys O O
may O O
serve O O
as O O
a O O
biological O O
model O O
for O O
study O O
of O O
comparative O O
efficacy O O
of O O
antimicrobial O O
agents O O
. O O

Modification O O
by O O
propranolol O O
of O O
cardiovascular O O
effects O O
of O O
induced O O
hypoglycaemia B B_DISEASE
. O O

The O O
cardiovascular O O
effects O O
of O O
hypoglycaemia B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O O
with O O
and O O
without O O
beta O O
- O O
blockade O O
, O O
were O O
compared O O
in O O
fourteen O O
healthy O O
men O O
. O O

Eight O O
received O O
insulin O O
alone O O
, O O
and O O
eight O O
, O O
including O O
two O O
of O O
the O O
original O O
insulin O O
- O O
only O O
group O O
, O O
were O O
given O O
propranolol O O
and O O
insulin O O
. O O

In O O
the O O
insulin O O
- O O
group O O
the O O
period O O
of O O
hypoglycaemia B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
associated O O
with O O
an O O
increase O O
in O O
heart O O
- O O
rate O O
and O O
a O O
fall O O
in O O
diastolic O O
blood O O
- O O
pressure O O
. O O

Typical O O
S O O
- O O
T O O
/ O O
T O O
changes O O
occurred O O
in O O
the O O
insulin O O
- O O
group O O
but O O
in O O
none O O
of O O
the O O
propranolol O O
- O O
insulin O O
group O O
. O O

Long O O
- O O
term O O
propranolol O O
therapy O O
in O O
pregnancy O O
: O O
maternal O O
and O O
fetal O O
outcome O O
. O O

Propranolol O O
, O O
a O O
beta O O
- O O
adrenergic O O
blocking O O
agent O O
, O O
has O O
found O O
an O O
important O O
position O O
in O O
the O O
practice O O
of O O
medicine O O
. O O

Its O O
use O O
in O O
pregnancy O O
, O O
however O O
, O O
is O O
an O O
open O O
question O O
as O O
a O O
number O O
of O O
detrimental O O
side O O
effects O O
have O O
been O O
reported O O
in O O
the O O
fetus O O
and O O
neonate O O
. O O

Ten O O
patients O O
and O O
12 O O
pregnancies O O
are O O
reported O O
where O O
chronic O O
propranolol O O
has O O
been O O
administered O O
. O O

Maternal O O
, O O
fetal O O
, O O
and O O
neonatal O O
complications O O
are O O
examined O O
. O O

We O O
conclude O O
that O O
previously O O
reported O O
hypoglycemia B B_DISEASE
, O O
hyperbilirubinemia B B_DISEASE
, O O
polycythemia B B_DISEASE
, O O
neonatal B B_DISEASE
apnea I I_DISEASE
, O O
and O O
bradycardia B B_DISEASE
are O O
not O O
invariable O O
and O O
cannot O O
be O O
statistically O O
correlated O O
with O O
chronic O O
propranolol O O
therapy O O
. O O

Growth B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
retardation I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O O
however O O
, O O
appears O O
to O O
be O O
significant O O
in O O
both O O
of O O
our O O
series O O
. O O

Central O O
excitatory O O
actions O O
of O O
flurazepam O O
. O O

Toxic O O
actions O O
of O O
flurazepam O O
( O O
FZP O O
) O O
were O O
studied O O
in O O
cats O O
, O O
mice O O
and O O
rats O O
. O O

High O O
doses O O
caused O O
an O O
apparent O O
central O O
excitation O O
, O O
most O O
clearly O O
seen O O
as O O
clonic O O
convulsions B B_DISEASE
, O O
superimposed O O
on O O
general O O
depression B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Following O O
a O O
lethal O O
dose O O
, O O
death O O
was O O
always O O
associated O O
with O O
convulsions B B_DISEASE
. O O

Comparing O O
the O O
relative O O
sensitivity O O
to O O
central O O
depression B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O O
excitation O O
revealed O O
that O O
rats O O
were O O
least O O
likely O O
to O O
have O O
convulsions B B_DISEASE
at O O
doses O O
that O O
did O O
not O O
first O O
cause O O
loss B B_DISEASE
of I I_DISEASE
consciousness I I_DISEASE
, O O
while O O
cats O O
most O O
clearly O O
showed O O
marked O O
central O O
excitatory O O
actions O O
. O O

Signs O O
of O O
FZP O O
toxocity B B_DISEASE
in O O
cats O O
included O O
excessive O O
salivation B B_DISEASE/B_ORGANISM_FUNCTION
, O O
extreme O O
apprehensive O O
behavior O O
, O O
retching O O
, O O
muscle B B_DISEASE
tremors I I_DISEASE
and O O
convulsions B B_DISEASE
. O O

As O O
a O O
function O O
of O O
dose O O
, O O
FZP O O
first O O
protected O O
against O O
convulsions B B_DISEASE
and O O
death O O
. O O

At O O
higher O O
doses O O
, O O
however O O
, O O
convulsions B B_DISEASE
again O O
emerged O O
. O O

These O O
doses O O
of O O
FZP O O
were O O
lower O O
than O O
those O O
that O O
would O O
alone O O
cause O O
convulsions B B_DISEASE
. O O

These O O
results O O
may O O
be O O
relevant O O
to O O
the O O
use O O
of O O
FZP O O
in O O
clinical O O
situations O O
in O O
which O O
there O O
is O O
increased O O
neural O O
excitability O O
, O O
such O O
as O O
epilepsy B B_DISEASE
or O O
sedative O O
- O O
hypnotic O O
drug O O
withdrawal O O
. O O

Use O O
of O O
propranolol O O
in O O
the O O
treatment O O
of O O
idiopathic B B_DISEASE
orthostatic I I_DISEASE
hypotension I I_DISEASE
. O O

Five O O
patients O O
with O O
idiopathic B B_DISEASE/B_GENE
orthostatic I I_DISEASE/I_GENE
hypotension I I_DISEASE/I_GENE
who O O
had O O
physiologic O O
and O O
biochemical O O
evidence O O
of O O
severe O O
autonomic O O
dysfunction O O
were O O
included O O
in O O
the O O
study O O
. O O

They O O
all O O
exhibited O O
markedly O O
reduced O O
plasma O O
catecholamines O O
and O O
plasma O O
renin O O
activity O O
in O O
both O O
recumbent O O
and O O
upright O O
positions O O
and O O
had O O
marked O O
hypersensitivity B B_DISEASE
to O O
the O O
pressor O O
effects O O
of O O
infused O O
norepinephrine O O
. O O

In O O
1 O O
patient O O
, O O
marked O O
hypertension B B_DISEASE
was O O
induced O O
by O O
propranolol O O
and O O
the O O
drug O O
had O O
to O O
be O O
withdrawn O O
. O O

It O O
otherwise O O
was O O
well O O
tolerated O O
and O O
no O O
important O O
side O O
effects O O
were O O
observed O O
. O O

Treatment O O
has O O
been O O
continued O O
in O O
3 O O
individuals O O
for O O
6 O O
- O O
13 O O
months O O
with O O
persistence O O
of O O
the O O
pressor O O
effect O O
, O O
although O O
there O O
appears O O
to O O
have O O
been O O
some O O
decrease O O
in O O
the O O
degree O O
of O O
response O O
with O O
time O O
. O O

The O O
studies O O
suggest O O
that O O
propranolol O O
is O O
a O O
useful O O
drug O O
in O O
selected O O
patients O O
with O O
severe O O
idiopathic B B_DISEASE
orthostatic I I_DISEASE
hypotension I I_DISEASE
. O O

Total O O
intravenous O O
anesthesia O O
with O O
etomidate O O
. O O

III O O
. O O

Some O O
observations O O
in O O
adults O O
. O O

The O O
investigation O O
was O O
discontinued O O
after O O
18 O O
patients O O
because O O
of O O
the O O
frequency O O
and O O
intensity O O
of O O
side O O
- O O
effects O O
, O O
particularly O O
pain B B_DISEASE
and O O
myoclonia B B_DISEASE
, O O
which O O
caused O O
the O O
technique O O
to O O
be O O
abandoned O O
in O O
two O O
cases O O
. O O

It O O
is O O
considered O O
unlikely O O
that O O
etomidate O O
will O O
prove O O
to O O
be O O
the O O
hypnotic O O
of O O
choice O O
for O O
a O O
totally O O
intravenous O O
anesthetic O O
technique O O
in O O
adults O O
because O O
of O O
the O O
high O O
incidence O O
of O O
myoclonia B B_DISEASE
after O O
prolonged O O
administration O O
. O O

Evidence O O
for O O
cardiac O O
beta O O
2 O O
- O O
adrenoceptors O O
in O O
man O O
. O O

We O O
compared O O
the O O
effects O O
of O O
single O O
doses O O
of O O
50 O O
mg O O
atenolol O O
( O O
cardioselective O O
) O O
, O O
40 O O
mg O O
propranolol O O
( O O
nonselective O O
) O O
, O O
and O O
placebo O O
on O O
both O O
exercise O O
- O O
and O O
isoproterenol O O
- O O
induced O O
tachycardia B B_DISEASE
in O O
two O O
experiments O O
involving O O
nine O O
normal O O
subjects O O
. O O

Maximal O O
exercise O O
heart O O
rate O O
was O O
reduced O O
from O O
187 O O
+ O O
/ O O
- O O
4 O O
( O O
SEM O O
) O O
after O O
placebo O O
to O O
146 O O
+ O O
/ O O
- O O
7 O O
bpm O O
after O O
atenolol O O
and O O
138 O O
+ O O
/ O O
- O O
6 O O
bpm O O
after O O
propranolol O O
, O O
but O O
there O O
were O O
no O O
differences O O
between O O
the O O
drugs O O
. O O

The O O
effects O O
on O O
isoproterenol O O
tachycardia B B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O O
determined O O
before O O
and O O
after O O
atropine O O
( O O
0 O O
. O O
04 O O
mg O O
/ O O
kg O O
IV O O
) O O
. O O

Isoproterenol O O
sensitivity O O
was O O
determined O O
as O O
the O O
intravenous O O
dose O O
that O O
increased O O
heart O O
rate O O
by O O
25 O O
bpm O O
( O O
CD25 O O
) O O
and O O
this O O
was O O
increased O O
from O O
1 O O
. O O
8 O O
+ O O
/ O O
- O O
0 O O
. O O
3 O O
micrograms O O
after O O
placebo O O
to O O
38 O O
. O O
9 O O
+ O O
/ O O
- O O
8 O O
. O O
3 O O
micrograms O O
after O O
propranolol O O
and O O
8 O O
. O O
3 O O
+ O O
/ O O
- O O
1 O O
. O O
7 O O
micrograms O O
after O O
atenolol O O
. O O

The O O
difference O O
in O O
the O O
effects O O
of O O
the O O
two O O
was O O
significant O O
. O O

After O O
atropine O O
the O O
CD25 O O
was O O
unchanged O O
after O O
placebo O O
( O O
2 O O
. O O
3 O O
+ O O
/ O O
- O O
0 O O
. O O
3 O O
micrograms O O
) O O
and O O
atenolol O O
( O O
7 O O
. O O
7 O O
+ O O
/ O O
- O O
1 O O
. O O
3 O O
micrograms O O
) O O
; O O
it O O
was O O
reduced O O
after O O
propranolol O O
( O O
24 O O
. O O
8 O O
+ O O
/ O O
- O O
5 O O
. O O
0 O O
micrograms O O
) O O
, O O
but O O
remained O O
different O O
from O O
atenolol O O
. O O

This O O
change O O
with O O
propranolol O O
sensitivity O O
was O O
calculated O O
as O O
the O O
apparent O O
Ka O O
, O O
this O O
was O O
unchanged O O
by O O
atropine O O
( O O
11 O O
. O O
7 O O
+ O O
/ O O
- O O
2 O O
. O O
1 O O
and O O
10 O O
. O O
1 O O
+ O O
/ O O
- O O
2 O O
. O O
5 O O
ml O O
/ O O
ng O O
) O O
. O O

These O O
data O O
are O O
consistent O O
with O O
the O O
hypothesis O O
that O O
exercise O O
- O O
induced O O
tachycardia B B_DISEASE
results O O
largely O O
from O O
beta O O
1 O O
- O O
receptor O O
activation O O
that O O
is O O
blocked O O
by O O
both O O
cardioselective O O
and O O
nonselective O O
drugs O O
, O O
whereas O O
isoproterenol O O
activates O O
both O O
beta O O
1 O O
- O O
and O O
beta O O
2 O O
- O O
receptors O O
so O O
that O O
after O O
cardioselective O O
blockade O O
there O O
remains O O
a O O
beta O O
2 O O
- O O
component O O
that O O
can O O
be O O
blocked O O
with O O
a O O
nonselective O O
drug O O
. O O

While O O
there O O
appear O O
to O O
be O O
beta O O
2 O O
- O O
receptors O O
in O O
the O O
human O O
heart O O
, O O
their O O
physiologic O O
or O O
pathologic O O
roles O O
remain O O
to O O
be O O
defined O O
. O O

Hormones O O
and O O
risk O O
of O O
breast B B_DISEASE
cancer I I_DISEASE
. O O

This O O
paper O O
reports O O
the O O
results O O
of O O
a O O
study O O
of O O
50 O O
menopausal O O
women O O
receiving O O
hormonal O O
replacement O O
therapy O O
. O O

The O O
majority O O
( O O
29 O O
) O O
had O O
surgical O O
menopause O O
; O O
their O O
mean O O
age O O
was O O
45 O O
. O O
7 O O
years O O
. O O

It O O
was O O
hypothesized O O
that O O
progestins O O
could O O
equilibrate O O
the O O
effects O O
of O O
the O O
estrogenic O O
stimulation O O
on O O
the O O
mammary O O
and O O
endometrial O O
target O O
tissues O O
of O O
women O O
on O O
hormonal O O
replacement O O
therapy O O
. O O

The O O
treatment O O
schedule O O
consisted O O
of O O
conjugated O O
estrogens O O
( O O
Premarin O O
) O O
1 O O
. O O
25 O O
mg O O
/ O O
day O O
for O O
21 O O
days O O
and O O
Medroxyprogesterone O O
acetate O O
10 O O
mg O O
/ O O
day O O
for O O
10 O O
days O O
in O O
each O O
month O O
. O O

The O O
mean O O
treatment O O
period O O
was O O
18 O O
months O O
. O O

During O O
the O O
follow O O
- O O
up O O
period O O
, O O
attention O O
was O O
paid O O
to O O
breast O O
modifications O O
as O O
evidenced O O
by O O
symptomatology O O
, O O
physical O O
examination O O
, O O
and O O
plate O O
thermography O O
. O O

Mastodynia B B_DISEASE_ADJECTIVE[DISEASE]
was O O
reported O O
by O O
21 O O
patients O O
, O O
and O O
physical O O
examination O O
revealed O O
a O O
light O O
increase O O
in O O
breast O O
firmness O O
in O O
12 O O
women O O
and O O
a O O
moderate O O
increase O O
in O O
breast O O
nodularity O O
in O O
2 O O
women O O
. O O

Themography O O
confirmed O O
the O O
existence O O
of O O
an O O
excessive O O
breast O O
stimulation O O
in O O
1 O O
women O O
who O O
complained O O
of O O
moderate O O
mastodynia B B_DISEASE
and O O
in O O
5 O O
of O O
the O O
7 O O
women O O
who O O
complained O O
of O O
severe O O
mastodynia B B_DISEASE
. O O

Normalization O O
was O O
obtained O O
by O O
halving O O
the O O
estrogen O O
dose O O
. O O

Early O O
infections B B_DISEASE
in O O
kidney O O
, O O
heart O O
, O O
and O O
liver O O
transplant O O
recipients O O
on O O
cyclosporine O O
. O O

Eighty O O
- O O
one O O
renal O O
, O O
seventeen O O
heart O O
, O O
and O O
twenty O O
- O O
four O O
liver O O
transplant O O
patients O O
were O O
followed O O
for O O
infection B B_DISEASE
. O O

Seventeen O O
renal O O
patients O O
received O O
azathioprine O O
( O O
Aza O O
) O O
and O O
prednisone O O
as O O
part O O
of O O
a O O
randomized O O
trial O O
of O O
immunosuppression O O
with O O
21 O O
cyclosporine O O
- O O
and O O
- O O
prednisone O O
- O O
treated O O
renal O O
transplant O O
patients O O
. O O

All O O
others O O
received O O
cyclosporine O O
and O O
prednisone O O
. O O

The O O
randomized O O
Aza O O
patients O O
had O O
more O O
overall O O
infections B B_DISEASE
( O O
P O O
less O O
than O O
0 O O
. O O
05 O O
) O O
and O O
more O O
nonviral O O
infections B B_DISEASE
( O O
P O O
less O O
than O O
0 O O
. O O
02 O O
) O O
than O O
the O O
randomized O O
cyclosporine O O
patients O O
. O O

Heart O O
and O O
liver O O
patients O O
had O O
more O O
infections B B_DISEASE
than O O
cyclosporine O O
renal O O
patients O O
but O O
fewer O O
infections B B_DISEASE
than O O
the O O
Aza O O
renal O O
patients O O
. O O

There O O
were O O
no O O
infectious O O
deaths O O
in O O
renal O O
transplant O O
patients O O
on O O
cyclosporine O O
or O O
Aza O O
, O O
but O O
infection B B_DISEASE
played O O
a O O
major O O
role O O
in O O
3 O O
out O O
of O O
6 O O
cardiac O O
transplant O O
deaths O O
and O O
in O O
8 O O
out O O
of O O
9 O O
liver O O
transplant O O
deaths O O
. O O

Renal O O
patients O O
on O O
cyclosporine O O
had O O
the O O
fewest O O
bacteremias B B_DISEASE_ADJECTIVE[DISEASE]
. O O

Analysis O O
of O O
site O O
of O O
infection B B_DISEASE
showed O O
a O O
preponderance O O
of O O
abdominal B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
infections I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
liver O O
patients O O
, O O
intrathoracic O O
infections B B_DISEASE/B_PERSON
in O O
heart O O
patients O O
, O O
and O O
urinary B B_DISEASE/B_PERSON
tract I I_DISEASE/I_PERSON
infections I I_DISEASE/I_PERSON
in O O
renal O O
patients O O
. O O

Pulmonary O O
infections B B_DISEASE
were O O
less O O
common O O
in O O
cyclosporine O O
- O O
treated O O
renal O O
patients O O
than O O
in O O
Aza O O
- O O
treated O O
patients O O
( O O
P O O
less O O
than O O
0 O O
. O O
05 O O
) O O
. O O

Aza O O
patients O O
had O O
significantly O O
more O O
staphylococcal B B_DISEASE
infections I I_DISEASE
than O O
all O O
other O O
transplant O O
groups O O
( O O
P O O
less O O
than O O
0 O O
. O O
005 O O
) O O
, O O
and O O
systemic O O
fungal B B_DISEASE
infections I I_DISEASE
occurred O O
only O O
in O O
the O O
liver O O
transplant O O
group O O
. O O

Cytomegalovirus O O
( O O
CMV O O
) O O
shedding O O
or O O
serological O O
rises O O
in O O
antibody O O
titer O O
, O O
or O O
both O O
occurred O O
in O O
78 O O
% O O
of O O
cyclosporine O O
patients O O
and O O
76 O O
% O O
of O O
Aza O O
patients O O
. O O

Of O O
the O O
cyclosporine O O
patients O O
, O O
15 O O
% O O
had O O
symptoms O O
related O O
to O O
CMV B B_DISEASE
infection I I_DISEASE
. O O

Serological O O
evidence O O
for O O
Epstein B B_DISEASE
Barr I I_DISEASE
Virus I I_DISEASE
infection I I_DISEASE
was O O
found O O
in O O
20 O O
% O O
of O O
65 O O
cyclosporine O O
patients O O
studied O O
. O O

Three O O
had O O
associated O O
symptoms O O
, O O
and O O
one O O
developed O O
a O O
lymphoma B B_DISEASE
. O O

Structure O O
- O O
activity O O
and O O
dose O O
- O O
effect O O
relationships O O
of O O
the O O
antagonism O O
of O O
picrotoxin O O
- O O
induced O O
seizures B B_DISEASE
by O O
cholecystokinin O O
, O O
fragments O O
and O O
analogues O O
of O O
cholecystokinin O O
in O O
mice O O
. O O

Intraperitoneal O O
administration O O
of O O
cholecystokinin O O
octapeptide O O
sulphate O O
ester O O
( O O
CCK O O
- O O
8 O O
- O O
SE O O
) O O
and O O
nonsulphated O O
cholecystokinin O O
octapeptide O O
( O O
CCK O O
- O O
8 O O
- O O
NS O O
) O O
enhanced O O
the O O
latency O O
of O O
seizures B B_DISEASE
induced O O
by O O
picrotoxin O O
in O O
mice O O
. O O

Experiments O O
with O O
N O O
- O O
and O O
C O O
- O O
terminal O O
fragments O O
revealed O O
that O O
the O O
C O O
- O O
terminal O O
tetrapeptide O O
( O O
CCK O O
- O O
5 O O
- O O
8 O O
) O O
was O O
the O O
active O O
centre O O
of O O
the O O
CCK O O
octapeptide O O
molecule O O
. O O

The O O
peptide O O
CCK O O
- O O
5 O O
- O O
8 O O
had O O
weak O O
anticonvulsant O O
activity O O
in O O
comparison O O
to O O
the O O
octapeptides O O
, O O
3 O O
. O O
2 O O
mumol O O
/ O O
kg O O
and O O
larger O O
doses O O
of O O
the O O
reference O O
drug O O
, O O
diazepam O O
, O O
totally O O
prevented O O
picrotoxin O O
- O O
induced O O
seizures B B_DISEASE
and O O
mortality O O
. O O

The O O
maximum O O
effect O O
of O O
the O O
peptides O O
tested O O
was O O
less O O
than O O
that O O
of O O
diazepam O O
. O O

Of O O
the O O
CCK O O
- O O
2 O O
- O O
8 O O
analogues O O
, O O
Ser O O
( O O
SO3H O O
) O O
7 O O
- O O
Ac O O
- O O
CCK O O
- O O
2 O O
- O O
8 O O
- O O
SE O O
and O O
Thr O O
( O O
SO3H O O
) O O
7 O O
- O O
Ac O O
- O O
CCK O O
- O O
2 O O
- O O
8 O O
- O O
SE O O
and O O
Hyp O O
( O O
SO3H O O
) O O
- O O
Ac O O
- O O
CCK O O
- O O
2 O O
- O O
8 O O
- O O
SE O O
were O O
slightly O O
more O O
active O O
than O O
CCK O O
- O O
8 O O
- O O
SE O O
. O O

Vasopressin O O
as O O
a O O
possible O O
contributor O O
to O O
hypertension B B_DISEASE
. O O

The O O
role O O
of O O
vasopressin O O
as O O
a O O
pressor O O
agent O O
to O O
the O O
hypertensive B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
process O O
was O O
examined O O
. O O

Vasopressin O O
plays O O
a O O
major O O
role O O
in O O
the O O
pathogenesis O O
of O O
DOCA O O
- O O
salt O O
hypertension B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
since O O
the O O
elevation O O
of O O
blood O O
pressure O O
was O O
not O O
substantial O O
in O O
the O O
rats O O
with O O
lithium O O
- O O
treated O O
diabetes B B_DISEASE
insipidus I I_DISEASE
after O O
DOCA O O
- O O
salt O O
treatment O O
. O O

Furthermore O O
, O O
the O O
pressor O O
action O O
of O O
vasopressin O O
appears O O
to O O
be O O
important O O
in O O
the O O
development O O
of O O
this O O
model O O
of O O
hypertension B B_DISEASE
, O O
since O O
the O O
enhanced O O
pressor O O
responsiveness O O
to O O
the O O
hormone O O
was O O
observed O O
in O O
the O O
initial O O
stage O O
of O O
hypertension B B_DISEASE/B_ORGANISM_FUNCTION
. O O

Increased O O
secretion O O
of O O
vasopressin O O
from O O
neurohypophysis O O
also O O
promotes O O
the O O
function O O
of O O
the O O
hormone O O
as O O
a O O
pathogenetic O O
factor O O
in O O
hypertension B B_DISEASE
. O O

An O O
unproportional O O
release O O
of O O
vasopressin O O
compared O O
to O O
plasma O O
osmolality O O
may O O
be O O
induced O O
by O O
the O O
absence O O
of O O
an O O
adjusting O O
control O O
of O O
angiotensin O O
II O O
forming O O
and O O
receptor O O
binding O O
capacity O O
for O O
sodium O O
balance O O
in O O
the O O
brain O O
. O O

However O O
, O O
the O O
role O O
of O O
vasopressin O O
remains O O
to O O
be O O
determined O O
in O O
human O O
essential O O
hypertension B B_DISEASE
. O O

Toxic B B_DISEASE_ADJECTIVE[DISEASE]
hepatitis I I_DISEASE_ADJECTIVE[DISEASE]
induced O O
by O O
disulfiram O O
in O O
a O O
non O O
- O O
alcoholic O O
. O O

A O O
reversible O O
toxic B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
liver I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
damage I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
observed O O
in O O
a O O
non O O
- O O
alcoholic O O
woman O O
treated O O
with O O
disulfiram O O
. O O

The O O
causative O O
relationship O O
was O O
proven O O
by O O
challenge O O
. O O

Atrial B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
thrombosis I I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
involving O O
the O O
heart O O
of O O
F O O
- O O
344 O O
rats O O
ingesting O O
quinacrine O O
hydrochloride O O
. O O

Quinacrine O O
hydrochloride O O
is O O
toxic O O
for O O
the O O
heart O O
of O O
F O O
- O O
344 O O
rats O O
. O O

Rats O O
treated O O
with O O
500 O O
ppm O O
quinacrine O O
hydrochloride O O
in O O
the O O
diet O O
all O O
developed O O
a O O
high O O
incidence O O
of O O
left O O
atrial B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
thrombosis I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
lesion O O
was O O
associated O O
with O O
cardiac B B_DISEASE
hypertrophy I I_DISEASE
and O O
dilatation O O
and O O
focal O O
myocardial B B_DISEASE
degeneration I I_DISEASE
. O O

Rats O O
died O O
from O O
cardiac B B_DISEASE
hypertrophy I I_DISEASE
with O O
severe O O
acute O O
and O O
chronic O O
congestion O O
of O O
the O O
lungs O O
, O O
liver O O
, O O
and O O
other O O
organs O O
. O O

Seventy O O
percent O O
of O O
rats O O
given O O
250 O O
ppm O O
quinacrine O O
hydrochloride O O
and O O
1 O O
, O O
000 O O
ppm O O
sodium O O
nitrite O O
simultaneously O O
in O O
the O O
diet O O
had O O
thrombosis B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
atria O O
of O O
the O O
heart O O
, O O
while O O
untreated O O
control O O
rats O O
in O O
this O O
laboratory O O
did O O
not O O
have O O
atrial B B_DISEASE/B_PERSON
thrombosis I I_DISEASE/I_PERSON
. O O

Sodium O O
nitrite O O
in O O
combination O O
with O O
quinacrine O O
hydrochloride O O
appeared O O
to O O
have O O
no O O
additional O O
effect O O
. O O

Alternating B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sinus I I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rhythm I I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
intermittent O O
sinoatrial B B_DISEASE
block I I_DISEASE
induced O O
by O O
propranolol O O
. O O

Alternating B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
sinus I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
rhythm I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
intermittent O O
sinoatrial B B_DISEASE
( I I_DISEASE
S I I_DISEASE
- I I_DISEASE
A I I_DISEASE
) I I_DISEASE
block I I_DISEASE
was O O
observed O O
in O O
a O O
57 O O
- O O
year O O
- O O
old O O
woman O O
, O O
under O O
treatment O O
for O O
angina B B_DISEASE
with O O
80 O O
mg O O
propranolol O O
daily O O
. O O

Following O O
these O O
basic O O
sinus O O
cycles O O
, O O
alternating B B_DISEASE/B_ORGANISM_FUNCTION
rhythm I I_DISEASE/I_ORGANISM_FUNCTION
started O O
with O O
the O O
longer O O
P O O
- O O
P O O
interval O O
. O O

The O O
long O O
P O O
- O O
P O O
intervals O O
ranged O O
between O O
1 O O
. O O
04 O O
- O O
1 O O
. O O
12 O O
s O O
and O O
the O O
short O O
P O O
- O O
P O O
intervals O O
between O O
0 O O
. O O
80 O O
- O O
0 O O
. O O
84 O O
s O O
, O O
respectively O O
. O O

There O O
were O O
small O O
changes O O
in O O
the O O
shape O O
of O O
the O O
P O O
waves O O
and O O
P O O
- O O
R O O
intervals O O
. O O

The O O
abnormal O O
rhythm O O
disappeared O O
with O O
the O O
withdrawal O O
of O O
propranolol O O
and O O
when O O
the O O
drug O O
was O O
restarted O O
a O O
2 O O
/ O O
1 O O
S B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
block I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
seen O O
. O O

This O O
was O O
accepted O O
as O O
evidence O O
for O O
propranolol O O
being O O
the O O
cause O O
of O O
this O O
conduction B B_DISEASE
disorder I I_DISEASE
. O O

Antitumor O O
effect O O
, O O
cardiotoxicity B B_DISEASE
, O O
and O O
nephrotoxicity B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
doxorubicin O O
in O O
the O O
IgM O O
solid O O
immunocytoma B B_DISEASE
- O O
bearing O O
LOU O O
/ O O
M O O
/ O O
WSL O O
rat O O
. O O

Antitumor O O
activity O O
, O O
cardiotoxicity B B_DISEASE
, O O
and O O
nephrotoxicity B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
by O O
doxorubicin O O
were O O
studied O O
in O O
LOU O O
/ O O
M O O
/ O O
WSL O O
inbred O O
rats O O
each O O
bearing O O
a O O
transplantable O O
solid O O
IgM O O
immunocytoma B B_DISEASE
. O O

Animals O O
with O O
a O O
tumor B B_DISEASE
( O O
diameter O O
, O O
15 O O
. O O
8 O O
+ O O
/ O O
- O O
3 O O
. O O
3 O O
mm O O
) O O
were O O
treated O O
with O O
iv O O
injections O O
of O O
doxorubicin O O
on O O
5 O O
consecutive O O
days O O
, O O
followed O O
by O O
1 O O
weekly O O
injection O O
for O O
7 O O
weeks O O
( O O
dose O O
range O O
, O O
0 O O
. O O
015 O O
- O O
4 O O
. O O
0 O O
mg O O
/ O O
kg O O
body O O
wt O O
) O O
. O O

Tumor B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
regression O O
was O O
observed O O
with O O
0 O O
. O O
5 O O
mg O O
doxorubicin O O
/ O O
kg O O
. O O

Complete O O
disappearance O O
of O O
the O O
tumor B B_DISEASE
was O O
induced O O
with O O
1 O O
. O O
0 O O
mg O O
doxorubicin O O
/ O O
kg O O
. O O

Histologic O O
evidence O O
of O O
cardiotoxicity B B_DISEASE
scored O O
as O O
grade O O
III O O
was O O
only O O
observed O O
at O O
a O O
dose O O
of O O
1 O O
. O O
0 O O
mg O O
doxorubicin O O
/ O O
kg O O
. O O

Light O O
microscopic O O
evidence O O
of O O
renal B B_DISEASE/B_GENE
damage I I_DISEASE/I_GENE
was O O
seen O O
above O O
a O O
dose O O
of O O
0 O O
. O O
5 O O
mg O O
doxorubicin O O
/ O O
kg O O
, O O
which O O
resulted O O
in O O
albuminuria B B_DISEASE
and O O
very O O
low O O
serum O O
albumin O O
levels O O
. O O

In O O
the O O
group O O
that O O
received O O
1 O O
. O O
0 O O
mg O O
doxorubicin O O
/ O O
kg O O
, O O
the O O
serum O O
albumin O O
level O O
decreased O O
from O O
33 O O
. O O
6 O O
+ O O
/ O O
- O O
4 O O
. O O
1 O O
to O O
1 O O
. O O
5 O O
+ O O
/ O O
- O O
0 O O
. O O
5 O O
g O O
/ O O
liter O O
. O O

Ascites B B_DISEASE
and O O
hydrothorax B B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
observed O O
simultaneously O O
. O O

The O O
same O O
experiments O O
were O O
performed O O
with O O
non O O
- O O
tumor B B_DISEASE
- O O
bearing O O
rats O O
, O O
in O O
which O O
no O O
major O O
differences O O
were O O
observed O O
. O O

In O O
conclusion O O
, O O
antitumor O O
activity O O
, O O
cardiotoxicity B B_DISEASE
, O O
and O O
nephrotoxicity B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
studied O O
simultaneously O O
in O O
the O O
same O O
LOU O O
/ O O
M O O
/ O O
WSL O O
rat O O
. O O

Albuminuria B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
due O O
to O O
renal B B_DISEASE
damage I I_DISEASE
led O O
to O O
extremely O O
low O O
serum O O
albumin O O
levels O O
, O O
so O O
ascites B B_DISEASE
and O O
hydrothorax B B_DISEASE
were O O
not O O
necessarily O O
a O O
consequence O O
of O O
the O O
observed O O
cardiomyopathy B B_DISEASE
. O O

Intraoperative O O
bradycardia B B_DISEASE
and O O
hypotension B B_DISEASE
associated O O
with O O
timolol O O
and O O
pilocarpine O O
eye O O
drops O O
. O O

A O O
69 O O
- O O
yr O O
- O O
old O O
man O O
, O O
who O O
was O O
concurrently O O
being O O
treated O O
with O O
pilocarpine O O
nitrate O O
and O O
timolol O O
maleate O O
eye O O
drops O O
, O O
developed O O
a O O
bradycardia B B_DISEASE
and O O
became O O
hypotensive B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
halothane O O
anaesthesia O O
. O O

Both O O
timolol O O
and O O
pilocarpine O O
were O O
subsequently O O
identified O O
in O O
a O O
24 O O
- O O
h O O
collection O O
of O O
urine O O
. O O

Timolol O O
( O O
but O O
not O O
pilocarpine O O
) O O
was O O
detected O O
in O O
a O O
sample O O
of O O
plasma O O
removed O O
during O O
surgery O O
; O O
the O O
plasma O O
concentration O O
of O O
timolol O O
( O O
2 O O
. O O
6 O O
ng O O
ml O O
- O O
1 O O
) O O
was O O
consistent O O
with O O
partial O O
beta O O
- O O
adrenoceptor O O
blockade O O
. O O

It O O
is O O
postulated O O
that O O
this O O
action O O
may O O
have O O
been O O
enhanced O O
during O O
halothane O O
anaesthesia O O
with O O
resultant O O
bradycardia B B_DISEASE
and O O
hypotension B B_DISEASE
. O O

Pilocarpine O O
may O O
have O O
had O O
a O O
contributory O O
effect O O
. O O

Succinylcholine O O
apnoea B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
: O O
attempted O O
reversal O O
with O O
anticholinesterases O O
. O O

Anticholinesterases O O
were O O
administered O O
in O O
an O O
attempt O O
to O O
antagonize O O
prolonged O O
neuromuscular B B_DISEASE
blockade I I_DISEASE
following O O
the O O
administration O O
of O O
succinylcholine O O
in O O
a O O
patient O O
later O O
found O O
to O O
be O O
homozygous O O
for O O
atypical O O
plasma O O
cholinesterase O O
. O O

Edrophonium O O
10 O O
mg O O
, O O
given O O
74 O O
min O O
after O O
succinylcholine O O
, O O
when O O
train O O
- O O
of O O
- O O
four O O
stimulation O O
was O O
characteristic O O
of O O
phase O O
II O O
block O O
, O O
produced O O
partial O O
antagonism O O
which O O
was O O
not O O
sustained O O
. O O

Repeated O O
doses O O
of O O
edrophonium O O
to O O
70 O O
mg O O
and O O
neostigmine O O
to O O
2 O O
. O O
5 O O
mg O O
did O O
not O O
antagonize O O
or O O
augment O O
the O O
block O O
. O O

Spontaneous O O
respiration O O
recommenced O O
200 O O
min O O
after O O
succinylcholine O O
administration O O
. O O

It O O
is O O
concluded O O
that O O
anticholinesterases O O
are O O
only O O
partially O O
effective O O
in O O
restoring O O
neuromuscular O O
function O O
in O O
succinylcholine O O
apnoea B B_DISEASE
despite O O
muscle O O
twitch O O
activity O O
typical O O
of O O
phase O O
II O O
block O O
. O O

Effect O O
of O O
doxorubicin O O
on O O
[ O O
omega O O
- O O
I O O
- O O
131 O O
] O O
heptadecanoic O O
acid O O
myocardial O O
scintigraphy O O
and O O
echocardiography O O
in O O
dogs O O
. O O

The O O
effects O O
of O O
serial O O
treatment O O
with O O
doxorubicin O O
on O O
dynamic O O
myocardial O O
scintigraphy O O
with O O
[ O O
omega O O
- O O
I O O
- O O
131 O O
] O O
heptadecanoic O O
acid O O
( O O
I O O
- O O
131 O O
HA O O
) O O
, O O
and O O
on O O
global O O
left O O
- O O
ventricular O O
function O O
determined O O
echocardiographically O O
, O O
were O O
studied O O
in O O
a O O
group O O
of O O
nine O O
mongrel O O
dogs O O
. O O

Total O O
extractable O O
myocardial O O
lipid O O
was O O
compared O O
postmortem O O
between O O
a O O
group O O
of O O
control O O
dogs O O
and O O
doxorubicin O O
- O O
treated O O
dogs O O
. O O

A O O
significant O O
increase O O
in O O
the O O
myocardial O O
t1 O O
/ O O
2 O O
of O O
the O O
I O O
- O O
131 O O
HA O O
was O O
observed O O
only O O
at O O
a O O
higher O O
cumulative O O
dose O O
, O O
10 O O
mg O O
/ O O
kg O O
. O O

No O O
significant O O
alteration O O
in O O
total O O
extractable O O
myocardial O O
lipids O O
was O O
observed O O
between O O
control O O
dogs O O
and O O
those O O
treated O O
with O O
doxorubicin O O
. O O

Our O O
findings O O
suggest O O
that O O
the O O
changes O O
leading O O
to O O
an O O
alteration O O
of O O
myocardial O O
dynamic O O
imaging O O
with O O
I O O
- O O
131 O O
HA O O
are O O
not O O
the O O
initiating O O
factor O O
in O O
doxorubicin O O
cardiotoxicity B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Hemodynamics O O
and O O
myocardial O O
metabolism O O
under O O
deliberate O O
hypotension B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

An O O
experimental O O
study O O
in O O
dogs O O
. O O

Coronary O O
blood O O
flow O O
, O O
cardiac O O
work O O
and O O
metabolism O O
were O O
studied O O
in O O
dogs O O
under O O
sodium O O
nitroprusside O O
( O O
SNP O O
) O O
and O O
trimetaphan O O
( O O
TMP O O
) O O
deliberate O O
hypotension B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
20 O O
% O O
and O O
40 O O
% O O
mean O O
pressure O O
decrease O O
from O O
baseline O O
) O O
. O O

Regarding O O
the O O
effects O O
of O O
drug O O
- O O
induced O O
hypotension B B_DISEASE
on O O
coronary O O
blood O O
flow O O
, O O
aortic O O
and O O
coronary O O
sinus O O
metabolic O O
data O O
( O O
pH O O
, O O
pO2 O O
, O O
pCO2 O O
) O O
we O O
could O O
confirm O O
that O O
nitroprusside O O
hypotension B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O O
be O O
safely O O
used O O
to O O
30 O O
% O O
mean O O
blood O O
pressure O O
decrease O O
from O O
control O O
, O O
trimetaphan O O
hypotension B B_DISEASE
to O O
20 O O
% O O
mean O O
blood O O
pressure O O
decrease O O
. O O

Cardiac O O
work O O
was O O
significantly O O
reduced O O
during O O
SNP O O
hypotension B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Evidence O O
for O O
a O O
selective O O
brain O O
noradrenergic O O
involvement O O
in O O
the O O
locomotor O O
stimulant O O
effects O O
of O O
amphetamine O O
in O O
the O O
rat O O
. O O

Male O O
rats O O
received O O
the O O
noradrenaline O O
neurotoxin O O
DSP4 O O
( O O
50 O O
mg O O
/ O O
kg O O
) O O
7 O O
days O O
prior O O
to O O
injection O O
of O O
D O O
- O O
amphetamine O O
( O O
10 O O
or O O
40 O O
mumol O O
/ O O
kg O O
i O O
. O O
p O O
. O O
) O O
. O O

The O O
hyperactivity B B_DISEASE
induced O O
by O O
D O O
- O O
amphetamine O O
( O O
10 O O
mumol O O
/ O O
kg O O
) O O
was O O
significantly O O
reduced O O
by O O
DSP4 O O
pretreatment O O
. O O

However O O
, O O
the O O
increased O O
rearings O O
and O O
the O O
amphetamine O O
- O O
induced O O
stereotypies B B_DISEASE_ADJECTIVE[DISEASE]
were O O
not O O
blocked O O
by O O
pretreatment O O
with O O
DSP4 O O
. O O

The O O
present O O
results O O
suggest O O
a O O
selective O O
involvement O O
of O O
central O O
noradrenergic O O
neurones O O
in O O
the O O
locomotor O O
stimulant O O
effect O O
of O O
amphetamine O O
in O O
the O O
rat O O
. O O

Accelerated B B_DISEASE_ADJECTIVE[DISEASE]
junctional I I_DISEASE_ADJECTIVE[DISEASE]
rhythms I I_DISEASE_ADJECTIVE[DISEASE]
during O O
oral O O
verapamil O O
therapy O O
. O O

This O O
study O O
examined O O
the O O
frequency O O
of O O
atrioventricular O O
( O O
AV O O
) O O
dissociation O O
and O O
accelerated B B_DISEASE
junctional I I_DISEASE
rhythms I I_DISEASE
in O O
59 O O
patients O O
receiving O O
oral O O
verapamil O O
. O O

Accelerated B B_DISEASE/B_PROTEIN[GENE]
junctional I B_DISEASE/I_PROTEIN[GENE]
rhythms I B_DISEASE/I_PROTEIN[GENE]
and O O
AV O O
dissociation O O
were O O
frequent O O
in O O
patients O O
with O O
supraventricular B B_DISEASE/B_PROTEIN[GENE]
tachyarrhythmias I B_DISEASE/I_PROTEIN[GENE]
, O O
particularly O O
AV O O
nodal O O
reentry O O
. O O

Verapamil O O
administration O O
to O O
these O O
patients O O
led O O
to O O
an O O
asymptomatic O O
increase O O
in O O
activity O O
of O O
these O O
junctional O O
pacemakers O O
. O O

In O O
patients O O
with O O
various O O
chest B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
pain I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
syndromes O O
, O O
verapamil O O
neither O O
increased O O
the O O
frequency O O
of O O
junctional O O
rhythms O O
nor O O
suppressed O O
their O O
role O O
as O O
escape O O
rhythms O O
under O O
physiologically O O
appropriate O O
circumstances O O
. O O

Interstrain O O
variation O O
in O O
acute O O
toxic O O
response O O
to O O
caffeine O O
among O O
inbred O O
mice O O
. O O

Five O O
phenotypic O O
characteristics O O
- O O
- O O
locomotor O O
activity O O
, O O
righting O O
ability O O
, O O
clonic B B_DISEASE/B_GENE
seizure I I_DISEASE/I_GENE
induction O O
, O O
stress O O
- O O
induced O O
lethality O O
, O O
death O O
without O O
external O O
stress O O
- O O
- O O
were O O
scored O O
at O O
various O O
caffeine O O
doses O O
in O O
drug O O
- O O
naive O O
animals O O
under O O
empirically O O
optimized O O
, O O
rigidly O O
constant O O
experimental O O
conditions O O
. O O

Mice O O
( O O
n O O
= O O
12 O O
for O O
each O O
point O O
) O O
received O O
single O O
IP O O
injections O O
of O O
a O O
fixed O O
volume O O
/ O O
g O O
body O O
weight O O
of O O
physiological O O
saline O O
carrier O O
with O O
or O O
without O O
caffeine O O
in O O
doses O O
ranging O O
from O O
125 O O
- O O
500 O O
mg O O
/ O O
kg O O
. O O

Loss O O
of O O
righting O O
ability O O
was O O
scored O O
at O O
1 O O
, O O
3 O O
, O O
5 O O
min O O
post O O
dosing O O
and O O
at O O
5 O O
min O O
intervals O O
thereafter O O
for O O
20 O O
min O O
. O O

In O O
the O O
same O O
animals O O
the O O
occurrence O O
of O O
clonic B B_DISEASE
seizures I I_DISEASE
was O O
scored O O
as O O
to O O
time O O
of O O
onset O O
and O O
severity O O
for O O
20 O O
min O O
after O O
drug O O
administration O O
. O O

When O O
these O O
proceeded O O
to O O
tonic B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
seizures I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
death O O
occurred O O
in O O
less O O
than O O
20 O O
min O O
. O O

In O O
other O O
animals O O
locomotor O O
activity O O
was O O
measured O O
15 O O
or O O
60 O O
min O O
after O O
caffeine O O
administration O O
. O O

By O O
any O O
single O O
behavioral O O
criterion O O
or O O
a O O
combination O O
of O O
these O O
criteria O O
, O O
marked O O
differences O O
in O O
response O O
to O O
toxic O O
caffeine O O
doses O O
were O O
observed O O
between O O
strains O O
. O O

These O O
results O O
indicate O O
that O O
behavioral O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
testing O O
of O O
alkylxanthines O O
in O O
a O O
single O O
mouse O O
strain O O
may O O
be O O
misleading O O
and O O
suggest O O
that O O
toxic O O
responses O O
of O O
the O O
central O O
nervous O O
system O O
to O O
this O O
class O O
of O O
compounds O O
are O O
genetically O O
influenced O O
in O O
mammals O O
. O O

Treatment O O
of O O
ovarian B B_DISEASE/B_LOCATION
cancer I I_DISEASE/I_LOCATION
with O O
a O O
combination O O
of O O
cis O O
- O O
platinum O O
, O O
adriamycin O O
, O O
cyclophosphamide O O
and O O
hexamethylmelamine O O
. O O

During O O
the O O
last O O
2 O O
1 O O
/ O O
2 O O
years O O
, O O
38 O O
patients O O
with O O
ovarian B B_DISEASE/B_GENE
cancer I I_DISEASE/I_GENE
were O O
treated O O
with O O
a O O
combination O O
of O O
cisplatinum O O
( O O
CPDD O O
) O O
, O O
50 O O
mg O O
/ O O
m2 O O
, O O
adriamycin O O
, O O
30 O O
mg O O
/ O O
m2 O O
, O O
cyclophosphamide O O
, O O
300 O O
mg O O
/ O O
m2 O O
, O O
on O O
day O O
1 O O
; O O
and O O
hexamethylmelamine O O
( O O
HMM O O
) O O
, O O
6 O O
mg O O
/ O O
kg O O
daily O O
, O O
for O O
14 O O
days O O
. O O

Each O O
course O O
was O O
repeated O O
monthly O O
. O O

2 O O
patients O O
had O O
stage O O
II O O
, O O
14 O O
stage O O
III O O
and O O
22 O O
stage O O
IV O O
disease O O
. O O

14 O O
of O O
the O O
38 O O
patients O O
were O O
previously O O
treated O O
with O O
chemotherapy O O
, O O
1 O O
with O O
radiation O O
, O O
6 O O
with O O
both O O
chemotherapy O O
and O O
radiation O O
, O O
and O O
17 O O
did O O
not O O
have O O
any O O
treatment O O
before O O
CPDD O O
combination O O
. O O

31 O O
of O O
the O O
38 O O
cases O O
( O O
81 O O
. O O
5 O O
% O O
) O O
demonstrated O O
objective O O
responses O O
lasting O O
for O O
2 O O
months O O
or O O
more O O
. O O

These O O
responses O O
were O O
partial O O
in O O
19 O O
and O O
complete O O
in O O
12 O O
cases O O
. O O

Hematologic B B_DISEASE
toxicity I I_DISEASE
was O O
moderate O O
and O O
with O O
reversible O O
anemia B B_DISEASE
developing O O
in O O
71 O O
% O O
of O O
patients O O
. O O

Gastrointestinal O O
side O O
effects O O
from O O
CPDD O O
were O O
universal O O
. O O

HMM O O
gastrointestinal B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
toxicity I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
necessitated O O
discontinuation O O
of O O
the O O
drug O O
in O O
5 O O
patients O O
. O O

Severe O O
nephrotoxicity B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
observed O O
in O O
2 O O
patients O O
but O O
was O O
reversible O O
. O O

Nontraumatic O O
dissecting B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
aneurysm I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
basilar O O
artery O O
. O O

A O O
case O O
of O O
nontraumatic O O
dissecting B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
aneurysm I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
basilar O O
artery O O
in O O
association O O
with O O
hypertension B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
smoke O O
, O O
and O O
oral O O
contraceptives O O
is O O
reported O O
in O O
a O O
young O O
female O O
patient O O
with O O
a O O
locked B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
syndrome I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

A O O
method O O
for O O
the O O
measurement O O
of O O
tremor B B_DISEASE/B_GENE
, O O
and O O
a O O
comparison O O
of O O
the O O
effects O O
of O O
tocolytic O O
beta O O
- O O
mimetics O O
. O O

A O O
method O O
permitting O O
measurement O O
of O O
finger O O
tremor B B_DISEASE/B_MEASURE
as O O
a O O
displacement O O
- O O
time O O
curve O O
is O O
described O O
, O O
using O O
a O O
test O O
system O O
with O O
simple O O
amplitude O O
calibration O O
. O O

The O O
coordinates O O
of O O
the O O
inversion O O
points O O
of O O
the O O
displacement O O
- O O
time O O
curves O O
were O O
transferred O O
through O O
graphical O O
input O O
equipment O O
to O O
punched O O
tape O O
. O O

By O O
means O O
of O O
a O O
computer O O
program O O
, O O
periods O O
and O O
amplitudes O O
of O O
tremor B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
oscillations O O
were O O
calculated O O
and O O
classified O O
. O O

The O O
event O O
frequency O O
for O O
each O O
class O O
of O O
periods O O
and O O
amplitudes O O
was O O
determined O O
. O O

The O O
actions O O
of O O
fenoterol O O
- O O
hydrobromide O O
, O O
ritodrin O O
- O O
HCl O O
and O O
placebo O O
given O O
to O O
10 O O
healthy O O
subjects O O
by O O
intravenous O O
infusion O O
in O O
a O O
double O O
- O O
blind O O
crossover O O
study O O
were O O
tested O O
by O O
this O O
method O O
. O O

At O O
therapeutic O O
doses O O
both O O
substances O O
raised O O
the O O
mean O O
tremor B B_DISEASE
amplitude O O
to O O
about O O
three O O
times O O
the O O
control O O
level O O
. O O

At O O
the O O
same O O
time O O
, O O
the O O
mean O O
period O O
within O O
each O O
class O O
of O O
amplitudes O O
shortened O O
by O O
10 O O
- O O
- O O
20 O O
ms O O
, O O
whereas O O
the O O
mean O O
periods O O
calculated O O
from O O
all O O
oscillations O O
together O O
did O O
not O O
change O O
significantly O O
. O O

After O O
the O O
end O O
of O O
fenoterol O O
- O O
hydrobromide O O
infusion O O
, O O
tremor B B_DISEASE/B_PROTEIN[GENE]
amplitudes O O
decreased O O
significantly O O
faster O O
than O O
those O O
following O O
ritodrin O O
- O O
HCl O O
infusion O O
. O O

Propylthiouracil O O
- O O
induced O O
hepatic B B_DISEASE
damage I I_DISEASE
. O O

Two O O
cases O O
of O O
propylthiouracil O O
- O O
induced O O
liver B B_DISEASE
damage I I_DISEASE
have O O
been O O
observed O O
. O O

The O O
first O O
case O O
is O O
of O O
an O O
acute O O
type O O
of O O
damage O O
, O O
proven O O
by O O
rechallenge O O
; O O
the O O
second O O
presents O O
a O O
clinical O O
and O O
histologic O O
picture O O
resembling O O
chronic B B_DISEASE/B_GENE
active I I_DISEASE/I_GENE
hepatitis I I_DISEASE/I_GENE
, O O
with O O
spontaneous O O
remission O O
. O O

Studies O O
on O O
the O O
bradycardia B B_DISEASE
induced O O
by O O
bepridil O O
. O O

Bepridil O O
, O O
a O O
novel O O
active O O
compound O O
for O O
prophylactic O O
treatment O O
of O O
anginal B B_DISEASE
attacks I I_DISEASE
, O O
induced O O
persistent O O
bradycardia B B_DISEASE
and O O
a O O
non O O
- O O
specific O O
anti O O
- O O
tachycardial B B_DISEASE_ADJECTIVE[DISEASE]
effect O O
, O O
the O O
mechanisms O O
of O O
which O O
were O O
investigated O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O

In O O
vivo O O
injection O O
of O O
bepridil O O
at O O
a O O
dose O O
of O O
5 O O
mg O O
/ O O
kg O O
( O O
i O O
. O O
v O O
. O O
) O O
into O O
6 O O
anaesthetized O O
dogs O O
which O O
had O O
undergone O O
ablation O O
of O O
all O O
the O O
extrinsic O O
cardiac O O
afferent O O
nerve O O
supply O O
, O O
together O O
with O O
a O O
bilateral O O
medullo O O
- O O
adrenalectomy O O
, O O
caused O O
a O O
marked O O
reduction O O
in O O
heart O O
rate O O
which O O
fell O O
from O O
98 O O
. O O
7 O O
+ O O
/ O O
- O O
4 O O
. O O
2 O O
beats O O
/ O O
min O O
to O O
76 O O
+ O O
/ O O
- O O
5 O O
. O O
3 O O
beats O O
/ O O
min O O
sustained O O
for O O
more O O
than O O
45 O O
min O O
. O O

This O O
effect O O
, O O
which O O
results O O
in O O
a O O
flattening O O
of O O
the O O
phase O O
0 O O
and O O
phase O O
4 O O
slope O O
, O O
together O O
with O O
a O O
longer O O
AP O O
duration O O
, O O
may O O
be O O
due O O
to O O
an O O
increase O O
in O O
the O O
time O O
constants O O
of O O
slow O O
inward O O
ionic O O
currents O O
( O O
already O O
demonstrated O O
elsewhere O O
) O O
, O O
but O O
also O O
to O O
an O O
increased O O
time O O
constant O O
for O O
deactivation O O
of O O
the O O
outward O O
potassium O O
current O O
( O O
Ip O O
) O O
. O O

Hepatitis B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
renal B B_DISEASE
tubular I I_DISEASE
acidosis I I_DISEASE
after O O
anesthesia O O
with O O
methoxyflurane O O
. O O

A O O
69 O O
- O O
year O O
- O O
old O O
man O O
operated O O
for O O
acute B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cholecystitis I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
under O O
methoxyflurane O O
anesthesia O O
developed O O
postoperatively O O
a O O
hepatic B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
insufficiency I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
syndrome I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
renal B B_DISEASE
tubular I I_DISEASE
acidosis I I_DISEASE
. O O

Massive O O
bleeding B B_DISEASE
appeared O O
during O O
surgery O O
which O O
lasted O O
for O O
six O O
hours O O
. O O

Postoperative O O
evolution O O
under O O
supportive O O
therapy O O
was O O
favourable O O
. O O

Complete O O
recovery O O
was O O
confirmed O O
by O O
repeated O O
controls O O
performed O O
over O O
a O O
period O O
of O O
one O O
year O O
after O O
surgery O O
. O O

Pituitary O O
response O O
to O O
luteinizing O O
hormone O O
- O O
releasing O O
hormone O O
during O O
haloperidol O O
- O O
induced O O
hyperprolactinemia B B_DISEASE
. O O

The O O
effects O O
of O O
a O O
6 O O
- O O
hour O O
infusion O O
with O O
haloperidol O O
on O O
serum O O
prolactin O O
and O O
luteinizing O O
hormone O O
( O O
LH O O
) O O
levels O O
was O O
studied O O
in O O
a O O
group O O
of O O
male O O
subjects O O
. O O

Five O O
hours O O
after O O
starting O O
the O O
infusions O O
, O O
a O O
study O O
of O O
the O O
pituitary O O
responses O O
to O O
LH O O
- O O
releasing O O
hormone O O
( O O
LH O O
- O O
RH O O
) O O
was O O
carried O O
out O O
. O O

Control O O
patients O O
received O O
infusions O O
of O O
0 O O
. O O
9 O O
% O O
NaCl O O
solution O O
. O O

During O O
the O O
course O O
of O O
haloperidol O O
infusions O O
, O O
significant O O
hyperprolactinemia B B_DISEASE
was O O
found O O
, O O
together O O
with O O
an O O
abolished O O
pituitary O O
response O O
to O O
LH O O
- O O
RH O O
, O O
as O O
compared O O
with O O
responses O O
of O O
control O O
subjects O O
. O O

Antirifampicin O O
antibodies O O
in O O
acute O O
rifampicin O O
- O O
associated O O
renal B B_DISEASE/B_GENE
failure I I_DISEASE/I_GENE
. O O

Antibodies O O
suggested O O
to O O
be O O
of O O
the O O
IgM O O
class O O
were O O
detected O O
in O O
all O O
3 O O
patients O O
with O O
hematological B B_DISEASE/B_GENE
disorders I I_DISEASE/I_GENE
. O O

The O O
pattern O O
of O O
non O O
- O O
specific O O
acute B B_DISEASE_ADJECTIVE[DISEASE]
tubular I I_DISEASE_ADJECTIVE[DISEASE]
necrosis I I_DISEASE_ADJECTIVE[DISEASE]
found O O
in O O
the O O
2 O O
biopsied O O
patients O O
, O O
indistinguishable O O
from O O
that O O
of O O
ischemic O O
origin O O
, O O
raised O O
the O O
possibility O O
of O O
a O O
vascular O O
- O O
mediated O O
damage O O
. O O

In O O
3 O O
patients O O
, O O
the O O
possibility O O
of O O
a O O
triggering O O
immunoallergic O O
mechanism O O
is O O
discussed O O
. O O

Cardiovascular O O
effects O O
of O O
hypotension B B_DISEASE
induced O O
by O O
adenosine O O
triphosphate O O
and O O
sodium O O
nitroprusside O O
on O O
dogs O O
with O O
denervated O O
hearts O O
. O O

Adenosine O O
triphosphate O O
( O O
ATP O O
) O O
and O O
sodium O O
nitroprusside O O
( O O
SNP O O
) O O
are O O
administered O O
to O O
patients O O
to O O
induce O O
and O O
control O O
hypotension B B_DISEASE
during O O
anesthesia O O
. O O

SNP O O
is O O
authorized O O
for O O
clinical O O
use O O
in O O
USA O O
and O O
UK O O
, O O
and O O
ATP O O
is O O
clinically O O
used O O
in O O
other O O
countries O O
such O O
as O O
Japan O O
. O O

We O O
investigated O O
how O O
these O O
two O O
drugs O O
act O O
on O O
the O O
cardiovascular O O
systems O O
of O O
20 O O
dogs O O
whose O O
hearts O O
had O O
been O O
denervated O O
by O O
a O O
procedure O O
we O O
had O O
devised O O
. O O

Before O O
, O O
during O O
and O O
after O O
induced O O
hypotension B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
we O O
measured O O
major O O
cardiovascular O O
parameters O O
. O O

Hypotension B B_DISEASE
induced O O
by O O
ATP O O
was O O
accompanied O O
by O O
significant O O
decreases O O
in O O
mean O O
pulmonary O O
arterial O O
pressure O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
, O O
central O O
venous O O
pressure O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
, O O
left O O
ventricular O O
end O O
- O O
diastolic O O
pressure O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
, O O
total O O
peripheral O O
resistance O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
, O O
rate O O
pressure O O
product O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
, O O
total O O
body O O
oxygen O O
consumption O O
( O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
, O O
and O O
heart O O
rate O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
; O O
all O O
these O O
variables O O
returned O O
normal O O
within O O
30 O O
min O O
after O O
ATP O O
was O O
stopped O O
. O O

Cardiac O O
output O O
did O O
not O O
change O O
. O O

During O O
hypotension B B_DISEASE
produced O O
by O O
SNP O O
similar O O
decreases O O
were O O
observed O O
in O O
mean O O
pulmonary O O
arterial O O
pressure O O
( O O
p O O
less O O
than O O
0 O O
. O O
01 O O
) O O
, O O
central O O
venous O O
pressure O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
, O O
left O O
ventricular O O
end O O
- O O
diastolic O O
pressure O O
( O O
p O O
less O O
than O O
0 O O
. O O
01 O O
) O O
, O O
total O O
peripheral O O
resistance O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
, O O
rate O O
pressure O O
product O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
, O O
and O O
oxygen O O
content O O
difference O O
between O O
arterial O O
and O O
mixed O O
venous O O
blood O O
( O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
, O O
while O O
heart O O
rate O O
( O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
and O O
cardiac O O
output O O
( O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
were O O
increased O O
. O O

Recoveries O O
of O O
heart O O
rate O O
and O O
left O O
ventricular O O
end O O
- O O
diastolic O O
pressure O O
were O O
not O O
shown O O
within O O
60 O O
min O O
after O O
SNP O O
had O O
been O O
stopped O O
. O O

Both O O
ATP O O
and O O
SNP O O
should O O
act O O
on O O
the O O
pacemaker O O
tissue O O
of O O
the O O
heart O O
. O O

Comparative O O
study O O
: O O
Endografine O O
( O O
diatrizoate O O
) O O
, O O
Vasurix O O
polyvidone O O
( O O
acetrizoate O O
) O O
, O O
Dimer O O
- O O
X O O
( O O
iocarmate O O
) O O
and O O
Hexabrix O O
( O O
ioxaglate O O
) O O
in O O
hysterosalpingography O O
. O O

Side O O
effects O O
of O O
hysterosalpingography O O
with O O
Dimer O O
- O O
X O O
, O O
Hexabrix O O
, O O
Vasurix O O
polyvidone O O
and O O
Endografine O O
in O O
142 O O
consecutive O O
patients O O
, O O
receiving O O
one O O
of O O
the O O
four O O
tested O O
media O O
were O O
evaluated O O
from O O
replies O O
to O O
postal O O
questionnaires O O
. O O

The O O
Dimer O O
- O O
X O O
group O O
had O O
a O O
higher O O
incidence O O
of O O
nausea B B_DISEASE
and O O
dizziness B B_DISEASE
. O O

The O O
Endografine O O
group O O
had O O
a O O
higher O O
incidence O O
of O O
abdominal B B_DISEASE
pain I I_DISEASE
. O O

These O O
differences O O
occur O O
especially O O
in O O
the O O
age O O
groups O O
under O O
30 O O
years O O
. O O

Post O O
- O O
suxamethonium O O
pains B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
Nigerian O O
surgical O O
patients O O
. O O

Contrary O O
to O O
an O O
earlier O O
report O O
by O O
Coxon O O
, O O
scoline O O
pain B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occurs O O
in O O
African O O
negroes O O
. O O

Its O O
incidence O O
was O O
determined O O
in O O
a O O
prospective O O
study O O
involving O O
a O O
total O O
of O O
100 O O
Nigerian O O
patients O O
( O O
50 O O
out O O
- O O
patients O O
and O O
50 O O
in O O
- O O
patients O O
) O O
. O O

About O O
62 O O
% O O
of O O
the O O
out O O
- O O
patients O O
developed O O
scoline O O
pain B B_DISEASE
as O O
compared O O
with O O
about O O
26 O O
% O O
among O O
the O O
in O O
- O O
patients O O
. O O

The O O
abolition O O
of O O
muscle O O
fasciculations B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
by O O
0 O O
. O O
075mg O O
/ O O
kg O O
dose O O
of O O
Fazadinium O O
) O O
did O O
not O O
influence O O
the O O
occurrence O O
of O O
scoline O O
pain B B_DISEASE
. O O

Neither O O
the O O
type O O
of O O
induction O O
agent O O
( O O
Althesin O O
or O O
Thiopentone O O
) O O
nor O O
the O O
salt O O
preparation O O
of O O
suxamethonium O O
used O O
( O O
chloride O O
or O O
bromide O O
) O O
, O O
affected O O
the O O
incidence O O
of O O
scoline O O
pain B B_DISEASE
. O O

Invasive O O
carcinoma B B_DISEASE
of I I_DISEASE
the I I_DISEASE
renal I I_DISEASE
pelvis I I_DISEASE
following O O
cyclophosphamide O O
therapy O O
for O O
nonmalignant O O
disease O O
. O O

A O O
47 O O
- O O
year O O
- O O
old O O
woman O O
with O O
right O O
hydroureteronephrosis B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
due O O
to O O
ureterovesical O O
junction O O
obstruction O O
had O O
gross O O
hematuria B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O O
being O O
treated O O
for O O
five O O
years O O
wtih O O
cyclophosphamide O O
for O O
cerebral B B_DISEASE
vasculitis I I_DISEASE
. O O

A O O
right O O
nephroureterectomy O O
was O O
required O O
for O O
control O O
of O O
bleeding B B_DISEASE
. O O

The O O
pathology O O
specimen O O
contained O O
clinically O O
occult O O
invasive O O
carcinoma B B_DISEASE
of I I_DISEASE
the I I_DISEASE
renal I I_DISEASE
pelvis I I_DISEASE
. O O

Although O O
the O O
ability O O
of O O
cyclophosphamide O O
to O O
cause O O
hemorrhagic B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
cystitis I B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
urine O O
cytologic O O
abnormalities O O
indistinguishable O O
from O O
high O O
grade O O
carcinoma B B_DISEASE
is O O
well O O
known O O
, O O
it O O
is O O
less O O
widely O O
appreciated O O
that O O
it O O
is O O
also O O
associated O O
with O O
carcinoma B B_DISEASE
of I I_DISEASE
the I I_DISEASE
urinary I I_DISEASE
tract I I_DISEASE
. O O

Twenty O O
carcinomas B B_DISEASE
of I I_DISEASE
the I I_DISEASE
urinary I I_DISEASE
bladder I I_DISEASE
and O O
one O O
carcinoma B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
of I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
the I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
prostate I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
have O O
been O O
reported O O
in O O
association O O
with O O
its O O
use O O
. O O

The O O
present O O
case O O
is O O
the O O
first O O
carcinoma B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
of I B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
the I B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
renal I B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
pelvis I B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
reported O O
in O O
association O O
with O O
cyclophosphamide O O
treatment O O
. O O

It O O
is O O
the O O
third O O
urinary B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tract I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cancer I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reported O O
in O O
association O O
with O O
cyclophosphamide O O
treatment O O
for O O
nonmalignant O O
disease O O
. O O

The O O
association O O
of O O
the O O
tumor B B_DISEASE
with O O
preexisting O O
hydroureteronephrosis B B_DISEASE
suggests O O
that O O
stasis O O
prolonged O O
and O O
intensified O O
exposure O O
of O O
upper O O
urinary O O
tract O O
epithelium O O
to O O
cyclophosphamide O O
. O O

Patients O O
who O O
are O O
candidates O O
for O O
long O O
- O O
term O O
cyclophosphamide O O
treatment O O
should O O
be O O
routinely O O
evaluated O O
for O O
obstructive B B_DISEASE_ADJECTIVE[DISEASE]
uropathy I I_DISEASE_ADJECTIVE[DISEASE]
. O O

Medial O O
changes O O
in O O
arterial O O
spasm B B_DISEASE/B_MEASURE
induced O O
by O O
L O O
- O O
norepinephrine O O
. O O

In O O
normal O O
rats O O
, O O
the O O
media O O
of O O
small O O
arteries O O
( O O
0 O O
. O O
4 O O
- O O
- O O
0 O O
. O O
2 O O
mm O O
in O O
diameter O O
) O O
previously O O
was O O
shown O O
to O O
contain O O
intracellular O O
vacuoles O O
, O O
identified O O
ultrastructurally O O
as O O
herniations O O
of O O
one O O
smooth O O
muscle O O
cell O O
into O O
another O O
. O O

In O O
the O O
media O O
of O O
the O O
saphenous O O
artery O O
and O O
its O O
distal O O
branch O O
, O O
vasoconstriction O O
induced O O
by O O
L O O
- O O
norepinephrine O O
produced O O
many O O
cell O O
- O O
to O O
- O O
cell O O
hernias B B_PERSON/B_DISEASE
within O O
15 O O
minutes O O
. O O

At O O
1 O O
day O O
their O O
number O O
was O O
reduced O O
to O O
about O O
1 O O
/ O O
10 O O
of O O
the O O
original O O
number O O
. O O

The O O
experimental O O
data O O
are O O
discussed O O
in O O
relation O O
to O O
medial O O
changes O O
observed O O
in O O
other O O
instances O O
of O O
arterial O O
spasm B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Endothelial O O
changes O O
that O O
developed O O
in O O
the O O
same O O
experimental O O
model O O
were O O
described O O
in O O
a O O
previous O O
paper O O
. O O

Bilateral O O
retinal B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
artery I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
choriocapillaris I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occlusion I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
following O O
the O O
injection O O
of O O
long O O
- O O
acting O O
corticosteroid O O
suspensions O O
in O O
combination O O
with O O
other O O
drugs O O
: O O
I O O
. O O

Clinical O O
studies O O
. O O

Two O O
well O O
- O O
documented O O
cases O O
of O O
bilateral O O
retinal B B_DISEASE/B_PERSON
artery I I_DISEASE/I_PERSON
and I I_DISEASE/I_PERSON
choriocapillaris I I_DISEASE/I_PERSON
occlusions I I_DISEASE/I_PERSON
with O O
blindness B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
following O O
head O O
and O O
neck O O
soft O O
- O O
tissue O O
injection O O
with O O
methylprednisolone O O
acetate O O
in O O
combination O O
with O O
lidocaine O O
, O O
epinephrine O O
, O O
or O O
penicillin O O
are O O
reported O O
. O O

The O O
acute O O
observations O O
included O O
hazy O O
sensorium O O
, O O
superior O O
gaze O O
palsy B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
pupillary B B_DISEASE
abnormalities I I_DISEASE
, O O
and O O
conjunctival O O
hemorrhages B B_DISEASE
with O O
edema B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Follow O O
- O O
up O O
changes O O
showed O O
marked O O
visual B B_DISEASE
loss I I_DISEASE
, O O
constricted O O
visual O O
fields O O
, O O
optic O O
nerve O O
pallor O O
, O O
vascular O O
attenuation O O
, O O
and O O
chorioretinal B B_DISEASE
atrophy I I_DISEASE
. O O

The O O
literature O O
is O O
reviewed O O
, O O
and O O
possible O O
causes O O
are O O
discussed O O
. O O

Abnormalities O O
of O O
the O O
pupil O O
and O O
visual O O
- O O
evoked O O
potential O O
in O O
quinine O O
amblyopia B B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
. O O

Total O O
blindness B B_DISEASE
with O O
a O O
transient O O
tonic B B_DISEASE_ADJECTIVE[DISEASE]
pupillary I I_DISEASE_ADJECTIVE[DISEASE]
response O O
, O O
denervation O O
supersensitivity O O
, O O
and O O
abnormal O O
visual O O
- O O
evoked O O
potentials O O
developed O O
in O O
a O O
54 O O
- O O
year O O
- O O
old O O
man O O
after O O
the O O
use O O
of O O
quinine O O
sulfate O O
for O O
leg B B_DISEASE
cramps I I_DISEASE
. O O

He O O
later O O
recovered O O
normal O O
visual O O
acuity O O
. O O

A O O
transient O O
tonic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pupillary I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
response O O
, O O
denervation O O
supersensitivity O O
, O O
and O O
abnormal O O
visual O O
- O O
evoked O O
potentials O O
in O O
quinine O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
to O O
our O O
knowledge O O
, O O
have O O
not O O
been O O
previously O O
reported O O
. O O

Suxamethonium O O
- O O
induced O O
jaw B B_DISEASE
stiffness I I_DISEASE
and O O
myalgia B B_DISEASE
associated O O
with O O
atypical O O
cholinesterase O O
: O O
case O O
report O O
. O O

An O O
11 O O
- O O
year O O
- O O
old O O
boy O O
was O O
given O O
halothane O O
, O O
nitrous O O
oxide O O
and O O
oxygen O O
, O O
pancuronium O O
0 O O
. O O
4 O O
mg O O
and O O
suxamethonium O O
100 O O
mg O O
for O O
induction O O
of O O
anaesthesia O O
. O O

In O O
response O O
to O O
this O O
a O O
marked O O
jaw B B_DISEASE
stiffness I I_DISEASE
occurred O O
which O O
lasted O O
for O O
two O O
minutes O O
and O O
the O O
anaesthesia O O
were O O
terminated O O
. O O

Four O O
hours O O
of O O
apnoea B B_DISEASE
ensued O O
and O O
he O O
suffered O O
generalized O O
severe O O
myalgia B B_DISEASE
lasting O O
for O O
one O O
week O O
. O O

This O O
was O O
verified O O
by O O
study O O
of O O
the O O
family O O
. O O

The O O
case O O
shows O O
that O O
prolonged B B_DISEASE
jaw I I_DISEASE
rigidity I I_DISEASE
and O O
myalgia B B_DISEASE
may O O
occur O O
after O O
suxamethonium O O
in O O
patients O O
with O O
atypical O O
cholinesterase O O
despite O O
pretreatment O O
with O O
pancuronium O O
. O O

Indomethacin O O
- O O
induced O O
hyperkalemia B B_DISEASE
in O O
three O O
patients O O
with O O
gouty B B_DISEASE/B_LOCATION
arthritis I I_DISEASE/I_LOCATION
. O O

We O O
describe O O
three O O
patients O O
in O O
whom O O
severe O O
, O O
life O O
- O O
threatening O O
hyperkalemia B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
renal B B_DISEASE
insufficiency I I_DISEASE
developed O O
after O O
treatment O O
of O O
acute O O
gouty B B_DISEASE/B_LOCATION
arthritis I I_DISEASE/I_LOCATION
with O O
indomethacin O O
. O O

This O O
complication O O
may O O
result O O
from O O
an O O
inhibition O O
of O O
prostaglandin O O
synthesis O O
and O O
consequent O O
hyporeninemic B B_DISEASE
hypoaidosteronism I I_DISEASE
. O O

Careful O O
attention O O
to O O
renal O O
function O O
and O O
potassium O O
balance O O
in O O
patients O O
receiving O O
indomethacin O O
or O O
other O O
nonsteroidal O O
anti O O
- O O
inflammatory O O
agents O O
, O O
particularly O O
in O O
those O O
patients O O
with O O
diabetes B B_DISEASE_ADJECTIVE[DISEASE]
mellitus I I_DISEASE_ADJECTIVE[DISEASE]
or O O
preexisting O O
renal B B_DISEASE
disease I I_DISEASE
, O O
will O O
help O O
prevent O O
this O O
potentially O O
serious O O
complication O O
. O O

Etomidate O O
: O O
a O O
foreshortened O O
clinical O O
trial O O
. O O

Unpremedicated O O
patients O O
were O O
given O O
fentanyl O O
1 O O
microgram O O
/ O O
kg O O
followed O O
by O O
etomidate O O
0 O O
. O O
3 O O
mg O O
/ O O
kg O O
. O O

Anaesthesia O O
was O O
maintained O O
with O O
intermittent O O
etomidate O O
in O O
2 O O
- O O
4 O O
mg O O
doses O O
. O O

Patients O O
were O O
interviewed O O
personally O O
later O O
the O O
same O O
day O O
, O O
and O O
by O O
questionnaire O O
three O O
to O O
four O O
weeks O O
later O O
. O O

Venous O O
pain B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occurred O O
in O O
68 O O
% O O
of O O
patients O O
and O O
50 O O
% O O
had O O
redness O O
, O O
pain B B_DISEASE
or O O
swelling B B_DISEASE
related O O
to O O
the O O
injection O O
site O O
, O O
in O O
some O O
cases O O
lasting O O
up O O
to O O
three O O
weeks O O
after O O
anaesthesia O O
. O O

Skeletal O O
movements O O
occurred O O
in O O
50 O O
% O O
of O O
patients O O
; O O
30 O O
% O O
experienced O O
respiratory B B_DISEASE
upset I I_DISEASE
, O O
one O O
sufficiently O O
severe O O
to O O
necessitate O O
abandoning O O
the O O
technique O O
. O O

Nausea B B_DISEASE
and O O
vomiting B B_DISEASE
occurred O O
in O O
40 O O
% O O
and O O
25 O O
% O O
had O O
disturbing O O
emergence O O
psychoses B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

Levodopa O O
- O O
induced O O
dyskinesias B B_DISEASE
are O O
improved O O
by O O
fluoxetine O O
. O O

We O O
evaluated O O
the O O
severity O O
of O O
motor B B_DISEASE
disability I I_DISEASE
and O O
dyskinesias B B_DISEASE_ADJECTIVE[DISEASE]
in O O
seven O O
levodopa O O
- O O
responsive O O
patients O O
with O O
Parkinson B B_DISEASE
' I I_DISEASE
s I I_DISEASE
disease I I_DISEASE
after O O
an O O
acute O O
challenge O O
with O O
the O O
mixed O O
dopamine O O
agonist O O
, O O
apomorphine O O
, O O
before O O
and O O
after O O
the O O
administration O O
of O O
fluoxetine O O
( O O
20 O O
mg O O
twice O O
per O O
day O O
) O O
for O O
11 O O
+ O O
/ O O
- O O
1 O O
days O O
. O O

After O O
fluoxetine O O
treatment O O
, O O
there O O
was O O
a O O
significant O O
47 O O
% O O
improvement O O
( O O
p O O
< O O
0 O O
. O O
05 O O
) O O
of O O
apomorphine O O
- O O
induced O O
dyskinesias B B_DISEASE
without O O
modification O O
of O O
parkinsonian B B_DISEASE
motor B I_DISEASE
disability I I_DISEASE
. O O

The O O
dyskinesias B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
were O O
reduced O O
predominantly O O
in O O
the O O
lower O O
limbs O O
during O O
the O O
onset O O
and O O
disappearance O O
of O O
dystonic B B_DISEASE
dyskinesias I I_DISEASE
( O O
onset O O
- O O
and O O
end O O
- O O
of O O
- O O
dose O O
dyskinesias B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
and O O
in O O
the O O
upper O O
limbs O O
during O O
choreic B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
mid I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
- I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
dose I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
dyskinesias I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
results O O
suggest O O
that O O
increased O O
brain O O
serotoninergic O O
transmission O O
with O O
fluoxetine O O
may O O
reduce O O
levodopa O O
- O O
or O O
dopamine O O
agonist O O
- O O
induced O O
dyskinesias B B_DISEASE
without O O
aggravating O O
parkinsonian B B_DISEASE
motor B I_DISEASE
disability I I_DISEASE
. O O

A O O
large O O
population O O
- O O
based O O
follow O O
- O O
up O O
study O O
of O O
trimethoprim O O
- O O
sulfamethoxazole O O
, O O
trimethoprim O O
, O O
and O O
cephalexin O O
for O O
uncommon O O
serious O O
drug B B_DISEASE
toxicity I I_DISEASE
. O O

We O O
conducted O O
a O O
population O O
- O O
based O O
45 O O
- O O
day O O
follow O O
- O O
up O O
study O O
of O O
232 O O
, O O
390 O O
people O O
who O O
were O O
prescribed O O
trimethoprim O O
- O O
sulfamethoxazole O O
( O O
TMP O O
- O O
SMZ O O
) O O
, O O
266 O O
, O O
951 O O
prescribed O O
trimethoprim O O
alone O O
, O O
and O O
196 O O
, O O
397 O O
prescribed O O
cephalexin O O
, O O
to O O
estimate O O
the O O
risk O O
of O O
serious O O
liver B B_DISEASE
, I I_DISEASE
blood I I_DISEASE
, I I_DISEASE
skin I I_DISEASE
, I I_DISEASE
and I I_DISEASE
renal I I_DISEASE
disorders I I_DISEASE
resulting O O
in O O
referral O O
or O O
hospitalization O O
associated O O
with O O
these O O
drugs O O
. O O

The O O
results O O
were O O
based O O
on O O
information O O
recorded O O
on O O
office O O
computers O O
by O O
selected O O
general O O
practitioners O O
in O O
the O O
United O O
Kingdom O O
, O O
together O O
with O O
a O O
review O O
of O O
clinical O O
records O O
. O O

The O O
risk O O
of O O
clinically O O
important O O
idiopathic O O
liver B B_DISEASE
disease I I_DISEASE
was O O
similar O O
for O O
persons O O
prescribed O O
TMP O O
- O O
SMZ O O
( O O
5 O O
. O O
2 O O
/ O O
100 O O
, O O
000 O O
) O O
and O O
those O O
prescribed O O
trimethoprim O O
alone O O
( O O
3 O O
. O O
8 O O
/ O O
100 O O
, O O
000 O O
) O O
. O O

Only O O
five O O
patients O O
experienced O O
blood O O
disorders O O
, O O
one O O
of O O
whom O O
was O O
exposed O O
to O O
TMP O O
- O O
SMZ O O
; O O
of O O
seven O O
with O O
erythema B B_DISEASE
multiforme I I_DISEASE
and O O
Stevens B B_DISEASE
- I I_DISEASE
Johnson I I_DISEASE
syndrome I I_DISEASE
, O O
four O O
were O O
exposed O O
to O O
TMP O O
- O O
SMZ O O
. O O

The O O
one O O
case O O
of O O
toxic B B_DISEASE
epidermal I I_DISEASE
necrolysis I I_DISEASE
occurred O O
in O O
a O O
patient O O
who O O
took O O
cephalexin O O
. O O

Finally O O
, O O
only O O
five O O
cases O O
of O O
acute O O
parenchymal O O
renal B B_DISEASE
disease I I_DISEASE
occurred O O
, O O
none O O
likely O O
to O O
be O O
caused O O
by O O
a O O
study O O
drug O O
. O O

Clinical O O
safety O O
of O O
lidocaine O O
in O O
patients O O
with O O
cocaine O O
- O O
associated O O
myocardial B B_DISEASE/B_LOCATION
infarction I I_DISEASE/I_LOCATION
. O O

STUDY O O
OBJECTIVE O O
: O O
To O O
evaluate O O
the O O
safety O O
of O O
lidocaine O O
in O O
the O O
setting O O
of O O
cocaine O O
- O O
induced O O
myocardial B B_DISEASE
infarction I I_DISEASE
( O O
MI B B_LOCATION/B_DISEASE
) O O
. O O

DESIGN O O
: O O
A O O
retrospective O O
, O O
multicenter O O
study O O
. O O

SETTING O O
: O O
Twenty O O
- O O
nine O O
university O O
, O O
university O O
- O O
affiliated O O
, O O
or O O
community O O
hospitals O O
during O O
a O O
6 O O
- O O
year O O
period O O
( O O
total O O
of O O
117 O O
cumulative O O
hospital O O
- O O
years O O
) O O
. O O

PARTICIPANTS O O
: O O
Patients O O
with O O
cocaine O O
- O O
associated O O
MI B B_DISEASE/B_LOCATION
who O O
received O O
lidocaine O O
in O O
the O O
emergency O O
department O O
. O O

RESULTS O O
: O O
Of O O
29 O O
patients O O
who O O
received O O
lidocaine O O
in O O
the O O
setting O O
of O O
cocaine O O
- O O
associated O O
MI B B_DISEASE
, O O
no O O
patient O O
died O O
; O O
exhibited O O
bradydysrhythmias B B_DISEASE
, O O
ventricular B B_DISEASE
tachycardia I I_DISEASE
, O O
or O O
ventricular B B_DISEASE
fibrillation I I_DISEASE
; O O
or O O
experienced O O
seizures B B_DISEASE
after O O
administration O O
of O O
lidocaine O O
( O O
95 O O
% O O
confidence O O
interval O O
, O O
0 O O
% O O
to O O
11 O O
% O O
) O O
. O O

CONCLUSION O O
: O O
Despite O O
theoretical O O
concerns O O
that O O
lidocaine O O
may O O
enhance O O
cocaine O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
use O O
of O O
lidocaine O O
in O O
patients O O
with O O
cocaine O O
- O O
associated O O
MI B B_DISEASE/B_LOCATION
was O O
not O O
associated O O
with O O
significant O O
cardiovascular B B_DISEASE_ADJECTIVE[DISEASE]
or I I_DISEASE_ADJECTIVE[DISEASE]
central I I_DISEASE_ADJECTIVE[DISEASE]
nervous I I_DISEASE_ADJECTIVE[DISEASE]
system I I_DISEASE_ADJECTIVE[DISEASE]
toxicity I I_DISEASE_ADJECTIVE[DISEASE]
. O O

Experimental O O
progressive O O
muscular B B_DISEASE
dystrophy I I_DISEASE
and O O
its O O
treatment O O
with O O
high O O
doses O O
anabolizing O O
agents O O
. O O

We O O
are O O
still O O
a O O
long O O
way O O
from O O
discovering O O
an O O
unequivocal O O
pathogenetic O O
interpretation O O
of O O
progressive O O
muscular B B_DISEASE
dystrophy I I_DISEASE
in O O
man O O
. O O

Noteworthy O O
efforts O O
have O O
been O O
made O O
in O O
the O O
experimental O O
field O O
; O O
a O O
recessive O O
autosomic O O
form O O
found O O
in O O
the O O
mouse O O
seems O O
to O O
bear O O
the O O
closest O O
resemblance O O
to O O
the O O
human O O
form O O
from O O
the O O
genetic O O
point O O
of O O
view O O
. O O

Myopathy B B_DISEASE
due O O
to O O
lack O O
of O O
vitamin O O
E O O
and O O
myopathy B B_DISEASE
induced O O
by O O
certain O O
viruses O O
have O O
much O O
in O O
common O O
anatomically O O
and O O
pathologically O O
with O O
the O O
human O O
form O O
. O O

The O O
authors O O
induced O O
myodystrophy B B_DISEASE
in O O
the O O
rat O O
by O O
giving O O
it O O
a O O
diet O O
lacking O O
in O O
vitamin O O
E O O
. O O

The O O
pharmacological O O
characteristics O O
of O O
vitamin O O
E O O
and O O
the O O
degenerative O O
changes O O
brought O O
about O O
by O O
its O O
deficiency O O
, O O
especially O O
in O O
the O O
muscles O O
, O O
are O O
illustrated O O
. O O

It O O
is O O
thus O O
confirmed O O
that O O
the O O
histological O O
characteristics O O
of O O
myopathic B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
rat O O
muscle O O
induced O O
experimentally O O
are O O
extraordinarily O O
similar O O
to O O
those O O
of O O
human O O
myopathy B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
as O O
confirmed O O
during O O
biopsies O O
performed O O
at O O
the O O
Orthopaedic O O
Traumatological O O
Centre O O
, O O
Florence O O
. O O

The O O
encouraging O O
results O O
obtained O O
in O O
various O O
authoratative O O
departments O O
in O O
myopathic B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
patients O O
by O O
using O O
anabolizing O O
steroids O O
have O O
encouraged O O
the O O
authors O O
to O O
investigate O O
the O O
beneficial O O
effects O O
of O O
one O O
anabolizing O O
agent O O
( O O
Dianabol O O
, O O
CIBA O O
) O O
at O O
high O O
doses O O
in O O
rats O O
rendered O O
myopathic B B_DISEASE_ADJECTIVE[DISEASE]
by O O
a O O
diet O O
deficient O O
in O O
vitamin O O
E O O
. O O

In O O
this O O
way O O
they O O
obtained O O
appreciable O O
changes O O
in O O
body O O
weight O O
( O O
increased O O
from O O
50 O O
to O O
70 O O
g O O
after O O
forty O O
days O O
at O O
a O O
dose O O
of O O
5 O O
mg O O
per O O
day O O
of O O
anabolizing O O
agent O O
) O O
, O O
but O O
most O O
of O O
all O O
they O O
found O O
histological O O
changes O O
due O O
to O O
" O O
regenerative O O
" O O
changes O O
in O O
the O O
muscle O O
tissue O O
, O O
which O O
however O O
maintained O O
its O O
myopathic B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characteristics O O
in O O
the O O
control O O
animals O O
that O O
were O O
not O O
treated O O
with O O
the O O
anabolizing O O
agent O O
. O O

The O O
authors O O
conclude O O
by O O
affirming O O
the O O
undoubted O O
efficacy O O
of O O
the O O
anabolizing O O
steroids O O
in O O
experimental O O
myopathic B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disease I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
but O O
they O O
have O O
reservations O O
as O O
to O O
the O O
transfer O O
of O O
the O O
results O O
into O O
the O O
human O O
field O O
, O O
where O O
high O O
dosage O O
cannot O O
be O O
carried O O
out O O
continuously O O
because O O
of O O
the O O
effects O O
of O O
the O O
drug O O
on O O
virility O O
; O O
because O O
the O O
tissue O O
injury O O
too O O
often O O
occurs O O
at O O
an O O
irreversible O O
stage O O
vis O O
- O O
a O O
- O O
vis O O
the O O
" O O
regeneration O O
" O O
of O O
the O O
muscle O O
tissue O O
; O O
and O O
finally O O
because O O
the O O
dystrophic O O
injurious O O
agent O O
is O O
certainly O O
not O O
the O O
lack O O
of O O
vitamin O O
E O O
but O O
something O O
as O O
yet O O
unknown O O
. O O

Paclitaxel O O
3 O O
- O O
hour O O
infusion O O
given O O
alone O O
and O O
combined O O
with O O
carboplatin O O
: O O
preliminary O O
results O O
of O O
dose O O
- O O
escalation O O
trials O O
. O O

Paclitaxel O O
( O O
Taxol O O
; O O
Bristol O O
- O O
Myers O O
Squibb O O
Company O O
, O O
Princeton O O
, O O
NJ O O
) O O
by O O
3 O O
- O O
hour O O
infusion O O
was O O
combined O O
with O O
carboplatin O O
in O O
a O O
phase O O
I O O
/ O O
II O O
study O O
directed O O
to O O
patients O O
with O O
non B B_DISEASE
- I I_DISEASE
small I I_DISEASE
cell I I_DISEASE
lung I I_DISEASE
cancer I I_DISEASE
. O O

Carboplatin O O
was O O
given O O
at O O
a O O
fixed O O
target O O
area O O
under O O
the O O
concentration O O
- O O
time O O
curve O O
of O O
6 O O
. O O
0 O O
by O O
the O O
Calvert O O
formula O O
, O O
whereas O O
paclitaxel O O
was O O
escalated O O
in O O
patient O O
cohorts O O
from O O
150 O O
mg O O
/ O O
m2 O O
( O O
dose O O
level O O
I O O
) O O
to O O
175 O O
, O O
200 O O
, O O
225 O O
, O O
and O O
250 O O
mg O O
/ O O
m2 O O
. O O

The O O
225 O O
mg O O
/ O O
m2 O O
level O O
was O O
expanded O O
for O O
the O O
phase O O
II O O
study O O
since O O
the O O
highest O O
level O O
achieved O O
( O O
250 O O
mg O O
/ O O
m2 O O
) O O
required O O
modification O O
because O O
of O O
nonhematologic O O
toxicities B B_DISEASE
( O O
arthralgia B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
sensory B B_DISEASE
neuropathy I I_DISEASE
) O O
. O O

Carboplatin O O
did O O
not O O
appear O O
to O O
add O O
to O O
the O O
hematologic B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toxicities I B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observed O O
, O O
and O O
the O O
paclitaxel O O
/ O O
carboplatin O O
combination O O
could O O
be O O
dosed O O
every O O
3 O O
weeks O O
. O O

The O O
dose O O
- O O
dependent O O
effect O O
of O O
misoprostol O O
on O O
indomethacin O O
- O O
induced O O
renal B B_DISEASE
dysfunction I I_DISEASE
in O O
well O O
compensated O O
cirrhosis B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Misoprostol O O
( O O
200 O O
micrograms O O
) O O
has O O
been O O
shown O O
to O O
acutely O O
counteract O O
the O O
indomethacin O O
- O O
induced O O
renal B B_DISEASE
dysfunction I I_DISEASE
in O O
well O O
compensated O O
cirrhotic B B_DISEASE
patients O O
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
determine O O
if O O
the O O
prophylactic O O
value O O
of O O
misoprostol O O
was O O
dose O O
- O O
dependent O O
. O O

Parameters O O
of O O
renal O O
hemodynamics O O
and O O
tubular O O
sodium O O
and O O
water O O
handling O O
were O O
assessed O O
by O O
clearance O O
techniques O O
in O O
26 O O
well O O
compensated O O
cirrhotic B B_DISEASE/B_PERSON
patients O O
before O O
and O O
after O O
an O O
oral O O
combination O O
of O O
50 O O
mg O O
of O O
indomethacin O O
and O O
various O O
doses O O
of O O
misoprostol O O
. O O

These O O
changes O O
were O O
maximal O O
in O O
the O O
hour O O
immediately O O
after O O
medications O O
and O O
slowly O O
returned O O
toward O O
base O O
- O O
line O O
levels O O
thereafter O O
. O O

These O O
results O O
suggest O O
that O O
the O O
renal O O
protective O O
effects O O
of O O
misoprostol O O
is O O
dose O O
- O O
dependent O O
. O O

However O O
, O O
until O O
this O O
apparent O O
ability O O
of O O
200 O O
micrograms O O
of O O
misoprostol O O
to O O
prevent O O
the O O
adverse O O
effects O O
of O O
indomethacin O O
on O O
renal O O
function O O
is O O
confirmed O O
with O O
chronic O O
frequent O O
dosing O O
, O O
it O O
would O O
be O O
prudent O O
to O O
avoid O O
nonsteroidal O O
anti O O
- O O
inflammatory O O
therapy O O
in O O
patients O O
with O O
cirrhosis B B_DISEASE/B_LOCATION
. O O

Increased O O
frequency O O
and O O
severity O O
of O O
angio B B_DISEASE
- I I_DISEASE
oedema I I_DISEASE
related O O
to O O
long O O
- O O
term O O
therapy O O
with O O
angiotensin O O
- O O
converting O O
enzyme O O
inhibitor O O
in O O
two O O
patients O O
. O O

Adverse O O
reactions O O
to O O
drugs O O
are O O
well O O
recognized O O
as O O
a O O
cause O O
of O O
acute O O
or O O
chronic O O
urticaria B B_DISEASE
, O O
and O O
angio B B_DISEASE
- I I_DISEASE
oedema I I_DISEASE
. O O

Angiotensin O O
- O O
converting O O
enzyme O O
( O O
ACE O O
) O O
inhibitors O O
, O O
used O O
to O O
treat O O
hypertension B B_DISEASE
and O O
congestive B B_DISEASE
heart I I_DISEASE
failure I I_DISEASE
, O O
were O O
introduced O O
in O O
Europe O O
in O O
the O O
middle O O
of O O
the O O
eighties O O
, O O
and O O
the O O
use O O
of O O
these O O
drugs O O
has O O
increased O O
progressively O O
. O O

Soon O O
after O O
the O O
introduction O O
of O O
ACE O O
inhibitors O O
, O O
acute O O
bouts O O
of O O
angio B B_DISEASE
- I I_DISEASE
oedema I I_DISEASE
were O O
reported O O
in O O
association O O
with O O
the O O
use O O
of O O
these O O
drugs O O
. O O

We O O
wish O O
to O O
draw O O
attention O O
to O O
the O O
possibility O O
of O O
adverse O O
reactions O O
to O O
ACE O O
inhibitors O O
after O O
long O O
- O O
term O O
use O O
and O O
in O O
patients O O
with O O
pre O O
- O O
existing O O
angio B B_DISEASE
- I I_DISEASE
oedema I I_DISEASE
. O O

Myoclonus B B_DISEASE_ADJECTIVE[DISEASE]
associated O O
with O O
lorazepam O O
therapy O O
in O O
very O O
- O O
low O O
- O O
birth O O
- O O
weight O O
infants O O
. O O

Lorazepam O O
is O O
being O O
used O O
with O O
increasing O O
frequency O O
as O O
a O O
sedative O O
in O O
the O O
newborn O O
and O O
the O O
young O O
infant O O
. O O

Three O O
young O O
infants O O
, O O
all O O
of O O
birth O O
weight O O
< O O
1 O O
, O O
500 O O
g O O
, O O
experienced O O
myoclonus B B_DISEASE
following O O
the O O
intravenous O O
administration O O
of O O
lorazepam O O
. O O

The O O
potential O O
neurotoxic B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O O
of O O
the O O
drug O O
( O O
and O O
its O O
vehicle O O
) O O
in O O
this O O
population O O
are O O
discussed O O
. O O

Injectable O O
lorazepam O O
should O O
be O O
used O O
with O O
caution O O
in O O
VLBW O O
infants O O
. O O

Transvenous O O
right O O
ventricular O O
pacing O O
during O O
cardiopulmonary O O
resuscitation O O
of O O
pediatric O O
patients O O
with O O
acute O O
cardiomyopathy B B_DISEASE
. O O

We O O
describe O O
the O O
cardiopulmonary O O
resuscitation O O
efforts O O
on O O
five O O
patients O O
who O O
presented O O
in O O
acute O O
circulatory B B_DISEASE/B_LOCATION
failure I I_DISEASE/I_LOCATION
from O O
myocardial B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dysfunction I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Three O O
patients O O
had O O
acute O O
viral O O
myocarditis B B_DISEASE
, O O
one O O
had O O
a O O
carbamazepine O O
- O O
induced O O
acute O O
eosinophilic B B_DISEASE
myocarditis I I_DISEASE
, O O
and O O
one O O
had O O
cardiac O O
hemosiderosis O O
resulting O O
in O O
acute O O
cardiogenic B B_DISEASE
shock I I_DISEASE
. O O

All O O
patients O O
were O O
continuously O O
monitored O O
with O O
central O O
venous O O
and O O
arterial O O
catheters O O
in O O
addition O O
to O O
routine O O
noninvasive O O
monitoring O O
. O O

An O O
introducer O O
sheath O O
, O O
a O O
pacemaker O O
, O O
and O O
sterile O O
pacing O O
wires O O
were O O
made O O
readily O O
available O O
for O O
the O O
patients O O
, O O
should O O
the O O
need O O
arise O O
to O O
terminate O O
resistant O O
cardiac O O
dysrhythmias B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

All O O
patients O O
developed O O
cardiocirculatory O O
arrest O O
associated O O
with O O
extreme O O
hypotension B B_DISEASE
and O O
dysrhythmias B B_DISEASE
within O O
the O O
first O O
48 O O
hours O O
of O O
their O O
admission O O
to O O
the O O
pediatric O O
intensive O O
care O O
unit O O
( O O
PICU O O
) O O
. O O

Right O O
ventricular O O
pacemaker O O
wires O O
were O O
inserted O O
in O O
all O O
of O O
them O O
during O O
cardiopulmonary O O
resuscitation O O
( O O
CPR O O
) O O
. O O

These O O
patients O O
had O O
a O O
second O O
event O O
of O O
cardiac B B_DISEASE
arrest I I_DISEASE
, O O
resulting O O
in O O
death O O
, O O
within O O
10 O O
to O O
60 O O
minutes O O
. O O

We O O
conclude O O
that O O
cardiac O O
pacing O O
during O O
resuscitative O O
efforts O O
in O O
pediatric O O
patients O O
suffering O O
from O O
acute O O
myocardial B B_DISEASE/B_LOCATION
dysfunction I I_DISEASE/I_LOCATION
may O O
not O O
have O O
long O O
- O O
term O O
value O O
in O O
and O O
of O O
itself O O
; O O
however O O
, O O
if O O
temporary O O
hemodynamic O O
stability O O
is O O
achieved O O
by O O
this O O
procedure O O
, O O
it O O
may O O
provide O O
additional O O
time O O
needed O O
to O O
institute O O
other O O
therapeutic O O
modalities O O
. O O

Efficacy O O
and O O
safety O O
of O O
granisetron O O
, O O
a O O
selective O O
5 O O
- O O
hydroxytryptamine O O
- O O
3 O O
receptor O O
antagonist O O
, O O
in O O
the O O
prevention O O
of O O
nausea B B_DISEASE
and O O
vomiting B B_DISEASE
induced O O
by O O
high O O
- O O
dose O O
cisplatin O O
. O O

PURPOSE O O
: O O
To O O
assess O O
the O O
antiemetic O O
effects O O
and O O
safety O O
profile O O
of O O
four O O
different O O
doses O O
of O O
granisetron O O
( O O
Kytril O O
; O O
SmithKline O O
Beecham O O
Pharmaceuticals O O
, O O
Philadelphia O O
, O O
PA O O
) O O
when O O
administered O O
as O O
a O O
single O O
intravenous O O
( O O
IV O O
) O O
dose O O
for O O
prophylaxis O O
of O O
cisplatin O O
- O O
induced O O
nausea B B_DISEASE
and O O
vomiting B B_DISEASE
. O O

PATIENTS O O
AND O O
METHODS O O
: O O
One O O
hundred O O
eighty O O
- O O
four O O
chemotherapy O O
- O O
naive O O
patients O O
receiving O O
high O O
- O O
dose O O
cisplatin O O
( O O
81 O O
to O O
120 O O
mg O O
/ O O
m2 O O
) O O
were O O
randomized O O
to O O
receive O O
one O O
of O O
four O O
granisetron O O
doses O O
( O O
5 O O
, O O
10 O O
, O O
20 O O
, O O
or O O
40 O O
micrograms O O
/ O O
kg O O
) O O
administered O O
before O O
chemotherapy O O
. O O

Patients O O
were O O
observed O O
on O O
an O O
inpatient O O
basis O O
for O O
18 O O
to O O
24 O O
hours O O
, O O
and O O
vital O O
signs O O
, O O
nausea B B_DISEASE
, O O
vomiting B B_DISEASE
, O O
retching O O
, O O
and O O
appetite O O
were O O
assessed O O
. O O

RESULTS O O
: O O
After O O
granisetron O O
doses O O
of O O
5 O O
, O O
10 O O
, O O
20 O O
, O O
and O O
40 O O
micrograms O O
/ O O
kg O O
, O O
a O O
major O O
response O O
( O O
< O O
or O O
= O O
two O O
vomiting B B_DISEASE
or O O
retching O O
episodes O O
, O O
and O O
no O O
antiemetic O O
rescue O O
) O O
was O O
recorded O O
in O O
23 O O
% O O
, O O
57 O O
% O O
, O O
58 O O
% O O
, O O
and O O
60 O O
% O O
of O O
patients O O
, O O
respectively O O
, O O
and O O
a O O
complete O O
response O O
( O O
no O O
vomiting B B_DISEASE
or O O
retching O O
, O O
and O O
no O O
antiemetic O O
rescue O O
) O O
in O O
18 O O
% O O
, O O
41 O O
% O O
, O O
40 O O
% O O
, O O
and O O
47 O O
% O O
of O O
patients O O
, O O
respectively O O
. O O

There O O
was O O
a O O
statistically O O
longer O O
time O O
to O O
first O O
episode O O
of O O
nausea B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
P O O
= O O
. O O
0015 O O
) O O
and O O
vomiting B B_DISEASE
( O O
P O O
= O O
. O O
0001 O O
) O O
, O O
and O O
fewer O O
patients O O
were O O
administered O O
additional O O
antiemetic O O
medication O O
in O O
the O O
10 O O
- O O
micrograms O O
/ O O
kg O O
dosing O O
groups O O
than O O
in O O
the O O
5 O O
- O O
micrograms O O
/ O O
kg O O
dosing O O
group O O
. O O

Headache B B_DISEASE
was O O
the O O
most O O
frequently O O
reported O O
adverse O O
event O O
( O O
20 O O
% O O
) O O
. O O

CONCLUSION O O
: O O
A O O
single O O
10 O O
- O O
, O O
20 O O
- O O
, O O
or O O
40 O O
- O O
micrograms O O
/ O O
kg O O
dose O O
of O O
granisetron O O
was O O
effective O O
in O O
controlling O O
vomiting B B_DISEASE
in O O
57 O O
% O O
to O O
60 O O
% O O
of O O
patients O O
who O O
received O O
cisplatin O O
at O O
doses O O
greater O O
than O O
81 O O
mg O O
/ O O
m2 O O
and O O
totally O O
prevented O O
vomiting B B_DISEASE
in O O
40 O O
% O O
to O O
47 O O
% O O
of O O
patients O O
. O O

There O O
were O O
no O O
statistically O O
significant O O
differences O O
in O O
efficacy O O
between O O
the O O
10 O O
- O O
micrograms O O
/ O O
kg O O
dose O O
and O O
the O O
20 O O
- O O
and O O
40 O O
- O O
micrograms O O
/ O O
kg O O
doses O O
. O O

Granisetron O O
was O O
well O O
tolerated O O
at O O
all O O
doses O O
. O O

Adverse O O
interaction O O
between O O
clonidine O O
and O O
verapamil O O
. O O

OBJECTIVE O O
: O O
To O O
report O O
two O O
cases O O
of O O
a O O
possible O O
adverse O O
interaction O O
between O O
clonidine O O
and O O
verapamil O O
resulting O O
in O O
atrioventricular B B_DISEASE
( I I_DISEASE
AV I I_DISEASE
) I I_DISEASE
block I I_DISEASE
in O O
both O O
patients O O
and O O
severe O O
hypotension B B_DISEASE
in O O
one O O
patient O O
. O O

CASE O O
SUMMARIES O O
: O O
A O O
54 O O
- O O
year O O
- O O
old O O
woman O O
with O O
hyperaldosteronism B B_DISEASE
was O O
treated O O
with O O
verapamil O O
480 O O
mg O O
/ O O
d O O
and O O
spironolactone O O
100 O O
mg O O
/ O O
d O O
. O O

After O O
the O O
addition O O
of O O
a O O
minimal O O
dose O O
of O O
clonidine O O
( O O
0 O O
. O O
15 O O
mg O O
bid O O
) O O
, O O
she O O
developed O O
complete O O
AV B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
block I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
severe O O
hypotension B B_DISEASE
, O O
which O O
resolved O O
upon O O
cessation O O
of O O
all O O
medications O O
. O O

A O O
65 O O
- O O
year O O
- O O
old O O
woman O O
was O O
treated O O
with O O
extended O O
- O O
release O O
verapamil O O
240 O O
mg O O
/ O O
d O O
. O O

After O O
the O O
addition O O
of O O
clonidine O O
0 O O
. O O
15 O O
mg O O
bid O O
she O O
developed O O
complete O O
AV B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
block I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
which O O
resolved O O
after O O
all O O
therapy O O
was O O
stopped O O
. O O

DISCUSSION O O
: O O
An O O
adverse O O
interaction O O
between O O
clonidine O O
and O O
verapamil O O
has O O
not O O
been O O
reported O O
previously O O
. O O

Clinicians O O
should O O
be O O
acquainted O O
with O O
this O O
possibly O O
fatal O O
interaction O O
between O O
two O O
commonly O O
used O O
antihypertensive O O
drugs O O
. O O

Pharmacological O O
studies O O
on O O
a O O
new O O
dihydrothienopyridine O O
calcium O O
antagonist O O
, O O
S O O
- O O
312 O O
- O O
d O O
. O O

S O O
- O O
312 O O
, O O
S O O
- O O
312 O O
- O O
d O O
, O O
but O O
not O O
S O O
- O O
312 O O
- O O
l O O
, O O
L O O
- O O
type O O
calcium O O
channel O O
antagonists O O
, O O
showed O O
anticonvulsant O O
effects O O
on O O
the O O
audiogenic B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
tonic I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
convulsions I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O O
DBA O O
/ O O
2 O O
mice O O
; O O
and O O
their O O
ED50 O O
values O O
were O O
18 O O
. O O
4 O O
( O O
12 O O
. O O
8 O O
- O O
27 O O
. O O
1 O O
) O O
mg O O
/ O O
kg O O
, O O
p O O
. O O
o O O
. O O
and O O
15 O O
. O O
0 O O
( O O
10 O O
. O O
2 O O
- O O
23 O O
. O O
7 O O
) O O
mg O O
/ O O
kg O O
, O O
p O O
. O O
o O O
. O O
, O O
respectively O O
, O O
while O O
that O O
of O O
flunarizine O O
was O O
34 O O
. O O
0 O O
( O O
26 O O
. O O
0 O O
- O O
44 O O
. O O
8 O O
) O O
mg O O
/ O O
kg O O
, O O
p O O
. O O
o O O
. O O

Although O O
moderate O O
anticonvulsant O O
effects O O
of O O
S O O
- O O
312 O O
- O O
d O O
in O O
higher O O
doses O O
were O O
observed O O
against O O
the O O
clonic O O
convulsions B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O O
by O O
pentylenetetrazole O O
( O O
85 O O
mg O O
/ O O
kg O O
, O O
s O O
. O O
c O O
. O O
) O O
or O O
bemegride O O
( O O
40 O O
mg O O
/ O O
kg O O
, O O
s O O
. O O
c O O
. O O
) O O
, O O
no O O
effects O O
were O O
observed O O
in O O
convulsions B B_DISEASE
induced O O
by O O
N O O
- O O
methyl O O
- O O
D O O
- O O
aspartate O O
, O O
picrotoxin O O
, O O
or O O
electroshock O O
in O O
Slc O O
: O O
ddY O O
mice O O
. O O

S O O
- O O
312 O O
- O O
d O O
may O O
be O O
useful O O
in O O
the O O
therapy O O
of O O
certain O O
types O O
of O O
human O O
epilepsy B B_DISEASE
. O O

Transmural O O
myocardial B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
sumatriptan O O
. O O

We O O
describe O O
a O O
47 O O
- O O
year O O
- O O
old O O
woman O O
with O O
an O O
acute O O
myocardial B B_DISEASE
infarction I I_DISEASE
after O O
administration O O
of O O
sumatriptan O O
6 O O
mg O O
subcutaneously O O
for O O
cluster B B_DISEASE
headache I I_DISEASE
. O O

The O O
patient O O
had O O
no O O
history O O
of O O
underlying O O
ischaemic B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
heart I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
disease I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
or O O
Prinzmetal B B_DISEASE
' I I_DISEASE
s I I_DISEASE
angina I I_DISEASE
. O O

Flumazenil O O
induces O O
seizures B B_DISEASE
and O O
death O O
in O O
mixed O O
cocaine O O
- O O
diazepam O O
intoxications O O
. O O

STUDY O O
HYPOTHESIS O O
: O O
Administration O O
of O O
the O O
benzodiazepine O O
antagonist O O
flumazenil O O
may O O
unmask O O
seizures B B_DISEASE
in O O
mixed O O
cocaine O O
- O O
benzodiazepine O O
intoxication O O
. O O

DESIGN O O
: O O
Male O O
Sprague O O
- O O
Dawley O O
rats O O
received O O
100 O O
mg O O
/ O O
kg O O
cocaine O O
IP O O
alone O O
, O O
5 O O
mg O O
/ O O
kg O O
diazepam O O
alone O O
, O O
or O O
a O O
combination O O
of O O
diazepam O O
and O O
cocaine O O
. O O

Three O O
minutes O O
later O O
, O O
groups O O
were O O
challenged O O
with O O
vehicle O O
or O O
flumazenil O O
5 O O
or O O
10 O O
mg O O
/ O O
kg O O
IP O O
. O O

Animal O O
behavior O O
, O O
seizures B B_DISEASE/B_ORGANISM_FUNCTION
( O O
time O O
to O O
and O O
incidence O O
) O O
, O O
death O O
( O O
time O O
to O O
and O O
incidence O O
) O O
, O O
and O O
cortical O O
EEG O O
tracings O O
were O O
recorded O O
. O O

INTERVENTIONS O O
: O O
Administration O O
of O O
flumazenil O O
to O O
animals O O
after O O
they O O
had O O
received O O
a O O
combination O O
dose O O
of O O
cocaine O O
and O O
diazepam O O
. O O

RESULTS O O
: O O
In O O
group O O
1 O O
, O O
animals O O
received O O
cocaine O O
followed O O
by O O
vehicle O O
. O O

This O O
resulted O O
in O O
100 O O
% O O
developing O O
seizures B B_DISEASE
and O O
death O O
. O O

Group O O
2 O O
received O O
diazepam O O
alone O O
followed O O
by O O
vehicle O O
. O O

Animals O O
became O O
somnolent O O
and O O
none O O
died O O
. O O

Group O O
3 O O
received O O
diazepam O O
followed O O
by O O
5 O O
mg O O
/ O O
kg O O
flumazenil O O
. O O

Animals O O
became O O
somnolent O O
after O O
diazepam O O
and O O
then O O
active O O
after O O
flumazenil O O
administration O O
. O O

In O O
group O O
4 O O
, O O
a O O
combination O O
of O O
cocaine O O
and O O
diazepam O O
was O O
administered O O
simultaneously O O
. O O

This O O
resulted O O
in O O
no O O
overt O O
or O O
EEG O O
- O O
detectable O O
seizures B B_DISEASE
and O O
a O O
50 O O
% O O
incidence O O
of O O
death O O
. O O

Group O O
5 O O
received O O
a O O
similar O O
combination O O
of O O
cocaine O O
and O O
diazepam O O
, O O
followed O O
later O O
by O O
5 O O
mg O O
/ O O
kg O O
flumazenil O O
. O O

This O O
resulted O O
in O O
an O O
increased O O
incidence O O
of O O
seizures B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
90 O O
% O O
( O O
P O O
< O O
. O O
01 O O
) O O
, O O
and O O
death O O
, O O
100 O O
% O O
( O O
P O O
< O O
or O O
= O O
. O O
01 O O
) O O
, O O
compared O O
with O O
group O O
4 O O
. O O

Group O O
6 O O
received O O
cocaine O O
and O O
diazepam O O
followed O O
by O O
10 O O
mg O O
/ O O
kg O O
flumazenil O O
. O O

This O O
also O O
resulted O O
in O O
an O O
increased O O
incidence O O
of O O
seizures B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
90 O O
% O O
( O O
P O O
< O O
or O O
= O O
. O O
01 O O
) O O
, O O
and O O
death O O
, O O
90 O O
% O O
( O O
P O O
< O O
or O O
= O O
. O O
05 O O
) O O
, O O
compared O O
with O O
group O O
4 O O
. O O

CONCLUSION O O
: O O
Flumazenil O O
can O O
unmask O O
seizures B B_DISEASE
and O O
increase O O
the O O
incidence O O
of O O
death O O
in O O
a O O
model O O
of O O
combined O O
cocaine O O
- O O
diazepam O O
intoxications O O
. O O

Mechanisms O O
for O O
protective O O
effects O O
of O O
free O O
radical O O
scavengers O O
on O O
gentamicin O O
- O O
mediated O O
nephropathy B B_DISEASE
in O O
rats O O
. O O

Studies O O
were O O
performed O O
to O O
examine O O
the O O
mechanisms O O
for O O
the O O
protective O O
effects O O
of O O
free O O
radical O O
scavengers O O
on O O
gentamicin O O
( O O
GM O O
) O O
- O O
mediated O O
nephropathy B B_DISEASE
. O O

Administration O O
of O O
GM O O
at O O
40 O O
mg O O
/ O O
kg O O
sc O O
for O O
13 O O
days O O
to O O
rats O O
induced O O
a O O
significant O O
reduction O O
in O O
renal O O
blood O O
flow O O
( O O
RBF O O
) O O
and O O
inulin O O
clearance O O
( O O
CIn O O
) O O
as O O
well O O
as O O
marked O O
tubular B B_DISEASE
damage I I_DISEASE
. O O

A O O
significant O O
reduction O O
in O O
urinary O O
guanosine O O
3 O O
' O O
, O O
5 O O
' O O
- O O
cyclic O O
monophosphate O O
( O O
cGMP O O
) O O
excretion O O
and O O
a O O
significant O O
increase O O
in O O
renal O O
cortical O O
renin O O
and O O
endothelin O O
- O O
1 O O
contents O O
were O O
also O O
observed O O
in O O
GM O O
- O O
mediated O O
nephropathy B B_DISEASE/B_BIO
. O O

SOD O O
did O O
not O O
attenuate O O
the O O
tubular B B_DISEASE_ADJECTIVE[DISEASE]
damage I I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
contrast O O
, O O
DMTU O O
significantly O O
reduced O O
the O O
tubular B B_DISEASE
damage I I_DISEASE
and O O
lipid O O
peroxidation O O
, O O
but O O
it O O
did O O
not O O
affect O O
renal O O
hemodynamics O O
and O O
vasoactive O O
substances O O
. O O

Neither O O
SOD O O
nor O O
DMTU O O
affected O O
the O O
renal O O
cortical O O
GM O O
content O O
in O O
GM O O
- O O
treated O O
rats O O
. O O

These O O
results O O
suggest O O
that O O
1 O O
) O O
both O O
SOD O O
and O O
DMTU O O
have O O
protective O O
effects O O
on O O
GM O O
- O O
mediated O O
nephropathy B B_DISEASE
, O O
2 O O
) O O
the O O
mechanisms O O
for O O
the O O
protective O O
effects O O
differ O O
for O O
SOD O O
and O O
DMTU O O
, O O
and O O
3 O O
) O O
superoxide O O
anions O O
play O O
a O O
critical O O
role O O
in O O
GM O O
- O O
induced O O
renal O O
vasoconstriction O O
. O O

Cephalothin O O
- O O
induced O O
immune O O
hemolytic B B_DISEASE_ADJECTIVE[DISEASE]
anemia I I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
patient O O
with O O
renal B B_DISEASE
disease I I_DISEASE
developed O O
Coombs O O
- O O
positive O O
hemolytic B B_DISEASE
anemia I I_DISEASE
while O O
receiving O O
cephalothin O O
therapy O O
. O O

In O O
addition O O
, O O
nonimmunologic O O
binding O O
of O O
normal O O
and O O
patient O O
' O O
s O O
serum O O
proteins O O
to O O
her O O
own O O
and O O
cephalothin O O
- O O
coated O O
normal O O
red O O
cells O O
was O O
demonstrated O O
. O O

Skin O O
tests O O
and O O
in O O
vitro O O
lymphocyte O O
stimulation O O
revealed O O
that O O
the O O
patient O O
was O O
sensitized O O
to O O
cephalothin O O
and O O
also O O
to O O
ampicillin O O
. O O

Careful O O
investigation O O
of O O
drug O O
- O O
induced O O
hemolytic B B_DISEASE_ADJECTIVE[DISEASE]
anemias I I_DISEASE_ADJECTIVE[DISEASE]
reveals O O
the O O
complexity O O
of O O
the O O
immune O O
mechanisms O O
involved O O
. O O

Assessment O O
of O O
cardiomyocyte O O
DNA O O
synthesis O O
during O O
hypertrophy B B_DISEASE/B_ORGANISM_FUNCTION
in O O
adult O O
mice O O
. O O

The O O
ability O O
of O O
cardiomyocytes O O
to O O
synthesize O O
DNA O O
in O O
response O O
to O O
experimentally O O
induced O O
cardiac B B_DISEASE
hypertrophy I I_DISEASE
was O O
assessed O O
in O O
adult O O
mice O O
. O O

Isoproterenol O O
delivered O O
by O O
osmotic O O
minipump O O
implantation O O
in O O
adult O O
C3Heb O O
/ O O
FeJ O O
mice O O
resulted O O
in O O
a O O
46 O O
% O O
increase O O
in O O
heart O O
weight O O
and O O
a O O
19 O O
. O O
3 O O
% O O
increase O O
in O O
cardiomyocyte O O
area O O
. O O

No O O
DNA O O
synthesis O O
, O O
as O O
assessed O O
by O O
autoradiographic O O
analysis O O
of O O
isolated O O
cardiomyocytes O O
, O O
was O O
observed O O
in O O
control O O
or O O
hypertrophic B B_DISEASE/B_ENT
hearts I I_DISEASE/I_ENT
. O O

A O O
survey O O
of O O
15 O O
independent O O
inbred O O
strains O O
of O O
mice O O
revealed O O
that O O
ventricular O O
cardiomyocyte O O
nuclear O O
number O O
ranged O O
from O O
3 O O
to O O
13 O O
% O O
mononucleate O O
, O O
suggesting O O
that O O
cardiomyocyte O O
terminal O O
differentiation O O
is O O
influenced O O
directly O O
or O O
indirectly O O
by O O
genetic O O
background O O
. O O

To O O
determine O O
whether O O
the O O
capacity O O
for O O
reactive O O
DNA O O
synthesis O O
was O O
also O O
subject O O
to O O
genetic O O
regulation O O
, O O
cardiac B B_DISEASE
hypertrophy I I_DISEASE
was O O
induced O O
in O O
the O O
strains O O
of O O
mice O O
comprising O O
the O O
extremes O O
of O O
the O O
nuclear O O
number O O
survey O O
. O O

These O O
data O O
indicate O O
that O O
adult O O
mouse O O
atrial O O
and O O
ventricular O O
cardiomyocytes O O
do O O
not O O
synthesize O O
DNA O O
in O O
response O O
to O O
isoproterenol O O
- O O
induced O O
cardiac B B_DISEASE_ADJECTIVE[DISEASE]
hypertrophy I I_DISEASE_ADJECTIVE[DISEASE]
. O O

Central O O
cardiovascular O O
effects O O
of O O
AVP O O
and O O
ANP O O
in O O
normotensive O O
and O O
spontaneously O O
hypertensive B B_DISEASE_ADJECTIVE[DISEASE]
rats O O
. O O

The O O
purpose O O
of O O
the O O
present O O
study O O
was O O
to O O
compare O O
influence O O
of O O
central O O
arginine O O
vasopressin O O
( O O
AVP O O
) O O
and O O
of O O
atrial O O
natriuretic O O
peptide O O
( O O
ANP O O
) O O
on O O
control O O
of O O
arterial O O
blood O O
pressure O O
( O O
MAP O O
) O O
and O O
heart O O
rate O O
( O O
HR O O
) O O
in O O
normotensive O O
( O O
WKY O O
) O O
and O O
spontaneously O O
hypertensive B B_DISEASE
( O O
SHR O O
) O O
rats O O
. O O

Three O O
series O O
of O O
experiments O O
were O O
performed O O
on O O
30 O O
WKY O O
and O O
30 O O
SHR O O
, O O
chronically O O
instrumented O O
with O O
guide O O
tubes O O
in O O
the O O
lateral O O
ventricle O O
( O O
LV O O
) O O
and O O
arterial O O
and O O
venous O O
catheters O O
. O O

MAP O O
and O O
HR O O
were O O
monitored O O
before O O
and O O
after O O
i O O
. O O
v O O
. O O
injections O O
of O O
either O O
vehicle O O
or O O
1 O O
, O O
10 O O
and O O
50 O O
ng O O
of O O
AVP O O
and O O
25 O O
, O O
125 O O
and O O
500 O O
ng O O
of O O
ANP O O
. O O

Sensitivity O O
of O O
cardiac O O
component O O
of O O
baroreflex O O
( O O
CCB O O
) O O
, O O
expressed O O
as O O
a O O
slope O O
of O O
the O O
regression O O
line O O
was O O
determined O O
from O O
relationships O O
between O O
systolic O O
arterial O O
pressure O O
( O O
SAP O O
) O O
and O O
HR O O
period O O
( O O
HRp O O
) O O
during O O
phenylephrine O O
( O O
Phe O O
) O O
- O O
induced O O
hypertension B B_DISEASE
and O O
sodium O O
nitroprusside O O
( O O
SN O O
) O O
- O O
induced O O
hypotension B B_DISEASE
. O O

Increases O O
of O O
MAP O O
occurred O O
after O O
LV O O
administration O O
of O O
1 O O
, O O
10 O O
and O O
50 O O
ng O O
of O O
AVP O O
in O O
WKY O O
and O O
of O O
10 O O
and O O
50 O O
ng O O
in O O
SHR O O
. O O

CCB O O
was O O
reduced O O
in O O
WKY O O
and O O
SHR O O
after O O
LV O O
administration O O
of O O
AVP O O
during O O
SN O O
- O O
induced O O
hypotension B B_DISEASE
. O O

Cutaneous O O
exposure O O
to O O
warfarin O O
- O O
like O O
anticoagulant O O
causing O O
an O O
intracerebral B B_DISEASE
hemorrhage I I_DISEASE
: O O
a O O
case O O
report O O
. O O

A O O
case O O
of O O
intercerebral O O
hematoma B B_DISEASE
due O O
to O O
warfarin O O
- O O
induced O O
coagulopathy B B_DISEASE
is O O
presented O O
. O O

The O O
39 O O
- O O
year O O
- O O
old O O
woman O O
had O O
spread O O
a O O
warfarin O O
- O O
type O O
rat O O
poison O O
around O O
her O O
house O O
weekly O O
using O O
her O O
bare O O
hands O O
, O O
with O O
no O O
washing O O
post O O
application O O
. O O

Percutaneous O O
absorption O O
of O O
warfarin O O
causing O O
coagulopathy B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
reported O O
three O O
times O O
in O O
the O O
past O O
, O O
is O O
a O O
significant O O
risk O O
if O O
protective O O
measures O O
, O O
such O O
as O O
gloves O O
, O O
are O O
not O O
used O O
. O O

An O O
adverse O O
drug O O
interaction O O
with O O
piroxicam O O
, O O
which O O
she O O
took O O
occasionally O O
, O O
may O O
have O O
exacerbated O O
the O O
coagulopathy B B_DISEASE
. O O

From O O
1986 O O
to O O
February O O
1993 O O
, O O
40 O O
children O O
aged O O
2 O O
months O O
to O O
18 O O
years O O
( O O
average O O
age O O
10 O O
. O O
4 O O
+ O O
/ O O
- O O
5 O O
. O O
8 O O
years O O
) O O
underwent O O
heart O O
transplantation O O
. O O

Indications O O
for O O
transplantation O O
were O O
idiopathic B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cardiomyopathy I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
52 O O
% O O
) O O
, O O
congenital B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
heart I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disease I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
35 O O
% O O
) O O
with O O
and O O
without O O
prior O O
repair O O
( O O
71 O O
% O O
and O O
29 O O
% O O
, O O
respectively O O
) O O
, O O
hypertrophic B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cardiomyopathy I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
5 O O
% O O
) O O
, O O
valvular B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
heart I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disease I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
3 O O
% O O
) O O
, O O
and O O
doxorubicin O O
cardiomyopathy B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
5 O O
% O O
) O O
. O O

Patients O O
were O O
managed O O
with O O
cyclosporine O O
and O O
azathioprine O O
. O O

No O O
prophylaxis O O
with O O
antilymphocyte O O
globulin O O
was O O
used O O
. O O

Steroids O O
were O O
given O O
to O O
39 O O
% O O
of O O
patients O O
for O O
refractory O O
rejection O O
, O O
but O O
weaning O O
was O O
always O O
attempted O O
and O O
generally O O
successful O O
( O O
64 O O
% O O
) O O
. O O

Five O O
patients O O
( O O
14 O O
% O O
) O O
received O O
maintenance O O
steroids O O
. O O

Four O O
patients O O
died O O
in O O
the O O
perioperative O O
period O O
and O O
one O O
died O O
4 O O
months O O
later O O
. O O

There O O
have O O
been O O
no O O
deaths O O
related O O
to O O
rejection O O
or O O
infection B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Average O O
follow O O
- O O
up O O
was O O
36 O O
+ O O
/ O O
- O O
19 O O
months O O
( O O
range O O
1 O O
to O O
65 O O
months O O
) O O
. O O

Cumulative O O
survival O O
is O O
88 O O
% O O
at O O
5 O O
years O O
. O O

Freedom O O
from O O
serious O O
infections B B_DISEASE
was O O
83 O O
% O O
at O O
1 O O
month O O
and O O
65 O O
% O O
at O O
1 O O
year O O
. O O

Twenty O O
- O O
one O O
patients O O
( O O
60 O O
% O O
) O O
have O O
undergone O O
annual O O
catheterizations O O
and O O
no O O
sign O O
of O O
graft O O
atherosclerosis B B_DISEASE
has O O
been O O
observed O O
. O O

Seizures B B_DISEASE
occurred O O
in O O
five O O
patients O O
( O O
14 O O
% O O
) O O
and O O
hypertension B B_DISEASE
was O O
treated O O
in O O
10 O O
patients O O
( O O
28 O O
% O O
) O O
. O O

No O O
patient O O
was O O
disabled O O
and O O
no O O
lymphoproliferative B B_DISEASE_ADJECTIVE[DISEASE]
disorder I I_DISEASE_ADJECTIVE[DISEASE]
was O O
observed O O
. O O
( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O

Delirium B B_DISEASE
during O O
fluoxetine O O
treatment O O
. O O

A O O
case O O
report O O
. O O

Only O O
a O O
few O O
reports O O
exist O O
, O O
however O O
, O O
on O O
the O O
relationship O O
between O O
the O O
serum O O
concentrations O O
of O O
selective O O
serotonin O O
reuptake O O
inhibitors O O
( O O
SSRIs O O
) O O
and O O
their O O
toxic O O
effects O O
. O O

In O O
some O O
cases O O
, O O
a O O
high O O
serum O O
concentration O O
of O O
citalopram O O
( O O
> O O
600 O O
nmol O O
/ O O
L O O
) O O
in O O
elderly O O
patients O O
has O O
been O O
associated O O
with O O
increased O O
somnolence B B_DISEASE
and O O
movement B B_DISEASE
difficulties I I_DISEASE
. O O

Widespread O O
cognitive B B_DISEASE_ADJECTIVE[DISEASE]
disorders I I_DISEASE_ADJECTIVE[DISEASE]
, O O
such O O
as O O
delirium B B_DISEASE/B_LOCATION
, O O
have O O
not O O
been O O
previously O O
linked O O
with O O
high O O
blood O O
levels O O
of O O
SSRIs O O
. O O

In O O
this O O
report O O
, O O
we O O
describe O O
a O O
patient O O
with O O
acute O O
hyperkinetic B B_DISEASE
delirium B I_DISEASE
connected O O
with O O
a O O
high O O
serum O O
total O O
fluoxetine O O
( O O
fluoxetine O O
plus O O
desmethylfluoxetine O O
) O O
concentration O O
. O O

Pulmonary B B_DISEASE
edema I I_DISEASE
and O O
shock B B_DISEASE
after O O
high O O
- O O
dose O O
aracytine O O
- O O
C O O
for O O
lymphoma B B_DISEASE
; O O
possible O O
role O O
of O O
TNF O O
- O O
alpha O O
and O O
PAF O O
. O O

Four O O
out O O
of O O
23 O O
consecutive O O
patients O O
treated O O
with O O
high O O
- O O
dose O O
Ara O O
- O O
C O O
for O O
lymphomas B B_DISEASE/B_GENE
in O O
our O O
institution O O
developed O O
a O O
strikingly O O
similar O O
syndrome O O
during O O
the O O
perfusion O O
. O O

It O O
was O O
characterized O O
by O O
the O O
onset O O
of O O
fever B B_DISEASE
, O O
diarrhea B B_DISEASE
, O O
shock B B_DISEASE
, O O
pulmonary B B_DISEASE
edema I I_DISEASE
, O O
acute B B_DISEASE
renal I I_DISEASE
failure I I_DISEASE
, O O
metabolic B B_DISEASE
acidosis I I_DISEASE
, O O
weight B B_DISEASE
gain I I_DISEASE
and O O
leukocytosis B B_DISEASE
. O O

Thorough O O
bacteriological O O
screening O O
failed O O
to O O
provide O O
evidence O O
of O O
infection B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

TNF O O
and O O
PAF O O
activity O O
was O O
found O O
in O O
the O O
serum O O
of O O
respectively O O
two O O
and O O
four O O
of O O
the O O
cases O O
, O O
but O O
not O O
in O O
the O O
six O O
controls O O
. O O

As O O
TNF O O
and O O
PAF O O
are O O
thought O O
to O O
be O O
involved O O
in O O
the O O
development O O
of O O
septic O O
shock B B_DISEASE
and O O
adult B B_DISEASE
respiratory I I_DISEASE
distress I I_DISEASE
syndrome I I_DISEASE
, O O
we O O
hypothesize O O
that O O
high O O
- O O
dose O O
Ara O O
- O O
C O O
may O O
be O O
associated O O
with O O
cytokine O O
release O O
. O O

Protective O O
effect O O
of O O
clentiazem O O
against O O
epinephrine O O
- O O
induced O O
cardiac B B_DISEASE
injury I I_DISEASE
in O O
rats O O
. O O

We O O
investigated O O
the O O
effects O O
of O O
clentiazem O O
, O O
a O O
1 O O
, O O
5 O O
- O O
benzothiazepine O O
calcium O O
antagonist O O
, O O
on O O
epinephrine O O
- O O
induced O O
cardiomyopathy B B_DISEASE
in O O
rats O O
. O O

With O O
2 O O
- O O
week O O
chronic O O
epinephrine O O
infusion O O
, O O
16 O O
of O O
30 O O
rats O O
died O O
within O O
4 O O
days O O
, O O
and O O
severe O O
ischemic B B_DISEASE
lesions I I_DISEASE
and O O
fibrosis B B_DISEASE
of O O
the O O
left O O
ventricles O O
were O O
observed O O
. O O

In O O
epinephrine O O
- O O
treated O O
rats O O
, O O
left O O
atrial O O
and O O
left O O
ventricular O O
papillary O O
muscle O O
contractile O O
responses O O
to O O
isoproterenol O O
were O O
reduced O O
, O O
but O O
responses O O
to O O
calcium O O
were O O
normal O O
or O O
enhanced O O
compared O O
to O O
controls O O
. O O

Left O O
ventricular O O
alpha O O
and O O
beta O O
adrenoceptor O O
densities O O
were O O
also O O
reduced O O
compared O O
to O O
controls O O
. O O

Treatment O O
with O O
clentiazem O O
prevented O O
epinephrine O O
- O O
induced O O
death O O
( O O
P O O
< O O
. O O
05 O O
) O O
, O O
and O O
attenuated O O
the O O
ventricular O O
ischemic B B_DISEASE
lesions I I_DISEASE
and O O
fibrosis B B_DISEASE
, O O
in O O
a O O
dose O O
- O O
dependent O O
manner O O
. O O

Clentiazem O O
also O O
did O O
not O O
prevent O O
the O O
enhanced O O
responses O O
to O O
calcium O O
seen O O
in O O
the O O
epinephrine O O
- O O
treated O O
animals O O
, O O
although O O
the O O
high O O
dose O O
of O O
clentiazem O O
partially O O
attenuated O O
the O O
maximal O O
response O O
to O O
calcium O O
compared O O
to O O
epinephrine O O
- O O
treated O O
animals O O
. O O

In O O
conclusion O O
, O O
clentiazem O O
attenuated O O
epinephrine O O
- O O
induced O O
cardiac B B_DISEASE
injury I I_DISEASE
, O O
possibly O O
through O O
its O O
effect O O
on O O
the O O
adrenergic O O
pathway O O
. O O

Kaliuretic O O
effect O O
of O O
L O O
- O O
dopa O O
treatment O O
in O O
parkinsonian B B_DISEASE/B_PERSON
patients O O
. O O

Hypokalemia B B_DISEASE
, O O
sometimes O O
severe O O
, O O
was O O
observed O O
in O O
some O O
L O O
- O O
dopa O O
- O O
treated O O
parkinsonian B B_DISEASE
patients O O
. O O

The O O
influence O O
of O O
L O O
- O O
dopa O O
on O O
the O O
renal O O
excretion O O
of O O
potassium O O
was O O
studied O O
in O O
3 O O
patients O O
with O O
hypokalemia B B_DISEASE/B_GENE
and O O
in O O
5 O O
normokalemic O O
patients O O
by O O
determination O O
of O O
renal O O
plasma O O
flow O O
, O O
glomerular O O
filtration O O
rate O O
, O O
plasma O O
concentration O O
of O O
potassium O O
and O O
sodium O O
as O O
well O O
as O O
urinary O O
excretion O O
of O O
potassium O O
, O O
sodium O O
and O O
aldosterone O O
. O O

L O O
- O O
Dopa O O
intake O O
was O O
found O O
to O O
cause O O
an O O
increased O O
excretion O O
of O O
potassium O O
, O O
and O O
sometimes O O
also O O
of O O
sodium O O
, O O
in O O
the O O
hypokalemic O O
but O O
not O O
in O O
the O O
normokalemic O O
patients O O
. O O

This O O
effect O O
on O O
the O O
renal O O
function O O
could O O
be O O
prohibited O O
by O O
the O O
administration O O
of O O
a O O
peripheral O O
dopa O O
decarbodylase O O
inhibitor O O
. O O

Cocaine O O
induced O O
myocardial B B_DISEASE_ADJECTIVE[DISEASE]
ischemia I I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
report O O
a O O
case O O
of O O
myocardial B B_DISEASE
ischemia I I_DISEASE
induced O O
by O O
cocaine O O
. O O

The O O
ischemia B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
probably O O
induced O O
by O O
coronary B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
artery I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spasm I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
reversed O O
by O O
nitroglycerin O O
and O O
calcium O O
blocking O O
agents O O
. O O

Doxorubicin O O
- O O
induced O O
cardiotoxicity B B_DISEASE
monitored O O
by O O
ECG O O
in O O
freely O O
moving O O
mice O O
. O O

A O O
new O O
model O O
to O O
test O O
potential O O
protectors O O
. O O

In O O
laboratory O O
animals O O
, O O
histology O O
is O O
most O O
commonly O O
used O O
to O O
study O O
doxorubicin O O
- O O
induced O O
cardiotoxicity B B_DISEASE
. O O

However O O
, O O
for O O
monitoring O O
during O O
treatment O O
, O O
large O O
numbers O O
of O O
animals O O
are O O
needed O O
. O O

With O O
this O O
model O O
we O O
investigated O O
the O O
effect O O
of O O
chronic O O
doxorubicin O O
administration O O
on O O
the O O
ECG O O
of O O
freely O O
moving O O
BALB O O
/ O O
c O O
mice O O
and O O
the O O
efficacy O O
of O O
ICRF O O
- O O
187 O O
as O O
a O O
protective O O
agent O O
. O O

The O O
ST O O
interval O O
significantly O O
widened O O
from O O
15 O O
. O O
0 O O
+ O O
/ O O
- O O
1 O O
. O O
5 O O
to O O
56 O O
. O O
8 O O
+ O O
/ O O
- O O
11 O O
. O O
8 O O
ms O O
in O O
week O O
10 O O
( O O
7 O O
weekly O O
doses O O
of O O
4 O O
mg O O
/ O O
kg O O
doxorubicin O O
given O O
i O O
. O O
v O O
. O O
plus O O
3 O O
weeks O O
of O O
observation O O
) O O
. O O

The O O
ECG O O
of O O
the O O
control O O
animals O O
did O O
not O O
change O O
during O O
the O O
entire O O
study O O
. O O

After O O
sacrifice O O
the O O
hearts O O
of O O
doxorubicin O O
- O O
treated O O
animals O O
were O O
enlarged O O
and O O
the O O
atria O O
were O O
hypertrophic B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

As O O
this O O
schedule O O
exerted O O
more O O
toxicity B B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
than O O
needed O O
to O O
investigate O O
protective O O
agents O O
, O O
the O O
protection O O
of O O
ICRF O O
- O O
187 O O
was O O
determined O O
using O O
a O O
dose O O
schedule O O
with O O
lower O O
general O O
toxicity B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O O
6 O O
weekly O O
doses O O
of O O
4 O O
mg O O
/ O O
kg O O
doxorubicin O O
given O O
i O O
. O O
v O O
. O O
plus O O
2 O O
weeks O O
of O O
observation O O
) O O
. O O

On O O
this O O
schedule O O
, O O
the O O
animals O O
' O O
hearts O O
appeared O O
normal O O
after O O
sacrifice O O
and O O
ICRF O O
- O O
187 O O
( O O
50 O O
mg O O
/ O O
kg O O
given O O
i O O
. O O
p O O
. O O
1 O O
h O O
before O O
doxorubicin O O
) O O
provided O O
almost O O
full O O
protection O O
. O O

These O O
data O O
were O O
confirmed O O
by O O
histology O O
. O O

The O O
results O O
indicate O O
that O O
this O O
new O O
model O O
is O O
very O O
sensitive O O
and O O
enables O O
monitoring O O
of O O
the O O
development O O
of O O
cardiotoxicity B B_DISEASE
with O O
time O O
. O O

These O O
findings O O
result O O
in O O
a O O
model O O
that O O
allows O O
the O O
testing O O
of O O
protectors O O
against O O
doxorubicin O O
- O O
induced O O
cardiotoxicity B B_DISEASE
as O O
demonstrated O O
by O O
the O O
protection O O
provided O O
by O O
ICRF O O
- O O
187 O O
. O O

Since O O
bupivacaine O O
and O O
epinephrine O O
may O O
both O O
precipitate O O
dysrhythmias B B_DISEASE
, O O
circulating O O
bupivacaine O O
during O O
regional O O
anesthesia O O
could O O
potentiate O O
dysrhythmogenic O O
effects O O
of O O
epinephrine O O
. O O

We O O
therefore O O
examined O O
whether O O
bupivacaine O O
alters O O
the O O
dysrhythmogenicity O O
of O O
subsequent O O
administration O O
of O O
epinephrine O O
in O O
conscious O O
, O O
healthy O O
dogs O O
and O O
in O O
anesthetized O O
dogs O O
with O O
myocardial B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infarction I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Forty O O
- O O
one O O
conscious O O
dogs O O
received O O
10 O O
micrograms O O
. O O
kg O O
- O O
1 O O
. O O
min O O
- O O
1 O O
epinephrine O O
. O O

Seventeen O O
animals O O
responded O O
with O O
ventricular B B_DISEASE
tachycardia I I_DISEASE
( O O
VT B B_PROTEIN[GENE]/B_DISEASE
) O O
within O O
3 O O
min O O
. O O

After O O
3 O O
h O O
, O O
these O O
responders O O
randomly O O
received O O
1 O O
or O O
2 O O
mg O O
/ O O
kg O O
bupivacaine O O
or O O
saline O O
over O O
5 O O
min O O
, O O
followed O O
by O O
10 O O
micrograms O O
. O O
kg O O
- O O
1 O O
. O O
min O O
- O O
1 O O
epinephrine O O
. O O

VT B B_DISEASE/B_PERSON
appeared O O
in O O
fewer O O
dogs O O
and O O
at O O
a O O
later O O
time O O
, O O
and O O
there O O
were O O
more O O
sinoatrial O O
beats O O
and O O
less O O
ectopies O O
. O O

Epinephrine O O
shortened O O
QT O O
less O O
after O O
bupivacaine O O
than O O
in O O
control O O
animals O O
. O O

One O O
day O O
after O O
experimental O O
myocardial B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
six O O
additional O O
halothane O O
- O O
anesthetized O O
dogs O O
received O O
4 O O
micrograms O O
. O O
kg O O
- O O
1 O O
. O O
min O O
- O O
1 O O
epinephrine O O
until O O
VT B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
appeared O O
. O O

After O O
45 O O
min O O
, O O
1 O O
mg O O
/ O O
kg O O
bupivacaine O O
was O O
injected O O
over O O
5 O O
min O O
, O O
again O O
followed O O
by O O
4 O O
micrograms O O
. O O
kg O O
- O O
1 O O
. O O
min O O
- O O
1 O O
epinephrine O O
. O O

In O O
these O O
dogs O O
, O O
the O O
prodysrhythmic O O
response O O
to O O
epinephrine O O
was O O
also O O
mitigated O O
by O O
preceding O O
bupivacaine O O
. O O

Bupivacaine O O
antagonizes O O
epinephrine O O
dysrhythmogenicity O O
in O O
conscious O O
dogs O O
susceptible O O
to O O
VT B B_DISEASE
and O O
in O O
anesthetized O O
dogs O O
with O O
spontaneous O O
postinfarct O O
dysrhythmias B B_DISEASE
. O O

Milk B B_DISEASE
- I I_DISEASE
alkali I I_DISEASE
syndrome I I_DISEASE
induced O O
by O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D O O
in O O
a O O
patient O O
with O O
hypoparathyroidism B B_DISEASE/B_LOCATION
. O O

Milk B B_DISEASE
- I I_DISEASE
alkali I I_DISEASE
syndrome I I_DISEASE
was O O
first O O
described O O
70 O O
years O O
ago O O
in O O
the O O
context O O
of O O
the O O
treatment O O
of O O
peptic B B_DISEASE/B_BIO
ulcer I B_DISEASE/I_BIO
disease I B_DISEASE/I_BIO
with O O
large O O
amounts O O
of O O
calcium O O
and O O
alkali O O
. O O

Although O O
with O O
current O O
ulcer B B_DISEASE/B_PERSON
therapy O O
( O O
H O O
- O O
2 O O
blockers O O
, O O
omeprazole O O
, O O
and O O
sucralfate O O
) O O
, O O
the O O
frequency O O
of O O
milk B B_DISEASE
- I I_DISEASE
alkali I I_DISEASE
syndrome I I_DISEASE
has O O
decreased O O
significantly O O
, O O
the O O
classic O O
triad O O
of O O
hypercalcemia B B_DISEASE
, O O
alkalosis B B_DISEASE/B_BACTERIUM[BIO]
, O O
and O O
renal B B_DISEASE
impairment I I_DISEASE
remains O O
the O O
hallmark O O
of O O
the O O
syndrome O O
. O O

Milk B B_DISEASE/B_PERSON
- I I_DISEASE/I_PERSON
alkali I I_DISEASE/I_PERSON
syndrome I I_DISEASE/I_PERSON
can O O
present O O
serious O O
and O O
occasionally O O
life O O
- O O
threatening O O
illness O O
unless O O
diagnosed O O
and O O
treated O O
appropriately O O
. O O

This O O
article O O
presents O O
a O O
patient O O
with O O
hypoparathyroidism B B_DISEASE/B_GENE
who O O
was O O
treated O O
with O O
calcium O O
carbonate O O
and O O
calcitriol O O
resulting O O
in O O
two O O
admissions O O
to O O
the O O
hospital O O
for O O
milk B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
alkali I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
syndrome I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

The O O
patient O O
was O O
successfully O O
treated O O
with O O
intravenous O O
pamidronate O O
on O O
his O O
first O O
admission O O
and O O
with O O
hydrocortisone O O
on O O
the O O
second O O
. O O

This O O
illustrates O O
intravenous O O
pamidronate O O
as O O
a O O
valuable O O
therapeutic O O
tool O O
when O O
milk B B_DISEASE/B_PERSON
- I I_DISEASE/I_PERSON
alkali I I_DISEASE/I_PERSON
syndrome I I_DISEASE/I_PERSON
presents O O
as O O
hypercalcemic B B_DISEASE/B_LOCATION
emergency I I_DISEASE/I_LOCATION
. O O

Famotidine O O
- O O
associated O O
delirium B B_DISEASE
. O O

A O O
series O O
of O O
six O O
cases O O
. O O

Famotidine O O
is O O
a O O
histamine O O
H2 O O
- O O
receptor O O
antagonist O O
used O O
in O O
inpatient O O
settings O O
for O O
prevention O O
of O O
stress O O
ulcers B B_DISEASE
and O O
is O O
showing O O
increasing O O
popularity O O
because O O
of O O
its O O
low O O
cost O O
. O O

Although O O
all O O
of O O
the O O
currently O O
available O O
H2 O O
- O O
receptor O O
antagonists O O
have O O
shown O O
the O O
propensity O O
to O O
cause O O
delirium B B_DISEASE
, O O
only O O
two O O
previously O O
reported O O
cases O O
have O O
been O O
associated O O
with O O
famotidine O O
. O O

The O O
authors O O
report O O
on O O
six O O
cases O O
of O O
famotidine O O
- O O
associated O O
delirium B B_DISEASE
in O O
hospitalized O O
patients O O
who O O
cleared O O
completely O O
upon O O
removal O O
of O O
famotidine O O
. O O

The O O
pharmacokinetics O O
of O O
famotidine O O
are O O
reviewed O O
, O O
with O O
no O O
change O O
in O O
its O O
metabolism O O
in O O
the O O
elderly O O
population O O
seen O O
. O O

The O O
implications O O
of O O
using O O
famotidine O O
in O O
elderly O O
persons O O
are O O
discussed O O
. O O

Encephalopathy B B_DISEASE
during O O
amitriptyline O O
therapy O O
: O O
are O O
neuroleptic B B_DISEASE
malignant I I_DISEASE
syndrome I I_DISEASE
and O O
serotonin B B_DISEASE
syndrome I I_DISEASE
spectrum O O
disorders O O
? O O

This O O
report O O
describes O O
a O O
case O O
of O O
encephalopathy B B_DISEASE
developed O O
in O O
the O O
course O O
of O O
amitriptyline O O
therapy O O
, O O
during O O
a O O
remission O O
of O O
unipolar B B_DISEASE
depression I I_DISEASE
. O O

Genetic O O
separation O O
of O O
tumor B B_DISEASE_ADJECTIVE[DISEASE]
growth O O
and O O
hemorrhagic B B_DISEASE_ADJECTIVE[DISEASE]
phenotypes O O
in O O
an O O
estrogen O O
- O O
induced O O
tumor B B_DISEASE
. O O

Chronic O O
administration O O
of O O
estrogen O O
to O O
the O O
Fischer O O
344 O O
( O O
F344 O O
) O O
rat O O
induces O O
growth O O
of O O
large O O
, O O
hemorrhagic B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
pituitary B B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
tumors I B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Ten O O
weeks O O
of O O
diethylstilbestrol O O
( O O
DES O O
) O O
treatment O O
caused O O
female O O
F344 O O
rat O O
pituitaries O O
to O O
grow O O
to O O
an O O
average O O
of O O
109 O O
. O O
2 O O
+ O O
/ O O
- O O
6 O O
. O O
3 O O
mg O O
( O O
mean O O
+ O O
/ O O
- O O
SE O O
) O O
versus O O
11 O O
. O O
3 O O
+ O O
/ O O
- O O
1 O O
. O O
4 O O
mg O O
for O O
untreated O O
rats O O
, O O
and O O
to O O
become O O
highly O O
hemorrhagic B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O O

Surprisingly O O
, O O
the O O
F1 O O
hybrid O O
tumors B B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O O
not O O
hemorrhagic B B_DISEASE_ADJECTIVE[DISEASE]
and O O
had O O
hemoglobin O O
content O O
and O O
outward O O
appearance O O
identical O O
to O O
that O O
of O O
BN O O
. O O

However O O
, O O
while O O
DES O O
- O O
induced O O
pituitary O O
growth O O
exhibited O O
quantitative O O
, O O
additive O O
inheritance O O
, O O
the O O
hemorrhagic B B_DISEASE
phenotype O O
exhibited O O
recessive O O
, O O
epistatic O O
inheritance O O
. O O

Only O O
5 O O
of O O
the O O
160 O O
F2 O O
pituitaries O O
exhibited O O
the O O
hemorrhagic B B_DISEASE_ADJECTIVE[DISEASE]
phenotype O O
; O O
36 O O
of O O
the O O
160 O O
F2 O O
pituitaries O O
were O O
in O O
the O O
F344 O O
range O O
of O O
mass O O
, O O
but O O
31 O O
of O O
these O O
were O O
not O O
hemorrhagic B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
indicating O O
that O O
the O O
hemorrhagic B B_DISEASE_ADJECTIVE[DISEASE]
phenotype O O
is O O
not O O
merely O O
a O O
consequence O O
of O O
extensive O O
growth O O
. O O

The O O
hemorrhagic B B_DISEASE/B_NUMBER[MEASURE]
F2 O O
pituitaries O O
were O O
all O O
among O O
the O O
most O O
massive O O
, O O
indicating O O
that O O
some O O
of O O
the O O
genes O O
regulate O O
both O O
phenotypes O O
. O O

Increased O O
expression O O
of O O
neuronal O O
nitric O O
oxide O O
synthase O O
in O O
bladder O O
afferent O O
pathways O O
following O O
chronic O O
bladder B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
irritation I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Immunocytochemical O O
techniques O O
were O O
used O O
to O O
examine O O
alterations O O
in O O
the O O
expression O O
of O O
neuronal O O
nitric O O
oxide O O
synthase O O
( O O
NOS O O
) O O
in O O
bladder O O
pathways O O
following O O
acute O O
and O O
chronic O O
irritation B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of I I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the I I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
urinary I I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tract I I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
rat O O
. O O

Chemical O O
cystitis B B_DISEASE
was O O
induced O O
by O O
cyclophosphamide O O
( O O
CYP O O
) O O
which O O
is O O
metabolized O O
to O O
acrolein O O
, O O
an O O
irritant O O
eliminated O O
in O O
the O O
urine O O
. O O

Injection O O
of O O
CYP O O
( O O
n O O
= O O
10 O O
, O O
75 O O
mg O O
/ O O
kg O O
, O O
i O O
. O O
p O O
. O O
) O O
2 O O
hours O O
prior O O
to O O
perfusion O O
( O O
acute O O
treatment O O
) O O
of O O
the O O
animals O O
increased O O
Fos O O
- O O
immunoreactivity O O
( O O
IR O O
) O O
in O O
neurons O O
in O O
the O O
dorsal O O
commissure O O
, O O
dorsal O O
horn O O
, O O
and O O
autonomic O O
regions O O
of O O
spinal O O
segments O O
( O O
L1 O O
- O O
L2 O O
and O O
L6 O O
- O O
S1 O O
) O O
which O O
receive O O
afferent O O
inputs O O
from O O
the O O
bladder O O
, O O
urethra O O
, O O
and O O
ureter O O
. O O

A O O
small O O
increase O O
( O O
1 O O
. O O
5 O O
- O O
fold O O
) O O
also O O
occurred O O
in O O
the O O
L1 O O
DRG O O
, O O
but O O
no O O
change O O
was O O
detected O O
in O O
the O O
L2 O O
and O O
L5 O O
DRG O O
. O O

Effects O O
of O O
a O O
new O O
calcium O O
antagonist O O
, O O
CD O O
- O O
832 O O
, O O
on O O
isoproterenol O O
- O O
induced O O
myocardial B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ischemia I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
dogs O O
with O O
partial O O
coronary B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stenosis I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Effects O O
of O O
CD O O
- O O
832 O O
on O O
isoproterenol O O
( O O
ISO O O
) O O
- O O
induced O O
myocardial B B_DISEASE
ischemia I I_DISEASE
were O O
studied O O
in O O
dogs O O
with O O
partial O O
coronary B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stenosis I B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
left O O
circumflex O O
coronary O O
artery O O
and O O
findings O O
were O O
compared O O
with O O
those O O
for O O
nifedipine O O
or O O
diltiazem O O
. O O

In O O
the O O
presence O O
of O O
coronary B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
artery I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stenosis I B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
3 O O
- O O
min O O
periods O O
of O O
intracoronary O O
ISO O O
infusion O O
( O O
10 O O
ng O O
/ O O
kg O O
/ O O
min O O
) O O
increased O O
heart O O
rate O O
and O O
maximal O O
rate O O
of O O
left O O
ventricular O O
pressure O O
rise O O
, O O
which O O
resulted O O
in O O
a O O
decrease O O
in O O
percentage O O
segmental O O
shortening O O
and O O
ST O O
- O O
segment O O
elevation O O
of O O
the O O
epicardial O O
electrocardiogram O O
. O O

After O O
the O O
control O O
ISO O O
infusion O O
with O O
stenosis B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
performed O O
, O O
equihypotensive O O
doses O O
of O O
CD O O
- O O
832 O O
( O O
3 O O
and O O
10 O O
micrograms O O
/ O O
kg O O
/ O O
min O O
, O O
n O O
= O O
7 O O
) O O
, O O
nifedipine O O
( O O
1 O O
and O O
3 O O
micrograms O O
/ O O
kg O O
/ O O
min O O
, O O
n O O
= O O
9 O O
) O O
or O O
diltiazem O O
( O O
10 O O
and O O
30 O O
micrograms O O
/ O O
kg O O
/ O O
min O O
, O O
n O O
= O O
7 O O
) O O
were O O
infused O O
5 O O
min O O
before O O
and O O
during O O
the O O
second O O
and O O
third O O
ISO O O
infusion O O
. O O

In O O
contrast O O
to O O
nifedipine O O
, O O
CD O O
- O O
832 O O
( O O
10 O O
micrograms O O
/ O O
kg O O
/ O O
min O O
) O O
prevented O O
the O O
decrease O O
in O O
percentage O O
segmental O O
shortening O O
from O O
32 O O
+ O O
/ O O
- O O
12 O O
% O O
to O O
115 O O
+ O O
/ O O
- O O
26 O O
% O O
of O O
the O O
control O O
value O O
( O O
P O O
< O O
. O O
01 O O
) O O
and O O
ST O O
- O O
segment O O
elevation O O
from O O
5 O O
. O O
6 O O
+ O O
/ O O
- O O
1 O O
. O O
0 O O
mV O O
to O O
1 O O
. O O
6 O O
+ O O
/ O O
- O O
1 O O
. O O
3 O O
mV O O
( O O
P O O
< O O
. O O
01 O O
) O O
at O O
3 O O
min O O
after O O
ISO O O
infusion O O
with O O
stenosis B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

Diltiazem O O
( O O
30 O O
micrograms O O
/ O O
kg O O
/ O O
min O O
) O O
also O O
prevented O O
the O O
decrease O O
in O O
percentage O O
segmental O O
shortening O O
from O O
34 O O
+ O O
/ O O
- O O
14 O O
% O O
to O O
63 O O
+ O O
/ O O
- O O
18 O O
% O O
of O O
the O O
control O O
value O O
( O O
P O O
< O O
. O O
05 O O
) O O
and O O
ST O O
- O O
segment O O
elevation O O
from O O
4 O O
. O O
7 O O
+ O O
/ O O
- O O
0 O O
. O O
7 O O
mV O O
to O O
2 O O
. O O
1 O O
+ O O
/ O O
- O O
0 O O
. O O
7 O O
mV O O
( O O
P O O
< O O
. O O
01 O O
) O O
at O O
3 O O
min O O
after O O
ISO O O
infusion O O
with O O
stenosis B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

These O O
data O O
show O O
that O O
CD O O
- O O
832 O O
improves O O
myocardial B B_DISEASE_ADJECTIVE[DISEASE]
ischemia I I_DISEASE_ADJECTIVE[DISEASE]
during O O
ISO O O
infusion O O
with O O
stenosis B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
suggest O O
that O O
the O O
negative O O
chronotropic O O
property O O
of O O
CD O O
- O O
832 O O
plays O O
a O O
major O O
role O O
in O O
the O O
beneficial O O
effects O O
of O O
CD O O
- O O
832 O O
. O O

The O O
effect O O
of O O
recombinant O O
human O O
insulin O O
- O O
like O O
growth O O
factor O O
- O O
I O O
on O O
chronic O O
puromycin O O
aminonucleoside O O
nephropathy B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
rats O O
. O O

We O O
recently O O
demonstrated O O
that O O
recombinant O O
hGH O O
exacerbates O O
renal O O
functional O O
and O O
structural O O
injury O O
in O O
chronic O O
puromycin O O
aminonucleoside O O
( O O
PAN O O
) O O
nephropathy B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
an O O
experimental O O
model O O
of O O
glomerular B B_DISEASE
disease I I_DISEASE
. O O

Therefore O O
, O O
we O O
examined O O
whether O O
recombinant O O
human O O
( O O
rh O O
) O O
IGF O O
- O O
I O O
is O O
a O O
safer O O
alternative O O
for O O
the O O
treatment O O
of O O
growth B B_DISEASE/B_GENE
failure I I_DISEASE/I_GENE
in O O
rats O O
with O O
chronic O O
PAN O O
nephropathy B B_DISEASE
. O O

The O O
glomerulopathy B B_DISEASE
was O O
induced O O
by O O
seven O O
serial O O
injections O O
of O O
PAN O O
over O O
12 O O
wk O O
. O O

Experimental O O
animals O O
( O O
n O O
= O O
6 O O
) O O
received O O
rhIGF O O
- O O
I O O
, O O
400 O O
micrograms O O
/ O O
d O O
, O O
whereas O O
control O O
rats O O
( O O
n O O
= O O
6 O O
) O O
received O O
the O O
vehicle O O
. O O

rhIGF O O
- O O
I O O
improved O O
weight O O
gain O O
by O O
14 O O
% O O
( O O
p O O
< O O
0 O O
. O O
05 O O
) O O
, O O
without O O
altering O O
hematocrit O O
or O O
blood O O
pressure O O
in O O
rats O O
with O O
renal B B_DISEASE/B_GENE
disease I I_DISEASE/I_GENE
. O O

Urinary O O
protein O O
excretion O O
was O O
unaltered O O
by O O
rhIGF O O
- O O
I O O
treatment O O
in O O
rats O O
with O O
chronic O O
PAN O O
nephropathy B B_DISEASE
. O O

After O O
12 O O
wk O O
, O O
the O O
inulin O O
clearance O O
was O O
higher O O
in O O
rhIGF O O
- O O
I O O
- O O
treated O O
rats O O
, O O
0 O O
. O O
48 O O
+ O O
/ O O
- O O
0 O O
. O O
08 O O
versus O O
0 O O
. O O
24 O O
+ O O
/ O O
- O O
0 O O
. O O
06 O O
mL O O
/ O O
min O O
/ O O
100 O O
g O O
of O O
body O O
weight O O
in O O
untreated O O
PAN O O
nephropathy B B_DISEASE/B_LOCATION
animals O O
, O O
p O O
< O O
0 O O
. O O
05 O O
. O O

The O O
improvement O O
in O O
GFR O O
was O O
not O O
associated O O
with O O
enhanced O O
glomerular B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
hypertrophy I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
or O O
increased O O
segmental O O
glomerulosclerosis B B_DISEASE/B_MEASURE
, O O
tubulointerstitial B B_DISEASE
injury I I_DISEASE
, O O
or O O
renal O O
cortical O O
malondialdehyde O O
content O O
. O O

In O O
rats O O
with O O
PAN O O
nephropathy B B_DISEASE
, O O
administration O O
of O O
rhIGF O O
- O O
I O O
increased O O
IGF O O
- O O
I O O
and O O
GH O O
receptor O O
gene O O
expression O O
, O O
without O O
altering O O
the O O
steady O O
state O O
level O O
of O O
IGF O O
- O O
I O O
receptor O O
mRNA O O
. O O

In O O
normal O O
rats O O
with O O
intact O O
kidneys O O
, O O
rhIGF O O
- O O
I O O
administration O O
( O O
n O O
= O O
4 O O
) O O
did O O
not O O
alter O O
weight O O
gain O O
, O O
blood O O
pressure O O
, O O
proteinuria B B_DISEASE/B_GENE
, O O
GFR O O
, O O
glomerular O O
planar O O
area O O
, O O
renal O O
cortical O O
malondialdehyde O O
content O O
, O O
or O O
glomerular O O
or O O
tubulointerstitial B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
damage I B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
compared O O
with O O
untreated O O
animals O O
( O O
n O O
= O O
4 O O
) O O
. O O

rhIGF O O
- O O
I O O
treatment O O
reduced O O
the O O
steady O O
state O O
renal O O
IGF O O
- O O
I O O
mRNA O O
level O O
but O O
did O O
not O O
modify O O
gene O O
expression O O
of O O
the O O
IGF O O
- O O
I O O
or O O
GH O O
receptors O O
. O O

We O O
conclude O O
that O O
: O O
1 O O
) O O
administration O O
of O O
rhIGF O O
- O O
I O O
improves O O
growth O O
and O O
GFR O O
in O O
rats O O
with O O
chronic O O
PAN O O
nephropathy B B_DISEASE
and O O
2 O O
) O O
unlike O O
rhGH O O
, O O
long O O
- O O
term O O
use O O
of O O
rhIGF O O
- O O
I O O
does O O
not O O
worsen O O
renal O O
functional O O
and O O
structural O O
injury O O
in O O
this O O
disease O O
model O O
. O O

Nefiracetam O O
( O O
DM O O
- O O
9384 O O
) O O
reverses O O
apomorphine O O
- O O
induced O O
amnesia B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
a O O
passive O O
avoidance O O
response O O
: O O
delayed O O
emergence O O
of O O
the O O
memory O O
retention O O
effects O O
. O O

Nefiracetam O O
is O O
a O O
novel O O
pyrrolidone O O
derivative O O
which O O
attenuates O O
scopolamine O O
- O O
induced O O
learning B B_DISEASE
and I I_DISEASE
post I I_DISEASE
- I I_DISEASE
training I I_DISEASE
consolidation I I_DISEASE
deficits I I_DISEASE
. O O

Given O O
that O O
apomorphine O O
inhibits O O
passive O O
avoidance O O
retention O O
when O O
given O O
during O O
training O O
or O O
in O O
a O O
defined O O
10 O O
- O O
12h O O
post O O
- O O
training O O
period O O
, O O
we O O
evaluated O O
the O O
ability O O
of O O
nefiracetam O O
to O O
attenuate O O
amnesia B B_DISEASE_ADJECTIVE[DISEASE]
induced O O
by O O
dopaminergic O O
agonism O O
. O O

A O O
step O O
- O O
down O O
passive O O
avoidance O O
paradigm O O
was O O
employed O O
and O O
nefiracetam O O
( O O
3 O O
mg O O
/ O O
kg O O
) O O
and O O
apomorphine O O
( O O
0 O O
. O O
5 O O
mg O O
/ O O
kg O O
) O O
were O O
given O O
alone O O
or O O
in O O
combination O O
during O O
training O O
and O O
at O O
the O O
10 O O
- O O
12h O O
post O O
- O O
training O O
period O O
of O O
consolidation O O
. O O

However O O
, O O
administration O O
of O O
nefiracetam O O
during O O
training O O
completely O O
reversed O O
the O O
amnesia B B_DISEASE_ADJECTIVE[DISEASE]
induced O O
by O O
apomorphine O O
at O O
the O O
10h O O
post O O
- O O
training O O
time O O
and O O
the O O
converse O O
was O O
also O O
true O O
. O O

These O O
effects O O
were O O
not O O
mediated O O
by O O
a O O
dopaminergic O O
mechanism O O
as O O
nefiracetam O O
, O O
at O O
millimolar O O
concentrations O O
, O O
failed O O
to O O
displace O O
either O O
[ O O
3H O O
] O O
SCH O O
23390 O O
or O O
[ O O
3H O O
] O O
spiperone O O
binding O O
from O O
D1 O O
or O O
D2 O O
dopamine O O
receptor O O
subtypes O O
, O O
respectively O O
. O O

Phenytoin O O
encephalopathy B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
as O O
probable O O
idiosyncratic O O
reaction O O
: O O
case O O
report O O
. O O

A O O
case O O
of O O
phenytoin O O
( O O
DPH O O
) O O
encephalopathy B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
increasing O O
seizures B B_DISEASE
and O O
EEG O O
and O O
mental O O
changes O O
is O O
described O O
. O O

Despite O O
adequate O O
oral O O
dosage O O
of O O
DPH O O
( O O
5 O O
mg O O
/ O O
kg O O
/ O O
daily O O
) O O
the O O
plasma O O
level O O
was O O
very O O
low O O
( O O
2 O O
. O O
8 O O
microgramg O O
/ O O
ml O O
) O O
. O O

The O O
encephalopathy B B_DISEASE
was O O
probably O O
an O O
idiosyncratic O O
and O O
not O O
toxic O O
or O O
allergic O O
reaction O O
. O O

In O O
fact O O
the O O
concentration O O
of O O
free O O
DPH O O
was O O
normal O O
, O O
the O O
patient O O
presented O O
a O O
retarded O O
morbilliform O O
rash B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
DPH O O
treatment O O
, O O
the O O
protidogram O O
was O O
normal O O
, O O
and O O
an O O
intradermic O O
DPH O O
injection O O
had O O
no O O
local O O
effect O O
. O O

The O O
authors O O
conclude O O
that O O
in O O
a O O
patient O O
starting O O
DPH O O
treatment O O
an O O
unexpected O O
increase O O
in O O
seizures B B_DISEASE
, O O
with O O
EEG O O
and O O
mental O O
changes O O
occurring O O
simultaneously O O
, O O
should O O
alert O O
the O O
physician O O
to O O
the O O
possible O O
need O O
for O O
eliminating O O
DPH O O
from O O
the O O
therapeutic O O
regimen O O
, O O
even O O
if O O
plasma O O
concentrations O O
are O O
low O O
. O O

Prevention O O
and O O
treatment O O
of O O
endometrial B B_DISEASE
disease I I_DISEASE
in O O
climacteric O O
women O O
receiving O O
oestrogen O O
therapy O O
. O O

The O O
treatment O O
regimens O O
are O O
described O O
in O O
74 O O
patients O O
with O O
endometrial B B_DISEASE/B_LOCATION
disease I I_DISEASE/I_LOCATION
among O O
850 O O
climacteric O O
women O O
receiving O O
oestrogen O O
therapy O O
. O O

Cystic O O
hyperplasia B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
associated O O
with O O
unopposed O O
oestrogen O O
therapy O O
without O O
progestagen O O
. O O

Two O O
courses O O
of O O
21 O O
days O O
of O O
5 O O
mg O O
norethisterone O O
daily O O
caused O O
reversion O O
to O O
normal O O
in O O
all O O
57 O O
cases O O
of O O
cystic O O
hyperplasia B B_DISEASE
and O O
6 O O
of O O
the O O
8 O O
cases O O
of O O
atypical O O
hyperplasia B B_DISEASE
. O O

4 O O
cases O O
of O O
endometrial B B_DISEASE/B_PERSON
carcinoma I I_DISEASE/I_PERSON
referred O O
from O O
elsewhere O O
demonstrated O O
the O O
problems O O
of O O
inappropriate O O
and O O
unsupervised O O
unopposed O O
oestrogen O O
therapy O O
and O O
the O O
difficulty O O
in O O
distinguishing O O
severe O O
hyperplasia B B_DISEASE
from O O
malignancy B B_DISEASE
. O O

Cyclical O O
low O O
- O O
dose O O
oestrogen O O
therapy O O
with O O
7 O O
- O O
- O O
13 O O
days O O
of O O
progestagen O O
does O O
not O O
seem O O
to O O
increase O O
the O O
risk O O
of O O
endometrial B B_DISEASE
hyperplasia I I_DISEASE
or O O
carcinoma B B_DISEASE/B_ORGANISM_FUNCTION
. O O

Effects O O
of O O
exercise O O
on O O
the O O
severity O O
of O O
isoproterenol O O
- O O
induced O O
myocardial B B_DISEASE
infarction I I_DISEASE
. O O

The O O
effect O O
of O O
exercise O O
on O O
the O O
severity O O
of O O
isoproterenol O O
- O O
induced O O
myocardial B B_DISEASE
infarction I I_DISEASE
was O O
studied O O
in O O
male O O
rats O O
. O O

Ninety O O
- O O
three O O
rats O O
were O O
randomly O O
divided O O
into O O
three O O
groups O O
. O O

The O O
exercise O O
- O O
isoproterenol O O
( O O
E O O
- O O
1 O O
) O O
and O O
exercise O O
control O O
( O O
EC O O
) O O
groups O O
exercised O O
daily O O
for O O
thirty O O
days O O
on O O
a O O
treadmill O O
at O O
1 O O
mph O O
, O O
2 O O
% O O
grade O O
while O O
animals O O
of O O
the O O
sedentary O O
- O O
isoproterenol O O
( O O
S O O
- O O
I O O
) O O
group O O
remained O O
sedentary O O
. O O

Eight O O
animals O O
were O O
assigned O O
to O O
the O O
sedentary O O
control O O
( O O
SC O O
) O O
group O O
which O O
remained O O
sedentary O O
throughout O O
the O O
experimental O O
period O O
. O O

Forty O O
- O O
eight O O
hours O O
after O O
the O O
final O O
exercise O O
period O O
, O O
S O O
- O O
I O O
and O O
E O O
- O O
I O O
animals O O
received O O
a O O
single O O
subcutaneous O O
injection O O
of O O
isoproterenol O O
( O O
250 O O
mg O O
/ O O
kg O O
body O O
weight O O
) O O
. O O

Animals O O
of O O
the O O
S O O
- O O
I O O
group O O
exhibited O O
significantly O O
( O O
Pp O O
less O O
than O O
0 O O
. O O
05 O O
) O O
greater O O
mortality O O
from O O
the O O
effects O O
of O O
isoproterenol O O
than O O
animals O O
of O O
the O O
E O O
- O O
I O O
group O O
. O O

Serum O O
CPK O O
activity O O
for O O
E O O
- O O
I O O
animals O O
was O O
significantly O O
( O O
p O O
less O O
than O O
0 O O
. O O
05 O O
) O O
greater O O
than O O
for O O
animals O O
in O O
the O O
S O O
- O O
I O O
and O O
EC O O
groups O O
twenty O O
hours O O
following O O
isoproterenol O O
injection O O
. O O

The O O
results O O
indicated O O
that O O
exercise O O
reduced O O
the O O
mortality O O
associated O O
with O O
the O O
effects O O
of O O
large O O
dosages O O
of O O
isoproterenol O O
but O O
had O O
little O O
on O O
the O O
severity O O
of O O
the O O
infarction B B_DISEASE
. O O

Human O O
corticotropin O O
- O O
releasing O O
hormone O O
and O O
thyrotropin O O
- O O
releasing O O
hormone O O
modulate O O
the O O
hypercapnic B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
ventilatory O O
response O O
in O O
humans O O
. O O

Human O O
corticotropin O O
- O O
releasing O O
hormone O O
( O O
hCRH O O
) O O
and O O
thyrotropin O O
- O O
releasing O O
hormone O O
( O O
TRH O O
) O O
are O O
known O O
to O O
stimulate O O
ventilation O O
after O O
i O O
. O O
v O O
. O O
administration O O
in O O
humans O O
. O O

Two O O
subsequent O O
CO2 O O
- O O
rebreathing O O
tests O O
were O O
performed O O
in O O
healthy O O
young O O
volunteers O O
. O O

During O O
the O O
first O O
test O O
0 O O
. O O
9 O O
% O O
NaCl O O
was O O
given O O
i O O
. O O
v O O
. O O
; O O
during O O
the O O
second O O
test O O
200 O O
micrograms O O
of O O
hCRH O O
( O O
n O O
= O O
12 O O
) O O
or O O
400 O O
micrograms O O
of O O
TRH O O
( O O
n O O
= O O
6 O O
) O O
was O O
administered O O
i O O
. O O
v O O
. O O
Nine O O
subjects O O
received O O
0 O O
. O O
9 O O
% O O
NaCl O O
i O O
. O O
v O O
. O O
during O O
both O O
rebreathing O O
manoeuvres O O
. O O

The O O
CO2 O O
- O O
response O O
curves O O
for O O
the O O
two O O
tests O O
were O O
compared O O
within O O
the O O
same O O
subject O O
. O O

In O O
the O O
hCRH O O
group O O
a O O
marked O O
parallel O O
shift O O
of O O
the O O
CO2 O O
- O O
response O O
curve O O
to O O
the O O
left O O
was O O
observed O O
after O O
hCRH O O
( O O
P O O
< O O
0 O O
. O O
01 O O
) O O
. O O

The O O
same O O
effect O O
occurred O O
following O O
TRH O O
but O O
was O O
less O O
striking O O
( O O
P O O
= O O
0 O O
. O O
05 O O
) O O
. O O

hCRH O O
and O O
TRH O O
caused O O
a O O
reduction O O
in O O
the O O
CO2 O O
threshold O O
. O O

The O O
CO2 O O
- O O
response O O
curves O O
in O O
the O O
control O O
group O O
were O O
nearly O O
identical O O
. O O

The O O
results O O
indicate O O
an O O
additive O O
effect O O
of O O
both O O
releasing O O
hormones O O
on O O
the O O
hypercapnic B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
ventilatory O O
response O O
in O O
humans O O
, O O
presumably O O
independent O O
of O O
central O O
chemosensitivity O O
. O O

Lamivudine O O
is O O
effective O O
in O O
suppressing O O
hepatitis B B_DISEASE
B I I_DISEASE
virus O O
DNA O O
in O O
Chinese O O
hepatitis O O
B O O
surface O O
antigen O O
carriers O O
: O O
a O O
placebo O O
- O O
controlled O O
trial O O
. O O

Lamivudine O O
is O O
a O O
novel O O
2 O O
' O O
, O O
3 O O
' O O
- O O
dideoxy O O
cytosine O O
analogue O O
that O O
has O O
potent O O
inhibitory O O
effects O O
on O O
hepatitis B B_DISEASE/B_GENE
B I I_DISEASE/I_GENE
virus O O
replication O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O

Forty O O
- O O
two O O
Chinese O O
HBsAg O O
carriers O O
were O O
randomized O O
to O O
receive O O
placebo O O
( O O
6 O O
patients O O
) O O
or O O
lamivudine O O
orally O O
in O O
dosages O O
of O O
25 O O
mg O O
, O O
100 O O
mg O O
, O O
or O O
300 O O
mg O O
daily O O
( O O
12 O O
patients O O
for O O
each O O
dosage O O
) O O
. O O

The O O
drug O O
was O O
given O O
for O O
4 O O
weeks O O
. O O

The O O
patients O O
were O O
closely O O
monitored O O
clinically O O
, O O
biochemically O O
, O O
and O O
serologically O O
up O O
to O O
4 O O
weeks O O
after O O
drug O O
treatment O O
. O O

All O O
36 O O
patients O O
receiving O O
lamivudine O O
had O O
a O O
decrease O O
in O O
hepatitis B B_DISEASE
B I I_DISEASE
virus O O
( O O
HBV O O
) O O
DNA O O
values O O
of O O
> O O
90 O O
% O O
( O O
P O O
< O O
. O O
001 O O
compared O O
with O O
placebo O O
) O O
. O O

HBV O O
DNA O O
values O O
returned O O
to O O
pretreatment O O
levels O O
within O O
4 O O
weeks O O
of O O
cessation O O
of O O
therapy O O
. O O

There O O
was O O
no O O
change O O
in O O
the O O
hepatitis B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
B I B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
e O O
antigen O O
status O O
or O O
in O O
aminotransferase O O
levels O O
. O O

No O O
serious O O
adverse O O
events O O
were O O
observed O O
. O O

The O O
suppression O O
was O O
> O O
90 O O
% O O
but O O
reversible O O
. O O

Population O O
- O O
based O O
study O O
of O O
risk O O
of O O
venous B B_DISEASE
thromboembolism I I_DISEASE
associated O O
with O O
various O O
oral O O
contraceptives O O
. O O

However O O
, O O
confounding O O
and O O
bias O O
in O O
the O O
design O O
of O O
these O O
studies O O
may O O
have O O
affected O O
the O O
findings O O
. O O

The O O
aim O O
of O O
our O O
study O O
was O O
to O O
re O O
- O O
examine O O
the O O
association O O
between O O
risk O O
of O O
VTE B B_DISEASE
and O O
OC O O
use O O
with O O
a O O
different O O
study O O
design O O
and O O
analysis O O
to O O
avoid O O
some O O
of O O
the O O
bias O O
and O O
confounding O O
of O O
the O O
earlier O O
studies O O
. O O

METHODS O O
: O O
We O O
used O O
computer O O
records O O
of O O
patients O O
from O O
143 O O
general O O
practices O O
in O O
the O O
UK O O
. O O

The O O
study O O
was O O
based O O
on O O
the O O
medical O O
records O O
of O O
about O O
540 O O
, O O
000 O O
women O O
born O O
between O O
1941 O O
and O O
1981 O O
. O O

All O O
women O O
who O O
had O O
a O O
recorded O O
diagnosis O O
of O O
deep B B_DISEASE/B_LOCATION
- I I_DISEASE/I_LOCATION
vein I I_DISEASE/I_LOCATION
thrombosis I I_DISEASE/I_LOCATION
, O O
venous B B_DISEASE
thrombosis I I_DISEASE
not O O
otherwise O O
specified O O
, O O
or O O
pulmonary O O
embolus O O
during O O
the O O
study O O
period O O
, O O
and O O
who O O
had O O
been O O
treated O O
with O O
an O O
anticoagulant O O
were O O
identified O O
as O O
potential O O
cases O O
of O O
VTE B B_DISEASE
. O O

We O O
did O O
a O O
cohort O O
analysis O O
to O O
estimate O O
and O O
compare O O
incidence O O
of O O
VTE B B_DISEASE/B_LOCATION
in O O
users O O
of O O
the O O
main O O
OC O O
preparations O O
, O O
and O O
a O O
nested O O
case O O
- O O
control O O
study O O
to O O
calculate O O
the O O
odds O O
ratios O O
of O O
VTE B B_DISEASE
associated O O
with O O
use O O
of O O
different O O
types O O
of O O
OC O O
, O O
after O O
adjustment O O
for O O
potential O O
confounding O O
factors O O
. O O

In O O
the O O
case O O
- O O
control O O
study O O
, O O
we O O
matched O O
cases O O
to O O
controls O O
by O O
exact O O
year O O
of O O
birth O O
, O O
practice O O
, O O
and O O
current O O
use O O
of O O
OCs O O
. O O

Of O O
the O O
83 O O
cases O O
of O O
VTE B B_DISEASE
associated O O
with O O
use O O
of O O
combined O O
OCs O O
, O O
43 O O
were O O
recorded O O
as O O
deep B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
vein I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
thrombosis I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
35 O O
as O O
pulmonary O O
thrombosis B B_DISEASE
, O O
and O O
five O O
as O O
venous B B_DISEASE/B_PERSON
thrombosis I I_DISEASE/I_PERSON
not O O
otherwise O O
specified O O
. O O

The O O
crude O O
rate O O
of O O
VTE B B_DISEASE
per O O
10 O O
, O O
000 O O
woman O O
- O O
years O O
was O O
4 O O
. O O
10 O O
in O O
current O O
users O O
of O O
any O O
OC O O
, O O
3 O O
. O O
10 O O
in O O
users O O
of O O
second O O
- O O
generation O O
OCs O O
, O O
and O O
4 O O
. O O
96 O O
in O O
users O O
of O O
third O O
- O O
generation O O
preparations O O
. O O

After O O
adjustment O O
for O O
age O O
, O O
the O O
rate O O
ratio O O
of O O
VTE B B_DISEASE
in O O
users O O
of O O
third O O
- O O
generation O O
relative O O
to O O
second O O
- O O
generation O O
OCs O O
was O O
1 O O
. O O
68 O O
( O O
95 O O
% O O
CI O O
1 O O
. O O
04 O O
- O O
2 O O
. O O
75 O O
) O O
. O O

Logistic O O
regression O O
showed O O
no O O
significant O O
difference O O
in O O
the O O
risk O O
of O O
VTE B B_DISEASE/B_GENE
between O O
users O O
of O O
third O O
- O O
generation O O
and O O
second O O
- O O
generation O O
OCs O O
. O O

Among O O
users O O
of O O
third O O
- O O
generation O O
progestagens O O
, O O
the O O
risk O O
of O O
VTE B B_DISEASE
was O O
higher O O
in O O
users O O
of O O
desogestrel O O
with O O
20 O O
g O O
ethinyloestradiol O O
than O O
in O O
users O O
of O O
gestodene O O
or O O
desogestrel O O
with O O
30 O O
g O O
ethinyloestradiol O O
. O O

With O O
all O O
second O O
- O O
generation O O
OCs O O
as O O
the O O
reference O O
, O O
the O O
odds O O
ratios O O
for O O
VTE B B_DISEASE/B_LOCATION
were O O
3 O O
. O O
49 O O
( O O
1 O O
. O O
21 O O
- O O
10 O O
. O O
12 O O
) O O
for O O
desogestrel O O
plus O O
20 O O
g O O
ethinyloestradiol O O
and O O
1 O O
. O O
18 O O
( O O
0 O O
. O O
66 O O
- O O
2 O O
. O O
17 O O
) O O
for O O
the O O
other O O
third O O
- O O
generation O O
progestagens O O
. O O

The O O
increased O O
odds O O
ratio O O
associated O O
with O O
products O O
containing O O
20 O O
micrograms O O
ethinyloestradiol O O
and O O
desogestrel O O
compared O O
with O O
the O O
30 O O
micrograms O O
product O O
is O O
biologically O O
implausible O O
, O O
and O O
is O O
likely O O
to O O
be O O
the O O
result O O
of O O
preferential O O
prescribing O O
and O O
, O O
thus O O
, O O
confounding O O
. O O

MK O O
- O O
801 O O
augments O O
pilocarpine O O
- O O
induced O O
electrographic O O
seizure B B_DISEASE
but O O
protects O O
against O O
brain B B_DISEASE
damage I I_DISEASE
in O O
rats O O
. O O

1 O O
. O O

The O O
authors O O
examined O O
the O O
anticonvulsant O O
effects O O
of O O
MK O O
- O O
801 O O
on O O
the O O
pilocarpine O O
- O O
induced O O
seizure B B_DISEASE
model O O
. O O

Intraperitoneal O O
injection O O
of O O
pilocarpine O O
( O O
400 O O
mg O O
/ O O
kg O O
) O O
induced O O
tonic B B_DISEASE
and I I_DISEASE
clonic I I_DISEASE
seizure I I_DISEASE
. O O

Scopolamine O O
( O O
10 O O
mg O O
/ O O
kg O O
) O O
and O O
pentobarbital O O
( O O
5 O O
mg O O
/ O O
kg O O
) O O
prevented O O
development O O
of O O
pilocarpine O O
- O O
induced O O
behavioral O O
seizure B B_DISEASE
but O O
MK O O
- O O
801 O O
( O O
0 O O
. O O
5 O O
mg O O
/ O O
kg O O
) O O
did O O
not O O
. O O

2 O O
. O O

An O O
electrical O O
seizure B B_DISEASE
measured O O
with O O
hippocampal O O
EEG O O
appeared O O
in O O
the O O
pilocarpine O O
- O O
treated O O
group O O
. O O

Scopolamine O O
and O O
pentobarbital O O
blocked O O
the O O
pilocarpine O O
- O O
induced O O
electrographic O O
seizure B B_DISEASE
, O O
MK O O
- O O
801 O O
treatment O O
augmented O O
the O O
electrographic O O
seizure B B_DISEASE
induced O O
by O O
pilocarpine O O
. O O

3 O O
. O O

Brain B B_DISEASE_ADJECTIVE[DISEASE]
damage I I_DISEASE_ADJECTIVE[DISEASE]
was O O
assessed O O
by O O
examining O O
the O O
hippocampus O O
microscopically O O
. O O

Pilocarpine O O
produced O O
neuronal B B_DISEASE
death I I_DISEASE
in O O
the O O
hippocampus O O
, O O
which O O
showed O O
pyknotic O O
changes O O
. O O

Pentobarbital O O
, O O
scopolamine O O
and O O
MK O O
- O O
801 O O
protected O O
the O O
brain B B_DISEASE_ADJECTIVE[DISEASE]
damage I I_DISEASE_ADJECTIVE[DISEASE]
by O O
pilocarpine O O
, O O
though O O
in O O
the O O
MK O O
- O O
801 O O
- O O
treated O O
group O O
, O O
the O O
pyramidal O O
cells O O
of O O
hippocampus O O
appeared O O
darker O O
than O O
normal O O
. O O

In O O
all O O
treatments O O
, O O
granule O O
cells O O
of O O
the O O
dentate O O
gyrus O O
were O O
not O O
affected O O
. O O

4 O O
. O O

These O O
results O O
indicate O O
that O O
status B B_DISEASE
epilepticus I I_DISEASE
induced O O
by O O
pilocarpine O O
is O O
initiated O O
by O O
cholinergic O O
overstimulation O O
and O O
propagated O O
by O O
glutamatergic O O
transmission O O
, O O
the O O
elevation O O
of O O
which O O
may O O
cause O O
brain B B_DISEASE
damage I I_DISEASE
through O O
an O O
excitatory O O
NMDA O O
receptor O O
- O O
mediated O O
mechanism O O
. O O

Paclitaxel O O
, O O
5 O O
- O O
fluorouracil O O
, O O
and O O
folinic O O
acid O O
in O O
metastatic O O
breast B B_DISEASE/B_LOCATION
cancer I I_DISEASE/I_LOCATION
: O O
BRE O O
- O O
26 O O
, O O
a O O
phase O O
II O O
trial O O
. O O

5 O O
- O O
Fluorouracil O O
plus O O
folinic O O
acid O O
and O O
paclitaxel O O
( O O
Taxol O O
; O O
Bristol O O
- O O
Myers O O
Squibb O O
Company O O
, O O
Princeton O O
, O O
NJ O O
) O O
are O O
effective O O
salvage O O
therapies O O
for O O
metastatic O O
breast B B_DISEASE/B_LOCATION
cancer I I_DISEASE/I_LOCATION
patients O O
. O O

Paclitaxel O O
and O O
5 O O
- O O
fluorouracil O O
have O O
additive O O
cytotoxicity B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
MCF O O
- O O
7 O O
cell O O
lines O O
. O O

We O O
performed O O
a O O
phase O O
II O O
trial O O
of O O
paclitaxel O O
175 O O
mg O O
/ O O
m2 O O
over O O
3 O O
hours O O
on O O
day O O
I O O
followed O O
by O O
folinic O O
acid O O
300 O O
mg O O
over O O
1 O O
hour O O
before O O
5 O O
- O O
fluorouracil O O
350 O O
mg O O
/ O O
m2 O O
on O O
days O O
1 O O
to O O
3 O O
every O O
28 O O
days O O
( O O
TFL O O
) O O
in O O
women O O
with O O
metastatic O O
breast B B_DISEASE/B_LOCATION
cancer I I_DISEASE/I_LOCATION
. O O

Analysis O O
is O O
reported O O
on O O
37 O O
patients O O
with O O
a O O
minimum O O
of O O
6 O O
months O O
follow O O
- O O
up O O
who O O
received O O
a O O
total O O
of O O
192 O O
cycles O O
of O O
TFL O O
: O O
nine O O
cycles O O
( O O
5 O O
% O O
) O O
were O O
associated O O
with O O
grade O O
3 O O
/ O O
4 O O
neutropenia B B_DISEASE
requiring O O
hospitalization O O
; O O
seven O O
( O O
4 O O
% O O
) O O
cycles O O
in O O
two O O
patients O O
required O O
granulocyte O O
colony O O
- O O
stimulating O O
factor O O
due O O
to O O
neutropenia B B_DISEASE
; O O
no O O
patient O O
required O O
platelet O O
transfusions O O
. O O

Grade O O
3 O O
/ O O
4 O O
nonhematologic O O
toxicities B B_DISEASE
were O O
uncommon O O
. O O

Among O O
the O O
34 O O
patients O O
evaluable O O
for O O
response O O
, O O
there O O
were O O
three O O
complete O O
responses O O
( O O
9 O O
% O O
) O O
and O O
18 O O
partial O O
responses O O
( O O
53 O O
% O O
) O O
for O O
an O O
overall O O
response O O
rate O O
of O O
62 O O
% O O
. O O

Of O O
the O O
19 O O
evaluable O O
patients O O
with O O
prior O O
doxorubicin O O
exposure O O
, O O
11 O O
( O O
58 O O
% O O
) O O
responded O O
compared O O
with O O
nine O O
of O O
15 O O
( O O
60 O O
% O O
) O O
without O O
prior O O
doxorubicin O O
. O O

Plasma O O
paclitaxel O O
concentrations O O
were O O
measured O O
at O O
the O O
completion O O
of O O
paclitaxel O O
infusion O O
and O O
at O O
24 O O
hours O O
in O O
19 O O
patients O O
. O O

TFL O O
is O O
an O O
active O O
, O O
well O O
- O O
tolerated O O
regimen O O
in O O
metastatic O O
breast B B_DISEASE/B_LOCATION
cancer I I_DISEASE/I_LOCATION
. O O

Efficacy O O
and O O
proarrhythmia B B_DISEASE_ADJECTIVE[DISEASE]
with O O
the O O
use O O
of O O
d O O
, O O
l O O
- O O
sotalol O O
for O O
sustained O O
ventricular B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tachyarrhythmias I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

This O O
study O O
prospectively O O
evaluated O O
the O O
clinical O O
efficacy O O
, O O
the O O
incidence O O
of O O
torsades B B_DISEASE
de I I_DISEASE
pointes I I_DISEASE
, O O
and O O
the O O
presumable O O
risk O O
factors O O
for O O
torsades B B_DISEASE
de I I_DISEASE
pointes I I_DISEASE
in O O
patients O O
treated O O
with O O
d O O
, O O
l O O
- O O
sotalol O O
for O O
sustained O O
ventricular B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tachyarrhythmias I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Eighty O O
- O O
one O O
consecutive O O
patients O O
( O O
54 O O
with O O
coronary B B_DISEASE_ADJECTIVE[DISEASE]
artery I I_DISEASE_ADJECTIVE[DISEASE]
disease I I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
20 O O
with O O
dilated B B_DISEASE
cardiomyopathy I I_DISEASE
) O O
with O O
inducible O O
sustained O O
ventricular B B_DISEASE
tachycardia I I_DISEASE
or O O
ventricular B B_DISEASE
fibrillation I I_DISEASE
received O O
oral O O
d O O
, O O
l O O
- O O
sotalol O O
to O O
prevent O O
induction O O
of O O
the O O
ventricular B B_DISEASE
tachyarrhythmia I I_DISEASE
. O O

During O O
oral O O
loading O O
with O O
d O O
, O O
l O O
- O O
sotalol O O
, O O
continuous O O
electrocardiographic O O
( O O
ECG O O
) O O
monitoring O O
was O O
performed O O
. O O

Those O O
patients O O
in O O
whom O O
d O O
, O O
l O O
- O O
sotalol O O
prevented O O
induction O O
of O O
ventricular B B_DISEASE
tachycardia I I_DISEASE
or O O
ventricular B B_DISEASE
fibrillation I I_DISEASE
were O O
discharged O O
with O O
the O O
drug O O
and O O
followed O O
up O O
on O O
an O O
outpatient O O
basis O O
for O O
21 O O
+ O O
/ O O
- O O
18 O O
months O O
. O O

Induction O O
of O O
the O O
ventricular B B_DISEASE
tachyarrhythmia I I_DISEASE
was O O
prevented O O
by O O
oral O O
d O O
, O O
l O O
- O O
sotalol O O
in O O
35 O O
( O O
43 O O
% O O
) O O
patients O O
; O O
the O O
ventricular B B_DISEASE
tachyarrhythmia I I_DISEASE
remained O O
inducible O O
in O O
40 O O
( O O
49 O O
% O O
) O O
patients O O
; O O
and O O
two O O
( O O
2 O O
. O O
5 O O
% O O
) O O
patients O O
did O O
not O O
tolerate O O
even O O
40 O O
mg O O
of O O
d O O
, O O
l O O
- O O
sotalol O O
once O O
daily O O
. O O

Four O O
( O O
5 O O
% O O
) O O
patients O O
had O O
from O O
torsades B B_DISEASE
de I I_DISEASE
pointes I I_DISEASE
during O O
the O O
initial O O
oral O O
treatment O O
with O O
d O O
, O O
l O O
- O O
sotalol O O
. O O

Neither O O
ECG O O
[ O O
sinus O O
- O O
cycle O O
length O O
( O O
SCL O O
) O O
, O O
QT O O
or O O
QTc O O
interval O O
, O O
or O O
U O O
wave O O
] O O
nor O O
clinical O O
parameters O O
identified O O
patients O O
at O O
risk O O
for O O
torsades B B_DISEASE
de I I_DISEASE
pointes I I_DISEASE
. O O

However O O
, O O
the O O
oral O O
dose O O
of O O
d O O
, O O
l O O
- O O
sotalol O O
was O O
significantly O O
lower O O
in O O
patients O O
with O O
torsades B B_DISEASE/B_LOCATION
de I I_DISEASE/I_LOCATION
pointes I I_DISEASE/I_LOCATION
( O O
200 O O
+ O O
/ O O
- O O
46 O O
vs O O
. O O
328 O O
+ O O
/ O O
- O O
53 O O
mg O O
/ O O
day O O
; O O
p O O
= O O
0 O O
. O O
0017 O O
) O O
. O O

Risk O O
factors O O
associated O O
with O O
the O O
development O O
of O O
torsades B B_DISEASE
de I I_DISEASE
pointes I I_DISEASE
were O O
the O O
appearance O O
of O O
an O O
U O O
wave O O
( O O
p O O
= O O
0 O O
. O O
049 O O
) O O
, O O
female O O
gender O O
( O O
p O O
= O O
0 O O
. O O
015 O O
) O O
, O O
and O O
significant O O
dose O O
- O O
corrected O O
changes O O
of O O
SCL O O
, O O
QT O O
interval O O
, O O
and O O
QTc O O
interval O O
( O O
p O O
< O O
0 O O
. O O
05 O O
) O O
. O O

During O O
follow O O
- O O
up O O
, O O
seven O O
( O O
20 O O
% O O
) O O
patients O O
had O O
a O O
nonfatal O O
ventricular B B_DISEASE/B_LOCATION
tachycardia I I_DISEASE/I_LOCATION
recurrence O O
, O O
and O O
two O O
( O O
6 O O
% O O
) O O
patients O O
died O O
suddenly O O
. O O

One O O
female O O
patient O O
with O O
stable O O
cardiac B B_DISEASE
disease I I_DISEASE
had O O
recurrent O O
torsades B B_DISEASE
de I I_DISEASE
pointes I I_DISEASE
after O O
2 O O
years O O
of O O
successful O O
treatment O O
with O O
d O O
, O O
l O O
- O O
sotalol O O
. O O

Torsades B B_DISEASE_ADJECTIVE[DISEASE]
de I I_DISEASE_ADJECTIVE[DISEASE]
pointes I I_DISEASE_ADJECTIVE[DISEASE]
occurred O O
early O O
during O O
treatment O O
even O O
with O O
low O O
doses O O
of O O
oral O O
d O O
, O O
l O O
- O O
sotalol O O
. O O

Pronounced O O
changes O O
in O O
the O O
surface O O
ECG O O
( O O
cycle O O
length O O
, O O
QT O O
, O O
and O O
QTc O O
) O O
in O O
relation O O
to O O
the O O
dose O O
of O O
oral O O
d O O
, O O
l O O
- O O
sotalol O O
might O O
identify O O
a O O
subgroup O O
of O O
patients O O
with O O
an O O
increased O O
risk O O
for O O
torsades B B_DISEASE
de I I_DISEASE
pointes I I_DISEASE
. O O

Other O O
ECG O O
parameters O O
before O O
the O O
application O O
of O O
d O O
, O O
l O O
- O O
sotalol O O
did O O
not O O
identify O O
patients O O
at O O
increased O O
risk O O
for O O
torsades B B_DISEASE
de I I_DISEASE
pointes I I_DISEASE
. O O

Recurrence O O
rates O O
of O O
ventricular B B_DISEASE
tachyarrhythmias I I_DISEASE
are O O
high O O
despite O O
complete O O
suppression O O
of O O
the O O
arrhythmia B B_DISEASE
during O O
programmed O O
stimulation O O
. O O

Therefore O O
programmed O O
electrical O O
stimulation O O
in O O
the O O
case O O
of O O
d O O
, O O
l O O
- O O
sotalol O O
seems O O
to O O
be O O
of O O
limited O O
prognostic O O
value O O
. O O

Chronic O O
hyperprolactinemia B B_DISEASE
and O O
changes O O
in O O
dopamine O O
neurons O O
. O O

In O O
young O O
animals O O
this O O
system O O
responds O O
to O O
acute O O
elevations O O
in O O
serum O O
PRL O O
by O O
increasing O O
its O O
activity O O
. O O

The O O
purpose O O
of O O
this O O
study O O
was O O
to O O
induce O O
hyperprolactinemia B B_DISEASE
in O O
rats O O
for O O
extended O O
periods O O
of O O
time O O
and O O
examine O O
its O O
effects O O
on O O
dopaminergic O O
systems O O
in O O
the O O
brain O O
. O O

Hyperprolactinemia B B_DISEASE/B_PROTEIN[GENE]
was O O
induced O O
by O O
treatment O O
with O O
haloperidol O O
, O O
a O O
dopamine O O
receptor O O
antagonist O O
, O O
and O O
Palkovits O O
' O O
microdissection O O
technique O O
in O O
combination O O
with O O
high O O
- O O
performance O O
liquid O O
chromatography O O
was O O
used O O
to O O
measure O O
neurotransmitter O O
concentrations O O
in O O
several O O
areas O O
of O O
the O O
brain O O
. O O

After O O
6 O O
months O O
of O O
hyperprolactinemia B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
dopamine O O
( O O
DA O O
) O O
concentrations O O
in O O
the O O
median O O
eminence O O
( O O
ME O O
) O O
increased O O
by O O
84 O O
% O O
over O O
the O O
control O O
group O O
. O O

Nine O O
months O O
of O O
hyperprolactinemia B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
produced O O
a O O
50 O O
% O O
increase O O
in O O
DA O O
concentrations O O
in O O
the O O
ME O O
over O O
the O O
control O O
group O O
. O O

However O O
, O O
DA O O
response O O
was O O
lost O O
if O O
a O O
9 O O
- O O
month O O
long O O
haloperidol O O
- O O
induced O O
hyperprolactinemia B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
followed O O
by O O
a O O
1 O O
1 O O
/ O O
2 O O
month O O
- O O
long O O
extremely O O
high O O
increase O O
in O O
serum O O
PRL O O
levels O O
produced O O
by O O
implantation O O
of O O
MMQ O O
cells O O
under O O
the O O
kidney O O
capsule O O
. O O

There O O
was O O
no O O
change O O
in O O
the O O
levels O O
of O O
DA O O
, O O
norepinephrine O O
( O O
NE O O
) O O
, O O
serotonin O O
( O O
5 O O
- O O
HT O O
) O O
, O O
or O O
their O O
metabolites O O
in O O
the O O
arcuate O O
nucleus O O
( O O
AN O O
) O O
, O O
medial O O
preoptic O O
area O O
( O O
MPA O O
) O O
, O O
caudate O O
putamen O O
( O O
CP O O
) O O
, O O
substantia O O
nigra O O
( O O
SN O O
) O O
, O O
and O O
zona O O
incerta O O
( O O
ZI O O
) O O
, O O
except O O
for O O
a O O
decrease O O
in O O
5 O O
- O O
hydroxyindoleacetic O O
acid O O
( O O
5 O O
- O O
HIAA O O
) O O
in O O
the O O
AN O O
after O O
6 O O
- O O
months O O
of O O
hyperprolactinemia B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
an O O
increase O O
in O O
DA O O
concentrations O O
in O O
the O O
AN O O
after O O
9 O O
- O O
months O O
of O O
hyperprolactinemia B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

These O O
results O O
demonstrate O O
that O O
hyperprolactinemia B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specifically O O
affects O O
TIDA O O
neurons O O
and O O
these O O
effects O O
vary O O
, O O
depending O O
on O O
the O O
duration O O
and O O
intensity O O
of O O
hyperprolactinemia B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Treatment O O
- O O
related O O
disseminated O O
necrotizing O O
leukoencephalopathy B B_DISEASE
with O O
characteristic O O
contrast O O
enhancement O O
of O O
the O O
white O O
matter O O
. O O

This O O
report O O
describes O O
unique O O
contrast O O
enhancement O O
of O O
the O O
white O O
matter O O
on O O
T1 O O
- O O
weighted O O
magnetic O O
resonance O O
images O O
of O O
two O O
patients O O
with O O
disseminated O O
necrotizing O O
leukoencephalopathy B B_DISEASE
, O O
which O O
developed O O
from O O
acute B B_DISEASE_ADJECTIVE[DISEASE]
lymphoblastic I I_DISEASE_ADJECTIVE[DISEASE]
leukemia I I_DISEASE_ADJECTIVE[DISEASE]
treated O O
with O O
high O O
- O O
dose O O
methotrexate O O
. O O

In O O
both O O
patients O O
, O O
the O O
enhancement O O
was O O
more O O
pronounced O O
near O O
the O O
base O O
of O O
the O O
brain O O
than O O
at O O
the O O
vertex O O
. O O

Necropsy O O
of O O
the O O
first O O
case O O
revealed O O
loss B B_DISEASE
of I I_DISEASE
myelination I I_DISEASE
and O O
necrosis B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
white O O
matter O O
. O O

Possible O O
mechanisms O O
causing O O
such O O
a O O
leukoencephalopathy B B_DISEASE_ADJECTIVE[DISEASE]
are O O
discussed O O
. O O

Thrombotic B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
complications O O
in O O
acute B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
promyelocytic I B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
leukemia I B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
during O O
all O O
- O O
trans O O
- O O
retinoic O O
acid O O
therapy O O
. O O

A O O
case O O
of O O
acute B B_DISEASE
renal I I_DISEASE
failure I I_DISEASE
, O O
due O O
to O O
occlusion B B_DISEASE
of I I_DISEASE
renal I I_DISEASE
vessels I I_DISEASE
in O O
a O O
patient O O
with O O
acute B B_DISEASE
promyelocytic I I_DISEASE
leukemia I I_DISEASE
( O O
APL B B_DISEASE
) O O
treated O O
with O O
all O O
- O O
trans O O
- O O
retinoic O O
acid O O
( O O
ATRA O O
) O O
and O O
tranexamic O O
acid O O
has O O
been O O
described O O
recently O O
. O O

We O O
report O O
a O O
case O O
of O O
acute B B_DISEASE/B_GENE
renal I I_DISEASE/I_GENE
failure I I_DISEASE/I_GENE
in O O
an O O
APL B B_DISEASE/B_MEASURE
patient O O
treated O O
with O O
ATRA O O
alone O O
. O O

This O O
case O O
further O O
supports O O
the O O
concern O O
about O O
thromboembolic B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
complications O O
associated O O
with O O
ATRA O O
therapy O O
in O O
APL B B_DISEASE/B_MEASURE
patients O O
. O O

The O O
patients O O
, O O
a O O
43 O O
- O O
year O O
- O O
old O O
man O O
, O O
presented O O
all O O
the O O
signs O O
and O O
symptoms O O
of O O
APL B B_DISEASE/B_GENE
and O O
was O O
included O O
in O O
a O O
treatment O O
protocol O O
with O O
ATRA O O
. O O

After O O
10 O O
days O O
of O O
treatment O O
, O O
he O O
developed O O
acute B B_DISEASE
renal I I_DISEASE
failure I I_DISEASE
that O O
was O O
completely O O
reversible O O
after O O
complete O O
remission O O
of O O
APL B B_DISEASE
was O O
achieved O O
and O O
therapy O O
discontinued O O
. O O

We O O
conclude O O
that O O
ATRA O O
is O O
a O O
valid O O
therapeutic O O
choice O O
for O O
patients O O
with O O
APL B B_DISEASE/B_LOCATION
, O O
although O O
the O O
procoagulant O O
tendency O O
is O O
not O O
completely O O
corrected O O
. O O

Thrombotic B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
events O O
, O O
however O O
, O O
could O O
be O O
avoided O O
by O O
using O O
low O O
- O O
dose O O
heparin O O
. O O

Pupillary O O
changes O O
associated O O
with O O
the O O
development O O
of O O
stimulant O O
- O O
induced O O
mania B B_DISEASE/B_LOCATION
: O O
a O O
case O O
report O O
. O O

A O O
30 O O
- O O
year O O
- O O
old O O
cocaine O O
- O O
dependent O O
man O O
who O O
was O O
a O O
subject O O
in O O
a O O
study O O
evaluating O O
the O O
anticraving O O
efficacy O O
of O O
the O O
stimulant O O
medication O O
diethylpropion O O
( O O
DEP O O
) O O
became O O
manic B B_DISEASE
during O O
his O O
second O O
week O O
on O O
the O O
study O O
drug O O
. O O

Pupillometric O O
changes O O
while O O
on O O
DEP O O
, O O
especially O O
changes O O
in O O
the O O
total O O
power O O
of O O
pupillary B B_DISEASE
oscillation I I_DISEASE
, O O
were O O
dramatically O O
different O O
than O O
those O O
observed O O
in O O
the O O
eight O O
other O O
study O O
subjects O O
who O O
did O O
not O O
become O O
manic B B_DISEASE/B_PERSON
. O O

The O O
large O O
changes O O
in O O
total O O
power O O
of O O
pupillary B B_DISEASE/B_PROTEIN[GENE]
oscillation I B_DISEASE/I_PROTEIN[GENE]
occurred O O
a O O
few O O
days O O
before O O
the O O
patient O O
became O O
fully O O
manic B B_DISEASE/B_PERSON
. O O

Such O O
medication O O
- O O
associated O O
changes O O
in O O
the O O
total O O
power O O
of O O
pupillary B B_DISEASE/B_PROTEIN[GENE]
oscillation I B_DISEASE/I_PROTEIN[GENE]
might O O
be O O
of O O
utility O O
in O O
identifying O O
persons O O
at O O
risk O O
for O O
manic B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
like O O
adverse O O
effects O O
during O O
the O O
medical O O
use O O
of O O
psychomotor O O
stimulants O O
or O O
sympathomimetic O O
agents O O
. O O

In O O
the O O
first O O
case O O
a O O
caesarean O O
section O O
was O O
done O O
one O O
week O O
after O O
replacement O O
of O O
warfarin O O
with O O
heparin O O
. O O

The O O
baby O O
died O O
of O O
cerebral B B_DISEASE
and I I_DISEASE
pulmonary I I_DISEASE
hemorrhage I I_DISEASE
. O O

The O O
second O O
mother O O
had O O
a O O
male O O
infant O O
by O O
caesarean O O
section O O
. O O

The O O
baby O O
showed O O
warfarin O O
- O O
induced O O
embryopathy B B_DISEASE
with O O
nasal B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
hypoplasia I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
stippled B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
epiphyses I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O O
chondrodysplasia B B_DISEASE/B_PROTEIN[GENE]
punctata I B_DISEASE/I_PROTEIN[GENE]
) O O
. O O

Nasal B B_DISEASE
hypoplasia I I_DISEASE
with O O
or O O
without O O
stippled B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
epiphyses I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
has O O
now O O
been O O
reported O O
in O O
11 O O
infants O O
born O O
to O O
mothers O O
treated O O
with O O
warfarin O O
during O O
the O O
first O O
trimester O O
, O O
and O O
a O O
causal O O
association O O
is O O
probable O O
. O O

The O O
negative O O
mucosal O O
potential O O
: O O
separating O O
central O O
and O O
peripheral O O
effects O O
of O O
NSAIDs O O
in O O
man O O
. O O

OBJECTIVE O O
: O O
We O O
wanted O O
to O O
test O O
whether O O
assessment O O
of O O
both O O
a O O
central O O
pain B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
related O O
signal O O
( O O
chemo O O
- O O
somatosensory O O
evoked O O
potential O O
, O O
CSSEP O O
) O O
and O O
a O O
concomitantly O O
recorded O O
peripheral O O
signal O O
( O O
negative O O
mucosal O O
potential O O
, O O
NMP O O
) O O
allows O O
for O O
separation O O
of O O
central O O
and O O
peripheral O O
effects O O
of O O
NSAIDs O O
. O O

For O O
this O O
purpose O O
, O O
experimental O O
conditions O O
were O O
created O O
in O O
which O O
NSAIDs O O
had O O
previously O O
been O O
observed O O
to O O
produce O O
effects O O
on O O
phasic O O
and O O
tonic O O
pain B B_DISEASE
by O O
either O O
central O O
or O O
peripheral O O
mechanisms O O
. O O

METHODS O O
: O O
According O O
to O O
a O O
double O O
- O O
blind O O
, O O
randomised O O
, O O
controlled O O
, O O
threefold O O
cross O O
- O O
over O O
design O O
, O O
18 O O
healthy O O
subjects O O
( O O
11 O O
males O O
, O O
7 O O
females O O
; O O
mean O O
age O O
26 O O
years O O
) O O
received O O
either O O
placebo O O
, O O
400 O O
mg O O
ibuprofen O O
, O O
or O O
800 O O
mg O O
ibuprofen O O
. O O

Phasic O O
pain B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O O
applied O O
by O O
means O O
of O O
short O O
pulses O O
of O O
CO2 O O
to O O
the O O
nasal O O
mucosa O O
( O O
stimulus O O
duration O O
500 O O
ms O O
, O O
interval O O
approximately O O
60 O O
s O O
) O O
, O O
and O O
tonic O O
pain B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
induced O O
in O O
the O O
nasal O O
cavity O O
by O O
means O O
of O O
dry O O
air O O
of O O
controlled O O
temperature O O
, O O
humidity O O
and O O
flow O O
rate O O
( O O
22 O O
degrees O O
C O O
, O O
0 O O
% O O
relative O O
humidity O O
, O O
145 O O
ml O O
. O O
s O O
- O O
1 O O
) O O
. O O

Both O O
CSSEPs O O
as O O
central O O
and O O
NMPs O O
as O O
peripheral O O
correlates O O
of O O
pain B B_DISEASE/B_GENE
were O O
obtained O O
in O O
response O O
to O O
the O O
CO2 O O
stimuli O O
. O O

Additionally O O
, O O
the O O
subjects O O
rated O O
the O O
intensity O O
of O O
both O O
phasic O O
and O O
tonic O O
pain B B_DISEASE
by O O
means O O
of O O
visual O O
analogue O O
scales O O
. O O

RESULTS O O
: O O
As O O
described O O
earlier O O
, O O
administration O O
of O O
ibuprofen O O
was O O
followed O O
by O O
a O O
decrease O O
in O O
tonic O O
pain B B_DISEASE/B_MEASURE
but O O
- O O
relative O O
to O O
placebo O O
- O O
an O O
increase O O
in O O
correlates O O
of O O
phasic O O
pain B B_DISEASE
, O O
indicating O O
a O O
specific O O
effect O O
of O O
ibuprofen O O
on O O
the O O
interaction O O
between O O
the O O
pain B B_DISEASE_ADJECTIVE[DISEASE]
stimuli O O
under O O
these O O
special O O
experimental O O
conditions O O
. O O

The O O
major O O
advantage O O
of O O
this O O
pain B B_DISEASE/B_SPECIES[BIO]
model O O
is O O
the O O
possibility O O
of O O
obtaining O O
peripheral O O
pain B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
related O O
activity O O
directly O O
using O O
a O O
non O O
- O O
invasive O O
technique O O
in O O
humans O O
. O O

Effect O O
of O O
D O O
- O O
Glucarates O O
on O O
basic O O
antibiotic O O
- O O
induced O O
renal B B_DISEASE
damage I I_DISEASE
in O O
rats O O
. O O

Oral O O
administration O O
of O O
2 O O
, O O
5 O O
- O O
di O O
- O O
O O O
- O O
acetyl O O
- O O
D O O
- O O
glucaro O O
- O O
1 O O
, O O
4 O O
- O O
6 O O
, O O
3 O O
- O O
dilactone O O
protected O O
rats O O
against O O
renal B B_DISEASE
failure I I_DISEASE
induced O O
by O O
kanamycin O O
- O O
dextran O O
. O O

The O O
protective O O
effect O O
was O O
prevalent O O
among O O
D O O
- O O
glucarates O O
, O O
and O O
also O O
to O O
other O O
saccharic O O
acid O O
, O O
hexauronic O O
acids O O
and O O
hexaaldonic O O
acids O O
, O O
although O O
to O O
a O O
lesser O O
degree O O
, O O
but O O
not O O
to O O
a O O
hexaaldose O O
, O O
sugar O O
alcohols O O
, O O
substances O O
inthe O O
TCA O O
cycle O O
and O O
other O O
acidic O O
compounds O O
. O O

D O O
- O O
Glucarates O O
were O O
effective O O
against O O
renal B B_DISEASE
damage I I_DISEASE
induced O O
by O O
peptide O O
antibiotics O O
as O O
well O O
as O O
various O O
aminoglycoside O O
antibitocis O O
. O O

Dose O O
- O O
responses O O
were O O
observed O O
in O O
the O O
protective O O
effect O O
of O O
D O O
- O O
Glucarates O O
. O O

With O O
a O O
D O O
- O O
glucarate O O
of O O
a O O
fixed O O
size O O
of O O
dose O O
, O O
approximately O O
the O O
same O O
degree O O
of O O
protection O O
was O O
obtained O O
against O O
renal B B_DISEASE
damages I I_DISEASE
induced O O
by O O
different O O
basic O O
antibiotics O O
despite O O
large O O
disparities O O
in O O
administration O O
doses O O
of O O
different O O
antibiotics O O
. O O

D O O
- O O
Glucarates O O
had O O
the O O
ability O O
to O O
prevent O O
renal B B_DISEASE
damage I I_DISEASE
but O O
not O O
to O O
cure O O
it O O
. O O

Rats O O
excreted O O
acidic O O
urine O O
when O O
they O O
were O O
spared O O
from O O
renal B B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
lesions I B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
by O O
monosaccharides O O
. O O

Acute O O
severe O O
depression B B_DISEASE
following O O
peri O O
- O O
operative O O
ondansetron O O
. O O

A O O
41 O O
- O O
year O O
- O O
old O O
woman O O
with O O
a O O
strong O O
history O O
of O O
postoperative B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
nausea I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
vomiting I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
presented O O
for O O
abdominal O O
hysterectomy O O
3 O O
months O O
after O O
a O O
previous O O
anaesthetic O O
where O O
ondansetron O O
prophylaxis O O
had O O
been O O
used O O
. O O

She O O
had O O
developed O O
a O O
severe O O
acute O O
major B B_DISEASE
depression I I_DISEASE
disorder I I_DISEASE
almost O O
immediately O O
thereafter O O
, O O
possibly O O
related O O
to O O
the O O
use O O
of O O
a O O
serotonin O O
antagonist O O
. O O

Nine O O
years O O
before O O
she O O
had O O
experienced O O
a O O
self O O
- O O
limited O O
puerperal O O
depressive B B_DISEASE
episode I I_DISEASE
. O O

Anaesthesia O O
with O O
a O O
propofol O O
infusion O O
and O O
avoidance O O
of O O
serotonin O O
antagonists O O
provided O O
a O O
nausea B B_DISEASE
- O O
free O O
postoperative O O
course O O
without O O
exacerbation O O
of O O
the O O
depression B B_DISEASE
disorder I I_DISEASE
. O O

Hypertensive B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
response O O
during O O
dobutamine O O
stress O O
echocardiography O O
. O O

Among O O
3 O O
, O O
129 O O
dobutamine O O
stress O O
echocardiographic O O
studies O O
, O O
a O O
hypertensive B B_DISEASE_ADJECTIVE[DISEASE]
response O O
, O O
defined O O
as O O
systolic O O
blood O O
pressure O O
( O O
BP O O
) O O
> O O
or O O
= O O
220 O O
mm O O
Hg O O
and O O
/ O O
or O O
diastolic O O
BP O O
> O O
or O O
= O O
110 O O
mm O O
Hg O O
, O O
occurred O O
in O O
30 O O
patients O O
( O O
1 O O
% O O
) O O
. O O

Patients O O
with O O
this O O
response O O
more O O
often O O
had O O
a O O
history O O
of O O
hypertension B B_DISEASE
and O O
had O O
higher O O
resting O O
systolic O O
and O O
diastolic O O
BP O O
before O O
dobutamine O O
infusion O O
. O O

Continuously O O
nebulized O O
albuterol O O
in O O
severe O O
exacerbations O O
of O O
asthma B B_DISEASE/B_LOCATION
in O O
adults O O
: O O
a O O
case O O
- O O
controlled O O
study O O
. O O

A O O
retrospective O O
, O O
case O O
- O O
controlled O O
analysis O O
comparing O O
patients O O
admitted O O
to O O
a O O
medical O O
intensive O O
care O O
unit O O
with O O
severe O O
exacerbations O O
of O O
asthma B B_DISEASE/B_LOCATION
who O O
received O O
continuously O O
nebulized O O
albuterol O O
( O O
CNA O O
) O O
versus O O
intermittent O O
albuterol O O
( O O
INA O O
) O O
treatments O O
is O O
reported O O
. O O

Forty O O
matched O O
pairs O O
of O O
patients O O
with O O
asthma B B_DISEASE/B_LOCATION
are O O
compared O O
. O O

CNA O O
was O O
administered O O
for O O
a O O
mean O O
of O O
11 O O
+ O O
/ O O
- O O
10 O O
hr O O
. O O

The O O
incidence O O
of O O
cardiac B B_DISEASE
dysrhythmias I I_DISEASE
was O O
similar O O
between O O
groups O O
. O O

Symptomatic O O
hypokalemia B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
did O O
not O O
occur O O
. O O

Paraplegia B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
following O O
intrathecal O O
methotrexate O O
: O O
report O O
of O O
a O O
case O O
and O O
review O O
of O O
the O O
literature O O
. O O

A O O
patient O O
who O O
developed O O
paraplegia B B_DISEASE
following O O
the O O
intrathecal O O
instillation O O
of O O
methotrexate O O
is O O
discribed O O
. O O

The O O
role O O
of O O
methotrexate O O
contaminants O O
, O O
local O O
folate B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deficiency I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
cranial O O
irradiation O O
in O O
the O O
pathogenesis O O
of O O
intrathecal O O
methotrexate O O
toxicity B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
unclear O O
. O O

The O O
incidence O O
of O O
neurotoxicity B B_DISEASE
may O O
be O O
reduced O O
by O O
employing O O
lower O O
doses O O
of O O
methotrexate O O
in O O
the O O
presence O O
of O O
central B B_DISEASE
nervous I I_DISEASE
system I I_DISEASE
leukemia I I_DISEASE
, O O
in O O
older O O
children O O
and O O
adults O O
, O O
and O O
in O O
the O O
presence O O
of O O
epidural O O
leakage O O
. O O

Only O O
preservative O O
- O O
free O O
methotrexate O O
in O O
Elliott O O
' O O
s O O
B O O
Solution O O
at O O
a O O
concentration O O
of O O
not O O
more O O
than O O
1 O O
mg O O
/ O O
ml O O
should O O
be O O
used O O
for O O
intrathecal O O
administration O O
. O O

Periodic O O
monitoring O O
of O O
cerebruspinal O O
fluid O O
methotrexate O O
levels O O
may O O
be O O
predictive O O
of O O
the O O
development O O
of O O
serious O O
neurotoxicity B B_DISEASE
. O O

Hyperosmolar B B_DISEASE
nonketotic I I_DISEASE
coma I I_DISEASE
precipitated O O
by O O
lithium O O
- O O
induced O O
nephrogenic B B_DISEASE
diabetes I I_DISEASE
insipidus I I_DISEASE
. O O

A O O
45 O O
- O O
year O O
- O O
old O O
man O O
, O O
with O O
a O O
10 O O
- O O
year O O
history O O
of O O
manic B B_DISEASE
depression I I_DISEASE
treated O O
with O O
lithium O O
, O O
was O O
admitted O O
with O O
hyperosmolar B B_DISEASE
, I I_DISEASE
nonketotic I I_DISEASE
coma I I_DISEASE
. O O

He O O
gave O O
a O O
five O O
- O O
year O O
history O O
of O O
polyuria B B_DISEASE
and O O
polydipsia B B_DISEASE
, O O
during O O
which O O
time O O
urinalysis O O
had O O
been O O
negative O O
for O O
glucose O O
. O O

After O O
recovery O O
from O O
hyperglycaemia B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
he O O
remained O O
polyuric B B_DISEASE_ADJECTIVE[DISEASE]
despite O O
normal O O
blood O O
glucose O O
concentrations O O
; O O
water O O
deprivation O O
testing O O
indicated O O
nephrogenic B B_DISEASE
diabetes I I_DISEASE
insipidus I I_DISEASE
, O O
likely O O
to O O
be O O
lithium O O
- O O
induced O O
. O O

We O O
hypothesize O O
that O O
when O O
this O O
man O O
developed O O
type B B_DISEASE
2 I I_DISEASE
diabetes I I_DISEASE
, O O
chronic O O
polyuria B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
due O O
to O O
nephrogenic B B_DISEASE
diabetes I I_DISEASE
insipidus I I_DISEASE
was O O
sufficient O O
to O O
precipitate O O
hyperosmolar O O
dehydration B B_DISEASE
. O O

Effects O O
of O O
the O O
intracoronary O O
infusion O O
of O O
cocaine O O
on O O
left O O
ventricular O O
systolic O O
and O O
diastolic O O
function O O
in O O
humans O O
. O O

BACKGROUND O O
: O O
In O O
dogs O O
, O O
a O O
large O O
amount O O
of O O
intravenous O O
cocaine O O
causes O O
a O O
profound O O
deterioration B B_DISEASE
of I I_DISEASE
left I I_DISEASE
ventricular I I_DISEASE
( I I_DISEASE
LV I I_DISEASE
) I I_DISEASE
systolic I I_DISEASE
function I I_DISEASE
and O O
an O O
increase O O
in O O
LV O O
end O O
- O O
diastolic O O
pressure O O
. O O

METHODS O O
AND O O
RESULTS O O
: O O
In O O
20 O O
patients O O
( O O
14 O O
men O O
and O O
6 O O
women O O
aged O O
39 O O
to O O
72 O O
years O O
) O O
referred O O
for O O
cardiac O O
catheterization O O
for O O
the O O
evaluation O O
of O O
chest B B_DISEASE/B_LOCATION
pain I I_DISEASE/I_LOCATION
, O O
we O O
measured O O
heart O O
rate O O
, O O
systemic O O
arterial O O
pressure O O
, O O
LV O O
pressure O O
and O O
its O O
first O O
derivative O O
( O O
dP O O
/ O O
dt O O
) O O
, O O
and O O
LV O O
volumes O O
and O O
ejection O O
fraction O O
before O O
and O O
during O O
the O O
final O O
2 O O
to O O
3 O O
minutes O O
of O O
a O O
15 O O
- O O
minute O O
intracoronary O O
infusion O O
of O O
saline O O
( O O
n O O
= O O
10 O O
, O O
control O O
subjects O O
) O O
or O O
cocaine O O
hydrochloride O O
1 O O
mg O O
/ O O
min O O
( O O
n O O
= O O
10 O O
) O O
. O O

No O O
variable O O
changed O O
with O O
saline O O
. O O

CONCLUSIONS O O
: O O
In O O
humans O O
, O O
the O O
intracoronary O O
infusion O O
of O O
cocaine O O
sufficient O O
in O O
amount O O
to O O
achieve O O
a O O
high O O
drug O O
concentration O O
in O O
coronary O O
sinus O O
blood O O
causes O O
a O O
deterioration B B_DISEASE
of I I_DISEASE
LV I I_DISEASE
systolic I I_DISEASE
and I I_DISEASE
diastolic I I_DISEASE
performance I I_DISEASE
. O O

Ascending O O
dose O O
tolerance O O
study O O
of O O
intramuscular O O
carbetocin O O
administered O O
after O O
normal O O
vaginal O O
birth O O
. O O

OBJECTIVE O O
: O O
To O O
determine O O
the O O
maximum O O
tolerated O O
dose O O
( O O
MTD O O
) O O
of O O
carbetocin O O
( O O
a O O
long O O
- O O
acting O O
synthetic O O
analogue O O
of O O
oxytocin O O
) O O
, O O
when O O
administered O O
immediately O O
after O O
vaginal O O
delivery O O
at O O
term O O
. O O

RESULTS O O
: O O
All O O
dosage O O
groups O O
consisted O O
of O O
three O O
women O O
, O O
except O O
those O O
with O O
100 O O
microg O O
( O O
n O O
= O O
6 O O
) O O
and O O
200 O O
microg O O
( O O
n O O
= O O
18 O O
) O O
. O O

Recorded O O
were O O
dose O O
- O O
limiting O O
adverse O O
events O O
: O O
hyper B B_DISEASE
- I I_DISEASE
or I I_DISEASE
hypotension I I_DISEASE
( O O
three O O
) O O
, O O
severe O O
abdominal B B_DISEASE
pain I I_DISEASE
( O O
0 O O
) O O
, O O
vomiting B B_DISEASE
( O O
0 O O
) O O
and O O
retained B B_DISEASE
placenta I I_DISEASE
( O O
four O O
) O O
. O O

Serious O O
adverse O O
events O O
occurred O O
in O O
seven O O
women O O
: O O
six O O
cases O O
with O O
blood B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
loss I B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
> O O
or O O
= O O
1000 O O
ml O O
, O O
four O O
cases O O
of O O
manual O O
placenta O O
removal O O
, O O
five O O
cases O O
of O O
additional O O
oxytocics O O
administration O O
and O O
five O O
cases O O
of O O
blood O O
transfusion O O
. O O

Maximum O O
blood B B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
loss I I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O O
greatest O O
at O O
the O O
upper O O
and O O
lower O O
dose O O
levels O O
, O O
and O O
lowest O O
in O O
the O O
70 O O
- O O
125 O O
microg O O
dose O O
range O O
. O O

Four O O
out O O
of O O
six O O
cases O O
with O O
blood B B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
loss I B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
> O O
or O O
= O O
1000 O O
ml O O
occurred O O
in O O
the O O
200 O O
microg O O
group O O
. O O

The O O
majority O O
of O O
additional O O
administration O O
of O O
oxytocics O O
( O O
4 O O
/ O O
5 O O
) O O
and O O
blood O O
transfusion O O
( O O
3 O O
/ O O
5 O O
) O O
occurred O O
in O O
the O O
dose O O
groups O O
of O O
200 O O
microg O O
. O O

CONCLUSION O O
: O O
The O O
MTD O O
was O O
calculated O O
to O O
be O O
at O O
200 O O
microg O O
carbetocin O O
. O O

Heparin O O
- O O
induced O O
thrombocytopenia B B_DISEASE
, O O
paradoxical O O
thromboembolism B B_DISEASE
, O O
and O O
other O O
side O O
effects O O
of O O
heparin O O
therapy O O
. O O

Although O O
several O O
new O O
anticoagulant O O
drugs O O
are O O
in O O
development O O
, O O
heparin O O
remains O O
the O O
drug O O
of O O
choice O O
for O O
most O O
anticoagulation O O
needs O O
. O O

The O O
clinical O O
effects O O
of O O
heparin O O
are O O
meritorious O O
, O O
but O O
side O O
effects O O
do O O
exist O O
. O O

Important O O
untoward O O
effects O O
of O O
heparin O O
therapy O O
including O O
heparin O O
- O O
induced O O
thrombocytopenia B B_DISEASE
, O O
heparin O O
- O O
associated O O
osteoporosis B B_DISEASE
, O O
eosinophilia B B_DISEASE
, O O
skin B B_DISEASE
reactions I I_DISEASE
, O O
allergic B B_DISEASE
reactions I I_DISEASE
other O O
than O O
thrombocytopenia B B_DISEASE
and O O
alopecia B B_DISEASE
will O O
be O O
discussed O O
in O O
this O O
article O O
. O O

Nonopaque O O
crystal O O
deposition O O
causing O O
ureteric B B_DISEASE
obstruction I I_DISEASE
in O O
patients O O
with O O
HIV O O
undergoing O O
indinavir O O
therapy O O
. O O

OBJECTIVE O O
: O O
We O O
describe O O
the O O
unique O O
CT O O
features O O
of O O
ureteric B B_DISEASE/B_LOCATION
calculi I I_DISEASE/I_LOCATION
in O O
six O O
HIV B B_DISEASE/B_PERSON
- I I_DISEASE/I_PERSON
infected I I_DISEASE/I_PERSON
patients O O
receiving O O
indinavir O O
, O O
the O O
most O O
commonly O O
used O O
HIV O O
protease O O
inhibitor O O
, O O
which O O
is O O
associated O O
with O O
an O O
increased O O
incidence O O
of O O
urolithiasis B B_DISEASE
. O O

CONCLUSION O O
: O O
Ureteric B B_DISEASE
obstruction I I_DISEASE
caused O O
by O O
precipitated O O
indinavir O O
crystals O O
may O O
be O O
difficult O O
to O O
diagnose O O
with O O
unenhanced O O
CT O O
. O O

Images O O
may O O
need O O
to O O
be O O
obtained O O
using O O
i O O
. O O
v O O
. O O
contrast O O
material O O
to O O
enable O O
diagnosis O O
of O O
ureteric B B_DISEASE
stones I I_DISEASE
or I I_DISEASE
obstruction I I_DISEASE
in O O
patients O O
with O O
HIV B B_DISEASE
infection I I_DISEASE
who O O
receive O O
indinavir O O
therapy O O
. O O

Ischemic B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colitis I B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
sumatriptan O O
use O O
. O O

Sumatriptan O O
succinate O O
, O O
a O O
serotonin O O
- O O
1 O O
( O O
5 O O
- O O
hydroxytryptamine O O
- O O
1 O O
) O O
receptor O O
agonist O O
, O O
is O O
an O O
antimigraine O O
drug O O
that O O
is O O
reported O O
to O O
act O O
by O O
selectively O O
constricting O O
intracranial O O
arteries O O
. O O

Cases O O
have O O
been O O
published O O
of O O
coronary B B_DISEASE
vasospasm I I_DISEASE
, O O
myocardial B B_DISEASE
ischemia I I_DISEASE
, O O
and O O
myocardial B B_DISEASE
infarction I I_DISEASE
occurring O O
after O O
sumatriptan O O
use O O
. O O

We O O
report O O
on O O
the O O
development O O
of O O
8 O O
serious O O
cases O O
of O O
ischemic B B_DISEASE
colitis I I_DISEASE
in O O
patients O O
with O O
migraine B B_DISEASE/B_LOCATION
treated O O
with O O
sumatriptan O O
. O O

Pallidotomy O O
with O O
the O O
gamma O O
knife O O
: O O
a O O
positive O O
experience O O
. O O

51 O O
patients O O
with O O
medically O O
refractory O O
Parkinson B B_DISEASE
' I I_DISEASE
s I I_DISEASE
disease I I_DISEASE
underwent O O
stereotactic O O
posteromedial O O
pallidotomy O O
between O O
August O O
1993 O O
and O O
February O O
1997 O O
for O O
treatment O O
of O O
bradykinesia B B_DISEASE
, O O
rigidity B B_DISEASE
, O O
and O O
L O O
- O O
DOPA O O
- O O
induced O O
dyskinesias B B_DISEASE
. O O

In O O
29 O O
patients O O
, O O
the O O
pallidotomies O O
were O O
performed O O
with O O
the O O
Leksell O O
Gamma O O
Knife O O
and O O
in O O
22 O O
they O O
were O O
performed O O
with O O
the O O
standard O O
radiofrequency O O
( O O
RF O O
) O O
method O O
. O O

Clinical O O
assessment O O
as O O
well O O
as O O
blinded O O
ratings O O
of O O
Unified O O
Parkinson B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
' I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
s I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
Disease I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
Rating O O
Scale O O
( O O
UPDRS O O
) O O
scores O O
were O O
carried O O
out O O
pre O O
- O O
and O O
postoperatively O O
. O O

Mean O O
follow O O
- O O
up O O
time O O
is O O
20 O O
. O O
6 O O
months O O
( O O
range O O
6 O O
- O O
48 O O
) O O
and O O
all O O
except O O
4 O O
patients O O
have O O
been O O
followed O O
more O O
than O O
one O O
year O O
. O O

85 O O
percent O O
of O O
patients O O
with O O
dyskinesias B B_DISEASE
were O O
relieved O O
of O O
symptoms O O
, O O
regardless O O
of O O
whether O O
the O O
pallidotomies O O
were O O
performed O O
with O O
the O O
Gamma O O
Knife O O
or O O
radiofrequency O O
methods O O
. O O

About O O
2 O O
/ O O
3 O O
of O O
the O O
patients O O
in O O
both O O
Gamma O O
Knife O O
and O O
radiofrequency O O
groups O O
showed O O
improvements O O
in O O
bradykinesia B B_DISEASE/B_MEASURE
and O O
rigidity B B_DISEASE
, O O
although O O
when O O
considered O O
as O O
a O O
group O O
neither O O
the O O
Gamma O O
Knife O O
nor O O
the O O
radiofrequency O O
group O O
showed O O
statistically O O
significant O O
improvements O O
in O O
UPDRS O O
scores O O
. O O

One O O
patient O O
in O O
the O O
Gamma O O
Knife O O
group O O
( O O
3 O O
. O O
4 O O
% O O
) O O
developed O O
a O O
homonymous B B_DISEASE
hemianopsia I I_DISEASE
9 O O
months O O
following O O
treatment O O
and O O
5 O O
patients O O
( O O
27 O O
. O O
7 O O
% O O
) O O
in O O
the O O
radiofrequency O O
group O O
became O O
transiently O O
confused O O
postoperatively O O
. O O

Gamma O O
Knife O O
pallidotomy O O
is O O
as O O
effective O O
as O O
radiofrequency O O
pallidotomy O O
in O O
controlling O O
certain O O
of O O
the O O
symptoms O O
of O O
Parkinson B B_DISEASE
' I I_DISEASE
s I I_DISEASE
disease I I_DISEASE
. O O

It O O
may O O
be O O
the O O
only O O
practical O O
technique O O
available O O
in O O
certain O O
patients O O
, O O
such O O
as O O
those O O
who O O
take O O
anticoagulants O O
, O O
have O O
bleeding B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
diatheses O O
or O O
serious O O
systemic O O
medical O O
illnesses O O
. O O

It O O
is O O
a O O
viable O O
option O O
for O O
other O O
patients O O
as O O
well O O
. O O

Centrally O O
mediated O O
cardiovascular O O
effects O O
of O O
intracisternal O O
application O O
of O O
carbachol O O
in O O
anesthetized O O
rats O O
. O O

The O O
pressor O O
response O O
to O O
the O O
intracisternal O O
( O O
i O O
. O O
c O O
. O O
) O O
injection O O
of O O
carbachol O O
( O O
1 O O
mug O O
) O O
in O O
anesthetized O O
rats O O
was O O
analyzed O O
. O O

This O O
response O O
was O O
significantly O O
reduced O O
by O O
the O O
intravenous O O
( O O
i O O
. O O
v O O
. O O
) O O
injection O O
of O O
guanethidine O O
( O O
5 O O
mg O O
) O O
, O O
hexamethonium O O
( O O
10 O O
mg O O
) O O
or O O
phentolamine O O
( O O
5 O O
mg O O
) O O
, O O
and O O
conversely O O
, O O
potentiated O O
by O O
i O O
. O O
v O O
. O O
desmethylimipramine O O
( O O
0 O O
. O O
3 O O
mg O O
) O O
, O O
while O O
propranolol O O
( O O
0 O O
. O O
5 O O
mg O O
) O O
i O O
. O O
v O O
. O O
selectively O O
inhibited O O
the O O
enlargement B B_DISEASE
of I I_DISEASE
pulse I I_DISEASE
pressure I I_DISEASE
and O O
the O O
tachycardia B B_DISEASE
following O O
i O O
. O O
c O O
. O O
carbachol O O
( O O
1 O O
mug O O
) O O
. O O

Neuroleptic B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
malignant I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
syndrome I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
methylphenidate O O
. O O

A O O
1 O O
- O O
year O O
- O O
old O O
female O O
presented O O
with O O
neuroleptic B B_DISEASE
malignant I I_DISEASE
syndrome I I_DISEASE
probably O O
caused O O
by O O
methylphenidate O O
. O O

She O O
had O O
defects O O
in O O
the O O
supratentorial O O
brain O O
including O O
the O O
basal O O
ganglia O O
and O O
the O O
striatum O O
( O O
multicystic B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
encephalomalacia I B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
) O O
due O O
to O O
severe O O
perinatal O O
hypoxic B B_DISEASE
- I I_DISEASE
ischemic I I_DISEASE
encephalopathy I I_DISEASE
, O O
which O O
was O O
considered O O
to O O
be O O
a O O
possible O O
predisposing O O
factor O O
causing O O
neuroleptic B B_DISEASE
malignant I I_DISEASE
syndrome I I_DISEASE
. O O

A O O
relative O O
gamma O O
- O O
aminobutyric O O
acid O O
- O O
ergic O O
deficiency O O
might O O
occur O O
because O O
diazepam O O
, O O
a O O
gamma O O
- O O
aminobutyric O O
acid O O
- O O
mimetic O O
agent O O
, O O
was O O
strikingly O O
effective O O
. O O

This O O
is O O
the O O
first O O
reported O O
patient O O
with O O
neuroleptic B B_DISEASE
malignant I I_DISEASE
syndrome I I_DISEASE
probably O O
caused O O
by O O
methylphenidate O O
. O O

Differential O O
effects O O
of O O
17alpha O O
- O O
ethinylestradiol O O
on O O
the O O
neutral O O
and O O
acidic O O
pathways O O
of O O
bile O O
salt O O
synthesis O O
in O O
the O O
rat O O
. O O

BS O O
pool O O
size O O
was O O
decreased O O
by O O
27 O O
% O O
but O O
total O O
BS O O
synthesis O O
was O O
not O O
affected O O
by O O
EE O O
in O O
intact O O
rats O O
. O O

Synthesis O O
of O O
cholate O O
was O O
reduced O O
by O O
68 O O
% O O
in O O
EE O O
- O O
treated O O
rats O O
, O O
while O O
that O O
of O O
chenodeoxycholate O O
was O O
increased O O
by O O
60 O O
% O O
. O O

The O O
recently O O
identified O O
Delta22 O O
- O O
isomer O O
of O O
beta O O
- O O
muricholate O O
contributed O O
for O O
5 O O
. O O
4 O O
% O O
and O O
18 O O
. O O
3 O O
% O O
( O O
P O O
< O O
0 O O
. O O
01 O O
) O O
to O O
the O O
pool O O
in O O
control O O
and O O
EE O O
- O O
treated O O
rats O O
, O O
respectively O O
, O O
but O O
could O O
not O O
be O O
detected O O
in O O
bile O O
after O O
exhaustion O O
of O O
the O O
pool O O
. O O

A O O
clear O O
reduction O O
of O O
BS O O
synthesis O O
was O O
found O O
in O O
bile O O
- O O
diverted O O
rats O O
treated O O
with O O
EE O O
, O O
yet O O
biliary O O
BS O O
composition O O
was O O
only O O
minimally O O
affected O O
. O O

Activity O O
of O O
CYP7A O O
was O O
decreased O O
by O O
EE O O
in O O
both O O
intact O O
and O O
bile O O
- O O
diverted O O
rats O O
, O O
whereas O O
the O O
activity O O
of O O
the O O
CYP27 O O
was O O
not O O
affected O O
. O O

Hepatic O O
mRNA O O
levels O O
of O O
CYP7A O O
were O O
significantly O O
reduced O O
by O O
EE O O
in O O
bile O O
- O O
diverted O O
rats O O
only O O
; O O
CYP27 O O
mRNA O O
levels O O
were O O
not O O
affected O O
by O O
EE O O
. O O

In O O
addition O O
, O O
mRNA O O
levels O O
of O O
sterol O O
12alpha O O
- O O
hydroxylase O O
and O O
lithocholate O O
6beta O O
- O O
hydroxylase O O
were O O
increased O O
by O O
bile O O
diversion O O
and O O
suppressed O O
by O O
EE O O
. O O

This O O
study O O
shows O O
that O O
17alpha O O
- O O
ethinylestradiol O O
( O O
EE O O
) O O
- O O
induced O O
intrahepatic B B_DISEASE
cholestasis I I_DISEASE
in O O
rats O O
is O O
associated O O
with O O
selective O O
inhibition O O
of O O
the O O
neutral O O
pathway O O
of O O
bile O O
salt O O
( O O
BS O O
) O O
synthesis O O
. O O

Glibenclamide O O
- O O
sensitive O O
hypotension B B_DISEASE
produced O O
by O O
helodermin O O
assessed O O
in O O
the O O
rat O O
. O O

The O O
results O O
were O O
also O O
compared O O
with O O
those O O
of O O
vasoactive O O
intestinal O O
polypeptide O O
( O O
VIP O O
) O O
. O O

Helodermin O O
produced O O
hypotension B B_DISEASE
in O O
a O O
dose O O
- O O
dependent O O
manner O O
with O O
approximately O O
similar O O
potency O O
and O O
duration O O
to O O
VIP O O
. O O

Hypotension B B_DISEASE
induced O O
by O O
both O O
peptides O O
was O O
significantly O O
attenuated O O
by O O
glibenclamide O O
, O O
which O O
abolished O O
a O O
levcromakalim O O
- O O
produced O O
decrease O O
in O O
arterial O O
blood O O
pressure O O
. O O

Oxyhemoglobin O O
did O O
not O O
affect O O
helodermin O O
- O O
induced O O
hypotension B B_DISEASE
, O O
whereas O O
it O O
shortened O O
the O O
duration O O
of O O
acetylcholine O O
( O O
ACh O O
) O O
- O O
produced O O
hypotension B B_DISEASE
. O O

These O O
findings O O
suggest O O
that O O
helodermin O O
- O O
produced O O
hypotension B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O O
partly O O
attributable O O
to O O
the O O
activation O O
of O O
glibenclamide O O
- O O
sensitive O O
K O O
+ O O
channels O O
( O O
K O O
( O O
ATP O O
) O O
channels O O
) O O
, O O
which O O
presumably O O
exist O O
on O O
arterial O O
smooth O O
muscle O O
cells O O
. O O

EDRF O O
( O O
endothelium O O
- O O
derived O O
relaxing O O
factor O O
) O O
/ O O
nitric O O
oxide O O
does O O
not O O
seem O O
to O O
play O O
an O O
important O O
role O O
in O O
the O O
peptide O O
- O O
produced O O
hypotension B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Long O O
- O O
term O O
efficacy O O
and O O
adverse O O
event O O
of O O
nifedipine O O
sustained O O
- O O
release O O
tablets O O
for O O
cyclosporin O O
A O O
- O O
induced O O
hypertension B B_DISEASE
in O O
patients O O
with O O
psoriasis B B_DISEASE/B_LOCATION
. O O

Thirteen O O
psoriatic B B_DISEASE/B_MEASURE
patients O O
with O O
hypertension B B_DISEASE
during O O
the O O
course O O
of O O
cyclosporin O O
A O O
therapy O O
were O O
treated O O
for O O
25 O O
months O O
with O O
a O O
calcium O O
channel O O
blocker O O
, O O
sustained O O
- O O
release O O
nifedipine O O
, O O
to O O
study O O
the O O
clinical O O
antihypertensive O O
effects O O
and O O
adverse O O
events O O
during O O
treatment O O
with O O
both O O
drugs O O
. O O

Seven O O
of O O
the O O
13 O O
patients O O
had O O
exhibited O O
a O O
subclinical O O
hypertensive B B_DISEASE_ADJECTIVE[DISEASE]
state O O
before O O
cyclosporin O O
A O O
therapy O O
. O O

Both O O
systolic O O
and O O
diastolic O O
blood O O
pressures O O
of O O
these O O
13 O O
patients O O
were O O
decreased O O
significantly O O
after O O
4 O O
weeks O O
of O O
nifedipine O O
therapy O O
, O O
and O O
blood O O
pressure O O
was O O
maintained O O
within O O
the O O
normal O O
range O O
thereafter O O
for O O
25 O O
months O O
. O O

The O O
adverse O O
events O O
during O O
combined O O
therapy O O
with O O
cyclosporin O O
A O O
and O O
nifedipine O O
included O O
an O O
increase O O
in O O
blood O O
urea O O
nitrogen O O
levels O O
in O O
9 O O
of O O
the O O
13 O O
patients O O
and O O
development O O
of O O
gingival B B_DISEASE
hyperplasia I I_DISEASE
in O O
2 O O
of O O
the O O
13 O O
patients O O
. O O

Our O O
findings O O
indicate O O
that O O
sustained O O
- O O
release O O
nifedipine O O
is O O
useful O O
for O O
hypertensive B B_DISEASE/B_LOCATION
psoriatic B I_DISEASE/I_LOCATION
patients O O
under O O
long O O
- O O
term O O
treatment O O
with O O
cyclosporin O O
A O O
, O O
but O O
that O O
these O O
patients O O
should O O
be O O
monitored O O
for O O
gingival B B_DISEASE
hyperplasia I I_DISEASE
. O O

